{"PMC7108139": [["Patient Specimens ::: METHODSIn Hong Kong, 2019-nCoV testing was performed by Public Health Laboratory Services Branch in Hong Kong for patients who fulfilled the reporting criteria or enhanced surveillance criteria [9].", [["patients", "ORGANISM", 136, 144], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 136, 144]]], ["A patient is considered to have laboratory-confirmed infection if 2019-nCoV was detected in their nasopharyngeal or sputum specimens.Patient Specimens ::: METHODSSaliva was collected by asking the patient to cough out saliva from their throat into a sterile container, and 2 mL of viral transport medium was added as we described previously [5, 6].", [["nasopharyngeal", "ANATOMY", 98, 112], ["sputum specimens", "ANATOMY", 116, 132], ["throat", "ANATOMY", 236, 242], ["infection", "DISEASE", 53, 62], ["cough", "DISEASE", 208, 213], ["patient", "ORGANISM", 2, 9], ["nasopharyngeal", "CANCER", 98, 112], ["sputum specimens", "CANCER", 116, 132], ["patient", "ORGANISM", 197, 204], ["saliva", "ORGANISM_SUBSTANCE", 218, 224], ["throat", "ORGANISM_SUBDIVISION", 236, 242], ["patient", "SPECIES", 2, 9], ["Patient", "SPECIES", 133, 140], ["patient", "SPECIES", 197, 204], ["infection", "PROBLEM", 53, 62], ["nCoV", "PROBLEM", 71, 75], ["sputum specimens", "TEST", 116, 132], ["METHODSSaliva", "TREATMENT", 155, 168], ["cough out saliva", "PROBLEM", 208, 224], ["a sterile container", "TREATMENT", 248, 267], ["viral transport medium", "TREATMENT", 281, 303], ["infection", "OBSERVATION", 53, 62], ["nasopharyngeal", "ANATOMY", 98, 112]]], ["This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW 13-372).Nucleic Acid Extraction and Real-time Reverse Transcription\u2013Quantitative Polymerase Chain Reaction for 2019-nCoV ::: METHODSSaliva specimens were subjected to total nucleic acid extraction by NucliSENS easyMAG (BioMerieux) as we described previously [5].", [["specimens", "ANATOMY", 274, 283], ["nucleic acid", "CHEMICAL", 308, 320], ["METHODSSaliva specimens", "CANCER", 260, 283], ["This study", "TEST", 0, 10], ["Nucleic Acid Extraction", "TREATMENT", 143, 166], ["METHODSSaliva specimens", "PROBLEM", 260, 283], ["total nucleic acid extraction", "TREATMENT", 302, 331]]], ["Each specimen was mixed with lysis buffer.", [["specimen", "ANATOMY", 5, 13], ["lysis buffer", "TREATMENT", 29, 41]]], ["After extraction, the total nucleic acid was recovered using 55 \u03bcL of elution buffer.", [["nucleic acid", "CHEMICAL", 28, 40], ["extraction", "TREATMENT", 6, 16], ["the total nucleic acid", "TEST", 18, 40], ["elution buffer", "TREATMENT", 70, 84]]], ["In-house 1-step real-time reverse transcription\u2013quantitative polymerase chain reaction (RT-qPCR) assay targeting the S gene of 2019-nCoV was performed using QuantiNova SYBR Green RT-PCR Kit (Qiagen) in a LightCycler 480 Real-Time PCR System (Roche), as we described previously [2].Viral Culture ::: METHODSViral culture of 2019-nCoV was conducted in a biosafety level-3 facility.", [["S gene", "DNA", 117, 123], ["2019", "DNA", 127, 131], ["nCoV", "DNA", 132, 136], ["reverse transcription\u2013quantitative polymerase chain reaction", "PROBLEM", 26, 86], ["RT-qPCR", "TEST", 88, 95], ["a LightCycler", "TREATMENT", 202, 215], ["Viral Culture", "TEST", 281, 294], ["METHODSViral culture", "TEST", 299, 319]]], ["Vero E6 cells were seeded with 1 mL of minimum essential medium (MEM) at 2 \u00d7 105 cells/mL in culture tubes and incubated at 37\u00b0C in a carbon dioxide incubator for 1\u20132 days until confluence for inoculation.", [["Vero E6 cells", "ANATOMY", 0, 13], ["cells", "ANATOMY", 81, 86], ["culture tubes", "ANATOMY", 93, 106], ["carbon dioxide", "CHEMICAL", 134, 148], ["carbon dioxide", "CHEMICAL", 134, 148], ["Vero E6 cells", "CELL", 0, 13], ["cells", "CELL", 81, 86], ["C", "SIMPLE_CHEMICAL", 127, 128], ["Vero E6 cells", "CELL_LINE", 0, 13], ["Vero E6", "SPECIES", 0, 7], ["Vero E6 cells", "TREATMENT", 0, 13], ["minimum essential medium (MEM)", "TREATMENT", 39, 69], ["culture tubes", "TREATMENT", 93, 106], ["a carbon dioxide incubator", "TREATMENT", 132, 158], ["inoculation", "PROBLEM", 193, 204], ["E6 cells", "OBSERVATION", 5, 13]]], ["Each saliva specimen was inoculated in duplicate; 1 tube contained tosylsulfonyl phenylalanyl chloromethyl ketone\u2013treated trypsin (0.5 \u03bcg/mL) in serum-free MEM and the other tube contained MEM with 1% fetal calf serum.", [["specimen", "ANATOMY", 12, 20], ["serum", "ANATOMY", 145, 150], ["fetal calf serum", "ANATOMY", 201, 217], ["tosylsulfonyl phenylalanyl chloromethyl ketone\u2013treated trypsin", "CHEMICAL", 67, 129], ["MEM", "CHEMICAL", 156, 159], ["tosylsulfonyl phenylalanyl chloromethyl", "CHEMICAL", 67, 106], ["saliva specimen", "ORGANISM_SUBSTANCE", 5, 20], ["tosylsulfonyl phenylalanyl chloromethyl ketone\u2013treated trypsin", "SIMPLE_CHEMICAL", 67, 129], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["tube", "TISSUE", 174, 178], ["fetal calf", "ORGANISM_SUBSTANCE", 201, 211], ["serum", "ORGANISM_SUBSTANCE", 212, 217], ["calf", "SPECIES", 207, 211], ["Each saliva specimen", "TEST", 0, 20], ["1 tube", "TREATMENT", 50, 56], ["tosylsulfonyl phenylalanyl chloromethyl ketone\u2013treated trypsin", "TREATMENT", 67, 129], ["serum-free MEM", "TREATMENT", 145, 159], ["1% fetal calf serum", "TREATMENT", 198, 217], ["tube", "OBSERVATION", 174, 178], ["fetal calf", "ANATOMY", 201, 211]]], ["Each tube was inoculated with 0.2 mL of saliva and was incubated in a slanted position so that the inoculum covered the monolayer for 60 minutes at 37\u00b0C. Then 1 mL of either MEM or trypsin MEM was added and incubated in a roller apparatus at a speed 12 to 15 revolutions per hour.", [["tube", "ANATOMY", 5, 9], ["monolayer", "ANATOMY", 120, 129], ["MEM", "CHEMICAL", 174, 177], ["MEM", "CHEMICAL", 189, 192], ["tube", "TISSUE", 5, 9], ["saliva", "ORGANISM_SUBSTANCE", 40, 46], ["monolayer", "CELL", 120, 129], ["Each tube", "TREATMENT", 0, 9], ["saliva", "TREATMENT", 40, 46], ["the inoculum", "TREATMENT", 95, 107], ["either MEM or trypsin MEM", "TREATMENT", 167, 192], ["tube", "OBSERVATION", 5, 9]]], ["Virus-induced cytopathic effect was examined daily for up to 7 days.RESULTSA total of 12 patients with laboratory-confirmed 2019-nCoV infection in Hong Kong were included.", [["infection", "DISEASE", 134, 143], ["Virus", "ORGANISM", 0, 5], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["Virus", "PROBLEM", 0, 5], ["cytopathic effect", "PROBLEM", 14, 31], ["nCoV infection", "PROBLEM", 129, 143], ["cytopathic", "OBSERVATION_MODIFIER", 14, 24], ["infection", "OBSERVATION", 134, 143]]], ["There were 5 female and 7 male patients.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["At the time of writing, all patients were still hospitalized.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36]]], ["Saliva specimens were collected at a median of 2 days after hospitalization (range, 0\u20137 days) (Figure 1).", [["Saliva specimens", "ANATOMY", 0, 16], ["Saliva specimens", "ORGANISM_SUBSTANCE", 0, 16], ["Saliva specimens", "TEST", 0, 16]]], ["The 2019-nCoV was detected in the initial saliva specimens of 11 patients (91.7%).", [["saliva specimens", "ANATOMY", 42, 58], ["saliva specimens", "ORGANISM_SUBSTANCE", 42, 58], ["patients", "ORGANISM", 65, 73], ["2019-nCoV", "DNA", 4, 13], ["patients", "SPECIES", 65, 73], ["the initial saliva specimens", "TEST", 30, 58]]], ["For patient K, the first saliva specimen collected on the day of hospital admission tested negative.", [["saliva specimen", "ANATOMY", 25, 40], ["patient", "ORGANISM", 4, 11], ["saliva", "ORGANISM", 25, 31], ["patient", "SPECIES", 4, 11], ["patient K", "TEST", 4, 13], ["the first saliva specimen", "TEST", 15, 40]]], ["The median viral load of the first available saliva specimens was 3.3 \u00d7 106 copies/mL (range, 9.9 \u00d7 102 to 1.2 \u00d7 108 copies/mL).RESULTSSerial saliva specimens were available for 6 patients.", [["saliva specimens", "ANATOMY", 45, 61], ["specimens", "ANATOMY", 149, 158], ["saliva", "ORGANISM", 45, 51], ["saliva specimens", "ORGANISM_SUBSTANCE", 142, 158], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["The median viral load", "TEST", 0, 21], ["saliva specimens", "TEST", 45, 61], ["range", "TEST", 87, 92], ["RESULTSSerial saliva specimens", "TEST", 128, 158]]], ["The viral load was highest in the earliest available specimens for 5 patients (83.3%).", [["specimens", "ANATOMY", 53, 62], ["specimens", "CANCER", 53, 62], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["The viral load", "TEST", 0, 14], ["viral load", "OBSERVATION", 4, 14]]], ["For patient H, the viral load was slightly higher on day 1 after hospitalization (6.8 \u00d7 107 copies/mL) than on the day of hospital admission (5.7 \u00d7 107 copies/mL).", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["the viral load", "TEST", 15, 29], ["slightly higher", "PROBLEM", 34, 49], ["viral load", "OBSERVATION", 19, 29]]], ["For patient B, viral shedding in saliva was still detected on day 11 after hospitalization.", [["patient", "ORGANISM", 4, 11], ["B", "CELL", 12, 13], ["saliva", "ORGANISM_SUBSTANCE", 33, 39], ["patient", "SPECIES", 4, 11], ["viral shedding in saliva", "PROBLEM", 15, 39]]], ["In 33 patients whose nasopharyngeal specimens tested negative for 2019-nCoV, all saliva specimens also tested negative.", [["nasopharyngeal specimens", "ANATOMY", 21, 45], ["specimens", "ANATOMY", 88, 97], ["patients", "ORGANISM", 6, 14], ["nasopharyngeal specimens", "CANCER", 21, 45], ["saliva specimens", "ORGANISM_SUBSTANCE", 81, 97], ["patients", "SPECIES", 6, 14], ["nasopharyngeal specimens", "TEST", 21, 45], ["all saliva specimens", "TEST", 77, 97], ["nasopharyngeal", "ANATOMY", 21, 35]]], ["At the time of writing, viral cultures were positive for 3 patients and negative for 2 patients.DISCUSSIONIn this study, we have demonstrated that 2019-nCoV could be detected in the saliva specimens of 11 of the 12 patients studied.", [["saliva specimens", "ANATOMY", 182, 198], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 87, 95], ["nCoV", "GENE_OR_GENE_PRODUCT", 152, 156], ["saliva specimens", "ORGANISM_SUBSTANCE", 182, 198], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 215, 223], ["viral cultures", "TEST", 24, 38], ["this study", "TEST", 109, 119], ["the saliva specimens", "TEST", 178, 198]]], ["Serial saliva specimens showed declines in salivary 2019-nCoV RNA levels after hospitalization.", [["saliva specimens", "ANATOMY", 7, 23], ["saliva specimens", "ORGANISM_SUBSTANCE", 7, 23], ["salivary", "ORGAN", 43, 51], ["Serial saliva specimens", "TEST", 0, 23]]], ["Viral culture demonstrated that live viruses were present in the saliva of 3 patients.DISCUSSIONThere are several advantages in using saliva specimens for the diagnosis of 2019-nCoV.", [["specimens", "ANATOMY", 141, 150], ["saliva", "ORGANISM_SUBSTANCE", 65, 71], ["patients", "ORGANISM", 77, 85], ["saliva", "ORGANISM", 134, 140], ["patients", "SPECIES", 77, 85], ["Viral culture", "TEST", 0, 13], ["live viruses", "PROBLEM", 32, 44], ["saliva specimens", "TEST", 134, 150]]], ["First, saliva specimens can be provided by the patient easily without any invasive procedures.", [["saliva specimens", "ANATOMY", 7, 23], ["saliva specimens", "ORGANISM_SUBSTANCE", 7, 23], ["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["saliva specimens", "TEST", 7, 23], ["any invasive procedures", "TREATMENT", 70, 93]]], ["Therefore, the use of saliva specimens could reduce the risk of nosocomial 2019-nCoV transmission.", [["saliva specimens", "ANATOMY", 22, 38], ["saliva", "ORGANISM", 22, 28], ["saliva specimens", "TREATMENT", 22, 38]]], ["Cases of 2019-nCoV infection among healthcare workers have been found, with at least 1 reported death [10].", [["infection", "DISEASE", 19, 28], ["death", "DISEASE", 96, 101], ["2019-nCoV", "ORGANISM", 9, 18], ["nCoV infection", "PROBLEM", 14, 28]]], ["Second, the use of saliva will allow specimen collection outside the hospitals where airborne-infection isolation rooms are not available, such as in outpatient clinics or in the community.", [["specimen", "ANATOMY", 37, 45], ["infection", "DISEASE", 94, 103], ["saliva", "ORGANISM_SUBSTANCE", 19, 25], ["saliva", "TREATMENT", 19, 25], ["specimen collection", "TEST", 37, 56], ["infection", "OBSERVATION", 94, 103]]], ["In the setting where a large number of individuals require screening, saliva would represent a practical noninvasive specimen type.", [["specimen", "ANATOMY", 117, 125], ["individuals", "ORGANISM", 39, 50], ["saliva", "ORGANISM_SUBSTANCE", 70, 76], ["screening", "TEST", 59, 68], ["saliva", "TREATMENT", 70, 76], ["a practical noninvasive specimen type", "PROBLEM", 93, 130], ["large", "OBSERVATION_MODIFIER", 23, 28], ["number", "OBSERVATION_MODIFIER", 29, 35]]], ["Third, since healthcare workers are not required to collect saliva specimens, the use of saliva specimens will eliminate the waiting time for specimen collection, and hence the results would be available much sooner.", [["specimens", "ANATOMY", 67, 76], ["saliva specimens", "ANATOMY", 89, 105], ["specimen", "ANATOMY", 142, 150], ["saliva", "ORGANISM", 60, 66], ["saliva", "ORGANISM", 89, 95], ["saliva specimens", "TEST", 60, 76], ["saliva specimens", "TREATMENT", 89, 105], ["specimen collection", "TEST", 142, 161]]], ["This is especially important in busy clinical settings where the number of available staff is limited.DISCUSSIONAmong patients with serial saliva specimens available, there was a general decline in viral load for most patients, but 1 patient had viral shedding in the saliva for at least 11 days after hospitalization.", [["specimens", "ANATOMY", 146, 155], ["saliva", "ANATOMY", 268, 274], ["patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 218, 226], ["patient", "ORGANISM", 234, 241], ["saliva", "ORGANISM_SUBSTANCE", 268, 274], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 218, 226], ["patient", "SPECIES", 234, 241], ["serial saliva specimens", "TEST", 132, 155], ["a general decline in viral load", "PROBLEM", 177, 208], ["viral shedding in the saliva", "PROBLEM", 246, 274], ["viral load", "OBSERVATION", 198, 208]]], ["The use of saliva is preferred over nasopharyngeal or oropharyngeal specimens for serial viral load monitoring because this would reduce the discomfort to the patient and reduce the health hazards to healthcare workers during repeated sampling.", [["nasopharyngeal", "ANATOMY", 36, 50], ["oropharyngeal specimens", "ANATOMY", 54, 77], ["saliva", "ORGANISM_SUBSTANCE", 11, 17], ["nasopharyngeal", "CANCER", 36, 50], ["oropharyngeal specimens", "CANCER", 54, 77], ["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 159, 166], ["saliva", "TREATMENT", 11, 17], ["nasopharyngeal or oropharyngeal specimens", "TEST", 36, 77], ["serial viral load monitoring", "TEST", 82, 110], ["the discomfort", "PROBLEM", 137, 151], ["repeated sampling", "TEST", 226, 243], ["oropharyngeal", "ANATOMY", 54, 67]]], ["Our experience with SARS in 2003 showed that viral load often peaked at day 10 after symptom onset.", [["SARS", "DISEASE", 20, 24], ["SARS", "PROBLEM", 20, 24], ["viral load", "PROBLEM", 45, 55], ["viral load", "OBSERVATION", 45, 55]]], ["Thus, early detection and isolation of cases was strategic for infection control and provides the window of opportunity for antiviral therapy to decrease the peak viral load.DISCUSSIONThe positive viral culture indicates that saliva contains live viruses that may allow transmission.", [["infection", "DISEASE", 63, 72], ["saliva", "ORGANISM_SUBSTANCE", 226, 232], ["early detection", "TEST", 6, 21], ["isolation of cases", "TREATMENT", 26, 44], ["infection control", "TREATMENT", 63, 80], ["antiviral therapy", "TREATMENT", 124, 141], ["the peak viral load", "PROBLEM", 154, 173], ["The positive viral culture", "TEST", 184, 210], ["saliva contains live viruses", "PROBLEM", 226, 254], ["peak viral load", "OBSERVATION", 158, 173], ["positive", "OBSERVATION_MODIFIER", 188, 196], ["viral culture", "OBSERVATION", 197, 210]]], ["Respiratory viruses are considered to be transmitted from person to person through direct or indirect contact, or via coarse or fine droplets.", [["Respiratory viruses", "DISEASE", 0, 19], ["person", "SPECIES", 58, 64], ["person", "SPECIES", 68, 74], ["Respiratory viruses", "PROBLEM", 0, 19], ["viruses", "OBSERVATION", 12, 19]]], ["Saliva can be emitted through cough, and respiratory droplets containing influenza virus can be found even during normal breathing [11].", [["respiratory droplets", "ANATOMY", 41, 61], ["cough", "DISEASE", 30, 35], ["influenza virus", "DISEASE", 73, 88], ["Saliva", "ORGANISM_SUBSTANCE", 0, 6], ["influenza virus", "ORGANISM", 73, 88], ["cough", "PROBLEM", 30, 35], ["respiratory droplets", "PROBLEM", 41, 61], ["influenza virus", "PROBLEM", 73, 88]]], ["Therefore, 2019-nCoV may be transmitted via saliva directly or indirectly even among patients without coughing or other respiratory symptoms.", [["respiratory", "ANATOMY", 120, 131], ["coughing", "DISEASE", 102, 110], ["respiratory symptoms", "DISEASE", 120, 140], ["2019-nCoV", "GENE_OR_GENE_PRODUCT", 11, 20], ["saliva", "ORGANISM_SUBSTANCE", 44, 50], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["coughing", "PROBLEM", 102, 110], ["other respiratory symptoms", "PROBLEM", 114, 140]]], ["Our findings reinforce the use of surgical masks as a control measure.DISCUSSIONSARS-CoV has been shown to infect epithelial cells in salivary gland ducts in rhesus macaques [12].", [["epithelial cells", "ANATOMY", 114, 130], ["salivary gland ducts", "ANATOMY", 134, 154], ["CoV", "ORGANISM", 85, 88], ["epithelial cells", "CELL", 114, 130], ["salivary gland ducts", "MULTI-TISSUE_STRUCTURE", 134, 154], ["macaques", "ORGANISM", 165, 173], ["CoV", "PROTEIN", 85, 88], ["epithelial cells", "CELL_TYPE", 114, 130], ["rhesus macaques", "SPECIES", 158, 173], ["rhesus macaques", "SPECIES", 158, 173], ["surgical masks", "TREATMENT", 34, 48], ["a control measure", "TREATMENT", 52, 69], ["epithelial cells", "OBSERVATION", 114, 130], ["salivary gland", "ANATOMY", 134, 148]]], ["The presence of 2019-nCoV in patients\u2019 saliva suggests the possibility of salivary gland infection.", [["salivary gland", "ANATOMY", 74, 88], ["salivary gland infection", "DISEASE", 74, 98], ["2019-nCoV", "GENE_OR_GENE_PRODUCT", 16, 25], ["patients", "ORGANISM", 29, 37], ["saliva", "ORGANISM_SUBSTANCE", 39, 45], ["salivary gland", "ORGAN", 74, 88], ["patients", "SPECIES", 29, 37], ["salivary gland infection", "PROBLEM", 74, 98], ["suggests the possibility of", "UNCERTAINTY", 46, 73], ["salivary gland", "ANATOMY", 74, 88], ["infection", "OBSERVATION", 89, 98]]], ["However, it should be noted that saliva specimens not only contain saliva secreted from major or minor salivary glands but also contain secretions coming down from the nasopharynx or coming up from the lung via the action of cilia lining the airway.", [["specimens", "ANATOMY", 40, 49], ["salivary glands", "ANATOMY", 103, 118], ["secretions", "ANATOMY", 136, 146], ["nasopharynx", "ANATOMY", 168, 179], ["lung", "ANATOMY", 202, 206], ["cilia", "ANATOMY", 225, 230], ["airway", "ANATOMY", 242, 248], ["saliva specimens", "ORGANISM_SUBSTANCE", 33, 49], ["saliva", "ORGANISM_SUBSTANCE", 67, 73], ["salivary glands", "ORGAN", 103, 118], ["nasopharynx", "ORGAN", 168, 179], ["lung", "ORGAN", 202, 206], ["cilia", "MULTI-TISSUE_STRUCTURE", 225, 230], ["airway", "MULTI-TISSUE_STRUCTURE", 242, 248], ["saliva specimens", "TEST", 33, 49], ["saliva secreted from major or minor salivary glands", "PROBLEM", 67, 118], ["secretions", "PROBLEM", 136, 146], ["salivary glands", "ANATOMY", 103, 118], ["secretions", "OBSERVATION", 136, 146], ["nasopharynx", "ANATOMY", 168, 179], ["lung", "ANATOMY", 202, 206], ["cilia lining", "OBSERVATION", 225, 237], ["airway", "ANATOMY", 242, 248]]], ["Further studies are required to delineate the sources of 2019-nCoV in saliva.DISCUSSIONOur results have demonstrated the potential for saliva to be a noninvasive specimen type for the diagnosis and viral load monitoring of 2019-nCoV.", [["specimen", "ANATOMY", 162, 170], ["2019-nCoV", "GENE_OR_GENE_PRODUCT", 57, 66], ["saliva", "ORGANISM_SUBSTANCE", 70, 76], ["saliva", "ORGANISM_SUBSTANCE", 135, 141], ["Further studies", "TEST", 0, 15], ["saliva", "PROBLEM", 135, 141], ["viral load monitoring", "TEST", 198, 219]]], ["Because saliva can be provided by patients without any invasive procedures, the use of saliva specimens will reduce the risk of nosocomial transmission of 2019-nCoV and is ideal for situations in which nasopharyngeal specimen collection may be contraindicated.", [["saliva specimens", "ANATOMY", 87, 103], ["nasopharyngeal specimen", "ANATOMY", 202, 225], ["saliva", "ORGANISM_SUBSTANCE", 8, 14], ["patients", "ORGANISM", 34, 42], ["saliva", "ORGANISM", 87, 93], ["nasopharyngeal specimen", "MULTI-TISSUE_STRUCTURE", 202, 225], ["patients", "SPECIES", 34, 42], ["any invasive procedures", "TREATMENT", 51, 74], ["saliva specimens", "TREATMENT", 87, 103], ["nosocomial transmission", "TEST", 128, 151], ["nasopharyngeal specimen collection", "TEST", 202, 236], ["nasopharyngeal", "ANATOMY", 202, 216]]]], "206be0740f4d299003d4e09cd6f9a32e6e351130": [["Introduction to HPSEHeparanase (HPSE) is an endo-\u03b2-d-endoglycosidase that is the only known mammalian enzyme able to cleave heparan sulfate (HS) moieties at certain positions [1] .", [["HPSEHeparanase", "CHEMICAL", 16, 30], ["HPSE", "CHEMICAL", 32, 36], ["heparan sulfate", "CHEMICAL", 124, 139], ["HPSEHeparanase", "CHEMICAL", 16, 30], ["heparan sulfate", "CHEMICAL", 124, 139], ["HPSEHeparanase", "SIMPLE_CHEMICAL", 16, 30], ["HPSE", "SIMPLE_CHEMICAL", 32, 36], ["endo-\u03b2-d-endoglycosidase", "GENE_OR_GENE_PRODUCT", 44, 68], ["heparan sulfate", "SIMPLE_CHEMICAL", 124, 139], ["HS", "SIMPLE_CHEMICAL", 141, 143], ["mammalian enzyme", "PROTEIN", 92, 108], ["an endo-\u03b2-d-endoglycosidase", "TREATMENT", 41, 68], ["known mammalian enzyme", "PROBLEM", 86, 108], ["heparan sulfate (HS) moieties", "TREATMENT", 124, 153]]], ["HPSE plays an important role in the degradation and modification of the extracellular matrix (ECM) [2] .", [["extracellular matrix", "ANATOMY", 72, 92], ["ECM", "ANATOMY", 94, 97], ["HPSE", "CHEMICAL", 0, 4], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["extracellular matrix", "CELLULAR_COMPONENT", 72, 92], ["ECM", "CELLULAR_COMPONENT", 94, 97], ["HPSE", "PROTEIN", 0, 4]]], ["It is a 58 kDa heterodimer composed of 50 kDa and 8 kDa subunits which bind noncovalently [2] .", [["58 kDa heterodimer", "PROTEIN", 8, 26], ["50 kDa and 8 kDa subunits", "PROTEIN", 39, 64], ["a 58 kDa heterodimer", "TREATMENT", 6, 26], ["50 kDa and 8 kDa subunits", "TREATMENT", 39, 64]]], ["The enzyme is initially synthesized in the endoplasmic reticulum as a 68 kDa precursor protein, modified in the Golgi apparatus to become a 65 kDa proenzyme, and transported to the exterior of the cell [3] .", [["endoplasmic reticulum", "ANATOMY", 43, 64], ["Golgi apparatus", "ANATOMY", 112, 127], ["cell", "ANATOMY", 197, 201], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 43, 64], ["Golgi", "CELLULAR_COMPONENT", 112, 117], ["cell", "CELL", 197, 201], ["68 kDa precursor protein", "PROTEIN", 70, 94], ["65 kDa proenzyme", "PROTEIN", 140, 156], ["The enzyme", "TEST", 0, 10], ["endoplasmic reticulum", "ANATOMY", 43, 64]]], ["Once there, it can bind to heparan sulfate proteoglycans (HSPGs), low-density lipoprotein-receptor-related protein (LRP), or mannose 6-phosphate [3] .", [["heparan sulfate", "CHEMICAL", 27, 42], ["mannose 6-phosphate", "CHEMICAL", 125, 144], ["sulfate", "CHEMICAL", 35, 42], ["mannose 6-phosphate", "CHEMICAL", 125, 144], ["heparan sulfate proteoglycans", "GENE_OR_GENE_PRODUCT", 27, 56], ["HSPGs", "GENE_OR_GENE_PRODUCT", 58, 63], ["low-density lipoprotein-receptor-related protein", "GENE_OR_GENE_PRODUCT", 66, 114], ["LRP", "GENE_OR_GENE_PRODUCT", 116, 119], ["mannose 6-phosphate [3]", "SIMPLE_CHEMICAL", 125, 148], ["heparan sulfate proteoglycans", "PROTEIN", 27, 56], ["HSPGs", "PROTEIN", 58, 63], ["low-density lipoprotein-receptor-related protein", "PROTEIN", 66, 114], ["LRP", "PROTEIN", 116, 119], ["heparan sulfate proteoglycans", "TREATMENT", 27, 56], ["HSPGs", "TEST", 58, 63], ["low-density lipoprotein", "TREATMENT", 66, 89], ["mannose", "TREATMENT", 125, 132]]], ["This binding causes the complex to become endocytosed and transported to a lysosome for processing [3] .", [["lysosome", "ANATOMY", 75, 83], ["lysosome", "CELLULAR_COMPONENT", 75, 83]]], ["The acidic pH of the lysosome activates the cathepsin L protease which cleaves a 6 kDa linker region in the HPSE enzyme and converts HPSE into its active heterodimer form [4] .", [["lysosome", "ANATOMY", 21, 29], ["HPSE", "CHEMICAL", 133, 137], ["HPSE", "CHEMICAL", 133, 137], ["lysosome", "CELLULAR_COMPONENT", 21, 29], ["cathepsin L protease", "GENE_OR_GENE_PRODUCT", 44, 64], ["HPSE", "SIMPLE_CHEMICAL", 133, 137], ["cathepsin L protease", "PROTEIN", 44, 64], ["6 kDa linker region", "PROTEIN", 81, 100], ["HPSE enzyme", "PROTEIN", 108, 119], ["HPSE", "PROTEIN", 133, 137], ["The acidic pH", "TEST", 0, 13], ["the lysosome", "TREATMENT", 17, 29], ["the cathepsin L protease", "TREATMENT", 40, 64], ["a 6 kDa linker region", "TREATMENT", 79, 100], ["the HPSE enzyme", "TEST", 104, 119]]], ["From there, HPSE can participate in a variety of roles: secretion into the exterior of a cell where it cleaves HS side chains; inside the cell, it complexes with autophagosomes and enables autophagy, binds to exosomes and induce their exit from the cell, and enters the nucleus to influence gene transcription [2] .Introduction to HPSEActive HPSE has been implicated in a variety of diseases, most notably cancer [5] .", [["cell", "ANATOMY", 89, 93], ["cell", "ANATOMY", 138, 142], ["autophagosomes", "ANATOMY", 162, 176], ["exosomes", "ANATOMY", 209, 217], ["cell", "ANATOMY", 249, 253], ["nucleus", "ANATOMY", 270, 277], ["cancer", "ANATOMY", 406, 412], ["HPSE", "CHEMICAL", 12, 16], ["HPSE", "CHEMICAL", 342, 346], ["cancer", "DISEASE", 406, 412], ["HPSE", "SIMPLE_CHEMICAL", 12, 16], ["cell", "CELL", 89, 93], ["cell", "CELL", 138, 142], ["autophagosomes", "CELLULAR_COMPONENT", 162, 176], ["exosomes", "CELL", 209, 217], ["cell", "CELL", 249, 253], ["nucleus", "CELLULAR_COMPONENT", 270, 277], ["cancer", "CANCER", 406, 412], ["HPSE", "PROTEIN", 12, 16], ["HS side chains", "PROTEIN", 111, 125], ["exosomes", "CELL_TYPE", 209, 217], ["diseases", "PROBLEM", 383, 391], ["cell", "ANATOMY", 138, 142], ["cancer", "OBSERVATION", 406, 412]]], ["Most tumors display increased levels of HPSE expression [6] .", [["tumors", "ANATOMY", 5, 11], ["tumors", "DISEASE", 5, 11], ["tumors", "CANCER", 5, 11], ["HPSE", "GENE_OR_GENE_PRODUCT", 40, 44], ["HPSE", "PROTEIN", 40, 44], ["Most tumors", "PROBLEM", 0, 11], ["increased levels of HPSE expression", "PROBLEM", 20, 55], ["tumors", "OBSERVATION", 5, 11], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["levels", "OBSERVATION_MODIFIER", 30, 36], ["HPSE expression", "OBSERVATION", 40, 55]]], ["Indeed, increasing HPSE levels have been correlated in enhanced tumor progression, size, metastasis, and angiogenesis [7] .", [["tumor", "ANATOMY", 64, 69], ["tumor", "DISEASE", 64, 69], ["HPSE", "GENE_OR_GENE_PRODUCT", 19, 23], ["tumor", "CANCER", 64, 69], ["HPSE", "PROTEIN", 19, 23], ["increasing HPSE levels", "PROBLEM", 8, 30], ["enhanced tumor progression", "PROBLEM", 55, 81], ["metastasis", "PROBLEM", 89, 99], ["angiogenesis", "PROBLEM", 105, 117], ["increasing", "OBSERVATION_MODIFIER", 8, 18], ["HPSE", "OBSERVATION", 19, 23], ["enhanced", "OBSERVATION_MODIFIER", 55, 63], ["tumor", "OBSERVATION", 64, 69], ["progression", "OBSERVATION_MODIFIER", 70, 81], ["size", "OBSERVATION_MODIFIER", 83, 87], ["metastasis", "OBSERVATION", 89, 99]]], ["Because of its role in promoting autophagy and exosome formation, HPSE has been shown to increase chemoresistance and longevity in cancer cells [8] .", [["exosome", "ANATOMY", 47, 54], ["cancer cells", "ANATOMY", 131, 143], ["HPSE", "CHEMICAL", 66, 70], ["cancer", "DISEASE", 131, 137], ["exosome", "CELLULAR_COMPONENT", 47, 54], ["HPSE", "SIMPLE_CHEMICAL", 66, 70], ["cancer cells", "CELL", 131, 143], ["HPSE", "PROTEIN", 66, 70], ["cancer cells", "CELL_TYPE", 131, 143], ["exosome formation", "PROBLEM", 47, 64], ["longevity in cancer cells", "PROBLEM", 118, 143], ["exosome formation", "OBSERVATION", 47, 64], ["increase", "OBSERVATION_MODIFIER", 89, 97], ["chemoresistance", "OBSERVATION", 98, 113]]], ["By degrading HS moieties, HPSE releases important growth factors, which were bound to HS, such as vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF).", [["HPSE", "CHEMICAL", 26, 30], ["HPSE", "CHEMICAL", 26, 30], ["HS moieties", "SIMPLE_CHEMICAL", 13, 24], ["HPSE", "SIMPLE_CHEMICAL", 26, 30], ["HS", "GENE_OR_GENE_PRODUCT", 86, 88], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 98, 132], ["VEGF", "GENE_OR_GENE_PRODUCT", 134, 138], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 144, 167], ["EGF", "GENE_OR_GENE_PRODUCT", 169, 172], ["HPSE", "PROTEIN", 26, 30], ["growth factors", "PROTEIN", 50, 64], ["vascular endothelial growth factor", "PROTEIN", 98, 132], ["VEGF", "PROTEIN", 134, 138], ["epidermal growth factor", "PROTEIN", 144, 167], ["EGF", "PROTEIN", 169, 172], ["vascular endothelial growth factor", "PROBLEM", 98, 132], ["epidermal growth factor", "PROBLEM", 144, 167], ["vascular endothelial", "ANATOMY", 98, 118]]], ["The cleavage of HSPGs also releases numerous cytokines and chemokines that can affect cellsignaling pathways and induce inflammatory responses [9] .", [["HSPGs", "GENE_OR_GENE_PRODUCT", 16, 21], ["HSPGs", "PROTEIN", 16, 21], ["cytokines", "PROTEIN", 45, 54], ["chemokines", "PROTEIN", 59, 69], ["The cleavage of HSPGs", "TREATMENT", 0, 21], ["numerous cytokines", "TREATMENT", 36, 54], ["chemokines", "TREATMENT", 59, 69], ["inflammatory responses", "PROBLEM", 120, 142]]], ["Because of the variety of roles, HPSE can play in a cell and its emerging implications in many types of viral diseases, there is a greater need to elucidate the cellular mechanisms and signaling pathways by which HPSE performs its major functions.", [["cell", "ANATOMY", 52, 56], ["cellular", "ANATOMY", 161, 169], ["viral diseases", "DISEASE", 104, 118], ["HPSE", "CHEMICAL", 213, 217], ["HPSE", "GENE_OR_GENE_PRODUCT", 33, 37], ["cell", "CELL", 52, 56], ["cellular", "CELL", 161, 169], ["HPSE", "GENE_OR_GENE_PRODUCT", 213, 217], ["HPSE", "PROTEIN", 33, 37], ["HPSE", "PROTEIN", 213, 217], ["viral diseases", "PROBLEM", 104, 118], ["viral diseases", "OBSERVATION", 104, 118]]], ["Our review of existing literature is designed to develop a more concise understanding of the signaling networks in which HPSE participates and thus, directly or indirectly, regulates viral infections.", [["viral infections", "DISEASE", 183, 199], ["HPSE", "GENE_OR_GENE_PRODUCT", 121, 125], ["HPSE", "PROTEIN", 121, 125], ["viral infections", "PROBLEM", 183, 199], ["viral infections", "OBSERVATION", 183, 199]]], ["We also highlight new therapeutic targets and approaches that have the potential to translate into new clinical breakthroughs against a variety of viral infections.Heparanase-Akt signalingAkt, also known as protein kinase B (PKB), is a serine/threonine kinase that plays a key role in cell growth, metabolism, and survival [10] .", [["cell", "ANATOMY", 285, 289], ["viral infections", "DISEASE", 147, 163], ["serine", "CHEMICAL", 236, 242], ["threonine", "CHEMICAL", 243, 252], ["Heparanase", "GENE_OR_GENE_PRODUCT", 164, 174], ["Akt", "GENE_OR_GENE_PRODUCT", 175, 178], ["Akt", "GENE_OR_GENE_PRODUCT", 188, 191], ["protein kinase B", "GENE_OR_GENE_PRODUCT", 207, 223], ["PKB", "GENE_OR_GENE_PRODUCT", 225, 228], ["serine", "AMINO_ACID", 236, 242], ["threonine", "AMINO_ACID", 243, 252], ["cell", "CELL", 285, 289], ["Heparanase", "PROTEIN", 164, 174], ["Akt", "PROTEIN", 175, 178], ["Akt", "PROTEIN", 188, 191], ["protein kinase B", "PROTEIN", 207, 223], ["PKB", "PROTEIN", 225, 228], ["serine/threonine kinase", "PROTEIN", 236, 259], ["viral infections", "PROBLEM", 147, 163], ["Heparanase", "TEST", 164, 174], ["Akt signalingAkt", "PROBLEM", 175, 191], ["protein kinase B (PKB", "TEST", 207, 228], ["a serine/threonine kinase", "TREATMENT", 234, 259], ["new", "OBSERVATION_MODIFIER", 18, 21], ["viral infections", "OBSERVATION", 147, 163]]], ["Three isoforms of Akt have been reported in the literature thus far: AKT1, AKT2, and AKT3 [11] .", [["Akt", "GENE_OR_GENE_PRODUCT", 18, 21], ["AKT1", "GENE_OR_GENE_PRODUCT", 69, 73], ["AKT2", "GENE_OR_GENE_PRODUCT", 75, 79], ["AKT3 [11]", "GENE_OR_GENE_PRODUCT", 85, 94], ["Akt", "PROTEIN", 18, 21], ["AKT1", "PROTEIN", 69, 73], ["AKT2", "PROTEIN", 75, 79], ["AKT3", "PROTEIN", 85, 89], ["Akt", "TEST", 18, 21], ["AKT1", "TEST", 69, 73], ["AKT2", "TEST", 75, 79], ["AKT3", "TEST", 85, 89]]], ["Akt has four phosphorylation sites: Ser-124, Thr-308, Thr-450, and Ser-473 [12] .", [["Ser", "CHEMICAL", 36, 39], ["Thr", "CHEMICAL", 45, 48], ["Thr", "CHEMICAL", 54, 57], ["Ser-473", "CHEMICAL", 67, 74], ["Akt", "GENE_OR_GENE_PRODUCT", 0, 3], ["Ser-124", "AMINO_ACID", 36, 43], ["Thr-308", "AMINO_ACID", 45, 52], ["Thr-450", "AMINO_ACID", 54, 61], ["Akt", "PROTEIN", 0, 3], ["phosphorylation sites", "PROTEIN", 13, 34], ["Ser", "TEST", 36, 39], ["Thr", "TEST", 45, 48], ["Thr", "TEST", 54, 57]]], ["However, phosphorylation of only two of the sites, Thr-308 and Ser-473, contributes to AKT activation [13] .", [["Ser-473", "CHEMICAL", 63, 70], ["Thr", "CHEMICAL", 51, 54], ["Ser", "CHEMICAL", 63, 66], ["Thr-308", "AMINO_ACID", 51, 58], ["Ser-473", "AMINO_ACID", 63, 70], ["AKT", "GENE_OR_GENE_PRODUCT", 87, 90], ["AKT", "PROTEIN", 87, 90], ["phosphorylation", "TEST", 9, 24], ["Thr", "TEST", 51, 54], ["Ser", "TEST", 63, 66], ["AKT activation", "PROBLEM", 87, 101], ["AKT activation", "OBSERVATION", 87, 101]]], ["Akt functions downstream of phosphoinositide 3-kinase (PI3K) [14] .", [["Akt", "GENE_OR_GENE_PRODUCT", 0, 3], ["phosphoinositide 3-kinase", "GENE_OR_GENE_PRODUCT", 28, 53], ["PI3K", "GENE_OR_GENE_PRODUCT", 55, 59], ["Akt", "PROTEIN", 0, 3], ["phosphoinositide 3-kinase", "PROTEIN", 28, 53], ["PI3K", "PROTEIN", 55, 59], ["Akt functions", "TEST", 0, 13], ["phosphoinositide", "TEST", 28, 44]]], ["Activation of a receptor tyrosine kinase (RTK) or a G-protein-coupled receptor (GPCR) can recruit and activate PI3K with the aid of the Ras family of GTPases [15] .", [["tyrosine", "CHEMICAL", 25, 33], ["tyrosine", "CHEMICAL", 25, 33], ["receptor tyrosine kinase", "GENE_OR_GENE_PRODUCT", 16, 40], ["RTK", "GENE_OR_GENE_PRODUCT", 42, 45], ["G-protein-coupled receptor", "GENE_OR_GENE_PRODUCT", 52, 78], ["GPCR", "GENE_OR_GENE_PRODUCT", 80, 84], ["PI3K", "GENE_OR_GENE_PRODUCT", 111, 115], ["Ras", "GENE_OR_GENE_PRODUCT", 136, 139], ["GTPases", "GENE_OR_GENE_PRODUCT", 150, 157], ["receptor tyrosine kinase", "PROTEIN", 16, 40], ["RTK", "PROTEIN", 42, 45], ["G-protein-coupled receptor", "PROTEIN", 52, 78], ["GPCR", "PROTEIN", 80, 84], ["PI3K", "PROTEIN", 111, 115], ["Ras family", "PROTEIN", 136, 146], ["GTPases", "PROTEIN", 150, 157], ["a receptor tyrosine kinase", "TREATMENT", 14, 40], ["a G-protein-coupled receptor (GPCR", "TREATMENT", 50, 84]]], ["The activation of PI3K converts phosphatidylinositol-4,5-biphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3) which is required for the translocation of inactive Akt to the plasma membrane [16] .", [["plasma membrane", "ANATOMY", 189, 204], ["phosphatidylinositol-4,5-biphosphate", "CHEMICAL", 32, 68], ["PIP2", "CHEMICAL", 70, 74], ["phosphatidylinositol-3,4,5-triphosphate", "CHEMICAL", 79, 118], ["phosphatidylinositol-4,5-biphosphate", "CHEMICAL", 32, 68], ["PIP2", "CHEMICAL", 70, 74], ["phosphatidylinositol-3,4,5-triphosphate", "CHEMICAL", 79, 118], ["PIP3", "CHEMICAL", 120, 124], ["PI3K", "GENE_OR_GENE_PRODUCT", 18, 22], ["phosphatidylinositol-4,5-biphosphate", "SIMPLE_CHEMICAL", 32, 68], ["PIP2", "SIMPLE_CHEMICAL", 70, 74], ["phosphatidylinositol-3,4,5-triphosphate", "SIMPLE_CHEMICAL", 79, 118], ["PIP3", "SIMPLE_CHEMICAL", 120, 124], ["Akt", "GENE_OR_GENE_PRODUCT", 178, 181], ["plasma membrane", "CELLULAR_COMPONENT", 189, 204], ["PI3K", "PROTEIN", 18, 22], ["PIP3", "PROTEIN", 120, 124], ["inactive Akt", "PROTEIN", 169, 181], ["phosphatidylinositol", "TEST", 32, 52], ["biphosphate (PIP2", "TREATMENT", 57, 74], ["phosphatidylinositol", "TEST", 79, 99], ["triphosphate (PIP3)", "TREATMENT", 106, 125]]], ["Phosphoinositide-dependent protein kinase 1 (PDK1) will then bind to the Akt-PIP3 complex and phosphorylate Akt at the Thr-308 position, thereby activating it [17] .", [["Phosphoinositide", "CHEMICAL", 0, 16], ["Phosphoinositide", "CHEMICAL", 0, 16], ["Thr", "CHEMICAL", 119, 122], ["Phosphoinositide-dependent protein kinase 1", "GENE_OR_GENE_PRODUCT", 0, 43], ["PDK1", "GENE_OR_GENE_PRODUCT", 45, 49], ["Akt", "GENE_OR_GENE_PRODUCT", 73, 76], ["PIP3", "GENE_OR_GENE_PRODUCT", 77, 81], ["Akt", "GENE_OR_GENE_PRODUCT", 108, 111], ["Thr-308", "AMINO_ACID", 119, 126], ["position", "AMINO_ACID", 127, 135], ["Phosphoinositide-dependent protein kinase 1", "PROTEIN", 0, 43], ["PDK1", "PROTEIN", 45, 49], ["Akt", "PROTEIN", 73, 76], ["PIP3 complex", "PROTEIN", 77, 89], ["Akt", "PROTEIN", 108, 111], ["Thr-308 position", "PROTEIN", 119, 135], ["Phosphoinositide-dependent protein kinase", "TEST", 0, 41], ["PDK1", "TEST", 45, 49], ["the Akt", "TEST", 69, 76], ["PIP3 complex", "TREATMENT", 77, 89], ["phosphorylate Akt", "TREATMENT", 94, 111]]], ["Mammalian target of rapamycin complex 2 (mTORC2) can then phosphorylate Akt at Ser-473 which is required for its maximal activation [18] .", [["rapamycin", "CHEMICAL", 20, 29], ["Ser-473", "CHEMICAL", 79, 86], ["rapamycin", "CHEMICAL", 20, 29], ["Ser", "CHEMICAL", 79, 82], ["Mammalian target of rapamycin complex 2", "GENE_OR_GENE_PRODUCT", 0, 39], ["mTORC2", "GENE_OR_GENE_PRODUCT", 41, 47], ["Akt", "GENE_OR_GENE_PRODUCT", 72, 75], ["Ser-473", "AMINO_ACID", 79, 86], ["Mammalian target of rapamycin complex 2", "PROTEIN", 0, 39], ["mTORC2", "PROTEIN", 41, 47], ["Akt", "PROTEIN", 72, 75], ["rapamycin complex 2 (mTORC2)", "TREATMENT", 20, 48]]], ["Akt phosphorylates over 100 different proteins, which can (1) activate them, stimulating growth and survival responses or (2) inactivate them, preventing them from stimulating apoptotic responses [19] .", [["Akt", "GENE_OR_GENE_PRODUCT", 0, 3], ["Akt", "PROTEIN", 0, 3], ["Akt phosphorylates", "TEST", 0, 18]]], ["For example, phosphorylation of FOXO and GSK3 proteins by Akt inhibits them, which promotes cell survival, proliferation, and metabolism [20] .", [["cell", "ANATOMY", 92, 96], ["FOXO", "GENE_OR_GENE_PRODUCT", 32, 36], ["GSK3", "GENE_OR_GENE_PRODUCT", 41, 45], ["Akt", "GENE_OR_GENE_PRODUCT", 58, 61], ["cell", "CELL", 92, 96], ["FOXO", "PROTEIN", 32, 36], ["GSK3 proteins", "PROTEIN", 41, 54], ["Akt", "PROTEIN", 58, 61], ["phosphorylation of FOXO and GSK3 proteins", "PROBLEM", 13, 54], ["cell survival", "OBSERVATION", 92, 105]]], ["Phosphorylation of TSC2 by Akt allows the downstream mTORC1 to become activated and initiate metabolism and growth [21] .", [["TSC2", "GENE_OR_GENE_PRODUCT", 19, 23], ["Akt", "GENE_OR_GENE_PRODUCT", 27, 30], ["mTORC1", "GENE_OR_GENE_PRODUCT", 53, 59], ["TSC2", "PROTEIN", 19, 23], ["Akt", "PROTEIN", 27, 30], ["mTORC1", "PROTEIN", 53, 59], ["Phosphorylation of TSC2", "TREATMENT", 0, 23], ["the downstream mTORC1", "TREATMENT", 38, 59]]], ["Other targets of Akt include transcription factors, cell cycle regulators, metabolic enzymes, and regulators of protein and vesicle trafficking [20] .Heparanase-Akt signalingTermination of this pathway can be achieved by multiple kinds of phosphatases.", [["cell", "ANATOMY", 52, 56], ["vesicle", "ANATOMY", 124, 131], ["Akt", "GENE_OR_GENE_PRODUCT", 17, 20], ["cell", "CELL", 52, 56], ["vesicle", "CELLULAR_COMPONENT", 124, 131], ["Heparanase", "GENE_OR_GENE_PRODUCT", 150, 160], ["Akt", "GENE_OR_GENE_PRODUCT", 161, 164], ["Akt", "PROTEIN", 17, 20], ["transcription factors", "PROTEIN", 29, 50], ["cell cycle regulators", "PROTEIN", 52, 73], ["metabolic enzymes", "PROTEIN", 75, 92], ["Heparanase", "PROTEIN", 150, 160], ["Akt", "PROTEIN", 161, 164], ["phosphatases", "PROTEIN", 239, 251], ["transcription factors", "PROBLEM", 29, 50], ["cell cycle regulators", "TEST", 52, 73], ["metabolic enzymes", "TEST", 75, 92], ["vesicle trafficking", "TEST", 124, 143], ["Heparanase", "TREATMENT", 150, 160], ["phosphatases", "TEST", 239, 251]]], ["The first uses the protein phosphatase and tensin homolog (PTEN) to dephosphorylate PIP3 back to PIP2, preventing Akt from being recruited to the plasma membrane [22] .", [["plasma membrane", "ANATOMY", 146, 161], ["phosphatase and tensin homolog", "GENE_OR_GENE_PRODUCT", 27, 57], ["PTEN", "GENE_OR_GENE_PRODUCT", 59, 63], ["PIP3", "GENE_OR_GENE_PRODUCT", 84, 88], ["PIP2", "GENE_OR_GENE_PRODUCT", 97, 101], ["Akt", "GENE_OR_GENE_PRODUCT", 114, 117], ["plasma membrane", "CELLULAR_COMPONENT", 146, 161], ["protein phosphatase and tensin homolog", "PROTEIN", 19, 57], ["PTEN", "PROTEIN", 59, 63], ["PIP3", "PROTEIN", 84, 88], ["PIP2", "PROTEIN", 97, 101], ["Akt", "PROTEIN", 114, 117], ["the protein phosphatase", "TREATMENT", 15, 38], ["tensin homolog (PTEN)", "TREATMENT", 43, 64], ["dephosphorylate PIP3", "TREATMENT", 68, 88], ["PIP2", "TREATMENT", 97, 101], ["Akt", "PROBLEM", 114, 117]]], ["The second method uses protein phosphatase 2A (PP2A) and PH domain leucine-rich repeat protein phosphatases (PHLPPs) to dephosphorylate Akt at the Thr-308 and Ser-473 positions, respectively [23] .Heparanase-Akt signalingCellular apoptosis is one method by which organisms fend off viral infections.", [["Cellular", "ANATOMY", 221, 229], ["leucine", "CHEMICAL", 67, 74], ["viral infections", "DISEASE", 282, 298], ["leucine", "CHEMICAL", 67, 74], ["Thr", "CHEMICAL", 147, 150], ["Ser", "CHEMICAL", 159, 162], ["protein phosphatase 2A", "GENE_OR_GENE_PRODUCT", 23, 45], ["PP2A", "GENE_OR_GENE_PRODUCT", 47, 51], ["PH domain leucine-rich repeat protein phosphatases", "GENE_OR_GENE_PRODUCT", 57, 107], ["PHLPPs", "GENE_OR_GENE_PRODUCT", 109, 115], ["Akt", "GENE_OR_GENE_PRODUCT", 136, 139], ["Thr-308", "AMINO_ACID", 147, 154], ["Ser-473", "AMINO_ACID", 159, 166], ["positions", "AMINO_ACID", 167, 176], ["Heparanase", "GENE_OR_GENE_PRODUCT", 197, 207], ["Akt", "GENE_OR_GENE_PRODUCT", 208, 211], ["protein phosphatase 2A", "PROTEIN", 23, 45], ["PP2A", "PROTEIN", 47, 51], ["PH domain leucine-rich repeat protein phosphatases", "PROTEIN", 57, 107], ["PHLPPs", "PROTEIN", 109, 115], ["Akt", "PROTEIN", 136, 139], ["Heparanase", "PROTEIN", 197, 207], ["Akt", "PROTEIN", 208, 211], ["protein phosphatase", "TEST", 23, 42], ["PP2A", "TEST", 47, 51], ["PH domain leucine", "TEST", 57, 74], ["protein phosphatases", "TEST", 87, 107], ["PHLPPs", "TEST", 109, 115], ["dephosphorylate Akt", "TEST", 120, 139], ["the Thr", "TEST", 143, 150], ["Heparanase", "TEST", 197, 207], ["Cellular apoptosis", "PROBLEM", 221, 239], ["viral infections", "PROBLEM", 282, 298], ["Cellular apoptosis", "OBSERVATION", 221, 239], ["viral infections", "OBSERVATION", 282, 298]]], ["Induction of apoptosis reduces the amount of replication which a virus can achieve in a host cell, choking off the supply of viral progeny [24] .", [["cell", "ANATOMY", 93, 97], ["host cell", "CELL", 88, 97], ["apoptosis", "PROBLEM", 13, 22], ["replication", "TREATMENT", 45, 56], ["a virus", "PROBLEM", 63, 70], ["apoptosis", "OBSERVATION", 13, 22], ["amount", "OBSERVATION_MODIFIER", 35, 41], ["host cell", "OBSERVATION", 88, 97]]], ["It is, therefore, in the interest of a virus to prolong the survival of the host cell.", [["cell", "ANATOMY", 81, 85], ["host cell", "CELL", 76, 85], ["a virus", "PROBLEM", 37, 44], ["virus", "OBSERVATION", 39, 44], ["host cell", "OBSERVATION", 76, 85]]], ["Accordingly, multiple types of viruses have been shown to stimulate Akt phosphorylation, including adenoviruses, poxviruses, HIV, papilloma viruses, herpesviruses, and influenza A [24] [25] [26] [27] .", [["HIV, papilloma viruses", "DISEASE", 125, 147], ["influenza", "DISEASE", 168, 177], ["Akt", "GENE_OR_GENE_PRODUCT", 68, 71], ["adenoviruses", "ORGANISM", 99, 111], ["HIV, papilloma viruses", "ORGANISM", 125, 147], ["herpesviruses", "ORGANISM", 149, 162], ["24] [25] [26] [27]", "SIMPLE_CHEMICAL", 181, 199], ["Akt", "PROTEIN", 68, 71], ["HIV", "SPECIES", 125, 128], ["HIV", "SPECIES", 125, 128], ["multiple types of viruses", "PROBLEM", 13, 38], ["Akt phosphorylation", "PROBLEM", 68, 87], ["adenoviruses", "PROBLEM", 99, 111], ["poxviruses", "PROBLEM", 113, 123], ["HIV", "PROBLEM", 125, 128], ["papilloma viruses", "PROBLEM", 130, 147], ["herpesviruses", "PROBLEM", 149, 162], ["influenza A", "PROBLEM", 168, 179], ["viruses", "OBSERVATION", 31, 38], ["papilloma viruses", "OBSERVATION", 130, 147]]], ["There appears to be a trend of mammalian DNA viruses utilizing the Akt pathway for their own benefit, leveraging its role as a master regulator of signaling [21] .", [["DNA", "CELLULAR_COMPONENT", 41, 44], ["Akt", "GENE_OR_GENE_PRODUCT", 67, 70], ["Akt", "PROTEIN", 67, 70], ["mammalian DNA viruses", "TREATMENT", 31, 52], ["the Akt pathway", "TREATMENT", 63, 78], ["appears to be", "UNCERTAINTY", 6, 19]]], ["For example, in the herpesvirus family, human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and Kaposi's sarcoma-associated herpesvirus (KSHV) each encode a unique protein that activates Akt [28, 29] .", [["human cytomegalovirus (HCMV)", "DISEASE", 40, 68], ["Epstein-Barr virus (EBV)", "DISEASE", 70, 94], ["Kaposi's sarcoma-associated herpesvirus", "DISEASE", 100, 139], ["herpesvirus", "ORGANISM", 20, 31], ["human cytomegalovirus", "ORGANISM", 40, 61], ["HCMV", "ORGANISM", 63, 67], ["Epstein-Barr virus", "ORGANISM", 70, 88], ["EBV", "ORGANISM", 90, 93], ["Kaposi's sarcoma-associated herpesvirus", "ORGANISM", 100, 139], ["KSHV", "ORGANISM", 141, 145], ["Akt", "GENE_OR_GENE_PRODUCT", 191, 194], ["Akt", "PROTEIN", 191, 194], ["human", "SPECIES", 40, 45], ["Barr virus", "SPECIES", 78, 88], ["Kaposi's sarcoma-associated herpesvirus", "SPECIES", 100, 139], ["human cytomegalovirus", "SPECIES", 40, 61], ["HCMV", "SPECIES", 63, 67], ["Epstein-Barr virus", "SPECIES", 70, 88], ["EBV", "SPECIES", 90, 93], ["Kaposi's sarcoma-associated herpesvirus", "SPECIES", 100, 139], ["KSHV", "SPECIES", 141, 145], ["human cytomegalovirus (HCMV", "PROBLEM", 40, 67], ["Epstein-Barr virus (EBV", "PROBLEM", 70, 93], ["Kaposi's sarcoma", "PROBLEM", 100, 116], ["associated herpesvirus", "PROBLEM", 117, 139], ["Akt", "TEST", 191, 194], ["Kaposi", "ANATOMY", 100, 106], ["sarcoma", "OBSERVATION", 109, 116]]], ["Activation of Akt signaling allows an infected cell with a latent virus to avoid apoptosis, immortalizing the cell in certain cases [30] .", [["cell", "ANATOMY", 47, 51], ["cell", "ANATOMY", 110, 114], ["Akt", "GENE_OR_GENE_PRODUCT", 14, 17], ["cell", "CELL", 47, 51], ["cell", "CELL", 110, 114], ["Akt", "PROTEIN", 14, 17], ["Akt signaling", "PROBLEM", 14, 27], ["an infected cell", "PROBLEM", 35, 51], ["a latent virus", "PROBLEM", 57, 71], ["apoptosis", "PROBLEM", 81, 90], ["infected cell", "OBSERVATION", 38, 51]]], ["Herpes simplex virus type 1 (HSV-1) activates Akt initially and later encodes for an Akt mimetic protein with its US3 gene [31] .", [["Herpes simplex virus", "DISEASE", 0, 20], ["Herpes simplex virus type 1", "ORGANISM", 0, 27], ["HSV-1", "ORGANISM", 29, 34], ["Akt", "GENE_OR_GENE_PRODUCT", 46, 49], ["Akt", "GENE_OR_GENE_PRODUCT", 85, 88], ["US3", "GENE_OR_GENE_PRODUCT", 114, 117], ["Akt", "PROTEIN", 46, 49], ["Akt mimetic protein", "PROTEIN", 85, 104], ["US3 gene", "DNA", 114, 122], ["Herpes simplex virus type 1", "SPECIES", 0, 27], ["HSV-1", "SPECIES", 29, 34], ["Herpes simplex virus type 1", "SPECIES", 0, 27], ["HSV-1", "SPECIES", 29, 34], ["Herpes simplex virus type", "TEST", 0, 25], ["HSV", "TEST", 29, 32], ["an Akt mimetic protein", "TREATMENT", 82, 104], ["simplex virus", "OBSERVATION", 7, 20]]], ["The mimetic protein was able to phosphorylate many of the same substrates as Akt, including tuberous sclerosis complex 2 (TSC2), FOXO1, and GSK3 [32] .", [["tuberous sclerosis", "DISEASE", 92, 110], ["Akt", "GENE_OR_GENE_PRODUCT", 77, 80], ["tuberous sclerosis complex 2", "GENE_OR_GENE_PRODUCT", 92, 120], ["TSC2", "GENE_OR_GENE_PRODUCT", 122, 126], ["FOXO1", "GENE_OR_GENE_PRODUCT", 129, 134], ["GSK3", "GENE_OR_GENE_PRODUCT", 140, 144], ["Akt", "PROTEIN", 77, 80], ["tuberous sclerosis complex 2", "PROTEIN", 92, 120], ["TSC2", "PROTEIN", 122, 126], ["FOXO1", "PROTEIN", 129, 134], ["GSK3", "PROTEIN", 140, 144], ["The mimetic protein", "TREATMENT", 0, 19], ["tuberous sclerosis complex", "PROBLEM", 92, 118], ["tuberous", "OBSERVATION_MODIFIER", 92, 100], ["sclerosis", "OBSERVATION", 101, 110]]], ["In addition, the HSV-1 immediate-early protein ICP0 stimulates the formation of the EIF4F complex, which is downstream of Akt and necessary for the onset of translation [21] .", [["HSV-1", "ORGANISM", 17, 22], ["ICP0", "GENE_OR_GENE_PRODUCT", 47, 51], ["EIF4F", "GENE_OR_GENE_PRODUCT", 84, 89], ["Akt", "GENE_OR_GENE_PRODUCT", 122, 125], ["HSV-1 immediate-early protein", "PROTEIN", 17, 46], ["ICP0", "PROTEIN", 47, 51], ["EIF4F complex", "PROTEIN", 84, 97], ["Akt", "PROTEIN", 122, 125], ["HSV-1", "SPECIES", 17, 22], ["the HSV", "TEST", 13, 20], ["early protein ICP0", "TREATMENT", 33, 51], ["EIF4F complex", "OBSERVATION_MODIFIER", 84, 97]]], ["Thus, even if the host cell successfully inhibits the PI3K-Akt axis, HSV-1 can still translate proteins necessary for its survival.", [["cell", "ANATOMY", 23, 27], ["host cell", "CELL", 18, 27], ["PI3K", "GENE_OR_GENE_PRODUCT", 54, 58], ["Akt", "GENE_OR_GENE_PRODUCT", 59, 62], ["HSV-1", "ORGANISM", 69, 74], ["PI3K", "PROTEIN", 54, 58], ["Akt", "PROTEIN", 59, 62], ["HSV-1", "SPECIES", 69, 74], ["the PI3K", "TEST", 50, 58], ["HSV", "TEST", 69, 72]]], ["However, the inhibition of Akt results in a reduction of viral load in certain viruses, highlighting the importance of the pathway in a productive infection [25] .", [["infection", "DISEASE", 147, 156], ["Akt", "GENE_OR_GENE_PRODUCT", 27, 30], ["Akt", "PROTEIN", 27, 30], ["viral load in certain viruses", "PROBLEM", 57, 86], ["a productive infection", "PROBLEM", 134, 156], ["viral load", "OBSERVATION", 57, 67], ["productive", "OBSERVATION_MODIFIER", 136, 146], ["infection", "OBSERVATION", 147, 156]]], ["Viruses have been shown to modify the PI3K pathway at nearly every point from PI3K to eukaryotic initiation factor 4F (EIF4F) [21] .", [["PI3K", "GENE_OR_GENE_PRODUCT", 38, 42], ["PI3K", "GENE_OR_GENE_PRODUCT", 78, 82], ["eukaryotic initiation factor 4F", "GENE_OR_GENE_PRODUCT", 86, 117], ["EIF4F", "GENE_OR_GENE_PRODUCT", 119, 124], ["PI3K", "PROTEIN", 38, 42], ["PI3K", "PROTEIN", 78, 82], ["eukaryotic initiation factor 4F", "PROTEIN", 86, 117], ["EIF4F", "PROTEIN", 119, 124], ["Viruses", "PROBLEM", 0, 7]]], ["Although many DNA viruses activate Akt during their life cycles, some RNA viruses benefit from Akt downregulation.", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["Akt", "GENE_OR_GENE_PRODUCT", 35, 38], ["Akt", "GENE_OR_GENE_PRODUCT", 95, 98], ["Akt", "PROTEIN", 35, 38], ["Akt", "PROTEIN", 95, 98], ["many DNA viruses activate", "PROBLEM", 9, 34], ["Akt", "PROBLEM", 35, 38], ["their life cycles", "TREATMENT", 46, 63], ["some RNA viruses", "PROBLEM", 65, 81], ["Akt downregulation", "TREATMENT", 95, 113], ["viruses", "OBSERVATION", 18, 25], ["Akt downregulation", "OBSERVATION", 95, 113]]], ["For example, the membrane protein of the severe acute respiratory syndrome coronavirus (SARS-CoV) inhibits Akt activation, which causes cytopathic effects in infected cells [33, 34] .Heparanase-Akt signalingMany viruses have been shown to up-regulate and exploit host HPSE during infection [9] .", [["membrane", "ANATOMY", 17, 25], ["cells", "ANATOMY", 167, 172], ["acute respiratory syndrome coronavirus", "DISEASE", 48, 86], ["SARS", "DISEASE", 88, 92], ["infection", "DISEASE", 280, 289], ["membrane", "CELLULAR_COMPONENT", 17, 25], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 41, 86], ["SARS-CoV", "ORGANISM", 88, 96], ["Akt", "GENE_OR_GENE_PRODUCT", 107, 110], ["cells", "CELL", 167, 172], ["Heparanase", "GENE_OR_GENE_PRODUCT", 183, 193], ["Akt", "GENE_OR_GENE_PRODUCT", 194, 197], ["HPSE", "GENE_OR_GENE_PRODUCT", 268, 272], ["membrane protein", "PROTEIN", 17, 33], ["Akt", "PROTEIN", 107, 110], ["infected cells", "CELL_TYPE", 158, 172], ["Heparanase", "PROTEIN", 183, 193], ["Akt", "PROTEIN", 194, 197], ["severe acute respiratory syndrome coronavirus", "SPECIES", 41, 86], ["SARS-CoV", "SPECIES", 88, 96], ["the membrane protein", "TEST", 13, 33], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 37, 86], ["Akt activation", "PROBLEM", 107, 121], ["cytopathic effects in infected cells", "PROBLEM", 136, 172], ["Heparanase", "TREATMENT", 183, 193], ["Akt signaling", "PROBLEM", 194, 207], ["Many viruses", "PROBLEM", 207, 219], ["host HPSE during infection", "PROBLEM", 263, 289], ["membrane protein", "OBSERVATION", 17, 33], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["respiratory syndrome coronavirus", "OBSERVATION", 54, 86], ["cytopathic", "OBSERVATION_MODIFIER", 136, 146], ["infected cells", "OBSERVATION", 158, 172], ["infection", "OBSERVATION", 280, 289]]], ["One method by which HPSE may aid them is the stimulation of Akt signaling.", [["HPSE", "CHEMICAL", 20, 24], ["HPSE", "SIMPLE_CHEMICAL", 20, 24], ["Akt", "GENE_OR_GENE_PRODUCT", 60, 63], ["Akt", "PROTEIN", 60, 63]]], ["HPSE has been shown to induce Akt phosphorylation in fibroblasts, endothelial cells, macrophages, and numerous tumor-derived cell lines [14, [35] [36] [37] [38] .", [["fibroblasts", "ANATOMY", 53, 64], ["endothelial cells", "ANATOMY", 66, 83], ["macrophages", "ANATOMY", 85, 96], ["tumor-derived cell lines", "ANATOMY", 111, 135], ["HPSE", "CHEMICAL", 0, 4], ["tumor", "DISEASE", 111, 116], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["Akt", "GENE_OR_GENE_PRODUCT", 30, 33], ["fibroblasts", "CELL", 53, 64], ["endothelial cells", "CELL", 66, 83], ["macrophages", "CELL", 85, 96], ["tumor-derived cell lines", "CELL", 111, 135], ["HPSE", "PROTEIN", 0, 4], ["Akt", "PROTEIN", 30, 33], ["fibroblasts", "CELL_TYPE", 53, 64], ["endothelial cells", "CELL_TYPE", 66, 83], ["macrophages", "CELL_TYPE", 85, 96], ["tumor-derived cell lines", "CELL_LINE", 111, 135], ["Akt phosphorylation in fibroblasts", "PROBLEM", 30, 64], ["endothelial cells", "TEST", 66, 83], ["macrophages", "TEST", 85, 96], ["numerous tumor", "PROBLEM", 102, 116], ["cell lines", "TEST", 125, 135], ["endothelial cells", "OBSERVATION", 66, 83], ["macrophages", "ANATOMY", 85, 96], ["numerous", "OBSERVATION_MODIFIER", 102, 110], ["tumor", "OBSERVATION", 111, 116], ["cell lines", "OBSERVATION", 125, 135]]], ["In addition, HPSE and Akt activation have been correlated in glioma cells, T cells, and lymphoma cells [2, 39] .", [["glioma cells", "ANATOMY", 61, 73], ["T cells", "ANATOMY", 75, 82], ["lymphoma cells", "ANATOMY", 88, 102], ["glioma", "DISEASE", 61, 67], ["lymphoma", "DISEASE", 88, 96], ["HPSE", "GENE_OR_GENE_PRODUCT", 13, 17], ["Akt", "GENE_OR_GENE_PRODUCT", 22, 25], ["glioma cells", "CELL", 61, 73], ["T cells", "CELL", 75, 82], ["lymphoma cells", "CELL", 88, 102], ["HPSE", "PROTEIN", 13, 17], ["Akt", "PROTEIN", 22, 25], ["glioma cells", "CELL_TYPE", 61, 73], ["T cells", "CELL_TYPE", 75, 82], ["lymphoma cells", "CELL_TYPE", 88, 102], ["Akt activation", "PROBLEM", 22, 36], ["glioma cells", "PROBLEM", 61, 73], ["T cells", "PROBLEM", 75, 82], ["lymphoma cells", "PROBLEM", 88, 102], ["glioma cells", "OBSERVATION", 61, 73], ["lymphoma cells", "OBSERVATION", 88, 102]]], ["However, in one study, the addition of HPSE alone to macrophages was unable to stimulate Akt phosphorylation [40] .", [["macrophages", "ANATOMY", 53, 64], ["HPSE", "CHEMICAL", 39, 43], ["HPSE", "CHEMICAL", 39, 43], ["HPSE", "SIMPLE_CHEMICAL", 39, 43], ["macrophages", "CELL", 53, 64], ["Akt", "GENE_OR_GENE_PRODUCT", 89, 92], ["macrophages", "CELL_TYPE", 53, 64], ["Akt", "PROTEIN", 89, 92], ["one study", "TEST", 12, 21], ["Akt phosphorylation", "TEST", 89, 108]]], ["The mechanism by which HPSE increases Akt phosphorylation levels is still under investigation, but it has been shown to be independent of mannose 6-phosphate receptor (MPR), low-density lipoprotein-receptor-related protein (LRP), heparan sulfate proteoglycans (HSPGs), and even HPSE enzymatic activity [14, 35] .", [["HPSE", "CHEMICAL", 23, 27], ["mannose 6-phosphate", "CHEMICAL", 138, 157], ["heparan sulfate", "CHEMICAL", 230, 245], ["HPSE", "CHEMICAL", 23, 27], ["mannose 6-phosphate", "CHEMICAL", 138, 157], ["HPSE", "SIMPLE_CHEMICAL", 23, 27], ["Akt", "GENE_OR_GENE_PRODUCT", 38, 41], ["mannose 6-phosphate receptor", "GENE_OR_GENE_PRODUCT", 138, 166], ["MPR", "GENE_OR_GENE_PRODUCT", 168, 171], ["low-density lipoprotein-receptor-related protein", "GENE_OR_GENE_PRODUCT", 174, 222], ["LRP", "GENE_OR_GENE_PRODUCT", 224, 227], ["heparan sulfate proteoglycans", "GENE_OR_GENE_PRODUCT", 230, 259], ["HSPGs", "GENE_OR_GENE_PRODUCT", 261, 266], ["HPSE", "SIMPLE_CHEMICAL", 278, 282], ["Akt", "PROTEIN", 38, 41], ["mannose 6-phosphate receptor", "PROTEIN", 138, 166], ["MPR", "PROTEIN", 168, 171], ["low-density lipoprotein-receptor-related protein", "PROTEIN", 174, 222], ["LRP", "PROTEIN", 224, 227], ["heparan sulfate proteoglycans", "PROTEIN", 230, 259], ["HSPGs", "PROTEIN", 261, 266], ["Akt phosphorylation levels", "TEST", 38, 64], ["mannose", "TEST", 138, 145], ["MPR", "TEST", 168, 171], ["protein (LRP", "TREATMENT", 215, 227], ["heparan sulfate proteoglycans", "TREATMENT", 230, 259]]], ["Non-enzymatic activity is likely localized to the C-terminal domain of the HPSE protein [41] .", [["C", "CHEMICAL", 50, 51], ["HPSE", "GENE_OR_GENE_PRODUCT", 75, 79], ["C-terminal domain", "PROTEIN", 50, 67], ["HPSE protein", "PROTEIN", 75, 87], ["Non-enzymatic activity", "PROBLEM", 0, 22], ["activity", "OBSERVATION", 14, 22]]], ["However, it appears to be mediated in part by lipid rafts: changes in lipid raft structure via lovastatin or methyl-beta-cyclodextrin (M\u03b2CD) have been shown to abrogate Akt phosphorylation despite the addition of HPSE in fibroblasts [35] .", [["lipid rafts", "ANATOMY", 46, 57], ["lipid raft", "ANATOMY", 70, 80], ["fibroblasts", "ANATOMY", 221, 232], ["lovastatin", "CHEMICAL", 95, 105], ["methyl-beta-cyclodextrin", "CHEMICAL", 109, 133], ["M\u03b2CD", "CHEMICAL", 135, 139], ["lovastatin", "CHEMICAL", 95, 105], ["methyl-beta-cyclodextrin", "CHEMICAL", 109, 133], ["M\u03b2CD", "CHEMICAL", 135, 139], ["lipid rafts", "CELLULAR_COMPONENT", 46, 57], ["lipid raft", "CELLULAR_COMPONENT", 70, 80], ["lovastatin", "SIMPLE_CHEMICAL", 95, 105], ["methyl-beta-cyclodextrin", "SIMPLE_CHEMICAL", 109, 133], ["M\u03b2CD", "SIMPLE_CHEMICAL", 135, 139], ["Akt", "GENE_OR_GENE_PRODUCT", 169, 172], ["HPSE", "SIMPLE_CHEMICAL", 213, 217], ["fibroblasts", "CELL", 221, 232], ["Akt", "PROTEIN", 169, 172], ["HPSE", "PROTEIN", 213, 217], ["fibroblasts", "CELL_TYPE", 221, 232], ["lipid raft structure", "TREATMENT", 70, 90], ["lovastatin", "TREATMENT", 95, 105], ["methyl-beta-cyclodextrin (M\u03b2CD", "TREATMENT", 109, 139], ["Akt phosphorylation", "TREATMENT", 169, 188], ["HPSE in fibroblasts", "TREATMENT", 213, 232], ["lipid rafts", "OBSERVATION", 46, 57], ["lipid raft", "OBSERVATION", 70, 80]]], ["In addition, the effects of HPSE on Akt phosphorylation were enhanced following the addition of heparin or heparan sulfate to the medium [14] .", [["HPSE", "CHEMICAL", 28, 32], ["heparin", "CHEMICAL", 96, 103], ["heparan sulfate", "CHEMICAL", 107, 122], ["HPSE", "CHEMICAL", 28, 32], ["HPSE", "SIMPLE_CHEMICAL", 28, 32], ["Akt", "GENE_OR_GENE_PRODUCT", 36, 39], ["heparin", "SIMPLE_CHEMICAL", 96, 103], ["heparan sulfate", "SIMPLE_CHEMICAL", 107, 122], ["Akt", "PROTEIN", 36, 39], ["Akt phosphorylation", "TREATMENT", 36, 55], ["heparin", "TREATMENT", 96, 103], ["heparan sulfate", "TREATMENT", 107, 122]]], ["HPSE was shown to mediate Akt phosphorylation at the Ser473 residue in anmTORC2-dependent manner as an siRNA targeting RICTOR, a subunit of mTORC2, diminished phospho-Akt levels [36] .Heparanase-Akt signalingTwo studies demonstrated that PI3K is necessary for HPSE-induced Akt activation [14, 36] .", [["HPSE", "CHEMICAL", 260, 264], ["Ser473", "CHEMICAL", 53, 59], ["phospho", "CHEMICAL", 159, 166], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["Akt", "GENE_OR_GENE_PRODUCT", 26, 29], ["Ser473", "AMINO_ACID", 53, 59], ["anmTORC2", "SIMPLE_CHEMICAL", 71, 79], ["RICTOR", "GENE_OR_GENE_PRODUCT", 119, 125], ["mTORC2", "GENE_OR_GENE_PRODUCT", 140, 146], ["phospho-Akt", "GENE_OR_GENE_PRODUCT", 159, 170], ["Heparanase", "GENE_OR_GENE_PRODUCT", 184, 194], ["Akt", "GENE_OR_GENE_PRODUCT", 195, 198], ["PI3K", "GENE_OR_GENE_PRODUCT", 238, 242], ["HPSE", "SIMPLE_CHEMICAL", 260, 264], ["Akt", "GENE_OR_GENE_PRODUCT", 273, 276], ["HPSE", "PROTEIN", 0, 4], ["Akt", "PROTEIN", 26, 29], ["Ser473 residue", "PROTEIN", 53, 67], ["anmTORC2", "PROTEIN", 71, 79], ["RICTOR", "PROTEIN", 119, 125], ["mTORC2", "PROTEIN", 140, 146], ["phospho", "PROTEIN", 159, 166], ["Akt", "PROTEIN", 167, 170], ["Heparanase", "PROTEIN", 184, 194], ["Akt", "PROTEIN", 195, 198], ["PI3K", "PROTEIN", 238, 242], ["HPSE", "PROTEIN", 260, 264], ["Akt", "PROTEIN", 273, 276], ["Akt phosphorylation", "PROBLEM", 26, 45], ["diminished phospho", "TEST", 148, 166], ["Akt levels", "TEST", 167, 177], ["Heparanase", "TEST", 184, 194], ["Two studies", "TEST", 208, 219], ["PI3K", "TEST", 238, 242], ["HPSE", "TEST", 260, 264], ["Akt activation", "TEST", 273, 287]]], ["HPSE-induced Akt phosphorylation did require the presence of the subunit p110\u03b1 of PI3K, the integrins \u03b1V\u03b23 or \u03b15\u03b21, and one of the tyrosine kinases FAK or PYK2 [36] .", [["HPSE", "CHEMICAL", 0, 4], ["tyrosine", "CHEMICAL", 131, 139], ["tyrosine", "CHEMICAL", 131, 139], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["Akt", "GENE_OR_GENE_PRODUCT", 13, 16], ["PI3K", "GENE_OR_GENE_PRODUCT", 82, 86], ["integrins \u03b1V\u03b23", "GENE_OR_GENE_PRODUCT", 92, 106], ["\u03b15\u03b21", "GENE_OR_GENE_PRODUCT", 110, 114], ["FAK", "GENE_OR_GENE_PRODUCT", 148, 151], ["PYK2", "GENE_OR_GENE_PRODUCT", 155, 159], ["Akt", "PROTEIN", 13, 16], ["subunit p110\u03b1", "PROTEIN", 65, 78], ["PI3K", "PROTEIN", 82, 86], ["integrins", "PROTEIN", 92, 101], ["\u03b1V\u03b23", "PROTEIN", 102, 106], ["\u03b15\u03b21", "PROTEIN", 110, 114], ["tyrosine kinases", "PROTEIN", 131, 147], ["FAK", "PROTEIN", 148, 151], ["PYK2", "PROTEIN", 155, 159], ["Akt phosphorylation", "PROBLEM", 13, 32], ["PI3K", "TEST", 82, 86], ["the integrins", "TEST", 88, 101], ["the tyrosine kinases FAK", "TEST", 127, 151], ["PYK2", "TEST", 155, 159]]], ["These results regarding the tyrosine kinases are consistent with the literature, as both FAK-dependent and independent mechanisms of Akt phosphorylation have been described [42, 43] .", [["tyrosine", "CHEMICAL", 28, 36], ["tyrosine", "CHEMICAL", 28, 36], ["FAK", "GENE_OR_GENE_PRODUCT", 89, 92], ["Akt", "GENE_OR_GENE_PRODUCT", 133, 136], ["tyrosine kinases", "PROTEIN", 28, 44], ["FAK", "PROTEIN", 89, 92], ["Akt", "PROTEIN", 133, 136], ["the tyrosine kinases", "TEST", 24, 44], ["Akt phosphorylation", "PROBLEM", 133, 152], ["consistent with", "UNCERTAINTY", 49, 64]]], ["The replaceable nature of the integrins and FAK/PYK2 suggests that the pathway has significant flexibility in terms of the specific proteins used.", [["integrins", "GENE_OR_GENE_PRODUCT", 30, 39], ["FAK", "GENE_OR_GENE_PRODUCT", 44, 47], ["PYK2", "GENE_OR_GENE_PRODUCT", 48, 52], ["integrins", "PROTEIN", 30, 39], ["FAK", "PROTEIN", 44, 47], ["PYK2", "PROTEIN", 48, 52], ["FAK/PYK2", "TEST", 44, 52], ["significant", "OBSERVATION_MODIFIER", 83, 94], ["flexibility", "OBSERVATION", 95, 106]]], ["Additionally, since Akt phosphorylation is enhanced when both components of a pair (the integrins \u03b1V\u03b23/\u03b15\u03b21 or FAK/PYK2) are functioning, these molecular players may exhibit synergistic effects or independently promote p-Akt formation.", [["Akt", "GENE_OR_GENE_PRODUCT", 20, 23], ["integrins \u03b1V\u03b23/\u03b15\u03b21", "GENE_OR_GENE_PRODUCT", 88, 107], ["FAK", "GENE_OR_GENE_PRODUCT", 111, 114], ["PYK2", "GENE_OR_GENE_PRODUCT", 115, 119], ["Akt", "GENE_OR_GENE_PRODUCT", 221, 224], ["Akt", "PROTEIN", 20, 23], ["integrins", "PROTEIN", 88, 97], ["V\u03b23", "PROTEIN", 99, 102], ["\u03b15\u03b21", "PROTEIN", 103, 107], ["FAK", "PROTEIN", 111, 114], ["PYK2", "PROTEIN", 115, 119], ["Akt", "PROTEIN", 221, 224], ["Akt phosphorylation", "PROBLEM", 20, 39], ["the integrins", "TEST", 84, 97], ["FAK/PYK2", "TREATMENT", 111, 119], ["synergistic effects", "PROBLEM", 174, 193]]], ["A 2009 review indicated that HPSE-induced Akt phosphorylation may require firmly attached cells, which may explain why certain integrins were necessary to activate the pathway [44] .Heparanase-Akt signalingIn two human cancer cell lines, the SRC family kinase (SFK) inhibitor PP2 was demonstrated to prevent HPSE from activating Akt [36, 39] .", [["cells", "ANATOMY", 90, 95], ["cancer cell lines", "ANATOMY", 219, 236], ["HPSE", "CHEMICAL", 29, 33], ["cancer", "DISEASE", 219, 225], ["PP2", "CHEMICAL", 276, 279], ["PP2", "CHEMICAL", 276, 279], ["HPSE", "SIMPLE_CHEMICAL", 29, 33], ["Akt", "GENE_OR_GENE_PRODUCT", 42, 45], ["cells", "CELL", 90, 95], ["integrins", "GENE_OR_GENE_PRODUCT", 127, 136], ["Heparanase", "GENE_OR_GENE_PRODUCT", 182, 192], ["Akt", "GENE_OR_GENE_PRODUCT", 193, 196], ["human", "ORGANISM", 213, 218], ["cancer cell lines", "CELL", 219, 236], ["SRC family kinase", "GENE_OR_GENE_PRODUCT", 242, 259], ["SFK", "GENE_OR_GENE_PRODUCT", 261, 264], ["PP2", "SIMPLE_CHEMICAL", 276, 279], ["HPSE", "SIMPLE_CHEMICAL", 308, 312], ["Akt", "GENE_OR_GENE_PRODUCT", 329, 332], ["Akt", "PROTEIN", 42, 45], ["integrins", "PROTEIN", 127, 136], ["Heparanase", "PROTEIN", 182, 192], ["Akt", "PROTEIN", 193, 196], ["human cancer cell lines", "CELL_LINE", 213, 236], ["SRC family kinase", "PROTEIN", 242, 259], ["SFK", "PROTEIN", 261, 264], ["Akt", "PROTEIN", 329, 332], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 213, 218], ["HPSE", "TEST", 29, 33], ["Akt phosphorylation", "PROBLEM", 42, 61], ["firmly attached cells", "TREATMENT", 74, 95], ["Heparanase", "TEST", 182, 192], ["Akt signaling", "PROBLEM", 193, 206], ["two human cancer cell lines", "TREATMENT", 209, 236], ["the SRC family kinase (SFK) inhibitor PP2", "TREATMENT", 238, 279], ["cancer cell lines", "OBSERVATION", 219, 236]]], ["The mechanism by which this occurs did not involve syndencan-4 or the following kinases in the SRC family: Src, YES, and FYN [36] .", [["syndencan-4", "CHEMICAL", 51, 62], ["syndencan-4", "GENE_OR_GENE_PRODUCT", 51, 62], ["SRC", "GENE_OR_GENE_PRODUCT", 95, 98], ["Src", "GENE_OR_GENE_PRODUCT", 107, 110], ["YES", "GENE_OR_GENE_PRODUCT", 112, 115], ["syndencan-4", "PROTEIN", 51, 62], ["kinases", "PROTEIN", 80, 87], ["SRC family", "PROTEIN", 95, 105], ["Src", "PROTEIN", 107, 110], ["YES", "PROTEIN", 112, 115], ["FYN", "PROTEIN", 121, 124]]], ["Because these three proteins are members of the SrcA subfamily, it may be the case that the mechanism is mediated by a member of the SrcB subfamily: Lck, Hck, Blk, or Lyn [45, 46] .", [["SrcA", "GENE_OR_GENE_PRODUCT", 48, 52], ["SrcB", "GENE_OR_GENE_PRODUCT", 133, 137], ["Lck", "GENE_OR_GENE_PRODUCT", 149, 152], ["Hck", "GENE_OR_GENE_PRODUCT", 154, 157], ["Blk", "GENE_OR_GENE_PRODUCT", 159, 162], ["Lyn", "GENE_OR_GENE_PRODUCT", 167, 170], ["SrcA subfamily", "PROTEIN", 48, 62], ["SrcB subfamily", "PROTEIN", 133, 147], ["Lck", "PROTEIN", 149, 152], ["Hck", "PROTEIN", 154, 157], ["Blk", "PROTEIN", 159, 162], ["Lyn", "PROTEIN", 167, 170], ["Lck", "TEST", 149, 152], ["Hck", "TEST", 154, 157]]], ["It may also be the case that PP2 inhibits an off-target member of the HPSE-Akt pathway.Heparanase-Akt signalingOther players in the HPSE-AKT pathway may include the GTPase Ras and the growth factor TGF-\u03b2.", [["PP2", "CHEMICAL", 29, 32], ["PP2", "CHEMICAL", 29, 32], ["PP2", "SIMPLE_CHEMICAL", 29, 32], ["HPSE", "GENE_OR_GENE_PRODUCT", 70, 74], ["Akt", "GENE_OR_GENE_PRODUCT", 75, 78], ["Heparanase", "GENE_OR_GENE_PRODUCT", 87, 97], ["Akt", "GENE_OR_GENE_PRODUCT", 98, 101], ["HPSE", "GENE_OR_GENE_PRODUCT", 132, 136], ["AKT", "GENE_OR_GENE_PRODUCT", 137, 140], ["Ras", "GENE_OR_GENE_PRODUCT", 172, 175], ["TGF-\u03b2.", "GENE_OR_GENE_PRODUCT", 198, 204], ["HPSE", "PROTEIN", 70, 74], ["Akt", "PROTEIN", 75, 78], ["Heparanase", "PROTEIN", 87, 97], ["Akt", "PROTEIN", 98, 101], ["HPSE", "PROTEIN", 132, 136], ["AKT", "PROTEIN", 137, 140], ["GTPase Ras", "PROTEIN", 165, 175], ["growth factor TGF-\u03b2.", "PROTEIN", 184, 204], ["PP2", "TEST", 29, 32], ["Heparanase", "TEST", 87, 97], ["Akt signaling", "PROBLEM", 98, 111], ["the GTPase Ras", "TEST", 161, 175], ["the growth factor TGF", "TEST", 180, 201]]], ["Cells with a mutant Ras gene were more receptive to the inhibition of Akt phosphorylation when given both HPSE and an HPSE inhibitor PG545 [47] .", [["Cells", "ANATOMY", 0, 5], ["HPSE", "CHEMICAL", 106, 110], ["PG545", "CHEMICAL", 133, 138], ["HPSE", "CHEMICAL", 106, 110], ["PG545", "CHEMICAL", 133, 138], ["Cells", "CELL", 0, 5], ["Ras", "GENE_OR_GENE_PRODUCT", 20, 23], ["Akt", "GENE_OR_GENE_PRODUCT", 70, 73], ["HPSE", "SIMPLE_CHEMICAL", 106, 110], ["mutant Ras gene", "DNA", 13, 28], ["Akt", "PROTEIN", 70, 73], ["a mutant Ras gene", "PROBLEM", 11, 28], ["Akt phosphorylation", "TREATMENT", 70, 89], ["an HPSE inhibitor", "TREATMENT", 115, 132]]], ["Finally, TGF-\u03b2 was reported to have dose-dependent effects on HPSE-induced Akt phosphorylation as it stimulated Akt activity at lower concentrations, but inhibited it at higher concentrations in tumor cells [48] .Heparanase-Akt signalingThe results of the above studies suggest a potential mechanism by which HPSE activates Akt (Fig. 1) .", [["tumor cells", "ANATOMY", 195, 206], ["HPSE", "CHEMICAL", 62, 66], ["tumor", "DISEASE", 195, 200], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 9, 14], ["HPSE", "SIMPLE_CHEMICAL", 62, 66], ["Akt", "GENE_OR_GENE_PRODUCT", 75, 78], ["Akt", "GENE_OR_GENE_PRODUCT", 112, 115], ["tumor cells", "CELL", 195, 206], ["Heparanase", "GENE_OR_GENE_PRODUCT", 213, 223], ["Akt", "GENE_OR_GENE_PRODUCT", 224, 227], ["HPSE", "SIMPLE_CHEMICAL", 309, 313], ["Akt", "GENE_OR_GENE_PRODUCT", 324, 327], ["Fig. 1", "GENE_OR_GENE_PRODUCT", 329, 335], ["TGF-\u03b2", "PROTEIN", 9, 14], ["Akt", "PROTEIN", 75, 78], ["Akt", "PROTEIN", 112, 115], ["tumor cells", "CELL_TYPE", 195, 206], ["Heparanase", "PROTEIN", 213, 223], ["Akt", "PROTEIN", 224, 227], ["Akt", "PROTEIN", 324, 327], ["TGF", "TEST", 9, 12], ["dependent effects", "PROBLEM", 41, 58], ["HPSE", "TEST", 62, 66], ["Akt phosphorylation", "TREATMENT", 75, 94], ["Heparanase", "TEST", 213, 223], ["Akt signaling", "PROBLEM", 224, 237], ["the above studies", "TEST", 252, 269], ["tumor cells", "OBSERVATION", 195, 206]]], ["Through an Fig. 1 Proposed mechanism by which HPSE activates Akt phosphorylation.", [["HPSE", "CHEMICAL", 46, 50], ["HPSE", "SIMPLE_CHEMICAL", 46, 50], ["Akt", "GENE_OR_GENE_PRODUCT", 61, 64], ["HPSE", "PROTEIN", 46, 50], ["Akt", "PROTEIN", 61, 64], ["Akt phosphorylation", "TEST", 61, 80], ["Fig", "OBSERVATION", 11, 14]]], ["HPSE uses an unknown signaling molecule to bind and activate an integrin bound to a lipid raft.", [["lipid raft", "ANATOMY", 84, 94], ["HPSE", "CHEMICAL", 0, 4], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["integrin", "GENE_OR_GENE_PRODUCT", 64, 72], ["lipid raft", "CELLULAR_COMPONENT", 84, 94], ["HPSE", "PROTEIN", 0, 4], ["integrin", "PROTEIN", 64, 72], ["a lipid raft", "TREATMENT", 82, 94]]], ["The proteins FAK or PYK2, with a possible role for a Src family kinase, activate the p85 subunit of PI3K.", [["FAK", "GENE_OR_GENE_PRODUCT", 13, 16], ["PYK2", "GENE_OR_GENE_PRODUCT", 20, 24], ["Src", "GENE_OR_GENE_PRODUCT", 53, 56], ["p85", "GENE_OR_GENE_PRODUCT", 85, 88], ["PI3K", "GENE_OR_GENE_PRODUCT", 100, 104], ["FAK", "PROTEIN", 13, 16], ["PYK2", "PROTEIN", 20, 24], ["Src family kinase", "PROTEIN", 53, 70], ["p85 subunit", "PROTEIN", 85, 96], ["PI3K", "PROTEIN", 100, 104], ["a Src family kinase", "TREATMENT", 51, 70]]], ["The p85 subunit activates the p110\u03b1 subunit of PI3K, pos-sibly with the aid of Ras.", [["p85", "GENE_OR_GENE_PRODUCT", 4, 7], ["PI3K", "GENE_OR_GENE_PRODUCT", 47, 51], ["Ras", "GENE_OR_GENE_PRODUCT", 79, 82], ["p85 subunit", "PROTEIN", 4, 15], ["p110\u03b1 subunit", "PROTEIN", 30, 43], ["PI3K", "PROTEIN", 47, 51], ["Ras", "PROTEIN", 79, 82]]], ["Activation of PI3K results in the phosphorylation of PIP2 to PIP3.", [["PI3K", "GENE_OR_GENE_PRODUCT", 14, 18], ["PIP2", "GENE_OR_GENE_PRODUCT", 53, 57], ["PIP3", "GENE_OR_GENE_PRODUCT", 61, 65], ["PI3K", "PROTEIN", 14, 18], ["PIP2", "PROTEIN", 53, 57], ["PIP3", "PROTEIN", 61, 65], ["Activation of PI3K", "TREATMENT", 0, 18], ["the phosphorylation of PIP2", "TREATMENT", 30, 57], ["PIP3", "TEST", 61, 65]]], ["PIP3 plays a dual role in recruiting Akt to the plasma membrane and activating mTORC2.", [["plasma membrane", "ANATOMY", 48, 63], ["PIP3", "GENE_OR_GENE_PRODUCT", 0, 4], ["Akt", "GENE_OR_GENE_PRODUCT", 37, 40], ["plasma membrane", "CELLULAR_COMPONENT", 48, 63], ["mTORC2", "GENE_OR_GENE_PRODUCT", 79, 85], ["PIP3", "PROTEIN", 0, 4], ["Akt", "PROTEIN", 37, 40], ["mTORC2", "PROTEIN", 79, 85]]], ["PDK1 and mTORC2 phosphorylate Akt at its Thr-308 and Ser-473 sites, respectively.", [["Thr", "CHEMICAL", 41, 44], ["Ser", "CHEMICAL", 53, 56], ["PDK1", "GENE_OR_GENE_PRODUCT", 0, 4], ["mTORC2", "GENE_OR_GENE_PRODUCT", 9, 15], ["Akt", "GENE_OR_GENE_PRODUCT", 30, 33], ["Thr-308", "AMINO_ACID", 41, 48], ["Ser-473 sites", "AMINO_ACID", 53, 66], ["PDK1", "PROTEIN", 0, 4], ["mTORC2", "PROTEIN", 9, 15], ["Akt", "PROTEIN", 30, 33], ["PDK1", "TEST", 0, 4], ["mTORC2 phosphorylate Akt", "TEST", 9, 33], ["Thr", "TEST", 41, 44]]], ["Phosphorylation of both sites is necessary for maximal activation of Akt unknown mechanism that is independent of its enzymatic activity, HPSE activates the \u03b1V\u03b23 and \u03b15\u03b21 integrins.", [["Akt", "GENE_OR_GENE_PRODUCT", 69, 72], ["HPSE", "SIMPLE_CHEMICAL", 138, 142], ["\u03b1V\u03b23", "GENE_OR_GENE_PRODUCT", 157, 161], ["\u03b15\u03b21 integrins", "GENE_OR_GENE_PRODUCT", 166, 180], ["Akt", "PROTEIN", 69, 72], ["HPSE", "PROTEIN", 138, 142], ["\u03b1V\u03b23", "PROTEIN", 157, 161], ["\u03b15\u03b21 integrins", "PROTEIN", 166, 180], ["Phosphorylation of both sites", "TREATMENT", 0, 29]]], ["Because lipid rafts have been shown to play a role in the regulation and activity of \u03b21 integrins [49] , it may be the case that the \u03b1V\u03b23 and \u03b15\u03b21 integrins must either be associated with a lipid raft in order to activate or cluster in a lipid raft upon activation.", [["lipid rafts", "ANATOMY", 8, 19], ["lipid raft", "ANATOMY", 190, 200], ["lipid raft", "ANATOMY", 238, 248], ["lipid rafts", "CELLULAR_COMPONENT", 8, 19], ["\u03b21 integrins", "GENE_OR_GENE_PRODUCT", 85, 97], ["\u03b1V\u03b23", "GENE_OR_GENE_PRODUCT", 133, 137], ["\u03b15\u03b21 integrins", "GENE_OR_GENE_PRODUCT", 142, 156], ["lipid raft", "CELLULAR_COMPONENT", 190, 200], ["lipid raft", "CELLULAR_COMPONENT", 238, 248], ["\u03b21 integrins", "PROTEIN", 85, 97], ["\u03b1V\u03b23", "PROTEIN", 133, 137], ["\u03b15\u03b21 integrins", "PROTEIN", 142, 156], ["lipid rafts", "TREATMENT", 8, 19], ["activity of \u03b21 integrins", "TREATMENT", 73, 97], ["a lipid raft", "TREATMENT", 188, 200]]], ["In either case, these integrins then recruit FAK which autophosphorylates itself at Tyr397 and phosphorylates PI3K at its p85 subunit [50] .", [["integrins", "GENE_OR_GENE_PRODUCT", 22, 31], ["FAK", "GENE_OR_GENE_PRODUCT", 45, 48], ["Tyr397", "AMINO_ACID", 84, 90], ["PI3K", "GENE_OR_GENE_PRODUCT", 110, 114], ["p85", "GENE_OR_GENE_PRODUCT", 122, 125], ["integrins", "PROTEIN", 22, 31], ["FAK", "PROTEIN", 45, 48], ["Tyr397", "PROTEIN", 84, 90], ["PI3K", "PROTEIN", 110, 114], ["p85 subunit", "PROTEIN", 122, 133], ["autophosphorylates", "TEST", 55, 73], ["phosphorylates PI3K", "TREATMENT", 95, 114]]], ["Similarly, the integrins recruit and induce the autophosphorylation of PYK2at Tyr402 [51] .", [["integrins", "GENE_OR_GENE_PRODUCT", 15, 24], ["PYK2at", "GENE_OR_GENE_PRODUCT", 71, 77], ["integrins", "PROTEIN", 15, 24], ["PYK2at", "PROTEIN", 71, 77]]], ["The interaction between integrins and PYK2 may be mediated by SFK.", [["integrins", "GENE_OR_GENE_PRODUCT", 24, 33], ["PYK2", "GENE_OR_GENE_PRODUCT", 38, 42], ["SFK", "GENE_OR_GENE_PRODUCT", 62, 65], ["integrins", "PROTEIN", 24, 33], ["PYK2", "PROTEIN", 38, 42], ["SFK", "PROTEIN", 62, 65]]], ["The SFK inhibitor PP2 has been shown to inhibit the phosphorylation of FAK and the p85 subunit of PI3K, along with p-Akt [50, 52] .", [["PP2", "CHEMICAL", 18, 21], ["PP2", "CHEMICAL", 18, 21], ["SFK", "GENE_OR_GENE_PRODUCT", 4, 7], ["PP2", "SIMPLE_CHEMICAL", 18, 21], ["FAK", "GENE_OR_GENE_PRODUCT", 71, 74], ["p85", "GENE_OR_GENE_PRODUCT", 83, 86], ["PI3K", "GENE_OR_GENE_PRODUCT", 98, 102], ["Akt", "GENE_OR_GENE_PRODUCT", 117, 120], ["SFK", "PROTEIN", 4, 7], ["FAK", "PROTEIN", 71, 74], ["p85 subunit", "PROTEIN", 83, 94], ["PI3K", "PROTEIN", 98, 102], ["Akt", "PROTEIN", 117, 120], ["The SFK inhibitor PP2", "TEST", 0, 21], ["FAK", "TEST", 71, 74], ["PI3K", "TEST", 98, 102]]], ["The p85 subunit contains Src homology 2 (SH2) domain, and since the p-FAK may bind to the p85 subunit of PI3K, both FAK and PI3K may be targets of the PP2 inhibitor [50, 53] .", [["PP2", "CHEMICAL", 151, 154], ["p85", "GENE_OR_GENE_PRODUCT", 4, 7], ["Src homology 2", "GENE_OR_GENE_PRODUCT", 25, 39], ["SH2", "GENE_OR_GENE_PRODUCT", 41, 44], ["p-FAK", "GENE_OR_GENE_PRODUCT", 68, 73], ["p85", "GENE_OR_GENE_PRODUCT", 90, 93], ["PI3K", "GENE_OR_GENE_PRODUCT", 105, 109], ["FAK", "GENE_OR_GENE_PRODUCT", 116, 119], ["PI3K", "GENE_OR_GENE_PRODUCT", 124, 128], ["PP2", "SIMPLE_CHEMICAL", 151, 154], ["p85 subunit", "PROTEIN", 4, 15], ["Src homology 2 (SH2) domain", "PROTEIN", 25, 52], ["p", "PROTEIN", 68, 69], ["FAK", "PROTEIN", 70, 73], ["p85 subunit", "PROTEIN", 90, 101], ["PI3K", "PROTEIN", 105, 109], ["FAK", "PROTEIN", 116, 119], ["PI3K", "PROTEIN", 124, 128], ["Src homology", "TEST", 25, 37], ["PI3K", "TEST", 105, 109], ["the PP2 inhibitor", "TREATMENT", 147, 164]]], ["Activation of the p85 subunit is required for the activation of the p110\u03b1 subunit of PI3K, which has been shown to be the essential catalytic site for the downstream phosphorylation of Akt [36, 50] .", [["p85", "GENE_OR_GENE_PRODUCT", 18, 21], ["PI3K", "GENE_OR_GENE_PRODUCT", 85, 89], ["Akt", "GENE_OR_GENE_PRODUCT", 185, 188], ["p85 subunit", "PROTEIN", 18, 29], ["p110\u03b1 subunit", "PROTEIN", 68, 81], ["PI3K", "PROTEIN", 85, 89], ["Akt", "PROTEIN", 185, 188], ["the p85 subunit", "TREATMENT", 14, 29], ["the p110\u03b1 subunit of PI3K", "TREATMENT", 64, 89]]], ["PYK2 may also activate the p85 subunit of PI3K as it shares a similar structure as FAK, even containing an SH2 domain [54] .", [["PYK2", "GENE_OR_GENE_PRODUCT", 0, 4], ["p85", "GENE_OR_GENE_PRODUCT", 27, 30], ["PI3K", "GENE_OR_GENE_PRODUCT", 42, 46], ["FAK", "GENE_OR_GENE_PRODUCT", 83, 86], ["PYK2", "PROTEIN", 0, 4], ["p85 subunit", "PROTEIN", 27, 38], ["PI3K", "PROTEIN", 42, 46], ["FAK", "PROTEIN", 83, 86], ["SH2 domain", "PROTEIN", 107, 117], ["the p85 subunit of PI3K", "TREATMENT", 23, 46]]], ["Additionally, since inhibition of PI3K reduces Akt phosphorylation, the mechanism of PYK2 is likely to be upstream of or acting on PI3K.", [["PI3K", "GENE_OR_GENE_PRODUCT", 34, 38], ["Akt", "GENE_OR_GENE_PRODUCT", 47, 50], ["PYK2", "GENE_OR_GENE_PRODUCT", 85, 89], ["PI3K", "GENE_OR_GENE_PRODUCT", 131, 135], ["PI3K", "PROTEIN", 34, 38], ["Akt", "PROTEIN", 47, 50], ["PYK2", "PROTEIN", 85, 89], ["PI3K", "PROTEIN", 131, 135], ["PI3K reduces", "TREATMENT", 34, 46], ["Akt phosphorylation", "PROBLEM", 47, 66], ["PYK2", "PROBLEM", 85, 89]]], ["However, since PYK2 is expressed in only a few types of cells [55] , it may not impact HPSE-induced signaling in many cell lines which is supported by studies showing significant loss of p-Akt with FAK inhibition alone [50] .", [["cells", "ANATOMY", 56, 61], ["cell lines", "ANATOMY", 118, 128], ["PYK2", "GENE_OR_GENE_PRODUCT", 15, 19], ["cells", "CELL", 56, 61], ["HPSE", "SIMPLE_CHEMICAL", 87, 91], ["cell lines", "CELL", 118, 128], ["Akt", "GENE_OR_GENE_PRODUCT", 189, 192], ["FAK", "GENE_OR_GENE_PRODUCT", 198, 201], ["PYK2", "PROTEIN", 15, 19], ["HPSE", "PROTEIN", 87, 91], ["cell lines", "CELL_LINE", 118, 128], ["Akt", "PROTEIN", 189, 192], ["FAK", "PROTEIN", 198, 201], ["significant loss of p", "PROBLEM", 167, 188], ["FAK inhibition", "TREATMENT", 198, 212], ["cell lines", "OBSERVATION", 118, 128], ["significant", "OBSERVATION_MODIFIER", 167, 178], ["loss", "OBSERVATION_MODIFIER", 179, 183]]], ["Once activation of the p110\u03b1 subunit of PI3K is achieved, PI3K converts PIP2 to PIP3 which has been shown to activate mTORC2 and bind to Akt at the plasma membrane [56] .", [["plasma membrane", "ANATOMY", 148, 163], ["PI3K", "GENE_OR_GENE_PRODUCT", 40, 44], ["PI3K", "GENE_OR_GENE_PRODUCT", 58, 62], ["PIP2", "SIMPLE_CHEMICAL", 72, 76], ["PIP3", "GENE_OR_GENE_PRODUCT", 80, 84], ["mTORC2", "GENE_OR_GENE_PRODUCT", 118, 124], ["Akt", "GENE_OR_GENE_PRODUCT", 137, 140], ["plasma membrane", "CELLULAR_COMPONENT", 148, 163], ["p110\u03b1 subunit", "PROTEIN", 23, 36], ["PI3K", "PROTEIN", 40, 44], ["PI3K", "PROTEIN", 58, 62], ["PIP3", "PROTEIN", 80, 84], ["mTORC2", "PROTEIN", 118, 124], ["Akt", "PROTEIN", 137, 140], ["PI3K", "TREATMENT", 40, 44], ["PIP2 to PIP3", "TREATMENT", 72, 84]]], ["In certain situations, Ras may interact with PI3K to amplify downstream Akt phosphorylation [57] .", [["Ras", "GENE_OR_GENE_PRODUCT", 23, 26], ["PI3K", "GENE_OR_GENE_PRODUCT", 45, 49], ["Akt", "GENE_OR_GENE_PRODUCT", 72, 75], ["Ras", "PROTEIN", 23, 26], ["PI3K", "PROTEIN", 45, 49], ["Akt", "PROTEIN", 72, 75], ["PI3K", "TREATMENT", 45, 49], ["Akt phosphorylation", "TEST", 72, 91]]], ["Once PIP3 is bound to Akt, PDK1 phosphorylates Akt at Thr308 in its \"activation loop\", partially activating it [58] .", [["Thr", "CHEMICAL", 54, 57], ["PIP3", "GENE_OR_GENE_PRODUCT", 5, 9], ["Akt", "GENE_OR_GENE_PRODUCT", 22, 25], ["PDK1", "GENE_OR_GENE_PRODUCT", 27, 31], ["Akt", "GENE_OR_GENE_PRODUCT", 47, 50], ["Thr308", "AMINO_ACID", 54, 60], ["PIP3", "PROTEIN", 5, 9], ["Akt", "PROTEIN", 22, 25], ["PDK1", "PROTEIN", 27, 31], ["Akt", "PROTEIN", 47, 50], ["Thr308", "PROTEIN", 54, 60], ["Akt", "TEST", 22, 25], ["PDK1 phosphorylates", "TEST", 27, 46], ["Akt", "TEST", 47, 50]]], ["Finally, mTORC2 then phosphorylates Akt at Ser473, fully activating it [18] .", [["mTORC2", "GENE_OR_GENE_PRODUCT", 9, 15], ["Akt", "GENE_OR_GENE_PRODUCT", 36, 39], ["Ser473", "AMINO_ACID", 43, 49], ["mTORC2", "PROTEIN", 9, 15], ["Akt", "PROTEIN", 36, 39], ["Ser473", "PROTEIN", 43, 49]]], ["Viral activation of HPSE may stimulate Akt phosphorylation, in part, through the above mechanism.", [["HPSE", "GENE_OR_GENE_PRODUCT", 20, 24], ["Akt", "GENE_OR_GENE_PRODUCT", 39, 42], ["HPSE", "PROTEIN", 20, 24], ["Akt", "PROTEIN", 39, 42], ["Viral activation of HPSE", "PROBLEM", 0, 24], ["Akt phosphorylation", "TEST", 39, 58]]], ["Although some viruses encode proteins which activate Akt independently of HPSE, the Akt-HPSE axis may constitute a positive feedback loop.", [["Akt", "GENE_OR_GENE_PRODUCT", 53, 56], ["HPSE", "GENE_OR_GENE_PRODUCT", 74, 78], ["Akt-HPSE", "GENE_OR_GENE_PRODUCT", 84, 92], ["Akt", "PROTEIN", 53, 56], ["HPSE", "PROTEIN", 74, 78], ["HPSE", "PROTEIN", 88, 92], ["some viruses encode proteins", "PROBLEM", 9, 37], ["a positive feedback loop", "PROBLEM", 113, 137], ["viruses", "OBSERVATION", 14, 21], ["feedback loop", "OBSERVATION", 124, 137]]], ["For example, the tegument protein of HSV-1 VP11/12 induces Akt activation and the US3 kinase phosphorylates multiple Akt substrates [59] .", [["HSV-1", "ORGANISM", 37, 42], ["VP11/12", "GENE_OR_GENE_PRODUCT", 43, 50], ["Akt", "GENE_OR_GENE_PRODUCT", 59, 62], ["US3 kinase", "GENE_OR_GENE_PRODUCT", 82, 92], ["Akt", "GENE_OR_GENE_PRODUCT", 117, 120], ["tegument protein", "PROTEIN", 17, 33], ["VP11/12", "PROTEIN", 43, 50], ["Akt", "PROTEIN", 59, 62], ["US3 kinase", "PROTEIN", 82, 92], ["Akt substrates", "PROTEIN", 117, 131], ["HSV-1", "SPECIES", 37, 42], ["HSV-1", "SPECIES", 37, 42], ["the tegument protein", "TEST", 13, 33], ["HSV", "TEST", 37, 40], ["Akt activation", "TEST", 59, 73], ["the US3 kinase phosphorylates", "TEST", 78, 107], ["Akt substrates", "TEST", 117, 131]]], ["Akt has been shown to regulate NF-\u0138B, which is necessary for HSV-1-induced HPSE upregulation [60, 61] .", [["Akt", "GENE_OR_GENE_PRODUCT", 0, 3], ["NF-\u0138B", "GENE_OR_GENE_PRODUCT", 31, 36], ["HSV-1", "ORGANISM", 61, 66], ["HPSE", "GENE_OR_GENE_PRODUCT", 75, 79], ["Akt", "PROTEIN", 0, 3], ["NF-\u0138B", "PROTEIN", 31, 36], ["HSV-1", "SPECIES", 61, 66], ["HSV", "TEST", 61, 64]]], ["If HPSE leads to the activation of Akt by the proposed mechanism, then it will sustain a prolonged pro-survival state of the cell that is advantageous to the virus.Heparanase-Akt signalingThere are still components of the HPSE-Akt pathway that remain under investigation: (1) How do lipid rafts and the \u03b1V\u03b23/\u03b15\u03b21 interact, if at all? (2) Do the integrins activate FAK directly or is there an unknown SFK mediating the interaction? (3) Can the unknown SFK directly phosphorylate PI3K? and (4) What is the mechanism by which Ras and TGF-\u03b2 stimulate Akt phosphorylation, and (5) why does TGF-\u03b2 inhibit Akt phosphorylation at higher concentrations?", [["cell", "ANATOMY", 125, 129], ["lipid rafts", "ANATOMY", 283, 294], ["HPSE", "CHEMICAL", 3, 7], ["Akt", "GENE_OR_GENE_PRODUCT", 35, 38], ["cell", "CELL", 125, 129], ["Heparanase", "GENE_OR_GENE_PRODUCT", 164, 174], ["Akt", "GENE_OR_GENE_PRODUCT", 175, 178], ["HPSE", "GENE_OR_GENE_PRODUCT", 222, 226], ["Akt", "GENE_OR_GENE_PRODUCT", 227, 230], ["lipid rafts", "CELLULAR_COMPONENT", 283, 294], ["\u03b1V\u03b23", "GENE_OR_GENE_PRODUCT", 303, 307], ["\u03b15\u03b21", "GENE_OR_GENE_PRODUCT", 308, 312], ["integrins", "GENE_OR_GENE_PRODUCT", 345, 354], ["FAK", "GENE_OR_GENE_PRODUCT", 364, 367], ["SFK", "GENE_OR_GENE_PRODUCT", 400, 403], ["SFK", "GENE_OR_GENE_PRODUCT", 451, 454], ["PI3K", "GENE_OR_GENE_PRODUCT", 478, 482], ["Ras", "GENE_OR_GENE_PRODUCT", 523, 526], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 531, 536], ["Akt", "GENE_OR_GENE_PRODUCT", 547, 550], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 585, 590], ["Akt", "GENE_OR_GENE_PRODUCT", 599, 602], ["Akt", "PROTEIN", 35, 38], ["Heparanase", "PROTEIN", 164, 174], ["Akt", "PROTEIN", 175, 178], ["HPSE", "PROTEIN", 222, 226], ["Akt", "PROTEIN", 227, 230], ["\u03b1V\u03b23", "PROTEIN", 303, 307], ["\u03b15\u03b21", "PROTEIN", 308, 312], ["integrins", "PROTEIN", 345, 354], ["FAK", "PROTEIN", 364, 367], ["SFK", "PROTEIN", 400, 403], ["SFK", "PROTEIN", 451, 454], ["PI3K", "PROTEIN", 478, 482], ["Ras", "PROTEIN", 523, 526], ["TGF-\u03b2", "PROTEIN", 531, 536], ["Akt", "PROTEIN", 547, 550], ["TGF-\u03b2", "PROTEIN", 585, 590], ["Akt", "PROTEIN", 599, 602], ["HPSE", "PROBLEM", 3, 7], ["the virus", "PROBLEM", 154, 163], ["Heparanase", "TEST", 164, 174], ["Akt signaling", "PROBLEM", 175, 188], ["Ras", "TEST", 523, 526], ["TGF", "TEST", 531, 534], ["Akt phosphorylation", "TEST", 547, 566], ["TGF", "TEST", 585, 588], ["Akt phosphorylation", "PROBLEM", 599, 618], ["SFK", "OBSERVATION", 400, 403]]], ["Additional work needs to be done to elucidate these aspects of the HPSE-Akt pathway.HPSE-VEGF signalingVascular endothelial growth factors are a family of proteins, which regulate vascular development, cell survival, and angiogenesis [62] .", [["vascular", "ANATOMY", 180, 188], ["cell", "ANATOMY", 202, 206], ["HPSE", "GENE_OR_GENE_PRODUCT", 67, 71], ["Akt", "GENE_OR_GENE_PRODUCT", 72, 75], ["HPSE-VEGF", "GENE_OR_GENE_PRODUCT", 84, 93], ["Vascular endothelial growth factors", "GENE_OR_GENE_PRODUCT", 103, 138], ["vascular", "MULTI-TISSUE_STRUCTURE", 180, 188], ["cell", "CELL", 202, 206], ["HPSE", "PROTEIN", 67, 71], ["Akt", "PROTEIN", 72, 75], ["HPSE", "PROTEIN", 84, 88], ["VEGF", "PROTEIN", 89, 93], ["Vascular endothelial growth factors", "PROTEIN", 103, 138], ["Vascular endothelial growth factors", "PROBLEM", 103, 138], ["VEGF", "OBSERVATION", 89, 93], ["Vascular endothelial", "ANATOMY", 103, 123], ["vascular", "ANATOMY", 180, 188], ["cell survival", "OBSERVATION", 202, 215]]], ["There are five known growth factors in the VEGF family: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and the placenta growth factor P1GF [62] .", [["VEGF", "GENE_OR_GENE_PRODUCT", 43, 47], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 56, 62], ["VEGF-B", "GENE_OR_GENE_PRODUCT", 64, 70], ["VEGF-C", "GENE_OR_GENE_PRODUCT", 72, 78], ["VEGF-D", "GENE_OR_GENE_PRODUCT", 80, 86], ["placenta", "ORGAN", 96, 104], ["P1GF", "GENE_OR_GENE_PRODUCT", 119, 123], ["growth factors", "PROTEIN", 21, 35], ["VEGF family", "PROTEIN", 43, 54], ["VEGF", "PROTEIN", 56, 60], ["VEGF", "PROTEIN", 64, 68], ["VEGF", "PROTEIN", 72, 76], ["VEGF", "PROTEIN", 80, 84], ["placenta growth factor", "PROTEIN", 96, 118], ["five known growth factors", "PROBLEM", 10, 35], ["VEGF", "TEST", 56, 60], ["VEGF", "TEST", 64, 68], ["VEGF", "TEST", 72, 76], ["growth", "OBSERVATION_MODIFIER", 21, 27], ["factors", "OBSERVATION", 28, 35], ["placenta", "ANATOMY", 96, 104]]], ["VEGF is created by most parenchymal cells and plays key roles in both autocrine and paracrine signaling [62] .", [["parenchymal cells", "ANATOMY", 24, 41], ["VEGF", "GENE_OR_GENE_PRODUCT", 0, 4], ["parenchymal cells", "CELL", 24, 41], ["VEGF", "PROTEIN", 0, 4], ["parenchymal cells", "CELL_TYPE", 24, 41], ["parenchymal cells", "OBSERVATION", 24, 41]]], ["There are three known receptor tyrosine kinases (RTKs) through which VEGFs bind: vascular endothelial growth factor receptor 1 (VEGFR1), VEGFR2, and VEGFR3 (also known as Flt1, Flk1, and Flt4, respectively).", [["tyrosine", "CHEMICAL", 31, 39], ["tyrosine", "CHEMICAL", 31, 39], ["receptor tyrosine kinases", "GENE_OR_GENE_PRODUCT", 22, 47], ["RTKs", "GENE_OR_GENE_PRODUCT", 49, 53], ["VEGFs", "GENE_OR_GENE_PRODUCT", 69, 74], ["vascular endothelial growth factor receptor 1", "GENE_OR_GENE_PRODUCT", 81, 126], ["VEGFR1", "GENE_OR_GENE_PRODUCT", 128, 134], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 137, 143], ["VEGFR3", "GENE_OR_GENE_PRODUCT", 149, 155], ["Flt1", "GENE_OR_GENE_PRODUCT", 171, 175], ["Flk1", "GENE_OR_GENE_PRODUCT", 177, 181], ["Flt4", "GENE_OR_GENE_PRODUCT", 187, 191], ["receptor tyrosine kinases", "PROTEIN", 22, 47], ["RTKs", "PROTEIN", 49, 53], ["VEGFs", "PROTEIN", 69, 74], ["vascular endothelial growth factor receptor 1", "PROTEIN", 81, 126], ["VEGFR1", "PROTEIN", 128, 134], ["VEGFR2", "PROTEIN", 137, 143], ["VEGFR3", "PROTEIN", 149, 155], ["Flt1", "PROTEIN", 171, 175], ["Flk1", "PROTEIN", 177, 181], ["Flt4", "PROTEIN", 187, 191], ["VEGFs bind", "TEST", 69, 79], ["vascular endothelial growth factor receptor", "TEST", 81, 124], ["VEGFR1", "TEST", 128, 134], ["VEGFR2", "TEST", 137, 143], ["VEGFR3", "TEST", 149, 155], ["Flt1", "TEST", 171, 175], ["Flk1", "TEST", 177, 181], ["receptor tyrosine kinases", "OBSERVATION", 22, 47], ["VEGFs", "ANATOMY", 69, 74], ["vascular endothelial", "ANATOMY", 81, 101], ["VEGFR3", "ANATOMY", 149, 155]]], ["Once a VEGF binds to a VEGFR, it induces a conformational change in the receptor, which phosphorylates the tyrosine residues on the receptor, activating the kinase for phosphorylation of downstream proteins, including PI3K-AKT, p38 MAPK, and ERK1/2 [62] .", [["tyrosine", "CHEMICAL", 107, 115], ["tyrosine", "CHEMICAL", 107, 115], ["VEGF", "GENE_OR_GENE_PRODUCT", 7, 11], ["VEGFR", "GENE_OR_GENE_PRODUCT", 23, 28], ["PI3K", "GENE_OR_GENE_PRODUCT", 218, 222], ["AKT", "GENE_OR_GENE_PRODUCT", 223, 226], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 228, 236], ["ERK1/2 [62]", "GENE_OR_GENE_PRODUCT", 242, 253], ["VEGF", "PROTEIN", 7, 11], ["VEGFR", "PROTEIN", 23, 28], ["downstream proteins", "PROTEIN", 187, 206], ["PI3K", "PROTEIN", 218, 222], ["AKT", "PROTEIN", 223, 226], ["p38 MAPK", "PROTEIN", 228, 236], ["ERK1/2", "PROTEIN", 242, 248], ["a conformational change in the receptor", "PROBLEM", 41, 80], ["the tyrosine residues", "PROBLEM", 103, 124], ["phosphorylation of downstream proteins", "TEST", 168, 206], ["PI3K", "TEST", 218, 222], ["p38 MAPK", "TEST", 228, 236], ["ERK1/2", "TEST", 242, 248]]], ["VEGF-A is one of the growth factors that can be bound and sequestered by HS [63] .HPSE-VEGF signalingVEGF upregulation has been observed in many different viral infections [64] [65] [66] .", [["viral infections", "DISEASE", 155, 171], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 0, 6], ["HPSE", "GENE_OR_GENE_PRODUCT", 82, 86], ["VEGF", "GENE_OR_GENE_PRODUCT", 87, 91], ["VEGF", "PROTEIN", 0, 4], ["growth factors", "PROTEIN", 21, 35], ["HPSE", "PROTEIN", 82, 86], ["VEGF", "PROTEIN", 87, 91], ["VEGF signalingVEGF upregulation", "PROBLEM", 87, 118]]], ["SARS-CoV-2-infected patients display higher VEGF expression [67] , which may be linked to increased endothelial cell permeabilization and contribute to the development of noncardiogenic pulmonary edema in acute respiratory distress syndrome [68] .", [["endothelial cell", "ANATOMY", 100, 116], ["pulmonary", "ANATOMY", 186, 195], ["respiratory", "ANATOMY", 211, 222], ["pulmonary edema", "DISEASE", 186, 201], ["acute respiratory distress syndrome", "DISEASE", 205, 240], ["SARS-CoV-2", "ORGANISM", 0, 10], ["patients", "ORGANISM", 20, 28], ["VEGF", "GENE_OR_GENE_PRODUCT", 44, 48], ["endothelial cell", "CELL", 100, 116], ["pulmonary", "ORGAN", 186, 195], ["VEGF", "PROTEIN", 44, 48], ["patients", "SPECIES", 20, 28], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["higher VEGF expression", "PROBLEM", 37, 59], ["increased endothelial cell permeabilization", "PROBLEM", 90, 133], ["noncardiogenic pulmonary edema", "PROBLEM", 171, 201], ["acute respiratory distress syndrome", "PROBLEM", 205, 240], ["higher VEGF", "OBSERVATION_MODIFIER", 37, 48], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["endothelial cell permeabilization", "OBSERVATION", 100, 133], ["noncardiogenic", "OBSERVATION_MODIFIER", 171, 185], ["pulmonary", "ANATOMY", 186, 195], ["edema", "OBSERVATION", 196, 201], ["acute", "OBSERVATION_MODIFIER", 205, 210], ["respiratory distress", "OBSERVATION", 211, 231]]], ["Uniquely, the Orf virus, a member of the poxvirus family, encodes a VEGF homolog which stimulates proangiogenic responses during infection [66, 69] .", [["infection", "DISEASE", 129, 138], ["Orf virus", "ORGANISM", 14, 23], ["VEGF", "GENE_OR_GENE_PRODUCT", 68, 72], ["poxvirus family", "PROTEIN", 41, 56], ["VEGF homolog", "PROTEIN", 68, 80], ["Orf virus", "SPECIES", 14, 23], ["the Orf virus", "PROBLEM", 10, 23], ["a VEGF homolog", "TREATMENT", 66, 80], ["infection", "PROBLEM", 129, 138]]], ["Certain viruses, such as EBV, KSHV, and the hepatitis viruses, are associated with oncogenic infections, and the increase in VEGF stimulates growth and angiogenesis [70] .", [["hepatitis viruses", "DISEASE", 44, 61], ["infections", "DISEASE", 93, 103], ["EBV", "ORGANISM", 25, 28], ["KSHV", "ORGANISM", 30, 34], ["hepatitis viruses", "ORGANISM", 44, 61], ["VEGF", "GENE_OR_GENE_PRODUCT", 125, 129], ["VEGF", "PROTEIN", 125, 129], ["EBV", "SPECIES", 25, 28], ["KSHV", "SPECIES", 30, 34], ["hepatitis viruses", "SPECIES", 44, 61], ["Certain viruses", "PROBLEM", 0, 15], ["EBV", "PROBLEM", 25, 28], ["KSHV", "PROBLEM", 30, 34], ["the hepatitis viruses", "PROBLEM", 40, 61], ["oncogenic infections", "PROBLEM", 83, 103], ["the increase in VEGF stimulates growth", "PROBLEM", 109, 147], ["viruses", "OBSERVATION", 8, 15], ["hepatitis viruses", "OBSERVATION", 44, 61], ["associated with", "UNCERTAINTY", 67, 82], ["oncogenic", "OBSERVATION_MODIFIER", 83, 92], ["infections", "OBSERVATION", 93, 103], ["increase", "OBSERVATION_MODIFIER", 113, 121]]], ["Non-oncogenic viruses, such as HSV-1 and DENV, also increase VEGF expression during infection, which is associated with severe complications.", [["infection", "DISEASE", 84, 93], ["HSV-1", "ORGANISM", 31, 36], ["DENV", "ORGANISM", 41, 45], ["VEGF", "GENE_OR_GENE_PRODUCT", 61, 65], ["VEGF", "PROTEIN", 61, 65], ["HSV-1", "SPECIES", 31, 36], ["HSV-1", "SPECIES", 31, 36], ["DENV", "SPECIES", 41, 45], ["Non-oncogenic viruses", "PROBLEM", 0, 21], ["HSV", "PROBLEM", 31, 34], ["DENV", "PROBLEM", 41, 45], ["increase VEGF expression during infection", "PROBLEM", 52, 93], ["severe complications", "PROBLEM", 120, 140], ["viruses", "OBSERVATION", 14, 21], ["DENV", "OBSERVATION", 41, 45], ["increase", "OBSERVATION_MODIFIER", 52, 60], ["VEGF expression", "OBSERVATION", 61, 76], ["infection", "OBSERVATION", 84, 93], ["associated with", "UNCERTAINTY", 104, 119], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["complications", "OBSERVATION", 127, 140]]], ["Upregulation of VEGF during an ocular HSV-1 infection can lead to corneal neovascularization, and elevated VEGF levels during DENV infections contribute to dengue hemorrhagic fever [71, 72] .", [["ocular", "ANATOMY", 31, 37], ["corneal", "ANATOMY", 66, 73], ["infection", "DISEASE", 44, 53], ["neovascularization", "DISEASE", 74, 92], ["DENV infections", "DISEASE", 126, 141], ["dengue hemorrhagic fever", "DISEASE", 156, 180], ["VEGF", "GENE_OR_GENE_PRODUCT", 16, 20], ["HSV-1", "ORGANISM", 38, 43], ["corneal", "TISSUE", 66, 73], ["VEGF", "GENE_OR_GENE_PRODUCT", 107, 111], ["DENV", "ORGANISM", 126, 130], ["VEGF", "PROTEIN", 16, 20], ["VEGF", "PROTEIN", 107, 111], ["HSV-1", "SPECIES", 38, 43], ["dengue hemorrhagic fever", "SPECIES", 156, 180], ["HSV-1", "SPECIES", 38, 43], ["DENV", "SPECIES", 126, 130], ["Upregulation of VEGF", "PROBLEM", 0, 20], ["an ocular HSV", "PROBLEM", 28, 41], ["1 infection", "PROBLEM", 42, 53], ["corneal neovascularization", "PROBLEM", 66, 92], ["elevated VEGF levels", "PROBLEM", 98, 118], ["DENV infections", "PROBLEM", 126, 141], ["dengue hemorrhagic fever", "PROBLEM", 156, 180], ["VEGF", "OBSERVATION", 16, 20], ["ocular", "ANATOMY", 31, 37], ["HSV", "OBSERVATION", 38, 41], ["infection", "OBSERVATION", 44, 53], ["corneal", "ANATOMY", 66, 73], ["neovascularization", "OBSERVATION", 74, 92]]], ["Inhibiting VEGF reduces the severity of viral infection and tumor growth [73] [74] [75] .HPSE-VEGF signalingLike its relationship with Akt, HPSE may be a key regulator of VEGF signaling.", [["tumor", "ANATOMY", 60, 65], ["viral infection", "DISEASE", 40, 55], ["tumor", "DISEASE", 60, 65], ["VEGF", "GENE_OR_GENE_PRODUCT", 11, 15], ["tumor", "CANCER", 60, 65], ["HPSE", "GENE_OR_GENE_PRODUCT", 89, 93], ["VEGF", "GENE_OR_GENE_PRODUCT", 94, 98], ["Akt", "GENE_OR_GENE_PRODUCT", 135, 138], ["HPSE", "GENE_OR_GENE_PRODUCT", 140, 144], ["VEGF", "GENE_OR_GENE_PRODUCT", 171, 175], ["VEGF", "PROTEIN", 11, 15], ["HPSE", "PROTEIN", 89, 93], ["VEGF", "PROTEIN", 94, 98], ["Akt", "PROTEIN", 135, 138], ["HPSE", "PROTEIN", 140, 144], ["VEGF", "PROTEIN", 171, 175], ["Inhibiting VEGF", "PROBLEM", 0, 15], ["viral infection", "PROBLEM", 40, 55], ["tumor growth", "PROBLEM", 60, 72], ["VEGF signaling", "PROBLEM", 171, 185], ["viral", "OBSERVATION_MODIFIER", 40, 45], ["infection", "OBSERVATION", 46, 55]]], ["HPSE has been shown to significantly increase VEGF expression in a variety of cell lines, particularly VEGF-C [76] .", [["cell lines", "ANATOMY", 78, 88], ["HPSE", "CHEMICAL", 0, 4], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["VEGF", "GENE_OR_GENE_PRODUCT", 46, 50], ["cell lines", "CELL", 78, 88], ["VEGF-C", "GENE_OR_GENE_PRODUCT", 103, 109], ["HPSE", "PROTEIN", 0, 4], ["VEGF", "PROTEIN", 46, 50], ["cell lines", "CELL_LINE", 78, 88], ["VEGF", "PROTEIN", 103, 107], ["cell lines", "TREATMENT", 78, 88], ["VEGF expression", "OBSERVATION", 46, 61], ["cell lines", "OBSERVATION", 78, 88]]], ["The mechanism by which HPSE up-regulates VEGF is independent of its enzymatic activity, but is instead mediated by the activation of a SFK [77] .", [["HPSE", "CHEMICAL", 23, 27], ["HPSE", "GENE_OR_GENE_PRODUCT", 23, 27], ["VEGF", "GENE_OR_GENE_PRODUCT", 41, 45], ["SFK", "GENE_OR_GENE_PRODUCT", 135, 138], ["HPSE", "PROTEIN", 23, 27], ["VEGF", "PROTEIN", 41, 45], ["SFK", "PROTEIN", 135, 138], ["HPSE", "TEST", 23, 27]]], ["A sixfold increase in phospho-SFK was found in HPSE-transfected cells [78, 79] .", [["cells", "ANATOMY", 64, 69], ["phospho", "CHEMICAL", 22, 29], ["phospho-SFK", "GENE_OR_GENE_PRODUCT", 22, 33], ["HPSE", "SIMPLE_CHEMICAL", 47, 51], ["cells", "CELL", 64, 69], ["phospho", "PROTEIN", 22, 29], ["SFK", "PROTEIN", 30, 33], ["HPSE-transfected cells", "CELL_LINE", 47, 69], ["A sixfold increase in phospho-SFK", "PROBLEM", 0, 33], ["HPSE", "TEST", 47, 51], ["sixfold", "OBSERVATION_MODIFIER", 2, 9], ["increase", "OBSERVATION_MODIFIER", 10, 18]]], ["Inhibition of SFK by PP2 abrogated VEGF stimulation upon HPSE addition [77] .", [["PP2", "CHEMICAL", 21, 24], ["HPSE", "CHEMICAL", 57, 61], ["PP2", "CHEMICAL", 21, 24], ["HPSE", "CHEMICAL", 57, 61], ["SFK", "GENE_OR_GENE_PRODUCT", 14, 17], ["PP2", "SIMPLE_CHEMICAL", 21, 24], ["VEGF", "GENE_OR_GENE_PRODUCT", 35, 39], ["HPSE", "SIMPLE_CHEMICAL", 57, 61], ["SFK", "PROTEIN", 14, 17], ["VEGF", "PROTEIN", 35, 39], ["Inhibition of SFK", "TREATMENT", 0, 17], ["VEGF stimulation", "TREATMENT", 35, 51], ["SFK", "OBSERVATION", 14, 17]]], ["Because PP2 and the antibody used were not specific for the Src protein, it may be the case that another member of the Src family was mediating the HPSE-VEGF mechanism [77] .", [["PP2", "CHEMICAL", 8, 11], ["PP2", "SIMPLE_CHEMICAL", 8, 11], ["Src", "GENE_OR_GENE_PRODUCT", 60, 63], ["Src", "GENE_OR_GENE_PRODUCT", 119, 122], ["HPSE", "GENE_OR_GENE_PRODUCT", 148, 152], ["VEGF", "GENE_OR_GENE_PRODUCT", 153, 157], ["PP2", "PROTEIN", 8, 11], ["Src protein", "PROTEIN", 60, 71], ["Src family", "PROTEIN", 119, 129], ["HPSE", "PROTEIN", 148, 152], ["VEGF", "PROTEIN", 153, 157], ["PP2", "TEST", 8, 11], ["the antibody", "TEST", 16, 28], ["the Src protein", "TEST", 56, 71]]], ["This SFK may be responsible for mediating FAK activation in the HPSE-Akt pathway discussed before [36] .", [["SFK", "GENE_OR_GENE_PRODUCT", 5, 8], ["FAK", "GENE_OR_GENE_PRODUCT", 42, 45], ["HPSE", "GENE_OR_GENE_PRODUCT", 64, 68], ["Akt", "GENE_OR_GENE_PRODUCT", 69, 72], ["SFK", "PROTEIN", 5, 8], ["FAK", "PROTEIN", 42, 45], ["HPSE", "PROTEIN", 64, 68], ["Akt", "PROTEIN", 69, 72], ["mediating FAK activation", "PROBLEM", 32, 56], ["may be responsible for", "UNCERTAINTY", 9, 31]]], ["In addition, only the secreted forms of HPSE were able to upregulate VEGF [77] .", [["HPSE", "GENE_OR_GENE_PRODUCT", 40, 44], ["VEGF", "GENE_OR_GENE_PRODUCT", 69, 73], ["HPSE", "PROTEIN", 40, 44], ["VEGF", "PROTEIN", 69, 73], ["VEGF", "TEST", 69, 73]]], ["These results suggest that HPSE acts on the exterior of the cell to increase VEGF expression in an SFK-dependent mechanism.HPSE-VEGF signalingHPSE may be able to directly release the VEGF bound to HS chains located on perlecan proteoglycans by cleaving HS [79, 80] .", [["cell", "ANATOMY", 60, 64], ["HPSE", "CHEMICAL", 27, 31], ["HPSE", "SIMPLE_CHEMICAL", 27, 31], ["cell", "CELL", 60, 64], ["VEGF", "GENE_OR_GENE_PRODUCT", 77, 81], ["SFK", "GENE_OR_GENE_PRODUCT", 99, 102], ["HPSE-VEGF", "GENE_OR_GENE_PRODUCT", 123, 132], ["VEGF", "GENE_OR_GENE_PRODUCT", 183, 187], ["HS chains", "GENE_OR_GENE_PRODUCT", 197, 206], ["perlecan proteoglycans", "GENE_OR_GENE_PRODUCT", 218, 240], ["HPSE", "PROTEIN", 27, 31], ["VEGF", "PROTEIN", 77, 81], ["SFK", "PROTEIN", 99, 102], ["HPSE", "PROTEIN", 123, 127], ["VEGF", "PROTEIN", 128, 132], ["VEGF", "PROTEIN", 183, 187], ["HS chains", "PROTEIN", 197, 206], ["perlecan proteoglycans", "PROTEIN", 218, 240], ["HPSE acts", "PROBLEM", 27, 36], ["increase", "OBSERVATION_MODIFIER", 68, 76], ["VEGF expression", "OBSERVATION", 77, 92]]], ["HPSE-induced VEGF-C upregulation enhanced tumor lymphangiogenesis in mouse models and was correlated with lymphatic vessel density in human patients [76] .", [["tumor", "ANATOMY", 42, 47], ["lymphatic vessel", "ANATOMY", 106, 122], ["HPSE", "CHEMICAL", 0, 4], ["tumor", "DISEASE", 42, 47], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["VEGF-C", "GENE_OR_GENE_PRODUCT", 13, 19], ["tumor", "CANCER", 42, 47], ["mouse", "ORGANISM", 69, 74], ["lymphatic vessel", "MULTI-TISSUE_STRUCTURE", 106, 122], ["human", "ORGANISM", 134, 139], ["patients", "ORGANISM", 140, 148], ["VEGF", "PROTEIN", 13, 17], ["mouse", "SPECIES", 69, 74], ["human", "SPECIES", 134, 139], ["patients", "SPECIES", 140, 148], ["mouse", "SPECIES", 69, 74], ["human", "SPECIES", 134, 139], ["HPSE", "TEST", 0, 4], ["VEGF", "PROBLEM", 13, 17], ["C upregulation enhanced tumor lymphangiogenesis in mouse models", "PROBLEM", 18, 81], ["enhanced", "OBSERVATION_MODIFIER", 33, 41], ["tumor lymphangiogenesis", "OBSERVATION", 42, 65], ["lymphatic vessel", "ANATOMY", 106, 122], ["density", "OBSERVATION", 123, 130]]], ["Thus, HPSE may possess enzymatic and non-enzymatic means of increasing VEGF signaling.", [["HPSE", "CHEMICAL", 6, 10], ["HPSE", "SIMPLE_CHEMICAL", 6, 10], ["VEGF", "GENE_OR_GENE_PRODUCT", 71, 75], ["VEGF", "PROTEIN", 71, 75], ["increasing VEGF signaling", "PROBLEM", 60, 85], ["increasing", "OBSERVATION_MODIFIER", 60, 70], ["VEGF signaling", "OBSERVATION", 71, 85]]], ["HPSE also indirectly impacts VEGFR2 via its role in syndecan shedding.", [["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 29, 35], ["syndecan", "GENE_OR_GENE_PRODUCT", 52, 60], ["HPSE", "PROTEIN", 0, 4], ["VEGFR2", "PROTEIN", 29, 35], ["syndecan", "PROTEIN", 52, 60], ["impacts", "OBSERVATION_MODIFIER", 21, 28], ["VEGFR2", "OBSERVATION", 29, 35]]], ["In brief, enzymatically active HPSE stimulates the ERK signaling pathway which up-regulates matrix metalloproteinase 9 (MMP-9) [81] .", [["HPSE", "CHEMICAL", 31, 35], ["HPSE", "CHEMICAL", 31, 35], ["HPSE", "SIMPLE_CHEMICAL", 31, 35], ["ERK", "GENE_OR_GENE_PRODUCT", 51, 54], ["matrix metalloproteinase 9", "GENE_OR_GENE_PRODUCT", 92, 118], ["MMP-9", "GENE_OR_GENE_PRODUCT", 120, 125], ["ERK", "PROTEIN", 51, 54], ["matrix metalloproteinase 9 (MMP-9", "PROTEIN", 92, 125], ["the ERK signaling pathway", "TEST", 47, 72], ["matrix metalloproteinase", "TEST", 92, 116], ["MMP", "TEST", 120, 123], ["active", "OBSERVATION_MODIFIER", 24, 30], ["HPSE", "OBSERVATION", 31, 35]]], ["MMP-9 then cleaves the syndecan-1 core protein from the cell surface [81] .", [["cell surface", "ANATOMY", 56, 68], ["MMP-9", "GENE_OR_GENE_PRODUCT", 0, 5], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 23, 33], ["cell surface", "CELLULAR_COMPONENT", 56, 68], ["MMP-9", "PROTEIN", 0, 5], ["syndecan-1 core protein", "PROTEIN", 23, 46], ["MMP", "TEST", 0, 3], ["the syndecan", "TEST", 19, 31], ["the cell surface", "TEST", 52, 68]]], ["When syndecan-1 sheds from the membrane, it can couple the integrin \u03b14\u03b21 (also known as VLA-4) and VEGFR2 together, forming a complex of three proteins [82] .", [["membrane", "ANATOMY", 31, 39], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 5, 15], ["membrane", "CELLULAR_COMPONENT", 31, 39], ["integrin \u03b14\u03b21", "GENE_OR_GENE_PRODUCT", 59, 72], ["VLA-4", "GENE_OR_GENE_PRODUCT", 88, 93], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 99, 105], ["syndecan-1", "PROTEIN", 5, 15], ["integrin \u03b14\u03b21", "PROTEIN", 59, 72], ["VLA-4", "PROTEIN", 88, 93], ["VEGFR2", "PROTEIN", 99, 105], ["VEGFR2", "TEST", 99, 105]]], ["The complex activates VEGFR2 which proceeds to enhance cell invasion, formation of endothelial tubes, and other tumorigenic responses [82] .", [["cell", "ANATOMY", 55, 59], ["endothelial tubes", "ANATOMY", 83, 100], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 22, 28], ["cell", "CELL", 55, 59], ["endothelial tubes", "TISSUE", 83, 100], ["VEGFR2", "PROTEIN", 22, 28], ["The complex activates VEGFR2", "PROBLEM", 0, 28], ["enhance cell invasion", "PROBLEM", 47, 68], ["endothelial tubes", "TREATMENT", 83, 100], ["enhance cell invasion", "OBSERVATION", 47, 68], ["endothelial tubes", "OBSERVATION", 83, 100]]], ["This mechanism is inhibited by synstatins, proteins which can competitively inhibit the binding of either \u03b14\u03b21 or VEGFR2 to shed syndecan-1 [82, 83] .HPSE-VEGF signalingThus, HPSE demonstrates three ways in which it activates the VEGF pathway (Fig. 2) .", [["synstatins", "SIMPLE_CHEMICAL", 31, 41], ["\u03b14\u03b21", "GENE_OR_GENE_PRODUCT", 106, 110], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 114, 120], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 129, 139], ["HPSE-VEGF", "GENE_OR_GENE_PRODUCT", 150, 159], ["VEGF", "GENE_OR_GENE_PRODUCT", 230, 234], ["\u03b14\u03b21", "PROTEIN", 106, 110], ["VEGFR2", "PROTEIN", 114, 120], ["syndecan", "PROTEIN", 129, 137], ["HPSE", "PROTEIN", 150, 154], ["VEGF", "PROTEIN", 155, 159], ["VEGF", "PROTEIN", 230, 234], ["syndecan", "TEST", 129, 137]]], ["Once secreted from the cell, it can induce SFK-mediated VEGF upregulation in an enzymatically independent manner.", [["cell", "ANATOMY", 23, 27], ["cell", "CELL", 23, 27], ["SFK", "GENE_OR_GENE_PRODUCT", 43, 46], ["VEGF", "GENE_OR_GENE_PRODUCT", 56, 60], ["SFK", "PROTEIN", 43, 46], ["VEGF", "PROTEIN", 56, 60], ["SFK-mediated VEGF upregulation", "TREATMENT", 43, 73]]], ["HPSE can also enzymatically cleave HS chains, liberating bound VEGF.", [["HPSE", "CHEMICAL", 0, 4], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["VEGF", "GENE_OR_GENE_PRODUCT", 63, 67], ["HS chains", "PROTEIN", 35, 44], ["VEGF", "PROTEIN", 63, 67], ["bound VEGF", "OBSERVATION", 57, 67]]], ["It may also activate VEGFR2 via its role in syndecan-1 shedding.", [["VEGFR2", "GENE_OR_GENE_PRODUCT", 21, 27], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 44, 54], ["VEGFR2", "PROTEIN", 21, 27], ["syndecan", "PROTEIN", 44, 52], ["VEGFR2", "OBSERVATION", 21, 27]]], ["Further studies must be done to investigate precisely if and how HPSE activates SFKs.", [["HPSE", "SIMPLE_CHEMICAL", 65, 69], ["SFKs", "GENE_OR_GENE_PRODUCT", 80, 84], ["HPSE", "PROTEIN", 65, 69], ["SFKs", "PROTEIN", 80, 84], ["Further studies", "TEST", 0, 15]]], ["Additionally, the mechanism by which an SFK up-regulates VEGF needs to be explored.HPSE-VEGF signalingIn case of an HSV-1 infection, its immediate-early protein ICP4 acts as a transcription factor that up-regulates VEGF expression [84] .", [["infection", "DISEASE", 122, 131], ["SFK", "GENE_OR_GENE_PRODUCT", 40, 43], ["VEGF", "GENE_OR_GENE_PRODUCT", 57, 61], ["HPSE-VEGF", "GENE_OR_GENE_PRODUCT", 83, 92], ["HSV-1", "ORGANISM", 116, 121], ["ICP4", "GENE_OR_GENE_PRODUCT", 161, 165], ["VEGF", "GENE_OR_GENE_PRODUCT", 215, 219], ["SFK", "PROTEIN", 40, 43], ["VEGF", "PROTEIN", 57, 61], ["HPSE", "PROTEIN", 83, 87], ["VEGF", "PROTEIN", 88, 92], ["immediate-early protein", "PROTEIN", 137, 160], ["ICP4", "PROTEIN", 161, 165], ["transcription factor", "PROTEIN", 176, 196], ["VEGF", "PROTEIN", 215, 219], ["HSV-1", "SPECIES", 116, 121], ["HSV-1", "SPECIES", 116, 121], ["an HSV-1 infection", "PROBLEM", 113, 131], ["early protein ICP4 acts", "TREATMENT", 147, 170], ["a transcription factor", "PROBLEM", 174, 196], ["VEGF", "OBSERVATION", 88, 92], ["HSV", "OBSERVATION", 116, 119], ["infection", "OBSERVATION", 122, 131]]], ["During the later stages of infection, HSV-1 up-regulates HPSE in an ICP34.5-dependent mechanism, which results in the cleavage of HS moieties from the cell surface [61] .", [["cell surface", "ANATOMY", 151, 163], ["infection", "DISEASE", 27, 36], ["HSV-1", "ORGANISM", 38, 43], ["HPSE", "GENE_OR_GENE_PRODUCT", 57, 61], ["ICP34.5", "GENE_OR_GENE_PRODUCT", 68, 75], ["cell surface", "CELLULAR_COMPONENT", 151, 163], ["HPSE", "PROTEIN", 57, 61], ["HS moieties", "PROTEIN", 130, 141], ["HSV-1", "SPECIES", 38, 43], ["infection", "PROBLEM", 27, 36], ["HSV", "TEST", 38, 41], ["HPSE", "TEST", 57, 61], ["the cleavage of HS moieties", "PROBLEM", 114, 141], ["infection", "OBSERVATION", 27, 36]]], ["Cleavage of HS releases VEGF which may then bind to VEGFR.", [["HS", "GENE_OR_GENE_PRODUCT", 12, 14], ["VEGF", "GENE_OR_GENE_PRODUCT", 24, 28], ["VEGFR", "GENE_OR_GENE_PRODUCT", 52, 57], ["HS", "DNA", 12, 14], ["VEGF", "PROTEIN", 24, 28], ["VEGFR", "PROTEIN", 52, 57]]], ["Additionally, HSV-1 induces syndecan-1 shedding, which activates VEGFR, as well [85] .", [["HSV-1", "ORGANISM", 14, 19], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 28, 38], ["VEGFR", "GENE_OR_GENE_PRODUCT", 65, 70], ["syndecan", "PROTEIN", 28, 36], ["VEGFR", "PROTEIN", 65, 70], ["HSV-1", "SPECIES", 14, 19], ["HSV", "TEST", 14, 17], ["syndecan", "TEST", 28, 36]]], ["Activation of VEGFR stimulates downstream ERK signaling and the associated induction of inflammatory cytokines [86] .", [["VEGFR", "GENE_OR_GENE_PRODUCT", 14, 19], ["ERK", "GENE_OR_GENE_PRODUCT", 42, 45], ["VEGFR", "PROTEIN", 14, 19], ["ERK", "PROTEIN", 42, 45], ["inflammatory cytokines", "PROTEIN", 88, 110], ["VEGFR stimulates", "TREATMENT", 14, 30], ["ERK signaling", "TEST", 42, 55], ["inflammatory cytokines", "PROBLEM", 88, 110], ["inflammatory", "OBSERVATION_MODIFIER", 88, 100]]], ["These (1) Extracellular HPSE increases VEGF transcription in an SFKdependent manner.", [["Extracellular", "ANATOMY", 10, 23], ["Extracellular HPSE", "SIMPLE_CHEMICAL", 10, 28], ["VEGF", "GENE_OR_GENE_PRODUCT", 39, 43], ["VEGF", "PROTEIN", 39, 43], ["Extracellular HPSE increases VEGF transcription", "PROBLEM", 10, 57], ["HPSE", "OBSERVATION", 24, 28], ["increases", "OBSERVATION_MODIFIER", 29, 38], ["VEGF", "OBSERVATION", 39, 43]]], ["(2) HPSE cleaves HS chains from perlecan, lib-erating VEGF to bind to VEGFR2 and stimulate downstream signaling.", [["HS chains", "GENE_OR_GENE_PRODUCT", 17, 26], ["perlecan", "GENE_OR_GENE_PRODUCT", 32, 40], ["VEGF", "GENE_OR_GENE_PRODUCT", 54, 58], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 70, 76], ["HPSE", "PROTEIN", 4, 8], ["HS chains", "PROTEIN", 17, 26], ["perlecan", "PROTEIN", 32, 40], ["VEGF", "PROTEIN", 54, 58], ["VEGFR2", "PROTEIN", 70, 76], ["HPSE cleaves HS chains", "TREATMENT", 4, 26]]], ["(3) HPSE activation leads to syndecan-1 shedding from the cell surface.", [["cell surface", "ANATOMY", 58, 70], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 29, 39], ["cell surface", "CELLULAR_COMPONENT", 58, 70], ["syndecan", "PROTEIN", 29, 37], ["HPSE activation leads", "TREATMENT", 4, 25], ["cell", "ANATOMY", 58, 62], ["surface", "ANATOMY_MODIFIER", 63, 70]]], ["The syndecan protein complexes with \u03b14\u03b21 and VEGFR2, activating the latter cytokines trigger immune cell infiltration, and, in the case of ocular infections, can lead to neovascularization of the cornea [86] .", [["immune cell", "ANATOMY", 93, 104], ["ocular", "ANATOMY", 139, 145], ["cornea", "ANATOMY", 196, 202], ["ocular infections", "DISEASE", 139, 156], ["neovascularization", "DISEASE", 170, 188], ["syndecan", "GENE_OR_GENE_PRODUCT", 4, 12], ["\u03b14\u03b21", "GENE_OR_GENE_PRODUCT", 36, 40], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 45, 51], ["immune cell", "CELL", 93, 104], ["ocular", "ORGAN", 139, 145], ["cornea", "ORGAN", 196, 202], ["syndecan protein complexes", "PROTEIN", 4, 30], ["\u03b14\u03b21", "PROTEIN", 36, 40], ["VEGFR2", "PROTEIN", 45, 51], ["cytokines", "PROTEIN", 75, 84], ["The syndecan protein complexes", "TEST", 0, 30], ["VEGFR2", "PROBLEM", 45, 51], ["immune cell infiltration", "PROBLEM", 93, 117], ["ocular infections", "PROBLEM", 139, 156], ["neovascularization of the cornea", "PROBLEM", 170, 202], ["protein complexes", "OBSERVATION", 13, 30], ["immune cell infiltration", "OBSERVATION", 93, 117], ["ocular", "ANATOMY", 139, 145], ["infections", "OBSERVATION", 146, 156], ["neovascularization", "OBSERVATION", 170, 188], ["cornea", "ANATOMY", 196, 202]]], ["Thus, while HSV-1 stimulates VEGF transcription directly, HPSE plays an important role in liberating extracellular VEGF to further bolster angiogenic responses.HPSE-ERK signalingThe extracellular signal-regulated kinase (ERK) signaling pathway modulates the proliferation, survival, and differentiation of cells [87] .", [["extracellular", "ANATOMY", 101, 114], ["cells", "ANATOMY", 306, 311], ["HSV-1", "ORGANISM", 12, 17], ["VEGF", "GENE_OR_GENE_PRODUCT", 29, 33], ["HPSE", "GENE_OR_GENE_PRODUCT", 58, 62], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 101, 114], ["VEGF", "GENE_OR_GENE_PRODUCT", 115, 119], ["HPSE-ERK", "GENE_OR_GENE_PRODUCT", 160, 168], ["extracellular signal-regulated kinase", "GENE_OR_GENE_PRODUCT", 182, 219], ["ERK", "GENE_OR_GENE_PRODUCT", 221, 224], ["cells", "CELL", 306, 311], ["VEGF", "PROTEIN", 29, 33], ["HPSE", "PROTEIN", 58, 62], ["VEGF", "PROTEIN", 115, 119], ["HPSE", "PROTEIN", 160, 164], ["ERK", "PROTEIN", 165, 168], ["extracellular signal-regulated kinase", "PROTEIN", 182, 219], ["ERK", "PROTEIN", 221, 224], ["HSV-1", "SPECIES", 12, 17], ["HSV", "TEST", 12, 15], ["extracellular VEGF", "TREATMENT", 101, 119], ["The extracellular signal", "TEST", 178, 202], ["the proliferation", "PROBLEM", 254, 271], ["proliferation", "OBSERVATION_MODIFIER", 258, 271]]], ["The process begins with the binding of ligands to a variety of membrane receptors: G-protein coupled receptors (GPCRs), RTKs, and ion channels among others [88] .", [["membrane", "ANATOMY", 63, 71], ["membrane", "CELLULAR_COMPONENT", 63, 71], ["G-protein coupled receptors", "GENE_OR_GENE_PRODUCT", 83, 110], ["GPCRs", "GENE_OR_GENE_PRODUCT", 112, 117], ["RTKs", "GENE_OR_GENE_PRODUCT", 120, 124], ["membrane receptors", "PROTEIN", 63, 81], ["G-protein coupled receptors", "PROTEIN", 83, 110], ["GPCRs", "PROTEIN", 112, 117], ["RTKs", "PROTEIN", 120, 124], ["GPCRs", "TEST", 112, 117], ["RTKs", "TEST", 120, 124]]], ["For example, one method by which the pathway begins involves the binding of epidermal growth factor and transforming growth factor \u03b1 (TGF\u03b1) to the epidermal growth factor receptor (EGFR), a tyrosine kinase [88] .", [["tyrosine", "CHEMICAL", 190, 198], ["tyrosine", "CHEMICAL", 190, 198], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 76, 99], ["transforming growth factor \u03b1", "GENE_OR_GENE_PRODUCT", 104, 132], ["TGF\u03b1", "GENE_OR_GENE_PRODUCT", 134, 138], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 147, 179], ["EGFR", "GENE_OR_GENE_PRODUCT", 181, 185], ["epidermal growth factor", "PROTEIN", 76, 99], ["transforming growth factor \u03b1", "PROTEIN", 104, 132], ["TGF\u03b1", "PROTEIN", 134, 138], ["epidermal growth factor receptor", "PROTEIN", 147, 179], ["EGFR", "PROTEIN", 181, 185], ["tyrosine kinase", "PROTEIN", 190, 205], ["epidermal growth factor", "PROBLEM", 76, 99], ["transforming growth factor", "PROBLEM", 104, 130], ["a tyrosine kinase", "TEST", 188, 205]]], ["EGFR dimerizes upon ligand binding and starts the signal transduction pathway, which sequentially forms a complex of the following proteins: ShC-Grb2, SOS, and the GTPase Ras [88] .", [["EGFR", "GENE_OR_GENE_PRODUCT", 0, 4], ["ShC-Grb2", "GENE_OR_GENE_PRODUCT", 141, 149], ["SOS", "GENE_OR_GENE_PRODUCT", 151, 154], ["Ras", "GENE_OR_GENE_PRODUCT", 171, 174], ["EGFR", "PROTEIN", 0, 4], ["ShC", "PROTEIN", 141, 144], ["Grb2", "PROTEIN", 145, 149], ["SOS", "PROTEIN", 151, 154], ["GTPase Ras", "PROTEIN", 164, 174], ["EGFR dimerizes upon ligand binding", "PROBLEM", 0, 34], ["the signal transduction pathway", "TEST", 46, 77], ["ShC", "TEST", 141, 144], ["SOS", "TEST", 151, 154], ["the GTPase Ras", "TEST", 160, 174]]], ["The ShC-Grb2-SOS-Ras complex activates Ras which marks the start of the MAPK pathway [88] .", [["ShC-", "GENE_OR_GENE_PRODUCT", 4, 8], ["Grb2", "GENE_OR_GENE_PRODUCT", 8, 12], ["SOS-Ras", "GENE_OR_GENE_PRODUCT", 13, 20], ["Ras", "GENE_OR_GENE_PRODUCT", 39, 42], ["MAPK", "GENE_OR_GENE_PRODUCT", 72, 76], ["Grb2", "PROTEIN", 8, 12], ["SOS", "PROTEIN", 13, 16], ["Ras complex", "PROTEIN", 17, 28], ["Ras", "PROTEIN", 39, 42], ["MAPK", "PROTEIN", 72, 76], ["The ShC-Grb2", "TEST", 0, 12], ["the MAPK pathway", "TEST", 68, 84]]], ["The MAPK pathway consists of the sequential phosphorylation of the three kinases: MAPK 3-kinase (MAPKKK), MAPK 2 kinase (MAPKK), and MAPK [89] .", [["MAPK", "GENE_OR_GENE_PRODUCT", 4, 8], ["MAPK 3-kinase", "GENE_OR_GENE_PRODUCT", 82, 95], ["MAPKKK", "GENE_OR_GENE_PRODUCT", 97, 103], ["MAPK 2 kinase", "GENE_OR_GENE_PRODUCT", 106, 119], ["MAPKK", "GENE_OR_GENE_PRODUCT", 121, 126], ["MAPK [89]", "GENE_OR_GENE_PRODUCT", 133, 142], ["MAPK", "PROTEIN", 4, 8], ["kinases", "PROTEIN", 73, 80], ["MAPK 3-kinase", "PROTEIN", 82, 95], ["MAPKKK", "PROTEIN", 97, 103], ["MAPK 2 kinase", "PROTEIN", 106, 119], ["MAPKK", "PROTEIN", 121, 126], ["MAPK", "PROTEIN", 133, 137], ["The MAPK pathway", "TEST", 0, 16], ["MAPK", "TEST", 82, 86], ["kinase", "TEST", 89, 95], ["MAPKKK", "TEST", 97, 103], ["MAPK", "TEST", 106, 110], ["kinase (MAPKK", "TEST", 113, 126], ["MAPK", "TEST", 133, 137]]], ["In mammalian cells, these kinases are known as Raf, MEK1/2, and finally ERK1/2 [90] .", [["cells", "ANATOMY", 13, 18], ["mammalian cells", "CELL", 3, 18], ["Raf", "GENE_OR_GENE_PRODUCT", 47, 50], ["MEK1", "GENE_OR_GENE_PRODUCT", 52, 56], ["2", "GENE_OR_GENE_PRODUCT", 57, 58], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 72, 78], ["mammalian cells", "CELL_TYPE", 3, 18], ["kinases", "PROTEIN", 26, 33], ["Raf", "PROTEIN", 47, 50], ["MEK1", "PROTEIN", 52, 56], ["ERK1/2", "PROTEIN", 72, 78], ["these kinases", "TEST", 20, 33], ["Raf", "TEST", 47, 50], ["MEK1", "TEST", 52, 56], ["ERK1/2", "TEST", 72, 78], ["mammalian cells", "OBSERVATION", 3, 18]]], ["Activated ERK then proceeds to translocate to the nucleus where it phosphorylates transcription factors that regulate activities such as proliferation, continued survival, and angiogenesis [88] .HPSE-ERK signalingFor similar reasons as the Akt and VEGF pathways, it is advantageous for viruses to exert control over the ERK signaling pathway.", [["nucleus", "ANATOMY", 50, 57], ["ERK", "GENE_OR_GENE_PRODUCT", 10, 13], ["nucleus", "CELLULAR_COMPONENT", 50, 57], ["HPSE-ERK", "GENE_OR_GENE_PRODUCT", 195, 203], ["Akt", "GENE_OR_GENE_PRODUCT", 240, 243], ["VEGF", "GENE_OR_GENE_PRODUCT", 248, 252], ["ERK", "GENE_OR_GENE_PRODUCT", 320, 323], ["ERK", "PROTEIN", 10, 13], ["transcription factors", "PROTEIN", 82, 103], ["HPSE", "PROTEIN", 195, 199], ["ERK", "PROTEIN", 200, 203], ["Akt", "PROTEIN", 240, 243], ["VEGF", "PROTEIN", 248, 252], ["ERK", "PROTEIN", 320, 323], ["phosphorylates transcription factors", "PROBLEM", 67, 103], ["VEGF pathways", "TEST", 248, 261], ["viruses", "PROBLEM", 286, 293], ["nucleus", "ANATOMY", 50, 57]]], ["Promoting survival and delaying apoptosis allow viruses time to replicate and produce infectious progeny.", [["delaying apoptosis", "PROBLEM", 23, 41], ["infectious", "OBSERVATION_MODIFIER", 86, 96]]], ["Notably, all three classes of herpesviruses hijack the ERK pathway for their own benefit.", [["herpesviruses", "ORGANISM", 30, 43], ["ERK", "GENE_OR_GENE_PRODUCT", 55, 58], ["ERK", "PROTEIN", 55, 58]]], ["The alphaherpesvirus HSV-1 activates ERK, which travels to the cell membrane and promotes the remodeling of the actin cortex [91] .", [["cell membrane", "ANATOMY", 63, 76], ["actin cortex", "ANATOMY", 112, 124], ["alphaherpesvirus HSV-1", "ORGANISM", 4, 26], ["ERK", "GENE_OR_GENE_PRODUCT", 37, 40], ["cell membrane", "CELLULAR_COMPONENT", 63, 76], ["actin", "GENE_OR_GENE_PRODUCT", 112, 117], ["ERK", "PROTEIN", 37, 40], ["actin", "PROTEIN", 112, 117], ["HSV-1", "SPECIES", 21, 26], ["alphaherpesvirus HSV-1", "SPECIES", 4, 26], ["The alphaherpesvirus HSV", "TEST", 0, 24], ["ERK", "TEST", 37, 40], ["alphaherpesvirus HSV", "OBSERVATION", 4, 24], ["cell membrane", "OBSERVATION", 63, 76], ["remodeling", "OBSERVATION_MODIFIER", 94, 104], ["actin cortex", "OBSERVATION", 112, 124]]], ["This promotes filopodia formation and subsequent viral surfing, which aids HSV-1 find a suitable attachment point on the cell membrane for fusion [91] .", [["filopodia", "ANATOMY", 14, 23], ["cell membrane", "ANATOMY", 121, 134], ["filopodia", "CELLULAR_COMPONENT", 14, 23], ["HSV-1", "ORGANISM", 75, 80], ["cell membrane", "CELLULAR_COMPONENT", 121, 134], ["HSV-1", "SPECIES", 75, 80], ["subsequent viral surfing", "TREATMENT", 38, 62], ["HSV", "TEST", 75, 78], ["filopodia formation", "OBSERVATION", 14, 33], ["cell membrane", "OBSERVATION", 121, 134]]], ["The betaherpesvirus HCMV uses the ERK pathway to remodel its chromatin sites, an essential step in reactivation from latency [92] .", [["chromatin sites", "ANATOMY", 61, 76], ["betaherpesvirus HCMV", "ORGANISM", 4, 24], ["ERK", "GENE_OR_GENE_PRODUCT", 34, 37], ["chromatin", "CELLULAR_COMPONENT", 61, 70], ["ERK", "PROTEIN", 34, 37], ["chromatin sites", "DNA", 61, 76], ["HCMV", "SPECIES", 20, 24], ["The betaherpesvirus HCMV", "TREATMENT", 0, 24], ["the ERK pathway", "TREATMENT", 30, 45], ["HCMV", "OBSERVATION", 20, 24], ["chromatin sites", "OBSERVATION", 61, 76]]], ["The gamma herpesvirus KHSV activates ERK signaling to up-regulate the transcription factor Fos and stimulate the transcription of genes necessary for replication [93] .", [["gamma herpesvirus", "ORGANISM", 4, 21], ["KHSV", "ORGANISM", 22, 26], ["ERK", "GENE_OR_GENE_PRODUCT", 37, 40], ["Fos", "GENE_OR_GENE_PRODUCT", 91, 94], ["KHSV", "PROTEIN", 22, 26], ["ERK", "PROTEIN", 37, 40], ["transcription factor", "PROTEIN", 70, 90], ["Fos", "PROTEIN", 91, 94], ["gamma herpesvirus", "SPECIES", 4, 21], ["The gamma herpesvirus KHSV", "TEST", 0, 26], ["gamma herpesvirus", "OBSERVATION", 4, 21]]], ["Additional DNA viruses that have been shown to impact ERK signaling include HPV, HBV, and vaccinia virus [94] [95] [96] .", [["DNA", "CELLULAR_COMPONENT", 11, 14], ["ERK", "GENE_OR_GENE_PRODUCT", 54, 57], ["HPV", "ORGANISM", 76, 79], ["HBV", "ORGANISM", 81, 84], ["vaccinia virus", "ORGANISM", 90, 104], ["ERK", "PROTEIN", 54, 57], ["vaccinia virus", "SPECIES", 90, 104], ["HPV", "SPECIES", 76, 79], ["HBV", "SPECIES", 81, 84], ["vaccinia virus", "SPECIES", 90, 104], ["Additional DNA viruses", "PROBLEM", 0, 22], ["ERK signaling", "TEST", 54, 67], ["HPV", "PROBLEM", 76, 79], ["HBV", "PROBLEM", 81, 84], ["vaccinia virus", "PROBLEM", 90, 104], ["DNA viruses", "OBSERVATION", 11, 22]]], ["Yellow fever virus, influenza, and HCV require an intact ERK pathway for successful replication [97] [98] [99] .", [["Yellow fever", "DISEASE", 0, 12], ["influenza", "DISEASE", 20, 29], ["Yellow fever virus", "ORGANISM", 0, 18], ["HCV", "ORGANISM", 35, 38], ["ERK", "GENE_OR_GENE_PRODUCT", 57, 60], ["ERK", "PROTEIN", 57, 60], ["Yellow fever virus", "SPECIES", 0, 18], ["Yellow fever virus", "SPECIES", 0, 18], ["HCV", "SPECIES", 35, 38], ["Yellow fever virus", "PROBLEM", 0, 18], ["influenza", "PROBLEM", 20, 29], ["HCV", "PROBLEM", 35, 38], ["fever virus", "OBSERVATION", 7, 18]]], ["The ERK pathway affects Ebola and Dengue viruses, as well, the former needing to repress ERK activity and the latter needing to stimulate it [99, 100] .", [["Ebola and Dengue viruses", "DISEASE", 24, 48], ["ERK", "GENE_OR_GENE_PRODUCT", 4, 7], ["Ebola", "ORGANISM", 24, 29], ["Dengue viruses", "ORGANISM", 34, 48], ["ERK", "GENE_OR_GENE_PRODUCT", 89, 92], ["ERK", "PROTEIN", 4, 7], ["ERK", "PROTEIN", 89, 92], ["Dengue viruses", "SPECIES", 34, 48], ["The ERK pathway", "TEST", 0, 15], ["Ebola", "PROBLEM", 24, 29], ["Dengue viruses", "PROBLEM", 34, 48], ["Ebola", "OBSERVATION_MODIFIER", 24, 29], ["Dengue viruses", "OBSERVATION", 34, 48]]], ["Overall, a wide range of viruses have been demonstrated to regulate the ERK pathway for their own uses.HPSE-ERK signalingAgain, HPSE influences the ERK pathway, and the mechanisms by which this occurs are discussed below.", [["ERK", "GENE_OR_GENE_PRODUCT", 72, 75], ["HPSE-ERK", "GENE_OR_GENE_PRODUCT", 103, 111], ["HPSE", "SIMPLE_CHEMICAL", 128, 132], ["ERK", "GENE_OR_GENE_PRODUCT", 148, 151], ["ERK", "PROTEIN", 72, 75], ["HPSE", "PROTEIN", 103, 107], ["ERK", "PROTEIN", 108, 111], ["HPSE", "PROTEIN", 128, 132], ["ERK", "PROTEIN", 148, 151], ["a wide range of viruses", "PROBLEM", 9, 32], ["the ERK pathway", "TEST", 144, 159], ["wide", "OBSERVATION_MODIFIER", 11, 15], ["viruses", "OBSERVATION", 25, 32]]], ["Enzymatically active HPSE has been shown to increase levels of ERK phosphorylation in macrophages, myeloma, and pituitary adenoma cells [81, 101] .", [["macrophages", "ANATOMY", 86, 97], ["myeloma", "ANATOMY", 99, 106], ["pituitary adenoma cells", "ANATOMY", 112, 135], ["HPSE", "CHEMICAL", 21, 25], ["myeloma", "DISEASE", 99, 106], ["pituitary adenoma", "DISEASE", 112, 129], ["HPSE", "SIMPLE_CHEMICAL", 21, 25], ["ERK", "GENE_OR_GENE_PRODUCT", 63, 66], ["macrophages", "CELL", 86, 97], ["myeloma", "CANCER", 99, 106], ["pituitary adenoma cells", "CELL", 112, 135], ["HPSE", "PROTEIN", 21, 25], ["ERK", "PROTEIN", 63, 66], ["macrophages", "CELL_TYPE", 86, 97], ["pituitary adenoma cells", "CELL_TYPE", 112, 135], ["ERK phosphorylation in macrophages", "PROBLEM", 63, 97], ["myeloma", "PROBLEM", 99, 106], ["pituitary adenoma cells", "PROBLEM", 112, 135], ["active", "OBSERVATION_MODIFIER", 14, 20], ["HPSE", "OBSERVATION", 21, 25], ["increase", "OBSERVATION_MODIFIER", 44, 52], ["ERK phosphorylation", "OBSERVATION", 63, 82], ["macrophages", "OBSERVATION_MODIFIER", 86, 97], ["myeloma", "OBSERVATION", 99, 106], ["pituitary", "ANATOMY", 112, 121], ["adenoma cells", "OBSERVATION", 122, 135]]], ["HPSE-induced ERK activation then enhances the expression of matrix metallopeptidase 9 (MMP-9), which is a syndecan-1 sheddase, along with urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) levels.", [["HPSE", "CHEMICAL", 0, 4], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["ERK", "GENE_OR_GENE_PRODUCT", 13, 16], ["matrix metallopeptidase 9", "GENE_OR_GENE_PRODUCT", 60, 85], ["MMP-9", "GENE_OR_GENE_PRODUCT", 87, 92], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 106, 116], ["urokinase-type plasminogen activator", "GENE_OR_GENE_PRODUCT", 138, 174], ["uPA", "GENE_OR_GENE_PRODUCT", 176, 179], ["uPA receptor", "GENE_OR_GENE_PRODUCT", 185, 197], ["uPAR", "GENE_OR_GENE_PRODUCT", 199, 203], ["ERK", "PROTEIN", 13, 16], ["matrix metallopeptidase 9", "PROTEIN", 60, 85], ["MMP-9", "PROTEIN", 87, 92], ["syndecan-1 sheddase", "PROTEIN", 106, 125], ["urokinase-type plasminogen activator", "PROTEIN", 138, 174], ["uPA", "PROTEIN", 176, 179], ["uPA receptor", "PROTEIN", 185, 197], ["uPAR", "PROTEIN", 199, 203], ["ERK activation", "PROBLEM", 13, 27], ["matrix metallopeptidase", "TEST", 60, 83], ["MMP", "TEST", 87, 90], ["urokinase-type plasminogen activator", "TREATMENT", 138, 174], ["uPA receptor (uPAR) levels", "TEST", 185, 211], ["ERK activation", "OBSERVATION", 13, 27]]], ["It has been shown that uPA and uPAR lead to the downstream activation of the proenzyme form of MMP-9 (pro-MMP-9) [102] .", [["uPA", "GENE_OR_GENE_PRODUCT", 23, 26], ["uPAR", "GENE_OR_GENE_PRODUCT", 31, 35], ["MMP-9", "GENE_OR_GENE_PRODUCT", 95, 100], ["pro-MMP-9", "GENE_OR_GENE_PRODUCT", 102, 111], ["uPA", "PROTEIN", 23, 26], ["uPAR", "PROTEIN", 31, 35], ["proenzyme form", "PROTEIN", 77, 91], ["MMP-9", "PROTEIN", 95, 100], ["pro-MMP-9", "PROTEIN", 102, 111], ["uPA", "PROBLEM", 23, 26], ["the proenzyme", "TEST", 73, 86], ["MMP", "TEST", 95, 98], ["pro-MMP", "TEST", 102, 109]]], ["Activation of uPA, uPAR, and pro-MMP-9 results in the formation of active MMP-9.", [["uPA", "GENE_OR_GENE_PRODUCT", 14, 17], ["uPAR", "GENE_OR_GENE_PRODUCT", 19, 23], ["pro-MMP-9", "GENE_OR_GENE_PRODUCT", 29, 38], ["MMP-9", "GENE_OR_GENE_PRODUCT", 74, 79], ["uPA", "PROTEIN", 14, 17], ["uPAR", "PROTEIN", 19, 23], ["pro-MMP-9", "PROTEIN", 29, 38], ["MMP-9", "PROTEIN", 74, 79], ["uPA", "TEST", 14, 17], ["uPAR", "TEST", 19, 23], ["pro-MMP", "TEST", 29, 36], ["active MMP", "TEST", 67, 77]]], ["Another study discovered that syndecan-1 shedding was greatly inhibited when the activation of MMP-9, uPA, or uPAR was blocked, further supporting the relationship of these three proteins in stimulating syndecan-1 shedding [81] .", [["syndecan-1", "GENE_OR_GENE_PRODUCT", 30, 40], ["MMP-9", "GENE_OR_GENE_PRODUCT", 95, 100], ["uPA", "GENE_OR_GENE_PRODUCT", 102, 105], ["uPAR", "GENE_OR_GENE_PRODUCT", 110, 114], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 203, 213], ["syndecan-1", "PROTEIN", 30, 40], ["MMP-9", "PROTEIN", 95, 100], ["uPA", "PROTEIN", 102, 105], ["uPAR", "PROTEIN", 110, 114], ["syndecan", "PROTEIN", 203, 211], ["Another study", "TEST", 0, 13], ["MMP", "TEST", 95, 98], ["uPA", "TREATMENT", 102, 105]]], ["However, it should be noted that in breast cancer cells, HPSE led to a decrease in MMP-9 expression, which suggests that the effect of HPSE may be cell-type dependent and elicit different pathways which impact MMP-9 expression [103] .HPSE-ERK signalingThe shed syndecan-1 can then bind to VEGF (also upregulated by HPSE), and the complex attaches integrins to VEGFR2 [104] .", [["breast cancer cells", "ANATOMY", 36, 55], ["cell", "ANATOMY", 147, 151], ["breast cancer", "DISEASE", 36, 49], ["HPSE", "CHEMICAL", 57, 61], ["HPSE", "CHEMICAL", 135, 139], ["HPSE", "CHEMICAL", 57, 61], ["breast cancer cells", "CELL", 36, 55], ["HPSE", "SIMPLE_CHEMICAL", 57, 61], ["MMP-9", "GENE_OR_GENE_PRODUCT", 83, 88], ["HPSE", "SIMPLE_CHEMICAL", 135, 139], ["cell", "CELL", 147, 151], ["MMP-9", "GENE_OR_GENE_PRODUCT", 210, 215], ["HPSE-ERK", "GENE_OR_GENE_PRODUCT", 234, 242], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 261, 271], ["VEGF", "GENE_OR_GENE_PRODUCT", 289, 293], ["HPSE", "GENE_OR_GENE_PRODUCT", 315, 319], ["integrins", "GENE_OR_GENE_PRODUCT", 347, 356], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 360, 366], ["breast cancer cells", "CELL_TYPE", 36, 55], ["MMP", "PROTEIN", 83, 86], ["MMP", "PROTEIN", 210, 213], ["HPSE", "PROTEIN", 234, 238], ["ERK", "PROTEIN", 239, 242], ["shed syndecan-1", "PROTEIN", 256, 271], ["VEGF", "PROTEIN", 289, 293], ["HPSE", "PROTEIN", 315, 319], ["integrins", "PROTEIN", 347, 356], ["VEGFR2", "PROTEIN", 360, 366], ["breast cancer cells", "PROBLEM", 36, 55], ["a decrease in MMP", "PROBLEM", 69, 86], ["cell-type dependent", "PROBLEM", 147, 166], ["MMP", "TEST", 210, 213], ["breast", "ANATOMY", 36, 42], ["cancer", "OBSERVATION", 43, 49], ["decrease", "OBSERVATION_MODIFIER", 71, 79]]], ["They synergistically enhance ERK phosphorylation and invasion of the endothelial layer in myeloma cells [104] .", [["endothelial layer", "ANATOMY", 69, 86], ["myeloma cells", "ANATOMY", 90, 103], ["myeloma", "DISEASE", 90, 97], ["ERK", "GENE_OR_GENE_PRODUCT", 29, 32], ["endothelial layer", "CELLULAR_COMPONENT", 69, 86], ["myeloma cells", "CELL", 90, 103], ["ERK", "PROTEIN", 29, 32], ["myeloma cells", "CELL_TYPE", 90, 103], ["ERK phosphorylation", "TEST", 29, 48], ["the endothelial layer in myeloma cells", "PROBLEM", 65, 103], ["ERK phosphorylation", "OBSERVATION", 29, 48], ["invasion", "OBSERVATION_MODIFIER", 53, 61], ["endothelial", "ANATOMY", 69, 80], ["layer", "OBSERVATION_MODIFIER", 81, 86], ["myeloma cells", "OBSERVATION", 90, 103]]], ["The same study demonstrated that VEGF alone could facilitate a lesser degree of endothelial invasion, while syndecan-1 alone had no effect [104] .", [["endothelial", "ANATOMY", 80, 91], ["VEGF", "GENE_OR_GENE_PRODUCT", 33, 37], ["endothelial", "CELL", 80, 91], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 108, 118], ["VEGF", "PROTEIN", 33, 37], ["syndecan", "PROTEIN", 108, 116], ["The same study", "TEST", 0, 14], ["VEGF", "PROBLEM", 33, 37], ["endothelial invasion", "PROBLEM", 80, 100], ["syndecan", "TEST", 108, 116], ["VEGF", "OBSERVATION", 33, 37], ["lesser", "OBSERVATION_MODIFIER", 63, 69], ["degree", "OBSERVATION_MODIFIER", 70, 76], ["endothelial", "ANATOMY", 80, 91], ["invasion", "OBSERVATION", 92, 100]]], ["Thus, instead of independently promoting invasive behavior, the shed syndecan-1 may be further enhancing the effects of VEGF.", [["syndecan-1", "GENE_OR_GENE_PRODUCT", 69, 79], ["VEGF", "GENE_OR_GENE_PRODUCT", 120, 124], ["shed syndecan-1", "PROTEIN", 64, 79], ["VEGF", "PROTEIN", 120, 124], ["VEGF", "PROBLEM", 120, 124], ["VEGF", "OBSERVATION", 120, 124]]], ["The cause of this synergistic effect has been hypothesized to be due to the syndecan-1 protecting VEGF from degradation or aiding the binding of VEGF to receptors on the cell surface, but it is currently unknown [104] .", [["cell surface", "ANATOMY", 170, 182], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 76, 86], ["VEGF", "GENE_OR_GENE_PRODUCT", 98, 102], ["VEGF", "GENE_OR_GENE_PRODUCT", 145, 149], ["cell surface", "CELLULAR_COMPONENT", 170, 182], ["syndecan-1", "PROTEIN", 76, 86], ["VEGF", "PROTEIN", 98, 102], ["VEGF", "PROTEIN", 145, 149], ["this synergistic effect", "PROBLEM", 13, 36], ["the syndecan", "PROBLEM", 72, 84], ["VEGF", "PROBLEM", 98, 102]]], ["The HPSE-VEGF-ERK pathway is thought to be taken advantage of during ocular HSV-1 infection to promote corneal neovascularization [86] .HPSE-ERK signalingBecause only enzymatically active variants of HPSE were shown to activate ERK phosphorylation in myeloma cells [81] , the mechanism by which HPSE leads to ERK activation likely involves a downstream signal resulting from HS degradation.", [["ocular", "ANATOMY", 69, 75], ["corneal", "ANATOMY", 103, 110], ["myeloma cells", "ANATOMY", 251, 264], ["infection", "DISEASE", 82, 91], ["neovascularization", "DISEASE", 111, 129], ["myeloma", "DISEASE", 251, 258], ["HPSE", "CHEMICAL", 295, 299], ["HPSE-VEGF", "GENE_OR_GENE_PRODUCT", 4, 13], ["ERK", "GENE_OR_GENE_PRODUCT", 14, 17], ["HSV-1", "ORGANISM", 76, 81], ["corneal", "TISSUE", 103, 110], ["HPSE-ERK", "GENE_OR_GENE_PRODUCT", 136, 144], ["HPSE", "GENE_OR_GENE_PRODUCT", 200, 204], ["ERK", "GENE_OR_GENE_PRODUCT", 228, 231], ["myeloma cells", "CELL", 251, 264], ["HPSE", "GENE_OR_GENE_PRODUCT", 295, 299], ["ERK", "GENE_OR_GENE_PRODUCT", 309, 312], ["HS", "GENE_OR_GENE_PRODUCT", 375, 377], ["HPSE", "PROTEIN", 4, 8], ["VEGF", "PROTEIN", 9, 13], ["ERK", "PROTEIN", 14, 17], ["HPSE", "PROTEIN", 136, 140], ["ERK", "PROTEIN", 141, 144], ["HPSE", "PROTEIN", 200, 204], ["ERK", "PROTEIN", 228, 231], ["myeloma cells", "CELL_TYPE", 251, 264], ["HPSE", "PROTEIN", 295, 299], ["ERK", "PROTEIN", 309, 312], ["HSV-1", "SPECIES", 76, 81], ["HSV-1", "SPECIES", 76, 81], ["The HPSE", "TEST", 0, 8], ["ERK pathway", "TEST", 14, 25], ["ocular HSV", "PROBLEM", 69, 79], ["1 infection", "PROBLEM", 80, 91], ["corneal neovascularization", "PROBLEM", 103, 129], ["ERK signaling", "TEST", 141, 154], ["enzymatically active variants of HPSE", "PROBLEM", 167, 204], ["ERK phosphorylation in myeloma cells", "PROBLEM", 228, 264], ["ERK activation", "TEST", 309, 323], ["a downstream signal", "PROBLEM", 340, 359], ["HS degradation", "PROBLEM", 375, 389], ["corneal", "ANATOMY", 103, 110], ["neovascularization", "OBSERVATION", 111, 129], ["myeloma cells", "OBSERVATION", 251, 264]]], ["One candidate for this signal has been suggested by Purushothaman et al. to be hepatocyte growth factor (HGF) as it has been shown to bind to the HSPG syndecan-1 via its HS moieties in myeloma cells and stimulate Met signaling via the c-Met receptor, which, in turn, activates the ERK pathway [105, 106] .", [["myeloma cells", "ANATOMY", 185, 198], ["myeloma", "DISEASE", 185, 192], ["Met", "CHEMICAL", 213, 216], ["hepatocyte growth factor", "GENE_OR_GENE_PRODUCT", 79, 103], ["HGF", "GENE_OR_GENE_PRODUCT", 105, 108], ["HSPG syndecan-1", "GENE_OR_GENE_PRODUCT", 146, 161], ["myeloma cells", "CELL", 185, 198], ["Met", "GENE_OR_GENE_PRODUCT", 213, 216], ["c-Met receptor", "GENE_OR_GENE_PRODUCT", 235, 249], ["ERK", "GENE_OR_GENE_PRODUCT", 281, 284], ["hepatocyte growth factor", "PROTEIN", 79, 103], ["HGF", "PROTEIN", 105, 108], ["HSPG syndecan-1", "PROTEIN", 146, 161], ["myeloma cells", "CELL_TYPE", 185, 198], ["Met", "PROTEIN", 213, 216], ["c-Met receptor", "PROTEIN", 235, 249], ["ERK", "PROTEIN", 281, 284], ["the HSPG syndecan", "TEST", 142, 159], ["its HS moieties", "TREATMENT", 166, 181], ["myeloma cells", "PROBLEM", 185, 198], ["the c-Met receptor", "TREATMENT", 231, 249], ["the ERK pathway", "TEST", 277, 292], ["hepatocyte", "ANATOMY", 79, 89], ["myeloma cells", "OBSERVATION", 185, 198]]], ["Although primarily made in mesenchymal cells, HGF is also produced in myeloma cells [107] .", [["mesenchymal cells", "ANATOMY", 27, 44], ["myeloma cells", "ANATOMY", 70, 83], ["myeloma", "DISEASE", 70, 77], ["mesenchymal cells", "CELL", 27, 44], ["HGF", "GENE_OR_GENE_PRODUCT", 46, 49], ["myeloma cells", "CELL", 70, 83], ["mesenchymal cells", "CELL_TYPE", 27, 44], ["HGF", "PROTEIN", 46, 49], ["myeloma cells", "CELL_TYPE", 70, 83], ["mesenchymal cells", "PROBLEM", 27, 44], ["myeloma cells", "PROBLEM", 70, 83], ["mesenchymal cells", "OBSERVATION", 27, 44], ["myeloma cells", "OBSERVATION", 70, 83]]], ["Enzymatically inactive HPSE has been shown to up-regulate HGF expression and secretion from the cell [108] .", [["cell", "ANATOMY", 96, 100], ["HPSE", "CHEMICAL", 23, 27], ["HPSE", "GENE_OR_GENE_PRODUCT", 23, 27], ["HGF", "GENE_OR_GENE_PRODUCT", 58, 61], ["cell", "CELL", 96, 100], ["HPSE", "PROTEIN", 23, 27], ["HGF", "PROTEIN", 58, 61], ["Enzymatically inactive HPSE", "PROBLEM", 0, 27], ["inactive", "OBSERVATION", 14, 22]]], ["Thus, the enzymatic activity of HPSE stimulates syndecan-1 shedding which enhances the effects of the HGF that was already up-regulated by a non-enzymatic domain of HPSE.", [["HPSE", "CHEMICAL", 32, 36], ["HPSE", "SIMPLE_CHEMICAL", 32, 36], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 48, 58], ["HGF", "GENE_OR_GENE_PRODUCT", 102, 105], ["HPSE", "SIMPLE_CHEMICAL", 165, 169], ["HPSE", "PROTEIN", 32, 36], ["syndecan", "PROTEIN", 48, 56], ["HGF", "PROTEIN", 102, 105], ["non-enzymatic domain", "PROTEIN", 141, 161], ["HPSE", "PROTEIN", 165, 169], ["the HGF", "PROBLEM", 98, 105], ["a non-enzymatic domain of HPSE", "PROBLEM", 139, 169]]], ["This may explain why non-enzymatically active HPSE is insufficient to stimulate ERK signaling.", [["HPSE", "CHEMICAL", 46, 50], ["HPSE", "CHEMICAL", 46, 50], ["HPSE", "SIMPLE_CHEMICAL", 46, 50], ["ERK", "GENE_OR_GENE_PRODUCT", 80, 83], ["ERK", "PROTEIN", 80, 83], ["non-enzymatically active HPSE", "PROBLEM", 21, 50]]], ["In addition, there is mixed evidence to support that HGF induces Akt phosphorylation via Met signaling in myeloma cells [105, 106] .", [["myeloma cells", "ANATOMY", 106, 119], ["myeloma", "DISEASE", 106, 113], ["Met", "CHEMICAL", 89, 92], ["HGF", "GENE_OR_GENE_PRODUCT", 53, 56], ["Akt", "GENE_OR_GENE_PRODUCT", 65, 68], ["Met", "GENE_OR_GENE_PRODUCT", 89, 92], ["myeloma cells", "CELL", 106, 119], ["HGF", "PROTEIN", 53, 56], ["Akt", "PROTEIN", 65, 68], ["Met", "PROTEIN", 89, 92], ["myeloma cells", "CELL_LINE", 106, 119], ["Akt phosphorylation", "TEST", 65, 84], ["myeloma cells", "PROBLEM", 106, 119], ["myeloma cells", "OBSERVATION", 106, 119]]], ["If true, this would supplement the pro-survival signal response from the ERK pathway via the PI3K/Akt pathway.HPSE-ERK signalingAnother facet of the HPSE-ERK axis includes the insulin receptor (IR).", [["ERK", "GENE_OR_GENE_PRODUCT", 73, 76], ["PI3K", "GENE_OR_GENE_PRODUCT", 93, 97], ["Akt", "GENE_OR_GENE_PRODUCT", 98, 101], ["HPSE-ERK", "GENE_OR_GENE_PRODUCT", 110, 118], ["HPSE", "GENE_OR_GENE_PRODUCT", 149, 153], ["ERK", "GENE_OR_GENE_PRODUCT", 154, 157], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 176, 192], ["IR", "GENE_OR_GENE_PRODUCT", 194, 196], ["ERK", "PROTEIN", 73, 76], ["PI3K", "PROTEIN", 93, 97], ["Akt", "PROTEIN", 98, 101], ["HPSE", "PROTEIN", 110, 114], ["ERK", "PROTEIN", 115, 118], ["HPSE", "PROTEIN", 149, 153], ["ERK", "PROTEIN", 154, 157], ["insulin receptor", "PROTEIN", 176, 192], ["IR", "PROTEIN", 194, 196], ["the ERK pathway", "TEST", 69, 84], ["the PI3K/Akt pathway", "TREATMENT", 89, 109], ["the HPSE", "TEST", 145, 153], ["the insulin receptor", "TREATMENT", 172, 192], ["facet", "OBSERVATION_MODIFIER", 136, 141], ["ERK axis", "OBSERVATION", 154, 162]]], ["Upregulation of enzymatically active HPSE has been shown to increase the phosphorylation levels of the IR, a tyrosine kinase, in myeloma cells [87] .", [["myeloma cells", "ANATOMY", 129, 142], ["HPSE", "CHEMICAL", 37, 41], ["tyrosine", "CHEMICAL", 109, 117], ["myeloma", "DISEASE", 129, 136], ["tyrosine", "CHEMICAL", 109, 117], ["HPSE", "GENE_OR_GENE_PRODUCT", 37, 41], ["IR", "GENE_OR_GENE_PRODUCT", 103, 105], ["myeloma cells", "CELL", 129, 142], ["HPSE", "PROTEIN", 37, 41], ["IR", "PROTEIN", 103, 105], ["tyrosine kinase", "PROTEIN", 109, 124], ["myeloma cells", "CELL_TYPE", 129, 142], ["Upregulation of enzymatically active HPSE", "PROBLEM", 0, 41], ["the phosphorylation levels", "TEST", 69, 95], ["a tyrosine kinase", "TEST", 107, 124], ["myeloma cells", "PROBLEM", 129, 142], ["enzymatically", "OBSERVATION_MODIFIER", 16, 29], ["active", "OBSERVATION_MODIFIER", 30, 36], ["HPSE", "OBSERVATION", 37, 41], ["myeloma cells", "OBSERVATION", 129, 142]]], ["Antibodies targeting the IR inhibit ERK activation [87] .", [["ERK", "GENE_OR_GENE_PRODUCT", 36, 39], ["ERK", "PROTEIN", 36, 39], ["Antibodies", "TEST", 0, 10]]], ["After HPSE activates the insulin receptor, the insulin receptor phosphorylates the insulin receptor substrate 1 (IRS-1) [87] .", [["HPSE", "SIMPLE_CHEMICAL", 6, 10], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 25, 41], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 47, 63], ["insulin receptor substrate 1", "GENE_OR_GENE_PRODUCT", 83, 111], ["IRS-1", "GENE_OR_GENE_PRODUCT", 113, 118], ["HPSE", "PROTEIN", 6, 10], ["insulin receptor", "PROTEIN", 25, 41], ["insulin receptor", "PROTEIN", 47, 63], ["insulin receptor substrate 1 (IRS-1", "PROTEIN", 83, 118], ["the insulin receptor", "TREATMENT", 21, 41], ["the insulin receptor phosphorylates", "TREATMENT", 43, 78], ["the insulin receptor substrate", "TREATMENT", 79, 109]]], ["Additionally, HPSE was demonstrated to activate protein kinase C(PKC) which up-regulates IRS-1 [87] .", [["HPSE", "CHEMICAL", 14, 18], ["HPSE", "SIMPLE_CHEMICAL", 14, 18], ["protein kinase C", "GENE_OR_GENE_PRODUCT", 48, 64], ["PKC", "GENE_OR_GENE_PRODUCT", 65, 68], ["IRS-1", "GENE_OR_GENE_PRODUCT", 89, 94], ["HPSE", "PROTEIN", 14, 18], ["protein kinase C", "PROTEIN", 48, 64], ["PKC", "PROTEIN", 65, 68], ["IRS", "PROTEIN", 89, 92], ["protein kinase C", "TEST", 48, 64], ["PKC", "TEST", 65, 68], ["IRS", "TEST", 89, 92]]], ["Thus, HPSE enhances pIRS-1 levels by increasing both the production of IRS-1 and its phosphorylation.", [["HPSE", "CHEMICAL", 6, 10], ["HPSE", "SIMPLE_CHEMICAL", 6, 10], ["pIRS-1", "GENE_OR_GENE_PRODUCT", 20, 26], ["IRS-1", "GENE_OR_GENE_PRODUCT", 71, 76], ["pIRS", "PROTEIN", 20, 24], ["IRS-1", "PROTEIN", 71, 76], ["pIRS", "TEST", 20, 24], ["IRS", "TEST", 71, 74]]], ["In other words, HPSE is responsible for increasing IRS-1 levels via PKC and for increasing phospho-IRS-1 levels via the insulin receptor.", [["HPSE", "CHEMICAL", 16, 20], ["HPSE", "SIMPLE_CHEMICAL", 16, 20], ["IRS-1", "GENE_OR_GENE_PRODUCT", 51, 56], ["PKC", "GENE_OR_GENE_PRODUCT", 68, 71], ["phospho-IRS-1", "GENE_OR_GENE_PRODUCT", 91, 104], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 120, 136], ["IRS", "PROTEIN", 51, 54], ["PKC", "PROTEIN", 68, 71], ["phospho-IRS-1", "PROTEIN", 91, 104], ["insulin receptor", "PROTEIN", 120, 136], ["increasing IRS", "PROBLEM", 40, 54], ["PKC", "TEST", 68, 71], ["increasing phospho-IRS", "TEST", 80, 102], ["the insulin receptor", "TREATMENT", 116, 136]]], ["High levels of pIRS-1 then induce ERK activation [87] .HPSE-ERK signalingThe results of these studies suggest that, in myeloma cells, HPSE increases VEGF which activates ERK (Fig. 3) .", [["myeloma cells", "ANATOMY", 119, 132], ["myeloma", "DISEASE", 119, 126], ["HPSE", "CHEMICAL", 134, 138], ["HPSE", "CHEMICAL", 134, 138], ["pIRS-1", "GENE_OR_GENE_PRODUCT", 15, 21], ["ERK", "GENE_OR_GENE_PRODUCT", 34, 37], ["HPSE-ERK", "GENE_OR_GENE_PRODUCT", 55, 63], ["myeloma cells", "CELL", 119, 132], ["HPSE", "SIMPLE_CHEMICAL", 134, 138], ["VEGF", "GENE_OR_GENE_PRODUCT", 149, 153], ["ERK", "GENE_OR_GENE_PRODUCT", 170, 173], ["Fig. 3", "GENE_OR_GENE_PRODUCT", 175, 181], ["pIRS", "PROTEIN", 15, 19], ["ERK", "PROTEIN", 34, 37], ["HPSE", "PROTEIN", 55, 59], ["ERK", "PROTEIN", 60, 63], ["myeloma cells", "CELL_LINE", 119, 132], ["VEGF", "PROTEIN", 149, 153], ["ERK", "PROTEIN", 170, 173], ["pIRS", "TEST", 15, 19], ["ERK activation", "TEST", 34, 48], ["these studies", "TEST", 88, 101], ["myeloma cells", "PROBLEM", 119, 132], ["HPSE increases VEGF", "PROBLEM", 134, 153], ["myeloma cells", "OBSERVATION", 119, 132], ["increases", "OBSERVATION_MODIFIER", 139, 148], ["VEGF", "OBSERVATION_MODIFIER", 149, 153]]], ["ERK then stimulates the expression of MMP-9 and uPA/ UPAR.", [["ERK", "GENE_OR_GENE_PRODUCT", 0, 3], ["MMP-9", "GENE_OR_GENE_PRODUCT", 38, 43], ["uPA", "GENE_OR_GENE_PRODUCT", 48, 51], ["UPAR", "GENE_OR_GENE_PRODUCT", 53, 57], ["ERK", "PROTEIN", 0, 3], ["MMP-9", "PROTEIN", 38, 43], ["uPA", "PROTEIN", 48, 51], ["UPAR", "PROTEIN", 53, 57], ["ERK", "TEST", 0, 3], ["MMP", "TEST", 38, 41], ["uPA/ UPAR", "TREATMENT", 48, 57]]], ["This increases syndecan-1 shedding which has been shown to increase angiogenesis and endothelial invasion by myeloma cells [104] .", [["endothelial", "ANATOMY", 85, 96], ["myeloma cells", "ANATOMY", 109, 122], ["myeloma", "DISEASE", 109, 116], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 15, 25], ["endothelial", "CELL", 85, 96], ["myeloma cells", "CELL", 109, 122], ["syndecan", "PROTEIN", 15, 23], ["myeloma cells", "CELL_TYPE", 109, 122], ["increase angiogenesis", "PROBLEM", 59, 80], ["endothelial invasion", "PROBLEM", 85, 105], ["myeloma cells", "PROBLEM", 109, 122], ["increase", "OBSERVATION_MODIFIER", 59, 67], ["angiogenesis", "OBSERVATION", 68, 80], ["endothelial", "ANATOMY", 85, 96], ["invasion", "OBSERVATION", 97, 105], ["myeloma cells", "OBSERVATION", 109, 122]]], ["In addition, the shed syndecan-1 can form a complex with VEGF to further enhance ERK signaling which may create a positive feedback loop.", [["syndecan-1", "GENE_OR_GENE_PRODUCT", 22, 32], ["VEGF", "GENE_OR_GENE_PRODUCT", 57, 61], ["ERK", "GENE_OR_GENE_PRODUCT", 81, 84], ["shed syndecan-1", "PROTEIN", 17, 32], ["VEGF", "PROTEIN", 57, 61], ["ERK", "PROTEIN", 81, 84], ["a complex with VEGF", "PROBLEM", 42, 61], ["ERK signaling", "TEST", 81, 94], ["a positive feedback loop", "PROBLEM", 112, 136], ["positive", "OBSERVATION_MODIFIER", 114, 122], ["feedback loop", "OBSERVATION", 123, 136]]], ["Removal of syndecan-1 from cells expressing high levels of HPSE reduced levels of ERK to baseline levels, highlighting the importance of syndecan-1 in magnifying the effects of VEGF and the larger effects on the ERK-signaling pathway [104] .", [["cells", "ANATOMY", 27, 32], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 11, 21], ["cells", "CELL", 27, 32], ["HPSE", "GENE_OR_GENE_PRODUCT", 59, 63], ["ERK", "GENE_OR_GENE_PRODUCT", 82, 85], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 137, 147], ["VEGF", "GENE_OR_GENE_PRODUCT", 177, 181], ["ERK", "GENE_OR_GENE_PRODUCT", 212, 215], ["syndecan-1", "PROTEIN", 11, 21], ["HPSE", "PROTEIN", 59, 63], ["ERK", "PROTEIN", 82, 85], ["syndecan-1", "PROTEIN", 137, 147], ["VEGF", "PROTEIN", 177, 181], ["ERK", "PROTEIN", 212, 215], ["Removal of syndecan", "TREATMENT", 0, 19], ["VEGF", "TREATMENT", 177, 181], ["the ERK", "TEST", 208, 215]]], ["In addition, HPSE-induced HGF activation along with the resultant HGF-syndecan-1 complex may also contribute to the activation of ERK signaling.", [["HPSE", "CHEMICAL", 13, 17], ["HPSE", "SIMPLE_CHEMICAL", 13, 17], ["HGF", "GENE_OR_GENE_PRODUCT", 26, 29], ["HGF", "GENE_OR_GENE_PRODUCT", 66, 69], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 70, 80], ["ERK", "GENE_OR_GENE_PRODUCT", 130, 133], ["HPSE", "PROTEIN", 13, 17], ["HGF", "PROTEIN", 26, 29], ["HGF", "PROTEIN", 66, 69], ["syndecan-1 complex", "PROTEIN", 70, 88], ["ERK", "PROTEIN", 130, 133], ["HPSE", "TEST", 13, 17], ["HGF activation", "PROBLEM", 26, 40], ["ERK signaling", "PROBLEM", 130, 143]]], ["Finally, HPSE can stimulate ERK activation via the insulin receptor pathway described previously.", [["HPSE", "CHEMICAL", 9, 13], ["HPSE", "SIMPLE_CHEMICAL", 9, 13], ["ERK", "GENE_OR_GENE_PRODUCT", 28, 31], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 51, 67], ["ERK", "PROTEIN", 28, 31], ["insulin receptor", "PROTEIN", 51, 67], ["the insulin receptor pathway", "TREATMENT", 47, 75]]], ["Thus, HPSE appears to exert its stimulatory effects on ERK phosphorylation from at least three mechanisms.", [["HPSE", "CHEMICAL", 6, 10], ["HPSE", "CHEMICAL", 6, 10], ["HPSE", "SIMPLE_CHEMICAL", 6, 10], ["ERK", "GENE_OR_GENE_PRODUCT", 55, 58], ["ERK", "PROTEIN", 55, 58], ["ERK phosphorylation", "TREATMENT", 55, 74]]], ["Future work must be done exploring the role of the HPSE-HGF relationship in ERK signaling and whether the proposed mechanisms are present in cells other than myeloma or other cancerous cell lines.", [["cells", "ANATOMY", 141, 146], ["myeloma", "ANATOMY", 158, 165], ["cancerous cell lines", "ANATOMY", 175, 195], ["myeloma", "DISEASE", 158, 165], ["HPSE", "GENE_OR_GENE_PRODUCT", 51, 55], ["HGF", "GENE_OR_GENE_PRODUCT", 56, 59], ["ERK", "GENE_OR_GENE_PRODUCT", 76, 79], ["cells", "CELL", 141, 146], ["myeloma", "CANCER", 158, 165], ["cancerous cell lines", "CELL", 175, 195], ["HPSE", "PROTEIN", 51, 55], ["HGF", "PROTEIN", 56, 59], ["ERK", "PROTEIN", 76, 79], ["myeloma", "CELL_LINE", 158, 165], ["cancerous cell lines", "CELL_LINE", 175, 195], ["the HPSE", "TEST", 47, 55], ["ERK signaling", "TEST", 76, 89], ["myeloma", "PROBLEM", 158, 165], ["other cancerous cell lines", "PROBLEM", 169, 195], ["myeloma", "OBSERVATION", 158, 165], ["cancerous cell lines", "OBSERVATION", 175, 195]]], ["Fig. 3 Proposed mechanism by which HPSE activates ERK signaling.", [["HPSE", "CHEMICAL", 35, 39], ["HPSE", "CHEMICAL", 35, 39], ["HPSE", "GENE_OR_GENE_PRODUCT", 35, 39], ["ERK", "GENE_OR_GENE_PRODUCT", 50, 53], ["ERK", "PROTEIN", 50, 53]]], ["HPSE may induce syndecan-1 shedding in an enzymatically dependent manner and HGF upregulation in an enzymatically independent manner.", [["HPSE", "CHEMICAL", 0, 4], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 16, 26], ["HGF", "GENE_OR_GENE_PRODUCT", 77, 80], ["syndecan", "PROTEIN", 16, 24], ["HGF", "PROTEIN", 77, 80], ["HGF upregulation", "TREATMENT", 77, 93]]], ["Downstream Met signaling results in p-ERK formation.", [["Met", "CHEMICAL", 11, 14], ["Met", "GENE_OR_GENE_PRODUCT", 11, 14], ["p-ERK", "GENE_OR_GENE_PRODUCT", 36, 41], ["ERK", "PROTEIN", 38, 41]]], ["Another mechanism involves the HPSE-mediated VEGF activation which can lead to p-ERK activation. p-ERK can stimulate uPA, uPAR, and pro-MMP9 expression which leads to syndecan-1 shedding.", [["HPSE", "GENE_OR_GENE_PRODUCT", 31, 35], ["VEGF", "GENE_OR_GENE_PRODUCT", 45, 49], ["ERK", "GENE_OR_GENE_PRODUCT", 81, 84], ["p-ERK", "GENE_OR_GENE_PRODUCT", 97, 102], ["uPA", "GENE_OR_GENE_PRODUCT", 117, 120], ["uPAR", "GENE_OR_GENE_PRODUCT", 122, 126], ["pro-MMP9", "GENE_OR_GENE_PRODUCT", 132, 140], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 167, 177], ["HPSE", "PROTEIN", 31, 35], ["VEGF", "PROTEIN", 45, 49], ["ERK", "PROTEIN", 81, 84], ["ERK", "PROTEIN", 99, 102], ["uPA", "PROTEIN", 117, 120], ["uPAR", "PROTEIN", 122, 126], ["pro-MMP9", "PROTEIN", 132, 140], ["syndecan", "PROTEIN", 167, 175], ["mediated VEGF activation", "PROBLEM", 36, 60], ["p-ERK activation", "PROBLEM", 79, 95], ["uPAR", "TEST", 122, 126], ["VEGF", "OBSERVATION", 45, 49]]], ["Shed syndecan-1 forms a complex with VEGF as described before, and the downstream VEGF signaling can activate ERK.", [["syndecan-1", "GENE_OR_GENE_PRODUCT", 5, 15], ["VEGF", "GENE_OR_GENE_PRODUCT", 37, 41], ["VEGF", "GENE_OR_GENE_PRODUCT", 82, 86], ["ERK", "GENE_OR_GENE_PRODUCT", 110, 113], ["Shed syndecan-1", "PROTEIN", 0, 15], ["VEGF", "PROTEIN", 37, 41], ["VEGF", "PROTEIN", 82, 86], ["ERK", "PROTEIN", 110, 113]]], ["Finally, enzymatically active HPSE can activate PKC, which up-regulates IRS-1, and the IR, which phosphorylates IRS-1. p-IRS-1 can then stimulate ERK activationHPSE-EGFR signalingThe epidermal growth factor receptor (EGFR) pathway is a key regulator of cell growth, proliferation, and survival [109] .", [["cell", "ANATOMY", 253, 257], ["HPSE", "CHEMICAL", 30, 34], ["HPSE", "SIMPLE_CHEMICAL", 30, 34], ["PKC", "GENE_OR_GENE_PRODUCT", 48, 51], ["IRS-1", "GENE_OR_GENE_PRODUCT", 72, 77], ["IRS-1", "GENE_OR_GENE_PRODUCT", 112, 117], ["p-IRS-1", "GENE_OR_GENE_PRODUCT", 119, 126], ["ERK", "GENE_OR_GENE_PRODUCT", 146, 149], ["EGFR", "GENE_OR_GENE_PRODUCT", 165, 169], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 183, 215], ["EGFR", "GENE_OR_GENE_PRODUCT", 217, 221], ["cell", "CELL", 253, 257], ["PKC", "PROTEIN", 48, 51], ["IRS-1", "PROTEIN", 72, 77], ["IRS-1", "PROTEIN", 112, 117], ["IRS-1", "PROTEIN", 121, 126], ["ERK", "PROTEIN", 146, 149], ["EGFR", "PROTEIN", 165, 169], ["epidermal growth factor receptor", "PROTEIN", 183, 215], ["EGFR", "PROTEIN", 217, 221], ["PKC", "TEST", 48, 51], ["ERK activationHPSE", "TEST", 146, 164], ["EGFR signaling", "PROBLEM", 165, 179], ["The epidermal growth factor receptor (EGFR) pathway", "TEST", 179, 230], ["cell growth", "PROBLEM", 253, 264], ["active", "OBSERVATION_MODIFIER", 23, 29]]], ["EGFRs are a subset of RTKs and consist of four different types: EGFR, HER2, HER3, and HER4 [110] .", [["EGFRs", "GENE_OR_GENE_PRODUCT", 0, 5], ["RTKs", "GENE_OR_GENE_PRODUCT", 22, 26], ["EGFR", "GENE_OR_GENE_PRODUCT", 64, 68], ["HER2", "GENE_OR_GENE_PRODUCT", 70, 74], ["HER3", "GENE_OR_GENE_PRODUCT", 76, 80], ["HER4", "GENE_OR_GENE_PRODUCT", 86, 90], ["EGFRs", "PROTEIN", 0, 5], ["RTKs", "PROTEIN", 22, 26], ["EGFR", "PROTEIN", 64, 68], ["HER2", "PROTEIN", 70, 74], ["HER3", "PROTEIN", 76, 80], ["HER4", "PROTEIN", 86, 90], ["EGFRs", "TEST", 0, 5], ["EGFR", "TEST", 64, 68], ["HER2", "TEST", 70, 74], ["HER3", "TEST", 76, 80], ["HER4", "TEST", 86, 90]]], ["EGFRs currently have 13 known ligands, including EGF, heparin-binding EGF-like growth factor (HB-EGF), and multiple neuregulins [111] .", [["heparin", "CHEMICAL", 54, 61], ["EGFRs", "GENE_OR_GENE_PRODUCT", 0, 5], ["EGF", "GENE_OR_GENE_PRODUCT", 49, 52], ["heparin-binding EGF-like growth factor", "GENE_OR_GENE_PRODUCT", 54, 92], ["HB-EGF", "GENE_OR_GENE_PRODUCT", 94, 100], ["EGFRs", "PROTEIN", 0, 5], ["EGF", "PROTEIN", 49, 52], ["heparin-binding EGF-like growth factor", "PROTEIN", 54, 92], ["HB", "PROTEIN", 94, 96], ["EGF", "PROTEIN", 97, 100], ["EGFRs", "TEST", 0, 5], ["13 known ligands", "PROBLEM", 21, 37], ["EGF", "TEST", 49, 52], ["heparin-binding EGF", "TEST", 54, 73], ["growth factor", "TEST", 79, 92], ["HB", "TEST", 94, 96]]], ["When a ligand binds to an EGFR, it induces either homo-or heterodimerization of the receptor and activates it [112] .", [["EGFR", "GENE_OR_GENE_PRODUCT", 26, 30], ["EGFR", "PROTEIN", 26, 30], ["an EGFR", "TEST", 23, 30]]], ["Activation of EGFR leads to its clathrin-mediated endocytosis [113] .", [["EGFR", "GENE_OR_GENE_PRODUCT", 14, 18], ["clathrin", "GENE_OR_GENE_PRODUCT", 32, 40], ["EGFR", "PROTEIN", 14, 18], ["clathrin", "PROTEIN", 32, 40], ["Activation of EGFR", "TREATMENT", 0, 18]]], ["Inside the cell, EGFR can activate numerous, critical pathways for growth, survival, and migration such as the PI3K-Akt, MAPK-ERK, and signal transducers and activators of transcription (STAT) pathways [109, 111] .HPSE-EGFR signalingCertain viruses utilize EGFR signaling during infection.", [["cell", "ANATOMY", 11, 15], ["infection", "DISEASE", 279, 288], ["cell", "CELL", 11, 15], ["EGFR", "GENE_OR_GENE_PRODUCT", 17, 21], ["PI3K", "GENE_OR_GENE_PRODUCT", 111, 115], ["Akt", "GENE_OR_GENE_PRODUCT", 116, 119], ["MAPK", "GENE_OR_GENE_PRODUCT", 121, 125], ["ERK", "GENE_OR_GENE_PRODUCT", 126, 129], ["signal transducers and activators of transcription", "GENE_OR_GENE_PRODUCT", 135, 185], ["STAT", "GENE_OR_GENE_PRODUCT", 187, 191], ["HPSE", "GENE_OR_GENE_PRODUCT", 214, 218], ["EGFR", "GENE_OR_GENE_PRODUCT", 219, 223], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["EGFR", "PROTEIN", 17, 21], ["PI3K", "PROTEIN", 111, 115], ["Akt", "PROTEIN", 116, 119], ["MAPK", "PROTEIN", 121, 125], ["ERK", "PROTEIN", 126, 129], ["signal transducers and activators of transcription", "PROTEIN", 135, 185], ["STAT", "PROTEIN", 187, 191], ["HPSE", "PROTEIN", 214, 218], ["EGFR", "PROTEIN", 219, 223], ["EGFR", "PROTEIN", 257, 261], ["the PI3K", "TEST", 107, 115], ["MAPK", "TEST", 121, 125], ["ERK", "TEST", 126, 129], ["signal transducers", "TEST", 135, 153], ["HPSE", "TEST", 214, 218], ["Certain viruses", "PROBLEM", 233, 248], ["EGFR signaling during infection", "PROBLEM", 257, 288], ["cell", "ANATOMY", 11, 15], ["infection", "OBSERVATION", 279, 288]]], ["EGFR signaling causes the development of pulmonary fibrosis through regulation of wound-healing genes during coronavirus infections [114] .", [["pulmonary", "ANATOMY", 41, 50], ["wound", "ANATOMY", 82, 87], ["pulmonary fibrosis", "DISEASE", 41, 59], ["coronavirus infections", "DISEASE", 109, 131], ["EGFR", "GENE_OR_GENE_PRODUCT", 0, 4], ["pulmonary", "ORGAN", 41, 50], ["wound", "PATHOLOGICAL_FORMATION", 82, 87], ["coronavirus", "ORGANISM", 109, 120], ["EGFR", "PROTEIN", 0, 4], ["wound-healing genes", "DNA", 82, 101], ["EGFR signaling", "PROBLEM", 0, 14], ["pulmonary fibrosis", "PROBLEM", 41, 59], ["wound", "PROBLEM", 82, 87], ["healing genes", "PROBLEM", 88, 101], ["coronavirus infections", "PROBLEM", 109, 131], ["pulmonary", "ANATOMY", 41, 50], ["fibrosis", "OBSERVATION", 51, 59], ["wound", "ANATOMY", 82, 87], ["healing", "OBSERVATION_MODIFIER", 88, 95]]], ["In an HBV infection, EGFR is required for the interaction of the virus with the host receptor NTCP and its subsequent internalization into the cell [115] .", [["cell", "ANATOMY", 143, 147], ["HBV infection", "DISEASE", 6, 19], ["HBV", "ORGANISM", 6, 9], ["EGFR", "GENE_OR_GENE_PRODUCT", 21, 25], ["NTCP", "GENE_OR_GENE_PRODUCT", 94, 98], ["cell", "CELL", 143, 147], ["EGFR", "PROTEIN", 21, 25], ["NTCP", "PROTEIN", 94, 98], ["HBV", "SPECIES", 6, 9], ["an HBV infection", "PROBLEM", 3, 19], ["EGFR", "TEST", 21, 25], ["the virus", "TREATMENT", 61, 70], ["the host receptor NTCP", "TREATMENT", 76, 98], ["HBV", "OBSERVATION_MODIFIER", 6, 9], ["infection", "OBSERVATION", 10, 19]]], ["Loss of EGFR results in an attenuation of HBV entry despite the virus still binding to NTCP [115] .", [["EGFR", "GENE_OR_GENE_PRODUCT", 8, 12], ["HBV", "ORGANISM", 42, 45], ["EGFR", "PROTEIN", 8, 12], ["HBV", "SPECIES", 42, 45], ["Loss of EGFR", "PROBLEM", 0, 12], ["HBV entry", "PROBLEM", 42, 51], ["the virus", "PROBLEM", 60, 69], ["NTCP", "TEST", 87, 91]]], ["Similar results have been found with HCV, except the virus interacts with CD81 instead of NTCP [116] .", [["HCV", "ORGANISM", 37, 40], ["CD81", "GENE_OR_GENE_PRODUCT", 74, 78], ["CD81", "PROTEIN", 74, 78], ["HCV", "SPECIES", 37, 40], ["HCV", "PROBLEM", 37, 40], ["the virus interacts", "PROBLEM", 49, 68], ["NTCP", "TEST", 90, 94]]], ["Binding of CD81 activates EGFR, which induces the endocytosis of the HCV-CD81-EGFR complex [116] .", [["CD81", "GENE_OR_GENE_PRODUCT", 11, 15], ["EGFR", "GENE_OR_GENE_PRODUCT", 26, 30], ["CD81", "GENE_OR_GENE_PRODUCT", 73, 77], ["EGFR", "GENE_OR_GENE_PRODUCT", 78, 82], ["CD81", "PROTEIN", 11, 15], ["EGFR", "PROTEIN", 26, 30], ["CD81", "PROTEIN", 73, 77], ["EGFR complex", "PROTEIN", 78, 90], ["HCV", "SPECIES", 69, 72], ["EGFR", "TEST", 26, 30], ["the HCV", "TEST", 65, 72]]], ["HCMV is yet another virus which stimulates EGFR, this time by directly binding to it with its gB protein [117] .", [["HCMV", "ORGANISM", 0, 4], ["EGFR", "GENE_OR_GENE_PRODUCT", 43, 47], ["EGFR", "PROTEIN", 43, 47], ["gB protein", "PROTEIN", 94, 104], ["HCMV", "SPECIES", 0, 4], ["HCMV", "PROBLEM", 0, 4], ["another virus", "PROBLEM", 12, 25], ["its gB protein", "TEST", 90, 104]]], ["Activation of EGFR is required for the entry of HCMV into host monocytes [117] .", [["monocytes", "ANATOMY", 63, 72], ["EGFR", "GENE_OR_GENE_PRODUCT", 14, 18], ["HCMV", "ORGANISM", 48, 52], ["monocytes", "CELL", 63, 72], ["EGFR", "PROTEIN", 14, 18], ["host monocytes", "CELL_TYPE", 58, 72], ["HCMV", "SPECIES", 48, 52], ["Activation of EGFR", "TREATMENT", 0, 18]]], ["The monocytes then migrate to peripheral tissues, further spreading the viral infection [117] .", [["monocytes", "ANATOMY", 4, 13], ["peripheral tissues", "ANATOMY", 30, 48], ["viral infection", "DISEASE", 72, 87], ["monocytes", "CELL", 4, 13], ["peripheral tissues", "TISSUE", 30, 48], ["monocytes", "CELL_TYPE", 4, 13], ["The monocytes", "PROBLEM", 0, 13], ["the viral infection", "PROBLEM", 68, 87], ["monocytes", "ANATOMY", 4, 13], ["peripheral tissues", "ANATOMY", 30, 48], ["viral", "OBSERVATION_MODIFIER", 72, 77], ["infection", "OBSERVATION", 78, 87]]], ["EGFR-dependent virus internalization is also seen in the Influenza A virus [118, 119] .", [["EGFR", "GENE_OR_GENE_PRODUCT", 0, 4], ["Influenza A virus", "ORGANISM", 57, 74], ["EGFR", "PROTEIN", 0, 4], ["Influenza A virus", "SPECIES", 57, 74], ["Influenza A virus", "SPECIES", 57, 74], ["EGFR", "TEST", 0, 4], ["dependent virus internalization", "PROBLEM", 5, 36], ["the Influenza A virus", "PROBLEM", 53, 74], ["dependent", "OBSERVATION_MODIFIER", 5, 14], ["virus internalization", "OBSERVATION", 15, 36]]], ["The viral protein hemagglutinin binds to sialic acid residues on the host cell surface [119] .", [["cell surface", "ANATOMY", 74, 86], ["sialic acid", "CHEMICAL", 41, 52], ["sialic acid", "CHEMICAL", 41, 52], ["sialic acid", "SIMPLE_CHEMICAL", 41, 52], ["cell surface", "CELLULAR_COMPONENT", 74, 86], ["viral protein hemagglutinin", "PROTEIN", 4, 31], ["The viral protein hemagglutinin binds", "TREATMENT", 0, 37], ["sialic acid residues", "PROBLEM", 41, 61], ["viral protein hemagglutinin", "OBSERVATION", 4, 31], ["sialic acid residues", "OBSERVATION", 41, 61], ["host cell", "OBSERVATION_MODIFIER", 69, 78], ["surface", "OBSERVATION_MODIFIER", 79, 86]]], ["This leads to a reorganization of lipid rafts in the cell membrane which stimulates nearby EGFRs [119] .", [["lipid rafts", "ANATOMY", 34, 45], ["cell membrane", "ANATOMY", 53, 66], ["lipid rafts", "CELLULAR_COMPONENT", 34, 45], ["cell membrane", "CELLULAR_COMPONENT", 53, 66], ["EGFRs", "PROTEIN", 91, 96], ["a reorganization of lipid rafts", "TREATMENT", 14, 45], ["lipid rafts", "OBSERVATION", 34, 45], ["cell membrane", "OBSERVATION", 53, 66]]], ["Following the EGFR activation, the Influenza A virus and the EGFR are endocytosed in a clathrin-dependent mechanism [119] .", [["EGFR", "GENE_OR_GENE_PRODUCT", 14, 18], ["Influenza A virus", "ORGANISM", 35, 52], ["EGFR", "GENE_OR_GENE_PRODUCT", 61, 65], ["clathrin", "GENE_OR_GENE_PRODUCT", 87, 95], ["EGFR", "PROTEIN", 14, 18], ["EGFR", "PROTEIN", 61, 65], ["clathrin", "PROTEIN", 87, 95], ["Influenza A virus", "SPECIES", 35, 52], ["Influenza A virus", "SPECIES", 35, 52], ["the EGFR activation", "TEST", 10, 29], ["the Influenza A virus", "PROBLEM", 31, 52], ["the EGFR", "TEST", 57, 65]]], ["Depletion of sialic acid, lipid rafts, EGFR, or clathrin severely inhibits viral infection [118, 119] .", [["lipid rafts", "ANATOMY", 26, 37], ["sialic acid", "CHEMICAL", 13, 24], ["viral infection", "DISEASE", 75, 90], ["sialic acid", "CHEMICAL", 13, 24], ["sialic acid", "SIMPLE_CHEMICAL", 13, 24], ["lipid rafts", "CELLULAR_COMPONENT", 26, 37], ["EGFR", "GENE_OR_GENE_PRODUCT", 39, 43], ["clathrin", "GENE_OR_GENE_PRODUCT", 48, 56], ["EGFR", "PROTEIN", 39, 43], ["clathrin", "PROTEIN", 48, 56], ["sialic acid", "TEST", 13, 24], ["lipid rafts", "TEST", 26, 37], ["EGFR", "PROBLEM", 39, 43], ["clathrin severely inhibits viral infection", "PROBLEM", 48, 90], ["sialic acid", "OBSERVATION", 13, 24]]], ["Other respiratory viruses that have been shown to activate EGFR include rhinovirus (RV) and respiratory syncytial virus (RSV) [120, 121] .", [["respiratory syncytial virus", "DISEASE", 92, 119], ["EGFR", "GENE_OR_GENE_PRODUCT", 59, 63], ["rhinovirus (RV)", "ORGANISM", 72, 87], ["respiratory syncytial virus", "ORGANISM", 92, 119], ["RSV", "ORGANISM", 121, 124], ["EGFR", "PROTEIN", 59, 63], ["respiratory syncytial virus", "SPECIES", 92, 119], ["RV", "SPECIES", 84, 86], ["respiratory syncytial virus", "SPECIES", 92, 119], ["RSV", "SPECIES", 121, 124], ["Other respiratory viruses", "PROBLEM", 0, 25], ["EGFR", "TEST", 59, 63], ["rhinovirus", "PROBLEM", 72, 82], ["respiratory syncytial virus", "PROBLEM", 92, 119], ["respiratory", "ANATOMY", 6, 17], ["viruses", "OBSERVATION", 18, 25], ["respiratory syncytial", "ANATOMY", 92, 113]]], ["Additionally, Influenza A, RV, and RSV all have demonstrated the ability to stimulate the production of IL-8 via EGFR activation [122] .", [["Influenza A", "ORGANISM", 14, 25], ["RV", "ORGANISM", 27, 29], ["RSV", "ORGANISM", 35, 38], ["IL-8", "GENE_OR_GENE_PRODUCT", 104, 108], ["EGFR", "GENE_OR_GENE_PRODUCT", 113, 117], ["IL-8", "PROTEIN", 104, 108], ["EGFR", "PROTEIN", 113, 117], ["Influenza A", "SPECIES", 14, 25], ["RSV", "SPECIES", 35, 38], ["Influenza", "PROBLEM", 14, 23], ["RV", "TEST", 27, 29], ["RSV", "PROBLEM", 35, 38], ["IL", "TEST", 104, 106], ["RV", "ANATOMY", 27, 29]]], ["IL-8 inhibits the transcription of IRF1, and suppression of IRF1 leads to a reduction in CXCL10 levels, key cytokine which stimulates the migration of NK cells and T lymphocytes to the site of infection [122] .", [["NK cells", "ANATOMY", 151, 159], ["T lymphocytes", "ANATOMY", 164, 177], ["site", "ANATOMY", 185, 189], ["infection", "DISEASE", 193, 202], ["IL-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["IRF1", "GENE_OR_GENE_PRODUCT", 35, 39], ["IRF1", "GENE_OR_GENE_PRODUCT", 60, 64], ["CXCL10", "GENE_OR_GENE_PRODUCT", 89, 95], ["NK cells", "CELL", 151, 159], ["T lymphocytes", "CELL", 164, 177], ["IL-8", "PROTEIN", 0, 4], ["IRF1", "PROTEIN", 35, 39], ["IRF1", "PROTEIN", 60, 64], ["CXCL10", "PROTEIN", 89, 95], ["cytokine", "PROTEIN", 108, 116], ["NK cells", "CELL_TYPE", 151, 159], ["T lymphocytes", "CELL_TYPE", 164, 177], ["IL", "TREATMENT", 0, 2], ["IRF1", "PROBLEM", 35, 39], ["a reduction in CXCL10 levels", "TEST", 74, 102], ["NK cells", "PROBLEM", 151, 159], ["T lymphocytes", "PROBLEM", 164, 177], ["infection", "PROBLEM", 193, 202], ["NK cells", "OBSERVATION", 151, 159], ["infection", "OBSERVATION", 193, 202]]], ["Further discussion of the interplay between viruses and EGFR signaling is covered in an excellent review by Zheng et al. [113] .", [["EGFR", "GENE_OR_GENE_PRODUCT", 56, 60], ["EGFR", "PROTEIN", 56, 60], ["viruses", "PROBLEM", 44, 51]]], ["HPSE expression increases EGFR phosphorylation levels in multiple tumor cell lines [39, 123] .", [["tumor cell lines", "ANATOMY", 66, 82], ["tumor", "DISEASE", 66, 71], ["HPSE", "GENE_OR_GENE_PRODUCT", 0, 4], ["EGFR", "GENE_OR_GENE_PRODUCT", 26, 30], ["tumor cell lines", "CELL", 66, 82], ["HPSE", "PROTEIN", 0, 4], ["EGFR", "PROTEIN", 26, 30], ["multiple tumor cell lines", "CELL_LINE", 57, 82], ["HPSE expression", "PROBLEM", 0, 15], ["EGFR phosphorylation levels", "TEST", 26, 53], ["multiple tumor cell lines", "TEST", 57, 82], ["multiple", "OBSERVATION_MODIFIER", 57, 65], ["tumor cell lines", "OBSERVATION", 66, 82]]], ["In addition, HPSE was correlated with HER2 levels in human brain metastatic breast cancer cells [124] .", [["brain metastatic breast cancer cells", "ANATOMY", 59, 95], ["breast cancer", "DISEASE", 76, 89], ["HPSE", "SIMPLE_CHEMICAL", 13, 17], ["HER2", "GENE_OR_GENE_PRODUCT", 38, 42], ["human", "ORGANISM", 53, 58], ["brain", "ORGAN", 59, 64], ["HPSE", "PROTEIN", 13, 17], ["HER2", "PROTEIN", 38, 42], ["human brain metastatic breast cancer cells", "CELL_TYPE", 53, 95], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["HER2 levels in human brain metastatic breast cancer cells", "PROBLEM", 38, 95], ["brain", "ANATOMY", 59, 64], ["metastatic", "OBSERVATION_MODIFIER", 65, 75], ["breast", "ANATOMY", 76, 82], ["cancer", "OBSERVATION", 83, 89]]], ["This mechanism appears to be mediated by the activation of Src and occurs even when the enzymatic activity of HPSE is abolished [6, 39, 101] .", [["HPSE", "CHEMICAL", 110, 114], ["Src", "GENE_OR_GENE_PRODUCT", 59, 62], ["HPSE", "SIMPLE_CHEMICAL", 110, 114], ["Src", "PROTEIN", 59, 62], ["appears to be", "UNCERTAINTY", 15, 28], ["Src", "OBSERVATION", 59, 62]]], ["It should be noted that the Src activity seen in these studies may be stemming from a SFK, not necessarily the Src protein.", [["Src", "GENE_OR_GENE_PRODUCT", 28, 31], ["SFK", "GENE_OR_GENE_PRODUCT", 86, 89], ["Src", "GENE_OR_GENE_PRODUCT", 111, 114], ["Src", "PROTEIN", 28, 31], ["SFK", "PROTEIN", 86, 89], ["Src protein", "PROTEIN", 111, 122], ["the Src activity", "PROBLEM", 24, 40], ["these studies", "TEST", 49, 62]]], ["Notably, activation of Akt and ERK was not observed in pancreatic cancer cells upon addition of HPSE, suggesting that the effects of HPSE on signaling pathways may be highly sensitive to the cell type being used [123] .", [["pancreatic cancer cells", "ANATOMY", 55, 78], ["cell", "ANATOMY", 191, 195], ["pancreatic cancer", "DISEASE", 55, 72], ["HPSE", "CHEMICAL", 96, 100], ["HPSE", "CHEMICAL", 133, 137], ["HPSE", "CHEMICAL", 96, 100], ["Akt", "GENE_OR_GENE_PRODUCT", 23, 26], ["ERK", "GENE_OR_GENE_PRODUCT", 31, 34], ["pancreatic cancer cells", "CELL", 55, 78], ["HPSE", "SIMPLE_CHEMICAL", 96, 100], ["HPSE", "SIMPLE_CHEMICAL", 133, 137], ["cell", "CELL", 191, 195], ["Akt", "PROTEIN", 23, 26], ["ERK", "PROTEIN", 31, 34], ["pancreatic cancer cells", "CELL_TYPE", 55, 78], ["activation of Akt", "PROBLEM", 9, 26], ["ERK", "TEST", 31, 34], ["pancreatic cancer cells", "PROBLEM", 55, 78], ["HPSE on signaling pathways", "PROBLEM", 133, 159], ["pancreatic", "ANATOMY", 55, 65], ["cancer", "OBSERVATION", 66, 72]]], ["HPSEinduced EGFR activation resulted in increased proliferation and invasiveness in vitro [39, 123] .", [["EGFR", "GENE_OR_GENE_PRODUCT", 12, 16], ["EGFR", "PROTEIN", 12, 16], ["increased proliferation", "PROBLEM", 40, 63], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["proliferation", "OBSERVATION_MODIFIER", 50, 63], ["invasiveness", "OBSERVATION_MODIFIER", 68, 80]]], ["In brain metastatic breast cancer cells, it was reported that EGF activated HER2 and EGFR, which caused HPSE to translocate to the nucleolus in a dose-and time-dependent manner [124] .", [["brain metastatic breast cancer cells", "ANATOMY", 3, 39], ["nucleolus", "ANATOMY", 131, 140], ["breast cancer", "DISEASE", 20, 33], ["brain metastatic breast cancer cells", "CELL", 3, 39], ["EGF", "GENE_OR_GENE_PRODUCT", 62, 65], ["HER2", "GENE_OR_GENE_PRODUCT", 76, 80], ["EGFR", "GENE_OR_GENE_PRODUCT", 85, 89], ["HPSE", "GENE_OR_GENE_PRODUCT", 104, 108], ["nucleolus", "CELLULAR_COMPONENT", 131, 140], ["brain metastatic breast cancer cells", "CELL_TYPE", 3, 39], ["EGF", "PROTEIN", 62, 65], ["HER2", "PROTEIN", 76, 80], ["EGFR", "PROTEIN", 85, 89], ["HPSE", "PROTEIN", 104, 108], ["brain metastatic breast cancer cells", "PROBLEM", 3, 39], ["EGF activated HER2", "PROBLEM", 62, 80], ["EGFR", "TEST", 85, 89], ["HPSE", "PROBLEM", 104, 108], ["brain", "ANATOMY", 3, 8], ["metastatic", "OBSERVATION_MODIFIER", 9, 19], ["breast", "ANATOMY", 20, 26], ["cancer", "OBSERVATION", 27, 33]]], ["Once in the nucleolus, enzymatically active HPSE activates Topoisomerase I (Topo 1), which enhances cell proliferation [124] .", [["nucleolus", "ANATOMY", 12, 21], ["cell", "ANATOMY", 100, 104], ["nucleolus", "CELLULAR_COMPONENT", 12, 21], ["HPSE", "SIMPLE_CHEMICAL", 44, 48], ["Topoisomerase I", "GENE_OR_GENE_PRODUCT", 59, 74], ["Topo 1", "GENE_OR_GENE_PRODUCT", 76, 82], ["cell", "CELL", 100, 104], ["HPSE", "PROTEIN", 44, 48], ["Topoisomerase I", "PROTEIN", 59, 74], ["Topo 1", "PROTEIN", 76, 82], ["Topoisomerase I (Topo", "TREATMENT", 59, 80], ["nucleolus", "ANATOMY", 12, 21], ["active", "OBSERVATION_MODIFIER", 37, 43], ["HPSE", "OBSERVATION", 44, 48], ["cell proliferation", "OBSERVATION", 100, 118]]], ["Interestingly enough, Topo1 has been reported to be inhibited by HS, suggesting that HPSE may cleave HS bound to Topo1 [124] .", [["Topo1", "CHEMICAL", 22, 27], ["HPSE", "CHEMICAL", 85, 89], ["Topo1", "GENE_OR_GENE_PRODUCT", 22, 27], ["HPSE", "SIMPLE_CHEMICAL", 85, 89], ["Topo1 [124]", "GENE_OR_GENE_PRODUCT", 113, 124], ["Topo1", "PROTEIN", 22, 27], ["HPSE", "PROTEIN", 85, 89], ["HS", "DNA", 101, 103], ["Topo1", "TREATMENT", 22, 27]]], ["This mechanism is completely arrested when both HER2 and EGFR are inhibited and partially arrested when only one of the receptors is inhibited [124] .", [["HER2", "GENE_OR_GENE_PRODUCT", 48, 52], ["EGFR", "GENE_OR_GENE_PRODUCT", 57, 61], ["HER2", "PROTEIN", 48, 52], ["EGFR", "PROTEIN", 57, 61], ["completely", "OBSERVATION_MODIFIER", 18, 28], ["arrested", "OBSERVATION", 29, 37]]], ["Thus, in different cell lines, the sequence of activation regarding HPSE and EGFR varies.", [["cell lines", "ANATOMY", 19, 29], ["cell lines", "CELL", 19, 29], ["HPSE", "GENE_OR_GENE_PRODUCT", 68, 72], ["EGFR", "GENE_OR_GENE_PRODUCT", 77, 81], ["cell lines", "CELL_LINE", 19, 29], ["HPSE", "PROTEIN", 68, 72], ["EGFR", "PROTEIN", 77, 81], ["different cell lines", "TREATMENT", 9, 29], ["HPSE", "TEST", 68, 72], ["EGFR varies", "TEST", 77, 88], ["different cell lines", "OBSERVATION", 9, 29]]], ["HPSE may induce the phosphorylation of EGFR, or EGFR may stimulate HPSE activity.HPSE-EGFR signalingIn addition to the EGFR proteins, HPSE was reported to increase the phosphorylation levels of the STAT3 and STAT5b proteins [6] .", [["HPSE", "CHEMICAL", 0, 4], ["HPSE", "CHEMICAL", 134, 138], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["EGFR", "GENE_OR_GENE_PRODUCT", 39, 43], ["EGFR", "GENE_OR_GENE_PRODUCT", 48, 52], ["HPSE", "GENE_OR_GENE_PRODUCT", 67, 71], ["HPSE", "GENE_OR_GENE_PRODUCT", 81, 85], ["EGFR", "GENE_OR_GENE_PRODUCT", 86, 90], ["EGFR", "GENE_OR_GENE_PRODUCT", 119, 123], ["HPSE", "GENE_OR_GENE_PRODUCT", 134, 138], ["STAT3", "GENE_OR_GENE_PRODUCT", 198, 203], ["STAT5b", "GENE_OR_GENE_PRODUCT", 208, 214], ["EGFR", "PROTEIN", 39, 43], ["EGFR", "PROTEIN", 48, 52], ["HPSE", "PROTEIN", 67, 71], ["HPSE", "PROTEIN", 81, 85], ["EGFR", "PROTEIN", 86, 90], ["EGFR proteins", "PROTEIN", 119, 132], ["HPSE", "PROTEIN", 134, 138], ["STAT3", "PROTEIN", 198, 203], ["STAT5b proteins", "PROTEIN", 208, 223], ["the phosphorylation of EGFR", "PROBLEM", 16, 43], ["EGFR", "PROBLEM", 48, 52], ["HPSE", "TEST", 81, 85], ["the EGFR proteins", "TEST", 115, 132], ["the phosphorylation levels", "TEST", 164, 190], ["the STAT3 and STAT5b proteins", "TEST", 194, 223], ["HPSE activity", "OBSERVATION", 67, 80]]], ["These two STAT proteins have been previously shown to be directly phosphorylated by Src [125, 126] .", [["STAT", "GENE_OR_GENE_PRODUCT", 10, 14], ["Src", "GENE_OR_GENE_PRODUCT", 84, 87], ["STAT proteins", "PROTEIN", 10, 23], ["Src", "PROTEIN", 84, 87], ["These two STAT proteins", "TEST", 0, 23]]], ["In particular, increased p-STAT3 in the cytoplasm correlated with the progression of tumors in a cohort of patients with head and neck squamous cell carcinoma [6] .", [["cytoplasm", "ANATOMY", 40, 49], ["tumors", "ANATOMY", 85, 91], ["head and neck squamous cell carcinoma", "ANATOMY", 121, 158], ["tumors", "DISEASE", 85, 91], ["head and neck squamous cell carcinoma", "DISEASE", 121, 158], ["STAT3", "GENE_OR_GENE_PRODUCT", 27, 32], ["cytoplasm", "ORGANISM_SUBSTANCE", 40, 49], ["tumors", "CANCER", 85, 91], ["patients", "ORGANISM", 107, 115], ["head and neck squamous cell carcinoma", "CANCER", 121, 158], ["p-STAT3", "PROTEIN", 25, 32], ["patients", "SPECIES", 107, 115], ["increased p-STAT3 in the cytoplasm", "PROBLEM", 15, 49], ["tumors", "PROBLEM", 85, 91], ["head and neck squamous cell carcinoma", "PROBLEM", 121, 158], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["p-STAT3", "OBSERVATION", 25, 32], ["progression", "OBSERVATION_MODIFIER", 70, 81], ["tumors", "OBSERVATION", 85, 91], ["head", "ANATOMY", 121, 125], ["neck", "ANATOMY", 130, 134], ["squamous cell carcinoma", "OBSERVATION", 135, 158]]], ["In another study, administration of an HPSE inhibitor markedly reduced the levels of pSTAT3 in pancreatic cells, further supporting the link between HPSE and STAT3 [127] .", [["pancreatic cells", "ANATOMY", 95, 111], ["HPSE", "SIMPLE_CHEMICAL", 39, 43], ["pSTAT3", "GENE_OR_GENE_PRODUCT", 85, 91], ["pancreatic cells", "CELL", 95, 111], ["HPSE", "GENE_OR_GENE_PRODUCT", 149, 153], ["STAT3", "GENE_OR_GENE_PRODUCT", 158, 163], ["pSTAT3", "PROTEIN", 85, 91], ["pancreatic cells", "CELL_TYPE", 95, 111], ["HPSE", "PROTEIN", 149, 153], ["STAT3", "PROTEIN", 158, 163], ["another study", "TEST", 3, 16], ["an HPSE inhibitor", "TREATMENT", 36, 53], ["pancreatic cells", "ANATOMY", 95, 111]]], ["Additionally, only cytoplasmic HPSE was able to induce the downstream phosphorylation of STAT3 via an SFK and EGFR [6] .", [["cytoplasmic", "ANATOMY", 19, 30], ["cytoplasmic", "ORGANISM_SUBSTANCE", 19, 30], ["HPSE", "GENE_OR_GENE_PRODUCT", 31, 35], ["STAT3", "GENE_OR_GENE_PRODUCT", 89, 94], ["SFK", "GENE_OR_GENE_PRODUCT", 102, 105], ["EGFR", "GENE_OR_GENE_PRODUCT", 110, 114], ["cytoplasmic HPSE", "PROTEIN", 19, 35], ["STAT3", "PROTEIN", 89, 94], ["SFK", "PROTEIN", 102, 105], ["EGFR", "PROTEIN", 110, 114], ["cytoplasmic HPSE", "PROBLEM", 19, 35]]], ["STAT3 induction then drives tumorigenesis and inflammatory responses [40] .HPSE-EGFR signalingThe results of these studies suggest the following mechanism: in certain cells, HPSE activates an SFK in an enzymatically independent manner which proceeds to stimulate EGFR.", [["cells", "ANATOMY", 167, 172], ["STAT3", "GENE_OR_GENE_PRODUCT", 0, 5], ["HPSE", "GENE_OR_GENE_PRODUCT", 75, 79], ["EGFR", "GENE_OR_GENE_PRODUCT", 80, 84], ["cells", "CELL", 167, 172], ["HPSE", "SIMPLE_CHEMICAL", 174, 178], ["SFK", "GENE_OR_GENE_PRODUCT", 192, 195], ["EGFR", "GENE_OR_GENE_PRODUCT", 263, 267], ["STAT3", "PROTEIN", 0, 5], ["HPSE", "PROTEIN", 75, 79], ["EGFR", "PROTEIN", 80, 84], ["HPSE", "PROTEIN", 174, 178], ["SFK", "PROTEIN", 192, 195], ["EGFR", "PROTEIN", 263, 267], ["STAT3 induction", "TREATMENT", 0, 15], ["inflammatory responses", "PROBLEM", 46, 68], ["HPSE", "TEST", 75, 79], ["these studies", "TEST", 109, 122]]], ["EGFR can then activate downstream pathways such as PI3K-Akt and MAPK-ERK.", [["EGFR", "GENE_OR_GENE_PRODUCT", 0, 4], ["PI3K", "GENE_OR_GENE_PRODUCT", 51, 55], ["Akt", "GENE_OR_GENE_PRODUCT", 56, 59], ["MAPK-ERK", "GENE_OR_GENE_PRODUCT", 64, 72], ["EGFR", "PROTEIN", 0, 4], ["PI3K", "PROTEIN", 51, 55], ["Akt", "PROTEIN", 56, 59], ["MAPK", "PROTEIN", 64, 68], ["ERK", "PROTEIN", 69, 72], ["EGFR", "TEST", 0, 4], ["downstream pathways", "TEST", 23, 42], ["PI3K", "TEST", 51, 55], ["MAPK", "TEST", 64, 68]]], ["It is unknown whether the SFK or downstream EGFR signaling is responsible for phosphorylating STAT3, as inhibitors of either SFK or EGFR abrogated STAT3 activation.", [["SFK", "GENE_OR_GENE_PRODUCT", 26, 29], ["EGFR", "GENE_OR_GENE_PRODUCT", 44, 48], ["STAT3", "GENE_OR_GENE_PRODUCT", 94, 99], ["SFK", "GENE_OR_GENE_PRODUCT", 125, 128], ["EGFR", "GENE_OR_GENE_PRODUCT", 132, 136], ["STAT3", "GENE_OR_GENE_PRODUCT", 147, 152], ["SFK", "PROTEIN", 26, 29], ["EGFR", "PROTEIN", 44, 48], ["STAT3", "PROTEIN", 94, 99], ["SFK", "PROTEIN", 125, 128], ["EGFR", "PROTEIN", 132, 136], ["STAT3", "PROTEIN", 147, 152], ["downstream EGFR signaling", "PROBLEM", 33, 58], ["phosphorylating STAT3", "TREATMENT", 78, 99], ["inhibitors", "TREATMENT", 104, 114], ["STAT3 activation", "PROBLEM", 147, 163]]], ["Activated STAT3 then drives tumorigenic responses.", [["STAT3", "GENE_OR_GENE_PRODUCT", 10, 15], ["STAT3", "PROTEIN", 10, 15]]], ["In brain metastatic breast cancer cells, EGF activates both EGFR and HER2 (Fig. 4) .", [["brain metastatic breast cancer cells", "ANATOMY", 3, 39], ["breast cancer", "DISEASE", 20, 33], ["brain metastatic breast cancer cells", "CELL", 3, 39], ["EGF", "GENE_OR_GENE_PRODUCT", 41, 44], ["EGFR", "GENE_OR_GENE_PRODUCT", 60, 64], ["HER2", "GENE_OR_GENE_PRODUCT", 69, 73], ["brain metastatic breast cancer cells", "CELL_TYPE", 3, 39], ["EGF", "PROTEIN", 41, 44], ["EGFR", "PROTEIN", 60, 64], ["HER2", "PROTEIN", 69, 73], ["Fig. 4", "PROTEIN", 75, 81], ["brain metastatic breast cancer cells", "PROBLEM", 3, 39], ["brain", "ANATOMY", 3, 8], ["metastatic", "OBSERVATION_MODIFIER", 9, 19], ["breast", "ANATOMY", 20, 26], ["cancer", "OBSERVATION", 27, 33]]], ["The downstream signaling cascade causes HPSE to translocate to the nucleolus and activate Topo1, an enzyme that drives cell proliferation.", [["nucleolus", "ANATOMY", 67, 76], ["cell", "ANATOMY", 119, 123], ["HPSE", "GENE_OR_GENE_PRODUCT", 40, 44], ["nucleolus", "CELLULAR_COMPONENT", 67, 76], ["Topo1", "GENE_OR_GENE_PRODUCT", 90, 95], ["cell", "CELL", 119, 123], ["HPSE", "PROTEIN", 40, 44], ["Topo1", "PROTEIN", 90, 95], ["The downstream signaling cascade", "PROBLEM", 0, 32], ["an enzyme", "TEST", 97, 106], ["cell proliferation", "PROBLEM", 119, 137], ["downstream", "OBSERVATION_MODIFIER", 4, 14], ["signaling cascade", "OBSERVATION", 15, 32], ["drives cell proliferation", "OBSERVATION", 112, 137]]], ["Since enzymatically inactive HPSE could not stimulate Topo1, HPSE may activate Topo1 by cleaving HS bound to it (Fig. 4) .HPSE-EGFR signalingAgain, the precise mechanism by which HPSE activates Src or an SFK is unknown and may be the subject of future studies.", [["HPSE", "CHEMICAL", 29, 33], ["HPSE", "CHEMICAL", 61, 65], ["HPSE", "SIMPLE_CHEMICAL", 29, 33], ["Topo1", "GENE_OR_GENE_PRODUCT", 54, 59], ["HPSE", "SIMPLE_CHEMICAL", 61, 65], ["Topo1", "GENE_OR_GENE_PRODUCT", 79, 84], ["HS", "GENE_OR_GENE_PRODUCT", 97, 99], ["HPSE", "GENE_OR_GENE_PRODUCT", 122, 126], ["EGFR", "GENE_OR_GENE_PRODUCT", 127, 131], ["HPSE", "GENE_OR_GENE_PRODUCT", 179, 183], ["Src", "GENE_OR_GENE_PRODUCT", 194, 197], ["SFK", "GENE_OR_GENE_PRODUCT", 204, 207], ["HPSE", "PROTEIN", 29, 33], ["Topo1", "PROTEIN", 54, 59], ["HPSE", "PROTEIN", 61, 65], ["Topo1", "PROTEIN", 79, 84], ["HS", "DNA", 97, 99], ["HPSE", "PROTEIN", 122, 126], ["EGFR", "PROTEIN", 127, 131], ["HPSE", "PROTEIN", 179, 183], ["Src", "PROTEIN", 194, 197], ["SFK", "PROTEIN", 204, 207], ["enzymatically inactive HPSE", "PROBLEM", 6, 33], ["EGFR signaling", "PROBLEM", 127, 141], ["future studies", "TEST", 245, 259], ["inactive", "OBSERVATION", 20, 28], ["SFK", "OBSERVATION", 204, 207]]], ["Elucidating the nature of the HPSE-SFK relationship could shed light not only on the EGFR signaling pathway but also on the other pathways discussed before.", [["HPSE", "GENE_OR_GENE_PRODUCT", 30, 34], ["SFK", "GENE_OR_GENE_PRODUCT", 35, 38], ["EGFR", "GENE_OR_GENE_PRODUCT", 85, 89], ["HPSE", "PROTEIN", 30, 34], ["SFK", "PROTEIN", 35, 38], ["EGFR", "PROTEIN", 85, 89]]], ["Additionally, it has not been confirmed that HPSE-mediated Topo1 activation is due to the cleavage of HS on Topo1, though it is likely.Role of HPSE in macrophage activationMacrophages are immune cells which detect and phagocytose foreign invaders that enter the body [128] .", [["macrophage", "ANATOMY", 151, 161], ["Macrophages", "ANATOMY", 172, 183], ["immune cells", "ANATOMY", 188, 200], ["body", "ANATOMY", 262, 266], ["HPSE", "CHEMICAL", 45, 49], ["HPSE", "GENE_OR_GENE_PRODUCT", 45, 49], ["Topo1", "GENE_OR_GENE_PRODUCT", 59, 64], ["HS", "GENE_OR_GENE_PRODUCT", 102, 104], ["Topo1", "GENE_OR_GENE_PRODUCT", 108, 113], ["HPSE", "GENE_OR_GENE_PRODUCT", 143, 147], ["macrophage", "CELL", 151, 161], ["Macrophages", "CELL", 172, 183], ["immune cells", "CELL", 188, 200], ["Topo1", "PROTEIN", 59, 64], ["HS", "DNA", 102, 104], ["Topo1", "PROTEIN", 108, 113], ["HPSE", "PROTEIN", 143, 147], ["Macrophages", "CELL_TYPE", 172, 183], ["immune cells", "CELL_TYPE", 188, 200], ["HPSE", "TEST", 45, 49], ["Topo1", "TREATMENT", 108, 113], ["immune cells", "PROBLEM", 188, 200], ["phagocytose foreign invaders", "PROBLEM", 218, 246], ["is likely", "UNCERTAINTY", 125, 134], ["HPSE", "OBSERVATION", 143, 147], ["macrophage activationMacrophages", "OBSERVATION", 151, 183], ["immune cells", "OBSERVATION", 188, 200], ["phagocytose", "OBSERVATION", 218, 229], ["foreign invaders", "OBSERVATION", 230, 246]]], ["They are present in nearly all human tissues [128] .", [["tissues", "ANATOMY", 37, 44], ["human", "ORGANISM", 31, 36], ["tissues", "TISSUE", 37, 44], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["human tissues", "ANATOMY", 31, 44]]], ["During a viral infection, macrophages engulf infected cells, degrade them in lysosomes, and present the processed antigens on MHC class II molecules on the cell membrane [129] .", [["macrophages", "ANATOMY", 26, 37], ["cells", "ANATOMY", 54, 59], ["lysosomes", "ANATOMY", 77, 86], ["cell membrane", "ANATOMY", 156, 169], ["viral infection", "DISEASE", 9, 24], ["macrophages", "CELL", 26, 37], ["cells", "CELL", 54, 59], ["lysosomes", "CELLULAR_COMPONENT", 77, 86], ["cell membrane", "CELLULAR_COMPONENT", 156, 169], ["macrophages", "CELL_TYPE", 26, 37], ["infected cells", "CELL_TYPE", 45, 59], ["MHC class II molecules", "PROTEIN", 126, 148], ["a viral infection", "PROBLEM", 7, 24], ["macrophages engulf infected cells", "PROBLEM", 26, 59], ["viral", "OBSERVATION_MODIFIER", 9, 14], ["infection", "OBSERVATION", 15, 24], ["macrophages", "OBSERVATION_MODIFIER", 26, 37], ["engulf", "OBSERVATION_MODIFIER", 38, 44], ["infected cells", "OBSERVATION", 45, 59], ["cell membrane", "OBSERVATION", 156, 169]]], ["T cells use T-cell receptors (TCRs) to bind to the MHC class II molecules which facilitates their activation [129] .", [["T cells", "ANATOMY", 0, 7], ["T-cell", "ANATOMY", 12, 18], ["T cells", "CELL", 0, 7], ["T-cell receptors", "GENE_OR_GENE_PRODUCT", 12, 28], ["TCRs", "GENE_OR_GENE_PRODUCT", 30, 34], ["T cells", "CELL_TYPE", 0, 7], ["T-cell receptors", "PROTEIN", 12, 28], ["TCRs", "PROTEIN", 30, 34], ["MHC class II molecules", "PROTEIN", 51, 73], ["T-cell receptors", "TREATMENT", 12, 28]]], ["As professional antigen-presenting cells (APCs), macrophages play a key role in both the innate and adaptive immune response [129] .Role of HPSE in macrophage activationHPSE was demonstrated to be necessary for the activation and proper functioning of macrophages including their ability to secrete cytokines, to move to the site of infection, and to phagocytose foreign material [130] .", [["antigen-presenting cells", "ANATOMY", 16, 40], ["APCs", "ANATOMY", 42, 46], ["macrophages", "ANATOMY", 49, 60], ["macrophage", "ANATOMY", 148, 158], ["macrophages", "ANATOMY", 252, 263], ["site", "ANATOMY", 325, 329], ["HPSE", "CHEMICAL", 140, 144], ["infection", "DISEASE", 333, 342], ["antigen-presenting cells", "CELL", 16, 40], ["APCs", "CELL", 42, 46], ["macrophages", "CELL", 49, 60], ["HPSE", "GENE_OR_GENE_PRODUCT", 140, 144], ["macrophage", "CELL", 148, 158], ["macrophages", "CELL", 252, 263], ["professional antigen-presenting cells", "CELL_TYPE", 3, 40], ["APCs", "CELL_TYPE", 42, 46], ["macrophages", "CELL_TYPE", 49, 60], ["HPSE", "PROTEIN", 140, 144], ["macrophages", "CELL_TYPE", 252, 263], ["cytokines", "PROTEIN", 299, 308], ["macrophages", "PROBLEM", 49, 60], ["macrophages", "PROBLEM", 252, 263], ["infection", "PROBLEM", 333, 342], ["HPSE", "OBSERVATION", 140, 144], ["infection", "OBSERVATION", 333, 342]]], ["Non-enzymatically active HPSE was able to maintain cytokine expression to normal levels, suggesting that the HS cleavage is not responsible for the effects of HPSE on macrophages [130] .", [["macrophages", "ANATOMY", 167, 178], ["HPSE", "CHEMICAL", 159, 163], ["HPSE", "SIMPLE_CHEMICAL", 25, 29], ["HPSE", "SIMPLE_CHEMICAL", 159, 163], ["macrophages", "CELL", 167, 178], ["HPSE", "PROTEIN", 25, 29], ["cytokine", "PROTEIN", 51, 59], ["macrophages", "CELL_TYPE", 167, 178], ["Non-enzymatically active HPSE", "PROBLEM", 0, 29], ["the HS cleavage", "PROBLEM", 105, 120], ["HPSE on macrophages", "PROBLEM", 159, 178], ["active", "OBSERVATION_MODIFIER", 18, 24], ["HPSE", "OBSERVATION", 25, 29]]], ["Macrophages are activated upon expression of the cytokine macrophage inflammatory protein-2 (MIP-2), but this process is impaired in macrophages from HPSE-KO cells [130] .", [["Macrophages", "ANATOMY", 0, 11], ["macrophages", "ANATOMY", 133, 144], ["HPSE-KO cells", "ANATOMY", 150, 163], ["Macrophages", "CELL", 0, 11], ["macrophage inflammatory protein-2", "GENE_OR_GENE_PRODUCT", 58, 91], ["MIP-2", "GENE_OR_GENE_PRODUCT", 93, 98], ["macrophages", "CELL", 133, 144], ["HPSE-KO cells", "CELL", 150, 163], ["Macrophages", "CELL_TYPE", 0, 11], ["cytokine macrophage inflammatory protein-2 (MIP-2", "PROTEIN", 49, 98], ["macrophages", "CELL_TYPE", 133, 144], ["HPSE-KO cells", "CELL_LINE", 150, 163], ["Macrophages", "PROBLEM", 0, 11], ["the cytokine macrophage inflammatory protein", "TEST", 45, 89], ["MIP", "TEST", 93, 96], ["HPSE", "TEST", 150, 154], ["cytokine macrophage", "OBSERVATION", 49, 68], ["inflammatory", "OBSERVATION_MODIFIER", 69, 81], ["impaired", "OBSERVATION_MODIFIER", 121, 129]]], ["Interestingly, certain chemotherapeutics can stimulate macrophage activation and polarization into an M2 (pro-tumorigenic) phenotype in an HPSE-dependent mechanism [131] .Role of HPSE in macrophage activationThe inhibition of each of the three subfamilies of MAPK signaling (ERK, JNK, and p38) reduced cytokine expression in macrophages.", [["macrophage", "ANATOMY", 55, 65], ["macrophage", "ANATOMY", 187, 197], ["macrophages", "ANATOMY", 325, 336], ["macrophage", "CELL", 55, 65], ["M2", "GENE_OR_GENE_PRODUCT", 102, 104], ["HPSE", "SIMPLE_CHEMICAL", 139, 143], ["HPSE", "GENE_OR_GENE_PRODUCT", 179, 183], ["macrophage", "CELL", 187, 197], ["MAPK", "GENE_OR_GENE_PRODUCT", 259, 263], ["ERK", "GENE_OR_GENE_PRODUCT", 275, 278], ["JNK", "GENE_OR_GENE_PRODUCT", 280, 283], ["p38", "GENE_OR_GENE_PRODUCT", 289, 292], ["macrophages", "CELL", 325, 336], ["HPSE", "PROTEIN", 179, 183], ["MAPK", "PROTEIN", 259, 263], ["ERK", "PROTEIN", 275, 278], ["JNK", "PROTEIN", 280, 283], ["p38", "PROTEIN", 289, 292], ["cytokine", "PROTEIN", 302, 310], ["macrophages", "CELL_TYPE", 325, 336], ["certain chemotherapeutics", "TREATMENT", 15, 40], ["MAPK signaling", "TEST", 259, 273], ["ERK", "TEST", 275, 278], ["JNK", "TEST", 280, 283], ["p38", "TEST", 289, 292], ["reduced cytokine expression in macrophages", "PROBLEM", 294, 336], ["HPSE", "OBSERVATION", 179, 183], ["macrophage activation", "OBSERVATION", 187, 208], ["cytokine expression", "OBSERVATION", 302, 321], ["macrophages", "ANATOMY", 325, 336]]], ["JNK signaling and, to a lesser extent, ERK phosphorylation were responsible for the expression of TNF-\u03b1, IL6, and MIP-2 [130] .", [["JNK", "GENE_OR_GENE_PRODUCT", 0, 3], ["ERK", "GENE_OR_GENE_PRODUCT", 39, 42], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 98, 103], ["IL6", "GENE_OR_GENE_PRODUCT", 105, 108], ["MIP-2", "GENE_OR_GENE_PRODUCT", 114, 119], ["JNK", "PROTEIN", 0, 3], ["ERK", "PROTEIN", 39, 42], ["TNF", "PROTEIN", 98, 101], ["\u03b1", "PROTEIN", 102, 103], ["IL6", "PROTEIN", 105, 108], ["JNK signaling", "TEST", 0, 13], ["ERK phosphorylation", "TEST", 39, 58], ["TNF", "TEST", 98, 101], ["IL6", "TEST", 105, 108], ["MIP", "TEST", 114, 117], ["lesser extent", "OBSERVATION_MODIFIER", 24, 37]]], ["However, IL6 expression stemmed from ERK and p38 signaling [130] .", [["IL6", "GENE_OR_GENE_PRODUCT", 9, 12], ["ERK", "GENE_OR_GENE_PRODUCT", 37, 40], ["p38", "GENE_OR_GENE_PRODUCT", 45, 48], ["IL6", "PROTEIN", 9, 12], ["ERK", "PROTEIN", 37, 40], ["p38", "PROTEIN", 45, 48], ["ERK", "TEST", 37, 40], ["p38 signaling", "TEST", 45, 58]]], ["In addition, the results of a transcription factor array revealed that c-Fos was downregulated in HPSE-KO macrophages, an effect which was replicated upon the addition of JNK and p38 inhibitors to HPSE-WT macrophages [130] .", [["HPSE-KO macrophages", "ANATOMY", 98, 117], ["HPSE-WT macrophages", "ANATOMY", 197, 216], ["c-Fos", "GENE_OR_GENE_PRODUCT", 71, 76], ["HPSE-KO macrophages", "CELL", 98, 117], ["JNK", "GENE_OR_GENE_PRODUCT", 171, 174], ["p38", "GENE_OR_GENE_PRODUCT", 179, 182], ["transcription factor", "PROTEIN", 30, 50], ["Fos", "PROTEIN", 73, 76], ["HPSE-KO macrophages", "CELL_LINE", 98, 117], ["JNK", "PROTEIN", 171, 174], ["HPSE-WT macrophages", "CELL_LINE", 197, 216], ["a transcription factor array", "TEST", 28, 56], ["c-Fos", "PROBLEM", 71, 76], ["JNK and p38 inhibitors", "TREATMENT", 171, 193], ["HPSE", "TEST", 197, 201], ["WT macrophages", "PROBLEM", 202, 216]]], ["Because Toll-like receptors (TLRs) have been shown to be upstream Fig. 4 Proposed role of HPSE in EGFR signaling in brain metastatic breast cancer cells.", [["brain metastatic breast cancer cells", "ANATOMY", 116, 152], ["breast cancer", "DISEASE", 133, 146], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 8, 27], ["TLRs", "GENE_OR_GENE_PRODUCT", 29, 33], ["HPSE", "GENE_OR_GENE_PRODUCT", 90, 94], ["EGFR", "GENE_OR_GENE_PRODUCT", 98, 102], ["brain metastatic breast cancer cells", "CELL", 116, 152], ["Toll-like receptors", "PROTEIN", 8, 27], ["TLRs", "PROTEIN", 29, 33], ["HPSE", "PROTEIN", 90, 94], ["EGFR", "PROTEIN", 98, 102], ["brain metastatic breast cancer cells", "CELL_TYPE", 116, 152], ["HPSE in EGFR signaling in brain metastatic breast cancer cells", "PROBLEM", 90, 152], ["HPSE", "OBSERVATION", 90, 94], ["brain", "ANATOMY", 116, 121], ["metastatic", "OBSERVATION_MODIFIER", 122, 132], ["breast", "ANATOMY", 133, 139], ["cancer cells", "OBSERVATION", 140, 152]]], ["Extracellular EGF binds to both EGFR and HER2 receptors on the cell membrane.", [["Extracellular", "ANATOMY", 0, 13], ["cell membrane", "ANATOMY", 63, 76], ["EGF", "GENE_OR_GENE_PRODUCT", 14, 17], ["EGFR", "GENE_OR_GENE_PRODUCT", 32, 36], ["HER2 receptors", "GENE_OR_GENE_PRODUCT", 41, 55], ["cell membrane", "CELLULAR_COMPONENT", 63, 76], ["EGF", "PROTEIN", 14, 17], ["EGFR", "PROTEIN", 32, 36], ["HER2 receptors", "PROTEIN", 41, 55], ["Extracellular EGF binds", "PROBLEM", 0, 23], ["both EGFR", "TEST", 27, 36], ["cell membrane", "OBSERVATION", 63, 76]]], ["Activation of these receptors results in the nucleolar translocation of HPSE, where it can activate Topo1.", [["nucleolar", "ANATOMY", 45, 54], ["nucleolar", "CELLULAR_COMPONENT", 45, 54], ["HPSE", "GENE_OR_GENE_PRODUCT", 72, 76], ["Topo1", "GENE_OR_GENE_PRODUCT", 100, 105], ["HPSE", "PROTEIN", 72, 76], ["Topo1", "PROTEIN", 100, 105], ["nucleolar translocation", "OBSERVATION", 45, 68]]], ["HPSE may cleave HS bound to Topo1, but this is yet to be confirmed.", [["HPSE", "CHEMICAL", 0, 4], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["Topo1", "GENE_OR_GENE_PRODUCT", 28, 33], ["HPSE", "PROTEIN", 0, 4], ["HS", "DNA", 16, 18], ["Topo1", "PROTEIN", 28, 33], ["Topo1", "TREATMENT", 28, 33]]], ["Topo1 proceeds to drive cell proliferation of the HPSE-induced cytokine response [132] , the authors proposed that HPSE activates membrane TLRs through an unknown mechanism.", [["cell", "ANATOMY", 24, 28], ["membrane", "ANATOMY", 130, 138], ["HPSE", "CHEMICAL", 115, 119], ["Topo1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 24, 28], ["HPSE", "GENE_OR_GENE_PRODUCT", 50, 54], ["HPSE", "SIMPLE_CHEMICAL", 115, 119], ["membrane", "CELLULAR_COMPONENT", 130, 138], ["TLRs", "GENE_OR_GENE_PRODUCT", 139, 143], ["Topo1", "PROTEIN", 0, 5], ["HPSE", "PROTEIN", 50, 54], ["cytokine", "PROTEIN", 63, 71], ["HPSE", "PROTEIN", 115, 119], ["membrane TLRs", "PROTEIN", 130, 143], ["Topo1", "TREATMENT", 0, 5], ["the HPSE", "TEST", 46, 54], ["drive cell proliferation", "OBSERVATION", 18, 42]]], ["The results of this study indicate that HPSE upregulation activates TLRs which stimulate ERK, p38, and JNK signaling.", [["HPSE", "GENE_OR_GENE_PRODUCT", 40, 44], ["TLRs", "GENE_OR_GENE_PRODUCT", 68, 72], ["ERK", "GENE_OR_GENE_PRODUCT", 89, 92], ["p38", "GENE_OR_GENE_PRODUCT", 94, 97], ["JNK", "GENE_OR_GENE_PRODUCT", 103, 106], ["HPSE", "PROTEIN", 40, 44], ["TLRs", "PROTEIN", 68, 72], ["ERK", "PROTEIN", 89, 92], ["p38", "PROTEIN", 94, 97], ["JNK", "PROTEIN", 103, 106], ["this study", "TEST", 15, 25], ["HPSE upregulation", "PROBLEM", 40, 57], ["ERK", "TEST", 89, 92], ["p38", "TEST", 94, 97], ["JNK signaling", "TEST", 103, 116]]], ["This trio of proteins proceed to activate c-Fos which finally induces the cytokines needed for macrophage function [130] .Role of HPSE in macrophage activationAnother study of HPSE and macrophage activation reported similar results with enzymatically inactive HPSE inducing the expression of the following cytokines: TNF\u03b1, IL-1, MCP-1, and MMP-9 [38] .", [["macrophage", "ANATOMY", 95, 105], ["macrophage", "ANATOMY", 138, 148], ["macrophage", "ANATOMY", 185, 195], ["HPSE", "CHEMICAL", 260, 264], ["c-Fos", "GENE_OR_GENE_PRODUCT", 42, 47], ["macrophage", "CELL", 95, 105], ["HPSE", "GENE_OR_GENE_PRODUCT", 130, 134], ["macrophage", "CELL", 138, 148], ["HPSE", "SIMPLE_CHEMICAL", 176, 180], ["macrophage", "CELL", 185, 195], ["HPSE", "SIMPLE_CHEMICAL", 260, 264], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 317, 321], ["IL-1", "GENE_OR_GENE_PRODUCT", 323, 327], ["MCP-1", "GENE_OR_GENE_PRODUCT", 329, 334], ["MMP-9", "GENE_OR_GENE_PRODUCT", 340, 345], ["c-Fos", "PROTEIN", 42, 47], ["cytokines", "PROTEIN", 74, 83], ["cytokines", "PROTEIN", 306, 315], ["TNF\u03b1", "PROTEIN", 317, 321], ["MCP", "PROTEIN", 329, 332], ["MMP", "PROTEIN", 340, 343], ["macrophage function", "TEST", 95, 114], ["Another study", "TEST", 159, 172], ["macrophage activation", "TEST", 185, 206], ["TNF", "TEST", 317, 320], ["IL", "TEST", 323, 325], ["MCP", "TEST", 329, 332], ["MMP", "TEST", 340, 343]]], ["In the same study, the authors showed that mechanism corresponds to the activation of PI3K/Akt and MAPK/ERK pathways [38] .", [["PI3K", "GENE_OR_GENE_PRODUCT", 86, 90], ["Akt", "GENE_OR_GENE_PRODUCT", 91, 94], ["MAPK", "GENE_OR_GENE_PRODUCT", 99, 103], ["ERK", "GENE_OR_GENE_PRODUCT", 104, 107], ["PI3K", "PROTEIN", 86, 90], ["Akt", "PROTEIN", 91, 94], ["MAPK", "PROTEIN", 99, 103], ["ERK", "PROTEIN", 104, 107], ["the same study", "TEST", 3, 17], ["PI3K", "TEST", 86, 90], ["Akt", "TEST", 91, 94], ["MAPK/ERK pathways", "TEST", 99, 116]]], ["TLR2, TLR4, and NF-\u03baB signaling were necessary for HPSEinduced cytokine production [38] .", [["TLR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR4", "GENE_OR_GENE_PRODUCT", 6, 10], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 16, 21], ["TLR2", "PROTEIN", 0, 4], ["TLR4", "PROTEIN", 6, 10], ["NF-\u03baB", "PROTEIN", 16, 21], ["cytokine", "PROTEIN", 63, 71], ["TLR2", "TEST", 0, 4], ["TLR4", "TEST", 6, 10], ["NF", "TREATMENT", 16, 18], ["HPSEinduced cytokine production", "PROBLEM", 51, 82]]], ["It appears that HPSE, by an unknown mechanism which does not involve enzymatic function or even the binding of HPSGs, activates TLR-2 and TLR-4.", [["HPSE", "SIMPLE_CHEMICAL", 16, 20], ["HPSGs", "GENE_OR_GENE_PRODUCT", 111, 116], ["TLR-2", "GENE_OR_GENE_PRODUCT", 128, 133], ["TLR-4", "GENE_OR_GENE_PRODUCT", 138, 143], ["HPSGs", "PROTEIN", 111, 116], ["TLR", "PROTEIN", 128, 131], ["TLR-4", "PROTEIN", 138, 143], ["HPSGs", "TEST", 111, 116], ["TLR", "TEST", 128, 131], ["TLR", "TEST", 138, 141], ["HPSE", "OBSERVATION", 16, 20]]], ["This stimulates NF-\u03baB, MAPK, and PI3K signaling which promotes the downstream induction of cytokines that the macrophages require for activation and proper functioning.", [["macrophages", "ANATOMY", 110, 121], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 16, 21], ["MAPK", "GENE_OR_GENE_PRODUCT", 23, 27], ["PI3K", "GENE_OR_GENE_PRODUCT", 33, 37], ["macrophages", "CELL", 110, 121], ["NF-\u03baB", "PROTEIN", 16, 21], ["MAPK", "PROTEIN", 23, 27], ["PI3K", "PROTEIN", 33, 37], ["cytokines", "PROTEIN", 91, 100], ["macrophages", "CELL_TYPE", 110, 121], ["This stimulates NF", "TEST", 0, 18], ["PI3K signaling", "PROBLEM", 33, 47], ["the downstream induction of cytokines", "TREATMENT", 63, 100]]], ["The mechanism by which TLRs activate NF-\u03baB and JNK signaling is well understood and elucidated in great detail in a review by Takeda and Akira [133] .Role of HPSE in macrophage activationYet, another study using mice with colitis reported a positive regulatory which shows HPSE-mediated macrophage activation [40] .", [["macrophage", "ANATOMY", 166, 176], ["macrophage", "ANATOMY", 287, 297], ["colitis", "DISEASE", 222, 229], ["TLRs", "GENE_OR_GENE_PRODUCT", 23, 27], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 37, 42], ["JNK", "GENE_OR_GENE_PRODUCT", 47, 50], ["HPSE", "GENE_OR_GENE_PRODUCT", 158, 162], ["macrophage", "CELL", 166, 176], ["mice", "ORGANISM", 212, 216], ["HPSE", "SIMPLE_CHEMICAL", 273, 277], ["macrophage", "CELL", 287, 297], ["TLRs", "PROTEIN", 23, 27], ["NF-\u03baB", "PROTEIN", 37, 42], ["JNK", "PROTEIN", 47, 50], ["HPSE", "PROTEIN", 273, 277], ["mice", "SPECIES", 212, 216], ["mice", "SPECIES", 212, 216], ["another study", "TEST", 192, 205], ["colitis", "PROBLEM", 222, 229], ["HPSE", "TEST", 273, 277]]], ["HPSE-induced NF-\u03baB signaling produced the following cytokines: IL-1, IL-6, MIP-1, MIP-2, and TNF-\u03b1.", [["HPSE", "CHEMICAL", 0, 4], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 13, 18], ["IL-1", "GENE_OR_GENE_PRODUCT", 63, 67], ["IL-6", "GENE_OR_GENE_PRODUCT", 69, 73], ["MIP-1", "GENE_OR_GENE_PRODUCT", 75, 80], ["MIP-2", "GENE_OR_GENE_PRODUCT", 82, 87], ["TNF-\u03b1.", "GENE_OR_GENE_PRODUCT", 93, 99], ["NF-\u03baB", "PROTEIN", 13, 18], ["cytokines", "PROTEIN", 52, 61], ["TNF", "PROTEIN", 93, 96], ["HPSE", "TEST", 0, 4], ["IL", "TEST", 63, 65], ["IL", "TEST", 69, 71], ["MIP", "TEST", 75, 78], ["MIP", "TEST", 82, 85], ["TNF", "TEST", 93, 96], ["TNF", "ANATOMY", 93, 96]]], ["Enzymatically active HPSE also sensitized macrophages to LPS-induced activation of TLR-4 [40] .", [["macrophages", "ANATOMY", 42, 53], ["HPSE", "CHEMICAL", 21, 25], ["LPS", "CHEMICAL", 57, 60], ["HPSE", "CHEMICAL", 21, 25], ["HPSE", "SIMPLE_CHEMICAL", 21, 25], ["macrophages", "CELL", 42, 53], ["LPS", "SIMPLE_CHEMICAL", 57, 60], ["TLR-4", "GENE_OR_GENE_PRODUCT", 83, 88], ["macrophages", "CELL_TYPE", 42, 53], ["TLR", "PROTEIN", 83, 86], ["LPS", "TEST", 57, 60], ["TLR", "TEST", 83, 86], ["active", "OBSERVATION_MODIFIER", 14, 20], ["HPSE", "OBSERVATION", 21, 25], ["sensitized macrophages", "OBSERVATION", 31, 53]]], ["Because HS is a known inhibitor of TLR4 and HPSE has been noted to significantly reduce the HS located on the macrophage exterior, HPSE-mediated HS cleavage may clear space on the macrophage membrane and allow more LPS to bind to the macrophage TLR [40] .Role of HPSE in macrophage activationThe activated macrophages then secret TNF\u03b1, which up-regulated HPSE expression in the epithelial cells [40] .", [["macrophage", "ANATOMY", 110, 120], ["macrophage membrane", "ANATOMY", 180, 199], ["macrophage", "ANATOMY", 234, 244], ["macrophage", "ANATOMY", 271, 281], ["macrophages", "ANATOMY", 306, 317], ["epithelial cells", "ANATOMY", 378, 394], ["HPSE", "CHEMICAL", 44, 48], ["LPS", "CHEMICAL", 215, 218], ["TLR4", "GENE_OR_GENE_PRODUCT", 35, 39], ["HPSE", "GENE_OR_GENE_PRODUCT", 44, 48], ["macrophage", "CELL", 110, 120], ["HPSE", "SIMPLE_CHEMICAL", 131, 135], ["macrophage membrane", "CELLULAR_COMPONENT", 180, 199], ["LPS", "SIMPLE_CHEMICAL", 215, 218], ["macrophage", "CELL", 234, 244], ["HPSE", "GENE_OR_GENE_PRODUCT", 263, 267], ["macrophage", "CELL", 271, 281], ["macrophages", "CELL", 306, 317], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 330, 334], ["HPSE", "GENE_OR_GENE_PRODUCT", 355, 359], ["epithelial cells", "CELL", 378, 394], ["TLR4", "PROTEIN", 35, 39], ["HPSE", "PROTEIN", 44, 48], ["HS", "DNA", 92, 94], ["macrophage TLR", "PROTEIN", 234, 248], ["HPSE", "PROTEIN", 263, 267], ["activated macrophages", "CELL_TYPE", 296, 317], ["TNF\u03b1", "PROTEIN", 330, 334], ["HPSE", "PROTEIN", 355, 359], ["epithelial cells", "CELL_TYPE", 378, 394], ["TLR4", "PROBLEM", 35, 39], ["the HS", "PROBLEM", 88, 94], ["the macrophage exterior", "TREATMENT", 106, 129], ["HS cleavage", "TREATMENT", 145, 156], ["the macrophage membrane", "TREATMENT", 176, 199], ["HPSE", "OBSERVATION", 263, 267], ["macrophage activation", "OBSERVATION", 271, 292], ["macrophages", "OBSERVATION", 306, 317], ["epithelial cells", "OBSERVATION", 378, 394]]], ["Since TNF\u03b1 and the early growth response 1 (EGR1) have both been shown to up-regulate HPSE [134, 135] and TNF\u03b1 stimulates EGR1 [136] , the authors hypothesized that the macrophage-secreted TNF\u03b1 directly up-regulates HPSE via EGFR1 [40] .", [["macrophage", "ANATOMY", 169, 179], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 6, 10], ["early growth response 1", "GENE_OR_GENE_PRODUCT", 19, 42], ["EGR1", "GENE_OR_GENE_PRODUCT", 44, 48], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 106, 110], ["EGR1", "GENE_OR_GENE_PRODUCT", 122, 126], ["macrophage", "CELL", 169, 179], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 189, 193], ["HPSE", "GENE_OR_GENE_PRODUCT", 216, 220], ["EGFR1", "GENE_OR_GENE_PRODUCT", 225, 230], ["TNF\u03b1", "PROTEIN", 6, 10], ["EGR1", "PROTEIN", 44, 48], ["HPSE", "PROTEIN", 86, 90], ["TNF\u03b1", "PROTEIN", 106, 110], ["EGR1", "PROTEIN", 122, 126], ["TNF\u03b1", "PROTEIN", 189, 193], ["HPSE", "PROTEIN", 216, 220], ["EGFR1", "PROTEIN", 225, 230], ["TNF", "TEST", 6, 9], ["HPSE", "TEST", 86, 90], ["TNF", "TEST", 106, 109], ["EGR1", "TEST", 122, 126], ["the macrophage", "TEST", 165, 179], ["secreted TNF", "TEST", 180, 192], ["EGFR1", "TEST", 225, 230]]], ["Activated macrophages also secrete cathepsin L in the extracellular space, which cleaves and activates the latent HPSE there [40] .", [["macrophages", "ANATOMY", 10, 21], ["extracellular space", "ANATOMY", 54, 73], ["macrophages", "CELL", 10, 21], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 35, 46], ["extracellular space", "CELLULAR_COMPONENT", 54, 73], ["Activated macrophages", "CELL_TYPE", 0, 21], ["cathepsin L", "PROTEIN", 35, 46], ["Activated macrophages", "PROBLEM", 0, 21], ["cathepsin L in the extracellular space", "TREATMENT", 35, 73], ["macrophages", "OBSERVATION", 10, 21], ["cathepsin L", "OBSERVATION_MODIFIER", 35, 46], ["extracellular space", "ANATOMY", 54, 73]]], ["The cycle continues, promoting a hyper inflammatory environment that aids tumorigenesis via an increase in vascularization and the chemokineIL-6 which promotes STAT3 signaling [40] .Role of HPSE in macrophage activationWe propose the following mechanism based on the results of these studies: HPSE activates TLR2 and TLR4 through an unknown mechanism, but one that may involve hyaluronic acid.", [["macrophage", "ANATOMY", 198, 208], ["hyaluronic acid", "CHEMICAL", 377, 392], ["chemokineIL-6", "GENE_OR_GENE_PRODUCT", 131, 144], ["STAT3", "GENE_OR_GENE_PRODUCT", 160, 165], ["HPSE", "GENE_OR_GENE_PRODUCT", 190, 194], ["macrophage", "CELL", 198, 208], ["HPSE", "SIMPLE_CHEMICAL", 293, 297], ["TLR2", "GENE_OR_GENE_PRODUCT", 308, 312], ["TLR4", "GENE_OR_GENE_PRODUCT", 317, 321], ["hyaluronic acid", "SIMPLE_CHEMICAL", 377, 392], ["chemokineIL-6", "PROTEIN", 131, 144], ["STAT3", "PROTEIN", 160, 165], ["HPSE", "PROTEIN", 190, 194], ["TLR2", "PROTEIN", 308, 312], ["TLR4", "PROTEIN", 317, 321], ["a hyper inflammatory environment", "PROBLEM", 31, 63], ["an increase in vascularization", "TREATMENT", 92, 122], ["the chemokineIL", "TREATMENT", 127, 142], ["these studies", "TEST", 278, 291], ["hyaluronic acid", "TREATMENT", 377, 392], ["inflammatory", "OBSERVATION_MODIFIER", 39, 51], ["increase", "OBSERVATION_MODIFIER", 95, 103], ["vascularization", "OBSERVATION", 107, 122], ["HPSE", "OBSERVATION", 190, 194]]], ["Downstream signaling from TLR2 and TLR4 activates p38, ERK, and JNK. p38 and ERK both function in IL1-\u03b2 production involving the transcription factor c-Fos.", [["TLR2", "GENE_OR_GENE_PRODUCT", 26, 30], ["TLR4", "GENE_OR_GENE_PRODUCT", 35, 39], ["p38", "GENE_OR_GENE_PRODUCT", 50, 53], ["ERK", "GENE_OR_GENE_PRODUCT", 55, 58], ["JNK", "GENE_OR_GENE_PRODUCT", 64, 67], ["p38", "GENE_OR_GENE_PRODUCT", 69, 72], ["ERK", "GENE_OR_GENE_PRODUCT", 77, 80], ["IL1-\u03b2", "GENE_OR_GENE_PRODUCT", 98, 103], ["c-Fos", "GENE_OR_GENE_PRODUCT", 150, 155], ["TLR2", "PROTEIN", 26, 30], ["TLR4", "PROTEIN", 35, 39], ["p38", "PROTEIN", 50, 53], ["ERK", "PROTEIN", 55, 58], ["JNK", "PROTEIN", 64, 67], ["p38", "PROTEIN", 69, 72], ["ERK", "PROTEIN", 77, 80], ["IL1", "PROTEIN", 98, 101], ["\u03b2", "PROTEIN", 102, 103], ["transcription factor c-Fos", "PROTEIN", 129, 155], ["TLR2", "TEST", 26, 30], ["p38", "TEST", 50, 53], ["ERK", "TEST", 55, 58], ["JNK", "TEST", 64, 67], ["p38", "TEST", 69, 72], ["ERK", "TEST", 77, 80], ["IL1", "TEST", 98, 101], ["TLR2", "ANATOMY_MODIFIER", 26, 30], ["JNK", "ANATOMY", 64, 67]]], ["The mechanism by which TLRs activate JNK is well understood and progresses through proteins such as IRAK-1, IRAK-4, TRAF6, and eventually TAK1.", [["TLRs", "GENE_OR_GENE_PRODUCT", 23, 27], ["JNK", "GENE_OR_GENE_PRODUCT", 37, 40], ["IRAK-1", "GENE_OR_GENE_PRODUCT", 100, 106], ["IRAK-4", "GENE_OR_GENE_PRODUCT", 108, 114], ["TRAF6", "GENE_OR_GENE_PRODUCT", 116, 121], ["TAK1", "GENE_OR_GENE_PRODUCT", 138, 142], ["TLRs", "PROTEIN", 23, 27], ["JNK", "PROTEIN", 37, 40], ["IRAK", "PROTEIN", 100, 104], ["IRAK-4", "PROTEIN", 108, 114], ["TRAF6", "PROTEIN", 116, 121], ["TAK1", "PROTEIN", 138, 142], ["IRAK", "TEST", 100, 104], ["IRAK", "TEST", 108, 112], ["TRAF6", "TEST", 116, 121]]], ["TAK1 then activates JNK and the IKK complex, the latter stimulating NF-\u03baB activation.", [["TAK1", "GENE_OR_GENE_PRODUCT", 0, 4], ["JNK", "GENE_OR_GENE_PRODUCT", 20, 23], ["IKK", "GENE_OR_GENE_PRODUCT", 32, 35], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 68, 73], ["TAK1", "PROTEIN", 0, 4], ["JNK", "PROTEIN", 20, 23], ["IKK complex", "PROTEIN", 32, 43], ["NF-\u03baB", "PROTEIN", 68, 73], ["JNK", "TEST", 20, 23]]], ["NF-\u03baB translocates to the nucleus, binds to the specific sequences on the genome, and induces the transcription of cytokines, such as IL-1, MCP-1, interferon, and TNF-\u03b1, along with MMP-9.", [["nucleus", "ANATOMY", 26, 33], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["nucleus", "CELLULAR_COMPONENT", 26, 33], ["genome", "CELLULAR_COMPONENT", 74, 80], ["IL-1", "GENE_OR_GENE_PRODUCT", 134, 138], ["MCP-1", "GENE_OR_GENE_PRODUCT", 140, 145], ["interferon", "GENE_OR_GENE_PRODUCT", 147, 157], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 163, 168], ["MMP-9", "GENE_OR_GENE_PRODUCT", 181, 186], ["NF-\u03baB", "PROTEIN", 0, 5], ["cytokines", "PROTEIN", 115, 124], ["IL-1", "PROTEIN", 134, 138], ["MCP", "PROTEIN", 140, 143], ["interferon", "PROTEIN", 147, 157], ["TNF", "PROTEIN", 163, 166], ["MMP-9", "PROTEIN", 181, 186], ["cytokines", "TREATMENT", 115, 124], ["IL", "TEST", 134, 136], ["MCP", "TEST", 140, 143], ["interferon", "TREATMENT", 147, 157], ["TNF", "TEST", 163, 166], ["MMP", "TEST", 181, 184], ["nucleus", "ANATOMY", 26, 33]]], ["JNK signaling stimulates c-Fos which leads to the production of TNF-\u03b1, IL6, and MIP2.", [["JNK", "GENE_OR_GENE_PRODUCT", 0, 3], ["c-Fos", "GENE_OR_GENE_PRODUCT", 25, 30], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL6", "GENE_OR_GENE_PRODUCT", 71, 74], ["MIP2", "GENE_OR_GENE_PRODUCT", 80, 84], ["JNK", "PROTEIN", 0, 3], ["Fos", "PROTEIN", 27, 30], ["TNF", "PROTEIN", 64, 67], ["IL6", "PROTEIN", 71, 74], ["MIP2", "PROTEIN", 80, 84], ["TNF", "TEST", 64, 67], ["IL6", "TREATMENT", 71, 74], ["MIP2", "TREATMENT", 80, 84]]], ["Syntheses of these cytokines stimulate the activation of macrophages (Fig. 5) .Role of HPSE in macrophage activationTLR4 can activate PI3K via a Myd88-independent mechanism utilizing the TRAM and TRIF proteins.", [["macrophages", "ANATOMY", 57, 68], ["macrophage", "ANATOMY", 95, 105], ["macrophages", "CELL", 57, 68], ["HPSE", "GENE_OR_GENE_PRODUCT", 87, 91], ["macrophage", "CELL", 95, 105], ["TLR4", "GENE_OR_GENE_PRODUCT", 116, 120], ["PI3K", "GENE_OR_GENE_PRODUCT", 134, 138], ["Myd88", "GENE_OR_GENE_PRODUCT", 145, 150], ["TRAM", "GENE_OR_GENE_PRODUCT", 187, 191], ["TRIF", "GENE_OR_GENE_PRODUCT", 196, 200], ["cytokines", "PROTEIN", 19, 28], ["macrophages", "CELL_TYPE", 57, 68], ["HPSE", "PROTEIN", 87, 91], ["TLR4", "PROTEIN", 116, 120], ["PI3K", "PROTEIN", 134, 138], ["Myd88", "PROTEIN", 145, 150], ["TRAM", "PROTEIN", 187, 191], ["TRIF proteins", "PROTEIN", 196, 209], ["these cytokines", "TREATMENT", 13, 28], ["HPSE in macrophage activationTLR4", "TREATMENT", 87, 120], ["a Myd88", "TREATMENT", 143, 150], ["the TRAM and TRIF proteins", "TREATMENT", 183, 209]]], ["PI3K continues the cascade through Akt which also activates NF-\u03baB via phosphorylation and degradation of I\u03baB.", [["PI3K", "GENE_OR_GENE_PRODUCT", 0, 4], ["Akt", "GENE_OR_GENE_PRODUCT", 35, 38], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 60, 65], ["I\u03baB.", "GENE_OR_GENE_PRODUCT", 105, 109], ["PI3K", "PROTEIN", 0, 4], ["Akt", "PROTEIN", 35, 38], ["NF-\u03baB", "PROTEIN", 60, 65], ["PI3K", "TEST", 0, 4], ["NF", "TEST", 60, 62]]], ["Akt also phosphorylates GSK-3\u03b2 which activates JNK.", [["Akt", "GENE_OR_GENE_PRODUCT", 0, 3], ["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 24, 30], ["JNK", "GENE_OR_GENE_PRODUCT", 47, 50], ["Akt", "PROTEIN", 0, 3], ["GSK-3\u03b2", "PROTEIN", 24, 30], ["JNK", "PROTEIN", 47, 50], ["phosphorylates GSK", "TEST", 9, 27]]], ["Thus, TLRs may activate JNK and NF-\u03baB signaling via two different pathways.", [["TLRs", "GENE_OR_GENE_PRODUCT", 6, 10], ["JNK", "GENE_OR_GENE_PRODUCT", 24, 27], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 32, 37], ["TLRs", "PROTEIN", 6, 10], ["JNK", "PROTEIN", 24, 27], ["NF-\u03baB", "PROTEIN", 32, 37], ["JNK", "TEST", 24, 27], ["NF", "TEST", 32, 34]]], ["More studies need to be done to elucidate the mechanism by which HPSE activates TLRs to stimulate cytokine production and how the TLRs may activate downstream pathways such as p38 and ERK.Function of HPSE in T-cell adhesionActive but not resting T cells are reported to produce HPSE [137] .", [["T-cell", "ANATOMY", 208, 214], ["T cells", "ANATOMY", 246, 253], ["HPSE", "CHEMICAL", 65, 69], ["HPSE", "SIMPLE_CHEMICAL", 65, 69], ["TLRs", "GENE_OR_GENE_PRODUCT", 80, 84], ["TLRs", "GENE_OR_GENE_PRODUCT", 130, 134], ["p38", "GENE_OR_GENE_PRODUCT", 176, 179], ["ERK", "GENE_OR_GENE_PRODUCT", 184, 187], ["HPSE", "GENE_OR_GENE_PRODUCT", 200, 204], ["T-cell", "CELL", 208, 214], ["resting T cells", "CELL", 238, 253], ["TLRs", "PROTEIN", 80, 84], ["cytokine", "PROTEIN", 98, 106], ["TLRs", "PROTEIN", 130, 134], ["p38", "PROTEIN", 176, 179], ["ERK", "PROTEIN", 184, 187], ["HPSE", "PROTEIN", 200, 204], ["T-cell adhesionActive but not resting T cells", "CELL_TYPE", 208, 253], ["More studies", "TEST", 0, 12], ["cytokine production", "TEST", 98, 117], ["resting T cells", "PROBLEM", 238, 253], ["HPSE", "TEST", 278, 282], ["HPSE", "OBSERVATION", 200, 204]]], ["Upon activation, EGR1-dependent HPSE expression level is induced in CD4+ antigen-specific T lymphocytes infiltrating the central nervous system during clinical disease [138] .", [["CD4+ antigen-specific T lymphocytes", "ANATOMY", 68, 103], ["central nervous system", "ANATOMY", 121, 143], ["EGR1", "GENE_OR_GENE_PRODUCT", 17, 21], ["HPSE", "GENE_OR_GENE_PRODUCT", 32, 36], ["CD4+ antigen", "GENE_OR_GENE_PRODUCT", 68, 80], ["T lymphocytes", "CELL", 90, 103], ["central nervous system", "ANATOMICAL_SYSTEM", 121, 143], ["EGR1", "PROTEIN", 17, 21], ["HPSE", "PROTEIN", 32, 36], ["CD4", "PROTEIN", 68, 71], ["T lymphocytes", "CELL_TYPE", 90, 103], ["EGR1-dependent HPSE expression level", "TEST", 17, 53], ["CD4", "TEST", 68, 71], ["antigen", "TEST", 73, 80], ["clinical disease", "PROBLEM", 151, 167], ["lymphocytes infiltrating", "OBSERVATION", 92, 116], ["central", "ANATOMY_MODIFIER", 121, 128], ["nervous system", "ANATOMY", 129, 143]]], ["HPSE has been demonstrated to bind to HS and adhere T cells to the ECM [139, 140] .", [["T cells", "ANATOMY", 52, 59], ["ECM", "ANATOMY", 67, 70], ["HPSE", "CHEMICAL", 0, 4], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["HS", "CELL", 38, 40], ["T cells", "CELL", 52, 59], ["ECM", "CELLULAR_COMPONENT", 67, 70], ["HPSE", "PROTEIN", 0, 4], ["T cells", "CELL_TYPE", 52, 59]]], ["The adhesive function of HPSE in binding T cells to the ECM was noted in lymphoma cells and cancerous lymphocytes [141, 142] .", [["T cells", "ANATOMY", 41, 48], ["ECM", "ANATOMY", 56, 59], ["lymphoma cells", "ANATOMY", 73, 87], ["cancerous lymphocytes", "ANATOMY", 92, 113], ["HPSE", "CHEMICAL", 25, 29], ["lymphoma", "DISEASE", 73, 81], ["HPSE", "SIMPLE_CHEMICAL", 25, 29], ["T cells", "CELL", 41, 48], ["ECM", "CELLULAR_COMPONENT", 56, 59], ["lymphoma cells", "CELL", 73, 87], ["cancerous lymphocytes", "CELL", 92, 113], ["HPSE", "PROTEIN", 25, 29], ["binding T cells", "CELL_TYPE", 33, 48], ["ECM", "PROTEIN", 56, 59], ["lymphoma cells", "CELL_TYPE", 73, 87], ["cancerous lymphocytes", "CELL_TYPE", 92, 113], ["lymphoma cells", "PROBLEM", 73, 87], ["cancerous lymphocytes", "TEST", 92, 113], ["adhesive", "OBSERVATION_MODIFIER", 4, 12], ["lymphoma cells", "OBSERVATION", 73, 87], ["cancerous lymphocytes", "OBSERVATION", 92, 113]]], ["The mechanism for these adhesive properties was reported to be reliant on the presence of \u03b21 integrin on T cells and vascular cell adhesion molecule (VCAM-1) on endothelial cells [140, 141] .", [["T cells", "ANATOMY", 105, 112], ["endothelial cells", "ANATOMY", 161, 178], ["\u03b21 integrin", "GENE_OR_GENE_PRODUCT", 90, 101], ["T cells", "CELL", 105, 112], ["vascular cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 117, 148], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 150, 156], ["endothelial cells", "CELL", 161, 178], ["\u03b21 integrin", "PROTEIN", 90, 101], ["T cells", "CELL_TYPE", 105, 112], ["vascular cell adhesion molecule", "PROTEIN", 117, 148], ["VCAM", "PROTEIN", 150, 154], ["endothelial cells", "CELL_TYPE", 161, 178], ["these adhesive properties", "TREATMENT", 18, 43], ["vascular cell adhesion molecule", "TEST", 117, 148], ["VCAM", "TEST", 150, 154], ["endothelial cells", "TEST", 161, 178], ["vascular", "ANATOMY", 117, 125], ["cell adhesion", "OBSERVATION", 126, 139]]], ["HPSE alone was shown to adhere to T cells under shear flow conditions.", [["T cells", "ANATOMY", 34, 41], ["HPSE", "CHEMICAL", 0, 4], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["T cells", "CELL", 34, 41], ["HPSE", "PROTEIN", 0, 4], ["T cells", "CELL_TYPE", 34, 41]]], ["The effect was enhanced with treatment of the chemokine SDF-1.", [["SDF-1", "GENE_OR_GENE_PRODUCT", 56, 61], ["chemokine", "PROTEIN", 46, 55], ["SDF-1", "PROTEIN", 56, 61], ["the chemokine SDF", "TEST", 42, 59]]], ["Treatment with an \u03b14\u03b21 integrin antibody partially inhibited the adhesion of T cells [140] .", [["T cells", "ANATOMY", 77, 84], ["\u03b14\u03b21 integrin", "GENE_OR_GENE_PRODUCT", 18, 31], ["T cells", "CELL", 77, 84], ["\u03b14\u03b21 integrin antibody", "PROTEIN", 18, 40], ["T cells", "CELL_TYPE", 77, 84], ["Treatment", "TREATMENT", 0, 9], ["an \u03b14\u03b21 integrin antibody", "TREATMENT", 15, 40]]], ["Pre-treatment with HPSE to cleave HSPGs significantly reduced the capability of a later addition of HPSE to mediate T-cell adhesion to the ECM.", [["T-cell", "ANATOMY", 116, 122], ["ECM", "ANATOMY", 139, 142], ["HPSE", "CHEMICAL", 19, 23], ["HPSE", "SIMPLE_CHEMICAL", 19, 23], ["HSPGs", "GENE_OR_GENE_PRODUCT", 34, 39], ["HPSE", "SIMPLE_CHEMICAL", 100, 104], ["T-cell", "CELL", 116, 122], ["ECM", "CELLULAR_COMPONENT", 139, 142], ["HPSE", "PROTEIN", 100, 104], ["HPSE to mediate T-cell adhesion", "TREATMENT", 100, 131], ["cell adhesion", "OBSERVATION", 118, 131]]], ["Thus, the authors concluded that HPSE could augment the integrin-mediated adhesion of T cells [140] .Function of HPSE in T-cell adhesionHPSE binding to the T cells leads to upregulation of ERK and Pyk-2 kinases [140] .", [["T cells", "ANATOMY", 86, 93], ["T-cell", "ANATOMY", 121, 127], ["T cells", "ANATOMY", 156, 163], ["HPSE", "CHEMICAL", 33, 37], ["HPSE", "SIMPLE_CHEMICAL", 33, 37], ["T cells", "CELL", 86, 93], ["HPSE", "GENE_OR_GENE_PRODUCT", 113, 117], ["T-cell", "CELL", 121, 127], ["T cells", "CELL", 156, 163], ["ERK", "GENE_OR_GENE_PRODUCT", 189, 192], ["Pyk-2", "GENE_OR_GENE_PRODUCT", 197, 202], ["T cells", "CELL_TYPE", 86, 93], ["HPSE", "PROTEIN", 113, 117], ["T cells", "CELL_TYPE", 156, 163], ["ERK", "PROTEIN", 189, 192], ["Pyk-2 kinases", "PROTEIN", 197, 210], ["ERK", "TEST", 189, 192], ["Pyk", "TEST", 197, 200]]], ["ERK phosphorylation may arise due to HPSE directly as described before.", [["ERK", "GENE_OR_GENE_PRODUCT", 0, 3], ["HPSE", "GENE_OR_GENE_PRODUCT", 37, 41], ["ERK", "PROTEIN", 0, 3], ["HPSE", "PROTEIN", 37, 41], ["ERK phosphorylation", "TEST", 0, 19], ["HPSE", "PROBLEM", 37, 41], ["HPSE", "OBSERVATION", 37, 41]]], ["However, HPSE also reportedly augmented the effects of the chemokine SDF-1\u03b1 on Pyk-2 and ERK phosphorylation, suggesting that it could play both a direct role and a indirect role in the activation of these kinases [140] .HPSE in NK-cell activation, migration, and invasionNatural killer (NK) cells are innate lymphocytes which can kill infected cells and tumor cells.", [["NK-cell", "ANATOMY", 229, 236], ["invasionNatural killer (NK) cells", "ANATOMY", 264, 297], ["lymphocytes", "ANATOMY", 309, 320], ["cells", "ANATOMY", 345, 350], ["tumor cells", "ANATOMY", 355, 366], ["HPSE", "CHEMICAL", 9, 13], ["tumor", "DISEASE", 355, 360], ["HPSE", "CHEMICAL", 9, 13], ["HPSE", "SIMPLE_CHEMICAL", 9, 13], ["SDF-1\u03b1", "GENE_OR_GENE_PRODUCT", 69, 75], ["Pyk-2", "GENE_OR_GENE_PRODUCT", 79, 84], ["ERK", "GENE_OR_GENE_PRODUCT", 89, 92], ["HPSE", "SIMPLE_CHEMICAL", 221, 225], ["NK-cell", "CELL", 229, 236], ["invasionNatural killer (NK) cells", "CELL", 264, 297], ["innate lymphocytes", "CELL", 302, 320], ["cells", "CELL", 345, 350], ["tumor cells", "CELL", 355, 366], ["chemokine", "PROTEIN", 59, 68], ["SDF-1\u03b1", "PROTEIN", 69, 75], ["Pyk", "PROTEIN", 79, 82], ["ERK", "PROTEIN", 89, 92], ["kinases", "PROTEIN", 206, 213], ["invasionNatural killer (NK) cells", "CELL_TYPE", 264, 297], ["innate lymphocytes", "CELL_TYPE", 302, 320], ["infected cells", "CELL_TYPE", 336, 350], ["tumor cells", "CELL_TYPE", 355, 366], ["the chemokine SDF", "TEST", 55, 72], ["Pyk", "TEST", 79, 82], ["ERK phosphorylation", "TEST", 89, 108], ["HPSE", "TEST", 221, 225], ["innate lymphocytes", "PROBLEM", 302, 320], ["tumor cells", "PROBLEM", 355, 366], ["NK", "ANATOMY", 229, 231], ["cell activation", "OBSERVATION", 232, 247], ["innate lymphocytes", "OBSERVATION", 302, 320], ["tumor cells", "OBSERVATION", 355, 366]]], ["Heparanase has been implicated in natural killer cell activation, migration, and invasion.", [["natural killer cell", "ANATOMY", 34, 53], ["Heparanase", "CHEMICAL", 0, 10], ["Heparanase", "GENE_OR_GENE_PRODUCT", 0, 10], ["natural killer cell", "CELL", 34, 53], ["Heparanase", "PROTEIN", 0, 10], ["Heparanase", "TREATMENT", 0, 10], ["natural killer cell activation", "TREATMENT", 34, 64], ["invasion", "PROBLEM", 81, 89], ["natural killer cell activation", "OBSERVATION", 34, 64], ["migration", "OBSERVATION_MODIFIER", 66, 75], ["invasion", "OBSERVATION_MODIFIER", 81, 89]]], ["NK cells express natural cytotoxicity receptors (NCRs) which are known to induce cytokine production and thereby cytolytic activity in response to contact with specific ligands on the surfaces of infected cells [143] .", [["NK cells", "ANATOMY", 0, 8], ["cells", "ANATOMY", 205, 210], ["NK cells", "CELL", 0, 8], ["natural cytotoxicity receptors", "GENE_OR_GENE_PRODUCT", 17, 47], ["NCRs", "GENE_OR_GENE_PRODUCT", 49, 53], ["cells", "CELL", 205, 210], ["NK cells", "CELL_TYPE", 0, 8], ["natural cytotoxicity receptors", "PROTEIN", 17, 47], ["NCRs", "PROTEIN", 49, 53], ["cytokine", "PROTEIN", 81, 89], ["infected cells", "CELL_TYPE", 196, 210], ["NK cells", "PROBLEM", 0, 8], ["natural cytotoxicity receptors", "PROBLEM", 17, 47], ["cytokine production", "PROBLEM", 81, 100], ["infected cells", "PROBLEM", 196, 210], ["infected cells", "OBSERVATION", 196, 210]]], ["HS acts as a co-ligand for NCR binding.", [["NCR", "GENE_OR_GENE_PRODUCT", 27, 30], ["HS", "DNA", 0, 2], ["NCR", "DNA", 27, 30], ["NCR binding", "PROBLEM", 27, 38]]], ["In case of tumor cells, higher secretion of HPSE by tumor cells cleaves HS from NK cells and impedes NCR binding which impedes the activation of NK cells.", [["tumor cells", "ANATOMY", 11, 22], ["tumor cells", "ANATOMY", 52, 63], ["NK cells", "ANATOMY", 80, 88], ["NK cells", "ANATOMY", 145, 153], ["tumor", "DISEASE", 11, 16], ["tumor", "DISEASE", 52, 57], ["tumor cells", "CELL", 11, 22], ["HPSE", "GENE_OR_GENE_PRODUCT", 44, 48], ["tumor cells", "CELL", 52, 63], ["HS", "CELL", 72, 74], ["NK cells", "CELL", 80, 88], ["NCR", "GENE_OR_GENE_PRODUCT", 101, 104], ["NK cells", "CELL", 145, 153], ["tumor cells", "CELL_TYPE", 11, 22], ["HPSE", "PROTEIN", 44, 48], ["tumor cells", "CELL_TYPE", 52, 63], ["NK cells", "CELL_TYPE", 80, 88], ["NK cells", "CELL_TYPE", 145, 153], ["tumor cells", "PROBLEM", 11, 22], ["higher secretion of HPSE", "PROBLEM", 24, 48], ["tumor cells", "PROBLEM", 52, 63], ["NK cells", "PROBLEM", 80, 88], ["impedes NCR binding", "PROBLEM", 93, 112], ["NK cells", "PROBLEM", 145, 153], ["tumor cells", "OBSERVATION", 11, 22], ["NK cells", "OBSERVATION", 80, 88], ["NK cells", "OBSERVATION", 145, 153]]], ["On the other side, NK cells lacking HPSE expression also lack tumor-invasive properties.", [["NK cells", "ANATOMY", 19, 27], ["tumor", "ANATOMY", 62, 67], ["tumor", "DISEASE", 62, 67], ["NK cells", "CELL", 19, 27], ["HPSE", "GENE_OR_GENE_PRODUCT", 36, 40], ["tumor", "CANCER", 62, 67], ["NK cells", "CELL_TYPE", 19, 27], ["HPSE", "PROTEIN", 36, 40]]], ["Therefore, the level of HS-NCR interactions regulates NK-cell activation, suggesting that maintaining optimal levels of HPSE is important for NK cell activation [143, 144] .Cellular entryHS is well established as an attachment receptor for HSV-1 [145] .", [["NK-cell", "ANATOMY", 54, 61], ["NK cell", "ANATOMY", 142, 149], ["Cellular", "ANATOMY", 173, 181], ["HS", "GENE_OR_GENE_PRODUCT", 24, 26], ["NK-cell", "CELL", 54, 61], ["HPSE", "GENE_OR_GENE_PRODUCT", 120, 124], ["NK cell", "CELL", 142, 149], ["HSV-1", "ORGANISM", 240, 245], ["HS", "DNA", 24, 26], ["NCR", "PROTEIN", 27, 30], ["HPSE", "PROTEIN", 120, 124], ["entryHS", "PROTEIN", 182, 189], ["HSV-1", "SPECIES", 240, 245], ["HS", "TEST", 24, 26], ["NK cell activation", "TEST", 142, 160], ["Cellular entryHS", "TEST", 173, 189], ["HSV", "TEST", 240, 243]]], ["Its glycoproteins gB and/or gC must bind to HS before entry can progress [145] .", [["gB", "GENE_OR_GENE_PRODUCT", 18, 20], ["gC", "GENE_OR_GENE_PRODUCT", 28, 30], ["glycoproteins gB", "PROTEIN", 4, 20], ["gC", "PROTEIN", 28, 30]]], ["Treatment of single-cell neurons with heparanase significantly reduced subsequent HSV-1 entry compared to mock-treated controls [146] .", [["single-cell neurons", "ANATOMY", 13, 32], ["single-cell neurons", "CELL", 13, 32], ["heparanase", "GENE_OR_GENE_PRODUCT", 38, 48], ["HSV-1", "ORGANISM", 82, 87], ["single-cell neurons", "CELL_LINE", 13, 32], ["heparanase", "PROTEIN", 38, 48], ["HSV-1", "SPECIES", 82, 87], ["single-cell neurons", "PROBLEM", 13, 32], ["heparanase", "TREATMENT", 38, 48], ["HSV", "TEST", 82, 85], ["cell neurons", "OBSERVATION", 20, 32]]], ["This study supports the idea that HSV-1 must only up-regulate HPSE once entry has concluded.", [["HSV-1", "ORGANISM", 34, 39], ["HPSE", "GENE_OR_GENE_PRODUCT", 62, 66], ["HPSE", "PROTEIN", 62, 66], ["HSV-1", "SPECIES", 34, 39], ["This study", "TEST", 0, 10], ["HSV", "TEST", 34, 37]]], ["Accordingly, the \u03b334.5 gene of HSV-1 was found to activate HPSE transcription and is expressed during the later stages of infection [61] .", [["infection", "DISEASE", 122, 131], ["\u03b334.5", "GENE_OR_GENE_PRODUCT", 17, 22], ["HSV-1", "ORGANISM", 31, 36], ["HPSE", "GENE_OR_GENE_PRODUCT", 59, 63], ["\u03b334.5 gene", "DNA", 17, 27], ["HPSE", "DNA", 59, 63], ["HSV-1", "SPECIES", 31, 36], ["HSV", "TEST", 31, 34], ["infection", "PROBLEM", 122, 131], ["HPSE transcription", "OBSERVATION", 59, 77], ["infection", "OBSERVATION", 122, 131]]], ["Alongside HSV-1, other viruses which use HS as attachment receptors are HSV-2, HPV, KSHV, and DENV [147] .", [["HSV-1", "ORGANISM", 10, 15], ["HSV-2", "ORGANISM", 72, 77], ["HPV", "ORGANISM", 79, 82], ["KSHV", "ORGANISM", 84, 88], ["attachment receptors", "PROTEIN", 47, 67], ["HSV-1", "SPECIES", 10, 15], ["HSV-1", "SPECIES", 10, 15], ["HSV-2", "SPECIES", 72, 77], ["HPV", "SPECIES", 79, 82], ["KSHV", "SPECIES", 84, 88], ["DENV", "SPECIES", 94, 98], ["Alongside HSV", "TEST", 0, 13], ["other viruses", "PROBLEM", 17, 30], ["attachment receptors", "TEST", 47, 67], ["HSV", "TEST", 72, 75], ["HPV", "PROBLEM", 79, 82], ["DENV", "PROBLEM", 94, 98]]], ["Pre-treatment of cells with HPSE prior to infection would be expected to hinder entry for these viruses.", [["cells", "ANATOMY", 17, 22], ["HPSE", "CHEMICAL", 28, 32], ["infection", "DISEASE", 42, 51], ["cells", "CELL", 17, 22], ["HPSE", "SIMPLE_CHEMICAL", 28, 32], ["Pre-treatment of cells", "PROBLEM", 0, 22], ["HPSE", "PROBLEM", 28, 32], ["infection", "PROBLEM", 42, 51], ["these viruses", "PROBLEM", 90, 103], ["infection", "OBSERVATION", 42, 51]]], ["The respiratory syncytial Fig. 5 Proposed mechanism of the role in HPSE in stimulating the production of cytokines necessary for macrophage activation.", [["macrophage", "ANATOMY", 129, 139], ["HPSE", "CHEMICAL", 67, 71], ["HPSE", "SIMPLE_CHEMICAL", 67, 71], ["macrophage", "CELL", 129, 139], ["cytokines", "PROTEIN", 105, 114], ["The respiratory syncytial Fig", "TREATMENT", 0, 29], ["cytokines", "TREATMENT", 105, 114], ["macrophage activation", "PROBLEM", 129, 150], ["respiratory", "OBSERVATION", 4, 15], ["syncytial Fig", "OBSERVATION", 16, 29]]], ["By binding to TLR2 or TLR4, HPSE can stimulate the inhibition of p105, causing the release of Tpl2 and downstream ERK activation.", [["HPSE", "CHEMICAL", 28, 32], ["TLR2", "GENE_OR_GENE_PRODUCT", 14, 18], ["TLR4", "GENE_OR_GENE_PRODUCT", 22, 26], ["HPSE", "SIMPLE_CHEMICAL", 28, 32], ["Tpl2", "GENE_OR_GENE_PRODUCT", 94, 98], ["ERK", "GENE_OR_GENE_PRODUCT", 114, 117], ["TLR2", "PROTEIN", 14, 18], ["TLR4", "PROTEIN", 22, 26], ["HPSE", "PROTEIN", 28, 32], ["p105", "PROTEIN", 65, 69], ["Tpl2", "PROTEIN", 94, 98], ["ERK", "PROTEIN", 114, 117], ["Tpl2", "PROBLEM", 94, 98]]], ["ERK signaling results in IL-1\u03b2 production.", [["ERK", "GENE_OR_GENE_PRODUCT", 0, 3], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 25, 30], ["ERK", "PROTEIN", 0, 3], ["ERK signaling", "TEST", 0, 13], ["IL", "TEST", 25, 27]]], ["Activation of TLR2/4 can stimulate p38, JNK, and NF-\u03baB signaling via an Myd88-dependent formation of a protein complex.", [["TLR2", "GENE_OR_GENE_PRODUCT", 14, 18], ["4", "GENE_OR_GENE_PRODUCT", 19, 20], ["p38", "GENE_OR_GENE_PRODUCT", 35, 38], ["JNK", "GENE_OR_GENE_PRODUCT", 40, 43], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 49, 54], ["Myd88", "GENE_OR_GENE_PRODUCT", 72, 77], ["TLR2/4", "PROTEIN", 14, 20], ["p38", "PROTEIN", 35, 38], ["JNK", "PROTEIN", 40, 43], ["NF-\u03baB", "PROTEIN", 49, 54], ["Myd88", "PROTEIN", 72, 77], ["protein complex", "PROTEIN", 103, 118], ["Activation of TLR2/4", "TREATMENT", 0, 20], ["p38", "TEST", 35, 38], ["JNK", "TEST", 40, 43], ["NF", "TEST", 49, 51], ["an Myd88", "TEST", 69, 77], ["a protein complex", "PROBLEM", 101, 118]]], ["Downstream signaling results in the synthesis of MCP-1, IL-6, IL-1, TNF-\u03b1, and MIP-2.", [["MCP-1", "GENE_OR_GENE_PRODUCT", 49, 54], ["IL-6", "GENE_OR_GENE_PRODUCT", 56, 60], ["IL-1", "GENE_OR_GENE_PRODUCT", 62, 66], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 68, 73], ["MIP-2", "GENE_OR_GENE_PRODUCT", 79, 84], ["MCP", "PROTEIN", 49, 52], ["TNF", "PROTEIN", 68, 71], ["MIP-2", "PROTEIN", 79, 84], ["the synthesis", "TEST", 32, 45], ["MCP", "TEST", 49, 52], ["IL", "TEST", 56, 58], ["IL", "TEST", 62, 64], ["TNF", "TEST", 68, 71], ["MIP", "TEST", 79, 82]]], ["Alternatively, the binding of HPSE to TLR4 in a TRAM-and TRIF-dependent mechanism which results in activation of PI3K and subsequently Akt.", [["HPSE", "GENE_OR_GENE_PRODUCT", 30, 34], ["TLR4", "GENE_OR_GENE_PRODUCT", 38, 42], ["TRAM", "GENE_OR_GENE_PRODUCT", 48, 52], ["TRIF", "GENE_OR_GENE_PRODUCT", 57, 61], ["PI3K", "GENE_OR_GENE_PRODUCT", 113, 117], ["Akt.", "GENE_OR_GENE_PRODUCT", 135, 139], ["HPSE", "PROTEIN", 30, 34], ["TLR4", "PROTEIN", 38, 42], ["TRAM", "PROTEIN", 48, 52], ["TRIF", "PROTEIN", 57, 61], ["PI3K", "PROTEIN", 113, 117], ["a TRAM", "TREATMENT", 46, 52], ["activation of PI3K", "PROBLEM", 99, 117]]], ["Akt stimulates GSK-3, further bolstering JNK signaling, and the IKK complex, activating NF-\u03baB signaling virus (RSV) appears to require HS moieties on the surface of certain cells to initiate a productive infection [148] .", [["surface", "ANATOMY", 154, 161], ["cells", "ANATOMY", 173, 178], ["infection", "DISEASE", 204, 213], ["Akt", "GENE_OR_GENE_PRODUCT", 0, 3], ["GSK-3", "GENE_OR_GENE_PRODUCT", 15, 20], ["JNK", "GENE_OR_GENE_PRODUCT", 41, 44], ["IKK", "GENE_OR_GENE_PRODUCT", 64, 67], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 88, 93], ["RSV", "ORGANISM", 111, 114], ["HS moieties", "SIMPLE_CHEMICAL", 135, 146], ["surface", "CELLULAR_COMPONENT", 154, 161], ["cells", "CELL", 173, 178], ["Akt", "PROTEIN", 0, 3], ["GSK-3", "PROTEIN", 15, 20], ["JNK", "PROTEIN", 41, 44], ["IKK complex", "PROTEIN", 64, 75], ["NF-\u03baB", "PROTEIN", 88, 93], ["RSV", "SPECIES", 111, 114], ["Akt stimulates GSK", "TEST", 0, 18], ["further bolstering JNK signaling", "TEST", 22, 54], ["the IKK complex", "PROBLEM", 60, 75], ["activating NF", "PROBLEM", 77, 90], ["B signaling virus (RSV", "PROBLEM", 92, 114], ["HS moieties", "TREATMENT", 135, 146], ["certain cells", "PROBLEM", 165, 178], ["a productive infection", "PROBLEM", 191, 213], ["productive", "OBSERVATION_MODIFIER", 193, 203], ["infection", "OBSERVATION", 204, 213]]], ["Exogenous addition of bacterial heparinase reduces the susceptibility of HEK-293 and Hep-2 cells to RSV infection [148] .", [["HEK-293", "ANATOMY", 73, 80], ["Hep-2 cells", "ANATOMY", 85, 96], ["RSV infection", "DISEASE", 100, 113], ["heparinase", "GENE_OR_GENE_PRODUCT", 32, 42], ["HEK-293", "CELL", 73, 80], ["Hep-2 cells", "CELL", 85, 96], ["RSV", "ORGANISM", 100, 103], ["bacterial heparinase", "PROTEIN", 22, 42], ["HEK-293", "CELL_LINE", 73, 80], ["Hep-2 cells", "CELL_LINE", 85, 96], ["HEK-293", "SPECIES", 73, 80], ["RSV", "SPECIES", 100, 103], ["bacterial heparinase", "TREATMENT", 22, 42], ["the susceptibility", "TEST", 51, 69], ["HEK", "TEST", 73, 76], ["Hep", "TEST", 85, 88], ["RSV infection", "PROBLEM", 100, 113], ["bacterial heparinase", "OBSERVATION", 22, 42], ["RSV", "ANATOMY", 100, 103], ["infection", "OBSERVATION", 104, 113]]], ["However, heparinase could not confer protection from RSV to HeLa cells [148] .Cellular entryThe novel coronavirus SARS-CoV-2 is a member of the \u03b2-coronavirus subfamily alongside SARS-CoV and MERS-CoV [149] .", [["HeLa cells", "ANATOMY", 60, 70], ["Cellular", "ANATOMY", 78, 86], ["heparinase", "GENE_OR_GENE_PRODUCT", 9, 19], ["RSV", "ORGANISM", 53, 56], ["HeLa cells", "CELL", 60, 70], ["coronavirus SARS-CoV-2", "ORGANISM", 102, 124], ["\u03b2-coronavirus", "GENE_OR_GENE_PRODUCT", 144, 157], ["SARS-CoV", "ORGANISM", 178, 186], ["MERS-CoV", "ORGANISM", 191, 199], ["heparinase", "PROTEIN", 9, 19], ["HeLa cells", "CELL_LINE", 60, 70], ["\u03b2-coronavirus subfamily", "PROTEIN", 144, 167], ["coronavirus SARS-CoV", "SPECIES", 102, 122], ["RSV", "SPECIES", 53, 56], ["SARS-CoV", "SPECIES", 114, 122], ["SARS-CoV", "SPECIES", 178, 186], ["MERS-CoV", "SPECIES", 191, 199], ["heparinase", "TREATMENT", 9, 19], ["HeLa cells", "TEST", 60, 70], ["The novel coronavirus SARS", "TEST", 92, 118], ["entry", "OBSERVATION_MODIFIER", 87, 92]]], ["Like SARS-CoV, SARS-Cov-2 encodes a spike glycoprotein used to bind to the angiotensin-converting enzyme 2 (ACE2) receptor of target cells during entry [150] .", [["cells", "ANATOMY", 133, 138], ["SARS", "DISEASE", 5, 9], ["angiotensin", "CHEMICAL", 75, 86], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 5, 13], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 75, 106], ["ACE2", "GENE_OR_GENE_PRODUCT", 108, 112], ["cells", "CELL", 133, 138], ["SARS-Cov-2", "DNA", 15, 25], ["spike glycoprotein", "PROTEIN", 36, 54], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 75, 122], ["target cells", "CELL_TYPE", 126, 138], ["SARS-CoV", "SPECIES", 5, 13], ["SARS", "PROBLEM", 5, 9], ["CoV", "PROBLEM", 10, 13], ["SARS", "PROBLEM", 15, 19], ["a spike glycoprotein", "TREATMENT", 34, 54], ["the angiotensin", "TEST", 71, 86]]], ["One study reported that \u03b1-coronavirus human coronavirus NL63 (HCoV-NL63) requires cell surface HS for attachment and entry.", [["cell surface", "ANATOMY", 82, 94], ["\u03b1-coronavirus", "ORGANISM", 24, 37], ["human", "ORGANISM", 38, 43], ["coronavirus NL63", "ORGANISM", 44, 60], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 62, 71], ["cell", "CELL", 82, 86], ["\u03b1-coronavirus human coronavirus NL63", "PROTEIN", 24, 60], ["HCoV", "PROTEIN", 62, 66], ["NL63", "PROTEIN", 67, 71], ["human", "SPECIES", 38, 43], ["coronavirus", "SPECIES", 44, 55], ["human coronavirus", "SPECIES", 38, 55], ["One study", "TEST", 0, 9], ["\u03b1-coronavirus human coronavirus", "TEST", 24, 55], ["HCoV", "TEST", 62, 66], ["cell surface HS", "TREATMENT", 82, 97]]], ["Addition of soluble HS competitively binds to HCov-NL63 and reduces viral adhesion in a dose-dependent manner regardless of the presence of ACE2 [151] .", [["HCov-NL63", "GENE_OR_GENE_PRODUCT", 46, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 140, 144], ["HCov", "PROTEIN", 46, 50], ["NL63", "PROTEIN", 51, 55], ["ACE2", "PROTEIN", 140, 144], ["soluble HS competitively", "TREATMENT", 12, 36], ["HCov", "TEST", 46, 50], ["viral adhesion", "PROBLEM", 68, 82], ["viral adhesion", "OBSERVATION", 68, 82]]], ["Another study reported that HSPGs are essential for SARS-CoV entry [152] .", [["HSPGs", "GENE_OR_GENE_PRODUCT", 28, 33], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 52, 60], ["HSPGs", "PROTEIN", 28, 33], ["SARS-CoV", "SPECIES", 52, 60], ["Another study", "TEST", 0, 13], ["HSPGs", "TEST", 28, 33], ["SARS", "PROBLEM", 52, 56]]], ["Prophylactic treatment of bacterial heparinase I or heparin to cells reduced SARS-CoV infectivity [152] .", [["cells", "ANATOMY", 63, 68], ["heparin", "CHEMICAL", 52, 59], ["heparinase I", "GENE_OR_GENE_PRODUCT", 36, 48], ["heparin", "SIMPLE_CHEMICAL", 52, 59], ["cells", "CELL", 63, 68], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 77, 85], ["bacterial heparinase I", "PROTEIN", 26, 48], ["SARS-CoV", "SPECIES", 77, 85], ["Prophylactic treatment", "TREATMENT", 0, 22], ["bacterial heparinase I", "TREATMENT", 26, 48], ["heparin", "TREATMENT", 52, 59], ["SARS", "PROBLEM", 77, 81], ["CoV infectivity", "PROBLEM", 82, 97], ["bacterial heparinase", "OBSERVATION", 26, 46]]], ["Thus, either loss of HS or competitive inhibition confers some protection to cells from SARS-CoV.", [["cells", "ANATOMY", 77, 82], ["SARS", "DISEASE", 88, 92], ["HS", "GENE_OR_GENE_PRODUCT", 21, 23], ["cells", "CELL", 77, 82], ["SARS-CoV", "ORGANISM", 88, 96], ["SARS-CoV", "SPECIES", 88, 96], ["loss of HS", "PROBLEM", 13, 23], ["competitive inhibition", "TREATMENT", 27, 49], ["CoV", "PROBLEM", 93, 96]]], ["Given the structural similarities between SARS-CoV and the novel SARS-CoV-2, it would be interesting to study the effects of HS removal on SARS-CoV-2 infections.", [["SARS", "DISEASE", 42, 46], ["SARS-CoV-2 infections", "DISEASE", 139, 160], ["SARS-CoV", "ORGANISM", 42, 50], ["SARS-CoV-2", "ORGANISM", 65, 75], ["SARS-CoV-2", "ORGANISM", 139, 149], ["SARS-CoV", "SPECIES", 42, 50], ["SARS-CoV", "SPECIES", 65, 73], ["SARS-CoV-2", "SPECIES", 139, 149], ["SARS", "TEST", 42, 46], ["HS removal", "TREATMENT", 125, 135], ["SARS", "PROBLEM", 139, 143], ["CoV-2 infections", "PROBLEM", 144, 160], ["infections", "OBSERVATION", 150, 160]]], ["As there are multiple ways to reduce viral contact with cell surface HS (HPSE, heparinase, heparin, soluble HS, and MMPs), investigating that this connection may shed light on SARS-CoV-2 entry and possible therapeutics.Enhancing disease severityDuring HSV-1 infections, transfection with a constitutively active HPSE protein (GS3-HPSE) worsened the symptoms of herpetic eye disease in vivo [61] .", [["cell surface", "ANATOMY", 56, 68], ["eye", "ANATOMY", 370, 373], ["heparin", "CHEMICAL", 91, 98], ["HSV-1 infections", "DISEASE", 252, 268], ["herpetic eye disease", "DISEASE", 361, 381], ["cell", "CELL", 56, 60], ["heparinase", "GENE_OR_GENE_PRODUCT", 79, 89], ["heparin", "SIMPLE_CHEMICAL", 91, 98], ["soluble HS", "GENE_OR_GENE_PRODUCT", 100, 110], ["MMPs", "GENE_OR_GENE_PRODUCT", 116, 120], ["CoV-2", "GENE_OR_GENE_PRODUCT", 181, 186], ["HSV-1", "ORGANISM", 252, 257], ["HPSE", "GENE_OR_GENE_PRODUCT", 312, 316], ["GS3-HPSE", "GENE_OR_GENE_PRODUCT", 326, 334], ["eye", "ORGAN", 370, 373], ["heparinase", "PROTEIN", 79, 89], ["MMPs", "PROTEIN", 116, 120], ["HPSE protein", "PROTEIN", 312, 324], ["GS3", "PROTEIN", 326, 329], ["HPSE", "PROTEIN", 330, 334], ["HSV-1", "SPECIES", 252, 257], ["HSV-1", "SPECIES", 252, 257], ["cell surface HS", "TREATMENT", 56, 71], ["heparinase", "TREATMENT", 79, 89], ["heparin", "TREATMENT", 91, 98], ["soluble HS", "TREATMENT", 100, 110], ["MMPs", "TREATMENT", 116, 120], ["CoV", "TEST", 181, 184], ["therapeutics", "TREATMENT", 206, 218], ["Enhancing disease severityDuring HSV", "PROBLEM", 219, 255], ["1 infections", "PROBLEM", 256, 268], ["a constitutively active HPSE protein", "PROBLEM", 288, 324], ["GS3", "TEST", 326, 329], ["the symptoms", "PROBLEM", 345, 357], ["herpetic eye disease", "PROBLEM", 361, 381], ["disease", "OBSERVATION", 229, 236], ["infections", "OBSERVATION", 258, 268], ["herpetic eye disease", "OBSERVATION", 361, 381]]], ["GS3-HPSE-transfected mice infected with HSV-1 exhibited increases in ocular discharge, ulcer formation, periorbital edema, and corneal vascularization [61] .", [["ocular", "ANATOMY", 69, 75], ["ulcer", "ANATOMY", 87, 92], ["periorbital edema", "ANATOMY", 104, 121], ["corneal", "ANATOMY", 127, 134], ["GS3", "CHEMICAL", 0, 3], ["ulcer", "DISEASE", 87, 92], ["periorbital edema", "DISEASE", 104, 121], ["GS3", "GENE_OR_GENE_PRODUCT", 0, 3], ["HPSE", "GENE_OR_GENE_PRODUCT", 4, 8], ["mice", "ORGANISM", 21, 25], ["HSV-1", "ORGANISM", 40, 45], ["ocular", "ORGAN", 69, 75], ["ulcer", "PATHOLOGICAL_FORMATION", 87, 92], ["periorbital edema", "PATHOLOGICAL_FORMATION", 104, 121], ["corneal", "TISSUE", 127, 134], ["GS3", "PROTEIN", 0, 3], ["HPSE", "PROTEIN", 4, 8], ["mice", "SPECIES", 21, 25], ["HSV-1", "SPECIES", 40, 45], ["mice", "SPECIES", 21, 25], ["HSV-1", "SPECIES", 40, 45], ["GS3", "TEST", 0, 3], ["HSV", "TEST", 40, 43], ["ocular discharge", "PROBLEM", 69, 85], ["ulcer formation", "PROBLEM", 87, 102], ["periorbital edema", "PROBLEM", 104, 121], ["corneal vascularization", "PROBLEM", 127, 150], ["increases", "OBSERVATION_MODIFIER", 56, 65], ["ocular", "ANATOMY", 69, 75], ["discharge", "OBSERVATION", 76, 85], ["ulcer", "OBSERVATION", 87, 92], ["periorbital", "ANATOMY", 104, 115], ["edema", "OBSERVATION", 116, 121], ["corneal vascularization", "ANATOMY", 127, 150]]], ["GS3-HPSE transfection resulted in a delayed wound-healing response in vivo and in vitro [61] .", [["wound", "ANATOMY", 44, 49], ["GS3-HPSE", "CHEMICAL", 0, 8], ["GS3", "GENE_OR_GENE_PRODUCT", 0, 3], ["wound", "PATHOLOGICAL_FORMATION", 44, 49], ["GS3", "PROTEIN", 0, 3], ["HPSE", "PROTEIN", 4, 8], ["HPSE transfection", "PROBLEM", 4, 21], ["a delayed wound", "PROBLEM", 34, 49], ["wound", "ANATOMY", 44, 49], ["healing response", "OBSERVATION_MODIFIER", 50, 66]]], ["Furthermore, overexpression of WT-HPSE inhibited the induction of the type I interferon response which stimulates antiviral signaling pathways [61] .Enhancing disease severityThe human papillomavirus (HPV) E6 gene induces upregulation of HPSE during infection in squamous cell carcinoma cells [153] .", [["squamous cell carcinoma cells", "ANATOMY", 263, 292], ["HPSE", "CHEMICAL", 34, 38], ["infection", "DISEASE", 250, 259], ["squamous cell carcinoma", "DISEASE", 263, 286], ["WT-HPSE", "ORGANISM", 31, 38], ["type I interferon", "GENE_OR_GENE_PRODUCT", 70, 87], ["human papillomavirus (HPV) E6", "ORGANISM", 179, 208], ["HPSE", "GENE_OR_GENE_PRODUCT", 238, 242], ["squamous cell carcinoma cells", "CELL", 263, 292], ["HPSE", "PROTEIN", 34, 38], ["type I interferon", "PROTEIN", 70, 87], ["human papillomavirus (HPV) E6 gene", "DNA", 179, 213], ["HPSE", "PROTEIN", 238, 242], ["squamous cell carcinoma cells", "CELL_TYPE", 263, 292], ["human", "SPECIES", 179, 184], ["human papillomavirus", "SPECIES", 179, 199], ["HPV", "SPECIES", 201, 204], ["WT", "TEST", 31, 33], ["the type I interferon response", "TREATMENT", 66, 96], ["Enhancing disease severity", "PROBLEM", 149, 175], ["The human papillomavirus (HPV)", "TREATMENT", 175, 205], ["HPSE during infection", "PROBLEM", 238, 259], ["squamous cell carcinoma cells", "PROBLEM", 263, 292], ["disease", "OBSERVATION", 159, 166], ["squamous cell carcinoma", "OBSERVATION", 263, 286]]], ["It is thought that the E6 protein inhibits p53 which normally limits HPSE transcription [153] .", [["E6", "GENE_OR_GENE_PRODUCT", 23, 25], ["p53", "GENE_OR_GENE_PRODUCT", 43, 46], ["HPSE", "GENE_OR_GENE_PRODUCT", 69, 73], ["E6 protein", "PROTEIN", 23, 33], ["p53", "PROTEIN", 43, 46], ["HPSE", "PROTEIN", 69, 73], ["the E6 protein inhibits p53", "TEST", 19, 46]]], ["Subsequent cleavage of HS by HPSE results in a loss of ECM integrity and facilitates tumor invasion and metastasis.", [["ECM", "ANATOMY", 55, 58], ["tumor", "ANATOMY", 85, 90], ["HPSE", "CHEMICAL", 29, 33], ["tumor", "DISEASE", 85, 90], ["ECM", "CELLULAR_COMPONENT", 55, 58], ["tumor", "CANCER", 85, 90], ["HS", "DNA", 23, 25], ["HPSE", "PROTEIN", 29, 33], ["a loss of ECM integrity", "PROBLEM", 45, 68], ["tumor invasion", "PROBLEM", 85, 99], ["metastasis", "PROBLEM", 104, 114], ["tumor invasion", "OBSERVATION", 85, 99], ["metastasis", "OBSERVATION", 104, 114]]], ["Furthermore, the release of growth factors from the HS fragments such as VEGF and HGF enhance tumor aggressiveness [153] .", [["HS fragments", "ANATOMY", 52, 64], ["tumor", "ANATOMY", 94, 99], ["tumor", "DISEASE", 94, 99], ["aggressiveness", "DISEASE", 100, 114], ["VEGF", "GENE_OR_GENE_PRODUCT", 73, 77], ["HGF", "GENE_OR_GENE_PRODUCT", 82, 85], ["tumor", "CANCER", 94, 99], ["growth factors", "PROTEIN", 28, 42], ["HS fragments", "DNA", 52, 64], ["VEGF", "PROTEIN", 73, 77], ["HGF", "PROTEIN", 82, 85], ["growth factors", "PROBLEM", 28, 42], ["the HS fragments", "PROBLEM", 48, 64], ["VEGF", "PROBLEM", 73, 77], ["HGF enhance tumor aggressiveness", "PROBLEM", 82, 114]]], ["A pyranoside analog given to cervical cancer cells increased p53 activity, reducing HPSE transcription, and cell proliferation [154] .Enhancing disease severityWhile still under investigation, a pair of studies has outlined a connection between HPSE and KSHV.", [["cervical cancer cells", "ANATOMY", 29, 50], ["cell", "ANATOMY", 108, 112], ["pyranoside", "CHEMICAL", 2, 12], ["cervical cancer", "DISEASE", 29, 44], ["pyranoside", "CHEMICAL", 2, 12], ["pyranoside", "SIMPLE_CHEMICAL", 2, 12], ["cervical cancer cells", "CELL", 29, 50], ["p53", "GENE_OR_GENE_PRODUCT", 61, 64], ["HPSE", "GENE_OR_GENE_PRODUCT", 84, 88], ["cell", "CELL", 108, 112], ["KSHV", "ORGANISM", 254, 258], ["cervical cancer cells", "CELL_TYPE", 29, 50], ["p53", "PROTEIN", 61, 64], ["HPSE", "PROTEIN", 84, 88], ["KSHV", "SPECIES", 254, 258], ["A pyranoside analog", "TREATMENT", 0, 19], ["cervical cancer cells", "PROBLEM", 29, 50], ["reducing HPSE transcription", "TREATMENT", 75, 102], ["Enhancing disease severity", "PROBLEM", 134, 160], ["a pair of studies", "TEST", 193, 210], ["cervical", "ANATOMY", 29, 37], ["cancer", "OBSERVATION", 38, 44], ["p53 activity", "OBSERVATION", 61, 73], ["disease", "OBSERVATION", 144, 151]]], ["One study found that the cellular miRNA 1258 (hsa-miR-1258) inhibits reactivation of KSHV from latency [155] .", [["cellular", "ANATOMY", 25, 33], ["hsa-miR-1258", "CHEMICAL", 46, 58], ["cellular", "CELL", 25, 33], ["hsa-miR-1258", "GENE_OR_GENE_PRODUCT", 46, 58], ["KSHV", "ORGANISM", 85, 89], ["cellular miRNA 1258", "DNA", 25, 44], ["KSHV", "SPECIES", 85, 89], ["One study", "TEST", 0, 9], ["the cellular miRNA", "TEST", 21, 39], ["hsa", "TEST", 46, 49]]], ["Hsa-miR-1258 also downregulates HPSE protein levels and restricts BMBC invasion [156] .", [["BMBC", "ANATOMY", 66, 70], ["Hsa-miR-1258", "CHEMICAL", 0, 12], ["Hsa-miR-1258", "GENE_OR_GENE_PRODUCT", 0, 12], ["HPSE", "GENE_OR_GENE_PRODUCT", 32, 36], ["Hsa", "PROTEIN", 0, 3], ["HPSE", "PROTEIN", 32, 36], ["Hsa-miR", "TEST", 0, 7], ["HPSE protein levels", "TEST", 32, 51], ["BMBC invasion", "PROBLEM", 66, 79]]], ["Finally, expression of hsa-miR-1258 declines in KSHVinfected cells, suggesting that the virus seeks to remove this impediment to reactivation during infection [155] .", [["KSHVinfected cells", "ANATOMY", 48, 66], ["hsa-miR-1258", "CHEMICAL", 23, 35], ["infection", "DISEASE", 149, 158], ["hsa-miR-1258", "GENE_OR_GENE_PRODUCT", 23, 35], ["KSHVinfected cells", "CELL", 48, 66], ["hsa-miR-1258", "PROTEIN", 23, 35], ["KSHVinfected cells", "CELL_LINE", 48, 66], ["hsa-miR", "TEST", 23, 30], ["KSHVinfected cells", "PROBLEM", 48, 66], ["the virus", "PROBLEM", 84, 93], ["reactivation during infection", "PROBLEM", 129, 158]]], ["It is possible that KSHV benefits from the increase in HPSE expression from inhibiting hsa-miR-1258, possibly through the induction of cell-survival signaling.Enhancing disease severityRSV up-regulates HPSE during infection in vivo [157] .", [["cell", "ANATOMY", 135, 139], ["hsa-miR-1258", "CHEMICAL", 87, 99], ["infection", "DISEASE", 214, 223], ["KSHV", "ORGANISM", 20, 24], ["HPSE", "GENE_OR_GENE_PRODUCT", 55, 59], ["hsa-miR-1258", "GENE_OR_GENE_PRODUCT", 87, 99], ["cell", "CELL", 135, 139], ["severityRSV", "GENE_OR_GENE_PRODUCT", 177, 188], ["HPSE", "GENE_OR_GENE_PRODUCT", 202, 206], ["HPSE", "PROTEIN", 55, 59], ["hsa", "PROTEIN", 87, 90], ["HPSE", "PROTEIN", 202, 206], ["KSHV", "SPECIES", 20, 24], ["the increase in HPSE expression", "PROBLEM", 39, 70], ["hsa-miR", "TEST", 87, 94], ["Enhancing disease severityRSV", "PROBLEM", 159, 188], ["HPSE during infection", "PROBLEM", 202, 223], ["possible", "UNCERTAINTY", 6, 14], ["KSHV", "OBSERVATION", 20, 24], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["HPSE expression", "OBSERVATION", 55, 70], ["disease", "OBSERVATION", 169, 176], ["infection", "OBSERVATION", 214, 223]]], ["In RSV infections, HPSE expression correlated with proteinuria severity [157] .Cellular egressMultiple viruses utilize HPSE to facilitate egress from the host cell.", [["cell", "ANATOMY", 159, 163], ["RSV infections", "DISEASE", 3, 17], ["proteinuria", "DISEASE", 51, 62], ["RSV", "ORGANISM", 3, 6], ["HPSE", "GENE_OR_GENE_PRODUCT", 19, 23], ["HPSE", "GENE_OR_GENE_PRODUCT", 119, 123], ["host cell", "CELL", 154, 163], ["HPSE", "PROTEIN", 19, 23], ["host cell", "CELL_TYPE", 154, 163], ["RSV", "SPECIES", 3, 6], ["RSV infections", "PROBLEM", 3, 17], ["HPSE expression", "TEST", 19, 34], ["proteinuria severity", "PROBLEM", 51, 71], ["Cellular egressMultiple viruses", "PROBLEM", 79, 110], ["RSV", "ANATOMY", 3, 6], ["infections", "OBSERVATION", 7, 17], ["viruses", "OBSERVATION", 103, 110], ["host cell", "OBSERVATION", 154, 163]]], ["HSV-1 up-regulates HPSE in the later stages of infection which goes on to cleave HS from the cell surface.", [["cell surface", "ANATOMY", 93, 105], ["infection", "DISEASE", 47, 56], ["HSV-1", "ORGANISM", 0, 5], ["HPSE", "GENE_OR_GENE_PRODUCT", 19, 23], ["HS", "GENE_OR_GENE_PRODUCT", 81, 83], ["cell surface", "CELLULAR_COMPONENT", 93, 105], ["HPSE", "PROTEIN", 19, 23], ["HSV-1", "SPECIES", 0, 5], ["HSV-1", "SPECIES", 0, 5], ["HSV", "TEST", 0, 3], ["HPSE", "PROBLEM", 19, 23], ["infection", "PROBLEM", 47, 56], ["infection", "OBSERVATION", 47, 56], ["cell surface", "OBSERVATION", 93, 105]]], ["While HS is an attachment receptor for the virus, its presence may restrict the release of mature virions.", [["virions", "ANATOMY", 98, 105], ["HS", "DNA", 6, 8], ["an attachment receptor", "TREATMENT", 12, 34], ["the virus", "PROBLEM", 39, 48], ["mature virions", "PROBLEM", 91, 105], ["mature virions", "OBSERVATION", 91, 105]]], ["Cleavage of HS allows for viral egress to occur more efficiently.", [["HS", "DNA", 12, 14], ["viral egress", "PROBLEM", 26, 38]]], ["Similar loss of HS via HPSE upregulation was found during HSV-2 infections as well [158] .", [["HSV-2 infections", "DISEASE", 58, 74], ["HS", "GENE_OR_GENE_PRODUCT", 16, 18], ["HPSE", "GENE_OR_GENE_PRODUCT", 23, 27], ["HSV-2", "ORGANISM", 58, 63], ["HS", "DNA", 16, 18], ["HPSE", "DNA", 23, 27], ["HSV-2", "SPECIES", 58, 63], ["Similar loss of HS via HPSE upregulation", "PROBLEM", 0, 40], ["HSV-2 infections", "PROBLEM", 58, 74], ["loss", "OBSERVATION_MODIFIER", 8, 12]]], ["Additionally, HPSE has recently been shown to mediate syndecan-1 shedding from the cell surface during HSV-1 infection [85] .", [["cell surface", "ANATOMY", 83, 95], ["HPSE", "CHEMICAL", 14, 18], ["infection", "DISEASE", 109, 118], ["HPSE", "GENE_OR_GENE_PRODUCT", 14, 18], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 54, 64], ["cell surface", "CELLULAR_COMPONENT", 83, 95], ["HSV-1", "ORGANISM", 103, 108], ["HPSE", "PROTEIN", 14, 18], ["syndecan", "PROTEIN", 54, 62], ["HSV-1", "SPECIES", 103, 108], ["HSV-1", "SPECIES", 103, 108], ["HSV", "PROBLEM", 103, 106], ["1 infection", "PROBLEM", 107, 118]]], ["HPSE up-regulates MMP-3 and MMP-7 which translocate to the cell surface and cleave syndecan-1.", [["cell surface", "ANATOMY", 59, 71], ["HPSE", "SIMPLE_CHEMICAL", 0, 4], ["MMP-3", "GENE_OR_GENE_PRODUCT", 18, 23], ["MMP-7", "GENE_OR_GENE_PRODUCT", 28, 33], ["cell surface", "CELLULAR_COMPONENT", 59, 71], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 83, 93], ["MMP-3", "PROTEIN", 18, 23], ["MMP-7", "PROTEIN", 28, 33], ["syndecan-1", "PROTEIN", 83, 93], ["HPSE", "TEST", 0, 4], ["MMP", "TEST", 18, 21], ["MMP", "TEST", 28, 31]]], ["Via a similar chain of reasoning, syndecan-1 shedding amplifies the loss of HS from the cell surface and promotes egress.", [["cell surface", "ANATOMY", 88, 100], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 34, 44], ["HS", "GENE_OR_GENE_PRODUCT", 76, 78], ["cell surface", "CELLULAR_COMPONENT", 88, 100], ["syndecan", "PROTEIN", 34, 42], ["HS", "DNA", 76, 78], ["the loss of HS", "PROBLEM", 64, 78], ["the cell surface", "TREATMENT", 84, 100]]], ["Overexpression of HPSE results in increased viral release both in vitro and in vivo [159] .", [["HPSE", "CHEMICAL", 18, 22], ["HPSE", "GENE_OR_GENE_PRODUCT", 18, 22], ["HPSE", "PROTEIN", 18, 22], ["increased viral release", "TREATMENT", 34, 57], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["viral", "OBSERVATION", 44, 49]]], ["Conversely, knockdown of HPSE reduces HSV-1 and HSV-2 infectivity [158, 159] .", [["HPSE", "CHEMICAL", 25, 29], ["HPSE", "GENE_OR_GENE_PRODUCT", 25, 29], ["HSV-1", "ORGANISM", 38, 43], ["HSV-2", "ORGANISM", 48, 53], ["HPSE", "PROTEIN", 25, 29], ["HSV-2", "SPECIES", 48, 53], ["HSV-1", "SPECIES", 38, 43], ["HSV-2", "SPECIES", 48, 53], ["HPSE", "TEST", 25, 29], ["HSV", "TEST", 38, 41], ["HSV", "TEST", 48, 51]]], ["Through a similar pathway involving the upregulation of HPSE and loss of HS, porcine reproductive and respiratory syndrome virus (PRRSV) utilizes HPSE to facilitate release from cells [160] .", [["cells", "ANATOMY", 178, 183], ["porcine reproductive and respiratory syndrome", "DISEASE", 77, 122], ["HPSE", "CHEMICAL", 146, 150], ["HPSE", "GENE_OR_GENE_PRODUCT", 56, 60], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 77, 128], ["PRRSV", "ORGANISM", 130, 135], ["HPSE", "GENE_OR_GENE_PRODUCT", 146, 150], ["cells", "CELL", 178, 183], ["HPSE", "PROTEIN", 56, 60], ["HS", "DNA", 73, 75], ["HPSE", "PROTEIN", 146, 150], ["PRRSV", "SPECIES", 130, 135], ["PRRSV", "SPECIES", 130, 135], ["HPSE", "PROBLEM", 56, 60], ["loss of HS", "PROBLEM", 65, 75], ["porcine reproductive", "PROBLEM", 77, 97], ["respiratory syndrome virus", "PROBLEM", 102, 128], ["HPSE", "OBSERVATION", 56, 60], ["loss", "OBSERVATION_MODIFIER", 65, 69], ["respiratory syndrome", "OBSERVATION", 102, 122]]], ["PRRSV activates NF-\u0138B signaling which up-regulates HPSE transcription [160] .Cellular egressHPV virions escape from the host cell by binding to HS moieties and growth factors on HSPGs.", [["Cellular", "ANATOMY", 77, 85], ["cell", "ANATOMY", 125, 129], ["PRRSV", "ORGANISM", 0, 5], ["NF-\u0138B", "GENE_OR_GENE_PRODUCT", 16, 21], ["HPSE", "GENE_OR_GENE_PRODUCT", 51, 55], ["host cell", "CELL", 120, 129], ["HSPGs", "GENE_OR_GENE_PRODUCT", 178, 183], ["NF-\u0138B", "PROTEIN", 16, 21], ["HPSE", "DNA", 51, 55], ["HS moieties", "PROTEIN", 144, 155], ["growth factors", "PROTEIN", 160, 174], ["HSPGs", "PROTEIN", 178, 183], ["PRRSV", "SPECIES", 0, 5], ["B signaling", "PROBLEM", 20, 31], ["Cellular egressHPV virions escape", "PROBLEM", 77, 110], ["egressHPV virions escape", "OBSERVATION", 86, 110], ["host cell", "OBSERVATION", 120, 129]]], ["As the HSPGs are naturally shed from the cell, the virus can spread to neighboring cells.", [["cell", "ANATOMY", 41, 45], ["cells", "ANATOMY", 83, 88], ["HSPGs", "GENE_OR_GENE_PRODUCT", 7, 12], ["cell", "CELL", 41, 45], ["cells", "CELL", 83, 88], ["HSPGs", "PROTEIN", 7, 12], ["neighboring cells", "CELL_TYPE", 71, 88], ["the virus", "PROBLEM", 47, 56], ["neighboring cells", "OBSERVATION", 71, 88]]], ["Exogenous HPSE promotes HPV release and infectivity via cleavage of HS, and MMPs likewise remove syndecan-1 proteins from the cell surface [161] .", [["cell surface", "ANATOMY", 126, 138], ["HPSE", "CHEMICAL", 10, 14], ["HPSE", "SIMPLE_CHEMICAL", 10, 14], ["HPV", "ORGANISM", 24, 27], ["HS", "GENE_OR_GENE_PRODUCT", 68, 70], ["MMPs", "GENE_OR_GENE_PRODUCT", 76, 80], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 97, 107], ["cell surface", "CELLULAR_COMPONENT", 126, 138], ["MMPs", "PROTEIN", 76, 80], ["syndecan-1 proteins", "PROTEIN", 97, 116], ["HPV", "SPECIES", 24, 27], ["Exogenous HPSE promotes HPV release", "TREATMENT", 0, 35], ["syndecan", "TEST", 97, 105]]], ["Pharmacological inhibition of HPSE inhibits viral release to the ECM as well [161] .ConclusionHPSE plays important enzymatic and non-enzymatic roles in the regulation of intracellular signaling pathways and viral infections.", [["ECM", "ANATOMY", 65, 68], ["intracellular", "ANATOMY", 170, 183], ["HPSE", "CHEMICAL", 30, 34], ["ConclusionHPSE", "CHEMICAL", 84, 98], ["viral infections", "DISEASE", 207, 223], ["HPSE", "SIMPLE_CHEMICAL", 30, 34], ["ECM", "CELLULAR_COMPONENT", 65, 68], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 170, 183], ["HPSE", "PROTEIN", 30, 34], ["Pharmacological inhibition of HPSE", "PROBLEM", 0, 34], ["intracellular signaling pathways", "PROBLEM", 170, 202], ["viral infections", "PROBLEM", 207, 223], ["non-enzymatic roles", "OBSERVATION", 129, 148], ["intracellular signaling", "OBSERVATION", 170, 193], ["viral infections", "OBSERVATION", 207, 223]]], ["The enzymatic activity of HPSE is utilized in the turnover of HSPGs on the cell surface.", [["cell surface", "ANATOMY", 75, 87], ["HPSE", "CHEMICAL", 26, 30], ["HPSE", "SIMPLE_CHEMICAL", 26, 30], ["HSPGs", "GENE_OR_GENE_PRODUCT", 62, 67], ["cell surface", "CELLULAR_COMPONENT", 75, 87], ["HPSE", "PROTEIN", 26, 30], ["HSPGs", "PROTEIN", 62, 67], ["enzymatic", "OBSERVATION_MODIFIER", 4, 13], ["activity", "OBSERVATION_MODIFIER", 14, 22], ["HPSE", "OBSERVATION", 26, 30], ["cell surface", "OBSERVATION", 75, 87]]], ["Cleavage of HS helps to remodel the ECM and release signaling molecules that function in autophagy, exosome synthesis, and cell motility [8] .", [["ECM", "ANATOMY", 36, 39], ["exosome", "ANATOMY", 100, 107], ["cell", "ANATOMY", 123, 127], ["ECM", "CELLULAR_COMPONENT", 36, 39], ["exosome", "CELLULAR_COMPONENT", 100, 107], ["cell", "CELL", 123, 127], ["signaling molecules", "PROTEIN", 52, 71], ["exosome synthesis", "TREATMENT", 100, 117]]], ["The non-enzymatic activity of HPSE also stimulates numerous cell-survival pathways as discussed in this review.", [["cell", "ANATOMY", 60, 64], ["HPSE", "CHEMICAL", 30, 34], ["HPSE", "CHEMICAL", 30, 34], ["HPSE", "SIMPLE_CHEMICAL", 30, 34], ["cell", "CELL", 60, 64], ["non-enzymatic activity", "OBSERVATION", 4, 26], ["numerous", "OBSERVATION_MODIFIER", 51, 59], ["cell", "OBSERVATION", 60, 64]]], ["Overexpression of HPSE transforms cell motility to invasiveness or platelet adhesion to thrombogenesis [162, 163] .", [["cell", "ANATOMY", 34, 38], ["platelet", "ANATOMY", 67, 75], ["thrombogenesis", "DISEASE", 88, 102], ["HPSE", "GENE_OR_GENE_PRODUCT", 18, 22], ["cell", "CELL", 34, 38], ["platelet", "CELL", 67, 75], ["HPSE", "PROTEIN", 18, 22], ["HPSE transforms cell motility", "PROBLEM", 18, 47], ["platelet adhesion", "PROBLEM", 67, 84], ["thrombogenesis", "TEST", 88, 102], ["HPSE transforms cell motility", "OBSERVATION", 18, 47]]], ["Depending on the context and timing, HPSE can exacerbate or protect against viral infections.ConclusionViruses often influence major cell-survival signaling pathways at various points, not just the initiation.", [["cell", "ANATOMY", 133, 137], ["HPSE", "CHEMICAL", 37, 41], ["viral infections", "DISEASE", 76, 92], ["HPSE", "SIMPLE_CHEMICAL", 37, 41], ["cell", "CELL", 133, 137], ["viral infections", "PROBLEM", 76, 92]]], ["However, viral activation of HPSE may sustain the activation of these pathways through the mechanisms proposed in this review.", [["HPSE", "CHEMICAL", 29, 33], ["HPSE", "GENE_OR_GENE_PRODUCT", 29, 33], ["HPSE", "PROTEIN", 29, 33], ["viral activation of HPSE", "PROBLEM", 9, 33], ["viral activation", "OBSERVATION", 9, 25]]], ["As approximately 20% of cancers are associated with viruses [164] , sustained pro-survival signaling would contribute to tumor proliferation and metastasis.", [["cancers", "ANATOMY", 24, 31], ["tumor", "ANATOMY", 121, 126], ["cancers", "DISEASE", 24, 31], ["tumor", "DISEASE", 121, 126], ["cancers", "CANCER", 24, 31], ["tumor", "CANCER", 121, 126], ["cancers", "PROBLEM", 24, 31], ["viruses", "PROBLEM", 52, 59], ["sustained pro-survival signaling", "PROBLEM", 68, 100], ["tumor proliferation", "PROBLEM", 121, 140], ["metastasis", "PROBLEM", 145, 155], ["cancers", "OBSERVATION", 24, 31], ["would contribute to", "UNCERTAINTY", 101, 120], ["tumor", "OBSERVATION", 121, 126], ["metastasis", "OBSERVATION", 145, 155]]], ["Both tumors and host cells can release HPSE in the tumor microenvironment, allowing HPSE to stimulate Akt, VEGFR, EGFR, ERK, and other pathways that aid in tumor progression.", [["tumors", "ANATOMY", 5, 11], ["cells", "ANATOMY", 21, 26], ["tumor", "ANATOMY", 51, 56], ["tumor", "ANATOMY", 156, 161], ["tumors", "DISEASE", 5, 11], ["tumor", "DISEASE", 51, 56], ["tumor", "DISEASE", 156, 161], ["tumors", "CANCER", 5, 11], ["host cells", "CELL", 16, 26], ["HPSE", "SIMPLE_CHEMICAL", 39, 43], ["tumor", "CANCER", 51, 56], ["HPSE", "SIMPLE_CHEMICAL", 84, 88], ["Akt", "GENE_OR_GENE_PRODUCT", 102, 105], ["VEGFR", "GENE_OR_GENE_PRODUCT", 107, 112], ["EGFR", "GENE_OR_GENE_PRODUCT", 114, 118], ["ERK", "GENE_OR_GENE_PRODUCT", 120, 123], ["tumor", "CANCER", 156, 161], ["host cells", "CELL_TYPE", 16, 26], ["HPSE", "PROTEIN", 39, 43], ["Akt", "PROTEIN", 102, 105], ["VEGFR", "PROTEIN", 107, 112], ["EGFR", "PROTEIN", 114, 118], ["ERK", "PROTEIN", 120, 123], ["Both tumors", "PROBLEM", 0, 11], ["host cells", "PROBLEM", 16, 26], ["Akt", "TEST", 102, 105], ["VEGFR", "TEST", 107, 112], ["EGFR", "TEST", 114, 118], ["ERK", "TEST", 120, 123], ["tumor progression", "PROBLEM", 156, 173], ["tumors", "OBSERVATION", 5, 11], ["host cells", "OBSERVATION", 16, 26], ["tumor", "OBSERVATION", 51, 56], ["tumor", "OBSERVATION", 156, 161]]], ["Thus, oncogenic viruses such as HPV may have an intimate relationship with HPSE-mediated signaling.ConclusionIn this review, we have discussed the complex interplay between HPSE, viruses, and cell-signaling pathways.", [["cell", "ANATOMY", 192, 196], ["HPV", "ORGANISM", 32, 35], ["HPSE", "GENE_OR_GENE_PRODUCT", 75, 79], ["HPSE", "GENE_OR_GENE_PRODUCT", 173, 177], ["cell", "CELL", 192, 196], ["HPSE", "PROTEIN", 75, 79], ["HPV", "SPECIES", 32, 35], ["oncogenic viruses", "PROBLEM", 6, 23], ["HPV", "PROBLEM", 32, 35], ["oncogenic viruses", "OBSERVATION", 6, 23], ["viruses", "OBSERVATION", 179, 186]]], ["It is very clear that HPSE is intricately intertwined with a variety of signaling pathways important for viral pathogenesis.", [["HPSE", "SIMPLE_CHEMICAL", 22, 26], ["signaling pathways", "TREATMENT", 72, 90], ["viral pathogenesis", "PROBLEM", 105, 123], ["very", "OBSERVATION_MODIFIER", 6, 10], ["clear", "OBSERVATION", 11, 16], ["HPSE", "OBSERVATION", 22, 26]]], ["It possesses remarkable flexibility, influencing known cell signaling via enzymatic and non-enzymatic mechanisms, and key regulatory molecules including PI3K-Akt, ERK, VEGFR, and EGFR.", [["cell", "ANATOMY", 55, 59], ["cell", "CELL", 55, 59], ["PI3K", "GENE_OR_GENE_PRODUCT", 153, 157], ["Akt", "GENE_OR_GENE_PRODUCT", 158, 161], ["ERK", "GENE_OR_GENE_PRODUCT", 163, 166], ["VEGFR", "GENE_OR_GENE_PRODUCT", 168, 173], ["EGFR", "GENE_OR_GENE_PRODUCT", 179, 183], ["regulatory molecules", "PROTEIN", 122, 142], ["PI3K", "PROTEIN", 153, 157], ["Akt", "PROTEIN", 158, 161], ["ERK", "PROTEIN", 163, 166], ["VEGFR", "PROTEIN", 168, 173], ["EGFR", "PROTEIN", 179, 183], ["influencing known cell signaling", "PROBLEM", 37, 69], ["enzymatic and non-enzymatic mechanisms", "PROBLEM", 74, 112], ["PI3K", "TEST", 153, 157], ["ERK", "TEST", 163, 166], ["VEGFR", "TEST", 168, 173], ["EGFR", "TEST", 179, 183], ["remarkable", "OBSERVATION_MODIFIER", 13, 23], ["flexibility", "OBSERVATION_MODIFIER", 24, 35], ["cell signaling", "OBSERVATION", 55, 69], ["non-enzymatic mechanisms", "OBSERVATION", 88, 112]]], ["Since viruses utilize the pathways regulated by these molecules during infection to promote cell survival or other aspects of viral lifecycle, they stand to gain from influencing HPSE activity, as well.", [["cell", "ANATOMY", 92, 96], ["infection", "DISEASE", 71, 80], ["cell", "CELL", 92, 96], ["HPSE", "GENE_OR_GENE_PRODUCT", 179, 183], ["viruses", "TREATMENT", 6, 13], ["infection", "PROBLEM", 71, 80], ["cell survival", "TREATMENT", 92, 105], ["viral lifecycle", "PROBLEM", 126, 141], ["viral lifecycle", "OBSERVATION", 126, 141], ["HPSE activity", "OBSERVATION", 179, 192]]], ["Along the same lines, HPSE plays an important role in fine-tuning of innate and adaptive immune responses against viral pathogens.", [["HPSE", "CHEMICAL", 22, 26], ["lines", "CELL", 15, 20], ["HPSE", "GENE_OR_GENE_PRODUCT", 22, 26], ["HPSE", "PROTEIN", 22, 26], ["innate and adaptive immune responses", "TREATMENT", 69, 105], ["viral pathogens", "PROBLEM", 114, 129], ["same lines", "OBSERVATION", 10, 20]]], ["While a large body of work has previously been done to elucidate the role of HPSE in cell signaling, many key details of the mechanisms are still unknown.", [["cell", "ANATOMY", 85, 89], ["HPSE", "GENE_OR_GENE_PRODUCT", 77, 81], ["cell", "CELL", 85, 89], ["HPSE", "PROTEIN", 77, 81], ["HPSE in cell signaling", "PROBLEM", 77, 99], ["large", "OBSERVATION_MODIFIER", 8, 13]]], ["Future studies will be needed to develop a more precise understanding of HPSE as a major regulator of infection.", [["HPSE", "DISEASE", 73, 77], ["infection", "DISEASE", 102, 111], ["HPSE", "GENE_OR_GENE_PRODUCT", 73, 77], ["Future studies", "TEST", 0, 14], ["infection", "PROBLEM", 102, 111], ["infection", "OBSERVATION", 102, 111]]], ["For now, it does appear to regulate certain viral infections and interact with major pro-survival signaling pathways.", [["infections", "DISEASE", 50, 60], ["viral infections", "PROBLEM", 44, 60]]], ["If confirmed in the future, insights gleaned from this molecule could pave the way for new and broad-spectrum therapies for many persistent and acute viral infections.", [["viral infections", "DISEASE", 150, 166], ["broad-spectrum therapies", "TREATMENT", 95, 119], ["many persistent and acute viral infections", "PROBLEM", 124, 166], ["persistent", "OBSERVATION_MODIFIER", 129, 139], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["viral infections", "OBSERVATION", 150, 166]]]], "128257aeaa754df04c04f24d3c92fc6d268d614b": [["Many hospitals have been overwhelmed by the large number of patients with COVID-19.", [["COVID-19", "CHEMICAL", 74, 82], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["COVID", "TEST", 74, 79], ["large", "OBSERVATION_MODIFIER", 44, 49]]], ["However, at Beijing Tiantan Hospital, a rapid response system has been in place so that routine care is not interrupted.", [["a rapid response system", "TREATMENT", 38, 61], ["routine care", "TREATMENT", 88, 100]]], ["We, therefore, would like to share our hospital-wide prevention and management policy during this pandemic to help other healthcare systems to function in this crisis.", [["management policy", "TREATMENT", 68, 85], ["this crisis", "PROBLEM", 155, 166]]], ["With 1650 beds, its annual inpatient admission exceeds 30 000 patients.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70]]], ["Its COVID-19 rapid response policy was reviewed for its functionality. results There are nine key components of this policy: an incident management system; a comprehensive infection prevention and control, outpatient triage and flow system; a designated fever clinic; patient screening and administration; optimised surgical operations, enhanced nucleic acid testing; screening of returning employees; and a supervision and feedback system.", [["infection", "DISEASE", 172, 181], ["fever", "DISEASE", 254, 259], ["nucleic acid", "CHEMICAL", 346, 358], ["patient", "ORGANISM", 268, 275], ["patient", "SPECIES", 268, 275], ["Its COVID", "TEST", 0, 9], ["an incident management system", "TREATMENT", 125, 154], ["a comprehensive infection prevention", "TREATMENT", 156, 192], ["patient screening", "TEST", 268, 285], ["optimised surgical operations", "TREATMENT", 306, 335], ["enhanced nucleic acid testing", "TEST", 337, 366], ["infection", "OBSERVATION", 172, 181]]], ["In addition, a specific protocol was designed for treating patients with acute stroke.", [["acute stroke", "DISEASE", 73, 85], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["a specific protocol", "TEST", 13, 32], ["acute stroke", "PROBLEM", 73, 85], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["stroke", "OBSERVATION", 79, 85]]], ["Conclusion A comprehensive policy is helpful to protect the employee from infection and to provide quality and uninterrupted care to all who need these, including patients with acute ischaemic stroke.", [["infection", "DISEASE", 74, 83], ["ischaemic stroke", "DISEASE", 183, 199], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["infection", "PROBLEM", 74, 83], ["acute ischaemic stroke", "PROBLEM", 177, 199], ["infection", "OBSERVATION", 74, 83], ["acute", "OBSERVATION_MODIFIER", 177, 182], ["ischaemic", "OBSERVATION_MODIFIER", 183, 192], ["stroke", "OBSERVATION", 193, 199]]]], "0ee305c74e36acae133e51b59c93a528bc536012": [["onset of symptoms.", [["symptoms", "PROBLEM", 9, 17], ["symptoms", "OBSERVATION", 9, 17]]], ["The most documented reason for admission to the intensive care unit has been the need for respiratory support.", [["respiratory", "ANATOMY", 90, 101], ["respiratory support", "TREATMENT", 90, 109], ["respiratory support", "OBSERVATION", 90, 109]]], ["Among these, around two-thirds of patients meet the criteria for ARDS.", [["ARDS", "DISEASE", 65, 69], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["ARDS", "PROBLEM", 65, 69], ["ARDS", "OBSERVATION", 65, 69]]], ["1 Care of critically-ill patients of COVID-19 is resource-intensive, which may become the bottleneck of management.", [["critically-ill", "DISEASE", 10, 24], ["COVID-19", "CHEMICAL", 37, 45], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["Apart from the low tidal volume ventilation, and prone positioning (PP) in severe ARDS, none of the other approaches have been shown to reduce mortality conclusively.", [["ARDS", "DISEASE", 82, 86], ["the low tidal volume ventilation", "TREATMENT", 11, 43], ["PP", "TEST", 68, 70], ["severe ARDS", "PROBLEM", 75, 86], ["low tidal", "OBSERVATION", 15, 24], ["volume ventilation", "OBSERVATION", 25, 43], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["ARDS", "OBSERVATION", 82, 86]]], ["PP has been to increase the average ratio of arterial oxygen tension to the fraction of inspired oxygen (PaO2/FiO2) by 35 mmHg.", [["arterial", "ANATOMY", 45, 53], ["PP", "CHEMICAL", 0, 2], ["oxygen", "CHEMICAL", 54, 60], ["oxygen", "CHEMICAL", 97, 103], ["oxygen", "CHEMICAL", 54, 60], ["oxygen", "CHEMICAL", 97, 103], ["FiO2", "CHEMICAL", 110, 114], ["arterial", "MULTI-TISSUE_STRUCTURE", 45, 53], ["oxygen", "SIMPLE_CHEMICAL", 54, 60], ["oxygen", "SIMPLE_CHEMICAL", 97, 103], ["PP", "TEST", 0, 2], ["arterial oxygen tension", "PROBLEM", 45, 68], ["inspired oxygen", "TREATMENT", 88, 103], ["PaO2", "TEST", 105, 109], ["FiO2", "TEST", 110, 114], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["average", "OBSERVATION_MODIFIER", 28, 35], ["arterial", "ANATOMY", 45, 53], ["oxygen tension", "OBSERVATION", 54, 68]]], ["2 Non-invasive methods of oxygen delivery, such as high flow nasal cannula (HFNC) and non-invasive ventilation (NIV), have been used in mild-moderate ARDS and may reduce the need for invasive mechanical ventilation (IMV).", [["nasal", "ANATOMY", 61, 66], ["oxygen", "CHEMICAL", 26, 32], ["ARDS", "DISEASE", 150, 154], ["oxygen", "CHEMICAL", 26, 32], ["oxygen", "SIMPLE_CHEMICAL", 26, 32], ["oxygen delivery", "TREATMENT", 26, 41], ["high flow nasal cannula (HFNC", "TREATMENT", 51, 80], ["non-invasive ventilation", "TREATMENT", 86, 110], ["NIV", "TREATMENT", 112, 115], ["mild-moderate ARDS", "PROBLEM", 136, 154], ["invasive mechanical ventilation", "TREATMENT", 183, 214], ["IMV", "TREATMENT", 216, 219], ["oxygen delivery", "OBSERVATION", 26, 41], ["mild", "OBSERVATION_MODIFIER", 136, 140], ["moderate", "OBSERVATION_MODIFIER", 141, 149], ["ARDS", "OBSERVATION", 150, 154]]], ["These methods of oxygen delivery are associated with the high aerosol generation, and thus, are less often preferred for managing patients with COVID-19.", [["oxygen", "CHEMICAL", 17, 23], ["oxygen", "CHEMICAL", 17, 23], ["COVID-19", "CHEMICAL", 144, 152], ["oxygen", "SIMPLE_CHEMICAL", 17, 23], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["oxygen delivery", "TREATMENT", 17, 32], ["the high aerosol generation", "PROBLEM", 53, 80], ["COVID", "TEST", 144, 149], ["oxygen delivery", "OBSERVATION", 17, 32], ["aerosol generation", "OBSERVATION", 62, 80]]], ["Although the use of a facemask while using HFNC reduces the possibility of infection transmission, it does not eliminate it.", [["HFNC", "CHEMICAL", 43, 47], ["infection", "DISEASE", 75, 84], ["a facemask", "TREATMENT", 20, 30], ["HFNC", "TREATMENT", 43, 47], ["infection transmission", "PROBLEM", 75, 97], ["infection", "OBSERVATION", 75, 84]]], ["Whether combining non-invasive methods of oxygen delivery, along with PP, helps in preventing the need for IMV is still an unanswered question.", [["oxygen", "CHEMICAL", 42, 48], ["oxygen", "CHEMICAL", 42, 48], ["oxygen", "SIMPLE_CHEMICAL", 42, 48], ["oxygen delivery", "TREATMENT", 42, 57], ["PP", "TREATMENT", 70, 72], ["IMV", "TREATMENT", 107, 110]]]], "fc3ffeac4b17df49064f434c0a588a22b263e362": [["IntroductionThe giant river prawn (Macrobrachium rosenbergii) is a species of global aquaculture importance, with culture rapidly expanding from <7,000 tonnes in 1980 to >287,000 tonnes worldwide in 2017 (FAO, 2019) .", [["river prawn", "ORGANISM", 22, 33], ["Macrobrachium rosenbergii", "ORGANISM", 35, 60], ["Macrobrachium rosenbergii", "SPECIES", 35, 60], ["giant river prawn", "SPECIES", 16, 33], ["Macrobrachium rosenbergii", "SPECIES", 35, 60], ["The giant river prawn", "TREATMENT", 12, 33], ["culture", "TEST", 114, 121]]], ["Production, particularly in developing parts of Asia, provides direct and indirect employment, a food source to alleviate poverty, and export income in a high value international market (New and Nair, 2012) .", [["poverty", "DISEASE", 122, 129]]], ["Despite the exponential growth of the prawn industry, disease has been a significant problem, and when mortalities occur they are usually high, causing widespread impacts to the socioeconomic balance in these countries (Pillai and Bonami, 2012) .IntroductionBangladesh is considered to be a favourable environment for farming M. rosenbergii, named 'Golda' by Bangladeshi farmers, due to its vast inland freshwater river systems with adjacent brackish areas and a suitable climate for culturing tropical and sub-tropical aquaculture species (Wahab et al., 2012) .", [["M. rosenbergii", "ORGANISM", 326, 340], ["M. rosenbergii", "SPECIES", 326, 340], ["M. rosenbergii", "SPECIES", 326, 340], ["disease", "PROBLEM", 54, 61], ["a significant problem", "PROBLEM", 71, 92], ["adjacent brackish areas", "PROBLEM", 433, 456], ["culturing tropical", "TEST", 484, 502], ["exponential", "OBSERVATION_MODIFIER", 12, 23], ["growth", "OBSERVATION_MODIFIER", 24, 30], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["problem", "OBSERVATION", 85, 92]]], ["In 2017, Bangladesh was the world's second largest producer of M. rosenbergii, producing 48,574 tonnes (FAO, 2019) .", [["M. rosenbergii", "ORGANISM", 63, 77], ["M. rosenbergii", "SPECIES", 63, 77], ["M. rosenbergii", "SPECIES", 63, 77]]], ["Despite this promising production figure, M. rosenbergii hatcheries have been experiencing mass mortalities of larvae, resulting in the number of hatcheries actively producing larvae declining by almost 80% over the past decade as they are unable to complete the production cycle and it becomes uneconomical to continue.", [["M. rosenbergii", "ORGANISM", 42, 56], ["hatcheries", "ORGANISM", 57, 67], ["M. rosenbergii", "SPECIES", 42, 56], ["M. rosenbergii", "SPECIES", 42, 56], ["mass mortalities of larvae", "PROBLEM", 91, 117], ["larvae", "OBSERVATION_MODIFIER", 176, 182], ["declining", "OBSERVATION_MODIFIER", 183, 192]]], ["Hatcheries experiencing mortalities reported that larvae had abnormal shapes, reduced appetite, issues with moulting and a gradual whitening of the body; finally resulting in either disappearance from the culture system, or mortality (SAFETI, Winrock and Worldfish, personal communication; Alam et al., 2019) .IntroductionTo compensate for the loss of hatchery-produced post-larvae, wild post-larvae are being caught from the vast river systems in the south of Bangladesh, violating a government ban on the capture of wild PL (Wahab et al., 2012) .", [["body", "ANATOMY", 148, 152], ["abnormal shapes", "DISEASE", 61, 76], ["body", "ORGANISM_SUBDIVISION", 148, 152], ["abnormal shapes", "PROBLEM", 61, 76], ["reduced appetite", "PROBLEM", 78, 94], ["moulting", "PROBLEM", 108, 116], ["a gradual whitening of the body", "PROBLEM", 121, 152], ["the culture system", "TEST", 201, 219], ["the loss of hatchery", "PROBLEM", 340, 360], ["shapes", "OBSERVATION_MODIFIER", 70, 76], ["body", "ANATOMY", 148, 152]]], ["Ahmed and Troell (2010) reviewed the potential for negative environmental impact associated with fishing for wild PL and identified two main issues; high levels of invertebrate and fish bycatch associated with fishing for larvae (and a subsequent decline in biodiversity) and, a reduction in numbers of larvae returning to the freshwater environment as adults to spawn (reducing natural M. rosenbergii abundance).", [["fish", "ORGANISM_SUBDIVISION", 181, 185], ["M. rosenbergii", "ORGANISM", 387, 401], ["M. rosenbergii", "SPECIES", 387, 401], ["M. rosenbergii", "SPECIES", 387, 401], ["larvae", "PROBLEM", 222, 228], ["reduction", "OBSERVATION_MODIFIER", 279, 288]]], ["As fishing for wild post-larvae increases due to the hatcheries being unable to complete production cycles, it is likely that the negative environmental impact caused by fishing will become more pronounced.IntroductionA number of surveys have been carried out by several organisations to determine possible causes for the mortalities observed in hatcheries in Bangladesh.", [["the hatcheries", "PROBLEM", 49, 63], ["the mortalities", "PROBLEM", 318, 333], ["more pronounced", "OBSERVATION_MODIFIER", 190, 205]]], ["The surveys identified many shortcomings, including deficiencies in water quality, water filtration systems, temperature fluctuations due to weather conditions, feeding practices, probiotic use, and poor quality inputs that had been exposed to formalin and bleaching (SAFETI, Winrock, Worldfish and BFRI, personal communication) .", [["formalin", "CHEMICAL", 244, 252], ["formalin", "CHEMICAL", 244, 252], ["deficiencies in water quality", "PROBLEM", 52, 81], ["water filtration systems", "TREATMENT", 83, 107], ["temperature fluctuations", "PROBLEM", 109, 133], ["weather conditions", "PROBLEM", 141, 159], ["feeding practices", "TREATMENT", 161, 178], ["many", "OBSERVATION_MODIFIER", 23, 27], ["shortcomings", "OBSERVATION", 28, 40], ["water quality", "OBSERVATION_MODIFIER", 68, 81]]], ["However, despite these constraints, hatcheries were successfully completing production cycles until 2011, suggesting that a new factor has arisen, which could be disease related.", [["a new factor", "PROBLEM", 122, 134]]], ["Biosecurity has been highlighted as a major issue, in relation to the spread of mortalities throughout the hatcheries of Bangladesh.IntroductionAs the culture of M. rosenbergii has increased globally, the incidence of diseases and emergence of novel pathogens has increased in parallel (Pillai and Bonami, 2012 Pillai and Bonami, 2012) .", [["Biosecurity", "DISEASE", 0, 11], ["M. rosenbergii", "ORGANISM", 162, 176], ["M. rosenbergii", "SPECIES", 162, 176], ["M. rosenbergii", "SPECIES", 162, 176], ["the culture", "TEST", 147, 158], ["M. rosenbergii", "PROBLEM", 162, 176], ["diseases", "PROBLEM", 218, 226], ["novel pathogens", "PROBLEM", 244, 259], ["spread", "OBSERVATION_MODIFIER", 70, 76], ["mortalities", "OBSERVATION", 80, 91], ["increased", "OBSERVATION_MODIFIER", 181, 190], ["globally", "OBSERVATION_MODIFIER", 191, 199], ["diseases", "OBSERVATION", 218, 226], ["increased", "OBSERVATION_MODIFIER", 264, 273]]], ["Spiroplasma eriocheiris (Srisala et al., 2018) has been shown to cause mortalities in later life stages of M. rosenbergii.", [["Spiroplasma eriocheiris", "ORGANISM", 0, 23], ["M. rosenbergii", "ORGANISM", 107, 121], ["Spiroplasma eriocheiris", "SPECIES", 0, 23], ["M. rosenbergii", "SPECIES", 107, 121], ["Spiroplasma eriocheiris", "SPECIES", 0, 23], ["M. rosenbergii", "SPECIES", 107, 121]]], ["Macrobrachium rosenbergii Nodavirus (MrNV) (Arcier et al., 1999) , in association with extra small virus (XSV) (Qian et al., 2003) , causes white tail disease (WTD), an OIE-listed disease.", [["tail", "ANATOMY", 146, 150], ["white tail disease", "DISEASE", 140, 158], ["WTD", "DISEASE", 160, 163], ["Macrobrachium rosenbergii Nodavirus", "ORGANISM", 0, 35], ["extra small virus", "ORGANISM", 87, 104], ["tail", "ORGANISM_SUBDIVISION", 146, 150], ["Macrobrachium rosenbergii", "SPECIES", 0, 25], ["Macrobrachium rosenbergii", "SPECIES", 0, 25], ["XSV", "SPECIES", 106, 109], ["Macrobrachium rosenbergii Nodavirus", "PROBLEM", 0, 35], ["extra small virus", "PROBLEM", 87, 104], ["white tail disease", "PROBLEM", 140, 158], ["an OIE-listed disease", "PROBLEM", 166, 187], ["rosenbergii Nodavirus", "OBSERVATION", 14, 35], ["white tail disease", "OBSERVATION", 140, 158], ["disease", "OBSERVATION", 180, 187]]], ["The viruses have caused devastation in the prawn hatchery industries of Thailand (Yoganandhan, Leartvibhas and Sriwongpuk, 2006) , China (Qian et al., 2003) , India (Hameed, Yoganandhan and Widada, 2004) , Taiwan (Wang et al., 2007) and Indonesia (Murwantoko et al., 2016) .", [["devastation", "PROBLEM", 24, 35], ["viruses", "OBSERVATION", 4, 11], ["devastation", "OBSERVATION_MODIFIER", 24, 35]]], ["Other viruses causing mortalities include Macrobrachium rosenbergii Taihu Virus (MrTV), a novel dicistrovirus associated with larval mortalities in China (Pan et al., 2016) , Infectious Hypodermal and Haematopoietic Necrosis Virus (IHHNV) (Hsieh et al., 2006) , and Decapod Iridescent Virus (DIV1) (Qiu et al., 2019) .", [["dicistrovirus", "DISEASE", 96, 109], ["larval mortalities", "DISEASE", 126, 144], ["Infectious Hypodermal and Haematopoietic Necrosis Virus", "DISEASE", 175, 230], ["Macrobrachium rosenbergii Taihu Virus", "ORGANISM", 42, 79], ["MrTV", "ORGANISM", 81, 85], ["Haematopoietic Necrosis Virus", "ORGANISM", 201, 230], ["Decapod Iridescent Virus", "ORGANISM", 266, 290], ["Macrobrachium rosenbergii", "SPECIES", 42, 67], ["Taihu Virus", "SPECIES", 68, 79], ["Macrobrachium rosenbergii Taihu Virus", "SPECIES", 42, 79], ["MrTV", "SPECIES", 81, 85], ["Infectious Hypodermal and Haematopoietic Necrosis Virus", "SPECIES", 175, 230], ["IHHNV", "SPECIES", 232, 237], ["Decapod Iridescent Virus", "SPECIES", 266, 290], ["Other viruses", "PROBLEM", 0, 13], ["mortalities", "PROBLEM", 22, 33], ["Macrobrachium rosenbergii Taihu Virus", "PROBLEM", 42, 79], ["a novel dicistrovirus", "PROBLEM", 88, 109], ["larval mortalities", "PROBLEM", 126, 144], ["Infectious Hypodermal", "PROBLEM", 175, 196], ["Haematopoietic Necrosis Virus", "PROBLEM", 201, 230], ["Decapod Iridescent Virus", "PROBLEM", 266, 290], ["viruses", "OBSERVATION", 6, 13], ["Infectious", "OBSERVATION_MODIFIER", 175, 185], ["Hypodermal", "ANATOMY", 186, 196], ["Haematopoietic", "ANATOMY", 201, 215], ["Necrosis", "OBSERVATION", 216, 224], ["Iridescent Virus", "OBSERVATION", 274, 290]]], ["Other pathogens have been identified to infect M. rosenbergii without large mortalities including: Macrobrachium Parvo-like Virus (MPV) (Gangnonngiw et al., 2009) and White Spot Syndrome Virus (WSSV) (Sahul Hameed, Charles and Anilkumar, 2000; Sarathi et al., 2008) .IntroductionWith the lack of immortal shrimp cell lines, disease challenges can be used to identify pathogenic agents infecting M. rosenbergii.", [["cell lines", "ANATOMY", 312, 322], ["White Spot Syndrome Virus", "DISEASE", 167, 192], ["M. rosenbergii", "ORGANISM", 47, 61], ["Macrobrachium Parvo-like Virus", "ORGANISM", 99, 129], ["White Spot Syndrome Virus", "ORGANISM", 167, 192], ["WSSV", "ORGANISM", 194, 198], ["shrimp cell lines", "CELL", 305, 322], ["M. rosenbergii", "ORGANISM", 395, 409], ["immortal shrimp cell lines", "CELL_LINE", 296, 322], ["M. rosenbergii", "SPECIES", 47, 61], ["Macrobrachium Parvo", "SPECIES", 99, 118], ["M. rosenbergii", "SPECIES", 395, 409], ["M. rosenbergii", "SPECIES", 47, 61], ["Macrobrachium Parvo-like Virus (MPV)", "SPECIES", 99, 135], ["White Spot Syndrome Virus", "SPECIES", 167, 192], ["WSSV", "SPECIES", 194, 198], ["M. rosenbergii", "SPECIES", 395, 409], ["Other pathogens", "PROBLEM", 0, 15], ["large mortalities", "PROBLEM", 70, 87], ["Macrobrachium Parvo-like Virus", "PROBLEM", 99, 129], ["White Spot Syndrome Virus", "PROBLEM", 167, 192], ["immortal shrimp cell lines", "TREATMENT", 296, 322], ["disease challenges", "TREATMENT", 324, 342], ["without", "UNCERTAINTY", 62, 69], ["large", "OBSERVATION_MODIFIER", 70, 75], ["mortalities", "OBSERVATION", 76, 87], ["Macrobrachium", "ANATOMY", 99, 112], ["immortal shrimp cell lines", "OBSERVATION", 296, 322]]], ["This technique was recently used to determine that MrNV alone can cause mortalities in M. rosenbergii in the absence of XSV (Gangnonngiw et al., 2020) .", [["MrNV", "CHEMICAL", 51, 55], ["MrNV", "GENE_OR_GENE_PRODUCT", 51, 55], ["M. rosenbergii", "ORGANISM", 87, 101], ["M. rosenbergii", "SPECIES", 87, 101], ["M. rosenbergii", "SPECIES", 87, 101], ["XSV", "SPECIES", 120, 123], ["This technique", "TREATMENT", 0, 14]]], ["Alam et al. (2019) attempted to determine the causative agent(s) associated with the larval mortalities in Bangladesh hatcheries using a screen for Vibrio spp., which are known to cause disease in larval stages of prawn culture (Khuntia et al., 2008) .", [["Vibrio spp.", "ORGANISM", 148, 159], ["Vibrio spp.", "SPECIES", 148, 159], ["Vibrio spp.", "SPECIES", 148, 159], ["the larval mortalities", "PROBLEM", 81, 103], ["a screen", "TEST", 135, 143], ["Vibrio spp.", "PROBLEM", 148, 159], ["disease", "PROBLEM", 186, 193], ["prawn culture", "TEST", 214, 227]]], ["However, this study was unable to find a strong correlation between the Vibrio species present and the levels of mortalities seen in larvae.", [["Vibrio species", "ORGANISM", 72, 86], ["this study", "TEST", 9, 19], ["the Vibrio species", "TEST", 68, 86], ["mortalities", "OBSERVATION", 113, 124]]], ["Larvae were also screened for the presence of MrNV and XSV, but neither of these were detected.", [["Larvae", "ORGANISM", 0, 6], ["MrNV", "GENE_OR_GENE_PRODUCT", 46, 50], ["XSV", "GENE_OR_GENE_PRODUCT", 55, 58], ["MrNV", "PROTEIN", 46, 50], ["XSV", "PROTEIN", 55, 58], ["XSV", "SPECIES", 55, 58], ["MrNV and XSV", "PROBLEM", 46, 58]]], ["Therefore, no significant pathogens have yet been associated with the large-scale larval mortalities in Bangladesh.", [["significant pathogens", "PROBLEM", 14, 35], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["pathogens", "OBSERVATION", 26, 35], ["large", "OBSERVATION_MODIFIER", 70, 75], ["larval mortalities", "OBSERVATION", 82, 100]]], ["The clinical signs of disease observed in these larvae associated with the current large-scale mortalities do not precisely fit those described for infection with any of the known larval prawn pathogens, therefore an approach to detect novel pathogens was needed to determine if there was a pathogenic cause for the mortalities.IntroductionIn this study we (1) carried out an experimental challenge trial using larvae sourced from a hatchery displaying disease, (2) generated and analysed metatranscriptomic libraries obtained from pools of larvae from experimental trials to identify any potential pathogens present in moribund animals, and (3) screened for pathogens identified as a risk in other hatcheries that had been experiencing mortalities to determine whether these agents were present.Collection of hatchery cultured larvae and wild broodstockLarvae were collected from five hatcheries in southern Bangladesh in production seasons of 2018 and 2019.", [["broodstockLarvae", "ANATOMY", 844, 860], ["infection", "DISEASE", 148, 157], ["larvae", "ORGANISM", 828, 834], ["broodstockLarvae", "CELL", 844, 860], ["metatranscriptomic libraries", "DNA", 489, 517], ["disease", "PROBLEM", 22, 29], ["these larvae", "PROBLEM", 42, 54], ["the current large-scale mortalities", "PROBLEM", 71, 106], ["infection", "PROBLEM", 148, 157], ["the known larval prawn pathogens", "PROBLEM", 170, 202], ["an approach", "TEST", 214, 225], ["novel pathogens", "PROBLEM", 236, 251], ["the mortalities", "PROBLEM", 312, 327], ["this study", "TEST", 343, 353], ["an experimental challenge trial", "TREATMENT", 373, 404], ["larvae", "TREATMENT", 411, 417], ["a hatchery displaying disease", "PROBLEM", 431, 460], ["experimental trials", "TREATMENT", 553, 572], ["any potential pathogens", "PROBLEM", 585, 608], ["pathogens", "PROBLEM", 659, 668], ["hatchery cultured larvae", "TREATMENT", 810, 834], ["wild broodstockLarvae", "PROBLEM", 839, 860], ["disease", "OBSERVATION", 22, 29], ["hatchery cultured larvae", "OBSERVATION", 810, 834]]], ["Batches of approximately 20-30 whole larvae were fixed in RNAlater.", [["larvae", "ORGANISM", 37, 43]]], ["In the same years, adult M. rosenbergii were collected from seven rivers also in southern Bangladesh (Figure 1 ).Preparation of infectious study materialTo produce materials for disease challenge, moribund larvae were collected from a hatchery that was experiencing mortalities at the time of the study.", [["M. rosenbergii", "ORGANISM", 25, 39], ["larvae", "ORGANISM", 206, 212], ["M. rosenbergii", "SPECIES", 25, 39], ["M. rosenbergii", "SPECIES", 25, 39], ["infectious study material", "TEST", 128, 153], ["disease challenge", "PROBLEM", 178, 195], ["moribund larvae", "PROBLEM", 197, 212], ["the study", "TEST", 293, 302], ["infectious", "OBSERVATION", 128, 138]]], ["Larvae were ground using a sterile pestle and mortar, suspended in phosphate buffered saline (PBS) and filtered through a 0.45 \u00b5m syringe filter.", [["pestle", "ANATOMY", 35, 41], ["phosphate", "CHEMICAL", 67, 76], ["phosphate", "CHEMICAL", 67, 76], ["Larvae", "ORGANISM", 0, 6], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 67, 92], ["a sterile pestle and mortar", "TREATMENT", 25, 52], ["phosphate buffered saline (PBS", "TREATMENT", 67, 97], ["a 0.45 \u00b5m syringe filter", "TREATMENT", 120, 144], ["syringe filter", "OBSERVATION", 130, 144]]], ["Larvae from a healthy hatchery that had not experienced mortalities in past production cycles were also collected and prepared in the same manner as a control treatment.In vivo tank experimentsExperimental larvae were obtained from Bangladesh Fisheries Research Institute's (BRFI) domesticated F1 broodstock.", [["a control treatment", "TREATMENT", 149, 168]]], ["After hatching, larvae were reared up to stage three, before splitting into three groups for different experimental tank exposures.In vivo tank experiments(1) Experimental larvae were directly immersed into filtered challenge medium from moribund larvae for 10 minutes prior to being transferred to a fibreglass tank.In vivo tank experiments(2) Experimental larvae were fed artemia that had been immersed in challenge medium from moribund larvae for 10 minutes.In vivo tank experiments(3) Experimental larvae were immersed into filtered challenge material from healthy larvae for 10 minutes prior to being transferred to a fibreglass tank.In vivo tank experimentsFor all experiments 4000\u00b1200 larvae were used, and experiments were carried out in 40 l fibreglass tanks heated to a constant temperature of 30\u00b0C with a submerged thermostat heater.", [["larvae", "ORGANISM", 172, 178], ["larvae", "ORGANISM", 358, 364], ["Experimental larvae", "TREATMENT", 159, 178], ["Experimental larvae", "TREATMENT", 345, 364], ["Experimental larvae", "PROBLEM", 489, 508], ["a submerged thermostat heater", "TREATMENT", 814, 843], ["experimental tank exposures", "OBSERVATION", 103, 130]]], ["Twenty to thirty larvae were collected every day for the first five days of the experiment and on days seven and ten.RNA extractionRNA was extracted using RIBOZOL\u2122 (VWR, Pennsylvania, U.S.).", [["RNA extractionRNA", "TEST", 117, 134], ["RIBOZOL", "TREATMENT", 155, 162]]], ["For larvae, approximately 20 larvae were added to 1 ml RIBOZOL, and for adults, approximately 5 mg of each tissue type (pleopod, hepatopancreas, gill, gut) was pooled and added to 1 ml of RIBOZOL.", [["tissue", "ANATOMY", 107, 113], ["pleopod", "ANATOMY", 120, 127], ["hepatopancreas", "ANATOMY", 129, 143], ["gill", "ANATOMY", 145, 149], ["gut", "ANATOMY", 151, 154], ["RIBOZOL", "CHEMICAL", 188, 195], ["tissue type", "TISSUE", 107, 118], ["hepatopancreas", "TISSUE", 129, 143], ["gill", "ORGAN", 145, 149], ["gut", "ORGANISM_SUBDIVISION", 151, 154], ["larvae", "PROBLEM", 4, 10], ["1 ml RIBOZOL", "TREATMENT", 50, 62], ["RIBOZOL", "TREATMENT", 188, 195], ["hepatopancreas", "ANATOMY", 129, 143], ["gill", "ANATOMY", 145, 149], ["gut", "ANATOMY", 151, 154]]], ["RNA extraction was carried out following the manufacturer's protocol, with a final resuspension in extracted with RNA, a DNAse step was carried out using DNAse1 (Sigma Aldrich, Missouri, U.S.), following the manufacturer's protocol.Double stranded cDNA synthesisFirst strand synthesis was performed in 25 \u03bcl reaction volumes using 5 \u03bcl of MMLV-RT 5X buffer (Promega, Wisconsin, UK), 1.25 \u03bcl of dNTPs (10mM) (Promega), 0.625 \u03bcl of recombinant RNasin (Promega), 1 \u03bcl of random hexamer primers (Promega) and 1 \u03bcg of RNA in 16.125 \u03bcl.", [["dNTPs", "CHEMICAL", 394, 399], ["dNTPs", "CHEMICAL", 394, 399], ["MMLV", "ORGANISM", 339, 343], ["dNTPs", "SIMPLE_CHEMICAL", 394, 399], ["RNasin", "GENE_OR_GENE_PRODUCT", 442, 448], ["recombinant RNasin", "PROTEIN", 430, 448], ["RNA extraction", "TREATMENT", 0, 14], ["the manufacturer's protocol", "TREATMENT", 41, 68], ["a final resuspension", "TREATMENT", 75, 95], ["RNA", "TREATMENT", 114, 117], ["a DNAse step", "TEST", 119, 131], ["the manufacturer's protocol", "TREATMENT", 204, 231], ["Double stranded cDNA synthesis", "TREATMENT", 232, 262], ["strand synthesis", "TREATMENT", 268, 284], ["MMLV", "TREATMENT", 339, 343], ["dNTPs (10mM) (Promega)", "TREATMENT", 394, 416], ["recombinant RNasin (Promega)", "TREATMENT", 430, 458], ["random hexamer primers", "TREATMENT", 468, 490], ["RNA", "TREATMENT", 513, 516]]], ["Prior to the addition of 1 \u03bcl of MMLV-RT enzyme (Promega), the reaction was incubated at 65\u00b0C in order to denature double stranded RNA.", [["MMLV", "ORGANISM", 33, 37], ["Promega", "ORGANISM", 49, 56], ["double stranded RNA", "RNA", 115, 134], ["MMLV", "TREATMENT", 33, 37], ["RT enzyme", "TREATMENT", 38, 47], ["the reaction", "PROBLEM", 59, 71], ["denature double stranded RNA", "PROBLEM", 106, 134], ["stranded RNA", "OBSERVATION", 122, 134]]], ["Following the addition of the MMLV-RT, the reaction was incubated at 37\u00b0C for 1 hour.", [["MMLV", "ORGANISM", 30, 34], ["the MMLV", "TREATMENT", 26, 34], ["the reaction", "PROBLEM", 39, 51]]], ["Second strand synthesis was performed immediately after first strand synthesis.", [["Second strand synthesis", "PROBLEM", 0, 23], ["first strand synthesis", "PROBLEM", 56, 78]]], ["Single stranded cDNA was incubated at 94\u00b0C for 2 minutes, followed by 10\u00b0C for 5 minutes.", [["Single stranded cDNA", "DNA", 0, 20]]], ["Following incubation, 2 \u03bcl Sequenase buffer (Thermo Fisher, Massachusetts, U.S.), 0.3 \u03bcl Sequenase (Thermo Fisher) and 7.7 \u03bcl molecular grade water (Thermo Fisher) were added.", [["incubation", "TREATMENT", 10, 20], ["\u03bcl molecular grade water (Thermo Fisher)", "TREATMENT", 123, 163]]], ["During incubation at 10\u00b0C, 1.2 \u03bcl 1:4 (Sequenase:Sequenase dilution buffer (Thermo Fisher)) diluted Sequenase was added to reactions and incubated at 37\u00b0C for 8 minutes and 94\u00b0C for 8 minutes prior to transfer to ice.Library PreparationThree pools of cDNA were constructed from in vivo tank experiments: (1) Challenge days 1-4 larvae from immersion and feeding challenges using filtered material from moribund larvae (2) Challenge days 5-10 larvae from immersion and feeding challenges using filtered material from moribund larvae and (3) Larvae from a hatchery that had been experiencing mass mortalities.", [["Sequenase", "CHEMICAL", 100, 109], ["Sequenase", "SIMPLE_CHEMICAL", 100, 109], ["cDNA", "DNA", 251, 255], ["Sequenase dilution buffer (Thermo Fisher)", "TREATMENT", 49, 90], ["feeding challenges", "TREATMENT", 353, 371], ["moribund larvae", "TREATMENT", 401, 416], ["feeding challenges", "TREATMENT", 467, 485], ["moribund larvae", "PROBLEM", 515, 530], ["mass mortalities", "PROBLEM", 589, 605], ["mass", "OBSERVATION", 589, 593]]], ["These pools were prepared for metatranscriptomic sequencing using the Illumina compatible Nextera XT library preparation kit (Illumina, California, U.S.) and sequenced on an Illumina MiSeq using v3 chemistry (Illumina).Sequence analysisThe generated raw Illumina paired-end sequence reads were trimmed to remove adaptor and low quality sequences using Trim galore! v0.5.0 (Krueger, 2015) .", [["Illumina MiSeq", "DNA", 174, 188], ["Illumina paired-end sequence reads", "DNA", 254, 288], ["adaptor and low quality sequences", "DNA", 312, 345], ["metatranscriptomic sequencing", "TREATMENT", 30, 59], ["the Illumina", "TREATMENT", 66, 78], ["an Illumina MiSeq", "TEST", 171, 188], ["Sequence analysis", "TEST", 219, 236], ["adaptor", "TREATMENT", 312, 319]]], ["Trimmed sequences were quality-checked using FastQC v0.11.8 (Andrews, 2010) before reads from individual pools were assembled using both rnaSPAdes v3.13.0 (Nurk et al., 2013) and the Iterative Virus Assembler (IVA) v1.0.8 (Hunt et al., 2015) .", [["Trimmed sequences", "TEST", 0, 17], ["FastQC", "TEST", 45, 51], ["both rnaSPAdes v", "TEST", 132, 148]]], ["Assembled contigs were subsequently annotated using the BLASTp algorithm of Diamond v3.13.0 (Buchfink et al 2015) and the full NCBI nonredundant (nr) protein database (downloaded November 2018), and the results were visualised using MEGAN6 Community Edition v6.12.3 (Huson et al., 2016) .", [["NCBI nonredundant (nr) protein database", "DNA", 127, 166]]], ["Paired reads from all samples were then mapped to the assembled contig representing the viral genome sequence using BWA-MEM v0.7.17 and SAMtools v1.9 with default parameters (Li and Durbin, 2009; Li et al., 2009) .", [["samples", "ANATOMY", 22, 29], ["viral genome sequence", "DNA", 88, 109], ["the viral genome sequence", "TEST", 84, 109], ["BWA", "TEST", 116, 119], ["MEM v", "TEST", 120, 125], ["SAMtools v", "TEST", 136, 146], ["default parameters", "TEST", 155, 173], ["viral genome", "OBSERVATION", 88, 100]]], ["The output from BWA-MEM was visualised with Integrative Genomics Viewer (IGV) v2.5.2 (Robinson et al., 2011) .", [["The output from BWA", "TEST", 0, 19], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["Assembly quality and accuracy were assessed with QualiMap v2.2.2 (Garc\u00eda- Alcalde et al., 2012) .Sequence analysisPredicted open reading frames (ORFs) were identified using four different tools: Prokka v1.11 (Seemann, 2014) FgenesV0 (SoftBerry.com), GeneMarkS v4.28 (Besemer, Lomsadze and Borodovsky, 2001) and Vgas (Zhang et al., 2019) .", [["open reading frames", "DNA", 124, 143], ["ORFs", "DNA", 145, 149], ["accuracy", "TEST", 21, 29], ["QualiMap v", "TEST", 49, 59], ["Garc\u00eda", "TEST", 66, 72]]], ["ORFs that were supported by two or more programs were analysed further.", [["ORFs", "DNA", 0, 4], ["ORFs", "PROBLEM", 0, 4]]], ["Supported ORFs were annotated using NCBI BLASTp and the full NCBI protein sequence database (downloaded December 2019) and protein motifs were identified by HHpred (Hildebrand et al., 2009; default parameters) and InterProScan 5 (Jones et al., 2014) .", [["ORFs", "DNA", 10, 14], ["NCBI BLASTp", "DNA", 36, 47], ["NCBI protein sequence", "DNA", 61, 82], ["protein motifs", "TEST", 123, 137]]], ["Predicted protein motifs were aligned against known nidovirus protein motifs using MAFFT (Katoh, Rozewicki and Yamada, 2017) and multiple sequence alignments (MSAs) were visualised in ESPRICT3 v3.0 (Robert and Gouet, 2014; default parameters) .Sequence analysisTransmembrane regions were identified using TMHMM v2.0 (Krogh et al., 2001; default parameters) .", [["nidovirus protein motifs", "DNA", 52, 76], ["Predicted protein motifs", "TEST", 0, 24], ["known nidovirus protein motifs", "PROBLEM", 46, 76], ["multiple sequence alignments", "TEST", 129, 157], ["Sequence analysis", "TEST", 244, 261], ["TMHMM", "TEST", 305, 310]]], ["Ribosomal frameshift identifiers were found using FSFinder2 using the virus genome settings (Byun et al 2007) .", [["FSFinder2", "DNA", 50, 59], ["Ribosomal frameshift identifiers", "PROBLEM", 0, 32], ["FSFinder2", "TREATMENT", 50, 59], ["the virus genome settings", "TREATMENT", 66, 91], ["frameshift", "OBSERVATION", 10, 20]]], ["Secondary structure of the 3' UTR was predicted using MFOLD (Zuker, 2003 ; default parameters).Phylogenetic analysesPhylogenetic analyses was performed using the RdRp protein domain as in Saberi et al. (2018) , conserved in known and proposed Nidovirlaes, on 15 Nidovirales with representatives from Arteriviradae, Roniviridae, Mesoniviridae, Mononiviridae, Euroniviridae, Coronavirinae and Torovirinae families and subfamilies.", [["Arteriviradae", "GENE_OR_GENE_PRODUCT", 300, 313], ["Roniviridae", "GENE_OR_GENE_PRODUCT", 315, 326], ["Mesoniviridae", "GENE_OR_GENE_PRODUCT", 328, 341], ["Mononiviridae", "GENE_OR_GENE_PRODUCT", 343, 356], ["Euroniviridae", "GENE_OR_GENE_PRODUCT", 358, 371], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 373, 386], ["Torovirinae", "GENE_OR_GENE_PRODUCT", 391, 402], ["3' UTR", "DNA", 27, 33], ["RdRp protein domain", "PROTEIN", 162, 181], ["Mononiviridae, Euroniviridae, Coronavirinae and Torovirinae families and subfamilies", "PROTEIN", 343, 427], ["Secondary structure of the 3' UTR", "PROBLEM", 0, 33], ["MFOLD (Zuker", "TREATMENT", 54, 66], ["Phylogenetic analyses", "TEST", 95, 116], ["Phylogenetic analyses", "TEST", 116, 137], ["the RdRp protein domain", "PROBLEM", 158, 181], ["Arteriviradae", "TREATMENT", 300, 313], ["Roniviridae", "TREATMENT", 315, 326], ["Mesoniviridae", "TREATMENT", 328, 341], ["Mononiviridae", "TREATMENT", 343, 356], ["Euroniviridae", "TREATMENT", 358, 371], ["Coronavirinae", "TREATMENT", 373, 386]]], ["Two representatives from the Astroviradae order of viruses were also aligned as an outgroup.", [["viruses", "PROBLEM", 51, 58], ["viruses", "OBSERVATION", 51, 58]]], ["MSAs were performed using default parameters in MAFFT (Katoh, Rozewicki and Yamada, 2017) .", [["MSAs", "TEST", 0, 4], ["default parameters", "TEST", 26, 44]]], ["Maximum Likelihood phylogenetic analyses were carried out using RaxML BlackBox v.8 (Stamatakis, 2014 ) (GTR evolutionary model; all parameters estimated from the data).", [["Maximum Likelihood phylogenetic analyses", "TEST", 0, 40], ["GTR evolutionary model", "TREATMENT", 104, 126]]], ["Two separate MC3 runs with randomly generated starting trees were carried out for 2 million generations each with 1 cold and 3 heated chains using a GTR model.", [["1 cold and 3 heated chains", "TREATMENT", 114, 140], ["a GTR model", "TREATMENT", 147, 158], ["MC3 runs", "OBSERVATION", 13, 21]]], ["The trees were sampled every 1000 generations and the first 500,000 generations discarded as burn-in.", [["burn", "DISEASE", 93, 97]]], ["All phylogenetic analyses were carried out on the Cipres server (Miller, Pfeiffer and Schwartz, 2010 ).Primer design and specific PCRPrimers specific to the predicted enveloping protein ORF of MrGV were designed using Initial denaturation was carried out at 94\u00b0C for 5 minutes, followed by 35 cycles of 94\u00b0C for 30 seconds, 63\u00b0C for 30 seconds and 72\u00b0C for 90 seconds.", [["MrGV", "GENE_OR_GENE_PRODUCT", 193, 197], ["enveloping protein ORF", "DNA", 167, 189], ["MrGV", "DNA", 193, 197], ["All phylogenetic analyses", "TEST", 0, 25], ["Initial denaturation", "TREATMENT", 218, 238]]], ["Amplicons were purified with Wizard\u00ae SV Gel and PCR Clean-Up System (Promega) and sequenced via the Eurofins TubeSeq service.", [["Amplicons", "TREATMENT", 0, 9], ["Wizard\u00ae SV Gel", "TREATMENT", 29, 43], ["PCR Clean", "TREATMENT", 48, 57]]], ["Primers were tested on larval samples from 5 hatcheries and wild adult M. rosenbergii sampled from the river networks surrounding the hatcheries.", [["samples", "ANATOMY", 30, 37], ["M. rosenbergii", "ORGANISM", 71, 85], ["river networks", "MULTI-TISSUE_STRUCTURE", 103, 117], ["M. rosenbergii", "SPECIES", 71, 85], ["M. rosenbergii", "SPECIES", 71, 85], ["larval samples", "TEST", 23, 37], ["hatcheries", "OBSERVATION", 134, 144]]], ["Penaeus monodon tissues infected with yellow head virus (YHV) were tested as a negative control.Specific PCR ScreensPCR screens for specific pathogens were carried out with the following primers: MrNV using MrNV2aF and MrNV2aR primers (Sahul Hameed et al., 2004) ; XSV using XSV-external forward and reverse primers (Sudhakaran, Yoganandhan and Ahmed, 2006) ; MrTV using MrTV472F and MrTV472R primers (Pan et al., 2016) ; WSSV using 146F1, 146R1, 146F2 and 146R2 primers (Lo et al. 1996) ; PmNV using 261F and 261R primers (Surachetpong et al., 2005) ; Spiroplasma eriocheiris using F28 and R5 primers (Ding et al., 2007) ; and YHV using YC-F1a, YC-F1b, YC-R1a, YC-R1b, YC-F2a, YC-F2b, YC-R2a and YC-R2b primers (Mohr et al., 2015) .", [["tissues", "ANATOMY", 16, 23], ["Penaeus monodon", "ORGANISM", 0, 15], ["tissues", "TISSUE", 16, 23], ["yellow head virus", "ORGANISM", 38, 55], ["MrNV2aF", "GENE_OR_GENE_PRODUCT", 207, 214], ["MrTV472F", "GENE_OR_GENE_PRODUCT", 371, 379], ["WSSV", "ORGANISM", 422, 426], ["146F1", "GENE_OR_GENE_PRODUCT", 433, 438], ["Spiroplasma eriocheiris", "ORGANISM", 553, 576], ["YC-F1b", "GENE_OR_GENE_PRODUCT", 646, 652], ["YC-R1a", "GENE_OR_GENE_PRODUCT", 654, 660], ["YC-R1b", "GENE_OR_GENE_PRODUCT", 662, 668], ["YC-F2a", "GENE_OR_GENE_PRODUCT", 670, 676], ["YC-F2b", "GENE_OR_GENE_PRODUCT", 678, 684], ["YC-R2a", "GENE_OR_GENE_PRODUCT", 686, 692], ["MrNV", "DNA", 196, 200], ["MrNV2aF and MrNV2aR primers", "DNA", 207, 234], ["XSV", "DNA", 265, 268], ["XSV-external forward and reverse primers", "DNA", 275, 315], ["MrTV", "DNA", 360, 364], ["MrTV472F and MrTV472R primers", "DNA", 371, 400], ["146F1, 146R1, 146F2 and 146R2 primers", "DNA", 433, 470], ["PmNV", "DNA", 490, 494], ["YHV", "DNA", 628, 631], ["YC", "DNA", 638, 640], ["F1a", "DNA", 641, 644], ["YC", "DNA", 646, 648], ["F1b", "DNA", 649, 652], ["YC", "DNA", 654, 656], ["R1a", "DNA", 657, 660], ["YC", "DNA", 662, 664], ["R1b", "DNA", 665, 668], ["YC", "DNA", 670, 672], ["F2a", "DNA", 673, 676], ["YC", "DNA", 678, 680], ["F2b", "DNA", 681, 684], ["YC", "DNA", 686, 688], ["R2a", "DNA", 689, 692], ["YC", "DNA", 697, 699], ["Penaeus monodon", "SPECIES", 0, 15], ["yellow head virus", "SPECIES", 38, 55], ["Spiroplasma eriocheiris", "SPECIES", 553, 576], ["yellow head virus", "SPECIES", 38, 55], ["YHV", "SPECIES", 57, 60], ["XSV", "SPECIES", 265, 268], ["WSSV", "SPECIES", 422, 426], ["Spiroplasma eriocheiris", "SPECIES", 553, 576], ["YHV", "SPECIES", 628, 631], ["Penaeus monodon tissues", "PROBLEM", 0, 23], ["yellow head virus", "PROBLEM", 38, 55], ["Specific PCR ScreensPCR screens", "TEST", 96, 127], ["specific pathogens", "PROBLEM", 132, 150], ["PmNV", "TEST", 490, 494], ["Spiroplasma eriocheiris", "PROBLEM", 553, 576], ["YC", "TEST", 646, 648], ["YC", "TEST", 654, 656], ["YC", "TEST", 662, 664], ["YC", "TEST", 670, 672], ["YC", "TEST", 678, 680], ["F2b", "TEST", 681, 684], ["YC", "TEST", 686, 688], ["R2a", "TEST", 689, 692], ["YC", "TEST", 697, 699], ["R2b primers", "TEST", 700, 711], ["monodon tissues", "OBSERVATION", 8, 23], ["infected", "OBSERVATION_MODIFIER", 24, 32], ["YC", "ANATOMY", 654, 656], ["YC", "ANATOMY", 662, 664]]], ["All PCR reactions were performed as above using cycling conditions specified in the original publications.In vivo tank experimentsAt the end of the 10-day disease challenge, mortalities exceeding 80% had occurred in all three experimental groups, including larvae exposed to an extract produced from a hatchery that at the time had not experienced mortalities (Fig. 2) .", [["extract", "ANATOMY", 278, 285], ["All PCR reactions", "TEST", 0, 17], ["cycling conditions", "TREATMENT", 48, 66], ["the 10-day disease challenge", "TREATMENT", 144, 172], ["mortalities", "TEST", 174, 185], ["tank experiments", "OBSERVATION", 114, 130]]], ["However, it was later discovered that the healthy hatchery experienced mass mortalities to a similar level of other hatcheries in the south of Bangladesh shortly after they were sampled for the experimental material.", [["mass mortalities", "PROBLEM", 71, 87], ["mass", "OBSERVATION", 71, 75]]], ["Larvae in the control treatment group showed a slightly lower mortality rate, with survivors up until day 15 of the challenge (data not shown).", [["Larvae", "TREATMENT", 0, 6], ["a slightly lower mortality rate", "PROBLEM", 45, 76], ["slightly", "OBSERVATION_MODIFIER", 47, 55]]], ["As the challenge progressed, reduction in swimming ability, feeding, and growth were observed in all treatments.", [["reduction", "OBSERVATION_MODIFIER", 29, 38]]], ["Moribund larvae appeared white in colour compared to healthy larvae. had BLASTx similarity to YHV.", [["YHV", "DNA", 94, 97], ["Moribund larvae", "PROBLEM", 0, 15], ["white in colour", "PROBLEM", 25, 40], ["larvae", "OBSERVATION", 9, 15], ["white", "OBSERVATION_MODIFIER", 25, 30]]], ["IVA assembly using a pool of all three libraries produced a full genome consensus sequence of 29.11 kb, with an average coverage of 1116x.", [["IVA", "CHEMICAL", 0, 3], ["full genome consensus sequence", "DNA", 60, 90]]], ["The two contigs produced by IVA assembly of library three mapped to the 29.11 kb consensus sequence.", [["IVA", "CHEMICAL", 28, 31], ["29.11 kb consensus sequence", "DNA", 72, 99]]], ["The full genome sequence is deposited on in supplementary materials.", [["full genome sequence", "DNA", 4, 24]]], ["Henceforth, we refer to this novel virus as Macrobrachium rosenbergii Golda Virus (MrGV).", [["Macrobrachium rosenbergii Golda Virus", "ORGANISM", 44, 81], ["MrGV", "CANCER", 83, 87], ["Macrobrachium rosenbergii", "SPECIES", 44, 69], ["Golda Virus", "SPECIES", 70, 81], ["Macrobrachium rosenbergii", "SPECIES", 44, 69], ["MrGV", "SPECIES", 83, 87], ["this novel virus", "PROBLEM", 24, 40]]], ["Mapping trimmed and quality-filtered reads from each individual library back to the consensus genome gave coverage of 5.37x for library one (pooled challenged larvae from days 1-4), 269.28x for library two (pooled challenged larvae from days 5-10) and 1462.64x coverage for library three (pooled larvae from a hatchery experiencing mortalities).", [["consensus genome", "DNA", 84, 100]]], ["To compare the efficiency of the rnaSPAdes assembly, assembled contigs from individual and pooled libraries were mapped back to the consensus genome.", [["rnaSPAdes", "DNA", 33, 42], ["consensus genome", "DNA", 132, 148], ["pooled libraries", "PROBLEM", 91, 107]]], ["Eleven contigs from library one mapped to MrGV with 0.25x coverage, thirty-two contigs from library two mapped with 2.53x coverage, fifty contigs from library three mapped with 5.04x coverage and 81 contigs from the pooled libraries mapped with 7.25x coverage. rnaSPAdes contigs from libraries two and three gave good coverage over the whole genome but failed to assemble the 5' and 3' ends.", [["3' ends", "CELLULAR_COMPONENT", 383, 390], ["MrGV", "DNA", 42, 46], ["rnaSPAdes contigs", "DNA", 261, 278], ["5' and 3' ends", "DNA", 376, 390], ["MrGV", "TEST", 42, 46], ["2.53x coverage", "TREATMENT", 116, 130], ["5.04x coverage", "TREATMENT", 177, 191], ["the pooled libraries", "TREATMENT", 212, 232], ["rnaSPAdes contigs from libraries", "PROBLEM", 261, 293]]], ["A comprehensive table of assembly statistics is in Table S1 .Open reading frame (ORF) prediction, genome prediction and motif identificationFgenesV0 predicted five protein-coding open reading frames (ORFs) in the positive sense direction, four of which were supported by GeneMarkS, Prokka and Vgas (Fig. 3) , which were investigated in more detail.", [["Open reading frame", "DNA", 61, 79], ["ORF", "DNA", 81, 84], ["FgenesV0", "DNA", 140, 148], ["protein-coding open reading frames", "DNA", 164, 198], ["ORFs", "DNA", 200, 204], ["genome prediction", "TEST", 98, 115], ["motif identification", "TEST", 120, 140], ["FgenesV0", "TEST", 140, 148], ["S1", "ANATOMY", 57, 59]]], ["The two longest ORFs, ORF1a and ORF1b, showed homology to the replicase polyproteins of yellow head virus (Evalues of 1x10 -29 and 0), whereas ORF3 showed homology to glycoproteins associated with species in the Negarnaviricota phylumIdentification of frameshift motifsAs Nidovirales typically translate ORF1a and ORF1b consecutively to produce pp1ab by -1 ribosomal frame shift (King et al., 2012) , FSFinder2 (Byun, Moon and Han, 2007 ) was used to identify -1 frameshift sites in the overlap between ORF1a and ORF1b.", [["ORF1a", "GENE_OR_GENE_PRODUCT", 22, 27], ["ORF1b", "GENE_OR_GENE_PRODUCT", 32, 37], ["yellow head virus", "ORGANISM", 88, 105], ["1x10 -29", "GENE_OR_GENE_PRODUCT", 118, 126], ["ORF3", "GENE_OR_GENE_PRODUCT", 143, 147], ["Negarnaviricota phylumIdentification", "ORGANISM", 212, 248], ["ORF1a", "GENE_OR_GENE_PRODUCT", 304, 309], ["ORF1b", "GENE_OR_GENE_PRODUCT", 314, 319], ["pp1ab", "GENE_OR_GENE_PRODUCT", 345, 350], ["ORF1a", "GENE_OR_GENE_PRODUCT", 503, 508], ["ORF1b", "GENE_OR_GENE_PRODUCT", 513, 518], ["ORFs", "DNA", 16, 20], ["ORF1a", "DNA", 22, 27], ["ORF1b", "DNA", 32, 37], ["replicase polyproteins", "PROTEIN", 62, 84], ["ORF3", "DNA", 143, 147], ["ORF1a", "PROTEIN", 304, 309], ["ORF1b", "PROTEIN", 314, 319], ["pp1ab", "PROTEIN", 345, 350], ["1 frameshift sites", "DNA", 461, 479], ["ORF1a", "DNA", 503, 508], ["ORF1b", "DNA", 513, 518], ["yellow head virus", "SPECIES", 88, 105], ["The two longest ORFs", "PROBLEM", 0, 20], ["ORF1a", "TEST", 22, 27], ["ORF1b", "TEST", 32, 37], ["yellow head virus", "PROBLEM", 88, 105], ["Evalues", "TEST", 107, 114], ["ORF3", "TEST", 143, 147], ["homology to glycoproteins", "PROBLEM", 155, 180], ["species", "PROBLEM", 197, 204], ["1 frameshift sites", "PROBLEM", 461, 479]]], ["Both major elements of -1 frameshifting were identified in the overlap: A slippery site at position 15090 nt with the sequence \"GGGTTTT\", proceeded by a stem-loop stimulatory structure located a few nucleotides downstream between positions 15107 and 15165 nt.Prediction of 3' UTR secondary structureAnalysis of the 3' UTR secondary structure following the final stop codon of the final 3' ORF revealed a thermodynamically stable RNA hairpin secondary structure (Fig. 4) .", [["nucleotides", "CHEMICAL", 199, 210], ["slippery site", "DNA", 74, 87], ["15090 nt", "DNA", 100, 108], ["GGGTTTT", "DNA", 128, 135], ["positions 15107 and 15165 nt", "DNA", 230, 258], ["3' ORF", "DNA", 386, 392], ["1 frameshifting", "PROBLEM", 24, 39], ["A slippery site", "TREATMENT", 72, 87], ["a stem-loop stimulatory structure", "TREATMENT", 151, 184], ["Analysis", "TEST", 299, 307], ["the 3' UTR secondary structure", "PROBLEM", 311, 341], ["the final 3' ORF", "TEST", 376, 392], ["a thermodynamically stable RNA hairpin secondary structure", "PROBLEM", 402, 460], ["major", "OBSERVATION_MODIFIER", 5, 10], ["1 frameshifting", "OBSERVATION", 24, 39], ["slippery", "OBSERVATION", 74, 82], ["few", "OBSERVATION_MODIFIER", 195, 198], ["thermodynamically", "OBSERVATION_MODIFIER", 404, 421], ["stable", "OBSERVATION_MODIFIER", 422, 428], ["RNA hairpin", "OBSERVATION", 429, 440]]], ["The predicted hairpin structure of MrGV is stabilised by three helices with a 12 nt hairpin loop (\u0394G=-40.5), in comparison to the GAV 3'-UTR structure, which forms a 8 nt hairpin loop stabilised by four helices (\u0394G=-32.40), previously identified in Wijegoonawardane et al. (2008) .Phylogenetic characterisation of MrGVA Bayesian consensus tree was produced based on the RdRp protein domain universally conserved in nidoviruses, including the RdRp sequence generated in this study for MrGV, and the only nidovirus protein domain able to align to the RdRp of Astrovirales (outgroup).", [["MrGV", "GENE_OR_GENE_PRODUCT", 35, 39], ["nidoviruses", "CANCER", 415, 426], ["MrGV", "GENE_OR_GENE_PRODUCT", 484, 488], ["Astrovirales", "GENE_OR_GENE_PRODUCT", 557, 569], ["MrGV", "PROTEIN", 35, 39], ["12 nt hairpin loop", "DNA", 78, 96], ["GAV 3'-UTR structure", "DNA", 130, 150], ["MrGVA Bayesian consensus tree", "DNA", 314, 343], ["RdRp protein domain", "PROTEIN", 370, 389], ["RdRp sequence", "DNA", 442, 455], ["MrGV", "PROTEIN", 484, 488], ["nidovirus protein domain", "PROTEIN", 503, 527], ["RdRp", "PROTEIN", 549, 553], ["Astrovirales", "PROTEIN", 557, 569], ["The predicted hairpin structure of MrGV", "PROBLEM", 0, 39], ["a 12 nt hairpin loop", "TREATMENT", 76, 96], ["\u0394G", "TEST", 98, 100], ["a 8 nt hairpin loop", "TREATMENT", 164, 183], ["\u0394G", "TEST", 212, 214], ["Phylogenetic characterisation of MrGVA Bayesian consensus tree", "PROBLEM", 281, 343], ["the RdRp protein domain", "TEST", 366, 389], ["the RdRp sequence", "TEST", 438, 455], ["this study", "TEST", 469, 479], ["MrGV", "TEST", 484, 488], ["nidovirus protein domain", "PROBLEM", 503, 527], ["hairpin structure", "OBSERVATION", 14, 31], ["hairpin loop", "OBSERVATION", 171, 183]]], ["All families within Nidovirales were monophyletic in our analyses.", [["Nidovirales", "CANCER", 20, 31]]], ["MrGV branched as sister to GAV and YHV within the Roniviridae clade (Fig. 5) .", [["MrGV", "GENE_OR_GENE_PRODUCT", 0, 4], ["GAV", "GENE_OR_GENE_PRODUCT", 27, 30], ["YHV", "GENE_OR_GENE_PRODUCT", 35, 38], ["MrGV", "PROTEIN", 0, 4], ["GAV", "DNA", 27, 30], ["YHV", "DNA", 35, 38], ["the Roniviridae clade", "TREATMENT", 46, 67]]], ["Other invertebrate-infecting Nidovirales shown in Fig. 5 include include Charynivirus-1 infecting the crab Charybdis, and Paguronivirus-1 infecting hermit crabs (Shi et al., 2016) , all branching within the Euronivirdivae clade.", [["Nidovirales", "ORGANISM", 29, 40], ["Charynivirus-1", "ORGANISM", 73, 87], ["crab Charybdis", "ORGANISM", 102, 116], ["Paguronivirus-1", "ORGANISM", 122, 137], ["hermit crabs", "ORGANISM", 148, 160], ["Charynivirus-1", "SPECIES", 73, 87], ["crab", "SPECIES", 102, 106], ["Paguronivirus-1", "SPECIES", 122, 137], ["Charynivirus-1", "SPECIES", 73, 87], ["Paguronivirus-1", "SPECIES", 122, 137], ["Charynivirus", "TEST", 73, 85], ["the crab Charybdis", "TEST", 98, 116], ["Paguronivirus", "TEST", 122, 135], ["infecting Nidovirales", "OBSERVATION", 19, 40]]], ["All invertebrate-infecting nidoviruses branched together with maximal Bayesian Posterior Probability.MSA of 3' ORFsAs MrGV branches within Roniviridae, which have a distinct 3' genome organisation to other nidoviruses (Cowley et al., 2004) , MrGV ORF2 and ORF3 were aligned against the corresponding ORFs of GAV.", [["nidoviruses", "ANATOMY", 27, 38], ["nidoviruses", "ORGANISM", 27, 38], ["Roniviridae", "GENE_OR_GENE_PRODUCT", 139, 150], ["MrGV ORF2", "GENE_OR_GENE_PRODUCT", 242, 251], ["ORF3", "GENE_OR_GENE_PRODUCT", 256, 260], ["GAV", "GENE_OR_GENE_PRODUCT", 308, 311], ["MrGV ORF2", "DNA", 242, 251], ["ORF3", "DNA", 256, 260], ["ORFs", "DNA", 300, 304], ["GAV", "DNA", 308, 311], ["MSA", "TEST", 101, 104], ["Roniviridae", "TREATMENT", 139, 150], ["Posterior", "ANATOMY_MODIFIER", 79, 88], ["branches", "ANATOMY_MODIFIER", 123, 131], ["distinct", "OBSERVATION_MODIFIER", 165, 173]]], ["This alignment (Fig. 6) showed similarities in protein sequences of the three 3' transmembrane helices of ORF3 of GAV to the predicted transmembrane helices of MrGV.", [["transmembrane", "ANATOMY", 135, 148], ["ORF3", "GENE_OR_GENE_PRODUCT", 106, 110], ["GAV", "GENE_OR_GENE_PRODUCT", 114, 117], ["MrGV", "GENE_OR_GENE_PRODUCT", 160, 164], ["3' transmembrane helices", "PROTEIN", 78, 102], ["ORF3", "PROTEIN", 106, 110], ["GAV", "PROTEIN", 114, 117], ["transmembrane helices", "PROTEIN", 135, 156], ["MrGV", "PROTEIN", 160, 164], ["This alignment (Fig.", "TEST", 0, 20], ["similarities in protein sequences", "PROBLEM", 31, 64], ["ORF3 of GAV", "TREATMENT", 106, 117]]], ["Sequence similarities were also seen in ORF2 of GAV to ORF2 of MrGV (18.24% residue similarity), as well as gp116 (15.40% residue similarity) and gp64 (17.03 % residue similarity) protein coding regions of ORF3 in comparison to the aligned regions in MrGV ORF3.Infection prevalence in hatchery-reared larvae and wild river-based adult populationsThe virus was not detected by specific PCR in any adult tissues from wild river populations across the two-year sampling period (119 animals) and S. eriocheiris was the only pathogen detected in adult M. rosenbergii (10/119).", [["adult tissues", "ANATOMY", 396, 409], ["GAV", "GENE_OR_GENE_PRODUCT", 48, 51], ["ORF2", "GENE_OR_GENE_PRODUCT", 55, 59], ["MrGV", "GENE_OR_GENE_PRODUCT", 63, 67], ["gp116", "GENE_OR_GENE_PRODUCT", 108, 113], ["ORF3", "GENE_OR_GENE_PRODUCT", 206, 210], ["MrGV ORF3", "GENE_OR_GENE_PRODUCT", 251, 260], ["adult tissues", "TISSUE", 396, 409], ["S. eriocheiris", "ORGANISM", 492, 506], ["M. rosenbergii", "ORGANISM", 547, 561], ["ORF2", "DNA", 40, 44], ["GAV", "DNA", 48, 51], ["ORF2", "DNA", 55, 59], ["MrGV", "DNA", 63, 67], ["gp116", "DNA", 108, 113], ["protein coding regions", "DNA", 180, 202], ["ORF3", "DNA", 206, 210], ["aligned regions", "DNA", 232, 247], ["MrGV ORF3", "DNA", 251, 260], ["S. eriocheiris", "SPECIES", 492, 506], ["M. rosenbergii", "SPECIES", 547, 561], ["S. eriocheiris", "SPECIES", 492, 506], ["M. rosenbergii", "SPECIES", 547, 561], ["MrGV", "TEST", 63, 67], ["gp64", "TEST", 146, 150], ["protein coding regions of ORF3", "PROBLEM", 180, 210], ["Infection prevalence", "PROBLEM", 261, 281], ["The virus", "PROBLEM", 346, 355], ["specific PCR", "TEST", 376, 388], ["S. eriocheiris", "PROBLEM", 492, 506], ["MrGV ORF3", "OBSERVATION", 251, 260], ["virus", "OBSERVATION", 350, 355]]], ["However, MrGV was detected in larvae from all three hatcheries sampled in 2018 production cycles and all five hatcheries sampled in 2019 production cycles with no other pathogens detected by PCR in hatchery larvae.", [["MrGV", "GENE_OR_GENE_PRODUCT", 9, 13], ["MrGV", "PROTEIN", 9, 13], ["MrGV", "TEST", 9, 13], ["other pathogens", "PROBLEM", 163, 178]]], ["No histopathological signs of infection were seen in the larvae (data not shown).Infection prevalence in hatchery-reared larvae and wild river-based adult populationsWe report and analyse the complete genome of a novel single-stranded positive-sense RNA virus infecting cultured M. rosenbergii from hatcheries in southern Bangladesh.", [["infection", "DISEASE", 30, 39], ["M. rosenbergii", "ORGANISM", 279, 293], ["M. rosenbergii", "SPECIES", 279, 293], ["M. rosenbergii", "SPECIES", 279, 293], ["histopathological signs of infection", "PROBLEM", 3, 39], ["Infection prevalence", "PROBLEM", 81, 101], ["a novel single-stranded positive-sense RNA virus", "PROBLEM", 211, 259], ["histopathological", "OBSERVATION_MODIFIER", 3, 20], ["signs", "OBSERVATION_MODIFIER", 21, 26], ["infection", "OBSERVATION", 30, 39]]], ["The novel virus, Macrobrachium rosenbergii Golda virus (MrGV), has a similar genome arrangement to viruses of the order Nidovirales, and appears to be most closely phylogenetically related to yellow head virus (YHV) and gill-associated virus (GAV), both infecting penaeid shrimp.Infection prevalence in hatchery-reared larvae and wild river-based adult populationsMrGV was detected by specific PCR in larvae from three hatcheries in 2018, two of which were experiencing mass mortality events when sampled, and one which was sampled just prior to a mass mortality event.", [["Macrobrachium rosenbergii Golda virus", "ORGANISM", 17, 54], ["MrGV", "GENE_OR_GENE_PRODUCT", 56, 60], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 120, 131], ["yellow head virus", "ORGANISM", 192, 209], ["YHV", "ORGANISM", 211, 214], ["gill-associated virus", "ORGANISM", 220, 241], ["GAV", "ORGANISM", 243, 246], ["penaeid shrimp", "ORGANISM", 264, 278], ["MrGV", "GENE_OR_GENE_PRODUCT", 364, 368], ["MrGV", "PROTEIN", 364, 368], ["Macrobrachium rosenbergii", "SPECIES", 17, 42], ["Golda virus", "SPECIES", 43, 54], ["yellow head virus", "SPECIES", 192, 209], ["gill-associated virus", "SPECIES", 220, 241], ["shrimp", "SPECIES", 272, 278], ["Macrobrachium rosenbergii Golda virus", "SPECIES", 17, 54], ["MrGV", "SPECIES", 56, 60], ["yellow head virus", "SPECIES", 192, 209], ["YHV", "SPECIES", 211, 214], ["GAV", "SPECIES", 243, 246], ["The novel virus", "PROBLEM", 0, 15], ["yellow head virus", "PROBLEM", 192, 209], ["gill-associated virus", "PROBLEM", 220, 241], ["Infection prevalence", "PROBLEM", 279, 299], ["MrGV", "TEST", 364, 368], ["mass mortality events", "PROBLEM", 470, 491], ["a mass mortality event", "PROBLEM", 546, 568], ["virus", "OBSERVATION", 10, 15], ["gill", "ANATOMY", 220, 224], ["virus", "OBSERVATION", 236, 241], ["infecting", "OBSERVATION_MODIFIER", 254, 263], ["penaeid shrimp", "OBSERVATION", 264, 278], ["mass", "OBSERVATION", 470, 474], ["mass", "OBSERVATION", 548, 552]]], ["In 2019 three of the hatcheries that had experienced mass mortalities the previous year were re-sampled during mass mortality events and were again positive for MrGV; two of these hatcheries underwent two production cycles, both suffering mass mortality events and were both PCR positive for MrGV.", [["MrGV", "GENE_OR_GENE_PRODUCT", 292, 296], ["MrGV", "PROTEIN", 292, 296], ["mass mortalities", "PROBLEM", 53, 69], ["mass mortality events", "PROBLEM", 111, 132], ["MrGV", "PROBLEM", 161, 165], ["two production cycles", "TREATMENT", 201, 222], ["mass mortality events", "PROBLEM", 239, 260], ["PCR", "TEST", 275, 278], ["MrGV", "TEST", 292, 296]]], ["In addition to the three hatcheries that were re-sampled in 2019, a further two hatcheries, none of which had been sampled in 2018, were sampled in 2019 during mass mortality events.", [["mass mortality events", "PROBLEM", 160, 181]]], ["These further two hatcheries were also PCR positive for MrGV.", [["MrGV", "GENE_OR_GENE_PRODUCT", 56, 60], ["MrGV", "PROTEIN", 56, 60], ["PCR", "TEST", 39, 42], ["MrGV", "TEST", 56, 60]]], ["Given the number of hatcheries affected by mass mortalities linked to MrGV, its temporal prevalence and spatial spread, with one of the hatcheries over 40 km in distance to the nearest hatchery that was PCR positive for MrGV, we suggest that this novel virus represents a very significant threat to M. rosenbergii aquaculture within Bangladesh, and may be a significant factor in the collapse of larval production in the industry of Bangladesh since 2010.Infection prevalence in hatchery-reared larvae and wild river-based adult populationsAll PCR screens of larvae collected from hatcheries experiencing mass mortalities for pathogens known to infect the larval stage of M. rosenbergii were negative: MrNV and XSV, the causative agents of white tail disease (Arcier et al., 1999; Qian et al., 2003) ; MrTV, a virus associated with mass larval mortalities in China (Pan et al., 2016) , Spiroplasma eriocheiris (Srisala et al., 2018) , and WSSV -shown to be able to infect M. rosenbergii experimentally (Sahul Hameed, Charles and Anilkumar, 2000) .", [["tail", "ANATOMY", 746, 750], ["white tail disease", "DISEASE", 740, 758], ["mass larval mortalities", "DISEASE", 832, 855], ["Spiroplasma eriocheiris", "DISEASE", 886, 909], ["MrGV", "GENE_OR_GENE_PRODUCT", 220, 224], ["M. rosenbergii", "ORGANISM", 299, 313], ["larvae", "ORGANISM", 559, 565], ["M. rosenbergii", "ORGANISM", 672, 686], ["MrNV", "GENE_OR_GENE_PRODUCT", 702, 706], ["XSV", "GENE_OR_GENE_PRODUCT", 711, 714], ["tail", "ORGANISM_SUBDIVISION", 746, 750], ["MrTV", "GENE_OR_GENE_PRODUCT", 802, 806], ["Spiroplasma eriocheiris", "ORGANISM", 886, 909], ["WSSV", "ORGANISM", 939, 943], ["M. rosenbergii", "ORGANISM", 972, 986], ["MrGV", "PROTEIN", 70, 74], ["M. rosenbergii", "SPECIES", 299, 313], ["M. rosenbergii", "SPECIES", 672, 686], ["Spiroplasma eriocheiris", "SPECIES", 886, 909], ["M. rosenbergii", "SPECIES", 972, 986], ["M. rosenbergii", "SPECIES", 299, 313], ["M. rosenbergii", "SPECIES", 672, 686], ["MrNV", "SPECIES", 702, 706], ["XSV", "SPECIES", 711, 714], ["Spiroplasma eriocheiris", "SPECIES", 886, 909], ["M. rosenbergii", "SPECIES", 972, 986], ["mass mortalities", "PROBLEM", 43, 59], ["spatial spread", "PROBLEM", 104, 118], ["PCR", "TEST", 203, 206], ["this novel virus", "PROBLEM", 242, 258], ["Infection prevalence", "PROBLEM", 455, 475], ["All PCR screens", "TEST", 540, 555], ["larvae", "PROBLEM", 559, 565], ["mass mortalities", "PROBLEM", 605, 621], ["pathogens", "PROBLEM", 626, 635], ["white tail disease", "PROBLEM", 740, 758], ["MrTV", "PROBLEM", 802, 806], ["a virus", "PROBLEM", 808, 815], ["mass larval mortalities", "PROBLEM", 832, 855], ["Spiroplasma eriocheiris", "PROBLEM", 886, 909], ["WSSV", "PROBLEM", 939, 943], ["mass", "OBSERVATION", 43, 47], ["temporal", "OBSERVATION_MODIFIER", 80, 88], ["spatial", "OBSERVATION_MODIFIER", 104, 111], ["spread", "OBSERVATION_MODIFIER", 112, 118], ["significant", "OBSERVATION_MODIFIER", 358, 369], ["collapse", "OBSERVATION", 384, 392], ["larval production", "OBSERVATION", 396, 413], ["mass", "OBSERVATION", 605, 609], ["Spiroplasma eriocheiris", "ANATOMY", 886, 909]]], ["Larvae were also screened for YHV and PmNV, viruses known to infect all life stages of marine shrimp species (Lightner and Redman, 1981; Boonyaratpalin et al., 1993) ; these screens were all negative.", [["Larvae", "ORGANISM", 0, 6], ["YHV", "GENE_OR_GENE_PRODUCT", 30, 33], ["PmNV", "GENE_OR_GENE_PRODUCT", 38, 42], ["YHV", "SPECIES", 30, 33], ["PmNV", "SPECIES", 38, 42], ["YHV", "PROBLEM", 30, 33], ["PmNV", "PROBLEM", 38, 42], ["viruses", "PROBLEM", 44, 51], ["marine shrimp species", "PROBLEM", 87, 108], ["these screens", "TEST", 168, 181], ["marine shrimp species", "OBSERVATION", 87, 108]]], ["Further to this, no sequences were assignable to any other known pathogens of M. rosenbergii in our metatranscriptomic data.", [["M. rosenbergii", "ORGANISM", 78, 92], ["M. rosenbergii", "SPECIES", 78, 92], ["M. rosenbergii", "SPECIES", 78, 92]]], ["Absence of these pathogens and no obvious bacterial cause observed by Alam et al. (2019) strongly suggests that the survival problems in Bangladesh hatcheries are not due to a currently known pathogen and that mass mortalities were linked either to hatchery practice factors or/and the emergence of a novel pathogenic agent.", [["these pathogens", "PROBLEM", 11, 26], ["obvious bacterial cause", "PROBLEM", 34, 57], ["the survival problems", "PROBLEM", 112, 133], ["a currently known pathogen", "PROBLEM", 174, 200], ["mass mortalities", "PROBLEM", 210, 226], ["a novel pathogenic agent", "TREATMENT", 299, 323], ["pathogens", "OBSERVATION", 17, 26], ["no obvious", "UNCERTAINTY", 31, 41]]], ["Despite numerous problems identified in hatchery practices (SAFETI, Winrock and Worldfish, personal communication), hatcheries were successfully producing until 2011, and since then, hatchery practices have not changed, suggesting that this is not the main source of mortality events.", [["mortality events", "PROBLEM", 267, 283]]], ["PCR screens of adult M. rosenbergii from rivers used to collect berried females as the supply of broodstock for the hatcheries were also all negative for MrGV, suggesting that broodstock may not be the entry route of MrGV into the hatcheries.", [["MrGV", "CHEMICAL", 217, 221], ["M. rosenbergii", "ORGANISM", 21, 35], ["MrGV", "GENE_OR_GENE_PRODUCT", 154, 158], ["MrGV", "GENE_OR_GENE_PRODUCT", 217, 221], ["MrGV", "PROTEIN", 217, 221], ["M. rosenbergii", "SPECIES", 21, 35], ["M. rosenbergii", "SPECIES", 21, 35], ["PCR screens", "TEST", 0, 11]]], ["Adults were also negative for all other pathogens as above, except for S. eriocheiris.", [["Adults", "ORGANISM", 0, 6], ["S. eriocheiris", "ORGANISM", 71, 85], ["Adults", "SPECIES", 0, 6], ["S. eriocheiris", "SPECIES", 71, 85], ["S. eriocheiris", "SPECIES", 71, 85], ["all other pathogens", "PROBLEM", 30, 49], ["S. eriocheiris", "PROBLEM", 71, 85], ["negative for", "UNCERTAINTY", 17, 29], ["pathogens", "OBSERVATION", 40, 49], ["eriocheiris", "OBSERVATION", 74, 85]]], ["All larvae sampled from hatcheries experiencing mortalities were negative for S. eriocheiris and no reads for any Spiroplasma species were detected in metatranscriptomic analysis of the moribund larvae, suggesting that S. eriocheiris is also not causing the mortalities in hatcheries.Infection prevalence in hatchery-reared larvae and wild river-based adult populationsNidoviruses (order Nidovirales) are enveloped positive-sense RNA viruses infecting a range of hosts including both vertebrates and invertebrates (King et al., 2012) .", [["S. eriocheiris", "ORGANISM", 78, 92], ["S. eriocheiris", "ORGANISM", 219, 233], ["Nidoviruses", "GENE_OR_GENE_PRODUCT", 369, 380], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 388, 399], ["S. eriocheiris", "SPECIES", 78, 92], ["S. eriocheiris", "SPECIES", 219, 233], ["S. eriocheiris", "SPECIES", 78, 92], ["S. eriocheiris", "SPECIES", 219, 233], ["All larvae", "PROBLEM", 0, 10], ["mortalities", "PROBLEM", 48, 59], ["S. eriocheiris", "PROBLEM", 78, 92], ["any Spiroplasma species", "PROBLEM", 110, 133], ["S. eriocheiris", "PROBLEM", 219, 233], ["Infection prevalence", "PROBLEM", 284, 304], ["Nidoviruses (order Nidovirales)", "TREATMENT", 369, 400], ["sense RNA viruses", "PROBLEM", 424, 441], ["moribund larvae", "OBSERVATION", 186, 201], ["eriocheiris", "OBSERVATION", 222, 233], ["mortalities", "OBSERVATION", 258, 269], ["sense RNA viruses", "OBSERVATION", 424, 441]]], ["The invertebrate nidoviruses are composed of families: Mesoniviridae, Roniviridae, Mononiviridae and Euroniviridae, with the latter two families discovered within the last four years (King et al., 2012; Shi et al., 2016; Saberi et al., 2018) .", [["nidoviruses", "GENE_OR_GENE_PRODUCT", 17, 28], ["Mesoniviridae", "GENE_OR_GENE_PRODUCT", 55, 68], ["Roniviridae", "GENE_OR_GENE_PRODUCT", 70, 81], ["Mononiviridae", "GENE_OR_GENE_PRODUCT", 83, 96], ["Euroniviridae", "GENE_OR_GENE_PRODUCT", 101, 114], ["Mesoniviridae", "TREATMENT", 55, 68], ["Roniviridae", "TREATMENT", 70, 81], ["Mononiviridae", "TREATMENT", 83, 96], ["Euroniviridae", "TREATMENT", 101, 114], ["invertebrate nidoviruses", "OBSERVATION", 4, 28]]], ["Roniviridae comprises one genus, Okavirus, composed of two closely related crustacean-infecting viruses: Gill-associated virus (GAV) and yellow head virus (YHV) (King et al., 2012) .", [["Roniviridae", "CHEMICAL", 0, 11], ["Gill-associated virus", "ORGANISM", 105, 126], ["GAV", "ORGANISM", 128, 131], ["yellow head virus", "ORGANISM", 137, 154], ["Gill-associated virus", "SPECIES", 105, 126], ["yellow head virus", "SPECIES", 137, 154], ["GAV", "SPECIES", 128, 131], ["yellow head virus", "SPECIES", 137, 154], ["YHV", "SPECIES", 156, 159], ["Roniviridae", "TREATMENT", 0, 11], ["infecting viruses", "PROBLEM", 86, 103], ["Gill-associated virus (GAV)", "PROBLEM", 105, 132], ["yellow head virus", "PROBLEM", 137, 154], ["infecting viruses", "OBSERVATION", 86, 103], ["Gill", "ANATOMY", 105, 109]]], ["Both GAV and YHV are associated with disease in marine shrimp farming, with the former initially associated with mid-crop mortality syndrome (MCMS) in Penaeus monodon in Australia (Spann, Vickers and Lester, 1995) and the latter first associated with yellow head disease (YHD) in P, monodon in Thailand (Limsuwan, 1991) .Infection prevalence in hatchery-reared larvae and wild river-based adult populationsPrior to this study, no nidoviruses had been discovered in Macrobrachium rosenbergii.Infection prevalence in hatchery-reared larvae and wild river-based adult populationsWhen amino acid sequences of MrGV were screened against the NCBI non-redundant protein database, there was weak similarity to YHV and even weaker similarity to other nidoviruses.Infection prevalence in hatchery-reared larvae and wild river-based adult populationsHowever, the only significant matches in pp1a and pp1ab were to this order, therefore we searched for protein motifs shared among other nidoviruses.", [["head", "ANATOMY", 258, 262], ["mid-crop mortality syndrome (MCMS) in Penaeus monodon", "DISEASE", 113, 166], ["yellow head disease", "DISEASE", 251, 270], ["YHD", "DISEASE", 272, 275], ["amino acid", "CHEMICAL", 581, 591], ["amino acid", "CHEMICAL", 581, 591], ["GAV", "GENE_OR_GENE_PRODUCT", 5, 8], ["YHV", "GENE_OR_GENE_PRODUCT", 13, 16], ["Penaeus monodon", "ORGANISM", 151, 166], ["head", "ORGANISM_SUBDIVISION", 258, 262], ["nidoviruses", "CANCER", 430, 441], ["Macrobrachium rosenbergii", "ORGANISM", 465, 490], ["amino acid", "AMINO_ACID", 581, 591], ["MrGV", "GENE_OR_GENE_PRODUCT", 605, 609], ["nidoviruses", "CANCER", 742, 753], ["pp1a", "GENE_OR_GENE_PRODUCT", 880, 884], ["pp1ab", "GENE_OR_GENE_PRODUCT", 889, 894], ["nidoviruses", "CANCER", 975, 986], ["GAV", "PROTEIN", 5, 8], ["YHV", "PROTEIN", 13, 16], ["MrGV", "PROTEIN", 605, 609], ["NCBI non-redundant protein database", "DNA", 636, 671], ["YHV", "DNA", 702, 705], ["pp1a", "PROTEIN", 880, 884], ["pp1ab", "PROTEIN", 889, 894], ["Penaeus monodon", "SPECIES", 151, 166], ["Macrobrachium rosenbergii", "SPECIES", 465, 490], ["YHV", "SPECIES", 13, 16], ["Macrobrachium rosenbergii", "SPECIES", 465, 490], ["disease", "PROBLEM", 37, 44], ["mid-crop mortality syndrome", "PROBLEM", 113, 140], ["yellow head disease", "PROBLEM", 251, 270], ["Infection prevalence", "PROBLEM", 321, 341], ["this study", "TEST", 415, 425], ["nidoviruses", "PROBLEM", 430, 441], ["Infection prevalence", "PROBLEM", 491, 511], ["amino acid sequences", "TEST", 581, 601], ["MrGV", "TEST", 605, 609], ["the NCBI non-redundant protein database", "TEST", 632, 671], ["weak similarity to YHV", "PROBLEM", 683, 705], ["Infection prevalence", "PROBLEM", 754, 774], ["protein motifs", "PROBLEM", 941, 955], ["marine", "OBSERVATION_MODIFIER", 48, 54], ["shrimp farming", "OBSERVATION", 55, 69], ["Penaeus monodon", "ANATOMY", 151, 166], ["head", "ANATOMY", 258, 262], ["disease", "OBSERVATION", 263, 270], ["significant", "OBSERVATION_MODIFIER", 857, 868], ["matches", "OBSERVATION", 869, 876]]], ["Through database searches we identified five protein motifs present in all known nidoviruses: A protease, an RNA-dependent RNA polymerase, a zinc-binding domain, a helicase and a methyltransferase-exoribonuclease complex.", [["zinc", "CHEMICAL", 141, 145], ["zinc", "CHEMICAL", 141, 145], ["nidoviruses", "CANCER", 81, 92], ["protease", "PROTEIN", 96, 104], ["RNA-dependent RNA polymerase", "PROTEIN", 109, 137], ["zinc-binding domain", "PROTEIN", 141, 160], ["helicase", "PROTEIN", 164, 172], ["methyltransferase", "PROTEIN", 179, 196], ["exoribonuclease complex", "PROTEIN", 197, 220], ["five protein motifs", "TREATMENT", 40, 59], ["A protease", "TREATMENT", 94, 104], ["an RNA-dependent RNA polymerase", "PROBLEM", 106, 137], ["a zinc-binding domain", "PROBLEM", 139, 160], ["a helicase", "TREATMENT", 162, 172], ["a methyltransferase-exoribonuclease complex", "TREATMENT", 177, 220]]], ["A further three domains were found by sequence alignment of MrGV to the protein motifs of nidovirus-specific RdRp-associated nucleotidyltransferase (NiRAN) and Sadenosylmethionine (SAM)-dependent N7-and 2'-O-methyltransferases (N-MT and O-MT, respectively).", [["Sadenosylmethionine", "CHEMICAL", 160, 179], ["Sadenosylmethionine", "CHEMICAL", 160, 179], ["N7", "CHEMICAL", 196, 198], ["MrGV", "GENE_OR_GENE_PRODUCT", 60, 64], ["nidovirus", "GENE_OR_GENE_PRODUCT", 90, 99], ["RdRp-associated nucleotidyltransferase", "GENE_OR_GENE_PRODUCT", 109, 147], ["NiRAN", "GENE_OR_GENE_PRODUCT", 149, 154], ["Sadenosylmethionine", "SIMPLE_CHEMICAL", 160, 179], ["SAM", "SIMPLE_CHEMICAL", 181, 184], ["2'-O-methyltransferases", "SIMPLE_CHEMICAL", 203, 226], ["N-MT", "SIMPLE_CHEMICAL", 228, 232], ["O-MT", "GENE_OR_GENE_PRODUCT", 237, 241], ["MrGV", "PROTEIN", 60, 64], ["protein motifs", "PROTEIN", 72, 86], ["nidovirus-specific RdRp-associated nucleotidyltransferase", "PROTEIN", 90, 147], ["NiRAN", "PROTEIN", 149, 154], ["Sadenosylmethionine (SAM)-dependent N7-and 2'-O-methyltransferases", "PROTEIN", 160, 226], ["N", "PROTEIN", 228, 229], ["MT", "PROTEIN", 230, 232], ["O", "PROTEIN", 237, 238], ["MT", "PROTEIN", 239, 241], ["A further three domains", "PROBLEM", 0, 23], ["the protein motifs", "TEST", 68, 86], ["nidovirus", "TEST", 90, 99], ["Sadenosylmethionine (SAM)", "TREATMENT", 160, 185], ["dependent N7", "TREATMENT", 186, 198], ["methyltransferases", "TREATMENT", 208, 226]]], ["We also identified nucleotide sequences within the overlap of ORF1a and ORF1b suggestive of a -1 ribosomal frameshift.", [["ribosomal", "ANATOMY", 97, 106], ["nucleotide", "CHEMICAL", 19, 29], ["ORF1a", "GENE_OR_GENE_PRODUCT", 62, 67], ["ORF1b", "GENE_OR_GENE_PRODUCT", 72, 77], ["ORF1a", "DNA", 62, 67], ["ORF1b", "DNA", 72, 77], ["nucleotide sequences", "TEST", 19, 39], ["ORF1a", "TEST", 62, 67], ["a -1 ribosomal frameshift", "PROBLEM", 92, 117], ["ribosomal frameshift", "OBSERVATION", 97, 117]]], ["The slippery sequence \"GGGTTTT\" proceeded downstream by a putative stem-loop stimulatory RNA structure suggests that pp1a and pp1ab are translated continuously by programmed ribosomal frameshift, a characteristic of nidoviruses (Fields, Knipe and Howley, 2007) .", [["ribosomal", "ANATOMY", 174, 183], ["GGGTTTT", "GENE_OR_GENE_PRODUCT", 23, 30], ["pp1a", "GENE_OR_GENE_PRODUCT", 117, 121], ["pp1ab", "GENE_OR_GENE_PRODUCT", 126, 131], ["ribosomal", "CELLULAR_COMPONENT", 174, 183], ["slippery sequence", "DNA", 4, 21], ["GGGTTTT", "DNA", 23, 30], ["pp1a", "PROTEIN", 117, 121], ["pp1ab", "PROTEIN", 126, 131], ["The slippery sequence", "TREATMENT", 0, 21], ["a putative stem-loop stimulatory RNA structure", "TREATMENT", 56, 102], ["pp1a", "TEST", 117, 121], ["programmed ribosomal frameshift", "PROBLEM", 163, 194], ["ribosomal frameshift", "OBSERVATION", 174, 194]]], ["The genome of Okavirus, the genus to which GAV and YHV belong, have a unique genome architecture to that of vertebrate nidoviruses -ORF2, encoding a nucleocapsid protein, is located upstream of the glycoprotein gene (ORF3) (Cowley et al., 2004) .", [["Okavirus", "GENE_OR_GENE_PRODUCT", 14, 22], ["GAV", "GENE_OR_GENE_PRODUCT", 43, 46], ["YHV", "GENE_OR_GENE_PRODUCT", 51, 54], ["nidoviruses", "GENE_OR_GENE_PRODUCT", 119, 130], ["ORF2", "GENE_OR_GENE_PRODUCT", 132, 136], ["ORF3", "GENE_OR_GENE_PRODUCT", 217, 221], ["GAV", "DNA", 43, 46], ["YHV", "DNA", 51, 54], ["vertebrate nidoviruses", "DNA", 108, 130], ["ORF2", "DNA", 132, 136], ["nucleocapsid protein", "PROTEIN", 149, 169], ["glycoprotein gene", "DNA", 198, 215], ["ORF3", "DNA", 217, 221], ["a nucleocapsid protein", "PROBLEM", 147, 169]]], ["This structure is also seen in MrGV, as well as sequence similarity of ORF2 and ORF3 to the corresponding ORFs in GAV.Infection prevalence in hatchery-reared larvae and wild river-based adult populationsA characteristic of positive-sense RNA viruses is the presence of a secondary RNA structure at the 3'-UTR; this is present in other members of the nidoviruses including Coronavirdae and Arteriviradae (Buck, 1996) .", [["GAV", "ANATOMY", 114, 117], ["MrGV", "GENE_OR_GENE_PRODUCT", 31, 35], ["ORF2", "GENE_OR_GENE_PRODUCT", 71, 75], ["ORF3", "GENE_OR_GENE_PRODUCT", 80, 84], ["GAV", "CANCER", 114, 117], ["nidoviruses", "GENE_OR_GENE_PRODUCT", 350, 361], ["MrGV", "PROTEIN", 31, 35], ["ORF2", "DNA", 71, 75], ["ORF3", "DNA", 80, 84], ["ORFs", "DNA", 106, 110], ["GAV", "DNA", 114, 117], ["secondary RNA structure", "RNA", 271, 294], ["3'-UTR", "DNA", 302, 308], ["ORF2", "TEST", 71, 75], ["ORF3", "TREATMENT", 80, 84], ["Infection prevalence", "PROBLEM", 118, 138], ["positive-sense RNA viruses", "PROBLEM", 223, 249], ["a secondary RNA structure", "PROBLEM", 269, 294], ["sense RNA viruses", "OBSERVATION", 232, 249], ["secondary RNA structure", "OBSERVATION", 271, 294]]], ["These 3'-UTR structures and/or specific sequences have been shown to be critical to polymerase recognition and minus-strand genomic RNA synthesis (Dreher, 1999) .", [["3'-UTR structures", "DNA", 6, 23], ["These 3'-UTR structures", "TEST", 0, 23], ["polymerase recognition", "TEST", 84, 106], ["strand genomic RNA synthesis", "PROBLEM", 117, 145]]], ["A 3'-UTR secondary structure has been identified in GAV and YHV, and appears to be well conserved, with complementary base-changes implemented in YHV genotypes to retain a conserved stem-loop structure stabilised by four helices (Wijegoonawardane et al., 2008) .", [["GAV", "GENE_OR_GENE_PRODUCT", 52, 55], ["YHV", "GENE_OR_GENE_PRODUCT", 60, 63], ["GAV", "PROTEIN", 52, 55], ["YHV", "PROTEIN", 60, 63], ["A 3'-UTR secondary structure", "PROBLEM", 0, 28], ["appears to be", "UNCERTAINTY", 69, 82], ["base", "OBSERVATION_MODIFIER", 118, 122], ["stem", "OBSERVATION_MODIFIER", 182, 186], ["loop structure", "OBSERVATION", 187, 201]]], ["In this study we used MFOLD to predict the secondary RNA structure of MrGV in the 3'UTR of the genome following the final stop codon of the 3' ORFs.Infection prevalence in hatchery-reared larvae and wild river-based adult populationsMFOLD predicted a stem loop structure of a similar size to that of GAV and YHV, with three helices stabilising a 12 nt hairpin loop.", [["stem loop", "ANATOMY", 251, 260], ["MrGV", "GENE_OR_GENE_PRODUCT", 70, 74], ["3'UTR", "CELLULAR_COMPONENT", 82, 87], ["genome", "CELLULAR_COMPONENT", 95, 101], ["GAV", "GENE_OR_GENE_PRODUCT", 300, 303], ["MrGV", "PROTEIN", 70, 74], ["3'UTR", "DNA", 82, 87], ["3' ORFs", "DNA", 140, 147], ["GAV", "PROTEIN", 300, 303], ["YHV", "PROTEIN", 308, 311], ["this study", "TEST", 3, 13], ["MFOLD", "TREATMENT", 22, 27], ["Infection prevalence", "PROBLEM", 148, 168], ["a stem loop structure", "PROBLEM", 249, 270], ["a 12 nt hairpin loop", "TREATMENT", 344, 364], ["secondary RNA structure", "OBSERVATION", 43, 66], ["stem loop", "OBSERVATION", 251, 260], ["size", "OBSERVATION_MODIFIER", 284, 288], ["hairpin loop", "OBSERVATION", 352, 364]]], ["It is hypothesised that the 3'-UTR RNA structure in GAV and YHV may act as a polymerase recognition site for minus-strand RNA synthesis (Wijegoonawardane et al., 2008) , and given the similarities in the 3'-UTR RNA structure in MrGV to GAV and YHV, this structure in MrGV may have a similar function.Infection prevalence in hatchery-reared larvae and wild river-based adult populationsBased on multiple sequence alignment of the RdRp protein motifs of a representation of families within Nidovirales, MrGV groups phylogenetically with family Roniviridae, which so far, exclusively comprises GAV and YHV.", [["GAV", "GENE_OR_GENE_PRODUCT", 52, 55], ["YHV", "GENE_OR_GENE_PRODUCT", 60, 63], ["MrGV", "GENE_OR_GENE_PRODUCT", 228, 232], ["GAV", "GENE_OR_GENE_PRODUCT", 236, 239], ["MrGV", "GENE_OR_GENE_PRODUCT", 267, 271], ["GAV", "CANCER", 591, 594], ["GAV", "PROTEIN", 52, 55], ["YHV", "PROTEIN", 60, 63], ["polymerase recognition site", "DNA", 77, 104], ["MrGV", "PROTEIN", 228, 232], ["GAV", "DNA", 236, 239], ["YHV", "DNA", 244, 247], ["MrGV", "PROTEIN", 267, 271], ["RdRp protein motifs", "PROTEIN", 429, 448], ["GAV", "PROTEIN", 591, 594], ["YHV", "PROTEIN", 599, 602], ["YHV", "SPECIES", 599, 602], ["the 3'-UTR RNA structure in GAV", "PROBLEM", 24, 55], ["a polymerase recognition site", "PROBLEM", 75, 104], ["strand RNA synthesis", "PROBLEM", 115, 135], ["Infection prevalence", "PROBLEM", 300, 320], ["the RdRp protein motifs", "TREATMENT", 425, 448], ["family Roniviridae", "TREATMENT", 535, 553], ["similar function", "OBSERVATION", 283, 299], ["RdRp protein motifs", "OBSERVATION", 429, 448]]], ["We hypothesise that MrGV also belongs to Roniviridae, however further sampling is needed to obtainadditional material for electron microscopy to visualise the virus in situ in order to confirm that virion morphology conforms with the rod-shaped characteristics of the family (King et al., 2012) .Infection prevalence in hatchery-reared larvae and wild river-based adult populationsOur study has also highlighted that choice of assembly tool is important in assembling viruses. rnaSPAdes was not able to assemble the complete MrGV genome, even when libraries were pooled to give higher coverage than single libraries alone; whereas IVA was able to assemble the full genome from the same pool of libraries.", [["MrGV", "GENE_OR_GENE_PRODUCT", 20, 24], ["Roniviridae", "GENE_OR_GENE_PRODUCT", 41, 52], ["MrGV", "GENE_OR_GENE_PRODUCT", 525, 529], ["MrGV", "PROTEIN", 20, 24], ["rnaSPAdes", "PROTEIN", 477, 486], ["MrGV genome", "DNA", 525, 536], ["Roniviridae", "TREATMENT", 41, 52], ["further sampling", "TEST", 62, 78], ["electron microscopy", "TEST", 122, 141], ["Infection prevalence", "PROBLEM", 296, 316], ["Our study", "TEST", 381, 390]]], ["It is likely that IVA was able to assemble the full genome as it is capable of assembling RNA sequences at highly variable depths (Hunt et al., 2015) , a useful tool in the case of the nidoviruses, which are prone to variability in sequencing depth due to the production of sub-genomic mRNAs (sgmRNAs).", [["IVA", "CHEMICAL", 18, 21], ["nidoviruses", "GENE_OR_GENE_PRODUCT", 185, 196], ["sgmRNAs", "GENE_OR_GENE_PRODUCT", 293, 300], ["RNA sequences", "DNA", 90, 103], ["sub-genomic mRNAs", "RNA", 274, 291], ["sgmRNAs", "DNA", 293, 300], ["IVA", "PROBLEM", 18, 21], ["assembling RNA sequences", "PROBLEM", 79, 103], ["the nidoviruses", "PROBLEM", 181, 196], ["sub-genomic mRNAs", "PROBLEM", 274, 291], ["sub", "OBSERVATION_MODIFIER", 274, 277], ["genomic mRNAs", "OBSERVATION", 278, 291]]], ["The presence of sgmRNAs were not assessed in this study but given that rnaSPAdes could not assemble the full genome, it is likely that these sgmRNAs do exist.", [["sgmRNAs", "GENE_OR_GENE_PRODUCT", 16, 23], ["rnaSPAdes", "GENE_OR_GENE_PRODUCT", 71, 80], ["sgmRNAs", "GENE_OR_GENE_PRODUCT", 141, 148], ["sgmRNAs", "PROTEIN", 16, 23], ["rnaSPAdes", "PROTEIN", 71, 80], ["sgmRNAs", "PROTEIN", 141, 148], ["sgmRNAs", "PROBLEM", 16, 23], ["this study", "TEST", 45, 55], ["these sgmRNAs", "PROBLEM", 135, 148], ["sgmRNAs", "OBSERVATION", 16, 23]]], ["Future work includes identifying the presence or absence of sgmRNAs and potential transcription regulation sites (TRSs).Infection prevalence in hatchery-reared larvae and wild river-based adult populationsSamples for histology or electron microscopy matching those used for molecular analyses were not available from the disease challenge studies carried out here.", [["Samples", "ANATOMY", 205, 212], ["sgmRNAs", "GENE_OR_GENE_PRODUCT", 60, 67], ["sgmRNAs", "PROTEIN", 60, 67], ["transcription regulation sites", "DNA", 82, 112], ["TRSs", "DNA", 114, 118], ["sgmRNAs", "PROBLEM", 60, 67], ["potential transcription regulation sites", "PROBLEM", 72, 112], ["Infection prevalence", "PROBLEM", 120, 140], ["Samples", "TEST", 205, 212], ["histology", "TEST", 217, 226], ["electron microscopy", "TEST", 230, 249], ["molecular analyses", "TEST", 274, 292], ["the disease challenge studies", "TEST", 317, 346]]], ["Therefore, there is currently no information about histopathological signs of disease caused by MrGV.Infection prevalence in hatchery-reared larvae and wild river-based adult populationsHistological samples were taken from the larvae sampled from hatcheries in 2019, however these animals were likely not to be moribund and were probably in the early stages of infection by MrGV and thus, though infected, no pathology was seen.", [["samples", "ANATOMY", 199, 206], ["infection", "DISEASE", 361, 370], ["MrGV", "GENE_OR_GENE_PRODUCT", 96, 100], ["Histological samples", "CANCER", 186, 206], ["animals", "ORGANISM", 281, 288], ["MrGV", "GENE_OR_GENE_PRODUCT", 374, 378], ["MrGV", "PROTEIN", 96, 100], ["MrGV", "SPECIES", 374, 378], ["disease", "PROBLEM", 78, 85], ["Infection prevalence", "PROBLEM", 101, 121], ["Histological samples", "TEST", 186, 206], ["infection", "PROBLEM", 361, 370], ["infected", "PROBLEM", 396, 404], ["pathology", "PROBLEM", 409, 418], ["disease", "OBSERVATION", 78, 85], ["likely not to be", "UNCERTAINTY", 294, 310], ["moribund", "OBSERVATION", 311, 319], ["early stages", "OBSERVATION_MODIFIER", 345, 357], ["infection", "OBSERVATION", 361, 370], ["infected", "OBSERVATION", 396, 404], ["no", "UNCERTAINTY", 406, 408], ["pathology", "OBSERVATION", 409, 418]]], ["Furthermore, RNA viruses infections are often difficult to visualise in histology sections.", [["sections", "ANATOMY", 82, 90], ["infections", "DISEASE", 25, 35], ["histology sections", "CANCER", 72, 90], ["RNA viruses infections", "PROBLEM", 13, 35], ["histology sections", "TEST", 72, 90], ["RNA viruses", "OBSERVATION", 13, 24]]], ["Further sampling is ongoing in order to visualise the virus infecting larval tissue(s) using transmission electron microscopy.Infection prevalence in hatchery-reared larvae and wild river-based adult populationsThe challenge experiment data from this study were unable to determine the route of entry of MrGV into the hatchery system as it was later determined that control animals were sourced from a hatchery assumed to be free of MrGV, but which after sampling larvae for the challenge experienced mass mortalities to a similar level as seen in other hatcheries in southern Bangladesh.", [["tissue", "ANATOMY", 77, 83], ["MrGV", "CHEMICAL", 304, 308], ["larval tissue", "TISSUE", 70, 83], ["MrGV", "GENE_OR_GENE_PRODUCT", 304, 308], ["MrGV", "GENE_OR_GENE_PRODUCT", 433, 437], ["MrGV", "PROTEIN", 304, 308], ["Further sampling", "TEST", 0, 16], ["transmission electron microscopy", "TEST", 93, 125], ["Infection prevalence", "PROBLEM", 126, 146], ["this study", "TEST", 246, 256], ["mass mortalities", "PROBLEM", 501, 517], ["mass", "OBSERVATION", 501, 505]]], ["Larvae were sampled from the apparently unaffected hatchery and fixed before challenging; these animals were screened by PCR for all pathogens as above and were only positive for MrGV, thus suggesting that animals were infected with MrGV prior to the challenge, explaining the high levels of mortality in 'control' animals.", [["MrGV", "CHEMICAL", 233, 237], ["Larvae", "ORGANISM", 0, 6], ["animals", "ORGANISM", 96, 103], ["MrGV", "GENE_OR_GENE_PRODUCT", 179, 183], ["MrGV", "GENE_OR_GENE_PRODUCT", 233, 237], ["MrGV", "PROTEIN", 179, 183], ["MrGV", "SPECIES", 233, 237], ["PCR", "TEST", 121, 124], ["all pathogens", "PROBLEM", 129, 142], ["MrGV", "TEST", 179, 183], ["MrGV", "TREATMENT", 233, 237]]], ["This confounding situation nonetheless further suggests the role and ubiquity of MrGV in mass mortality events across multiple hatcheries in Bangladesh.", [["MrGV", "GENE_OR_GENE_PRODUCT", 81, 85], ["MrGV", "PROTEIN", 81, 85], ["mass mortality events", "PROBLEM", 89, 110], ["mass", "OBSERVATION", 89, 93], ["multiple", "OBSERVATION_MODIFIER", 118, 126], ["hatcheries", "OBSERVATION", 127, 137]]], ["Future work to identify how the virus is entering the hatcheries is ongoing to suggest preventative methods that could be implemented to ensure biosecurity.", [["the virus", "PROBLEM", 28, 37], ["preventative methods", "TREATMENT", 87, 107]]], ["This is the first study, to our knowledge, to use a metatransciptomic approach to investigate the mass mortalities experienced in hatchery-reared prawn larvae in Bangladesh.", [["the first study", "TEST", 8, 23], ["a metatransciptomic approach", "TREATMENT", 50, 78], ["the mass mortalities", "PROBLEM", 94, 114], ["mass", "OBSERVATION", 98, 102]]], ["Previous studies have investigated possible agents involved in mortality events using PCR screens and microbial culture, but required the agent to have gene sequences sufficiently similar to known pathogens to amplify with PCR primers or culturable on media respectively, thus limiting the detection of more genetically divergent pathogens, possibly including many viruses.", [["PCR primers", "DNA", 223, 234], ["Previous studies", "TEST", 0, 16], ["agents", "TREATMENT", 44, 50], ["PCR screens", "TEST", 86, 97], ["microbial culture", "TEST", 102, 119], ["the agent", "TREATMENT", 134, 143], ["gene sequences", "TEST", 152, 166], ["known pathogens", "PROBLEM", 191, 206], ["PCR primers", "TEST", 223, 234], ["more genetically divergent pathogens", "PROBLEM", 303, 339], ["many viruses", "PROBLEM", 360, 372], ["divergent", "OBSERVATION_MODIFIER", 320, 329], ["pathogens", "OBSERVATION", 330, 339], ["viruses", "OBSERVATION", 365, 372]]], ["The metatranscriptomic approach used in this study to discover the agent involved in the Bangladesh mortalities was able to identify and characterise a novel pathogen that would likely have not been identified by most commonly employed methods.", [["The metatranscriptomic approach", "TREATMENT", 0, 31], ["this study", "TEST", 40, 50], ["a novel pathogen", "PROBLEM", 150, 166]]], ["Furthermore, this method can be used to rapidly detect and comprehensively analyse new and cryptic viral linages, of relevance to both animal and human health.", [["human", "ORGANISM", 146, 151], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 146, 151], ["cryptic viral linages", "PROBLEM", 91, 112], ["viral linages", "OBSERVATION", 99, 112]]], ["Hatcheries denoted with a red diamond (1-5) and river sampling sites denoted with blue diamond (6: Shibsa River, 7: Rupsa River, 8: Katcha River, 9: Kocha River, 10: Biskhali River, 11: Payra River, 12: Karnaphuli River).Figure 2:Larval mortalities observed in tank experiments.", [["a red diamond", "PROBLEM", 24, 37], ["river sampling sites", "TREATMENT", 48, 68], ["Larval mortalities", "PROBLEM", 230, 248], ["red diamond", "OBSERVATION_MODIFIER", 26, 37]]], ["Treatment 1 = Larvae directly immersed into filtered material from moribund larvae.", [["Treatment", "TREATMENT", 0, 9], ["moribund larvae", "PROBLEM", 67, 82], ["moribund larvae", "OBSERVATION", 67, 82]]], ["Treatment 2 = Larvae fed artemia that had been immersed into the filtered material from moribund larvae.", [["Treatment 2 = Larvae fed artemia", "TREATMENT", 0, 32], ["moribund larvae", "OBSERVATION", 88, 103]]], ["Treatment 3 = Experimental larvae were directly immersed into filtered material from healthy larvae.", [["Treatment", "TREATMENT", 0, 9], ["Experimental larvae", "TREATMENT", 14, 33]]]], "793844acb8a16ac131b11fc73bc144193155c378": [["DIAGNOSTIC APPROACHAs with any case, establishing a comprehensive history of the foal, the mare and of the yard is crucial in establishing differential diagnoses.", [["foal", "ORGANISM_SUBDIVISION", 81, 85]]], ["The age of the foal, history of passive transfer, parasite control and previous disease history are all important, as is information pertaining to any other clinically affected animals from the same environment and husbandry practices in the affected yard.", [["passive transfer", "TREATMENT", 32, 48], ["parasite control", "TREATMENT", 50, 66], ["previous disease history", "PROBLEM", 71, 95]]], ["A good history combined with a thorough physical examination is often enough to form a presumptive diagnosis, and is often all that is available at the initiation of treatment.DIAGNOSTIC APPROACHThe physical examination should include assessment of all major body systems, hydration status and should identify any concurrent abnormalities.", [["body", "ANATOMY", 259, 263], ["body", "ORGANISM_SUBDIVISION", 259, 263], ["a thorough physical examination", "TEST", 29, 60], ["treatment", "TREATMENT", 166, 175], ["DIAGNOSTIC APPROACHThe physical examination", "TEST", 176, 219], ["assessment", "TEST", 235, 245], ["any concurrent abnormalities", "PROBLEM", 310, 338], ["good", "OBSERVATION_MODIFIER", 2, 6], ["abnormalities", "OBSERVATION", 325, 338]]], ["A haematological profile and, if available, an acute-phase protein profile are useful in determining the aetiology.", [["A haematological profile", "TEST", 0, 24], ["an acute-phase protein profile", "TEST", 44, 74]]], ["Initial treatment will involve stabilising cardiovascular and electrolyte aberrations and therefore blood gas analysis, if available, is very helpful.DIAGNOSTIC APPROACHFaecal samples taken directly from the rectum and placed immediately in selenite broth are useful for specific tests as indicated by the case, such as bacterial culture for Salmonella, microscopic evaluation for parasitic stages or ELISA analysis for clostridial toxins or rotavirus isolation.DIAGNOSTIC APPROACHThere are many causes of diarrhoea in the older foal, including infectious and non-infectious causes.", [["cardiovascular", "ANATOMY", 43, 57], ["blood", "ANATOMY", 100, 105], ["samples", "ANATOMY", 176, 183], ["rectum", "ANATOMY", 208, 214], ["selenite", "CHEMICAL", 241, 249], ["diarrhoea", "DISEASE", 506, 515], ["selenite", "CHEMICAL", 241, 249], ["cardiovascular", "MULTI-TISSUE_STRUCTURE", 43, 57], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["APPROACHFaecal samples", "CANCER", 161, 183], ["rectum", "ORGAN", 208, 214], ["selenite", "SIMPLE_CHEMICAL", 241, 249], ["rotavirus", "ORGANISM", 442, 451], ["Salmonella", "SPECIES", 342, 352], ["rotavirus", "SPECIES", 442, 451], ["Initial treatment", "TREATMENT", 0, 17], ["stabilising cardiovascular and electrolyte aberrations", "PROBLEM", 31, 85], ["blood gas analysis", "TEST", 100, 118], ["DIAGNOSTIC APPROACHFaecal samples", "TEST", 150, 183], ["specific tests", "TEST", 271, 285], ["bacterial culture", "TEST", 320, 337], ["Salmonella", "PROBLEM", 342, 352], ["microscopic evaluation", "TEST", 354, 376], ["parasitic stages", "PROBLEM", 381, 397], ["ELISA analysis", "TEST", 401, 415], ["clostridial toxins", "PROBLEM", 420, 438], ["rotavirus isolation", "PROBLEM", 442, 461], ["diarrhoea", "PROBLEM", 506, 515], ["infectious and non-infectious causes", "PROBLEM", 545, 581], ["rectum", "ANATOMY", 208, 214], ["diarrhoea", "OBSERVATION", 506, 515], ["infectious", "OBSERVATION_MODIFIER", 545, 555], ["non-infectious", "OBSERVATION", 560, 574]]], ["Table 1 lists the most common infectious causes of diarrhoea in older foals.DIAGNOSTIC APPROACHNon-infectious causes include: G Antibiotic-related diarrhoea G lactose insufficiency G dietary hypersensitivity G errors of feeding, e.g. incorrect formulation, volume, concentration VIRAL DIARRHOEA Cells at the tips of the villi are destroyed, the gut loses absorptive capacity and lactase is destroyed.", [["Cells", "ANATOMY", 295, 300], ["villi", "ANATOMY", 320, 325], ["gut", "ANATOMY", 345, 348], ["diarrhoea", "DISEASE", 51, 60], ["diarrhoea", "DISEASE", 147, 156], ["lactose", "CHEMICAL", 159, 166], ["insufficiency", "DISEASE", 167, 180], ["hypersensitivity", "DISEASE", 191, 207], ["lactose", "CHEMICAL", 159, 166], ["foals", "ORGANISM", 70, 75], ["G lactose", "SIMPLE_CHEMICAL", 157, 166], ["Cells", "CELL", 295, 300], ["villi", "MULTI-TISSUE_STRUCTURE", 320, 325], ["gut", "ORGANISM_SUBDIVISION", 345, 348], ["lactase", "GENE_OR_GENE_PRODUCT", 379, 386], ["lactase", "PROTEIN", 379, 386], ["foals", "SPECIES", 70, 75], ["diarrhoea", "PROBLEM", 51, 60], ["G Antibiotic", "TREATMENT", 126, 138], ["diarrhoea", "PROBLEM", 147, 156], ["lactose insufficiency", "PROBLEM", 159, 180], ["dietary hypersensitivity G errors of feeding", "TREATMENT", 183, 227], ["VIRAL DIARRHOEA", "PROBLEM", 279, 294], ["lactase", "TEST", 379, 386], ["most common", "OBSERVATION_MODIFIER", 18, 29], ["infectious", "OBSERVATION", 30, 40], ["diarrhoea", "OBSERVATION", 51, 60], ["tips", "OBSERVATION_MODIFIER", 308, 312], ["villi", "ANATOMY", 320, 325], ["destroyed", "OBSERVATION", 330, 339], ["absorptive capacity", "OBSERVATION", 355, 374]]], ["Maldigestion and malabsorption occur, often combined with increased gut secretion.", [["gut", "ANATOMY", 68, 71], ["Maldigestion", "DISEASE", 0, 12], ["malabsorption", "DISEASE", 17, 30], ["gut", "ORGANISM_SUBDIVISION", 68, 71], ["Maldigestion", "PROBLEM", 0, 12], ["malabsorption", "PROBLEM", 17, 30], ["increased gut secretion", "PROBLEM", 58, 81], ["malabsorption", "OBSERVATION", 17, 30], ["secretion", "OBSERVATION", 72, 81]]], ["As the cells in the crypts are not affected malabsorption is usually a transient change.", [["cells", "ANATOMY", 7, 12], ["crypts", "ANATOMY", 20, 26], ["malabsorption", "DISEASE", 44, 57], ["cells", "CELL", 7, 12], ["crypts", "MULTI-TISSUE_STRUCTURE", 20, 26], ["affected malabsorption", "PROBLEM", 35, 57], ["not", "UNCERTAINTY", 31, 34], ["affected", "OBSERVATION_MODIFIER", 35, 43], ["malabsorption", "OBSERVATION", 44, 57], ["transient", "OBSERVATION_MODIFIER", 71, 80], ["change", "OBSERVATION", 81, 87]]], ["Diarrhoea is a result of the osmotic gradient drawing water into the gut lumen.", [["gut lumen", "ANATOMY", 69, 78], ["Diarrhoea", "DISEASE", 0, 9], ["gut lumen", "MULTI-TISSUE_STRUCTURE", 69, 78], ["Diarrhoea", "PROBLEM", 0, 9], ["the osmotic gradient", "TREATMENT", 25, 45], ["osmotic gradient", "OBSERVATION", 29, 45], ["gut", "ANATOMY", 69, 72], ["lumen", "ANATOMY_MODIFIER", 73, 78]]], ["There is no protein leakage.RotavirusRotavirus infection is the most common cause of viral diarrhoea in the foal.", [["Rotavirus", "DISEASE", 28, 37], ["Rotavirus infection", "DISEASE", 37, 56], ["viral diarrhoea", "DISEASE", 85, 100], ["RotavirusRotavirus", "ORGANISM", 28, 46], ["foal", "ORGANISM_SUBDIVISION", 108, 112], ["RotavirusRotavirus", "SPECIES", 28, 46], ["protein leakage", "PROBLEM", 12, 27], ["RotavirusRotavirus infection", "PROBLEM", 28, 56], ["viral diarrhoea in the foal", "PROBLEM", 85, 112], ["no", "UNCERTAINTY", 9, 11], ["protein leakage", "OBSERVATION", 12, 27], ["infection", "OBSERVATION", 47, 56], ["most common", "OBSERVATION_MODIFIER", 64, 75], ["viral", "OBSERVATION_MODIFIER", 85, 90], ["diarrhoea", "OBSERVATION", 91, 100]]], ["Various serotypes have been identified, all of which belong to group A. Foals are infected via oro-faecal transmission, often at 1-8 hypersecretion or direct invasion of the mucosa.", [["oro-faecal", "ANATOMY", 95, 105], ["mucosa", "ANATOMY", 174, 180], ["mucosa", "MULTI-TISSUE_STRUCTURE", 174, 180], ["Various serotypes", "PROBLEM", 0, 17], ["8 hypersecretion", "PROBLEM", 131, 147], ["direct invasion of the mucosa", "PROBLEM", 151, 180], ["serotypes", "OBSERVATION", 8, 17], ["hypersecretion", "OBSERVATION", 133, 147], ["invasion", "OBSERVATION", 158, 166], ["mucosa", "ANATOMY", 174, 180]]], ["E. coli is commonly cultured in faeces and therefore diagnosis should be based on PCR demonstrating toxin production.", [["faeces", "ANATOMY", 32, 38], ["E. coli", "ORGANISM", 0, 7], ["faeces", "ORGANISM_SUBSTANCE", 32, 38], ["toxin", "SIMPLE_CHEMICAL", 100, 105], ["toxin", "PROTEIN", 100, 105], ["E. coli", "SPECIES", 0, 7], ["E. coli", "SPECIES", 0, 7], ["E. coli", "PROBLEM", 0, 7], ["PCR", "TEST", 82, 85], ["toxin production", "PROBLEM", 100, 116], ["coli", "OBSERVATION", 3, 7]]], ["If E. coli septicaemia is present aggressive treatment may be required.", [["septicaemia", "DISEASE", 11, 22], ["E. coli", "ORGANISM", 3, 10], ["E. coli", "SPECIES", 3, 10], ["E. coli", "SPECIES", 3, 10], ["E. coli septicaemia", "PROBLEM", 3, 22], ["aggressive treatment", "TREATMENT", 34, 54], ["coli septicaemia", "OBSERVATION", 6, 22]]], ["Clinical signs vary from mild transient diarrhoea to more severe signs.SalmonellosisAll reported cases of Salmonella infection are from the species Salmonella enterica, which contains six subspecies and over 2000 serovars.", [["diarrhoea", "DISEASE", 40, 49], ["Salmonellosis", "DISEASE", 71, 84], ["Salmonella infection", "DISEASE", 106, 126], ["Salmonella enterica", "ORGANISM", 148, 167], ["Salmonella enterica", "SPECIES", 148, 167], ["Salmonella", "SPECIES", 106, 116], ["Salmonella enterica", "SPECIES", 148, 167], ["Clinical signs", "TEST", 0, 14], ["mild transient diarrhoea", "PROBLEM", 25, 49], ["more severe signs", "PROBLEM", 53, 70], ["Salmonellosis", "PROBLEM", 71, 84], ["Salmonella infection", "PROBLEM", 106, 126], ["the species Salmonella enterica", "PROBLEM", 136, 167], ["mild", "OBSERVATION_MODIFIER", 25, 29], ["transient", "OBSERVATION_MODIFIER", 30, 39], ["diarrhoea", "OBSERVATION", 40, 49], ["more severe", "OBSERVATION_MODIFIER", 53, 64], ["Salmonella infection", "OBSERVATION", 106, 126], ["species", "OBSERVATION_MODIFIER", 140, 147], ["Salmonella enterica", "OBSERVATION", 148, 167], ["six", "OBSERVATION_MODIFIER", 184, 187], ["subspecies", "OBSERVATION_MODIFIER", 188, 198]]], ["The prevalence of each serovar varies between studies: S. typhimurium and S. enteritidis are the most prevalent in Europe.", [["S. enteritidis", "DISEASE", 74, 88], ["S. typhimurium", "ORGANISM", 55, 69], ["S. enteritidis", "ORGANISM", 74, 88], ["S. typhimurium", "SPECIES", 55, 69], ["S. enteritidis", "SPECIES", 74, 88], ["S. typhimurium", "SPECIES", 55, 69], ["S. enteritidis", "SPECIES", 74, 88], ["S. typhimurium", "PROBLEM", 55, 69], ["S. enteritidis", "PROBLEM", 74, 88], ["enteritidis", "OBSERVATION", 77, 88], ["most prevalent", "OBSERVATION_MODIFIER", 97, 111]]], ["S. anatum and S. agona have been found to be more prevalent in Australia and Kentucky respectively.", [["S. anatum", "ORGANISM", 0, 9], ["S. agona", "ORGANISM", 14, 22], ["S. anatum", "SPECIES", 0, 9], ["S. agona", "SPECIES", 14, 22], ["S. anatum", "SPECIES", 0, 9], ["S. agona", "SPECIES", 14, 22], ["S. agona", "PROBLEM", 14, 22]]], ["The primary route of infection is thought to be oral transmission, through contaminated feed and water, faeces of infected animals or the environment.", [["oral", "ANATOMY", 48, 52], ["infection", "DISEASE", 21, 30], ["oral", "ORGANISM_SUBDIVISION", 48, 52], ["faeces", "ORGANISM_SUBDIVISION", 104, 110], ["infection", "PROBLEM", 21, 30], ["oral transmission", "TREATMENT", 48, 65], ["infection", "OBSERVATION", 21, 30], ["thought to be", "UNCERTAINTY", 34, 47], ["infected", "OBSERVATION", 114, 122]]], ["Salmonella can persist in the environment in dry faeces for several years and surface water for four months.", [["Salmonella", "CHEMICAL", 0, 10], ["faeces", "ORGANISM_SUBDIVISION", 49, 55], ["Salmonella", "SPECIES", 0, 10], ["Salmonella", "PROBLEM", 0, 10]]], ["It can cause diarrhoea in foals of any age but is most commonly identified in those between one and four months of age.", [["diarrhoea", "DISEASE", 13, 22], ["foals", "ORGANISM", 26, 31], ["diarrhoea", "PROBLEM", 13, 22], ["most commonly", "OBSERVATION_MODIFIER", 50, 63]]], ["Nosocomial infection is common.Clinical signsClinical signs vary but often include pyrexia, acute fetid diarrhoea and hypotensive shock.", [["Nosocomial infection", "DISEASE", 0, 20], ["pyrexia", "DISEASE", 83, 90], ["diarrhoea", "DISEASE", 104, 113], ["hypotensive shock", "DISEASE", 118, 135], ["Nosocomial infection", "PROBLEM", 0, 20], ["Clinical signsClinical signs vary", "PROBLEM", 31, 64], ["pyrexia", "PROBLEM", 83, 90], ["acute fetid diarrhoea", "PROBLEM", 92, 113], ["hypotensive shock", "PROBLEM", 118, 135], ["infection", "OBSERVATION", 11, 20], ["pyrexia", "OBSERVATION", 83, 90], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["hypotensive shock", "OBSERVATION", 118, 135]]], ["Signs of septicaemia may precede the onset of diarrhoea.", [["septicaemia", "DISEASE", 9, 20], ["diarrhoea", "DISEASE", 46, 55], ["septicaemia", "PROBLEM", 9, 20], ["diarrhoea", "PROBLEM", 46, 55], ["septicaemia", "OBSERVATION", 9, 20], ["diarrhoea", "OBSERVATION", 46, 55]]], ["Signs of localised infections such as synovitis, osteomyelitis, uveitis or physitis may be present.", [["infections", "DISEASE", 19, 29], ["synovitis", "DISEASE", 38, 47], ["osteomyelitis", "DISEASE", 49, 62], ["uveitis", "DISEASE", 64, 71], ["physitis", "DISEASE", 75, 83], ["localised infections", "PROBLEM", 9, 29], ["synovitis", "PROBLEM", 38, 47], ["osteomyelitis", "PROBLEM", 49, 62], ["uveitis", "PROBLEM", 64, 71], ["physitis", "PROBLEM", 75, 83], ["localised", "OBSERVATION_MODIFIER", 9, 18], ["infections", "OBSERVATION", 19, 29], ["synovitis", "OBSERVATION", 38, 47], ["osteomyelitis", "OBSERVATION", 49, 62], ["uveitis", "OBSERVATION", 64, 71]]], ["Haematology often identifies a substantial neutropenia, with toxic change and a left shift.DiagnosisAs shedding is intermittent in faeces, it is recommended that bacterial culture and isolation from five sequential faecal samples be taken; it will be several days before the results are available.", [["faeces", "ANATOMY", 131, 137], ["faecal samples", "ANATOMY", 215, 229], ["neutropenia", "DISEASE", 43, 54], ["faeces", "ORGANISM_SUBSTANCE", 131, 137], ["faecal samples", "ORGANISM_SUBSTANCE", 215, 229], ["a substantial neutropenia", "PROBLEM", 29, 54], ["toxic change", "PROBLEM", 61, 73], ["a left shift", "PROBLEM", 78, 90], ["intermittent in faeces", "PROBLEM", 115, 137], ["bacterial culture", "TEST", 162, 179], ["isolation", "TREATMENT", 184, 193], ["five sequential faecal samples", "TEST", 199, 229], ["substantial", "OBSERVATION_MODIFIER", 31, 42], ["neutropenia", "OBSERVATION", 43, 54], ["toxic", "OBSERVATION_MODIFIER", 61, 66], ["left", "ANATOMY_MODIFIER", 80, 84], ["shift", "OBSERVATION", 85, 90], ["intermittent", "OBSERVATION_MODIFIER", 115, 127]]], ["Faecal culture has poor sensitivity, approximately 55%, for one sample, which is improved when using selenite-enriched broth.", [["Faecal culture", "ANATOMY", 0, 14], ["selenite", "CHEMICAL", 101, 109], ["selenite", "CHEMICAL", 101, 109], ["Faecal", "ORGANISM_SUBSTANCE", 0, 6], ["selenite", "SIMPLE_CHEMICAL", 101, 109], ["Faecal culture", "TEST", 0, 14], ["poor sensitivity", "PROBLEM", 19, 35], ["poor sensitivity", "OBSERVATION_MODIFIER", 19, 35], ["improved", "OBSERVATION_MODIFIER", 81, 89]]], ["Culture allows typing of isolates, which is important in tracing outbreaks of disease.", [["Culture", "TEST", 0, 7], ["isolates", "PROBLEM", 25, 33], ["disease", "PROBLEM", 78, 85], ["disease", "OBSERVATION", 78, 85]]], ["Rectal mucosal biopsies are more sensitive than faecal isolation but are more invasive.", [["Rectal mucosal", "ANATOMY", 0, 14], ["faecal", "ANATOMY", 48, 54], ["Rectal mucosal biopsies", "MULTI-TISSUE_STRUCTURE", 0, 23], ["faecal", "ORGANISM_SUBSTANCE", 48, 54], ["Rectal mucosal biopsies", "TEST", 0, 23], ["faecal isolation", "TREATMENT", 48, 64], ["mucosal", "ANATOMY", 7, 14], ["biopsies", "OBSERVATION", 15, 23]]], ["A faecal PCR, which detects the histadine transport operon gene of S. typhimurium, is available.", [["histadine", "CHEMICAL", 32, 41], ["histadine", "CHEMICAL", 32, 41], ["faecal", "ORGANISM_SUBSTANCE", 2, 8], ["histadine", "GENE_OR_GENE_PRODUCT", 32, 41], ["S. typhimurium", "ORGANISM", 67, 81], ["histadine transport operon gene", "DNA", 32, 63], ["S. typhimurium", "SPECIES", 67, 81], ["S. typhimurium", "SPECIES", 67, 81], ["A faecal PCR", "TEST", 0, 12], ["S. typhimurium", "PROBLEM", 67, 81]]], ["This provides quicker results and has a greater sensitivity than faecal culture.", [["faecal culture", "ANATOMY", 65, 79], ["faecal culture", "TEST", 65, 79]]], ["Blood culture is also used in septicaemic foals.DiagnosisPost-mortem examination reveals a diffuse haemorrhagic or fibrinous inflammation of the large colon.", [["Blood", "ANATOMY", 0, 5], ["fibrinous", "ANATOMY", 115, 124], ["colon", "ANATOMY", 151, 156], ["haemorrhagic", "DISEASE", 99, 111], ["inflammation of the large colon", "DISEASE", 125, 156], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["foals", "ORGANISM", 42, 47], ["colon", "ORGAN", 151, 156], ["Blood culture", "TEST", 0, 13], ["DiagnosisPost-mortem examination", "TEST", 48, 80], ["a diffuse haemorrhagic or fibrinous inflammation of the large colon", "PROBLEM", 89, 156], ["diffuse", "OBSERVATION_MODIFIER", 91, 98], ["haemorrhagic", "OBSERVATION_MODIFIER", 99, 111], ["fibrinous", "OBSERVATION_MODIFIER", 115, 124], ["inflammation", "OBSERVATION", 125, 137], ["large", "ANATOMY_MODIFIER", 145, 150], ["colon", "ANATOMY", 151, 156]]], ["Pseudomembranes may be present.", [["Pseudomembranes", "PROBLEM", 0, 15], ["may be", "UNCERTAINTY", 16, 22]]], ["Enlarged mesenteric lymph nodes may be haemorrhagic or oedematous.", [["mesenteric lymph nodes", "ANATOMY", 9, 31], ["haemorrhagic", "DISEASE", 39, 51], ["mesenteric lymph nodes", "MULTI-TISSUE_STRUCTURE", 9, 31], ["Enlarged mesenteric lymph nodes", "PROBLEM", 0, 31], ["haemorrhagic", "PROBLEM", 39, 51], ["oedematous", "PROBLEM", 55, 65], ["mesenteric", "ANATOMY", 9, 19], ["lymph nodes", "OBSERVATION", 20, 31], ["may be", "UNCERTAINTY", 32, 38], ["haemorrhagic", "OBSERVATION_MODIFIER", 39, 51], ["oedematous", "OBSERVATION", 55, 65]]], ["Similar changes may be seen in the stomach and small intestine.", [["stomach", "ANATOMY", 35, 42], ["small intestine", "ANATOMY", 47, 62], ["stomach", "ORGAN", 35, 42], ["small intestine", "ORGAN", 47, 62], ["may be seen", "UNCERTAINTY", 16, 27], ["stomach", "ANATOMY", 35, 42], ["small intestine", "ANATOMY", 47, 62]]], ["Histological changes include mononuclear cell infiltrate, and occlusion of the capillaries in the lamina propria by fibrin.", [["mononuclear cell", "ANATOMY", 29, 45], ["capillaries", "ANATOMY", 79, 90], ["lamina propria", "ANATOMY", 98, 112], ["mononuclear cell", "CELL", 29, 45], ["capillaries", "TISSUE", 79, 90], ["lamina propria", "TISSUE", 98, 112], ["fibrin", "GENE_OR_GENE_PRODUCT", 116, 122], ["fibrin", "PROTEIN", 116, 122], ["Histological changes", "PROBLEM", 0, 20], ["mononuclear cell infiltrate", "PROBLEM", 29, 56], ["occlusion of the capillaries in the lamina propria", "PROBLEM", 62, 112], ["fibrin", "PROBLEM", 116, 122], ["mononuclear cell infiltrate", "OBSERVATION", 29, 56], ["occlusion", "OBSERVATION", 62, 71], ["capillaries", "ANATOMY_MODIFIER", 79, 90], ["lamina propria", "ANATOMY", 98, 112], ["fibrin", "OBSERVATION", 116, 122]]], ["Foci of hepatic necrosis may be present.", [["hepatic", "ANATOMY", 8, 15], ["hepatic necrosis", "DISEASE", 8, 24], ["hepatic", "ORGAN", 8, 15], ["hepatic necrosis", "PROBLEM", 8, 24], ["hepatic", "ANATOMY", 8, 15], ["necrosis", "OBSERVATION", 16, 24], ["may be", "UNCERTAINTY", 25, 31]]], ["2 weeks of age, although some older foals can be affected and may show less severe clinical signs.", [["foals", "ORGANISM", 36, 41], ["less severe clinical signs", "PROBLEM", 71, 97]]], ["The virus is highly contagious, often occurring in outbreaks, and can persist in the environment for several months.", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["highly", "OBSERVATION_MODIFIER", 13, 19], ["contagious", "OBSERVATION_MODIFIER", 20, 30]]], ["Clinical signs vary from depression and failure to suck to more severe disease.", [["depression", "DISEASE", 25, 35], ["Clinical signs", "PROBLEM", 0, 14], ["depression", "PROBLEM", 25, 35], ["failure to suck", "PROBLEM", 40, 55], ["more severe disease", "PROBLEM", 59, 78], ["depression", "OBSERVATION", 25, 35], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["disease", "OBSERVATION", 71, 78]]], ["Initially foals will be pyrexic.", [["foals", "ORGANISM", 10, 15], ["pyrexic", "PROBLEM", 24, 31]]], ["Diarrhoea is often a green to grey colour and is non fetid.DiagnosisDiagnosis is made by demonstrating viral particles in faeces using a commercial ELISA test, latex agglutination or electron microscopy.", [["faeces", "ANATOMY", 122, 128], ["Diarrhoea", "DISEASE", 0, 9], ["non fetid", "CANCER", 49, 58], ["faeces", "ORGANISM_SUBSTANCE", 122, 128], ["Diarrhoea", "PROBLEM", 0, 9], ["a green to grey colour", "PROBLEM", 19, 41], ["viral particles in faeces", "PROBLEM", 103, 128], ["a commercial ELISA test", "TEST", 135, 158], ["latex agglutination", "TEST", 160, 179], ["electron microscopy", "TEST", 183, 202], ["green to grey colour", "OBSERVATION_MODIFIER", 21, 41], ["non fetid", "OBSERVATION_MODIFIER", 49, 58], ["viral particles", "OBSERVATION", 103, 118]]], ["Electron microscopy is the gold standard but it is not routinely available and results take several days.", [["Electron microscopy", "TEST", 0, 19]]], ["Virus isolation is difficult as rotaviruses are difficult to grow in cell culture.TreatmentTreatment consists of maintaining hydration, oral electrolyte solutions may be sufficient, and anti-ulcer medication.", [["cell culture", "ANATOMY", 69, 81], ["oral", "ANATOMY", 136, 140], ["Virus", "ORGANISM", 0, 5], ["rotaviruses", "ORGANISM", 32, 43], ["cell culture", "CELL", 69, 81], ["oral", "ORGANISM_SUBDIVISION", 136, 140], ["Virus isolation", "TREATMENT", 0, 15], ["rotaviruses", "PROBLEM", 32, 43], ["cell culture", "TEST", 69, 81], ["maintaining hydration", "TREATMENT", 113, 134], ["oral electrolyte solutions", "TREATMENT", 136, 162], ["anti-ulcer medication", "TREATMENT", 186, 207]]], ["Hyperimmune plasma is available and can be administered prophylactically intravenously to at-risk foals.", [["Hyperimmune plasma", "ANATOMY", 0, 18], ["intravenously", "ANATOMY", 73, 86], ["plasma", "ORGANISM_SUBSTANCE", 12, 18], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 73, 86], ["foals", "ORGANISM", 98, 103], ["Hyperimmune plasma", "TEST", 0, 18]]], ["Colostral antibodies are not protective alone as cellular immunity is thought to be an important aspect of recovery.TreatmentThese foals do best being maintained on mares' milk as this contains locally-protective IgM.PreventionInactivated vaccines have been developed for use in mares during the eighth, ninth and tenth months of gestation, and are shown to increase antibody levels in mares and their foals for up to 90 days.Coronavirus and adenovirusCoronavirus and adenovirus infections are much rarer in the foal, although there are case reports in the literature of these viruses as causes of clinical diarrhoea in immune-suppressed animals.BACTERIAL ENTERITISWith the exception of E. coli infection, in bacterial infections such as Salmonella and Clostridia the bacteria invade the mucosa and submucosa causing extensive damage.", [["cellular", "ANATOMY", 49, 57], ["milk", "ANATOMY", 172, 176], ["mucosa", "ANATOMY", 788, 794], ["submucosa", "ANATOMY", 799, 808], ["adenovirus infections", "DISEASE", 468, 489], ["diarrhoea", "DISEASE", 607, 616], ["E. coli infection", "DISEASE", 687, 704], ["bacterial infections", "DISEASE", 709, 729], ["Colostral antibodies", "GENE_OR_GENE_PRODUCT", 0, 20], ["cellular", "CELL", 49, 57], ["mares", "ORGANISM", 165, 170], ["milk", "ORGANISM_SUBSTANCE", 172, 176], ["IgM.", "ORGANISM", 213, 217], ["mares", "ORGANISM", 279, 284], ["mares", "ORGANISM", 386, 391], ["adenovirusCoronavirus", "ORGANISM", 442, 463], ["adenovirus", "ORGANISM", 468, 478], ["foal", "ORGANISM_SUBDIVISION", 512, 516], ["E. coli", "ORGANISM", 687, 694], ["mucosa", "MULTI-TISSUE_STRUCTURE", 788, 794], ["submucosa", "MULTI-TISSUE_STRUCTURE", 799, 808], ["Colostral antibodies", "PROTEIN", 0, 20], ["E. coli", "SPECIES", 687, 694], ["adenovirus", "SPECIES", 468, 478], ["E. coli", "SPECIES", 687, 694], ["Salmonella", "SPECIES", 738, 748], ["Colostral antibodies", "TEST", 0, 20], ["Treatment", "TREATMENT", 116, 125], ["mares' milk", "TREATMENT", 165, 176], ["Inactivated vaccines", "TREATMENT", 227, 247], ["antibody levels", "TEST", 367, 382], ["Coronavirus", "PROBLEM", 426, 437], ["adenovirusCoronavirus", "PROBLEM", 442, 463], ["adenovirus infections", "PROBLEM", 468, 489], ["these viruses", "PROBLEM", 571, 584], ["clinical diarrhoea", "PROBLEM", 598, 616], ["E. coli infection", "PROBLEM", 687, 704], ["bacterial infections", "PROBLEM", 709, 729], ["Salmonella", "PROBLEM", 738, 748], ["Clostridia the bacteria", "PROBLEM", 753, 776], ["extensive damage", "PROBLEM", 817, 833], ["adenovirusCoronavirus", "OBSERVATION", 442, 463], ["viruses", "OBSERVATION", 577, 584], ["E. coli", "OBSERVATION_MODIFIER", 687, 694], ["infection", "OBSERVATION", 695, 704], ["bacterial", "OBSERVATION_MODIFIER", 709, 718], ["infections", "OBSERVATION", 719, 729], ["mucosa", "ANATOMY", 788, 794], ["submucosa", "ANATOMY", 799, 808], ["extensive", "OBSERVATION_MODIFIER", 817, 826], ["damage", "OBSERVATION", 827, 833]]], ["Cells at the base of the crypts are more severely affected, hence the changes are more persistent.", [["Cells", "ANATOMY", 0, 5], ["crypts", "ANATOMY", 25, 31], ["Cells", "CELL", 0, 5], ["crypts", "MULTI-TISSUE_STRUCTURE", 25, 31], ["base", "ANATOMY_MODIFIER", 13, 17], ["crypts", "OBSERVATION", 25, 31], ["more severely", "OBSERVATION_MODIFIER", 36, 49], ["affected", "OBSERVATION_MODIFIER", 50, 58], ["more", "OBSERVATION_MODIFIER", 82, 86], ["persistent", "OBSERVATION_MODIFIER", 87, 97]]], ["Polymorph leukocyte invasion and inflammation of the deeper layers of the intestinal wall occur.", [["leukocyte", "ANATOMY", 10, 19], ["deeper layers", "ANATOMY", 53, 66], ["intestinal wall", "ANATOMY", 74, 89], ["leukocyte", "CELL", 10, 19], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 74, 89], ["Polymorph leukocyte invasion", "PROBLEM", 0, 28], ["inflammation", "PROBLEM", 33, 45], ["leukocyte invasion", "OBSERVATION", 10, 28], ["inflammation", "OBSERVATION", 33, 45], ["deeper", "ANATOMY_MODIFIER", 53, 59], ["layers", "ANATOMY_MODIFIER", 60, 66], ["intestinal wall", "ANATOMY", 74, 89]]], ["There is a loss of absorptive and secretory function, leakage of plasma proteins and intestinal spasms.", [["secretory", "ANATOMY", 34, 43], ["plasma", "ANATOMY", 65, 71], ["intestinal", "ANATOMY", 85, 95], ["intestinal spasms", "DISEASE", 85, 102], ["plasma", "ORGANISM_SUBSTANCE", 65, 71], ["intestinal", "ORGAN", 85, 95], ["plasma proteins", "PROTEIN", 65, 80], ["a loss of absorptive and secretory function", "PROBLEM", 9, 52], ["leakage of plasma proteins", "PROBLEM", 54, 80], ["intestinal spasms", "PROBLEM", 85, 102], ["loss", "OBSERVATION_MODIFIER", 11, 15], ["absorptive", "OBSERVATION_MODIFIER", 19, 29], ["secretory function", "OBSERVATION", 34, 52], ["leakage", "OBSERVATION_MODIFIER", 54, 61], ["plasma proteins", "OBSERVATION", 65, 80], ["intestinal", "ANATOMY", 85, 95], ["spasms", "OBSERVATION", 96, 102]]], ["Diarrhoea is often profuse, fetid and haemorrhagic.E. coliE. coli is one of the most common causes of sepsis in foals but it is not usually associated with diarrhoea, unlike in farm animals.", [["fetid", "ANATOMY", 28, 33], ["Diarrhoea", "DISEASE", 0, 9], ["fetid", "DISEASE", 28, 33], ["haemorrhagic", "DISEASE", 38, 50], ["sepsis", "DISEASE", 102, 108], ["diarrhoea", "DISEASE", 156, 165], ["coli", "ORGANISM", 61, 65], ["foals", "ORGANISM", 112, 117], ["coli", "SPECIES", 61, 65], ["E. coliE", "SPECIES", 51, 59], ["coli", "SPECIES", 61, 65], ["Diarrhoea", "PROBLEM", 0, 9], ["haemorrhagic", "PROBLEM", 38, 50], ["coli", "PROBLEM", 61, 65], ["sepsis in foals", "PROBLEM", 102, 117], ["diarrhoea", "PROBLEM", 156, 165], ["often", "OBSERVATION_MODIFIER", 13, 18], ["profuse", "OBSERVATION_MODIFIER", 19, 26], ["haemorrhagic", "OBSERVATION_MODIFIER", 38, 50], ["coliE", "OBSERVATION", 54, 59], ["one of the most common", "OBSERVATION_MODIFIER", 69, 91], ["sepsis", "OBSERVATION", 102, 108]]], ["There is no relationship between its presence in faeces and the incidence of diarrhoea.", [["diarrhoea", "DISEASE", 77, 86], ["faeces", "ORGANISM_SUBDIVISION", 49, 55], ["diarrhoea", "PROBLEM", 77, 86], ["no relationship", "UNCERTAINTY", 9, 24], ["diarrhoea", "OBSERVATION", 77, 86]]], ["Diarrhoea may be caused by the production of an enterotoxin resulting inTreatmentThe use of antimicrobials is controversial, as they do appear to increase the risk of faecal shedding of Salmonella, and affect the normal gut flora.", [["faecal", "ANATOMY", 167, 173], ["gut flora", "ANATOMY", 220, 229], ["Diarrhoea", "DISEASE", 0, 9], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 48, 59], ["faecal", "ORGANISM_SUBSTANCE", 167, 173], ["gut flora", "PATHOLOGICAL_FORMATION", 220, 229], ["enterotoxin", "PROTEIN", 48, 59], ["Salmonella", "SPECIES", 186, 196], ["Diarrhoea", "PROBLEM", 0, 9], ["an enterotoxin", "TREATMENT", 45, 59], ["antimicrobials", "TREATMENT", 92, 106], ["faecal shedding of Salmonella", "PROBLEM", 167, 196]]], ["Antibiotics are more indicated in neutropenic horses at risk of bacterial translocation across the damaged epithelium.", [["epithelium", "ANATOMY", 107, 117], ["epithelium", "TISSUE", 107, 117], ["Antibiotics", "TREATMENT", 0, 11], ["neutropenic horses", "PROBLEM", 34, 52], ["bacterial translocation", "PROBLEM", 64, 87], ["the damaged epithelium", "PROBLEM", 95, 117], ["bacterial translocation", "OBSERVATION", 64, 87], ["damaged epithelium", "OBSERVATION", 99, 117]]], ["The ideal antibiotic would be an antibiotic such as enrofloxacin that is bactericidal, affects Gram -ve bacteria, has intracellular penetration, minimal resistance and minimal effect on the commensal flora.", [["intracellular", "ANATOMY", 118, 131], ["enrofloxacin", "CHEMICAL", 52, 64], ["enrofloxacin", "CHEMICAL", 52, 64], ["enrofloxacin", "SIMPLE_CHEMICAL", 52, 64], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 118, 131], ["The ideal antibiotic", "TREATMENT", 0, 20], ["an antibiotic", "TREATMENT", 30, 43], ["enrofloxacin", "TREATMENT", 52, 64], ["bactericidal", "PROBLEM", 73, 85], ["Gram -ve bacteria", "PROBLEM", 95, 112], ["intracellular penetration", "PROBLEM", 118, 143], ["minimal resistance", "PROBLEM", 145, 163], ["minimal effect on the commensal flora", "PROBLEM", 168, 205], ["intracellular penetration", "OBSERVATION", 118, 143], ["minimal resistance", "OBSERVATION", 145, 163], ["minimal", "OBSERVATION_MODIFIER", 168, 175], ["effect", "OBSERVATION_MODIFIER", 176, 182], ["commensal flora", "OBSERVATION", 190, 205]]], ["However, enrofloxacin is contraindicated in foals due to its effects on cartilage maturation.", [["cartilage", "ANATOMY", 72, 81], ["enrofloxacin", "CHEMICAL", 9, 21], ["enrofloxacin", "CHEMICAL", 9, 21], ["enrofloxacin", "SIMPLE_CHEMICAL", 9, 21], ["foals", "ORGANISM", 44, 49], ["cartilage", "TISSUE", 72, 81], ["enrofloxacin", "TREATMENT", 9, 21], ["cartilage maturation", "TREATMENT", 72, 92]]], ["If antibiotics are deemed necessary, broad-spectrum coverage should be provided.", [["antibiotics", "TREATMENT", 3, 14], ["broad-spectrum coverage", "TREATMENT", 37, 60]]], ["Multidrug resistance is a particular problem with S. typhimurium DT 104, particularly in other species, e.g. humans.TreatmentClostridiosis C. perfringens type A colonises the intestinal tract of neonatal foals within the first few days of life and as a result is normally cultured in the faeces.", [["intestinal tract", "ANATOMY", 175, 191], ["faeces", "ANATOMY", 288, 294], ["Clostridiosis C. perfringens type A", "CHEMICAL", 125, 160], ["S. typhimurium", "ORGANISM", 50, 64], ["DT 104", "ORGANISM", 65, 71], ["humans", "ORGANISM", 109, 115], ["Clostridiosis", "ORGANISM", 125, 138], ["C. perfringens type A", "ORGANISM", 139, 160], ["intestinal tract", "ORGAN", 175, 191], ["foals", "ORGANISM_SUBDIVISION", 204, 209], ["faeces", "ORGANISM_SUBDIVISION", 288, 294], ["S. typhimurium", "SPECIES", 50, 64], ["humans", "SPECIES", 109, 115], ["C. perfringens", "SPECIES", 139, 153], ["S. typhimurium", "SPECIES", 50, 64], ["humans", "SPECIES", 109, 115], ["C. perfringens type A", "SPECIES", 139, 160], ["Multidrug resistance", "PROBLEM", 0, 20], ["a particular problem", "PROBLEM", 24, 44], ["S. typhimurium DT", "PROBLEM", 50, 67], ["TreatmentClostridiosis C. perfringens", "PROBLEM", 116, 153], ["neonatal foals", "PROBLEM", 195, 209], ["perfringens type", "OBSERVATION_MODIFIER", 142, 158], ["intestinal tract", "ANATOMY", 175, 191]]], ["C. perfringens type C and type A can be associated with diarrhoea in older foals.", [["diarrhoea", "DISEASE", 56, 65], ["C. perfringens type C", "ORGANISM", 0, 21], ["type A", "GENE_OR_GENE_PRODUCT", 26, 32], ["C. perfringens", "SPECIES", 0, 14], ["C. perfringens", "SPECIES", 0, 14], ["C. perfringens type C and type A", "PROBLEM", 0, 32], ["diarrhoea in older foals", "PROBLEM", 56, 80], ["perfringens", "OBSERVATION", 3, 14], ["type C", "OBSERVATION_MODIFIER", 15, 21]]], ["Colostrum has been associated with an increased risk of clinical signs: it is postulated that trypsin inhibitors, present in the dam's colostrum to protect IgG, may allow toxins to persist.Clinical signs and diagnosisClinical signs include acute abdominal pain, fever and haemorrhagic diarrhoea (Fig. 1) and are associated with a mortality.", [["colostrum", "ANATOMY", 135, 144], ["abdominal", "ANATOMY", 246, 255], ["Colostrum", "CHEMICAL", 0, 9], ["abdominal pain", "DISEASE", 246, 260], ["fever", "DISEASE", 262, 267], ["haemorrhagic diarrhoea", "DISEASE", 272, 294], ["trypsin", "GENE_OR_GENE_PRODUCT", 94, 101], ["colostrum", "ORGANISM", 135, 144], ["IgG", "GENE_OR_GENE_PRODUCT", 156, 159], ["abdominal", "ORGANISM_SUBDIVISION", 246, 255], ["IgG", "PROTEIN", 156, 159], ["trypsin inhibitors", "TREATMENT", 94, 112], ["IgG", "TREATMENT", 156, 159], ["toxins", "PROBLEM", 171, 177], ["Clinical signs", "TEST", 189, 203], ["diagnosisClinical signs", "PROBLEM", 208, 231], ["acute abdominal pain", "PROBLEM", 240, 260], ["fever", "PROBLEM", 262, 267], ["haemorrhagic diarrhoea", "PROBLEM", 272, 294], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["abdominal", "ANATOMY", 246, 255], ["pain", "OBSERVATION", 256, 260], ["fever", "OBSERVATION", 262, 267], ["haemorrhagic", "OBSERVATION_MODIFIER", 272, 284]]], ["C. difficile can be cultured in healthy foals, unlike healthy adult horses, but it can also be a primary pathogen, being less associated with previous antibiotic therapy than in adults.Clinical signs and diagnosisSerum biochemical changes are highly variable.", [["C. difficile", "DISEASE", 0, 12], ["C. difficile", "ORGANISM", 0, 12], ["foals", "ORGANISM", 40, 45], ["horses", "ORGANISM", 68, 74], ["C. difficile", "SPECIES", 0, 12], ["C. difficile", "SPECIES", 0, 12], ["C. difficile", "PROBLEM", 0, 12], ["a primary pathogen", "PROBLEM", 95, 113], ["previous antibiotic therapy", "TREATMENT", 142, 169], ["Clinical signs", "TEST", 185, 199], ["diagnosisSerum biochemical changes", "PROBLEM", 204, 238], ["difficile", "OBSERVATION", 3, 12]]], ["Abdominocentesis may yield an exudate if severe enteritis is present.", [["Abdominocentesis", "DISEASE", 0, 16], ["enteritis", "DISEASE", 48, 57], ["Abdominocentesis", "TREATMENT", 0, 16], ["an exudate", "PROBLEM", 27, 37], ["severe enteritis", "PROBLEM", 41, 57], ["exudate", "OBSERVATION", 30, 37], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["enteritis", "OBSERVATION", 48, 57]]], ["Gas and fluid distension of the small and large intestine may be visible on ultrasonography and radiography.", [["fluid", "ANATOMY", 8, 13], ["intestine", "ANATOMY", 48, 57], ["Gas", "ORGANISM_SUBSTANCE", 0, 3], ["intestine", "ORGAN", 48, 57], ["Gas", "TEST", 0, 3], ["fluid distension of the small and large intestine", "PROBLEM", 8, 57], ["ultrasonography", "TEST", 76, 91], ["radiography", "TEST", 96, 107], ["fluid distension", "OBSERVATION", 8, 24], ["small", "OBSERVATION_MODIFIER", 32, 37], ["large intestine", "ANATOMY", 42, 57], ["may be", "UNCERTAINTY", 58, 64]]], ["Rectal swabs may reveal many Gram +ve rods.", [["Rectal swabs", "ANATOMY", 0, 12], ["Rectal swabs", "TEST", 0, 12], ["many Gram +ve rods", "PROBLEM", 24, 42], ["ve rods", "OBSERVATION", 35, 42]]], ["Bacterial culture and toxin isolation from faecal samples are required.TreatmentIn foals with C. perfringens symptomatic treatment should be provided.", [["faecal samples", "ANATOMY", 43, 57], ["C. perfringens", "DISEASE", 94, 108], ["faecal samples", "CANCER", 43, 57], ["foals", "ORGANISM", 83, 88], ["C. perfringens", "ORGANISM", 94, 108], ["C. perfringens", "SPECIES", 94, 108], ["C. perfringens", "SPECIES", 94, 108], ["Bacterial culture", "TEST", 0, 17], ["toxin isolation from faecal samples", "TEST", 22, 57], ["TreatmentIn foals", "TREATMENT", 71, 88], ["C. perfringens symptomatic treatment", "TREATMENT", 94, 130]]], ["Analgesics such as butorphanol combined with anti-ulcer medication may be necessary.", [["butorphanol", "CHEMICAL", 19, 30], ["butorphanol", "CHEMICAL", 19, 30], ["butorphanol", "SIMPLE_CHEMICAL", 19, 30], ["Analgesics", "TREATMENT", 0, 10], ["butorphanol", "TREATMENT", 19, 30], ["anti-ulcer medication", "TREATMENT", 45, 66]]], ["DTO smectite and probiotics containing Saccharomyces have all been described.", [["DTO smectite", "CHEMICAL", 0, 12], ["DTO", "SIMPLE_CHEMICAL", 0, 3], ["DTO smectite", "TREATMENT", 0, 12], ["probiotics containing Saccharomyces", "TREATMENT", 17, 52]]], ["Broadspectrum antibiotics, e.g. penicillin in combination with amikacin or cephalosporins and metronidazole, should be given and milk should be withheld as malabsorption results in osmotic diarrhoea.", [["milk", "ANATOMY", 129, 133], ["penicillin", "CHEMICAL", 32, 42], ["amikacin", "CHEMICAL", 63, 71], ["cephalosporins", "CHEMICAL", 75, 89], ["metronidazole", "CHEMICAL", 94, 107], ["malabsorption", "DISEASE", 156, 169], ["diarrhoea", "DISEASE", 189, 198], ["penicillin", "CHEMICAL", 32, 42], ["amikacin", "CHEMICAL", 63, 71], ["cephalosporins", "CHEMICAL", 75, 89], ["metronidazole", "CHEMICAL", 94, 107], ["penicillin", "SIMPLE_CHEMICAL", 32, 42], ["amikacin", "SIMPLE_CHEMICAL", 63, 71], ["cephalosporins", "SIMPLE_CHEMICAL", 75, 89], ["metronidazole", "SIMPLE_CHEMICAL", 94, 107], ["milk", "ORGANISM_SUBSTANCE", 129, 133], ["Broadspectrum antibiotics", "TREATMENT", 0, 25], ["penicillin", "TREATMENT", 32, 42], ["amikacin", "TREATMENT", 63, 71], ["cephalosporins", "TREATMENT", 75, 89], ["metronidazole", "TREATMENT", 94, 107], ["milk", "TREATMENT", 129, 133], ["malabsorption", "PROBLEM", 156, 169], ["osmotic diarrhoea", "PROBLEM", 181, 198], ["osmotic diarrhoea", "OBSERVATION", 181, 198]]], ["Oral antitoxins to type C and D have been described but there is no evidence to support a beneficial effect of this.", [["Oral", "ANATOMY", 0, 4], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["type C", "GENE_OR_GENE_PRODUCT", 19, 25], ["D", "SIMPLE_CHEMICAL", 30, 31], ["Oral antitoxins", "TREATMENT", 0, 15], ["type C and D", "PROBLEM", 19, 31], ["no evidence to", "UNCERTAINTY", 65, 79]]], ["Hyperimmune plasma is available.Rhodococcus equiR. equi is an aerobic Gram +ve bacillus and saprophytic soil inhabitant.", [["Hyperimmune plasma", "ANATOMY", 0, 18], ["plasma", "ORGANISM_SUBSTANCE", 12, 18], ["Rhodococcus equiR", "ORGANISM", 32, 49], ["equi", "ORGANISM", 51, 55], ["equi", "SPECIES", 51, 55], ["Rhodococcus equiR", "SPECIES", 32, 49], ["equi", "SPECIES", 51, 55], ["Hyperimmune plasma", "TEST", 0, 18], ["an aerobic Gram", "TEST", 59, 74], ["ve bacillus", "PROBLEM", 76, 87], ["saprophytic soil inhabitant", "PROBLEM", 92, 119], ["bacillus", "ANATOMY", 79, 87], ["saprophytic", "OBSERVATION_MODIFIER", 92, 103], ["soil inhabitant", "OBSERVATION", 104, 119]]], ["It is an intracellular bacterium which resides in macrophages, resulting in necrosis of lymphatic tissue within Peyer's patches of the gastrointestinal tract.", [["intracellular", "ANATOMY", 9, 22], ["macrophages", "ANATOMY", 50, 61], ["lymphatic tissue", "ANATOMY", 88, 104], ["gastrointestinal tract", "ANATOMY", 135, 157], ["necrosis", "DISEASE", 76, 84], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 9, 22], ["macrophages", "CELL", 50, 61], ["lymphatic tissue", "TISSUE", 88, 104], ["gastrointestinal tract", "ORGAN", 135, 157], ["macrophages", "CELL_TYPE", 50, 61], ["an intracellular bacterium", "PROBLEM", 6, 32], ["necrosis of lymphatic tissue", "PROBLEM", 76, 104], ["intracellular bacterium", "OBSERVATION", 9, 32], ["macrophages", "OBSERVATION", 50, 61], ["necrosis", "OBSERVATION", 76, 84], ["lymphatic tissue", "OBSERVATION", 88, 104], ["gastrointestinal tract", "ANATOMY", 135, 157]]], ["Infection can result in bronchopneumonia or enteric infection with septicaemic forms sequestering the organism into joints, bone, eyes or the liver.", [["joints", "ANATOMY", 116, 122], ["bone", "ANATOMY", 124, 128], ["eyes", "ANATOMY", 130, 134], ["liver", "ANATOMY", 142, 147], ["Infection", "DISEASE", 0, 9], ["bronchopneumonia", "DISEASE", 24, 40], ["enteric infection", "DISEASE", 44, 61], ["joints", "MULTI-TISSUE_STRUCTURE", 116, 122], ["bone", "TISSUE", 124, 128], ["eyes", "ORGAN", 130, 134], ["liver", "ORGAN", 142, 147], ["Infection", "PROBLEM", 0, 9], ["bronchopneumonia", "PROBLEM", 24, 40], ["enteric infection", "PROBLEM", 44, 61], ["septicaemic forms sequestering the organism into joints, bone, eyes or the liver", "PROBLEM", 67, 147], ["bronchopneumonia", "OBSERVATION", 24, 40], ["enteric", "OBSERVATION_MODIFIER", 44, 51], ["infection", "OBSERVATION", 52, 61], ["joints", "ANATOMY", 116, 122], ["bone", "ANATOMY", 124, 128], ["eyes", "ANATOMY", 130, 134], ["liver", "ANATOMY", 142, 147]]], ["Affected foals are usually 2-3 months of age and often present with lethargy, depression, fever, suppurative colitis or colic.", [["lethargy", "DISEASE", 68, 76], ["depression", "DISEASE", 78, 88], ["fever", "DISEASE", 90, 95], ["suppurative colitis", "DISEASE", 97, 116], ["colic", "DISEASE", 120, 125], ["foals", "ORGANISM", 9, 14], ["Affected foals", "PROBLEM", 0, 14], ["lethargy", "PROBLEM", 68, 76], ["depression", "PROBLEM", 78, 88], ["fever", "PROBLEM", 90, 95], ["suppurative colitis", "PROBLEM", 97, 116], ["colic", "PROBLEM", 120, 125], ["suppurative", "OBSERVATION_MODIFIER", 97, 108], ["colitis", "OBSERVATION", 109, 116], ["colic", "OBSERVATION", 120, 125]]], ["It is rare to get alimentary signs without pulmonary involvement.", [["pulmonary", "ANATOMY", 43, 52], ["pulmonary", "ORGAN", 43, 52], ["pulmonary involvement", "PROBLEM", 43, 64], ["without", "UNCERTAINTY", 35, 42], ["pulmonary", "ANATOMY", 43, 52], ["involvement", "OBSERVATION", 53, 64]]], ["Approximately 50% of those with bronchopneumonia also have intestinal pathology.DiagnosisThe organism is easily isolated from diarrhoeic faeces.", [["intestinal", "ANATOMY", 59, 69], ["faeces", "ANATOMY", 137, 143], ["bronchopneumonia", "DISEASE", 32, 48], ["intestinal", "ORGAN", 59, 69], ["faeces", "ORGANISM_SUBSTANCE", 137, 143], ["bronchopneumonia", "PROBLEM", 32, 48], ["intestinal pathology", "PROBLEM", 59, 79], ["The organism", "PROBLEM", 89, 101], ["diarrhoeic faeces", "PROBLEM", 126, 143], ["bronchopneumonia", "OBSERVATION", 32, 48], ["intestinal", "ANATOMY", 59, 69], ["pathology", "OBSERVATION", 70, 79], ["diarrhoeic faeces", "OBSERVATION", 126, 143]]], ["Culture and identification via PCR is the gold standard for diagnosis.", [["Culture", "TEST", 0, 7], ["PCR", "TEST", 31, 34]]], ["Serological tests, including western blots, ELISAs and haemolysis inhibition, are available.TreatmentMacrolides and rifampicin (5 mg/kg q 12h PO) act synergistically to provide good penetration of abscesses and cells.", [["abscesses", "ANATOMY", 197, 206], ["cells", "ANATOMY", 211, 216], ["haemolysis", "DISEASE", 55, 65], ["Macrolides", "CHEMICAL", 101, 111], ["rifampicin", "CHEMICAL", 116, 126], ["abscesses", "DISEASE", 197, 206], ["Macrolides", "CHEMICAL", 101, 111], ["rifampicin", "CHEMICAL", 116, 126], ["Macrolides", "SIMPLE_CHEMICAL", 101, 111], ["rifampicin", "SIMPLE_CHEMICAL", 116, 126], ["abscesses", "PATHOLOGICAL_FORMATION", 197, 206], ["cells", "CELL", 211, 216], ["Serological tests", "TEST", 0, 17], ["western blots", "TEST", 29, 42], ["ELISAs", "TEST", 44, 50], ["haemolysis inhibition", "TEST", 55, 76], ["TreatmentMacrolides", "TREATMENT", 92, 111], ["rifampicin", "TREATMENT", 116, 126], ["abscesses and cells", "PROBLEM", 197, 216], ["abscesses", "OBSERVATION", 197, 206]]], ["Erythromycin can itself result in diarrhoea and hyperthermia.", [["Erythromycin", "CHEMICAL", 0, 12], ["diarrhoea", "DISEASE", 34, 43], ["hyperthermia", "DISEASE", 48, 60], ["Erythromycin", "CHEMICAL", 0, 12], ["Erythromycin", "SIMPLE_CHEMICAL", 0, 12], ["Erythromycin", "TREATMENT", 0, 12], ["diarrhoea", "PROBLEM", 34, 43], ["hyperthermia", "PROBLEM", 48, 60], ["diarrhoea", "OBSERVATION", 34, 43], ["hyperthermia", "OBSERVATION", 48, 60]]], ["If this occurs, a gentamicin and rifampicin combination may have to be used.", [["gentamicin", "CHEMICAL", 18, 28], ["rifampicin", "CHEMICAL", 33, 43], ["gentamicin", "CHEMICAL", 18, 28], ["rifampicin", "CHEMICAL", 33, 43], ["gentamicin", "SIMPLE_CHEMICAL", 18, 28], ["rifampicin", "SIMPLE_CHEMICAL", 33, 43], ["a gentamicin", "TREATMENT", 16, 28], ["rifampicin combination", "TREATMENT", 33, 55]]], ["Various erythromycin preparations are available, but erythromycin estolate has the best absorption, fewest side effects and a lower dosing frequency.", [["erythromycin", "CHEMICAL", 8, 20], ["erythromycin", "CHEMICAL", 53, 65], ["estolate", "CHEMICAL", 66, 74], ["erythromycin", "CHEMICAL", 8, 20], ["erythromycin estolate", "CHEMICAL", 53, 74], ["erythromycin", "SIMPLE_CHEMICAL", 8, 20], ["erythromycin estolate", "SIMPLE_CHEMICAL", 53, 74], ["Various erythromycin preparations", "TREATMENT", 0, 33], ["erythromycin estolate", "TREATMENT", 53, 74], ["fewest side effects", "PROBLEM", 100, 119], ["a lower dosing frequency", "TREATMENT", 124, 148]]], ["Azithromycin has the advantage that it only needs to be given once a day and clarithromycin only twice a day compared to erythromycin which requires three or four times daily dosing.", [["Azithromycin", "CHEMICAL", 0, 12], ["clarithromycin", "CHEMICAL", 77, 91], ["erythromycin", "CHEMICAL", 121, 133], ["Azithromycin", "CHEMICAL", 0, 12], ["clarithromycin", "CHEMICAL", 77, 91], ["erythromycin", "CHEMICAL", 121, 133], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["clarithromycin", "SIMPLE_CHEMICAL", 77, 91], ["erythromycin", "SIMPLE_CHEMICAL", 121, 133], ["Azithromycin", "TREATMENT", 0, 12], ["clarithromycin", "TREATMENT", 77, 91], ["erythromycin", "TREATMENT", 121, 133]]], ["Clarithromycin has been associated with better treatment outcomes.TreatmentPlasma has been given prophylactically on endemic farms and hyperimmune preparations are available.", [["Clarithromycin", "CHEMICAL", 0, 14], ["Clarithromycin", "CHEMICAL", 0, 14], ["Clarithromycin", "SIMPLE_CHEMICAL", 0, 14], ["Plasma", "ORGANISM_SUBSTANCE", 75, 81], ["hyperimmune", "ORGANISM", 135, 146], ["Clarithromycin", "TREATMENT", 0, 14], ["TreatmentPlasma", "TREATMENT", 66, 81], ["endemic farms", "TREATMENT", 117, 130], ["hyperimmune preparations", "TREATMENT", 135, 159]]], ["Vaccinating mares has not been effective in preventing disease and recent research looking at foal vaccines, using killed bacterin, has been disappointing.", [["mares", "ORGANISM", 12, 17], ["foal", "ORGANISM_SUBDIVISION", 94, 98], ["Vaccinating mares", "TREATMENT", 0, 17], ["disease", "PROBLEM", 55, 62], ["foal vaccines", "TREATMENT", 94, 107], ["killed bacterin", "TREATMENT", 115, 130], ["disease", "OBSERVATION", 55, 62]]], ["Vaccination was more successful using non-attenuated organisms orally, which results in increased IgG levels.Lawsonia intracellularisProliferative enteropathy caused by Lawsonia intracellularis causes diarrhoea in foals of 4-7 months of age (Fig. 2) .", [["Proliferative enteropathy", "DISEASE", 133, 158], ["Lawsonia intracellularis", "DISEASE", 169, 193], ["diarrhoea", "DISEASE", 201, 210], ["IgG", "GENE_OR_GENE_PRODUCT", 98, 101], ["Lawsonia intracellularis", "ORGANISM", 109, 133], ["Lawsonia intracellularis", "ORGANISM", 169, 193], ["IgG", "PROTEIN", 98, 101], ["Lawsonia intracellularis", "SPECIES", 109, 133], ["Lawsonia intracellularis", "SPECIES", 169, 193], ["Lawsonia intracellularis", "SPECIES", 109, 133], ["Lawsonia intracellularis", "SPECIES", 169, 193], ["Vaccination", "TREATMENT", 0, 11], ["non-attenuated organisms", "PROBLEM", 38, 62], ["increased IgG levels", "PROBLEM", 88, 108], ["Lawsonia intracellularis", "PROBLEM", 109, 133], ["Proliferative enteropathy", "PROBLEM", 133, 158], ["Lawsonia intracellularis", "PROBLEM", 169, 193], ["diarrhoea", "PROBLEM", 201, 210], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["IgG levels", "OBSERVATION", 98, 108], ["enteropathy", "OBSERVATION", 147, 158], ["Lawsonia intracellularis", "OBSERVATION", 169, 193]]], ["Typical lesions are seen along the jejunum and ileum and can be seen ultrasonographically as a profoundly thickened small intestinal wall (Figs.", [["lesions", "ANATOMY", 8, 15], ["jejunum", "ANATOMY", 35, 42], ["ileum", "ANATOMY", 47, 52], ["small intestinal wall", "ANATOMY", 116, 137], ["lesions", "PATHOLOGICAL_FORMATION", 8, 15], ["jejunum", "MULTI-TISSUE_STRUCTURE", 35, 42], ["ileum", "ORGAN", 47, 52], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 122, 137], ["Typical lesions", "PROBLEM", 0, 15], ["a profoundly thickened small intestinal wall", "PROBLEM", 93, 137], ["lesions", "OBSERVATION", 8, 15], ["jejunum", "ANATOMY", 35, 42], ["ileum", "ANATOMY", 47, 52], ["profoundly", "OBSERVATION_MODIFIER", 95, 105], ["thickened", "OBSERVATION", 106, 115], ["small", "OBSERVATION_MODIFIER", 116, 121], ["intestinal wall", "ANATOMY", 122, 137]]], ["3 and 4) , leading to a decrease in gut lumen.Lawsonia intracellularisClinical signs include diarrhoea, colic, anorexia, weight loss, a failure to thrive and ventral oedema.", [["gut lumen", "ANATOMY", 36, 45], ["ventral oedema", "ANATOMY", 158, 172], ["diarrhoea", "DISEASE", 93, 102], ["colic", "DISEASE", 104, 109], ["anorexia", "DISEASE", 111, 119], ["weight loss", "DISEASE", 121, 132], ["ventral oedema", "DISEASE", 158, 172], ["gut lumen", "MULTI-TISSUE_STRUCTURE", 36, 45], ["a decrease in gut lumen", "PROBLEM", 22, 45], ["Lawsonia intracellularisClinical signs", "PROBLEM", 46, 84], ["diarrhoea", "PROBLEM", 93, 102], ["colic", "PROBLEM", 104, 109], ["anorexia", "PROBLEM", 111, 119], ["weight loss", "PROBLEM", 121, 132], ["a failure to thrive", "PROBLEM", 134, 153], ["ventral oedema", "PROBLEM", 158, 172], ["decrease", "OBSERVATION_MODIFIER", 24, 32], ["gut", "ANATOMY", 36, 39], ["lumen", "ANATOMY_MODIFIER", 40, 45], ["diarrhoea", "OBSERVATION", 93, 102], ["colic", "ANATOMY", 104, 109], ["anorexia", "OBSERVATION", 111, 119], ["weight loss", "OBSERVATION", 121, 132], ["ventral", "ANATOMY_MODIFIER", 158, 165], ["oedema", "OBSERVATION", 166, 172]]], ["Hypoalbuminaemia with neutrophilia are characteristic laboratory findings and confirmation of the diagnosis can be made via faecal PCR or identification of the organism within the intestinal mucosal crypt cells at biopsy.Lawsonia intracellularisThe treatment of choice is a prolonged course of oxytetracycline.", [["faecal", "ANATOMY", 124, 130], ["intestinal mucosal crypt cells", "ANATOMY", 180, 210], ["Hypoalbuminaemia", "DISEASE", 0, 16], ["neutrophilia", "DISEASE", 22, 34], ["oxytetracycline", "CHEMICAL", 294, 309], ["oxytetracycline", "CHEMICAL", 294, 309], ["faecal", "ORGANISM_SUBSTANCE", 124, 130], ["intestinal mucosal crypt cells", "CELL", 180, 210], ["Lawsonia intracellularis", "ORGANISM", 221, 245], ["oxytetracycline", "SIMPLE_CHEMICAL", 294, 309], ["intestinal mucosal crypt cells", "CELL_TYPE", 180, 210], ["Lawsonia intracellularis", "SPECIES", 221, 245], ["Lawsonia intracellularis", "SPECIES", 221, 245], ["Hypoalbuminaemia", "PROBLEM", 0, 16], ["neutrophilia", "PROBLEM", 22, 34], ["faecal PCR", "TEST", 124, 134], ["the organism", "PROBLEM", 156, 168], ["biopsy", "TEST", 214, 220], ["Lawsonia intracellularis", "PROBLEM", 221, 245], ["a prolonged course of oxytetracycline", "TREATMENT", 272, 309], ["neutrophilia", "OBSERVATION", 22, 34], ["intestinal mucosal", "ANATOMY", 180, 198], ["crypt cells", "OBSERVATION", 199, 210]]], ["The use of macrolides in conjunction with rifampicin, for their intracellular penetration, has also been described.PARASITIC DIARRHOEAMigrating larvae result in inflammation and infiltration of the intestinal wall; some also cause vascular damage and motility disturbances.Large strongylesTraditionally the large strongyles were associated with colic and diarrhoea, but interval worming strategies have dramatically reduced their incidence.", [["intracellular", "ANATOMY", 64, 77], ["intestinal wall", "ANATOMY", 198, 213], ["vascular", "ANATOMY", 231, 239], ["macrolides", "CHEMICAL", 11, 21], ["rifampicin", "CHEMICAL", 42, 52], ["inflammation", "DISEASE", 161, 173], ["vascular damage", "DISEASE", 231, 246], ["colic", "DISEASE", 345, 350], ["diarrhoea", "DISEASE", 355, 364], ["macrolides", "CHEMICAL", 11, 21], ["rifampicin", "CHEMICAL", 42, 52], ["macrolides", "SIMPLE_CHEMICAL", 11, 21], ["rifampicin", "SIMPLE_CHEMICAL", 42, 52], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 77], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 198, 213], ["vascular", "MULTI-TISSUE_STRUCTURE", 231, 239], ["macrolides", "TREATMENT", 11, 21], ["rifampicin", "TREATMENT", 42, 52], ["their intracellular penetration", "PROBLEM", 58, 89], ["PARASITIC DIARRHOEAMigrating larvae", "PROBLEM", 115, 150], ["inflammation", "PROBLEM", 161, 173], ["infiltration of the intestinal wall", "PROBLEM", 178, 213], ["vascular damage", "PROBLEM", 231, 246], ["motility disturbances", "PROBLEM", 251, 272], ["Large strongyles", "PROBLEM", 273, 289], ["the large strongyles", "PROBLEM", 303, 323], ["colic", "PROBLEM", 345, 350], ["diarrhoea", "PROBLEM", 355, 364], ["interval worming strategies", "PROBLEM", 370, 397], ["intracellular penetration", "OBSERVATION", 64, 89], ["DIARRHOEAMigrating larvae", "OBSERVATION", 125, 150], ["inflammation", "OBSERVATION", 161, 173], ["infiltration", "OBSERVATION", 178, 190], ["intestinal wall", "ANATOMY", 198, 213], ["vascular", "ANATOMY", 231, 239], ["damage", "OBSERVATION", 240, 246], ["motility disturbances", "OBSERVATION", 251, 272], ["strongyles", "OBSERVATION", 279, 289], ["large", "OBSERVATION_MODIFIER", 307, 312], ["strongyles", "OBSERVATION", 313, 323], ["colic", "ANATOMY", 345, 350], ["diarrhoea", "OBSERVATION", 355, 364], ["dramatically", "OBSERVATION_MODIFIER", 403, 415], ["reduced", "OBSERVATION_MODIFIER", 416, 423]]], ["S. vulgaris, followed by S. edentatus and S. equinus, is the most important large strongyle implicated in gastrointestinal tract (GIT) disease.", [["gastrointestinal tract", "ANATOMY", 106, 128], ["GIT", "ANATOMY", 130, 133], ["S. vulgaris", "DISEASE", 0, 11], ["S. equinus", "DISEASE", 42, 52], ["gastrointestinal tract (GIT) disease", "DISEASE", 106, 142], ["S. vulgaris", "ORGANISM", 0, 11], ["S. edentatus", "ORGANISM", 25, 37], ["S. equinus", "ORGANISM", 42, 52], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 106, 128], ["GIT", "ORGAN", 130, 133], ["S. vulgaris", "SPECIES", 0, 11], ["S. edentatus", "SPECIES", 25, 37], ["S. equinus", "SPECIES", 42, 52], ["S. vulgaris", "SPECIES", 0, 11], ["S. edentatus", "SPECIES", 25, 37], ["S. equinus", "SPECIES", 42, 52], ["disease", "PROBLEM", 135, 142], ["vulgaris", "OBSERVATION", 3, 11], ["strongyle", "OBSERVATION", 82, 91], ["gastrointestinal tract", "ANATOMY", 106, 128], ["disease", "OBSERVATION", 135, 142]]], ["Ingestion of a large number of larvae results in acute strongylosis which usually presents as colic.", [["strongylosis", "DISEASE", 55, 67], ["colic", "DISEASE", 94, 99], ["acute strongylosis", "PROBLEM", 49, 67], ["colic", "PROBLEM", 94, 99], ["large", "OBSERVATION_MODIFIER", 15, 20], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["strongylosis", "OBSERVATION", 55, 67], ["colic", "ANATOMY", 94, 99]]], ["Chronic infection is more likely to manifest as debilitation and possibly diarrhoea.CyathostomiasisDiarrhoea is the result of fourth-stage larval migration through the intestinal mucosa and submucosa, resulting in increased secretion and albumin loss, causing oedema, reduced absorption and infiltration of inflammatory mediators.", [["intestinal mucosa", "ANATOMY", 168, 185], ["submucosa", "ANATOMY", 190, 199], ["Chronic infection", "DISEASE", 0, 17], ["diarrhoea", "DISEASE", 74, 83], ["CyathostomiasisDiarrhoea", "DISEASE", 84, 108], ["albumin loss", "DISEASE", 238, 250], ["oedema", "DISEASE", 260, 266], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 168, 185], ["submucosa", "MULTI-TISSUE_STRUCTURE", 190, 199], ["albumin", "GENE_OR_GENE_PRODUCT", 238, 245], ["oedema", "PATHOLOGICAL_FORMATION", 260, 266], ["inflammatory mediators", "PROTEIN", 307, 329], ["Chronic infection", "PROBLEM", 0, 17], ["debilitation", "PROBLEM", 48, 60], ["diarrhoea", "PROBLEM", 74, 83], ["CyathostomiasisDiarrhoea", "PROBLEM", 84, 108], ["fourth-stage larval migration", "PROBLEM", 126, 155], ["increased secretion", "PROBLEM", 214, 233], ["albumin loss", "PROBLEM", 238, 250], ["oedema", "PROBLEM", 260, 266], ["reduced absorption", "PROBLEM", 268, 286], ["infiltration of inflammatory mediators", "PROBLEM", 291, 329], ["infection", "OBSERVATION", 8, 17], ["more likely", "UNCERTAINTY", 21, 32], ["debilitation", "OBSERVATION", 48, 60], ["possibly", "UNCERTAINTY", 65, 73], ["diarrhoea", "OBSERVATION", 74, 83], ["fourth-stage", "OBSERVATION_MODIFIER", 126, 138], ["larval migration", "OBSERVATION", 139, 155], ["intestinal mucosa", "ANATOMY", 168, 185], ["submucosa", "ANATOMY", 190, 199], ["increased", "OBSERVATION_MODIFIER", 214, 223], ["secretion", "OBSERVATION", 224, 233], ["albumin loss", "OBSERVATION", 238, 250], ["oedema", "OBSERVATION", 260, 266], ["reduced", "OBSERVATION_MODIFIER", 268, 275], ["absorption", "OBSERVATION_MODIFIER", 276, 286], ["infiltration", "OBSERVATION_MODIFIER", 291, 303], ["inflammatory mediators", "OBSERVATION", 307, 329]]], ["Cyathostomes also recruit a mononuclear inflammation of the lamina propria and a chronic granulomatous colitis has been described.", [["mononuclear", "ANATOMY", 28, 39], ["lamina propria", "ANATOMY", 60, 74], ["mononuclear inflammation", "DISEASE", 28, 52], ["granulomatous colitis", "DISEASE", 89, 110], ["lamina propria", "TISSUE", 60, 74], ["granulomatous colitis", "PATHOLOGICAL_FORMATION", 89, 110], ["a mononuclear inflammation of the lamina propria", "PROBLEM", 26, 74], ["a chronic granulomatous colitis", "PROBLEM", 79, 110], ["mononuclear inflammation", "OBSERVATION", 28, 52], ["lamina", "ANATOMY_MODIFIER", 60, 66], ["propria", "ANATOMY", 67, 74], ["chronic", "OBSERVATION_MODIFIER", 81, 88], ["granulomatous", "OBSERVATION_MODIFIER", 89, 102], ["colitis", "OBSERVATION", 103, 110]]], ["Cyathostomes are often associated with chronic diarrhoea although they can also occur in acute cases.", [["Cyathostomes", "DISEASE", 0, 12], ["diarrhoea", "DISEASE", 47, 56], ["chronic diarrhoea", "PROBLEM", 39, 56], ["chronic", "OBSERVATION_MODIFIER", 39, 46], ["diarrhoea", "OBSERVATION", 47, 56]]], ["Anthelmintic administration in the presence of a heavy encysted burden may cause rapid larval death and acute inflammation.CyathostomiasisYoung horses are most commonly affected and present with weight loss, reduced or normal appetite, ill thrift, intermittent fever and diarrhoea.", [["death", "DISEASE", 94, 99], ["inflammation", "DISEASE", 110, 122], ["Cyathostomiasis", "DISEASE", 123, 138], ["weight loss", "DISEASE", 195, 206], ["ill thrift", "DISEASE", 236, 246], ["intermittent fever", "DISEASE", 248, 266], ["diarrhoea", "DISEASE", 271, 280], ["Anthelmintic administration", "TREATMENT", 0, 27], ["a heavy encysted burden", "PROBLEM", 47, 70], ["rapid larval death", "PROBLEM", 81, 99], ["acute inflammation", "PROBLEM", 104, 122], ["weight loss", "PROBLEM", 195, 206], ["ill thrift", "PROBLEM", 236, 246], ["intermittent fever", "PROBLEM", 248, 266], ["diarrhoea", "PROBLEM", 271, 280], ["heavy", "OBSERVATION_MODIFIER", 49, 54], ["encysted", "OBSERVATION", 55, 63], ["may cause", "UNCERTAINTY", 71, 80], ["rapid", "OBSERVATION_MODIFIER", 81, 86], ["larval death", "OBSERVATION", 87, 99], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["inflammation", "OBSERVATION", 110, 122], ["intermittent", "OBSERVATION_MODIFIER", 248, 260], ["fever", "OBSERVATION", 261, 266], ["diarrhoea", "OBSERVATION", 271, 280]]], ["These occur on the re-emergence of hypobiotic larvae in the large intestinal mucosa, in late winter and early spring.DiagnosisAs disease is caused by the larval stages of the worm, faecal egg counts are not helpful.", [["intestinal mucosa", "ANATOMY", 66, 83], ["worm", "ANATOMY", 175, 179], ["egg", "ANATOMY", 188, 191], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 66, 83], ["worm", "ORGANISM_SUBDIVISION", 175, 179], ["faecal", "ORGANISM_SUBSTANCE", 181, 187], ["egg", "ORGANISM_SUBSTANCE", 188, 191], ["hypobiotic larvae", "PROBLEM", 35, 52], ["DiagnosisAs disease", "PROBLEM", 117, 136], ["the worm", "PROBLEM", 171, 179], ["faecal egg counts", "TEST", 181, 198], ["large", "OBSERVATION_MODIFIER", 60, 65], ["intestinal mucosa", "ANATOMY", 66, 83], ["late winter", "OBSERVATION_MODIFIER", 88, 99]]], ["Haematology often reveals a neutrophilic leukocytosis and eosinophilia.", [["neutrophilic", "ANATOMY", 28, 40], ["leukocytosis", "DISEASE", 41, 53], ["eosinophilia", "DISEASE", 58, 70], ["a neutrophilic leukocytosis", "PROBLEM", 26, 53], ["eosinophilia", "PROBLEM", 58, 70], ["neutrophilic", "OBSERVATION_MODIFIER", 28, 40], ["leukocytosis", "OBSERVATION", 41, 53], ["eosinophilia", "OBSERVATION", 58, 70]]], ["Biochemistry may reveal a profound hypoalbuminaemia and hyperglobulinaemia.", [["hypoalbuminaemia", "DISEASE", 35, 51], ["hyperglobulinaemia", "DISEASE", 56, 74], ["Biochemistry", "TEST", 0, 12], ["a profound hypoalbuminaemia", "PROBLEM", 24, 51], ["hyperglobulinaemia", "PROBLEM", 56, 74], ["profound", "OBSERVATION_MODIFIER", 26, 34], ["hypoalbuminaemia", "OBSERVATION", 35, 51]]], ["Molecular tools for identification of larval and egg stages are being developed.", [["Molecular tools", "TEST", 0, 15], ["larval and egg stages", "PROBLEM", 38, 59]]], ["Other research is aimed at developing methods to allow early detection of anthelmintic resistant genotypes.", [["anthelmintic resistant genotypes", "PROBLEM", 74, 106], ["anthelmintic resistant genotypes", "OBSERVATION", 74, 106]]], ["ELISA experiments using serum from experimentally infected ponies and an endemically infected population have shown increased levels of larva-specific antibodies (IgG(T)).", [["serum", "ANATOMY", 24, 29], ["serum", "ORGANISM_SUBSTANCE", 24, 29], ["ponies", "ORGANISM", 59, 65], ["IgG(T)", "GENE_OR_GENE_PRODUCT", 163, 169], ["larva-specific antibodies", "PROTEIN", 136, 161], ["IgG(T)", "PROTEIN", 163, 169], ["ELISA experiments", "TEST", 0, 17], ["serum", "TEST", 24, 29], ["experimentally infected ponies", "PROBLEM", 35, 65], ["an endemically infected population", "PROBLEM", 70, 104], ["increased levels of larva-specific antibodies", "PROBLEM", 116, 161], ["increased", "OBSERVATION_MODIFIER", 116, 125]]], ["The levels of the antibody response correlated well with the mucosal burden (Matthews et al., 2004) .TreatmentSpecific treatment includes either a five-day course of fenbendazole or a dose of moxidectin, although this should be avoided in foals less than four months of age.", [["mucosal", "ANATOMY", 61, 68], ["fenbendazole", "CHEMICAL", 166, 178], ["moxidectin", "CHEMICAL", 192, 202], ["fenbendazole", "CHEMICAL", 166, 178], ["moxidectin", "CHEMICAL", 192, 202], ["mucosal", "ORGAN", 61, 68], ["fenbendazole", "SIMPLE_CHEMICAL", 166, 178], ["moxidectin", "SIMPLE_CHEMICAL", 192, 202], ["foals", "ORGANISM", 239, 244], ["The levels", "TEST", 0, 10], ["the antibody response", "TEST", 14, 35], ["TreatmentSpecific treatment", "TREATMENT", 101, 128], ["fenbendazole", "TREATMENT", 166, 178], ["moxidectin", "TREATMENT", 192, 202], ["mucosal", "ANATOMY", 61, 68]]], ["Corticosteroids are often administered concurrently to reduce the inflammatory reaction in the intestinal mucosa, which has been shown to be more severe with the five-day fenbendazole treatment.", [["intestinal mucosa", "ANATOMY", 95, 112], ["fenbendazole", "CHEMICAL", 171, 183], ["fenbendazole", "CHEMICAL", 171, 183], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 95, 112], ["fenbendazole", "SIMPLE_CHEMICAL", 171, 183], ["Corticosteroids", "TREATMENT", 0, 15], ["the inflammatory reaction in the intestinal mucosa", "PROBLEM", 62, 112], ["fenbendazole treatment", "TREATMENT", 171, 193], ["inflammatory", "OBSERVATION", 66, 78], ["intestinal mucosa", "ANATOMY", 95, 112], ["more severe", "OBSERVATION_MODIFIER", 141, 152]]], ["Non-steroidal anti-inflammatory drugs, such as flunixin meglumine, have the advantage of being less immunosuppressive.AscaridiasisAscaridiasis is reported to affect 30-60% of foals.", [["flunixin meglumine", "CHEMICAL", 47, 65], ["AscaridiasisAscaridiasis", "CHEMICAL", 118, 142], ["flunixin meglumine", "CHEMICAL", 47, 65], ["flunixin meglumine", "SIMPLE_CHEMICAL", 47, 65], ["foals", "ORGANISM", 175, 180], ["Non-steroidal anti-inflammatory drugs", "TREATMENT", 0, 37], ["flunixin meglumine", "TREATMENT", 47, 65], ["AscaridiasisAscaridiasis", "PROBLEM", 118, 142], ["anti-inflammatory drugs", "OBSERVATION", 14, 37]]], ["Embryonated eggs ingested from the environment hatch in the GIT and then undergo hepatopulmonary migration.", [["eggs", "ANATOMY", 12, 16], ["GIT", "ANATOMY", 60, 63], ["hepatopulmonary", "ANATOMY", 81, 96], ["GIT", "ORGAN", 60, 63], ["Embryonated eggs", "PROBLEM", 0, 16], ["hepatopulmonary migration", "TREATMENT", 81, 106], ["GIT", "ANATOMY", 60, 63], ["hepatopulmonary", "ANATOMY", 81, 96], ["migration", "OBSERVATION", 97, 106]]], ["The pre-patent period is ten weeks.AscaridiasisClinical disease can manifest as respiratory infection or intestinal damage resulting in weight loss, diarrhoea and occasionally colic.", [["respiratory", "ANATOMY", 80, 91], ["intestinal", "ANATOMY", 105, 115], ["AscaridiasisClinical disease", "DISEASE", 35, 63], ["respiratory infection", "DISEASE", 80, 101], ["intestinal damage", "DISEASE", 105, 122], ["weight loss", "DISEASE", 136, 147], ["diarrhoea", "DISEASE", 149, 158], ["colic", "DISEASE", 176, 181], ["intestinal", "ORGAN", 105, 115], ["AscaridiasisClinical disease", "PROBLEM", 35, 63], ["respiratory infection", "PROBLEM", 80, 101], ["intestinal damage", "PROBLEM", 105, 122], ["weight loss", "PROBLEM", 136, 147], ["diarrhoea", "PROBLEM", 149, 158], ["occasionally colic", "PROBLEM", 163, 181], ["disease", "OBSERVATION", 56, 63], ["respiratory", "ANATOMY", 80, 91], ["infection", "OBSERVATION", 92, 101], ["intestinal", "ANATOMY", 105, 115], ["damage", "OBSERVATION", 116, 122], ["weight loss", "OBSERVATION", 136, 147], ["occasionally", "OBSERVATION_MODIFIER", 163, 175], ["colic", "OBSERVATION", 176, 181]]], ["Ivermectin, fenbendazole and pyrantel are all effective and routine worming before six weeks of age will reduce pasture contamination.", [["Ivermectin", "CHEMICAL", 0, 10], ["fenbendazole", "CHEMICAL", 12, 24], ["pyrantel", "CHEMICAL", 29, 37], ["Ivermectin", "CHEMICAL", 0, 10], ["fenbendazole", "CHEMICAL", 12, 24], ["pyrantel", "CHEMICAL", 29, 37], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["fenbendazole", "SIMPLE_CHEMICAL", 12, 24], ["pyrantel", "SIMPLE_CHEMICAL", 29, 37], ["Ivermectin", "TREATMENT", 0, 10], ["fenbendazole", "TREATMENT", 12, 24], ["pyrantel", "TREATMENT", 29, 37], ["pasture contamination", "PROBLEM", 112, 133]]], ["In the past few years, widespread resistance of Parascaris equorum to ivermectin has been identified, therefore this may not be the most effective treatment on studs with a history of resistance.CryptosporidiosisCryptosporidium parvum has been associated with sporadic cases of malabsorptive diarrhoea in foals.", [["Parascaris equorum", "CHEMICAL", 48, 66], ["ivermectin", "CHEMICAL", 70, 80], ["CryptosporidiosisCryptosporidium parvum", "DISEASE", 195, 234], ["diarrhoea", "DISEASE", 292, 301], ["ivermectin", "CHEMICAL", 70, 80], ["Parascaris equorum", "ORGANISM", 48, 66], ["ivermectin", "SIMPLE_CHEMICAL", 70, 80], ["CryptosporidiosisCryptosporidium parvum", "ORGANISM", 195, 234], ["foals", "ORGANISM", 305, 310], ["Parascaris equorum", "SPECIES", 48, 66], ["CryptosporidiosisCryptosporidium parvum", "SPECIES", 195, 234], ["Parascaris equorum", "SPECIES", 48, 66], ["CryptosporidiosisCryptosporidium parvum", "SPECIES", 195, 234], ["widespread resistance of Parascaris equorum", "PROBLEM", 23, 66], ["ivermectin", "TREATMENT", 70, 80], ["resistance", "PROBLEM", 184, 194], ["CryptosporidiosisCryptosporidium parvum", "PROBLEM", 195, 234], ["malabsorptive diarrhoea in foals", "PROBLEM", 278, 310], ["widespread", "OBSERVATION_MODIFIER", 23, 33], ["resistance", "OBSERVATION_MODIFIER", 34, 44], ["parvum", "OBSERVATION", 228, 234], ["malabsorptive diarrhoea", "OBSERVATION", 278, 301]]], ["It physically occupies the absorptive surface of the distal small intestine.", [["absorptive surface", "ANATOMY", 27, 45], ["distal small intestine", "ANATOMY", 53, 75], ["absorptive surface", "CELLULAR_COMPONENT", 27, 45], ["small intestine", "ORGAN", 60, 75], ["absorptive", "OBSERVATION_MODIFIER", 27, 37], ["surface", "OBSERVATION_MODIFIER", 38, 45], ["distal", "ANATOMY_MODIFIER", 53, 59], ["small intestine", "ANATOMY", 60, 75]]], ["Most affected foals are 14-21 days old.", [["foals", "ORGANISM", 14, 19]]], ["Immunocompromised foals may be more susceptible.", [["foals", "ORGANISM", 18, 23], ["foals", "SPECIES", 18, 23], ["Immunocompromised foals", "PROBLEM", 0, 23]]], ["Diagnosis is based on the identification of oocytes following acid-fast staining of faecal samples, electron microscopy, flow cytometry or immunofluorescence assay.", [["oocytes", "ANATOMY", 44, 51], ["faecal samples", "ANATOMY", 84, 98], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 44, 51], ["acid-fast staining of faecal samples", "PROBLEM", 62, 98], ["electron microscopy", "TEST", 100, 119], ["flow cytometry", "TEST", 121, 135], ["immunofluorescence assay", "TEST", 139, 163], ["faecal", "ANATOMY", 84, 90]]], ["This is a contagious and zoonotic organism.LACTOSE INTOLERANCEAny condition which results in a loss of the small intestinal mucosal brush border may cause secondary lactase deficiency and subsequent lactose intolerance.", [["intestinal mucosal brush border", "ANATOMY", 113, 144], ["lactose", "CHEMICAL", 199, 206], ["lactose", "CHEMICAL", 199, 206], ["intestinal mucosal brush", "TISSUE", 113, 137], ["lactase", "GENE_OR_GENE_PRODUCT", 165, 172], ["lactose", "SIMPLE_CHEMICAL", 199, 206], ["a contagious and zoonotic organism", "PROBLEM", 8, 42], ["LACTOSE INTOLERANCEAny condition", "PROBLEM", 43, 75], ["a loss of the small intestinal mucosal brush border", "PROBLEM", 93, 144], ["secondary lactase deficiency", "PROBLEM", 155, 183], ["subsequent lactose intolerance", "PROBLEM", 188, 218], ["contagious", "OBSERVATION_MODIFIER", 10, 20], ["zoonotic", "OBSERVATION_MODIFIER", 25, 33], ["small", "OBSERVATION_MODIFIER", 107, 112], ["intestinal mucosal", "ANATOMY", 113, 131], ["secondary lactase deficiency", "OBSERVATION", 155, 183], ["lactose intolerance", "OBSERVATION", 199, 218]]], ["This results in physiological diarrhoea due to the osmotic gradient of lactose within the intestinal lumen, drawing fluid in.", [["intestinal lumen", "ANATOMY", 90, 106], ["fluid", "ANATOMY", 116, 121], ["diarrhoea", "DISEASE", 30, 39], ["lactose", "CHEMICAL", 71, 78], ["lactose", "CHEMICAL", 71, 78], ["lactose", "SIMPLE_CHEMICAL", 71, 78], ["intestinal lumen", "MULTI-TISSUE_STRUCTURE", 90, 106], ["physiological diarrhoea", "PROBLEM", 16, 39], ["the osmotic gradient of lactose", "PROBLEM", 47, 78], ["diarrhoea", "OBSERVATION", 30, 39], ["intestinal lumen", "ANATOMY", 90, 106], ["fluid", "OBSERVATION", 116, 121]]], ["Affected foals are often lethargic and show a failure to thrive or have weight loss.", [["weight loss", "DISEASE", 72, 83], ["foals", "ORGANISM", 9, 14], ["Affected foals", "PROBLEM", 0, 14], ["lethargic", "PROBLEM", 25, 34], ["a failure to thrive", "PROBLEM", 44, 63], ["weight loss", "PROBLEM", 72, 83]]], ["They may have a history of persistent diarrhoea with recurrent colic from a young age.", [["diarrhoea", "DISEASE", 38, 47], ["colic", "DISEASE", 63, 68], ["persistent diarrhoea", "PROBLEM", 27, 47], ["recurrent colic", "PROBLEM", 53, 68], ["persistent", "OBSERVATION_MODIFIER", 27, 37], ["diarrhoea", "OBSERVATION", 38, 47], ["recurrent", "OBSERVATION_MODIFIER", 53, 62], ["colic", "OBSERVATION", 63, 68]]], ["The diagnosis can be confirmed by a lactose tolerance test but diagnosis is often made by the response to treatment, supplementing with the lactase enzyme.", [["lactose", "CHEMICAL", 36, 43], ["lactose", "CHEMICAL", 36, 43], ["lactose", "SIMPLE_CHEMICAL", 36, 43], ["lactase enzyme", "GENE_OR_GENE_PRODUCT", 140, 154], ["lactase enzyme", "PROTEIN", 140, 154], ["a lactose tolerance test", "TEST", 34, 58], ["treatment", "TREATMENT", 106, 115], ["the lactase enzyme", "TEST", 136, 154]]], ["Early weaning is necessary in these cases.SYMPTOMATIC TREATMENTIt is usually necessary to initiate treatment in the absence of diagnostic information.", [["Early weaning", "TREATMENT", 0, 13], ["treatment", "TREATMENT", 99, 108]]], ["The priorities include correcting fluid and electrolyte disturbances, controlling endotoxaemia, reducing intestinal inflammation, promoting mucosal repair and encouraging re-establishment of the normal intestinal flora.FluidsFluid deficits should be corrected immediately; often a polyionic crystalloid solution is best.", [["fluid", "ANATOMY", 34, 39], ["intestinal", "ANATOMY", 105, 115], ["mucosal", "ANATOMY", 140, 147], ["intestinal flora", "ANATOMY", 202, 218], ["endotoxaemia", "DISEASE", 82, 94], ["inflammation", "DISEASE", 116, 128], ["Fluid deficits", "DISEASE", 225, 239], ["fluid", "ORGANISM_SUBSTANCE", 34, 39], ["intestinal", "ORGAN", 105, 115], ["mucosal", "MULTI-TISSUE_STRUCTURE", 140, 147], ["intestinal flora", "PATHOLOGICAL_FORMATION", 202, 218], ["correcting fluid and electrolyte disturbances", "PROBLEM", 23, 68], ["endotoxaemia", "PROBLEM", 82, 94], ["reducing intestinal inflammation", "PROBLEM", 96, 128], ["promoting mucosal repair", "TREATMENT", 130, 154], ["FluidsFluid deficits", "PROBLEM", 219, 239], ["a polyionic crystalloid solution", "TREATMENT", 279, 311], ["fluid", "OBSERVATION", 34, 39], ["electrolyte disturbances", "OBSERVATION", 44, 68], ["intestinal", "ANATOMY", 105, 115], ["inflammation", "OBSERVATION", 116, 128], ["mucosal repair", "OBSERVATION", 140, 154], ["normal intestinal flora", "OBSERVATION", 195, 218], ["Fluid deficits", "OBSERVATION", 225, 239]]], ["Deficits should be calculated based on clinical dehydration and body weight, and continually reassessed and adjusted as necessary.", [["body", "ANATOMY", 64, 68], ["dehydration", "DISEASE", 48, 59], ["body", "ORGANISM_SUBDIVISION", 64, 68], ["Deficits", "PROBLEM", 0, 8], ["clinical dehydration", "PROBLEM", 39, 59], ["body weight", "TEST", 64, 75]]], ["Once fluid deficits have been rectified, persisting metabolic acidosis can be corrected as necessary using bicarbonate added to the fluids, guided by blood gas measurements.FluidsIf the damage to the intestine is severe it is best to withhold milk, to reduce any exacerbation of the diarrhoea via an osmotic effect.", [["fluid", "ANATOMY", 5, 10], ["blood", "ANATOMY", 150, 155], ["intestine", "ANATOMY", 200, 209], ["milk", "ANATOMY", 243, 247], ["fluid deficits", "DISEASE", 5, 19], ["acidosis", "DISEASE", 62, 70], ["bicarbonate", "CHEMICAL", 107, 118], ["diarrhoea", "DISEASE", 283, 292], ["bicarbonate", "CHEMICAL", 107, 118], ["bicarbonate", "SIMPLE_CHEMICAL", 107, 118], ["blood", "ORGANISM_SUBSTANCE", 150, 155], ["intestine", "ORGAN", 200, 209], ["milk", "ORGANISM_SUBSTANCE", 243, 247], ["fluid deficits", "PROBLEM", 5, 19], ["persisting metabolic acidosis", "PROBLEM", 41, 70], ["bicarbonate", "TREATMENT", 107, 118], ["the fluids", "TREATMENT", 128, 138], ["blood gas measurements", "TEST", 150, 172], ["Fluids", "TREATMENT", 173, 179], ["the damage to the intestine", "PROBLEM", 182, 209], ["milk", "TREATMENT", 243, 247], ["the diarrhoea", "PROBLEM", 279, 292], ["an osmotic effect", "TREATMENT", 297, 314], ["persisting", "OBSERVATION_MODIFIER", 41, 51], ["metabolic acidosis", "OBSERVATION", 52, 70], ["intestine", "ANATOMY", 200, 209], ["severe", "OBSERVATION", 213, 219], ["osmotic effect", "OBSERVATION", 300, 314]]], ["However in mild cases the protective immunity provided by the IgA has been advocated.", [["IgA", "GENE_OR_GENE_PRODUCT", 62, 65], ["IgA", "PROTEIN", 62, 65], ["mild", "OBSERVATION_MODIFIER", 11, 15]]], ["If the absorptive capacity of the intestine is deemed to be normal, enteral fluids would be a cheaper option, but can be labour intensive in the field situation.FluidsIf treatment is ongoing it will be necessary to supplement these fluids with glucose in the form of dextrose, to meet the higher-than-normal energy requirements of the sick, catabolic foal.", [["intestine", "ANATOMY", 34, 43], ["glucose", "CHEMICAL", 244, 251], ["dextrose", "CHEMICAL", 267, 275], ["glucose", "CHEMICAL", 244, 251], ["dextrose", "CHEMICAL", 267, 275], ["intestine", "ORGAN", 34, 43], ["glucose", "SIMPLE_CHEMICAL", 244, 251], ["dextrose", "SIMPLE_CHEMICAL", 267, 275], ["foal", "ORGANISM_SUBDIVISION", 351, 355], ["enteral fluids", "TREATMENT", 68, 82], ["a cheaper option", "TREATMENT", 92, 108], ["Fluids", "TREATMENT", 161, 167], ["treatment", "TREATMENT", 170, 179], ["these fluids", "TREATMENT", 226, 238], ["glucose", "TREATMENT", 244, 251], ["dextrose", "TREATMENT", 267, 275], ["absorptive capacity", "OBSERVATION_MODIFIER", 7, 26], ["intestine", "ANATOMY", 34, 43], ["normal", "OBSERVATION", 60, 66]]], ["Other electrolyte supplementation may be required, as determined by biochemistry analysis, and should be administered slowly to prevent side effects such as cardiac arrhythmias with potassium supplementation, or central pontine myelinolysis with sodium.FluidsColloids provide additional oncotic support, especially in hypoproteinaemic foals, which may otherwise sequester fluid into the extravascular space.", [["cardiac", "ANATOMY", 157, 164], ["pontine", "ANATOMY", 220, 227], ["fluid", "ANATOMY", 372, 377], ["extravascular space", "ANATOMY", 387, 406], ["cardiac arrhythmias", "DISEASE", 157, 176], ["potassium", "CHEMICAL", 182, 191], ["myelinolysis", "DISEASE", 228, 240], ["sodium", "CHEMICAL", 246, 252], ["potassium", "CHEMICAL", 182, 191], ["sodium", "CHEMICAL", 246, 252], ["cardiac", "ORGAN", 157, 164], ["potassium", "SIMPLE_CHEMICAL", 182, 191], ["pontine", "ORGANISM_SUBDIVISION", 220, 227], ["sodium", "SIMPLE_CHEMICAL", 246, 252], ["foals", "ORGANISM_SUBDIVISION", 335, 340], ["extravascular space", "IMMATERIAL_ANATOMICAL_ENTITY", 387, 406], ["Other electrolyte supplementation", "TREATMENT", 0, 33], ["biochemistry analysis", "TEST", 68, 89], ["side effects", "PROBLEM", 136, 148], ["cardiac arrhythmias", "PROBLEM", 157, 176], ["potassium supplementation", "TREATMENT", 182, 207], ["central pontine myelinolysis", "PROBLEM", 212, 240], ["sodium", "TREATMENT", 246, 252], ["FluidsColloids", "TREATMENT", 253, 267], ["additional oncotic support", "TREATMENT", 276, 302], ["cardiac", "ANATOMY", 157, 164], ["arrhythmias", "OBSERVATION", 165, 176], ["pontine myelinolysis", "OBSERVATION", 220, 240], ["oncotic support", "OBSERVATION", 287, 302], ["fluid", "OBSERVATION", 372, 377], ["extravascular space", "ANATOMY", 387, 406]]], ["In this situation plasma would also provide valuable anti-inflammatory mediators and proteins.Anti-endotoxic therapyEndotoxaemia results when the body's defence mechanisms are compromised and lipopolysaccharides (LPS) from Gram -ve bacteria are absorbed into the intestine.", [["plasma", "ANATOMY", 18, 24], ["body", "ANATOMY", 146, 150], ["intestine", "ANATOMY", 263, 272], ["lipopolysaccharides", "CHEMICAL", 192, 211], ["LPS", "CHEMICAL", 213, 216], ["plasma", "ORGANISM_SUBSTANCE", 18, 24], ["body", "ORGANISM_SUBDIVISION", 146, 150], ["lipopolysaccharides", "SIMPLE_CHEMICAL", 192, 211], ["LPS", "SIMPLE_CHEMICAL", 213, 216], ["intestine", "ORGAN", 263, 272], ["anti-inflammatory mediators", "PROTEIN", 53, 80], ["valuable anti-inflammatory mediators", "TREATMENT", 44, 80], ["Anti-endotoxic therapyEndotoxaemia", "TEST", 94, 128], ["the body's defence mechanisms", "TEST", 142, 171], ["lipopolysaccharides", "PROBLEM", 192, 211], ["LPS", "TEST", 213, 216], ["Gram -ve bacteria", "PROBLEM", 223, 240], ["intestine", "ANATOMY", 263, 272]]], ["In the normal horse there are many of these Gram -ve bacteria in the large colon.", [["colon", "ANATOMY", 75, 80], ["horse", "ORGANISM", 14, 19], ["Gram", "GENE_OR_GENE_PRODUCT", 44, 48], ["colon", "ORGAN", 75, 80], ["horse", "SPECIES", 14, 19], ["these Gram", "TEST", 38, 48], ["ve bacteria in the large colon", "PROBLEM", 50, 80], ["normal horse", "OBSERVATION_MODIFIER", 7, 19], ["ve bacteria", "OBSERVATION", 50, 61], ["large", "ANATOMY_MODIFIER", 69, 74], ["colon", "ANATOMY", 75, 80]]], ["One of the effects of endotoxin is peripheral vasodilation, which results in decreased systemic vascular resistance and relative hypovolaemia.Anti-endotoxic therapyIn addition to fluid therapy, hyperimmune plasma containing anti-lipid A antibodies, which bind LPS and prevent the initiation of the inflammatory cascade, has been shown to be of clinical benefit to adult horses.", [["vascular", "ANATOMY", 96, 104], ["fluid", "ANATOMY", 179, 184], ["plasma", "ANATOMY", 206, 212], ["endotoxin", "CHEMICAL", 22, 31], ["hypovolaemia", "DISEASE", 129, 141], ["LPS", "CHEMICAL", 260, 263], ["endotoxin", "SIMPLE_CHEMICAL", 22, 31], ["peripheral", "TISSUE", 35, 45], ["vascular", "MULTI-TISSUE_STRUCTURE", 96, 104], ["hyperimmune", "ORGANISM", 194, 205], ["plasma", "ORGANISM_SUBSTANCE", 206, 212], ["anti-lipid A antibodies", "GENE_OR_GENE_PRODUCT", 224, 247], ["LPS", "SIMPLE_CHEMICAL", 260, 263], ["horses", "ORGANISM", 370, 376], ["anti-lipid A antibodies", "PROTEIN", 224, 247], ["endotoxin", "TREATMENT", 22, 31], ["peripheral vasodilation", "PROBLEM", 35, 58], ["decreased systemic vascular resistance", "PROBLEM", 77, 115], ["relative hypovolaemia", "PROBLEM", 120, 141], ["Anti-endotoxic therapy", "TREATMENT", 142, 164], ["fluid therapy", "TREATMENT", 179, 192], ["hyperimmune plasma", "TREATMENT", 194, 212], ["anti-lipid A antibodies", "TREATMENT", 224, 247], ["bind LPS", "TREATMENT", 255, 263], ["the inflammatory cascade", "PROBLEM", 294, 318], ["peripheral vasodilation", "OBSERVATION", 35, 58], ["decreased", "OBSERVATION_MODIFIER", 77, 86], ["systemic vascular resistance", "OBSERVATION", 87, 115], ["hypovolaemia", "OBSERVATION", 129, 141], ["fluid therapy", "OBSERVATION", 179, 192], ["inflammatory", "OBSERVATION", 298, 310]]], ["In foals these preparations have been shown experimentally to cause a worsening in clinical signs and increased levels of IL-6 and TNF and should therefore be used with caution (Durando et al., 1994) .Anti-endotoxic therapyDi-tri-octahedral smectite is a hydrated aluminamagnesium silicate which is administered to absorb exotoxins and endotoxins.", [["therapyDi-tri-octahedral smectite", "CHEMICAL", 216, 249], ["aluminamagnesium silicate", "CHEMICAL", 264, 289], ["therapyDi-tri-octahedral smectite", "CHEMICAL", 216, 249], ["aluminamagnesium silicate", "CHEMICAL", 264, 289], ["foals", "ORGANISM", 3, 8], ["IL-6", "GENE_OR_GENE_PRODUCT", 122, 126], ["TNF", "GENE_OR_GENE_PRODUCT", 131, 134], ["therapyDi-tri-octahedral smectite", "SIMPLE_CHEMICAL", 216, 249], ["aluminamagnesium silicate", "SIMPLE_CHEMICAL", 264, 289], ["IL-6", "PROTEIN", 122, 126], ["TNF", "PROTEIN", 131, 134], ["exotoxins", "PROTEIN", 322, 331], ["a worsening in clinical signs", "PROBLEM", 68, 97], ["increased levels of IL", "PROBLEM", 102, 124], ["TNF", "TREATMENT", 131, 134], ["Anti-endotoxic therapyDi-tri-octahedral smectite", "TREATMENT", 201, 249], ["a hydrated aluminamagnesium silicate", "TREATMENT", 253, 289], ["endotoxins", "PROBLEM", 336, 346], ["worsening", "OBSERVATION_MODIFIER", 70, 79], ["increased", "OBSERVATION_MODIFIER", 102, 111]]], ["It has been shown to bind toxins in vitro, possibly due to its negative charge which attracts positively-charged exotoxins and endotoxins.", [["exotoxins", "GENE_OR_GENE_PRODUCT", 113, 122], ["exotoxins", "PROTEIN", 113, 122], ["its negative charge", "PROBLEM", 59, 78], ["endotoxins", "PROBLEM", 127, 137], ["possibly due to", "UNCERTAINTY", 43, 58]]], ["Polymixin B (PMB) is a bactericidal antibiotic which targets Gram -ve organisms; at lower doses it binds to the lipid A of LPS.", [["Polymixin B", "CHEMICAL", 0, 11], ["PMB", "CHEMICAL", 13, 16], ["LPS", "CHEMICAL", 123, 126], ["Polymixin B", "CHEMICAL", 0, 11], ["PMB", "CHEMICAL", 13, 16], ["Polymixin B", "SIMPLE_CHEMICAL", 0, 11], ["PMB", "SIMPLE_CHEMICAL", 13, 16], ["LPS", "SIMPLE_CHEMICAL", 123, 126], ["Polymixin B (PMB)", "TREATMENT", 0, 17], ["a bactericidal antibiotic", "TREATMENT", 21, 46], ["Gram -ve organisms", "PROBLEM", 61, 79]]], ["Its efficacy has been demonstrated in experimentally-induced endotoxaemia but this may be reduced once LPS exposure has already occurred.Intestinal protectantsAnti-ulcer therapy is important to reduce the incidence of gastric ulcers.", [["Intestinal", "ANATOMY", 137, 147], ["gastric", "ANATOMY", 218, 225], ["endotoxaemia", "DISEASE", 61, 73], ["LPS", "CHEMICAL", 103, 106], ["gastric ulcers", "DISEASE", 218, 232], ["LPS", "SIMPLE_CHEMICAL", 103, 106], ["Intestinal", "ORGAN", 137, 147], ["gastric ulcers", "PATHOLOGICAL_FORMATION", 218, 232], ["endotoxaemia", "PROBLEM", 61, 73], ["LPS exposure", "PROBLEM", 103, 115], ["Intestinal protectants", "TREATMENT", 137, 159], ["Anti-ulcer therapy", "TREATMENT", 159, 177], ["gastric ulcers", "PROBLEM", 218, 232], ["endotoxaemia", "OBSERVATION", 61, 73], ["may be", "UNCERTAINTY", 83, 89], ["reduced", "OBSERVATION_MODIFIER", 90, 97], ["protectants", "OBSERVATION", 148, 159], ["gastric", "ANATOMY", 218, 225], ["ulcers", "OBSERVATION", 226, 232]]], ["Omeprazole is the drug of choice, although it is expensive.", [["Omeprazole", "CHEMICAL", 0, 10], ["Omeprazole", "CHEMICAL", 0, 10], ["Omeprazole", "SIMPLE_CHEMICAL", 0, 10], ["Omeprazole", "TREATMENT", 0, 10]]], ["Sucralfate or an H2 antagonist, such as ranitidine or cimetidine are cheaper alternatives but are less efficacious.", [["Sucralfate", "CHEMICAL", 0, 10], ["ranitidine", "CHEMICAL", 40, 50], ["cimetidine", "CHEMICAL", 54, 64], ["Sucralfate", "CHEMICAL", 0, 10], ["ranitidine", "CHEMICAL", 40, 50], ["cimetidine", "CHEMICAL", 54, 64], ["Sucralfate", "SIMPLE_CHEMICAL", 0, 10], ["ranitidine", "SIMPLE_CHEMICAL", 40, 50], ["cimetidine", "SIMPLE_CHEMICAL", 54, 64], ["Sucralfate", "TREATMENT", 0, 10], ["an H2 antagonist", "TREATMENT", 14, 30], ["ranitidine", "TREATMENT", 40, 50], ["cimetidine", "TREATMENT", 54, 64], ["cheaper alternatives", "TREATMENT", 69, 89]]], ["The use of bismuth salicylate to decrease inflammation and secretion in the large colon has been described.", [["colon", "ANATOMY", 82, 87], ["bismuth salicylate", "CHEMICAL", 11, 29], ["inflammation", "DISEASE", 42, 54], ["bismuth salicylate", "CHEMICAL", 11, 29], ["bismuth salicylate", "SIMPLE_CHEMICAL", 11, 29], ["colon", "ORGAN", 82, 87], ["bismuth salicylate", "TREATMENT", 11, 29], ["decrease inflammation", "PROBLEM", 33, 54], ["secretion in the large colon", "PROBLEM", 59, 87], ["decrease", "OBSERVATION_MODIFIER", 33, 41], ["inflammation", "OBSERVATION", 42, 54], ["secretion", "OBSERVATION", 59, 68], ["large", "ANATOMY_MODIFIER", 76, 81], ["colon", "ANATOMY", 82, 87]]], ["Bismuth coats the mucosa whilst the salicylate has anti-prostaglandin effects.", [["mucosa", "ANATOMY", 18, 24], ["salicylate", "CHEMICAL", 36, 46], ["Bismuth", "CHEMICAL", 0, 7], ["salicylate", "CHEMICAL", 36, 46], ["mucosa", "MULTI-TISSUE_STRUCTURE", 18, 24], ["salicylate", "SIMPLE_CHEMICAL", 36, 46], ["anti-prostaglandin", "SIMPLE_CHEMICAL", 51, 69], ["Bismuth", "TREATMENT", 0, 7], ["the salicylate", "TREATMENT", 32, 46], ["anti-prostaglandin effects", "TREATMENT", 51, 77], ["mucosa", "ANATOMY", 18, 24]]], ["A relatively new commercial preparation containing montmorillonite is available (Diarsanyl \u00ae , CEVA Animal Health), which claims to be much more absorbent than other available formulations.Intestinal protectantsSucralfate has been advocated for gastric-acid-related diseases, but its efficacy in the large colon is questionable.", [["Intestinal", "ANATOMY", 189, 199], ["gastric", "ANATOMY", 245, 252], ["colon", "ANATOMY", 306, 311], ["montmorillonite", "CHEMICAL", 51, 66], ["Sucralfate", "CHEMICAL", 211, 221], ["montmorillonite", "CHEMICAL", 51, 66], ["Sucralfate", "CHEMICAL", 211, 221], ["montmorillonite", "SIMPLE_CHEMICAL", 51, 66], ["Diarsanyl", "SIMPLE_CHEMICAL", 81, 90], ["Intestinal", "ORGAN", 189, 199], ["Sucralfate", "SIMPLE_CHEMICAL", 211, 221], ["gastric", "ORGAN", 245, 252], ["colon", "ORGAN", 306, 311], ["A relatively new commercial preparation containing montmorillonite", "TREATMENT", 0, 66], ["Intestinal protectantsSucralfate", "TREATMENT", 189, 221], ["gastric-acid-related diseases", "PROBLEM", 245, 274], ["relatively", "OBSERVATION_MODIFIER", 2, 12], ["new", "OBSERVATION_MODIFIER", 13, 16], ["gastric", "ANATOMY", 245, 252], ["diseases", "OBSERVATION", 266, 274], ["large colon", "ANATOMY", 300, 311]]], ["Misoprostol has been shown to enhance intestinal mucosal healing in models of colitis in the horse and other species; this has not been confirmed clinically.", [["intestinal mucosal", "ANATOMY", 38, 56], ["Misoprostol", "CHEMICAL", 0, 11], ["colitis", "DISEASE", 78, 85], ["Misoprostol", "CHEMICAL", 0, 11], ["Misoprostol", "SIMPLE_CHEMICAL", 0, 11], ["intestinal mucosal", "MULTI-TISSUE_STRUCTURE", 38, 56], ["colitis", "PATHOLOGICAL_FORMATION", 78, 85], ["horse", "ORGANISM", 93, 98], ["horse", "SPECIES", 93, 98], ["Misoprostol", "TREATMENT", 0, 11], ["intestinal mucosal healing", "PROBLEM", 38, 64], ["colitis in the horse and other species", "PROBLEM", 78, 116], ["intestinal mucosal", "ANATOMY", 38, 56], ["healing", "OBSERVATION", 57, 64], ["colitis", "OBSERVATION", 78, 85]]], ["Systemic absorption acts to re-establish blood flow and mucus production.Anti-inflammatoriesMany mediators have been implicated in the inflammatory response of the intestinal cells.", [["blood", "ANATOMY", 41, 46], ["mucus", "ANATOMY", 56, 61], ["intestinal cells", "ANATOMY", 164, 180], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["mucus", "ORGANISM_SUBSTANCE", 56, 61], ["intestinal cells", "CELL", 164, 180], ["intestinal cells", "CELL_TYPE", 164, 180], ["Systemic absorption acts", "TREATMENT", 0, 24], ["blood flow", "TEST", 41, 51], ["mucus production", "PROBLEM", 56, 72], ["Anti-inflammatories", "TREATMENT", 73, 92], ["mucus production", "OBSERVATION", 56, 72], ["inflammatory", "OBSERVATION_MODIFIER", 135, 147], ["intestinal cells", "ANATOMY", 164, 180]]], ["NF-\u00ceB is the start of a common signalling pathway that activates genes encoding for pro-inflammatory cytokines, including TNF\u00b7, IL1 and IL6.", [["NF-\u00ceB", "GENE_OR_GENE_PRODUCT", 0, 5], ["TNF\u00b7", "GENE_OR_GENE_PRODUCT", 122, 126], ["IL1", "GENE_OR_GENE_PRODUCT", 128, 131], ["IL6", "GENE_OR_GENE_PRODUCT", 136, 139], ["NF-\u00ceB", "PROTEIN", 0, 5], ["pro-inflammatory cytokines", "PROTEIN", 84, 110], ["TNF\u00b7", "PROTEIN", 122, 126], ["IL1", "PROTEIN", 128, 131], ["IL6", "PROTEIN", 136, 139], ["pro-inflammatory cytokines", "PROBLEM", 84, 110], ["TNF\u00b7, IL1 and IL6", "TREATMENT", 122, 139]]], ["Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) activity and subsequent production of reactive oxygen metabolites.", [["oxygen", "CHEMICAL", 123, 129], ["oxygen", "CHEMICAL", 123, 129], ["Non-steroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 0, 37], ["NSAIDs", "SIMPLE_CHEMICAL", 39, 45], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 55, 69], ["COX", "GENE_OR_GENE_PRODUCT", 71, 74], ["reactive oxygen metabolites", "SIMPLE_CHEMICAL", 114, 141], ["cyclooxygenase", "PROTEIN", 55, 69], ["COX", "PROTEIN", 71, 74], ["Non-steroidal anti-inflammatory drugs", "TREATMENT", 0, 37], ["NSAIDs)", "TREATMENT", 39, 46], ["cyclooxygenase (COX) activity", "TREATMENT", 55, 84], ["reactive oxygen metabolites", "PROBLEM", 114, 141], ["reactive", "OBSERVATION_MODIFIER", 114, 122], ["oxygen metabolites", "OBSERVATION", 123, 141]]], ["However other prostaglandins are cytoprotective and important for mucosal repair, therefore caution must be taken to avoid further mucosal damage.", [["mucosal", "ANATOMY", 66, 73], ["mucosal", "ANATOMY", 131, 138], ["prostaglandins", "CHEMICAL", 14, 28], ["prostaglandins", "CHEMICAL", 14, 28], ["prostaglandins", "SIMPLE_CHEMICAL", 14, 28], ["mucosal", "MULTI-TISSUE_STRUCTURE", 66, 73], ["mucosal", "TISSUE", 131, 138], ["mucosal repair", "TREATMENT", 66, 80], ["caution", "TREATMENT", 92, 99], ["further mucosal damage", "PROBLEM", 123, 145], ["repair", "OBSERVATION", 74, 80], ["mucosal", "ANATOMY", 131, 138], ["damage", "OBSERVATION", 139, 145]]], ["Flunixin is currently the NSAID of choice, although the advantage of more selective COX inhibition is being investigated.AntibioticsThe use of antibiotics in treating the diarrhoeic patient is controversial.", [["Flunixin", "CHEMICAL", 0, 8], ["diarrhoeic", "DISEASE", 171, 181], ["Flunixin", "CHEMICAL", 0, 8], ["Flunixin", "SIMPLE_CHEMICAL", 0, 8], ["NSAID", "SIMPLE_CHEMICAL", 26, 31], ["COX", "GENE_OR_GENE_PRODUCT", 84, 87], ["patient", "ORGANISM", 182, 189], ["COX", "PROTEIN", 84, 87], ["patient", "SPECIES", 182, 189], ["Flunixin", "TREATMENT", 0, 8], ["the NSAID of choice", "TREATMENT", 22, 41], ["more selective COX inhibition", "TREATMENT", 69, 98], ["Antibiotics", "TREATMENT", 121, 132], ["antibiotics", "TREATMENT", 143, 154]]], ["There is sufficient documented evidence of an adverse effect of their use, however they may be indicated if an animal is severely neutropenic or septicaemic.", [["neutropenic", "DISEASE", 130, 141], ["septicaemic", "DISEASE", 145, 156], ["severely neutropenic", "PROBLEM", 121, 141], ["septicaemic", "PROBLEM", 145, 156], ["adverse", "OBSERVATION_MODIFIER", 46, 53], ["severely", "OBSERVATION_MODIFIER", 121, 129], ["neutropenic", "OBSERVATION", 130, 141]]], ["In these cases broad-spectrum drugs should be administered until culture and sensitivity results are available.", [["broad-spectrum drugs", "TREATMENT", 15, 35], ["culture", "TEST", 65, 72]]], ["The aim of this therapy is to provide broad-spectrum coverage to reduce bacterial translocation across the damaged intestinal wall, not to target the specific organism causing the diarrhoea.", [["intestinal wall", "ANATOMY", 115, 130], ["diarrhoea", "DISEASE", 180, 189], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 115, 130], ["this therapy", "TREATMENT", 11, 23], ["broad-spectrum coverage", "TREATMENT", 38, 61], ["bacterial translocation", "PROBLEM", 72, 95], ["the diarrhoea", "PROBLEM", 176, 189], ["bacterial translocation", "OBSERVATION", 72, 95], ["intestinal wall", "ANATOMY", 115, 130], ["diarrhoea", "OBSERVATION", 180, 189]]], ["Those antibiotics which specifically target the bacterial wall, e.g. penicillins, may in theory result in an increased release of LPS and worsening of clinical disease.ProbioticsProbiotics are used to restore the gastrointestinal flora when disease is associated with a disturbance.", [["wall", "ANATOMY", 58, 62], ["gastrointestinal flora", "ANATOMY", 213, 235], ["penicillins", "CHEMICAL", 69, 80], ["LPS", "CHEMICAL", 130, 133], ["penicillins", "CHEMICAL", 69, 80], ["penicillins", "SIMPLE_CHEMICAL", 69, 80], ["LPS", "SIMPLE_CHEMICAL", 130, 133], ["gastrointestinal flora", "PATHOLOGICAL_FORMATION", 213, 235], ["Those antibiotics", "TREATMENT", 0, 17], ["penicillins", "TREATMENT", 69, 80], ["LPS", "PROBLEM", 130, 133], ["clinical disease", "PROBLEM", 151, 167], ["ProbioticsProbiotics", "TREATMENT", 168, 188], ["the gastrointestinal flora", "PROBLEM", 209, 235], ["disease", "PROBLEM", 241, 248], ["a disturbance", "PROBLEM", 268, 281], ["bacterial wall", "OBSERVATION", 48, 62], ["increased", "OBSERVATION_MODIFIER", 109, 118], ["worsening", "OBSERVATION_MODIFIER", 138, 147], ["gastrointestinal", "ANATOMY", 213, 229]]], ["Products containing bacteria, including Bifidobacterium spp., Lactobacillus spp. and Enterobacter spp., and yeasts such as Saccharomyces have been developed.", [["Bifidobacterium spp.", "ORGANISM", 40, 60], ["Lactobacillus spp.", "ORGANISM", 62, 80], ["Enterobacter spp.", "ORGANISM", 85, 102], ["Saccharomyces", "ORGANISM", 123, 136], ["Bifidobacterium spp.", "SPECIES", 40, 60], ["Lactobacillus spp.", "SPECIES", 62, 80], ["Enterobacter spp.", "SPECIES", 85, 102], ["Bifidobacterium spp.", "SPECIES", 40, 60], ["Lactobacillus spp.", "SPECIES", 62, 80], ["Enterobacter spp.", "SPECIES", 85, 102], ["bacteria", "PROBLEM", 20, 28], ["Bifidobacterium spp.", "TREATMENT", 40, 60], ["Lactobacillus spp.", "PROBLEM", 62, 80], ["Enterobacter spp.", "PROBLEM", 85, 102], ["yeasts", "PROBLEM", 108, 114], ["Saccharomyces", "PROBLEM", 123, 136], ["bacteria", "OBSERVATION_MODIFIER", 20, 28], ["Enterobacter spp.", "OBSERVATION", 85, 102]]], ["Concerns over their use include the lack of evidence of a clinical benefit, no information on required dosing regimens and inaccurate label descriptions.", [["dosing regimens", "TREATMENT", 103, 118]]], ["Transfaunation has been used to re-establish gut microflora by transferring the caecal contents of a healthy horse to restore the microflora of another.AnthelminticsAn appropriate worming program, to eliminate prepatent worm burdens, is important in foals.", [["gut microflora", "ANATOMY", 45, 59], ["caecal", "ANATOMY", 80, 86], ["gut microflora", "MULTI-TISSUE_STRUCTURE", 45, 59], ["caecal", "ORGANISM_SUBDIVISION", 80, 86], ["horse", "ORGANISM", 109, 114], ["foals", "ORGANISM_SUBDIVISION", 250, 255], ["horse", "SPECIES", 109, 114], ["gut microflora", "TREATMENT", 45, 59], ["prepatent worm burdens", "PROBLEM", 210, 232], ["caecal", "ANATOMY", 80, 86]]], ["Moxidectin is not recommended in foals less than four months old, and should therefore be avoided.", [["Moxidectin", "CHEMICAL", 0, 10], ["Moxidectin", "CHEMICAL", 0, 10], ["Moxidectin", "SIMPLE_CHEMICAL", 0, 10], ["Moxidectin", "TREATMENT", 0, 10]]], ["Ivermectin, fenbendazole or pyrantel are the drugs of choice, according to the likely worm burden and resistance history on the farm.Motility modifiersIf no infectious cause is suspected, intestinal motility can be reduced temporarily using codeine phosphate.", [["intestinal", "ANATOMY", 188, 198], ["Ivermectin", "CHEMICAL", 0, 10], ["fenbendazole", "CHEMICAL", 12, 24], ["pyrantel", "CHEMICAL", 28, 36], ["codeine phosphate", "CHEMICAL", 241, 258], ["Ivermectin", "CHEMICAL", 0, 10], ["fenbendazole", "CHEMICAL", 12, 24], ["pyrantel", "CHEMICAL", 28, 36], ["codeine phosphate", "CHEMICAL", 241, 258], ["Ivermectin", "SIMPLE_CHEMICAL", 0, 10], ["fenbendazole", "SIMPLE_CHEMICAL", 12, 24], ["pyrantel", "SIMPLE_CHEMICAL", 28, 36], ["intestinal", "ORGAN", 188, 198], ["codeine phosphate", "SIMPLE_CHEMICAL", 241, 258], ["Ivermectin", "TREATMENT", 0, 10], ["fenbendazole", "TREATMENT", 12, 24], ["pyrantel", "TREATMENT", 28, 36], ["Motility modifiers", "TREATMENT", 133, 151], ["infectious cause", "PROBLEM", 157, 173], ["intestinal motility", "PROBLEM", 188, 207], ["codeine phosphate", "TREATMENT", 241, 258], ["no", "UNCERTAINTY", 154, 156], ["infectious", "OBSERVATION", 157, 167], ["intestinal", "ANATOMY", 188, 198]]], ["As 75% of cases of diarrhoea are thought to be idiopathic this is a useful treatment in many cases.", [["diarrhoea", "DISEASE", 19, 28], ["diarrhoea", "PROBLEM", 19, 28], ["idiopathic", "PROBLEM", 47, 57], ["a useful treatment", "TREATMENT", 66, 84], ["thought to be", "UNCERTAINTY", 33, 46], ["idiopathic", "OBSERVATION", 47, 57]]], ["However, if it is used in the presence of endotoxin, it can facilitate increased absorption and perpetuate disease.CONTROLMany of the causes of diarrhoea in the foal are infectious.", [["endotoxin", "CHEMICAL", 42, 51], ["diarrhoea", "DISEASE", 144, 153], ["endotoxin", "SIMPLE_CHEMICAL", 42, 51], ["foal", "ORGANISM_SUBDIVISION", 161, 165], ["endotoxin", "TREATMENT", 42, 51], ["increased absorption and perpetuate disease", "PROBLEM", 71, 114], ["diarrhoea", "PROBLEM", 144, 153], ["infectious", "PROBLEM", 170, 180], ["diarrhoea", "OBSERVATION", 144, 153], ["infectious", "OBSERVATION", 170, 180]]], ["Good biosecurity is essential to minimise the transmission of disease to other stock on the premises and to prevent disease being transferred from the premises to other establishments.CONTROLHusbandry practices should be optimised to reduce the environmental contamination and opportunity for transfer between groups: G affected foals should be isolated immediately when clinical signs are seen G affected foals should be handled, ideally by separate personnel wearing appropriate barrier clothing G other in-contact animals should be kept separately, and rectal temperatures monitored daily to identify and separate any further cases as soon as possible G housing stock in groups of similar ages should reduce the incidence of disease, by preventing exposure of na\u00efve animals G equipment and housing should be cleaned and then disinfected thoroughly after removal of the affected animals.", [["rectal", "ANATOMY", 556, 562], ["foals", "ORGANISM", 329, 334], ["foals", "ORGANISM", 406, 411], ["rectal", "ORGANISM_SUBDIVISION", 556, 562], ["disease", "PROBLEM", 62, 69], ["disease", "PROBLEM", 116, 123], ["CONTROLHusbandry practices", "TREATMENT", 184, 210], ["G affected foals", "PROBLEM", 318, 334], ["clinical signs", "PROBLEM", 371, 385], ["rectal temperatures", "TEST", 556, 575], ["disease", "PROBLEM", 728, 735], ["na\u00efve animals G equipment", "TREATMENT", 763, 788], ["removal", "TREATMENT", 857, 864], ["biosecurity", "OBSERVATION", 5, 16], ["disease", "OBSERVATION", 728, 735]]]], "PMC7457163": [["INTRODUCTIONThe World Health Organization (WHO) announced a disease outbreak on January 5, 2020, reporting that their China Country Office received notification on December 31, 2019 of multiple cases of pneumonia of undetermined etiology in Wuhan City in Hubei Province, China[1].", [["pneumonia", "DISEASE", 203, 212], ["pneumonia", "PROBLEM", 203, 212], ["pneumonia", "OBSERVATION", 203, 212]]], ["This outbreak has since ballooned into a worldwide pandemic.", [["ballooned", "OBSERVATION_MODIFIER", 24, 33], ["worldwide", "OBSERVATION_MODIFIER", 41, 50], ["pandemic", "OBSERVATION", 51, 59]]], ["Patterns of radiographic findings have now been described in this illness.", [["radiographic findings", "PROBLEM", 12, 33]]], ["The intention of this study is to review published literature for the range of radiographic findings in these patients and review the overall role of imaging.INTRODUCTIONThe WHO\u2019s original report mentioned 44 cases diagnosed as of January 3, 2020 with 11 (25%) of those stricken being severely ill.", [["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["this study", "TEST", 17, 27], ["radiographic findings", "TEST", 79, 100], ["imaging", "TEST", 150, 157], ["severely ill", "PROBLEM", 285, 297], ["severely", "OBSERVATION_MODIFIER", 285, 293], ["ill", "OBSERVATION", 294, 297]]], ["Some of the patients shared a common work location at the Huanan Seafood market[1].", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["The seafood market being a common link suggests the possibility of animal to human transmission.", [["human", "ORGANISM", 77, 82], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["suggests the possibility", "UNCERTAINTY", 39, 63]]], ["A betacoronavirus has been identified as the cause of the illness and is similar to the viruses that cause severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome[2].", [["betacoronavirus", "CHEMICAL", 2, 17], ["acute respiratory syndrome", "DISEASE", 114, 140], ["SARS", "DISEASE", 142, 146], ["Middle East Respiratory Syndrome", "DISEASE", 152, 184], ["betacoronavirus", "GENE_OR_GENE_PRODUCT", 2, 17], ["A betacoronavirus", "PROBLEM", 0, 17], ["the illness", "PROBLEM", 54, 65], ["the viruses", "PROBLEM", 84, 95], ["severe acute respiratory syndrome", "PROBLEM", 107, 140], ["SARS)", "PROBLEM", 142, 147], ["Middle East Respiratory Syndrome", "PROBLEM", 152, 184], ["illness", "OBSERVATION", 58, 65], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["respiratory syndrome", "OBSERVATION", 120, 140], ["Middle", "ANATOMY_MODIFIER", 152, 158], ["Respiratory Syndrome", "OBSERVATION", 164, 184]]], ["Based upon comparative genomic analysis, this novel coronavirus likely emerged from an animal reservoir of a bat, with a Malayan pangolin potentially serving as an intermediate host[3].INTRODUCTIONThe novel virus was officially named \u201cSevere Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2)\u201d by the International Committee on Taxonomy of Viruses[2].", [["Acute Respiratory Syndrome coronavirus", "DISEASE", 242, 280], ["coronavirus", "ORGANISM", 52, 63], ["pangolin", "GENE_OR_GENE_PRODUCT", 129, 137], ["Severe Acute Respiratory Syndrome coronavirus", "SPECIES", 235, 280], ["comparative genomic analysis", "TEST", 11, 39], ["this novel coronavirus", "PROBLEM", 41, 63], ["a Malayan pangolin", "TREATMENT", 119, 137], ["The novel virus", "PROBLEM", 197, 212], ["Severe Acute Respiratory Syndrome coronavirus", "PROBLEM", 235, 280], ["SARS", "TEST", 284, 288], ["CoV", "TEST", 289, 292], ["virus", "OBSERVATION", 207, 212], ["Severe", "OBSERVATION_MODIFIER", 235, 241], ["Acute", "OBSERVATION_MODIFIER", 242, 247], ["Respiratory Syndrome", "OBSERVATION", 248, 268]]], ["On February 11, 2020 the WHO named the disease caused by the virus \u201ccoronavirus disease 2019 (COVID-19)\u201d[4].", [["coronavirus disease", "DISEASE", 68, 87], ["the disease", "PROBLEM", 35, 46], ["the virus \u201ccoronavirus disease", "PROBLEM", 57, 87], ["COVID", "TEST", 94, 99]]], ["In rapid course over the last few months, the virus has spread worldwide causing a global pandemic.", [["the virus", "PROBLEM", 42, 51], ["a global pandemic", "PROBLEM", 81, 98], ["rapid", "OBSERVATION_MODIFIER", 3, 8], ["course", "OBSERVATION_MODIFIER", 9, 15], ["global", "OBSERVATION_MODIFIER", 83, 89], ["pandemic", "OBSERVATION_MODIFIER", 90, 98]]], ["As of April 18, 2020, there have been 2160207 confirmed cases and 146088 deaths reported globally[5].", [["deaths", "DISEASE", 73, 79]]], ["Also as of April 18, 2020, the United States has 690714 confirmed cases and 35443 deaths[6].CLINICAL PICTUREThe presentation of COVID-19 is most remarkable for pulmonary symptoms that if become serious can quickly turn deadly.", [["pulmonary", "ANATOMY", 160, 169], ["deaths", "DISEASE", 82, 88], ["pulmonary", "ORGAN", 160, 169], ["COVID", "TEST", 128, 133], ["pulmonary symptoms", "PROBLEM", 160, 178], ["pulmonary", "ANATOMY", 160, 169], ["symptoms", "OBSERVATION", 170, 178]]], ["In a series of 41 patients, the clinical symptoms of COVID-19 commonly included fever (98%), cough (76%), and myalgia (44%)[7].", [["COVID", "DISEASE", 53, 58], ["fever", "DISEASE", 80, 85], ["cough", "DISEASE", 93, 98], ["myalgia", "DISEASE", 110, 117], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["the clinical symptoms", "PROBLEM", 28, 49], ["COVID", "TEST", 53, 58], ["fever", "PROBLEM", 80, 85], ["cough", "PROBLEM", 93, 98], ["myalgia", "PROBLEM", 110, 117]]], ["Dyspnea was present in 22 of 40 patients (55%) in the same study and became apparent a mean of 8.0 d after onset of symptoms.", [["Dyspnea", "DISEASE", 0, 7], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["Dyspnea", "PROBLEM", 0, 7], ["the same study", "TEST", 50, 64], ["symptoms", "PROBLEM", 116, 124]]], ["Respiratory symptoms progressed to acute respiratory distress syndrome (ARDS) in 29% of all cases.", [["Respiratory", "ANATOMY", 0, 11], ["respiratory", "ANATOMY", 41, 52], ["Respiratory symptoms", "DISEASE", 0, 20], ["acute respiratory distress syndrome", "DISEASE", 35, 70], ["ARDS", "DISEASE", 72, 76], ["Respiratory symptoms", "PROBLEM", 0, 20], ["acute respiratory distress syndrome", "PROBLEM", 35, 70], ["ARDS", "PROBLEM", 72, 76], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory distress", "OBSERVATION", 41, 61], ["ARDS", "OBSERVATION", 72, 76]]], ["Another study focused on 21 moderately ill hospitalized patients who did not require oxygen therapy and found, among this group, fever (86%) and cough (57%) to be the most common presenting symptoms[8].", [["oxygen", "CHEMICAL", 85, 91], ["fever", "DISEASE", 129, 134], ["cough", "DISEASE", 145, 150], ["oxygen", "CHEMICAL", 85, 91], ["patients", "ORGANISM", 56, 64], ["oxygen", "SIMPLE_CHEMICAL", 85, 91], ["patients", "SPECIES", 56, 64], ["Another study", "TEST", 0, 13], ["oxygen therapy", "TREATMENT", 85, 99], ["fever", "PROBLEM", 129, 134], ["cough", "PROBLEM", 145, 150]]], ["According to the Centers for Disease Control and Prevention, pulmonary disease is considered severe in 14% of cases with symptoms including dyspnea, hypoxia or > 50% lung involvement on imaging and is considered critical in 5% of cases with symptoms including respiratory failure, shock or multi-organ failure[9].", [["pulmonary", "ANATOMY", 61, 70], ["lung", "ANATOMY", 166, 170], ["respiratory", "ANATOMY", 260, 271], ["multi-organ", "ANATOMY", 290, 301], ["pulmonary disease", "DISEASE", 61, 78], ["dyspnea", "DISEASE", 140, 147], ["hypoxia", "DISEASE", 149, 156], ["respiratory failure", "DISEASE", 260, 279], ["shock", "DISEASE", 281, 286], ["multi-organ failure", "DISEASE", 290, 309], ["pulmonary", "ORGAN", 61, 70], ["lung", "ORGAN", 166, 170], ["Disease Control", "TREATMENT", 29, 44], ["pulmonary disease", "PROBLEM", 61, 78], ["symptoms", "PROBLEM", 121, 129], ["dyspnea", "PROBLEM", 140, 147], ["hypoxia", "PROBLEM", 149, 156], ["> 50% lung involvement", "PROBLEM", 160, 182], ["imaging", "TEST", 186, 193], ["symptoms", "PROBLEM", 241, 249], ["respiratory failure", "PROBLEM", 260, 279], ["shock", "PROBLEM", 281, 286], ["multi-organ failure", "PROBLEM", 290, 309], ["Disease", "OBSERVATION", 29, 36], ["pulmonary", "ANATOMY", 61, 70], ["disease", "OBSERVATION", 71, 78], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["hypoxia", "OBSERVATION", 149, 156], ["lung", "ANATOMY", 166, 170], ["respiratory failure", "OBSERVATION", 260, 279], ["shock", "OBSERVATION", 281, 286], ["multi-organ failure", "OBSERVATION", 290, 309]]], ["With the accumulation of data on hospitalized patients, it is now possible to examine characteristics and comorbidities related to COVID-19.", [["COVID-19", "CHEMICAL", 131, 139], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["comorbidities", "PROBLEM", 106, 119], ["COVID", "TEST", 131, 136], ["accumulation", "OBSERVATION_MODIFIER", 9, 21]]], ["A large study of 5700 patients in the New York City area showed hypertension (56.6%), obesity (41.7%) and diabetes (33.8%) to be the most common comorbidities[10].PATHOLOGYPatterns of histopathology have been described to a limited extent.", [["hypertension", "DISEASE", 64, 76], ["obesity", "DISEASE", 86, 93], ["diabetes", "DISEASE", 106, 114], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["A large study", "TEST", 0, 13], ["hypertension", "PROBLEM", 64, 76], ["obesity", "PROBLEM", 86, 93], ["diabetes", "PROBLEM", 106, 114], ["histopathology", "PROBLEM", 184, 198], ["large", "OBSERVATION_MODIFIER", 2, 7], ["hypertension", "OBSERVATION", 64, 76], ["histopathology", "OBSERVATION", 184, 198]]], ["According to Xu et al[11] biopsy and autopsy reports are \u201cbarely accessible\u201d in this fast-moving crisis.", [["biopsy and autopsy", "TEST", 26, 44], ["moving crisis", "PROBLEM", 90, 103]]], ["This group published a pathology case report of postmortem biopsy specimens from a patient that died of a severe case of COVID-19.", [["postmortem biopsy specimens", "ANATOMY", 48, 75], ["postmortem biopsy specimens", "CANCER", 48, 75], ["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90], ["postmortem biopsy specimens", "TEST", 48, 75], ["COVID", "TEST", 121, 126], ["severe", "OBSERVATION_MODIFIER", 106, 112]]], ["The pulmonary specimens showed desquamated pneumocytes and hyaline membrane formation consistent with ARDS in the right lung, and pulmonary edema and hyaline membrane formation consistent with early ARDS in the left lung.", [["pulmonary specimens", "ANATOMY", 4, 23], ["pneumocytes", "ANATOMY", 43, 54], ["hyaline membrane", "ANATOMY", 59, 75], ["right lung", "ANATOMY", 114, 124], ["pulmonary", "ANATOMY", 130, 139], ["hyaline membrane", "ANATOMY", 150, 166], ["left lung", "ANATOMY", 211, 220], ["ARDS", "DISEASE", 102, 106], ["pulmonary edema", "DISEASE", 130, 145], ["ARDS", "DISEASE", 199, 203], ["pulmonary specimens", "CANCER", 4, 23], ["pneumocytes", "CELL", 43, 54], ["hyaline membrane", "TISSUE", 59, 75], ["lung", "ORGAN", 120, 124], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 130, 145], ["hyaline membrane", "TISSUE", 150, 166], ["lung", "ORGAN", 216, 220], ["The pulmonary specimens", "TEST", 0, 23], ["desquamated pneumocytes", "PROBLEM", 31, 54], ["hyaline membrane formation", "PROBLEM", 59, 85], ["ARDS in the right lung", "PROBLEM", 102, 124], ["pulmonary edema", "PROBLEM", 130, 145], ["hyaline membrane formation", "PROBLEM", 150, 176], ["early ARDS in the left lung", "PROBLEM", 193, 220], ["pulmonary", "ANATOMY", 4, 13], ["desquamated pneumocytes", "OBSERVATION", 31, 54], ["hyaline membrane formation", "OBSERVATION", 59, 85], ["consistent with", "UNCERTAINTY", 86, 101], ["ARDS", "OBSERVATION", 102, 106], ["right", "ANATOMY_MODIFIER", 114, 119], ["lung", "ANATOMY", 120, 124], ["pulmonary", "ANATOMY", 130, 139], ["edema", "OBSERVATION", 140, 145], ["hyaline membrane formation", "OBSERVATION", 150, 176], ["consistent with", "UNCERTAINTY", 177, 192], ["early", "OBSERVATION_MODIFIER", 193, 198], ["ARDS", "OBSERVATION", 199, 203], ["left", "ANATOMY_MODIFIER", 211, 215], ["lung", "ANATOMY", 216, 220]]], ["Bilateral interstitial infiltrates, predominantly lymphocytic in nature, were also seen on histopathologic evaluation.", [["interstitial infiltrates", "ANATOMY", 10, 34], ["lymphocytic", "ANATOMY", 50, 61], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 10, 34], ["Bilateral interstitial infiltrates", "PROBLEM", 0, 34], ["lymphocytic", "PROBLEM", 50, 61], ["histopathologic evaluation", "TEST", 91, 117], ["interstitial", "ANATOMY_MODIFIER", 10, 22], ["infiltrates", "OBSERVATION", 23, 34], ["predominantly", "OBSERVATION_MODIFIER", 36, 49], ["lymphocytic", "OBSERVATION_MODIFIER", 50, 61]]], ["Additionally, there were viral cytopathic-type changes in pneumocytes within the alveolar spaces.", [["pneumocytes", "ANATOMY", 58, 69], ["alveolar spaces", "ANATOMY", 81, 96], ["pneumocytes", "CELL", 58, 69], ["alveolar spaces", "MULTI-TISSUE_STRUCTURE", 81, 96], ["pneumocytes", "CELL_TYPE", 58, 69], ["viral cytopathic-type changes in pneumocytes within the alveolar spaces", "PROBLEM", 25, 96], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["cytopathic", "OBSERVATION_MODIFIER", 31, 41], ["type", "OBSERVATION_MODIFIER", 42, 46], ["pneumocytes", "OBSERVATION", 58, 69], ["alveolar", "ANATOMY_MODIFIER", 81, 89]]], ["This single case study did not identify any viral inclusions within the pathology specimens.", [["specimens", "ANATOMY", 82, 91], ["specimens", "CANCER", 82, 91], ["This single case study", "TEST", 0, 22], ["any viral inclusions", "PROBLEM", 40, 60], ["the pathology specimens", "TEST", 68, 91]]], ["A more recent report of three cases where histopathology was obtained showed direct evidence on electron microscopy of viral inclusions within endothelial cells in one patient\u2019s transplanted kidney[12].", [["endothelial cells", "ANATOMY", 143, 160], ["kidney", "ANATOMY", 191, 197], ["endothelial cells", "CELL", 143, 160], ["patient", "ORGANISM", 168, 175], ["kidney", "ORGAN", 191, 197], ["endothelial cells", "CELL_TYPE", 143, 160], ["patient", "SPECIES", 168, 175], ["histopathology", "TEST", 42, 56], ["electron microscopy", "TEST", 96, 115], ["viral inclusions within endothelial cells", "PROBLEM", 119, 160], ["viral inclusions", "OBSERVATION", 119, 135], ["endothelial cells", "OBSERVATION", 143, 160], ["kidney", "ANATOMY", 191, 197]]], ["Using light microscopy and immunohistochemical staining, the group also found endothelial cell inflammation and apoptosis in many organs including the heart, kidney, liver and small bowel.", [["endothelial cell", "ANATOMY", 78, 94], ["organs", "ANATOMY", 130, 136], ["heart", "ANATOMY", 151, 156], ["kidney", "ANATOMY", 158, 164], ["liver", "ANATOMY", 166, 171], ["small bowel", "ANATOMY", 176, 187], ["endothelial cell", "CELL", 78, 94], ["organs", "ORGAN", 130, 136], ["heart", "ORGAN", 151, 156], ["kidney", "ORGAN", 158, 164], ["liver", "ORGAN", 166, 171], ["bowel", "ORGAN", 182, 187], ["light microscopy", "TEST", 6, 22], ["immunohistochemical staining", "TEST", 27, 55], ["endothelial cell inflammation", "PROBLEM", 78, 107], ["apoptosis in many organs including the heart, kidney, liver and small bowel", "PROBLEM", 112, 187], ["endothelial cell inflammation", "OBSERVATION", 78, 107], ["apoptosis", "OBSERVATION", 112, 121], ["heart", "ANATOMY", 151, 156], ["kidney", "ANATOMY", 158, 164], ["liver", "ANATOMY", 166, 171], ["small bowel", "ANATOMY", 176, 187]]], ["Laboratory findings of bloodwork on COVID-19 patients generally show a picture of viral infection with low lymphocyte counts.", [["lymphocyte", "ANATOMY", 107, 117], ["viral infection", "DISEASE", 82, 97], ["patients", "ORGANISM", 45, 53], ["lymphocyte", "CELL", 107, 117], ["patients", "SPECIES", 45, 53], ["bloodwork", "TEST", 23, 32], ["COVID", "TEST", 36, 41], ["viral infection", "PROBLEM", 82, 97], ["low lymphocyte counts", "PROBLEM", 103, 124], ["viral", "OBSERVATION_MODIFIER", 82, 87], ["infection", "OBSERVATION", 88, 97], ["low lymphocyte counts", "OBSERVATION", 103, 124]]], ["In a study of 99 patients, most subjects had a decreased absolute value of lymphocytes in the peripheral blood[13].", [["lymphocytes", "ANATOMY", 75, 86], ["peripheral blood", "ANATOMY", 94, 110], ["patients", "ORGANISM", 17, 25], ["lymphocytes", "CELL", 75, 86], ["peripheral blood", "ORGANISM_SUBSTANCE", 94, 110], ["lymphocytes", "CELL_TYPE", 75, 86], ["patients", "SPECIES", 17, 25], ["a study", "TEST", 3, 10], ["a decreased absolute value of lymphocytes", "PROBLEM", 45, 86], ["peripheral", "ANATOMY_MODIFIER", 94, 104], ["blood", "ANATOMY", 105, 110]]], ["Another study of 34 patients found 50% had a decreased lymphocyte count[14].", [["lymphocyte", "ANATOMY", 55, 65], ["patients", "ORGANISM", 20, 28], ["lymphocyte", "CELL", 55, 65], ["patients", "SPECIES", 20, 28], ["Another study", "TEST", 0, 13], ["a decreased lymphocyte count", "PROBLEM", 43, 71]]], ["This finding may be secondary to the virus causing an immune response in which chemokines recruit specific immune cells such as lymphocytes to the site of infection[13,15].", [["immune cells", "ANATOMY", 107, 119], ["lymphocytes", "ANATOMY", 128, 139], ["site", "ANATOMY", 147, 151], ["infection", "DISEASE", 155, 164], ["immune cells", "CELL", 107, 119], ["lymphocytes", "CELL", 128, 139], ["chemokines", "PROTEIN", 79, 89], ["immune cells", "CELL_TYPE", 107, 119], ["lymphocytes", "CELL_TYPE", 128, 139], ["the virus", "PROBLEM", 33, 42], ["an immune response", "PROBLEM", 51, 69], ["immune cells", "PROBLEM", 107, 119], ["lymphocytes", "PROBLEM", 128, 139], ["infection", "PROBLEM", 155, 164], ["may be", "UNCERTAINTY", 13, 19], ["virus", "OBSERVATION", 37, 42], ["immune response", "OBSERVATION", 54, 69], ["infection", "OBSERVATION", 155, 164]]], ["In addition, studies have found increased prothrombin time and D-dimer in COVID-19 patients admitted to the intensive care unit[16,17].", [["prothrombin", "GENE_OR_GENE_PRODUCT", 42, 53], ["D-dimer", "GENE_OR_GENE_PRODUCT", 63, 70], ["patients", "ORGANISM", 83, 91], ["prothrombin", "PROTEIN", 42, 53], ["D-dimer", "PROTEIN", 63, 70], ["patients", "SPECIES", 83, 91], ["studies", "TEST", 13, 20], ["increased prothrombin time", "PROBLEM", 32, 58], ["D-dimer", "TEST", 63, 70], ["COVID", "TEST", 74, 79], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["prothrombin", "OBSERVATION", 42, 53]]], ["Other laboratory findings include elevations in C-reactive protein and erythrocyte sedimentation rate[13].Methods ::: REVIEW OF IMAGING LITERATUREThis study reviews the published literature for the range of radiographic findings evident in patients suffering from SARS-CoV-2 infection.", [["erythrocyte", "ANATOMY", 71, 82], ["SARS-CoV-2 infection", "DISEASE", 264, 284], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 48, 66], ["erythrocyte", "CELL", 71, 82], ["patients", "ORGANISM", 240, 248], ["SARS-CoV-2", "ORGANISM", 264, 274], ["C-reactive protein", "PROTEIN", 48, 66], ["patients", "SPECIES", 240, 248], ["SARS-CoV", "SPECIES", 264, 272], ["Other laboratory findings", "TEST", 0, 25], ["elevations in C-reactive protein", "PROBLEM", 34, 66], ["erythrocyte sedimentation rate", "TEST", 71, 101], ["IMAGING LITERATUREThis study", "TEST", 128, 156], ["radiographic findings", "TEST", 207, 228], ["SARS", "PROBLEM", 264, 268], ["CoV-2 infection", "PROBLEM", 269, 284], ["elevations", "OBSERVATION_MODIFIER", 34, 44], ["reactive protein", "OBSERVATION", 50, 66], ["infection", "OBSERVATION", 275, 284]]], ["Towards this end, we searched PubMed for the following terms on April 6, 2020 without imposing a starting date limit: \u201cCovid\u201d, \u201c19\u201d, \u201cRadiology\u201d, \u201cRadiography\u201d, \u201cComputed Tomography (CT)\u201d, \u201cImaging\u201d, \u201cChest Radiographs (CXR)\u201d, \u201cX-Ray\u201d, \u201cPositron Emission Tomography (PET)\u201d, \u201cUltrasound\u201d, \u201cSonography\u201d, \u201cMagnetic Resonance Imaging\u201d, and \u201cAngiography\u201d.", [["Radiography", "TEST", 147, 158], ["Computed Tomography", "TEST", 162, 181], ["CT", "TEST", 183, 185], ["Imaging", "TEST", 190, 197], ["Chest Radiographs", "TEST", 201, 218], ["CXR", "TEST", 220, 223], ["Positron Emission Tomography", "TEST", 237, 265], ["\u201cUltrasound", "TEST", 274, 285], ["Sonography", "TEST", 289, 299], ["Angiography", "TEST", 337, 348], ["Chest", "ANATOMY", 201, 206]]], ["After excluding articles that were outside the realm of investigation, a total of 133 articles were systematically reviewed to extract any radiographic data, both objective and subjective.", [["any radiographic data", "TEST", 135, 156]]], ["In light of the swift development of new and increasing data, the study also included a look at preprinted manuscripts available on medRxiv.org and covered those that appeared most relevant with an indication of the unpublished status to date.", [["new and increasing data", "PROBLEM", 37, 60], ["the study", "TEST", 62, 71], ["new", "OBSERVATION_MODIFIER", 37, 40]]], ["The data within each article were organized in groups into the following categories: Study design (case study or series or letter etc.); Number of cases; Location (Country where imaged); Imaging Modality; Biological Sex; Age; COVID-19 lab diagnosis; Radiographic findings.", [["Imaging", "TEST", 187, 194], ["COVID", "TEST", 226, 231], ["Radiographic findings", "TEST", 250, 271]]], ["The subtopics for radiographic findings include disease distribution, progression and focal and generalized patterns of disease.Results ::: REVIEW OF IMAGING LITERATUREStudy design was represented by 39 case reports and 78 case series reports.", [["radiographic findings", "TEST", 18, 39], ["disease distribution", "PROBLEM", 48, 68], ["progression", "PROBLEM", 70, 81], ["focal and generalized patterns of disease", "PROBLEM", 86, 127], ["disease", "OBSERVATION", 48, 55], ["progression", "OBSERVATION_MODIFIER", 70, 81], ["focal", "OBSERVATION_MODIFIER", 86, 91], ["generalized", "OBSERVATION_MODIFIER", 96, 107], ["patterns", "OBSERVATION_MODIFIER", 108, 116], ["disease", "OBSERVATION", 120, 127]]], ["These were all retrospective review studies.", [["all retrospective review studies", "TEST", 11, 43]]], ["The range of number of participants within each series report shows very small series of 2-10 cases being the most common (28/78) and representing over one third of these studies (35.9%).", [["participants", "SPECIES", 23, 35], ["these studies", "TEST", 165, 178], ["range", "OBSERVATION_MODIFIER", 4, 9]]], ["Table 1 shows the breakdown of number of participants per study.Results ::: REVIEW OF IMAGING LITERATUREThe case distribution by country where the imaging was performed in this data set is as follows: China 99; Italy 8; United States 5; Korea 4; Taiwan 3; Germany 2; Japan 2; Singapore 2; Turkey 2; Brazil 1; Thailand 1; and Vietnam 1.", [["participants", "SPECIES", 41, 53], ["IMAGING LITERATURE", "TEST", 86, 104], ["the imaging", "TEST", 143, 154], ["breakdown", "OBSERVATION_MODIFIER", 18, 27]]], ["It is difficult to assess the number of laboratory proven cases in our literature review, however the vast majority of studies mention that the cases were laboratory confirmed mostly using real-time reverse transcription polymerase chain reaction (RT-PCR) technique on samples obtained via bronchoalveolar lavage, endotracheal aspirate, nasopharyngeal swab or oropharyngeal swab.Results ::: REVIEW OF IMAGING LITERATUREThe number of instances in which an imaging modality was utilized and focused upon in the various studies is as follows: CT 121, plain CXR 8, PET 4, and Sonography 4.", [["samples", "ANATOMY", 269, 276], ["bronchoalveolar lavage", "ANATOMY", 290, 312], ["endotracheal", "ANATOMY", 314, 326], ["nasopharyngeal swab", "ANATOMY", 337, 356], ["oropharyngeal swab", "ANATOMY", 360, 378], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 290, 312], ["endotracheal aspirate", "MULTI-TISSUE_STRUCTURE", 314, 335], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 337, 356], ["oropharyngeal swab", "ORGANISM_SUBSTANCE", 360, 378], ["samples", "TEST", 269, 276], ["bronchoalveolar lavage", "TEST", 290, 312], ["endotracheal aspirate", "TEST", 314, 335], ["nasopharyngeal swab", "TEST", 337, 356], ["oropharyngeal swab", "TEST", 360, 378], ["IMAGING LITERATURE", "TEST", 401, 419], ["an imaging modality", "TEST", 452, 471], ["CT", "TEST", 540, 542], ["plain CXR", "TEST", 548, 557], ["PET", "TEST", 561, 564], ["Sonography", "TEST", 572, 582], ["bronchoalveolar lavage", "OBSERVATION", 290, 312], ["endotracheal", "ANATOMY", 314, 326], ["nasopharyngeal", "ANATOMY", 337, 351], ["oropharyngeal swab", "ANATOMY", 360, 378]]], ["Due to the significant and often fulminant pulmonary pathology present with SARS-CoV-2 infection, radiographic imaging has concentrated mainly on CXR and CT.", [["pulmonary", "ANATOMY", 43, 52], ["SARS-CoV-2 infection", "DISEASE", 76, 96], ["pulmonary", "ORGAN", 43, 52], ["SARS-CoV", "SPECIES", 76, 84], ["the significant and often fulminant pulmonary pathology", "PROBLEM", 7, 62], ["SARS", "PROBLEM", 76, 80], ["CoV-2 infection", "PROBLEM", 81, 96], ["radiographic imaging", "TEST", 98, 118], ["CXR", "TEST", 146, 149], ["CT", "TEST", 154, 156], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["often", "OBSERVATION_MODIFIER", 27, 32], ["fulminant", "OBSERVATION_MODIFIER", 33, 42], ["pulmonary", "ANATOMY", 43, 52], ["pathology", "OBSERVATION", 53, 62], ["infection", "OBSERVATION", 87, 96]]], ["An overall review of the published data shows pulmonary findings on both CXR and chest CT with infiltrates nearly universally bilateral, peripheral and often multi-lobar with adjacent reactive pleural changes.", [["pulmonary", "ANATOMY", 46, 55], ["multi-lobar", "ANATOMY", 158, 169], ["pleural", "ANATOMY", 193, 200], ["pulmonary", "ORGAN", 46, 55], ["pleural", "ORGAN", 193, 200], ["the published data", "TEST", 21, 39], ["pulmonary findings", "PROBLEM", 46, 64], ["both CXR", "TEST", 68, 76], ["chest CT", "TEST", 81, 89], ["infiltrates", "PROBLEM", 95, 106], ["adjacent reactive pleural changes", "PROBLEM", 175, 208], ["pulmonary", "ANATOMY", 46, 55], ["chest", "ANATOMY", 81, 86], ["infiltrates", "OBSERVATION", 95, 106], ["bilateral", "ANATOMY_MODIFIER", 126, 135], ["peripheral", "ANATOMY_MODIFIER", 137, 147], ["reactive", "OBSERVATION_MODIFIER", 184, 192], ["pleural", "ANATOMY", 193, 200], ["changes", "OBSERVATION", 201, 208]]], ["Ground glass opacities (GGO) were frequently present either with or without concurrent consolidation, crazy paving (ground glass density superimposed with thickening of the interlobular septa and intralobular lines) and rounded morphology.", [["interlobular septa", "ANATOMY", 173, 191], ["intralobular lines", "ANATOMY", 196, 214], ["interlobular septa", "MULTI-TISSUE_STRUCTURE", 173, 191], ["intralobular lines", "CELL", 196, 214], ["Ground glass opacities", "PROBLEM", 0, 22], ["GGO", "PROBLEM", 24, 27], ["concurrent consolidation", "PROBLEM", 76, 100], ["crazy paving (ground glass density", "PROBLEM", 102, 136], ["thickening of the interlobular septa and intralobular lines", "PROBLEM", 155, 214], ["rounded morphology", "PROBLEM", 220, 238], ["glass opacities", "OBSERVATION", 7, 22], ["GGO", "OBSERVATION_MODIFIER", 24, 27], ["without", "UNCERTAINTY", 68, 75], ["concurrent", "OBSERVATION_MODIFIER", 76, 86], ["consolidation", "OBSERVATION", 87, 100], ["crazy", "OBSERVATION_MODIFIER", 102, 107], ["ground glass density", "OBSERVATION", 116, 136], ["thickening", "OBSERVATION", 155, 165], ["interlobular", "ANATOMY_MODIFIER", 173, 185], ["septa", "ANATOMY_MODIFIER", 186, 191], ["intralobular lines", "OBSERVATION", 196, 214], ["rounded", "OBSERVATION_MODIFIER", 220, 227], ["morphology", "OBSERVATION_MODIFIER", 228, 238]]], ["Pleural effusions, lymphadenopathy and pneumothorax are seldom mentioned.", [["Pleural effusions", "ANATOMY", 0, 17], ["Pleural effusions", "DISEASE", 0, 17], ["lymphadenopathy", "DISEASE", 19, 34], ["pneumothorax", "DISEASE", 39, 51], ["Pleural effusions", "PATHOLOGICAL_FORMATION", 0, 17], ["Pleural effusions", "PROBLEM", 0, 17], ["lymphadenopathy", "PROBLEM", 19, 34], ["pneumothorax", "PROBLEM", 39, 51], ["effusions", "OBSERVATION", 8, 17], ["lymphadenopathy", "OBSERVATION", 19, 34], ["pneumothorax", "OBSERVATION", 39, 51]]], ["Other imaging modalities noted in our review included rare mention of 18F labeled fluorodeoxyglucose positron emission tomography (18F-FDG-PET), sonography and magnetic resonance (MR).CXR highlights ::: REVIEW OF IMAGING LITERATURECXR are described in the literature but the data are relatively scant as compared to CT.", [["18F", "CHEMICAL", 70, 73], ["fluorodeoxyglucose", "CHEMICAL", 82, 100], ["18F-FDG", "CHEMICAL", 131, 138], ["18F labeled fluorodeoxyglucose", "SIMPLE_CHEMICAL", 70, 100], ["18F-FDG", "SIMPLE_CHEMICAL", 131, 138], ["CXR", "PROTEIN", 184, 187], ["Other imaging modalities", "TEST", 0, 24], ["emission tomography", "TEST", 110, 129], ["FDG-PET", "TEST", 135, 142], ["sonography", "TEST", 145, 155], ["CXR", "TEST", 184, 187], ["IMAGING LITERATURECXR", "TEST", 213, 234], ["the data", "TEST", 271, 279], ["CT", "TEST", 316, 318], ["scant", "OBSERVATION", 295, 300]]], ["In a series of two female patients, the CXR for each subject showed bilateral consolidation in the lower lung fields with follow up showing patchy consolidation[18].", [["lower lung", "ANATOMY", 99, 109], ["patients", "ORGANISM", 26, 34], ["lung", "ORGAN", 105, 109], ["CXR", "PROTEIN", 40, 43], ["patients", "SPECIES", 26, 34], ["the CXR", "TEST", 36, 43], ["bilateral consolidation in the lower lung fields", "PROBLEM", 68, 116], ["patchy consolidation", "PROBLEM", 140, 160], ["bilateral", "ANATOMY_MODIFIER", 68, 77], ["consolidation", "OBSERVATION", 78, 91], ["lower", "ANATOMY_MODIFIER", 99, 104], ["lung", "ANATOMY", 105, 109], ["fields", "ANATOMY_MODIFIER", 110, 116], ["patchy", "OBSERVATION_MODIFIER", 140, 146], ["consolidation", "OBSERVATION", 147, 160]]], ["Another case study included chest radiography, the first described in Taiwan, and showed bilateral, ill-defined and patchy opacities consistent with pneumonia[17].", [["chest", "ANATOMY", 28, 33], ["opacities", "DISEASE", 123, 132], ["pneumonia", "DISEASE", 149, 158], ["Another case study", "TEST", 0, 18], ["chest radiography", "TEST", 28, 45], ["bilateral, ill-defined and patchy opacities", "PROBLEM", 89, 132], ["pneumonia", "PROBLEM", 149, 158], ["chest", "ANATOMY", 28, 33], ["bilateral", "ANATOMY_MODIFIER", 89, 98], ["ill", "OBSERVATION_MODIFIER", 100, 103], ["patchy", "OBSERVATION_MODIFIER", 116, 122], ["opacities", "OBSERVATION", 123, 132], ["consistent with", "UNCERTAINTY", 133, 148], ["pneumonia", "OBSERVATION", 149, 158]]], ["Another study of 21 patients which focused on chest CT also included 5 patients with CXR[19].", [["chest", "ANATOMY", 46, 51], ["patients", "ORGANISM", 20, 28], ["chest", "ORGANISM_SUBDIVISION", 46, 51], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 71, 79], ["Another study", "TEST", 0, 13], ["chest CT", "TEST", 46, 54], ["CXR", "TEST", 85, 88], ["chest", "ANATOMY", 46, 51]]], ["In this study the CXR failed to demonstrate early GGO in two patients and missed the peripheral nature of the infiltrates in another patient.", [["GGO", "DISEASE", 50, 53], ["patients", "ORGANISM", 61, 69], ["patient", "ORGANISM", 133, 140], ["CXR", "PROTEIN", 18, 21], ["patients", "SPECIES", 61, 69], ["patient", "SPECIES", 133, 140], ["this study", "TEST", 3, 13], ["the CXR", "TEST", 14, 21], ["early GGO", "PROBLEM", 44, 53], ["the infiltrates", "PROBLEM", 106, 121], ["early", "OBSERVATION_MODIFIER", 44, 49], ["GGO", "OBSERVATION", 50, 53], ["peripheral nature", "OBSERVATION_MODIFIER", 85, 102], ["infiltrates", "OBSERVATION", 110, 121]]], ["This suggests that CXR performed early in disease course may lack the sensitivity needed to detect COVID-19 related lung disease.", [["lung", "ANATOMY", 116, 120], ["lung disease", "DISEASE", 116, 128], ["lung", "ORGAN", 116, 120], ["CXR", "PROTEIN", 19, 22], ["CXR", "TEST", 19, 22], ["the sensitivity", "TEST", 66, 81], ["COVID-19 related lung disease", "PROBLEM", 99, 128], ["lung", "ANATOMY", 116, 120], ["disease", "OBSERVATION", 121, 128]]], ["Such studies led to the use of chest CT to diagnose COVID-19 lung disease at earlier stages, particularly in the earlier months of the outbreak.CXR highlights ::: REVIEW OF IMAGING LITERATUREA larger study out of Hong Kong examines the usefulness of CXR[20].", [["chest", "ANATOMY", 31, 36], ["lung", "ANATOMY", 61, 65], ["lung disease", "DISEASE", 61, 73], ["chest", "ORGANISM_SUBDIVISION", 31, 36], ["lung", "ORGAN", 61, 65], ["CXR", "PROTEIN", 144, 147], ["Such studies", "TEST", 0, 12], ["chest CT", "TEST", 31, 39], ["19 lung disease", "PROBLEM", 58, 73], ["CXR", "TEST", 144, 147], ["IMAGING", "TEST", 173, 180], ["larger study", "TEST", 193, 205], ["CXR", "TEST", 250, 253], ["chest", "ANATOMY", 31, 36], ["lung", "ANATOMY", 61, 65], ["disease", "OBSERVATION", 66, 73]]], ["They studied 64 RT-PCR positive cases of COVID-19 and determined consolidation to be the most common CXR finding in 30/64 (47%).", [["CXR", "CANCER", 101, 104], ["COVID-19", "SPECIES", 41, 49], ["COVID", "TEST", 41, 46], ["consolidation", "PROBLEM", 65, 78], ["consolidation", "OBSERVATION", 65, 78]]], ["Also commonly noted were GGO 21/64 (33%), peripheral infiltrates 26/64 (41%), lower lung zone involvement 32/64 (50%) and bilaterality 32/64 (50%).", [["peripheral infiltrates", "ANATOMY", 42, 64], ["lower lung zone", "ANATOMY", 78, 93], ["peripheral infiltrates", "DISEASE", 42, 64], ["bilaterality", "DISEASE", 122, 134], ["lung", "ORGAN", 84, 88], ["GGO", "TEST", 25, 28], ["peripheral infiltrates", "PROBLEM", 42, 64], ["lower lung zone involvement", "PROBLEM", 78, 105], ["bilaterality", "TEST", 122, 134], ["peripheral", "ANATOMY_MODIFIER", 42, 52], ["infiltrates", "OBSERVATION", 53, 64], ["lower", "ANATOMY_MODIFIER", 78, 83], ["lung", "ANATOMY", 84, 88], ["zone", "ANATOMY_MODIFIER", 89, 93]]], ["Pleural effusion was uncommonly present in 2/64 (3%).", [["Pleural effusion", "ANATOMY", 0, 16], ["Pleural effusion", "DISEASE", 0, 16], ["Pleural", "PATHOLOGICAL_FORMATION", 0, 7], ["Pleural effusion", "PROBLEM", 0, 16], ["effusion", "OBSERVATION", 8, 16]]], ["They found peak severity on CXR at 10-12 d from the onset of symptoms.", [["peak severity", "PROBLEM", 11, 24], ["CXR", "TEST", 28, 31], ["symptoms", "PROBLEM", 61, 69], ["peak", "OBSERVATION_MODIFIER", 11, 15], ["severity", "OBSERVATION_MODIFIER", 16, 24]]], ["They concluded that CXR depicts similar findings as CT.", [["CXR", "PROTEIN", 20, 23], ["CXR", "TEST", 20, 23], ["CT", "TEST", 52, 54]]], ["Their study found RT-PCR to be more sensitive 58/64 (91%) to early disease than the CXR 44/64 (69%).", [["Their study", "TEST", 0, 11], ["RT-PCR", "TEST", 18, 24], ["early disease", "PROBLEM", 61, 74], ["the CXR", "TEST", 80, 87]]], ["Similarly, a recent study out of Italy retrospectively analyzed 240 RT-PCR positive cases to determine the most common lung alterations found using CXR with respect to time since symptom onset[21].", [["lung", "ANATOMY", 119, 123], ["lung alterations", "DISEASE", 119, 135], ["lung", "ORGAN", 119, 123], ["CXR", "PROTEIN", 148, 151], ["a recent study", "TEST", 11, 25], ["RT-PCR", "TEST", 68, 74], ["the most common lung alterations", "PROBLEM", 103, 135], ["CXR", "TEST", 148, 151], ["symptom onset", "PROBLEM", 179, 192], ["lung", "ANATOMY", 119, 123], ["alterations", "OBSERVATION", 124, 135]]], ["Abnormalities most frequently occurred bilaterally and peripherally, with reticular alteration being the most common finding in early phases of the disease.", [["reticular", "ANATOMY", 74, 83], ["Abnormalities", "PROBLEM", 0, 13], ["reticular alteration", "PROBLEM", 74, 94], ["the disease", "PROBLEM", 144, 155], ["bilaterally", "ANATOMY_MODIFIER", 39, 50], ["peripherally", "ANATOMY_MODIFIER", 55, 67], ["reticular", "OBSERVATION_MODIFIER", 74, 83], ["alteration", "OBSERVATION", 84, 94], ["most common", "OBSERVATION_MODIFIER", 105, 116], ["early phases", "OBSERVATION_MODIFIER", 128, 140], ["disease", "OBSERVATION", 148, 155]]], ["GGO became predominant in later phases and consolidation, while occurring less frequently, also increased with time.", [["GGO", "DISEASE", 0, 3], ["GGO", "PROBLEM", 0, 3], ["consolidation", "PROBLEM", 43, 56], ["predominant", "OBSERVATION_MODIFIER", 11, 22], ["later phases", "OBSERVATION_MODIFIER", 26, 38], ["consolidation", "OBSERVATION", 43, 56], ["less", "OBSERVATION_MODIFIER", 74, 78], ["increased", "OBSERVATION_MODIFIER", 96, 105]]], ["CXR showed abnormalities in 75% of the RT-PCR confirmed cases.", [["CXR", "PROTEIN", 0, 3], ["CXR", "TEST", 0, 3], ["abnormalities", "PROBLEM", 11, 24], ["the RT", "TEST", 35, 41], ["PCR", "TEST", 42, 45], ["abnormalities", "OBSERVATION", 11, 24], ["RT", "ANATOMY", 39, 41]]], ["Therefore, while it has not generally been recommended due to low sensitivity, these observations confirm recent suggestions that CXR should be considered as a feasible imaging technique in diagnosing COVID pneumonia.", [["pneumonia", "DISEASE", 207, 216], ["low sensitivity", "PROBLEM", 62, 77], ["CXR", "TEST", 130, 133], ["a feasible imaging technique", "TEST", 158, 186], ["pneumonia", "PROBLEM", 207, 216], ["pneumonia", "OBSERVATION", 207, 216]]], ["Figure 1 depicts original CXR in laboratory positive cases of COVID-19 from our institution.CT highlights ::: REVIEW OF IMAGING LITERATURECT has been widely used to evaluate lung pathology associated with COVID-19.", [["lung", "ANATOMY", 174, 178], ["COVID-19", "CHEMICAL", 205, 213], ["lung", "ORGAN", 174, 178], ["CXR", "DNA", 26, 29], ["original CXR", "TEST", 17, 29], ["COVID", "TEST", 62, 67], ["CT", "TEST", 92, 94], ["IMAGING LITERATURECT", "TEST", 120, 140], ["lung pathology", "PROBLEM", 174, 188], ["COVID", "TEST", 205, 210], ["lung", "ANATOMY", 174, 178], ["pathology", "OBSERVATION", 179, 188]]], ["During the time period reviewed, the larger series studies in which CT was performed reveal a range of pulmonary findings.", [["pulmonary", "ANATOMY", 103, 112], ["pulmonary", "ORGAN", 103, 112], ["the larger series studies", "TEST", 33, 58], ["CT", "TEST", 68, 70], ["pulmonary", "ANATOMY", 103, 112]]], ["Han et al[22] in a study of 108 COVID-19 patients found 70 (65%) had infiltrates in two or more lobes with almost all the infiltrates (97%) peripherally located.", [["lobes", "ANATOMY", 96, 101], ["patients", "ORGANISM", 41, 49], ["lobes", "CANCER", 96, 101], ["patients", "SPECIES", 41, 49], ["a study", "TEST", 17, 24], ["COVID", "TEST", 32, 37], ["infiltrates in two or more lobes", "PROBLEM", 69, 101], ["the infiltrates", "PROBLEM", 118, 133], ["infiltrates", "OBSERVATION", 69, 80], ["lobes", "ANATOMY_MODIFIER", 96, 101], ["almost", "OBSERVATION_MODIFIER", 107, 113], ["all", "OBSERVATION_MODIFIER", 114, 117], ["infiltrates", "OBSERVATION", 122, 133]]], ["When only present in a single lobe, the right lower lobe was the most common in 30/38 (79%).", [["lobe", "ANATOMY", 30, 34], ["right lower lobe", "ANATOMY", 40, 56], ["lobe", "CANCER", 30, 34], ["lower lobe", "ORGAN", 46, 56], ["lobe", "ANATOMY_MODIFIER", 30, 34], ["right lower lobe", "ANATOMY", 40, 56]]], ["Overall, the findings commonly included patchy GGO (86%) and GGO with consolidation (41%), vascular thickening (80%), crazy paving (40%), air bronchograms (48%), and a halo sign (an area of GGO surrounded by consolidation, 64%).", [["vascular", "ANATOMY", 91, 99], ["GGO", "DISEASE", 47, 50], ["GGO", "DISEASE", 61, 64], ["air bronchograms", "DISEASE", 138, 154], ["GGO", "DISEASE", 190, 193], ["vascular", "MULTI-TISSUE_STRUCTURE", 91, 99], ["patchy GGO", "PROBLEM", 40, 50], ["GGO", "PROBLEM", 61, 64], ["consolidation", "PROBLEM", 70, 83], ["vascular thickening", "PROBLEM", 91, 110], ["crazy paving", "TEST", 118, 130], ["air bronchograms", "PROBLEM", 138, 154], ["a halo sign", "PROBLEM", 166, 177], ["GGO", "PROBLEM", 190, 193], ["consolidation", "PROBLEM", 208, 221], ["patchy", "OBSERVATION_MODIFIER", 40, 46], ["GGO", "OBSERVATION", 47, 50], ["GGO", "OBSERVATION", 61, 64], ["consolidation", "OBSERVATION", 70, 83], ["vascular", "ANATOMY", 91, 99], ["thickening", "OBSERVATION", 100, 110], ["air bronchograms", "OBSERVATION", 138, 154], ["halo sign", "OBSERVATION", 168, 177], ["area", "OBSERVATION_MODIFIER", 182, 186], ["GGO", "OBSERVATION", 190, 193], ["consolidation", "OBSERVATION", 208, 221]]], ["Lymph node enlargement, effusion and pleural thickening were absent.CT highlights ::: REVIEW OF IMAGING LITERATURELiu et al[23] in a study of 73 COVID-19 patients grouped laboratory positive patients by disease severity in order to assess for differences in CT appearance.", [["Lymph node", "ANATOMY", 0, 10], ["pleural", "ANATOMY", 37, 44], ["Lymph node enlargement", "DISEASE", 0, 22], ["effusion", "DISEASE", 24, 32], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 0, 10], ["pleural", "ORGAN", 37, 44], ["patients", "ORGANISM", 154, 162], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 154, 162], ["patients", "SPECIES", 191, 199], ["Lymph node enlargement", "PROBLEM", 0, 22], ["effusion", "PROBLEM", 24, 32], ["pleural thickening", "PROBLEM", 37, 55], ["CT", "TEST", 68, 70], ["IMAGING", "TEST", 96, 103], ["a study", "TEST", 131, 138], ["COVID", "TEST", 145, 150], ["disease severity", "PROBLEM", 203, 219], ["CT appearance", "TEST", 258, 271], ["node enlargement", "OBSERVATION", 6, 22], ["effusion", "OBSERVATION", 24, 32], ["pleural", "ANATOMY", 37, 44], ["thickening", "OBSERVATION", 45, 55]]], ["In mild illness (6 patients), 8% had bilateral infiltrates, 50% showed no lung changes, and 50% had an enlarged hilus and thickened lung texture.", [["lung", "ANATOMY", 74, 78], ["hilus", "ANATOMY", 112, 117], ["lung", "ANATOMY", 132, 136], ["illness", "DISEASE", 8, 15], ["patients", "ORGANISM", 19, 27], ["lung", "ORGAN", 74, 78], ["hilus", "MULTI-TISSUE_STRUCTURE", 112, 117], ["lung", "ORGAN", 132, 136], ["patients", "SPECIES", 19, 27], ["mild illness", "PROBLEM", 3, 15], ["bilateral infiltrates", "PROBLEM", 37, 58], ["lung changes", "PROBLEM", 74, 86], ["an enlarged hilus", "PROBLEM", 100, 117], ["thickened lung texture", "PROBLEM", 122, 144], ["mild", "OBSERVATION_MODIFIER", 3, 7], ["illness", "OBSERVATION", 8, 15], ["bilateral", "ANATOMY_MODIFIER", 37, 46], ["infiltrates", "OBSERVATION", 47, 58], ["no", "UNCERTAINTY", 71, 73], ["lung", "ANATOMY", 74, 78], ["changes", "OBSERVATION", 79, 86], ["enlarged", "OBSERVATION", 103, 111], ["hilus", "ANATOMY", 112, 117], ["thickened", "OBSERVATION", 122, 131], ["lung", "ANATOMY", 132, 136], ["texture", "OBSERVATION_MODIFIER", 137, 144]]], ["In moderate illness (43 patients), 100% of cases showed GGO bilaterally and peripherally with GGO as the single manifestation in the lungs in 12/43 (28%).", [["lungs", "ANATOMY", 133, 138], ["illness", "DISEASE", 12, 19], ["GGO", "DISEASE", 56, 59], ["GGO", "DISEASE", 94, 97], ["patients", "ORGANISM", 24, 32], ["lungs", "ORGAN", 133, 138], ["patients", "SPECIES", 24, 32], ["moderate illness", "PROBLEM", 3, 19], ["GGO bilaterally", "PROBLEM", 56, 71], ["peripherally with GGO", "PROBLEM", 76, 97], ["moderate", "OBSERVATION_MODIFIER", 3, 11], ["illness", "OBSERVATION", 12, 19], ["GGO", "OBSERVATION", 56, 59], ["bilaterally", "ANATOMY_MODIFIER", 60, 71], ["peripherally", "ANATOMY_MODIFIER", 76, 88], ["GGO", "OBSERVATION", 94, 97], ["lungs", "ANATOMY", 133, 138]]], ["Other common findings in this group were paving stone sign (35%), inter and intralobular septal thickening (27%) and air bronchogram (7%).", [["stone", "ANATOMY", 48, 53], ["intralobular septal", "ANATOMY", 76, 95], ["air bronchogram", "ANATOMY", 117, 132], ["intralobular septal", "TISSUE", 76, 95], ["stone sign", "TEST", 48, 58], ["inter and intralobular septal thickening", "PROBLEM", 66, 106], ["air bronchogram", "TEST", 117, 132], ["stone", "OBSERVATION", 48, 53], ["intralobular", "ANATOMY_MODIFIER", 76, 88], ["septal", "ANATOMY_MODIFIER", 89, 95], ["thickening", "OBSERVATION", 96, 106], ["air bronchogram", "OBSERVATION", 117, 132]]], ["In severe disease (21 patients), 76% had bilateral, extensive GGO, 24% had consolidation and 67% had peribronchial thickening.", [["peribronchial", "ANATOMY", 101, 114], ["GGO", "DISEASE", 62, 65], ["patients", "ORGANISM", 22, 30], ["peribronchial", "TISSUE", 101, 114], ["patients", "SPECIES", 22, 30], ["severe disease", "PROBLEM", 3, 17], ["bilateral, extensive GGO", "PROBLEM", 41, 65], ["consolidation", "PROBLEM", 75, 88], ["peribronchial thickening", "PROBLEM", 101, 125], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["disease", "OBSERVATION", 10, 17], ["bilateral", "ANATOMY_MODIFIER", 41, 50], ["extensive", "OBSERVATION_MODIFIER", 52, 61], ["GGO", "OBSERVATION", 62, 65], ["consolidation", "OBSERVATION", 75, 88], ["peribronchial", "ANATOMY", 101, 114], ["thickening", "OBSERVATION", 115, 125]]], ["Critical disease (3 patients) showed confluent lesions, multi-lobe involvement, pulmonary fibrosis and white lung.", [["lesions", "ANATOMY", 47, 54], ["multi-lobe", "ANATOMY", 56, 66], ["pulmonary", "ANATOMY", 80, 89], ["white lung", "ANATOMY", 103, 113], ["pulmonary fibrosis", "DISEASE", 80, 98], ["patients", "ORGANISM", 20, 28], ["lesions", "PATHOLOGICAL_FORMATION", 47, 54], ["lobe", "MULTI-TISSUE_STRUCTURE", 62, 66], ["pulmonary", "ORGAN", 80, 89], ["lung", "ORGAN", 109, 113], ["patients", "SPECIES", 20, 28], ["Critical disease", "PROBLEM", 0, 16], ["confluent lesions", "PROBLEM", 37, 54], ["multi-lobe involvement", "PROBLEM", 56, 78], ["pulmonary fibrosis", "PROBLEM", 80, 98], ["white lung", "PROBLEM", 103, 113], ["disease", "OBSERVATION", 9, 16], ["confluent", "OBSERVATION_MODIFIER", 37, 46], ["lesions", "OBSERVATION", 47, 54], ["multi", "OBSERVATION_MODIFIER", 56, 61], ["lobe", "ANATOMY_MODIFIER", 62, 66], ["pulmonary", "ANATOMY", 80, 89], ["fibrosis", "OBSERVATION", 90, 98], ["white", "OBSERVATION_MODIFIER", 103, 108], ["lung", "ANATOMY", 109, 113]]], ["Short term follow-up CT scans show dramatic improvement in 12 cases with only four patients having residual linear densities.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["Short term follow-up CT scans", "TEST", 0, 29], ["residual linear densities", "PROBLEM", 99, 124], ["dramatic", "OBSERVATION_MODIFIER", 35, 43], ["improvement", "OBSERVATION_MODIFIER", 44, 55], ["residual", "OBSERVATION_MODIFIER", 99, 107], ["linear", "OBSERVATION_MODIFIER", 108, 114], ["densities", "OBSERVATION", 115, 124]]], ["Overall these larger studies highlight the prevalence of GGO in the lung periphery often bilaterally, that with severe disease tend to coalesce into more dense consolidation.CT highlights ::: REVIEW OF IMAGING LITERATUREWhile the majority of the articles we reviewed were imaged in Asia, recent studies also suggest similar radiographic findings in other areas of the world.", [["lung periphery", "ANATOMY", 68, 82], ["GGO", "DISEASE", 57, 60], ["GGO", "CANCER", 57, 60], ["lung periphery", "MULTI-TISSUE_STRUCTURE", 68, 82], ["these larger studies", "TEST", 8, 28], ["GGO in the lung periphery", "PROBLEM", 57, 82], ["severe disease", "PROBLEM", 112, 126], ["more dense consolidation", "PROBLEM", 149, 173], ["CT", "TEST", 174, 176], ["IMAGING", "TEST", 202, 209], ["recent studies", "TEST", 288, 302], ["similar radiographic findings", "PROBLEM", 316, 345], ["larger", "OBSERVATION_MODIFIER", 14, 20], ["GGO", "OBSERVATION", 57, 60], ["lung", "ANATOMY", 68, 72], ["periphery", "ANATOMY_MODIFIER", 73, 82], ["bilaterally", "ANATOMY_MODIFIER", 89, 100], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["disease", "OBSERVATION", 119, 126], ["more", "OBSERVATION_MODIFIER", 149, 153], ["dense", "OBSERVATION_MODIFIER", 154, 159], ["consolidation", "OBSERVATION", 160, 173]]], ["For example, in one study from Italy, GGO were the most prominent abnormality noted on CT in RT-PCR positive COVID-19 patients where they were present in 58/58 (100%) of cases[24].", [["GGO", "CANCER", 38, 41], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["one study", "TEST", 16, 25], ["GGO", "PROBLEM", 38, 41], ["the most prominent abnormality", "PROBLEM", 47, 77], ["CT", "TEST", 87, 89], ["GGO", "OBSERVATION", 38, 41], ["most prominent", "OBSERVATION_MODIFIER", 51, 65]]], ["Commonly noted findings in this study were: Multi-lobe involvement (93%), bilateral infiltrates (91%), consolidation (72%), crazy paving pattern (39%), rounded morphology (32%) and linear opacities (27%), while pleural effusion (3%) and cavitation (0%) were uncommonly seen.", [["pleural", "ANATOMY", 211, 218], ["opacities", "DISEASE", 188, 197], ["pleural effusion", "DISEASE", 211, 227], ["cavitation", "DISEASE", 237, 247], ["this study", "TEST", 27, 37], ["Multi-lobe involvement", "PROBLEM", 44, 66], ["bilateral infiltrates", "PROBLEM", 74, 95], ["consolidation", "PROBLEM", 103, 116], ["crazy paving pattern", "TEST", 124, 144], ["rounded morphology", "TEST", 152, 170], ["linear opacities", "PROBLEM", 181, 197], ["pleural effusion", "PROBLEM", 211, 227], ["cavitation", "PROBLEM", 237, 247], ["lobe", "ANATOMY_MODIFIER", 50, 54], ["bilateral", "ANATOMY_MODIFIER", 74, 83], ["infiltrates", "OBSERVATION", 84, 95], ["consolidation", "OBSERVATION", 103, 116], ["rounded", "OBSERVATION_MODIFIER", 152, 159], ["morphology", "OBSERVATION_MODIFIER", 160, 170], ["32%", "OBSERVATION_MODIFIER", 172, 175], ["linear", "OBSERVATION_MODIFIER", 181, 187], ["opacities", "OBSERVATION", 188, 197], ["pleural", "ANATOMY", 211, 218], ["effusion", "OBSERVATION", 219, 227], ["cavitation", "OBSERVATION_MODIFIER", 237, 247]]], ["Additional interesting findings from this Italian study include perilesional sub-segmental vessels enlargement (> 3 mm, mean of 3.9 mm \u00b1 0.6) in 89% of cases.", [["perilesional sub-segmental vessels", "ANATOMY", 64, 98], ["segmental vessels", "MULTI-TISSUE_STRUCTURE", 81, 98], ["this Italian study", "TEST", 37, 55], ["perilesional sub-segmental vessels enlargement", "PROBLEM", 64, 110], ["mean", "TEST", 120, 124], ["perilesional", "ANATOMY_MODIFIER", 64, 76], ["segmental", "ANATOMY_MODIFIER", 81, 90], ["vessels", "ANATOMY", 91, 98], ["enlargement", "OBSERVATION", 99, 110]]], ["In our review, vessel enlargement in COVID-19 was not often mentioned, but was described by Han et al[22] (80%), Bai et al[25] (59%), and Zhao et al[26] (71%).", [["vessel", "ANATOMY", 15, 21], ["vessel enlargement", "DISEASE", 15, 33], ["vessel", "MULTI-TISSUE_STRUCTURE", 15, 21], ["vessel enlargement", "PROBLEM", 15, 33], ["COVID", "TEST", 37, 42], ["Zhao et al", "TEST", 138, 148], ["vessel", "ANATOMY", 15, 21], ["enlargement", "OBSERVATION", 22, 33]]], ["The notable contrast in this Italian study was the presence of mediastinal lymphadenopathy that was noted in 58% of cases.CT highlights ::: REVIEW OF IMAGING LITERATUREDisease progression through CT imaging is documented by Shi et al[27] in a case study followed over three weeks with four CT scans[27].", [["mediastinal lymphadenopathy", "ANATOMY", 63, 90], ["mediastinal lymphadenopathy", "DISEASE", 63, 90], ["this Italian study", "TEST", 24, 42], ["mediastinal lymphadenopathy", "PROBLEM", 63, 90], ["CT", "TEST", 122, 124], ["IMAGING", "TEST", 150, 157], ["CT imaging", "TEST", 196, 206], ["a case study", "TEST", 241, 253], ["four CT scans", "TEST", 285, 298], ["notable", "OBSERVATION_MODIFIER", 4, 11], ["contrast", "OBSERVATION", 12, 20], ["mediastinal", "ANATOMY", 63, 74], ["lymphadenopathy", "OBSERVATION", 75, 90]]], ["This patient was SARS-CoV-2 positive and was treated with anti-viral and anti-inflammatory medications and supportive care.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["SARS-CoV", "TEST", 17, 25], ["anti-viral", "TREATMENT", 58, 68], ["anti-inflammatory medications", "TREATMENT", 73, 102], ["supportive care", "TREATMENT", 107, 122]]], ["On day eight from onset of symptoms, there are bilateral peripheral multifocal GGO.", [["GGO", "DISEASE", 79, 82], ["symptoms", "PROBLEM", 27, 35], ["bilateral peripheral multifocal GGO", "PROBLEM", 47, 82], ["bilateral", "ANATOMY_MODIFIER", 47, 56], ["peripheral", "ANATOMY_MODIFIER", 57, 67], ["multifocal", "OBSERVATION_MODIFIER", 68, 78], ["GGO", "OBSERVATION", 79, 82]]], ["A day 15 scan shows mixed GGO and consolidation.", [["GGO", "DISEASE", 26, 29], ["A day 15 scan", "TEST", 0, 13], ["mixed GGO", "PROBLEM", 20, 29], ["consolidation", "PROBLEM", 34, 47], ["mixed", "OBSERVATION_MODIFIER", 20, 25], ["GGO", "OBSERVATION", 26, 29], ["consolidation", "OBSERVATION", 34, 47]]], ["A day 19 scan shows similar yet resolving findings and is followed by a day 31 scan showing complete healing.", [["A day 19 scan", "TEST", 0, 13], ["a day 31 scan", "TEST", 70, 83], ["complete healing", "PROBLEM", 92, 108], ["resolving", "OBSERVATION_MODIFIER", 32, 41], ["complete", "OBSERVATION_MODIFIER", 92, 100], ["healing", "OBSERVATION", 101, 108]]], ["A larger series of moderately ill hospitalized patients demonstrated a peak in severity of CT findings approximately 10 d after symptom onset[8].", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["CT findings", "TEST", 91, 102], ["symptom onset", "PROBLEM", 128, 141], ["larger", "OBSERVATION_MODIFIER", 2, 8], ["moderately", "OBSERVATION_MODIFIER", 19, 29]]], ["Ling et al[28] described their experience with 295 RT-PCR positive COVID-19 cases.", [["RT-PCR", "TEST", 51, 57], ["COVID", "TEST", 67, 72]]], ["They found 49 cases had negative initial CT scans and 15/49 developed findings after 3-6 d, while 34/49 CT scans remained negative.", [["initial CT scans", "TEST", 33, 49], ["CT scans", "TEST", 104, 112], ["negative", "OBSERVATION", 122, 130]]], ["They suggest that since clinical symptoms and CT findings are not always present in COVID-19 careful screening and isolation practices are critical.CT highlights ::: REVIEW OF IMAGING LITERATUREBernheim et al[29] give another perspective on disease progression by looking at CT appearance relative to duration of symptoms in their review of 121 patients from China.", [["patients", "ORGANISM", 345, 353], ["patients", "SPECIES", 345, 353], ["clinical symptoms", "PROBLEM", 24, 41], ["CT findings", "TEST", 46, 57], ["COVID", "TEST", 84, 89], ["careful screening", "TEST", 93, 110], ["isolation practices", "TREATMENT", 115, 134], ["CT", "TEST", 148, 150], ["IMAGING", "TEST", 176, 183], ["disease progression", "PROBLEM", 241, 260], ["symptoms", "PROBLEM", 313, 321]]], ["Bilaterality increased in incidence when patients were scanned later relative to symptom onset: Early (0-2 d, 28%), intermediate (3-5 d, 76%) and late (6-12 d, 88%).", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["increased", "OBSERVATION_MODIFIER", 13, 22]]], ["Additionally, the group found the following increasing over time: GGO and consolidation both bilaterally and peripherally, total lung involvement, linear opacities, crazy paving pattern and reverse halo sign (central ground glass density with surrounding consolidation).", [["lung", "ANATOMY", 129, 133], ["opacities", "DISEASE", 154, 163], ["lung", "ORGAN", 129, 133], ["GGO", "PROBLEM", 66, 69], ["consolidation both bilaterally", "PROBLEM", 74, 104], ["total lung involvement", "PROBLEM", 123, 145], ["linear opacities", "PROBLEM", 147, 163], ["crazy paving pattern", "PROBLEM", 165, 185], ["reverse halo sign", "PROBLEM", 190, 207], ["central ground glass density", "PROBLEM", 209, 237], ["surrounding consolidation", "PROBLEM", 243, 268], ["GGO", "OBSERVATION", 66, 69], ["consolidation", "OBSERVATION", 74, 87], ["bilaterally", "ANATOMY_MODIFIER", 93, 104], ["peripherally", "ANATOMY_MODIFIER", 109, 121], ["total", "OBSERVATION_MODIFIER", 123, 128], ["lung", "ANATOMY", 129, 133], ["involvement", "OBSERVATION", 134, 145], ["linear", "OBSERVATION_MODIFIER", 147, 153], ["opacities", "OBSERVATION", 154, 163], ["crazy", "OBSERVATION_MODIFIER", 165, 170], ["reverse", "OBSERVATION_MODIFIER", 190, 197], ["halo", "OBSERVATION_MODIFIER", 198, 202], ["central", "OBSERVATION_MODIFIER", 209, 216], ["ground glass density", "OBSERVATION", 217, 237], ["surrounding", "OBSERVATION_MODIFIER", 243, 254], ["consolidation", "OBSERVATION", 255, 268]]], ["A rounded morphology of the infiltrates was seen in 54% of all the patients and was most prevalent in the intermediate group (67%).", [["infiltrates", "ANATOMY", 28, 39], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["the infiltrates", "PROBLEM", 24, 39], ["rounded", "OBSERVATION_MODIFIER", 2, 9], ["morphology", "OBSERVATION_MODIFIER", 10, 20], ["infiltrates", "OBSERVATION", 28, 39]]], ["Figure 2 depicts original chest CT images in laboratory positive cases of SARS-CoV-2 from our institution.CT highlights ::: REVIEW OF IMAGING LITERATURERegarding distribution of pulmonary findings in COVID-19, two studies showed a predominance of multilobar involvement.", [["pulmonary", "ANATOMY", 178, 187], ["multilobar", "ANATOMY", 247, 257], ["SARS", "DISEASE", 74, 78], ["pulmonary", "ORGAN", 178, 187], ["multilobar", "CANCER", 247, 257], ["SARS-CoV", "SPECIES", 74, 82], ["original chest CT images", "TEST", 17, 41], ["SARS", "TEST", 74, 78], ["CT", "TEST", 106, 108], ["IMAGING", "TEST", 134, 141], ["COVID", "TEST", 200, 205], ["two studies", "TEST", 210, 221], ["multilobar involvement", "PROBLEM", 247, 269], ["chest", "ANATOMY", 26, 31], ["pulmonary", "ANATOMY", 178, 187], ["predominance", "OBSERVATION_MODIFIER", 231, 243], ["multilobar involvement", "OBSERVATION", 247, 269]]], ["Five lobes were involved in 27% of 121 cases and 44.4% of 63 cases[29,30].", [["lobes", "ANATOMY", 5, 10], ["lobes", "CANCER", 5, 10], ["Five lobes", "TEST", 0, 10], ["cases", "TEST", 61, 66], ["lobes", "ANATOMY_MODIFIER", 5, 10]]], ["This is consistent with an imaging picture of viral pneumonia rather than bacterial lobar pneumonia.", [["lobar", "ANATOMY", 84, 89], ["pneumonia", "DISEASE", 52, 61], ["lobar pneumonia", "DISEASE", 84, 99], ["an imaging picture", "TEST", 24, 42], ["viral pneumonia", "PROBLEM", 46, 61], ["bacterial lobar pneumonia", "PROBLEM", 74, 99], ["consistent with", "UNCERTAINTY", 8, 23], ["viral", "OBSERVATION_MODIFIER", 46, 51], ["pneumonia", "OBSERVATION", 52, 61], ["bacterial", "OBSERVATION_MODIFIER", 74, 83], ["lobar", "OBSERVATION_MODIFIER", 84, 89], ["pneumonia", "OBSERVATION", 90, 99]]], ["Regarding central versus peripheral distribution of infiltrates, Bernheim\u2019s group found none of the 121 cases with a central peribronchovascular distribution[29].", [["peribronchovascular", "ANATOMY", 125, 144], ["infiltrates", "PROBLEM", 52, 63], ["Bernheim\u2019s group", "TEST", 65, 81], ["a central peribronchovascular distribution", "PROBLEM", 115, 157], ["central", "ANATOMY_MODIFIER", 10, 17], ["peripheral", "ANATOMY_MODIFIER", 25, 35], ["distribution", "OBSERVATION_MODIFIER", 36, 48], ["infiltrates", "OBSERVATION", 52, 63], ["central", "ANATOMY_MODIFIER", 117, 124], ["peribronchovascular", "ANATOMY_MODIFIER", 125, 144]]], ["Conversely, peripheral pathology was present in 52% of all cases, and became more prominent as a finding later in the disease course (64% in intermediate time-point scans, 72% in late scans).Specific populations ::: REVIEW OF IMAGING LITERATUREA few studies evaluated COVID-19 in a pediatric population.", [["COVID-19", "DNA", 268, 276], ["peripheral pathology", "TEST", 12, 32], ["scans", "TEST", 165, 170], ["late scans", "TEST", 179, 189], ["IMAGING LITERATUREA", "TEST", 226, 245], ["few studies", "TEST", 246, 257], ["COVID", "TEST", 268, 273], ["peripheral", "ANATOMY_MODIFIER", 12, 22], ["pathology", "OBSERVATION", 23, 32], ["more prominent", "OBSERVATION_MODIFIER", 77, 91]]], ["In a series of five confirmed positive cases of (age range of 10 mo \u2013 6 years), three pediatric patients had modest patchy GGO.", [["GGO", "DISEASE", 123, 126], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["modest patchy GGO", "PROBLEM", 109, 126], ["modest", "OBSERVATION_MODIFIER", 109, 115], ["patchy", "OBSERVATION_MODIFIER", 116, 122], ["GGO", "OBSERVATION", 123, 126]]], ["The other two cases showed normal findings on CT, and none of these patients had CXR[31].", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["CT", "TEST", 46, 48], ["CXR", "TEST", 81, 84], ["normal", "OBSERVATION", 27, 33]]], ["Another group that evaluated 4 pediatric cases found the CT scans to be nonspecific and mild[32].", [["the CT scans", "TEST", 53, 65], ["nonspecific", "OBSERVATION_MODIFIER", 72, 83], ["mild", "OBSERVATION_MODIFIER", 88, 92]]], ["These small samples suggest milder disease in a pediatric population.Specific populations ::: REVIEW OF IMAGING LITERATUREA more recent study includes radiographic findings from nine COVID-19 infected pediatric patients[33].", [["samples", "ANATOMY", 12, 19], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["These small samples", "TEST", 0, 19], ["milder disease", "PROBLEM", 28, 42], ["IMAGING LITERATUREA", "TEST", 104, 123], ["recent study", "TEST", 129, 141], ["radiographic findings", "TEST", 151, 172], ["small", "OBSERVATION_MODIFIER", 6, 11], ["milder", "OBSERVATION_MODIFIER", 28, 34], ["disease", "OBSERVATION", 35, 42]]], ["Compared to adults, these patients also presented with less severe symptoms.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["less severe symptoms", "PROBLEM", 55, 75], ["less", "OBSERVATION_MODIFIER", 55, 59], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["symptoms", "OBSERVATION", 67, 75]]], ["Ground glass opacities, patchy, high-density shadows, and parenchymal bands were the most common CT findings, however, some of these infected pediatric patients showed no abnormal CT features.Specific populations ::: REVIEW OF IMAGING LITERATUREA few investigations looked at COVID-19 in pregnancy.", [["parenchymal bands", "ANATOMY", 58, 75], ["parenchymal bands", "CANCER", 58, 75], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["Ground glass opacities", "PROBLEM", 0, 22], ["patchy, high-density shadows", "PROBLEM", 24, 52], ["parenchymal bands", "PROBLEM", 58, 75], ["abnormal CT features", "PROBLEM", 171, 191], ["IMAGING LITERATUREA", "TEST", 227, 246], ["few investigations", "TEST", 247, 265], ["COVID", "TEST", 276, 281], ["glass opacities", "OBSERVATION", 7, 22], ["patchy", "OBSERVATION_MODIFIER", 24, 30], ["high", "OBSERVATION_MODIFIER", 32, 36], ["-density", "OBSERVATION_MODIFIER", 36, 44], ["shadows", "OBSERVATION_MODIFIER", 45, 52], ["parenchymal", "ANATOMY_MODIFIER", 58, 69], ["bands", "OBSERVATION", 70, 75], ["most common", "OBSERVATION_MODIFIER", 85, 96], ["infected", "OBSERVATION", 133, 141], ["no", "UNCERTAINTY", 168, 170], ["abnormal", "OBSERVATION_MODIFIER", 171, 179]]], ["One study followed 15 confirmed COVID-19 positive pregnant women ranging from gestational week 12-38[34].", [["women", "ORGANISM", 59, 64], ["women", "SPECIES", 59, 64], ["One study", "TEST", 0, 9], ["COVID", "TEST", 32, 37]]], ["CT findings were reported to be similar to non-pregnant patients with GGO early in the time course, and further consolidation and crazy paving pattern with progression.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["CT findings", "TEST", 0, 11], ["GGO", "PROBLEM", 70, 73], ["further consolidation", "PROBLEM", 104, 125], ["crazy paving pattern", "PROBLEM", 130, 150], ["GGO", "OBSERVATION", 70, 73], ["consolidation", "OBSERVATION", 112, 125], ["crazy", "OBSERVATION_MODIFIER", 130, 135], ["progression", "OBSERVATION_MODIFIER", 156, 167]]], ["Delivery itself did not exacerbate the pneumonia in 10 cesarean sections and one vaginal delivery.", [["sections", "ANATOMY", 64, 72], ["vaginal", "ANATOMY", 81, 88], ["pneumonia", "DISEASE", 39, 48], ["vaginal", "ORGANISM_SUBDIVISION", 81, 88], ["Delivery", "TREATMENT", 0, 8], ["the pneumonia", "PROBLEM", 35, 48], ["10 cesarean sections", "TREATMENT", 52, 72], ["one vaginal delivery", "TREATMENT", 77, 97], ["pneumonia", "OBSERVATION", 39, 48]]], ["Additionally, this group found no infections in the neonates (n = 11).", [["infections", "DISEASE", 34, 44], ["infections in the neonates", "PROBLEM", 34, 60], ["no", "UNCERTAINTY", 31, 33], ["infections", "OBSERVATION", 34, 44]]], ["Another study of COVID-19 positive patients (41 pregnant; 14 non-pregnant) examined pulmonary findings on CT and showed that consolidation was statistically more common in pregnant patients than non-pregnant patients, and conversely, GGO with reticulation was significantly less common in pregnant patients than non-pregnant patients[23].", [["pulmonary", "ANATOMY", 84, 93], ["GGO", "DISEASE", 234, 237], ["COVID-19", "CELL", 17, 25], ["patients", "ORGANISM", 35, 43], ["pulmonary", "ORGAN", 84, 93], ["patients", "ORGANISM", 181, 189], ["patients", "ORGANISM", 208, 216], ["patients", "ORGANISM", 298, 306], ["patients", "ORGANISM", 325, 333], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 181, 189], ["patients", "SPECIES", 208, 216], ["patients", "SPECIES", 298, 306], ["patients", "SPECIES", 325, 333], ["Another study", "TEST", 0, 13], ["COVID", "TEST", 17, 22], ["pulmonary findings", "TEST", 84, 102], ["CT", "TEST", 106, 108], ["consolidation", "PROBLEM", 125, 138], ["GGO", "PROBLEM", 234, 237], ["reticulation", "PROBLEM", 243, 255], ["pulmonary", "ANATOMY", 84, 93], ["consolidation", "OBSERVATION", 125, 138]]], ["These differences may relate to the physiological and anatomic changes of pregnancy.Other modalities highlights ::: REVIEW OF IMAGING LITERATUREAlthough CT and CXR predominate the imaging landscape in COVID-19, there are a few studies of other modalities.", [["CXR", "PROTEIN", 160, 163], ["the physiological and anatomic changes of pregnancy", "PROBLEM", 32, 83], ["IMAGING LITERATUREAlthough", "TEST", 126, 152], ["CT", "TEST", 153, 155], ["CXR", "TEST", 160, 163], ["the imaging landscape", "TEST", 176, 197], ["COVID", "TEST", 201, 206], ["may relate to", "UNCERTAINTY", 18, 31]]], ["Qin et al[35] studied 4 presumptively positive cases of COVID-19 that underwent 18F-FDG PET/CT.", [["18F-FDG", "CHEMICAL", 80, 87], ["18F-FDG", "SIMPLE_CHEMICAL", 80, 87], ["COVID", "TEST", 56, 61], ["18F", "TEST", 80, 83], ["FDG PET/CT", "TEST", 84, 94]]], ["According to the group, the nuclear scans were performed before the infectivity of the virus was apparent and this was the first PET study on presumptive positive patients in Wuhan, China.", [["nuclear", "ANATOMY", 28, 35], ["nuclear", "CELLULAR_COMPONENT", 28, 35], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["the nuclear scans", "TEST", 24, 41], ["the infectivity of the virus", "PROBLEM", 64, 92], ["the first PET study", "TEST", 119, 138]]], ["They found uptake in ground glass and/or consolidated opacities peripherally located in more than two lobes of the lung.", [["opacities", "ANATOMY", 54, 63], ["lobes", "ANATOMY", 102, 107], ["lung", "ANATOMY", 115, 119], ["opacities", "DISEASE", 54, 63], ["lobes", "ORGAN", 102, 107], ["lung", "ORGAN", 115, 119], ["uptake in ground glass", "PROBLEM", 11, 33], ["consolidated opacities", "PROBLEM", 41, 63], ["uptake", "OBSERVATION_MODIFIER", 11, 17], ["ground glass", "OBSERVATION", 21, 33], ["consolidated", "OBSERVATION_MODIFIER", 41, 53], ["opacities", "OBSERVATION", 54, 63], ["peripherally", "OBSERVATION_MODIFIER", 64, 76], ["two lobes", "ANATOMY_MODIFIER", 98, 107], ["lung", "ANATOMY", 115, 119]]], ["Of note, they found no disseminated lesions suggesting tropism of the disease for the lungs.", [["lesions", "ANATOMY", 36, 43], ["lungs", "ANATOMY", 86, 91], ["lesions", "PATHOLOGICAL_FORMATION", 36, 43], ["lungs", "ORGAN", 86, 91], ["disseminated lesions", "PROBLEM", 23, 43], ["the disease for the lungs", "PROBLEM", 66, 91], ["no", "UNCERTAINTY", 20, 22], ["disseminated", "OBSERVATION_MODIFIER", 23, 35], ["lesions", "OBSERVATION", 36, 43], ["tropism", "OBSERVATION", 55, 62], ["disease", "OBSERVATION", 70, 77], ["lungs", "ANATOMY", 86, 91]]], ["Also, in three of four cases, they found 18F-FDG uptake in nearby (hilar, mediastinal and subclavian) non-enlarged lymph nodes suggesting lymphadenitis.", [["hilar", "ANATOMY", 67, 72], ["mediastinal", "ANATOMY", 74, 85], ["subclavian", "ANATOMY", 90, 100], ["lymph nodes", "ANATOMY", 115, 126], ["lymphadenitis", "DISEASE", 138, 151], ["18F-FDG", "CHEMICAL", 41, 48], ["18F-FDG", "SIMPLE_CHEMICAL", 41, 48], ["hilar", "MULTI-TISSUE_STRUCTURE", 67, 72], ["subclavian", "MULTI-TISSUE_STRUCTURE", 90, 100], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 115, 126], ["18F-FDG uptake in nearby (hilar, mediastinal and subclavian) non-enlarged lymph nodes", "PROBLEM", 41, 126], ["lymphadenitis", "PROBLEM", 138, 151], ["FDG uptake", "OBSERVATION", 45, 55], ["nearby", "OBSERVATION_MODIFIER", 59, 65], ["hilar", "ANATOMY", 67, 72], ["mediastinal", "ANATOMY", 74, 85], ["subclavian", "ANATOMY", 90, 100], ["non-enlarged", "OBSERVATION_MODIFIER", 102, 114], ["lymph nodes", "OBSERVATION", 115, 126], ["suggesting", "UNCERTAINTY", 127, 137], ["lymphadenitis", "OBSERVATION", 138, 151]]], ["There was also a single case report in the literature of 18F-FDG PET/CT imaging in a COVID-19 confirmed positive case that shows avid uptake of the tracer in areas of consolidation bilaterally and uptake in hilar and mediastinal lymph nodes as well[36].", [["hilar", "ANATOMY", 207, 212], ["mediastinal lymph nodes", "ANATOMY", 217, 240], ["18F-FDG", "CHEMICAL", 57, 64], ["18F-FDG", "SIMPLE_CHEMICAL", 57, 64], ["hilar", "MULTI-TISSUE_STRUCTURE", 207, 212], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 229, 240], ["FDG PET", "TEST", 61, 68], ["CT imaging", "TEST", 69, 79], ["a COVID", "TEST", 83, 90], ["avid uptake of the tracer", "PROBLEM", 129, 154], ["consolidation bilaterally", "PROBLEM", 167, 192], ["uptake in hilar and mediastinal lymph nodes", "PROBLEM", 197, 240], ["avid uptake", "OBSERVATION", 129, 140], ["tracer", "OBSERVATION_MODIFIER", 148, 154], ["areas", "OBSERVATION_MODIFIER", 158, 163], ["consolidation", "OBSERVATION", 167, 180], ["bilaterally", "ANATOMY_MODIFIER", 181, 192], ["uptake", "OBSERVATION_MODIFIER", 197, 203], ["hilar", "ANATOMY", 207, 212], ["mediastinal", "ANATOMY", 217, 228], ["lymph nodes", "OBSERVATION", 229, 240]]], ["The risk to perform nuclear scans in COVID-19 patients is noted, as the high infectivity of the virus and the extended length of time the patient stays in the radiology suite for PET imaging is much lengthier than most other tests[37].Other modalities highlights ::: REVIEW OF IMAGING LITERATUREThere is a published case report and a 20 case series report describing the use of sonography in COVID-19, in a point-of-care setting[38,39].", [["nuclear", "ANATOMY", 20, 27], ["nuclear", "CELLULAR_COMPONENT", 20, 27], ["patients", "ORGANISM", 46, 54], ["patient", "ORGANISM", 138, 145], ["patients", "SPECIES", 46, 54], ["patient", "SPECIES", 138, 145], ["nuclear scans", "TEST", 20, 33], ["COVID", "TEST", 37, 42], ["the high infectivity of the virus", "PROBLEM", 68, 101], ["PET imaging", "TEST", 179, 190], ["sonography", "TEST", 378, 388], ["COVID", "TEST", 392, 397]]], ["The lung sonograms were performed using a portable device at the bedside and in both studies demonstrated evidence of irregular pleural lines, sub-pleural consolidation, areas of white thick lungs and thick irregular vertical artifacts suggesting interstitial-alveolar damage.", [["lung", "ANATOMY", 4, 8], ["pleural lines", "ANATOMY", 128, 141], ["pleural", "ANATOMY", 147, 154], ["lungs", "ANATOMY", 191, 196], ["interstitial", "ANATOMY", 247, 259], ["alveolar", "ANATOMY", 260, 268], ["interstitial-alveolar damage", "DISEASE", 247, 275], ["lung", "ORGAN", 4, 8], ["pleural lines", "CELL", 128, 141], ["pleural", "MULTI-TISSUE_STRUCTURE", 147, 154], ["lungs", "ORGAN", 191, 196], ["alveolar", "TISSUE", 260, 268], ["The lung sonograms", "TEST", 0, 18], ["a portable device", "TEST", 40, 57], ["both studies", "TEST", 80, 92], ["irregular pleural lines", "PROBLEM", 118, 141], ["sub-pleural consolidation", "PROBLEM", 143, 168], ["white thick lungs", "PROBLEM", 179, 196], ["thick irregular vertical artifacts", "PROBLEM", 201, 235], ["interstitial-alveolar damage", "PROBLEM", 247, 275], ["lung", "ANATOMY", 4, 8], ["evidence of", "UNCERTAINTY", 106, 117], ["irregular", "OBSERVATION_MODIFIER", 118, 127], ["pleural", "ANATOMY", 128, 135], ["lines", "OBSERVATION", 136, 141], ["sub", "OBSERVATION_MODIFIER", 143, 146], ["pleural", "ANATOMY", 147, 154], ["consolidation", "OBSERVATION", 155, 168], ["areas", "OBSERVATION_MODIFIER", 170, 175], ["white", "OBSERVATION_MODIFIER", 179, 184], ["thick", "OBSERVATION_MODIFIER", 185, 190], ["lungs", "ANATOMY", 191, 196], ["thick", "OBSERVATION_MODIFIER", 201, 206], ["irregular", "OBSERVATION_MODIFIER", 207, 216], ["vertical artifacts", "OBSERVATION", 217, 235], ["suggesting", "UNCERTAINTY", 236, 246], ["interstitial", "ANATOMY_MODIFIER", 247, 259], ["alveolar damage", "OBSERVATION", 260, 275]]], ["The authors highlight the advantage of reducing infectious exposure to other patients and healthcare workers by performing the study at the bedside.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["the study", "TEST", 123, 132]]], ["In addition, they believe it to be easily repeatable and widely available particularly in a low resource setting.Other modalities highlights ::: REVIEW OF IMAGING LITERATUREA more recently published paper by Soldati et al[40] is a proposed guide to standardize the performance of lung ultrasound exams in patients with COVID-19.", [["lung", "ANATOMY", 280, 284], ["lung", "ORGAN", 280, 284], ["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 305, 313], ["IMAGING LITERATUREA", "TEST", 155, 174], ["lung ultrasound exams", "TEST", 280, 301], ["COVID", "TEST", 319, 324], ["lung", "ANATOMY", 280, 284]]], ["The group presents an important point that because sonography is more portable and available in a wider range of settings throughout the world, as compared to other imaging modalities, it is more accessible to low and middle income countries and will, thus, improve the disparity often present in trials with imaging endpoints.", [["sonography", "TEST", 51, 61], ["other imaging modalities", "TEST", 159, 183], ["imaging endpoints", "TEST", 309, 326]]], ["Regarding specificity of lung ultrasound, a separate study showed that in the not-very-early stages of COVID-19, lung ultrasound can provide relative disease specificity when bilateral and patchy artifactual findings and signs of multifocal white lung are present[41].", [["lung", "ANATOMY", 25, 29], ["lung", "ANATOMY", 113, 117], ["lung", "ANATOMY", 247, 251], ["lung", "ORGAN", 25, 29], ["lung", "ORGAN", 113, 117], ["lung", "ORGAN", 247, 251], ["lung ultrasound", "TEST", 25, 40], ["a separate study", "TEST", 42, 58], ["COVID", "TEST", 103, 108], ["lung ultrasound", "TEST", 113, 128], ["relative disease specificity", "PROBLEM", 141, 169], ["bilateral and patchy artifactual findings", "PROBLEM", 175, 216], ["multifocal white lung", "PROBLEM", 230, 251], ["lung", "ANATOMY", 25, 29], ["lung", "ANATOMY", 113, 117], ["bilateral", "ANATOMY_MODIFIER", 175, 184], ["patchy", "OBSERVATION_MODIFIER", 189, 195], ["artifactual", "OBSERVATION", 196, 207], ["multifocal", "OBSERVATION_MODIFIER", 230, 240], ["white", "OBSERVATION_MODIFIER", 241, 246], ["lung", "ANATOMY", 247, 251]]], ["In addition, there is a more recently published study of lung ultrasound (LUS) in a pediatric population with confirmed COVID-19[42].", [["lung", "ANATOMY", 57, 61], ["lung", "ORGAN", 57, 61], ["lung ultrasound", "TEST", 57, 72], ["COVID", "TEST", 120, 125], ["lung", "ANATOMY", 57, 61]]], ["This was an observational study of 10 consecutive symptomatic pediatric patients admitted to two tertiary medical centers in Rome.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["an observational study", "TEST", 9, 31]]], ["In these cases, LUS was performed using the Soldati et al[40] acquisition protocol referenced above.", [["LUS", "TEST", 16, 19], ["the Soldati et al[40] acquisition protocol", "TREATMENT", 40, 82]]], ["A LUS was performed via a portable device at the bedside while awaiting RT-PCR results.", [["A LUS", "TEST", 0, 5], ["a portable device", "TEST", 24, 41], ["RT-PCR", "TEST", 72, 78]]], ["Abnormal LUS findings were noted in every case.", [["LUS", "MULTI-TISSUE_STRUCTURE", 9, 12], ["Abnormal LUS findings", "PROBLEM", 0, 21]]], ["Vertical artifacts (70%) and pleural irregularities (60%) were the most common abnormalities detected.", [["pleural", "ANATOMY", 29, 36], ["pleural irregularities", "DISEASE", 29, 51], ["pleural", "ORGAN", 29, 36], ["Vertical artifacts", "PROBLEM", 0, 18], ["pleural irregularities", "PROBLEM", 29, 51], ["the most common abnormalities", "PROBLEM", 63, 92], ["artifacts", "OBSERVATION", 9, 18], ["pleural", "ANATOMY", 29, 36], ["irregularities", "OBSERVATION", 37, 51], ["most common", "OBSERVATION_MODIFIER", 67, 78], ["abnormalities", "OBSERVATION", 79, 92]]], ["Pleural effusions were notably absent in all 10 patients.", [["Pleural effusions", "ANATOMY", 0, 17], ["Pleural effusions", "DISEASE", 0, 17], ["Pleural effusions", "CANCER", 0, 17], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["Pleural effusions", "PROBLEM", 0, 17], ["effusions", "OBSERVATION", 8, 17]]], ["The group argues LUS has a distinct advantage in following COVID-19 in children because it does not use ionizing radiation.Other modalities highlights ::: REVIEW OF IMAGING LITERATUREA panel of international experts in sonography reviewed its use in COVID-19 and cover a multitude of important topics[43].", [["LUS", "MULTI-TISSUE_STRUCTURE", 17, 20], ["children", "ORGANISM", 71, 79], ["children", "SPECIES", 71, 79], ["ionizing radiation", "TREATMENT", 104, 122], ["IMAGING LITERATUREA panel", "TEST", 165, 190], ["sonography", "TEST", 219, 229], ["distinct", "OBSERVATION_MODIFIER", 27, 35], ["advantage", "OBSERVATION_MODIFIER", 36, 45]]], ["They discuss the need to establish appropriate use of sonography by thoroughly evaluating both the sensitivity of the technique in varying degrees of COVID-19 lung involvement and the positive and negative predictive values under varied conditions.", [["lung", "ANATOMY", 159, 163], ["lung", "ORGAN", 159, 163], ["sonography", "TEST", 54, 64], ["the technique", "TEST", 114, 127], ["COVID", "TEST", 150, 155], ["lung", "ANATOMY", 159, 163]]], ["The group highlights the potential benefits of sonography to evaluate for the following: Progression of pulmonary involvement, post-procedure changes, presence of pneumothorax, ventricular function, fluid status and presence and drainage of pleural effusions.", [["pulmonary", "ANATOMY", 104, 113], ["ventricular", "ANATOMY", 177, 188], ["fluid", "ANATOMY", 199, 204], ["pleural effusions", "ANATOMY", 241, 258], ["pneumothorax", "DISEASE", 163, 175], ["pleural effusions", "DISEASE", 241, 258], ["pulmonary", "ORGAN", 104, 113], ["ventricular", "MULTI-TISSUE_STRUCTURE", 177, 188], ["pleural effusions", "PATHOLOGICAL_FORMATION", 241, 258], ["sonography", "TEST", 47, 57], ["pulmonary involvement", "PROBLEM", 104, 125], ["post-procedure changes", "TREATMENT", 127, 149], ["pneumothorax", "PROBLEM", 163, 175], ["ventricular function", "TEST", 177, 197], ["fluid status", "PROBLEM", 199, 211], ["drainage", "TREATMENT", 229, 237], ["pleural effusions", "PROBLEM", 241, 258], ["pulmonary", "ANATOMY", 104, 113], ["involvement", "OBSERVATION", 114, 125], ["pneumothorax", "OBSERVATION", 163, 175], ["ventricular", "ANATOMY", 177, 188], ["fluid status", "OBSERVATION", 199, 211], ["drainage", "OBSERVATION_MODIFIER", 229, 237], ["pleural", "ANATOMY", 241, 248], ["effusions", "OBSERVATION", 249, 258]]], ["The challenges of using sonography are described and include prolonged exposure to the operator, the need for scanner boards and transducers that can be disinfected thoroughly and the corollary of the need for scanner covers that protect the machine itself without overheating it.Other modalities highlights ::: REVIEW OF IMAGING LITERATUREThere is a report of MR being used to evaluate a single SARS-CoV-2 patient showing mild pulmonary symptoms but with a severe progressive encephalopathy[44].", [["pulmonary", "ANATOMY", 428, 437], ["pulmonary symptoms", "DISEASE", 428, 446], ["encephalopathy", "DISEASE", 477, 491], ["patient", "ORGANISM", 407, 414], ["pulmonary", "ORGAN", 428, 437], ["MR", "PROTEIN", 361, 363], ["patient", "SPECIES", 407, 414], ["sonography", "TEST", 24, 34], ["scanner boards", "TREATMENT", 110, 124], ["transducers", "TREATMENT", 129, 140], ["scanner covers", "TREATMENT", 210, 224], ["MR", "TEST", 361, 363], ["a single SARS-CoV", "TEST", 387, 404], ["mild pulmonary symptoms", "PROBLEM", 423, 446], ["a severe progressive encephalopathy", "PROBLEM", 456, 491], ["mild", "OBSERVATION_MODIFIER", 423, 427], ["pulmonary", "ANATOMY", 428, 437], ["symptoms", "OBSERVATION", 438, 446], ["severe", "OBSERVATION_MODIFIER", 458, 464], ["progressive", "OBSERVATION_MODIFIER", 465, 476], ["encephalopathy", "OBSERVATION", 477, 491]]], ["A gadolinium enhanced MR scan of the brain was performed but revealed no pathology.", [["brain", "ANATOMY", 37, 42], ["gadolinium", "CHEMICAL", 2, 12], ["gadolinium", "CHEMICAL", 2, 12], ["brain", "ORGAN", 37, 42], ["MR", "PROTEIN", 22, 24], ["A gadolinium enhanced MR scan of the brain", "TEST", 0, 42], ["pathology", "PROBLEM", 73, 82], ["brain", "ANATOMY", 37, 42], ["no", "UNCERTAINTY", 70, 72], ["pathology", "OBSERVATION", 73, 82]]], ["A more recent case report compares lung findings in a chest CT to those found in a cardiac MR performed two days later to rule out myocarditis[45].", [["lung", "ANATOMY", 35, 39], ["chest", "ANATOMY", 54, 59], ["cardiac", "ANATOMY", 83, 90], ["myocarditis", "DISEASE", 131, 142], ["lung", "ORGAN", 35, 39], ["MR", "PROTEIN", 91, 93], ["a chest CT", "TEST", 52, 62], ["a cardiac MR", "TEST", 81, 93], ["myocarditis", "PROBLEM", 131, 142], ["lung", "ANATOMY", 35, 39], ["chest", "ANATOMY", 54, 59], ["cardiac", "ANATOMY", 83, 90], ["myocarditis", "OBSERVATION", 131, 142]]], ["The black-blood single shot fast spin echo sequence showed pulmonary infiltrates and consolidation closely matching those in the CT.Other modalities highlights ::: REVIEW OF IMAGING LITERATUREAs emphasized by the overwhelming dominance of pulmonary symptoms and the PET/CT finding of tropism for the lungs, it is not surprising that there is little written regarding radiographic findings in other organs systems.", [["blood", "ANATOMY", 10, 15], ["pulmonary", "ANATOMY", 59, 68], ["pulmonary", "ANATOMY", 239, 248], ["lungs", "ANATOMY", 300, 305], ["organs", "ANATOMY", 398, 404], ["pulmonary symptoms", "DISEASE", 239, 257], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 59, 80], ["pulmonary", "ORGAN", 239, 248], ["lungs", "ORGAN", 300, 305], ["organs", "ORGAN", 398, 404], ["The black-blood single shot fast spin echo sequence", "TEST", 0, 51], ["pulmonary infiltrates", "PROBLEM", 59, 80], ["consolidation", "PROBLEM", 85, 98], ["the CT", "TEST", 125, 131], ["IMAGING LITERATUREAs", "TEST", 174, 194], ["pulmonary symptoms", "PROBLEM", 239, 257], ["the PET/CT", "TEST", 262, 272], ["radiographic findings in other organs systems", "PROBLEM", 367, 412], ["pulmonary", "ANATOMY", 59, 68], ["infiltrates", "OBSERVATION", 69, 80], ["consolidation", "OBSERVATION", 85, 98], ["pulmonary", "ANATOMY", 239, 248], ["lungs", "ANATOMY", 300, 305]]], ["The literature review revealed cardiac injury, defined by elevation in serum cardiac biomarkers, is common among patients hospitalized with COVID-19.", [["cardiac", "ANATOMY", 31, 38], ["serum cardiac", "ANATOMY", 71, 84], ["cardiac injury", "DISEASE", 31, 45], ["COVID-19", "CHEMICAL", 140, 148], ["cardiac", "ORGAN", 31, 38], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["cardiac", "ORGAN", 77, 84], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["The literature review", "TEST", 0, 21], ["cardiac injury", "PROBLEM", 31, 45], ["elevation", "PROBLEM", 58, 67], ["serum cardiac biomarkers", "TEST", 71, 95], ["COVID", "TEST", 140, 145], ["cardiac", "ANATOMY", 31, 38], ["injury", "OBSERVATION", 39, 45], ["elevation", "OBSERVATION_MODIFIER", 58, 67]]], ["In a study from Wuhan, China of 416 consecutive hospitalized patients, cardiac injury was found in 82 (19.7%) cases and was statistically associated with older age, comorbidities such as hypertension, a tendency to require mechanical ventilation and higher in-hospital mortality[46].", [["cardiac", "ANATOMY", 71, 78], ["cardiac injury", "DISEASE", 71, 85], ["hypertension", "DISEASE", 187, 199], ["patients", "ORGANISM", 61, 69], ["cardiac", "ORGAN", 71, 78], ["patients", "SPECIES", 61, 69], ["cardiac injury", "PROBLEM", 71, 85], ["comorbidities", "PROBLEM", 165, 178], ["hypertension", "PROBLEM", 187, 199], ["a tendency", "PROBLEM", 201, 211], ["mechanical ventilation", "TREATMENT", 223, 245], ["cardiac", "ANATOMY", 71, 78], ["injury", "OBSERVATION", 79, 85], ["hypertension", "OBSERVATION", 187, 199]]], ["This same study mentioned renal injury in 8/416 (1.9%) and coagulopathy in 12/416 (2.9%).", [["renal", "ANATOMY", 26, 31], ["renal injury", "DISEASE", 26, 38], ["coagulopathy", "DISEASE", 59, 71], ["renal", "ORGAN", 26, 31], ["This same study", "TEST", 0, 15], ["renal injury", "PROBLEM", 26, 38], ["coagulopathy", "TEST", 59, 71], ["renal", "ANATOMY", 26, 31], ["injury", "OBSERVATION", 32, 38], ["coagulopathy", "OBSERVATION", 59, 71]]], ["Another study in preprint found acute myocardial injury in 6/53 (11.3%) cases[47].", [["myocardial", "ANATOMY", 38, 48], ["acute myocardial injury", "DISEASE", 32, 55], ["myocardial", "MULTI-TISSUE_STRUCTURE", 38, 48], ["Another study", "TEST", 0, 13], ["acute myocardial injury", "PROBLEM", 32, 55], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["myocardial", "ANATOMY", 38, 48], ["injury", "OBSERVATION", 49, 55]]], ["Neurologic issues have also been reported in the literature.", [["Neurologic issues", "PROBLEM", 0, 17]]], ["In a different study from Wuhan, China, neurologic manifestations were found in 78 of 214 (36.4%) consecutive hospitalized patients[48].", [["neurologic", "ANATOMY", 40, 50], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131]]], ["Symptoms included headache, loss of taste or smell, dizziness, impaired consciousness, myopathy and stroke.", [["headache", "DISEASE", 18, 26], ["loss of taste or smell", "DISEASE", 28, 50], ["dizziness", "DISEASE", 52, 61], ["impaired consciousness", "DISEASE", 63, 85], ["myopathy", "DISEASE", 87, 95], ["stroke", "DISEASE", 100, 106], ["Symptoms", "PROBLEM", 0, 8], ["headache", "PROBLEM", 18, 26], ["loss of taste", "PROBLEM", 28, 41], ["smell", "PROBLEM", 45, 50], ["dizziness", "PROBLEM", 52, 61], ["impaired consciousness", "PROBLEM", 63, 85], ["myopathy", "PROBLEM", 87, 95], ["stroke", "PROBLEM", 100, 106], ["myopathy", "OBSERVATION", 87, 95], ["stroke", "OBSERVATION", 100, 106]]], ["Gastrointestinal symptoms associated with COVID-19 have been described as well.", [["Gastrointestinal", "ANATOMY", 0, 16], ["COVID-19", "CHEMICAL", 42, 50], ["COVID-19", "CHEMICAL", 42, 50], ["Gastrointestinal", "ORGAN", 0, 16], ["Gastrointestinal symptoms", "PROBLEM", 0, 25], ["COVID", "TEST", 42, 47]]], ["For example, one study found 5 of 34 (14.7%) patients complained of diarrhea upon hospital admission[17].ROLE OF THE RADIOLOGISTThe use of imaging in COVID-19 is debated within the radiology community.", [["diarrhea", "DISEASE", 68, 76], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["one study", "TEST", 13, 22], ["diarrhea", "PROBLEM", 68, 76], ["imaging", "TEST", 139, 146], ["diarrhea", "OBSERVATION", 68, 76]]], ["Many of the major radiology professional societies have recently come out with statements on this subject.", [["major", "OBSERVATION_MODIFIER", 12, 17]]], ["The American College of Radiology states: Viral testing is the only specific method of diagnosis as recommended by the Centers for Disease Control; generally, chest imaging findings are not specific; and chest CT is considered \u201cUsually Not Appropriate\u201d in standard acute respiratory illness[49].", [["chest", "ANATOMY", 159, 164], ["chest", "ANATOMY", 204, 209], ["respiratory", "ANATOMY", 271, 282], ["acute respiratory illness", "DISEASE", 265, 290], ["chest", "ORGAN", 159, 164], ["chest", "ORGAN", 204, 209], ["Viral testing", "TEST", 42, 55], ["Disease Control", "TREATMENT", 131, 146], ["chest imaging findings", "TEST", 159, 181], ["chest CT", "TEST", 204, 212], ["standard acute respiratory illness", "PROBLEM", 256, 290], ["chest", "ANATOMY", 159, 164], ["chest", "ANATOMY", 204, 209], ["acute", "OBSERVATION_MODIFIER", 265, 270]]], ["Because of these considerations, joined with additional complex issues relating to infection control, the American College of Radiology says performing CT is not advised for screening for COVID-19 infection.", [["infection", "DISEASE", 83, 92], ["infection", "DISEASE", 197, 206], ["COVID-19", "SPECIES", 188, 196], ["additional complex issues", "PROBLEM", 45, 70], ["infection control", "TREATMENT", 83, 100], ["CT", "TEST", 152, 154], ["screening", "TEST", 174, 183], ["COVID-19 infection", "PROBLEM", 188, 206], ["infection", "OBSERVATION", 83, 92], ["infection", "OBSERVATION", 197, 206]]], ["They advise radiologists to become acquainted with the CT appearance of the disease so it can be recognized in patients imaged for a concurrent medical issue.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["the CT", "TEST", 51, 57], ["the disease", "PROBLEM", 72, 83], ["disease", "OBSERVATION", 76, 83]]], ["Similarly, the Society for Cardiovascular Magnetic Resonance states cardiovascular MR should not be performed in COVID-19 patients unless absolutely clinically necessary[50].", [["cardiovascular", "ANATOMY", 68, 82], ["patients", "ORGANISM", 122, 130], ["MR", "PROTEIN", 83, 85], ["patients", "SPECIES", 122, 130], ["cardiovascular MR", "TEST", 68, 85]]], ["Our medical center follows these guidelines and reserves advanced imaging for when it is critical to clinical care, rather than using it as a first-line diagnostic tool in COVID-19 patients.ROLE OF THE RADIOLOGISTTo understand the debate it is important to know that the current diagnostic gold standard for SARS-CoV-2 infection is laboratory RT-PCR testing to identify viral ribonucleic acid from the aforementioned biological samples.", [["samples", "ANATOMY", 428, 435], ["SARS", "DISEASE", 308, 312], ["infection", "DISEASE", 319, 328], ["ribonucleic acid", "CHEMICAL", 376, 392], ["patients", "ORGANISM", 181, 189], ["SARS-CoV-2", "ORGANISM", 308, 318], ["patients", "SPECIES", 181, 189], ["SARS-CoV", "SPECIES", 308, 316], ["advanced imaging", "TEST", 57, 73], ["SARS", "PROBLEM", 308, 312], ["CoV-2 infection", "PROBLEM", 313, 328], ["laboratory RT", "TEST", 332, 345], ["PCR testing", "TEST", 346, 357], ["viral ribonucleic acid", "TEST", 370, 392], ["ribonucleic acid", "OBSERVATION", 376, 392]]], ["This process, in many settings, takes significantly longer than performing a CT scan and has been shown to have a lower sensitivity (60%) than chest CT (97%)[51].", [["a CT scan", "TEST", 75, 84], ["a lower sensitivity", "PROBLEM", 112, 131], ["chest CT", "TEST", 143, 151], ["chest", "ANATOMY", 143, 148]]], ["Similarly, another group showed a lower sensitivity of RT-PCR (71%) as compared to chest CT (98%)[52].", [["RT-PCR", "TEST", 55, 61], ["chest CT", "TEST", 83, 91], ["chest", "ANATOMY", 83, 88]]], ["Thus, diagnostic testing via chest CT was recommended in various studies and has been used clinically, mostly outside the United States.", [["chest", "ANATOMY", 29, 34], ["chest", "ORGAN", 29, 34], ["diagnostic testing", "TEST", 6, 24], ["chest CT", "TEST", 29, 37], ["various studies", "TEST", 57, 72], ["chest", "ANATOMY", 29, 34]]], ["For example, an Italian preprint study supports using chest CT because it is known as the gold standard for interstitial pneumonia[53].", [["interstitial", "ANATOMY", 108, 120], ["interstitial pneumonia", "DISEASE", 108, 130], ["an Italian preprint study", "TEST", 13, 38], ["chest CT", "TEST", 54, 62], ["interstitial pneumonia", "PROBLEM", 108, 130], ["chest", "ANATOMY", 54, 59], ["interstitial", "ANATOMY_MODIFIER", 108, 120], ["pneumonia", "OBSERVATION", 121, 130]]], ["They found CT to have a sensitivity of 95.48%.", [["CT", "TEST", 11, 13], ["a sensitivity", "TEST", 22, 35]]], ["The group also points out that diagnostic accuracy is influenced by the prevalence of the disease, and thus, during a pandemic the predictive value gives a more precise measure of CT reliability.", [["diagnostic accuracy", "TEST", 31, 50], ["the disease", "PROBLEM", 86, 97], ["CT reliability", "TEST", 180, 194], ["disease", "OBSERVATION", 90, 97]]], ["Their study showed a high negative predictive value of > 90% and positive predictive value of 69%-84%.", [["Their study", "TEST", 0, 11]]], ["Therefore, they argue CT is fast, reliable and good for first-line triage where the virus is widespread.ROLE OF THE RADIOLOGISTIn a region of Japan with lower disease incidence, Himoto et al[54] studied the diagnostic performance of typical CT features of COVID-19 when imaged more than three days following symptom onset.", [["CT", "TEST", 22, 24], ["the virus", "PROBLEM", 80, 89], ["lower disease incidence", "PROBLEM", 153, 176], ["COVID", "TEST", 256, 261], ["symptom onset", "PROBLEM", 308, 321], ["virus", "OBSERVATION", 84, 89], ["widespread", "OBSERVATION_MODIFIER", 93, 103]]], ["The group concluded CT has an important supplemental role in identifying COVID-19 pneumonia and differentiating it from other forms of pneumonia, which can be clinically useful while awaiting the RT-PCR results.", [["pneumonia", "DISEASE", 82, 91], ["pneumonia", "DISEASE", 135, 144], ["COVID-19", "SPECIES", 73, 81], ["CT", "TEST", 20, 22], ["COVID", "TEST", 73, 78], ["pneumonia", "PROBLEM", 82, 91], ["pneumonia", "PROBLEM", 135, 144], ["the RT-PCR", "TEST", 192, 202], ["pneumonia", "OBSERVATION", 82, 91], ["pneumonia", "OBSERVATION", 135, 144]]], ["Specifically, of the 21 patients they studied, six were RT-PCR positive for COVID-19 and 15 suffered from pneumonia of other origin.", [["pneumonia", "DISEASE", 106, 115], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["RT-PCR", "TEST", 56, 62], ["COVID", "TEST", 76, 81], ["pneumonia", "PROBLEM", 106, 115], ["pneumonia", "OBSERVATION", 106, 115], ["origin", "ANATOMY_MODIFIER", 125, 131]]], ["Of the six positive cases, 100% showed GGO with or without consolidation bilaterally with peripheral predominance.", [["GGO", "DISEASE", 39, 42], ["GGO", "PROBLEM", 39, 42], ["consolidation bilaterally", "PROBLEM", 59, 84], ["peripheral predominance", "PROBLEM", 90, 113], ["GGO", "OBSERVATION", 39, 42], ["without", "UNCERTAINTY", 51, 58], ["consolidation", "OBSERVATION", 59, 72], ["bilaterally", "ANATOMY_MODIFIER", 73, 84], ["peripheral", "ANATOMY_MODIFIER", 90, 100], ["predominance", "OBSERVATION_MODIFIER", 101, 113]]], ["Rounded morphology and a higher number of lobes affected were significantly higher in COVID-19 infection as compared to other pneumoniae.", [["lobes", "ANATOMY", 42, 47], ["infection", "DISEASE", 95, 104], ["lobes", "ORGAN", 42, 47], ["COVID-19", "ORGANISM", 86, 94], ["COVID-19", "SPECIES", 86, 94], ["Rounded morphology", "PROBLEM", 0, 18], ["a higher number of lobes", "PROBLEM", 23, 47], ["COVID-19 infection", "PROBLEM", 86, 104], ["other pneumoniae", "PROBLEM", 120, 136], ["morphology", "OBSERVATION_MODIFIER", 8, 18], ["higher", "OBSERVATION_MODIFIER", 25, 31], ["number", "OBSERVATION_MODIFIER", 32, 38], ["lobes", "ANATOMY_MODIFIER", 42, 47], ["significantly", "OBSERVATION_MODIFIER", 62, 75], ["higher", "OBSERVATION_MODIFIER", 76, 82], ["infection", "OBSERVATION", 95, 104], ["pneumoniae", "OBSERVATION", 126, 136]]], ["Their radiologists showed high sensitivity (100% and 83%) in detecting COVID-19 pneumonia.", [["pneumonia", "DISEASE", 80, 89], ["COVID-19", "SPECIES", 71, 79], ["high sensitivity", "PROBLEM", 26, 42], ["COVID", "TEST", 71, 76], ["pneumonia", "PROBLEM", 80, 89], ["high", "OBSERVATION_MODIFIER", 26, 30], ["pneumonia", "OBSERVATION", 80, 89]]], ["They found the highest specificity (93% and 80%) when using criteria of bilateral GGO, peripheral predominance and absence of any airway abnormalities, nodules, mediastinal adenopathy and pleural effusion.ROLE OF THE RADIOLOGISTDangis et al[55] in a report in press, found low-dose submillisievert chest CT to show a high degree of sensitivity, specificity, positive predictive value, negative predictive value and accuracy overall (86,7%, 93.6%, 91.1%, 90.3%, and 90.2%, respectively) and after 48 h of symptoms (95.6%, 93.2%, 91.5%, 96.5%, and 94.4%, respectively).", [["airway", "ANATOMY", 130, 136], ["nodules", "ANATOMY", 152, 159], ["mediastinal adenopathy", "ANATOMY", 161, 183], ["pleural", "ANATOMY", 188, 195], ["GGO", "DISEASE", 82, 85], ["airway abnormalities", "DISEASE", 130, 150], ["adenopathy", "DISEASE", 173, 183], ["pleural effusion", "DISEASE", 188, 204], ["airway", "MULTI-TISSUE_STRUCTURE", 130, 136], ["nodules", "PATHOLOGICAL_FORMATION", 152, 159], ["pleural", "ORGAN", 188, 195], ["bilateral GGO", "PROBLEM", 72, 85], ["peripheral predominance", "PROBLEM", 87, 110], ["any airway abnormalities", "PROBLEM", 126, 150], ["nodules", "PROBLEM", 152, 159], ["mediastinal adenopathy", "PROBLEM", 161, 183], ["pleural effusion", "PROBLEM", 188, 204], ["submillisievert chest CT", "TEST", 282, 306], ["a high degree of sensitivity", "PROBLEM", 315, 343], ["accuracy", "TEST", 415, 423], ["symptoms", "TEST", 504, 512], ["highest", "OBSERVATION_MODIFIER", 15, 22], ["bilateral", "ANATOMY_MODIFIER", 72, 81], ["GGO", "OBSERVATION", 82, 85], ["peripheral", "ANATOMY_MODIFIER", 87, 97], ["predominance", "OBSERVATION", 98, 110], ["airway", "ANATOMY", 130, 136], ["abnormalities", "OBSERVATION", 137, 150], ["nodules", "OBSERVATION", 152, 159], ["mediastinal", "ANATOMY", 161, 172], ["adenopathy", "OBSERVATION", 173, 183], ["pleural", "ANATOMY", 188, 195], ["effusion", "OBSERVATION", 196, 204], ["chest", "ANATOMY", 298, 303], ["high degree", "OBSERVATION_MODIFIER", 317, 328]]], ["They also relay the advantage of finding concurrent bacterial pneumonia in COVID-19 true positive cases (7 of 72 cases, 9.7%) and finding alternative diagnoses in true negative cases (18 of 102 cases, 17.6%).", [["pneumonia", "DISEASE", 62, 71], ["concurrent bacterial pneumonia", "PROBLEM", 41, 71], ["COVID", "TEST", 75, 80], ["bacterial", "OBSERVATION_MODIFIER", 52, 61], ["pneumonia", "OBSERVATION", 62, 71]]], ["As described early on in this crisis by Kim[56], the role of the radiologist includes detecting lung abnormalities at the earliest time point in the disease course, gauging the severity and progress of disease, and identifying radiographic findings that suggest concomitant bacterial co-infections.", [["lung", "ANATOMY", 96, 100], ["lung abnormalities", "DISEASE", 96, 114], ["bacterial co-infections", "DISEASE", 274, 297], ["lung", "ORGAN", 96, 100], ["lung abnormalities", "PROBLEM", 96, 114], ["disease", "PROBLEM", 202, 209], ["radiographic findings", "TEST", 227, 248], ["concomitant bacterial co-infections", "PROBLEM", 262, 297], ["lung", "ANATOMY", 96, 100], ["abnormalities", "OBSERVATION", 101, 114], ["disease", "OBSERVATION", 149, 156], ["disease", "OBSERVATION", 202, 209], ["concomitant", "OBSERVATION_MODIFIER", 262, 273], ["bacterial", "OBSERVATION_MODIFIER", 274, 283], ["co-infections", "OBSERVATION", 284, 297]]], ["Overall, in the current state of affairs when testing is readily and quickly available, CT is reserved for complicated cases and to rule out concomitant pathology.", [["testing", "TEST", 46, 53], ["CT", "TEST", 88, 90], ["concomitant pathology", "PROBLEM", 141, 162], ["pathology", "OBSERVATION", 153, 162]]], ["Alternatively, where RT-PCR testing is slower, CT imaging can be used to characterize and diagnose COVID-19 pneumonia.ROLE OF THE RADIOLOGISTThe American College of Radiology emphasizes in boldface type on their website, \u201c... knowledge of this new condition is rapidly evolving, and not all of the published and publicly available information is complete or up-to-date\u201d[49].", [["pneumonia", "DISEASE", 108, 117], ["COVID-19", "SPECIES", 99, 107], ["RT-PCR testing", "TEST", 21, 35], ["CT imaging", "TEST", 47, 57], ["COVID", "TEST", 99, 104], ["pneumonia", "PROBLEM", 108, 117], ["this new condition", "PROBLEM", 239, 257], ["pneumonia", "OBSERVATION", 108, 117]]], ["In a recent report by Wynants et al[57] a critical assessment is made of published and preprint reports of prediction models of COVID-19 disease.", [["a critical assessment", "TEST", 40, 61], ["COVID-19 disease", "PROBLEM", 128, 144]]], ["The group found all 31 of the analyzed prediction models to have a high risk of bias relating to a multitude of reasons including using non-representative controls, excluding cases that had not experienced the target event by the end of the study and performing inadequate statistical analyses.", [["the study", "TEST", 237, 246]]], ["They recommend that the medical community proceed with caution in using the prediction models available.", [["the prediction models", "TEST", 72, 93]]], ["Clinical radiologists should stay abreast of updated professional guidelines and, as always, read current literature with a critical eye.", [["eye", "ANATOMY", 133, 136], ["eye", "ORGAN", 133, 136], ["eye", "ANATOMY", 133, 136]]], ["A notable example was released by the Canadian Society of Thoracic Radiology in conjunction with the Canadian Association of Radiologists covering thoracic imaging in suspected and confirmed COVID-19 cases[59].", [["thoracic", "ANATOMY", 147, 155], ["thoracic", "ORGAN", 147, 155], ["thoracic imaging", "TEST", 147, 163], ["COVID", "TEST", 191, 196], ["Thoracic", "ANATOMY", 58, 66], ["thoracic", "ANATOMY", 147, 155]]], ["Imaging at point-of-care is safer.", [["Imaging", "TEST", 0, 7]]], ["However, if thoughtful and viable institutional policies are in place to create a decontaminated and safe radiology suite, then advanced imaging should be instituted to better understand the manifestation and progression of this deadly disease.", [["advanced imaging", "TEST", 128, 144], ["this deadly disease", "PROBLEM", 224, 243]]], ["SARS-CoV-2 infections could spread further and wider over time before we fully understand its mechanism of action.", [["SARS", "DISEASE", 0, 4], ["infections", "DISEASE", 11, 21], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 5, 8], ["2 infections", "PROBLEM", 9, 21], ["infections", "OBSERVATION", 11, 21]]], ["Clearly, we need to be vigilant about safety, but we need to be equally vigilant about elucidating the pathology at hand.", [["hand", "ANATOMY", 116, 120], ["hand", "ORGANISM_SUBDIVISION", 116, 120]]], ["Collecting robust data via advanced imaging in a safe environment should also be a priority.ROLE OF THE RADIOLOGISTFor radiologists, another pertinent issue is overall quality in reported findings.", [["advanced imaging", "TEST", 27, 43]]], ["In a recent article, Salehi et al[60] systematically reviewed 37 published studies on diagnostic findings in CT of the chest in COVID-19 disease[60].", [["chest", "ANATOMY", 119, 124], ["chest", "ORGANISM_SUBDIVISION", 119, 124], ["diagnostic findings", "TEST", 86, 105], ["CT of the chest", "TEST", 109, 124], ["chest", "ANATOMY", 119, 124]]], ["They found wide variability in the terminology used in imaging reporting which can lead to confusion for healthcare providers.", [["confusion", "DISEASE", 91, 100], ["wide variability", "PROBLEM", 11, 27], ["imaging", "TEST", 55, 62], ["confusion", "PROBLEM", 91, 100], ["wide", "OBSERVATION_MODIFIER", 11, 15], ["variability", "OBSERVATION_MODIFIER", 16, 27]]], ["This is the first proposal of a reporting and data system for COVID-19.", [["COVID", "TEST", 62, 67]]], ["The group proposed a comprehensive lexicon to be used for typical and atypical findings in CT of COVID-19 patients with a grading system corresponding to the suspicion for lung involvement.", [["lung", "ANATOMY", 172, 176], ["patients", "ORGANISM", 106, 114], ["lung", "ORGAN", 172, 176], ["patients", "SPECIES", 106, 114], ["CT of COVID", "TEST", 91, 102], ["lung involvement", "PROBLEM", 172, 188], ["suspicion for", "UNCERTAINTY", 158, 171], ["lung", "ANATOMY", 172, 176], ["involvement", "OBSERVATION", 177, 188]]], ["Radiology practices should strongly consider implementing a structured reporting system for consistency and optimization in quality of patient care.ROLE OF THE RADIOLOGISTAs more is learned about COVID-19, there likely will be an expanded role for imaging and radiology research.", [["patient", "ORGANISM", 135, 142], ["patient", "SPECIES", 135, 142], ["COVID", "TEST", 196, 201], ["imaging", "TEST", 248, 255]]], ["For example, mentioned above in relatively few publications was enlargement of pulmonary vessels[22,24-26].", [["pulmonary vessels", "ANATOMY", 79, 96], ["pulmonary vessels", "MULTI-TISSUE_STRUCTURE", 79, 96], ["enlargement of pulmonary vessels", "PROBLEM", 64, 96], ["few", "OBSERVATION_MODIFIER", 43, 46], ["publications", "OBSERVATION", 47, 59], ["enlargement", "OBSERVATION", 64, 75], ["pulmonary vessels", "ANATOMY", 79, 96]]], ["This finding potentially could have been present in other studies but was perhaps missed because vascular enlargement is most commonly measured subjectively in clinical radiology.", [["vascular", "ANATOMY", 97, 105], ["vascular enlargement", "DISEASE", 97, 117], ["vascular", "MULTI-TISSUE_STRUCTURE", 97, 105], ["other studies", "TEST", 52, 65], ["vascular enlargement", "PROBLEM", 97, 117], ["vascular", "ANATOMY", 97, 105], ["enlargement", "OBSERVATION", 106, 117]]], ["As was noted in laboratory findings, these patients can have increased prothrombin time and D-dimer levels suggesting a hypercoagulable state[17].", [["D-dimer", "CHEMICAL", 92, 99], ["patients", "ORGANISM", 43, 51], ["prothrombin", "GENE_OR_GENE_PRODUCT", 71, 82], ["D-dimer", "GENE_OR_GENE_PRODUCT", 92, 99], ["prothrombin", "PROTEIN", 71, 82], ["patients", "SPECIES", 43, 51], ["increased prothrombin time", "PROBLEM", 61, 87], ["D-dimer levels", "TEST", 92, 106], ["a hypercoagulable state", "PROBLEM", 118, 141], ["hypercoagulable state", "OBSERVATION", 120, 141]]], ["Thus, CT angiography may become more prominent in evaluation of thromboembolic complications.", [["thromboembolic", "DISEASE", 64, 78], ["CT angiography", "TEST", 6, 20], ["evaluation", "TEST", 50, 60], ["thromboembolic complications", "PROBLEM", 64, 92], ["more prominent", "OBSERVATION_MODIFIER", 32, 46], ["thromboembolic", "OBSERVATION", 64, 78]]], ["Qanadli and Rotzinger[61] promote this idea as they write in support of structured CT reporting for COVID-19, while strongly advocating for the inclusion of vascular abnormalities therein[61].", [["vascular", "ANATOMY", 157, 165], ["vascular abnormalities", "DISEASE", 157, 179], ["vascular", "MULTI-TISSUE_STRUCTURE", 157, 165], ["structured CT", "TEST", 72, 85], ["COVID", "TEST", 100, 105], ["vascular abnormalities", "PROBLEM", 157, 179], ["vascular", "ANATOMY", 157, 165], ["abnormalities", "OBSERVATION", 166, 179]]], ["Objective analysis of pulmonary segmental and sub-segmental arterial branches on CT could also prove to be an interesting way to evaluate COVID-19 perfusion abnormalities.", [["pulmonary segmental", "ANATOMY", 22, 41], ["sub-segmental arterial branches", "ANATOMY", 46, 77], ["pulmonary segmental", "MULTI-TISSUE_STRUCTURE", 22, 41], ["arterial branches", "MULTI-TISSUE_STRUCTURE", 60, 77], ["Objective analysis", "TEST", 0, 18], ["CT", "TEST", 81, 83], ["COVID", "TEST", 138, 143], ["19 perfusion abnormalities", "PROBLEM", 144, 170], ["pulmonary", "ANATOMY", 22, 31], ["segmental", "ANATOMY_MODIFIER", 32, 41], ["sub", "ANATOMY_MODIFIER", 46, 49], ["segmental", "ANATOMY_MODIFIER", 50, 59], ["arterial", "ANATOMY", 60, 68], ["branches", "ANATOMY_MODIFIER", 69, 77], ["perfusion abnormalities", "OBSERVATION", 147, 170]]], ["Dual energy CT, not regularly used in the clinical domain for this purpose, could be researched to measure lung perfusion in COVID-19 patients.ROLE OF THE RADIOLOGISTOther imaging modalities may also have a larger role in future investigations of COVID-19.", [["lung", "ANATOMY", 107, 111], ["COVID-19", "CHEMICAL", 247, 255], ["lung", "ORGAN", 107, 111], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["Dual energy CT", "TEST", 0, 14], ["lung perfusion", "TEST", 107, 121], ["COVID", "TEST", 125, 130], ["THE RADIOLOGISTOther imaging modalities", "TEST", 151, 190], ["COVID", "TEST", 247, 252], ["lung", "ANATOMY", 107, 111], ["perfusion", "OBSERVATION", 112, 121]]], ["With a better understanding of the pathophysiology of SARS-CoV-2 infection, PET-CT has the potential to delineate involvement of the hematopoietic and other organ systems using 18F-FDG and other, novel radiotracers.", [["hematopoietic", "ANATOMY", 133, 146], ["organ", "ANATOMY", 157, 162], ["SARS", "DISEASE", 54, 58], ["infection", "DISEASE", 65, 74], ["18F-FDG", "CHEMICAL", 177, 184], ["SARS-CoV-2", "ORGANISM", 54, 64], ["hematopoietic", "CELL", 133, 146], ["organ", "ORGAN", 157, 162], ["18F-FDG", "SIMPLE_CHEMICAL", 177, 184], ["SARS-CoV", "SPECIES", 54, 62], ["SARS", "PROBLEM", 54, 58], ["CoV-2 infection", "PROBLEM", 59, 74], ["PET-CT", "TEST", 76, 82], ["the hematopoietic and other organ systems", "PROBLEM", 129, 170], ["hematopoietic", "ANATOMY", 133, 146]]], ["MR will be useful to better define cardiovascular, neurologic, gastrointestinal and renal sequelae.", [["cardiovascular", "ANATOMY", 35, 49], ["neurologic", "ANATOMY", 51, 61], ["gastrointestinal", "ANATOMY", 63, 79], ["renal", "ANATOMY", 84, 89], ["cardiovascular, neurologic, gastrointestinal and renal sequelae", "DISEASE", 35, 98], ["cardiovascular", "ANATOMICAL_SYSTEM", 35, 49], ["gastrointestinal", "ANATOMICAL_SYSTEM", 63, 79], ["renal", "ORGAN", 84, 89], ["MR", "PROTEIN", 0, 2], ["MR", "TEST", 0, 2], ["cardiovascular, neurologic, gastrointestinal and renal sequelae", "PROBLEM", 35, 98], ["gastrointestinal", "ANATOMY", 63, 79], ["renal", "ANATOMY", 84, 89], ["sequelae", "OBSERVATION", 90, 98]]], ["Sonography will likewise be useful in characterizing sequelae in multiple organ systems.ROLE OF ARTIFICIAL INTELLIGENCEAn entirely different angle of research involves combining imaging with artificial intelligence (AI).", [["organ", "ANATOMY", 74, 79], ["organ", "ORGAN", 74, 79], ["Sonography", "TEST", 0, 10], ["sequelae in multiple organ systems", "PROBLEM", 53, 87], ["combining imaging", "TEST", 168, 185], ["different", "OBSERVATION_MODIFIER", 131, 140], ["angle", "OBSERVATION_MODIFIER", 141, 146]]], ["The SARS-CoV-2 pandemic has overwhelmed health care systems.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["SARS-CoV", "SPECIES", 4, 12]]], ["Putting AI to work as intelligence augmentation needs to be a priority in order to assist physicians and public health experts during this and future crises.", [["intelligence augmentation", "TREATMENT", 22, 47]]], ["For radiologists the overarching goal of AI is to read imaging studies expeditiously and accurately, preferably in a triaged fashion.", [["imaging studies", "TEST", 55, 70]]], ["Augmented intelligence can integrate data from disparate sources to develop predictive models in diagnostics[62].", [["Augmented intelligence", "PROBLEM", 0, 22]]], ["By integrating imaging data, radiology reports and clinical information, AI will be a powerful tool for rapidly cataloguing information to assist radiologists and clinicians to best care for patients[63].ROLE OF ARTIFICIAL INTELLIGENCEAs described by Rijn et al[64], following an initial time investment by a radiologist to train a deep learning system, tasks such as image segmentation can be performed with speed and accuracy[64].", [["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["integrating imaging data", "TEST", 3, 27], ["a deep learning system", "TREATMENT", 330, 352], ["image segmentation", "TEST", 368, 386], ["ARTIFICIAL INTELLIGENCEAs", "OBSERVATION", 212, 237]]], ["Articles in preprint archives describe training and testing of convolutional neural networks on CXR[65,66].", [["convolutional neural networks", "ANATOMY", 63, 92], ["neural networks", "MULTI-TISSUE_STRUCTURE", 77, 92], ["CXR", "TEST", 96, 99]]], ["Deep learning algorithms based upon 2D and 3D learning models on non-contrast chest CT are being developed to aid in detection, quantification and analysis of progression in COVID-19 and are also found in print and in preprint repositories[67-69].", [["Deep learning algorithms", "PROBLEM", 0, 24], ["non-contrast chest CT", "TEST", 65, 86], ["quantification", "TEST", 128, 142], ["COVID", "TEST", 174, 179], ["chest", "ANATOMY", 78, 83], ["progression", "OBSERVATION_MODIFIER", 159, 170]]], ["An additional recent CT study tested an AI model that combines CT image data with multiple clinical factors and performed well compared to an experienced thoracic radiologist[70].", [["An additional recent CT study", "TEST", 0, 29], ["CT image data", "TEST", 63, 76], ["thoracic", "ANATOMY", 154, 162]]], ["A final and important addition to the conversation is the potential for AI-derived radiographic imaging biomarkers to enhance predictive population health[71,72].", [["AI", "TEST", 72, 74], ["radiographic imaging biomarkers", "TEST", 83, 114]]], ["Utilizing AI in this manner could literally change the course of a multitude of diseases, including the current pandemic.STUDY LIMITATIONSThis review study has some limitations.", [["AI", "TREATMENT", 10, 12], ["diseases", "PROBLEM", 80, 88], ["review study", "TEST", 143, 155], ["diseases", "OBSERVATION", 80, 88]]], ["First, the majority of studies reviewed have a small number of subjects.", [["small", "OBSERVATION_MODIFIER", 47, 52]]], ["Of our 117 case and series studies combined, 67 (57.3%) of these had 1-10 subjects with more than half of these, 39 in total, being single case studies.", [["series studies", "TEST", 20, 34], ["single case studies", "TEST", 132, 151]]], ["The lack of many larger series studies represents the novelty of COVID-19 and over time larger studies will surface in the literature.", [["COVID", "TEST", 65, 70]]], ["Another limitation is the possibility that some cases and series reports are represented more than once within the dataset.", [["is the possibility", "UNCERTAINTY", 19, 37]]], ["Also, this review did not attempt to identify image acquisition parameters or image quality.", [["image acquisition parameters", "TEST", 46, 74]]], ["Finally, these early case and series reports are chiefly representative of hospitalized patients.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96]]], ["Therefore, they do not represent the community-based experience of COVID-19.CONCLUSIONThe radiology literature reveals general hallmarks of SARS-CoV-2 infections.", [["SARS-CoV-2 infections", "DISEASE", 140, 161], ["COVID-19", "CHEMICAL", 67, 75], ["SARS-CoV-2", "ORGANISM", 140, 150], ["SARS-CoV", "SPECIES", 140, 148], ["COVID", "TEST", 67, 72], ["SARS", "PROBLEM", 140, 144], ["CoV-2 infections", "PROBLEM", 145, 161], ["SARS", "OBSERVATION", 140, 144], ["infections", "OBSERVATION", 151, 161]]], ["These include CXR findings of bilateral pulmonary infiltrates with a tendency toward the lung periphery and chest CT findings of bilateral and peripheral ground glass and consolidated opacities, with an absence of concomitant pulmonary nodules, cavitation, adenopathy and pleural effusions.", [["pulmonary infiltrates", "ANATOMY", 40, 61], ["lung periphery", "ANATOMY", 89, 103], ["pulmonary nodules", "ANATOMY", 226, 243], ["pleural effusions", "ANATOMY", 272, 289], ["opacities", "DISEASE", 184, 193], ["cavitation", "DISEASE", 245, 255], ["adenopathy", "DISEASE", 257, 267], ["pleural effusions", "DISEASE", 272, 289], ["pulmonary", "ORGAN", 40, 49], ["lung periphery", "MULTI-TISSUE_STRUCTURE", 89, 103], ["pulmonary nodules", "PATHOLOGICAL_FORMATION", 226, 243], ["pleural effusions", "CANCER", 272, 289], ["CXR findings", "TEST", 14, 26], ["bilateral pulmonary infiltrates", "PROBLEM", 30, 61], ["a tendency toward the lung periphery", "PROBLEM", 67, 103], ["chest CT", "TEST", 108, 116], ["bilateral and peripheral ground glass and consolidated opacities", "PROBLEM", 129, 193], ["concomitant pulmonary nodules", "PROBLEM", 214, 243], ["cavitation", "PROBLEM", 245, 255], ["adenopathy", "PROBLEM", 257, 267], ["pleural effusions", "PROBLEM", 272, 289], ["bilateral", "ANATOMY_MODIFIER", 30, 39], ["pulmonary", "ANATOMY", 40, 49], ["infiltrates", "OBSERVATION", 50, 61], ["lung", "ANATOMY", 89, 93], ["periphery", "ANATOMY_MODIFIER", 94, 103], ["chest", "ANATOMY", 108, 113], ["bilateral", "ANATOMY_MODIFIER", 129, 138], ["peripheral", "ANATOMY_MODIFIER", 143, 153], ["ground glass", "OBSERVATION", 154, 166], ["consolidated", "OBSERVATION_MODIFIER", 171, 183], ["opacities", "OBSERVATION", 184, 193], ["concomitant", "OBSERVATION_MODIFIER", 214, 225], ["pulmonary", "ANATOMY", 226, 235], ["nodules", "OBSERVATION", 236, 243], ["cavitation", "OBSERVATION_MODIFIER", 245, 255], ["adenopathy", "OBSERVATION", 257, 267], ["pleural", "ANATOMY", 272, 279], ["effusions", "OBSERVATION", 280, 289]]], ["The cutoff for this study was April 6, 2020 \u2013 since then, multiple studies have been published with results that mirror those discussed in this review.", [["this study", "TEST", 15, 25], ["multiple studies", "TEST", 58, 74]]], ["Radiologists will need to follow accumulating published data of radiographic findings in COVID-19 to confirm and reassess these earliest reported studies and to continue to address best radiographic practices.", [["radiographic findings", "TEST", 64, 85]]]], "bda3f6c3ad7b1b4f36e8d4d89995ab71f8f5894d": [["Overview of the structure and pharmacological properties of flavaglinesFlavaglines, also called rocaglates, represent a distinctive class of cyclopenta [b] benzofurans produced in nature by plants of the genus Aglaia that grow in Southeast Asia [1] .", [["Flavaglines", "CHEMICAL", 71, 82], ["rocaglates", "CHEMICAL", 96, 106], ["cyclopenta [b] benzofurans", "CHEMICAL", 141, 167], ["flavaglines", "CHEMICAL", 60, 71], ["Flavaglines", "CHEMICAL", 71, 82], ["rocaglates", "CHEMICAL", 96, 106], ["cyclopenta [b] benzofurans", "CHEMICAL", 141, 167], ["flavaglines", "SIMPLE_CHEMICAL", 60, 71], ["Flavaglines", "SIMPLE_CHEMICAL", 71, 82], ["rocaglates", "SIMPLE_CHEMICAL", 96, 106], ["cyclopenta [b] benzofurans", "SIMPLE_CHEMICAL", 141, 167], ["flavaglinesFlavaglines", "TREATMENT", 60, 82], ["cyclopenta [b] benzofurans", "TREATMENT", 141, 167], ["genus Aglaia", "ANATOMY", 204, 216]]], ["Some of these plants are used in traditional Chinese medicine to treat contused wounds, cough, diarrhea, fever, and inflammation.", [["wounds", "ANATOMY", 80, 86], ["wounds", "DISEASE", 80, 86], ["cough", "DISEASE", 88, 93], ["diarrhea", "DISEASE", 95, 103], ["fever", "DISEASE", 105, 110], ["inflammation", "DISEASE", 116, 128], ["wounds", "PATHOLOGICAL_FORMATION", 80, 86], ["traditional Chinese medicine", "TREATMENT", 33, 61], ["contused wounds", "PROBLEM", 71, 86], ["cough", "PROBLEM", 88, 93], ["diarrhea", "PROBLEM", 95, 103], ["fever", "PROBLEM", 105, 110], ["inflammation", "PROBLEM", 116, 128], ["plants", "OBSERVATION", 14, 20], ["contused", "OBSERVATION_MODIFIER", 71, 79], ["wounds", "OBSERVATION", 80, 86], ["cough", "OBSERVATION", 88, 93], ["fever", "OBSERVATION", 105, 110], ["inflammation", "OBSERVATION", 116, 128]]], ["Rocaglamide (1, Figure 1 ) was originally discovered by King and collaborators in 1982.", [["Rocaglamide", "CHEMICAL", 0, 11], ["Rocaglamide", "CHEMICAL", 0, 11], ["Rocaglamide", "SIMPLE_CHEMICAL", 0, 11], ["Rocaglamide", "TREATMENT", 0, 11]]], ["Since then more than one hundred other natural flavaglines, such as silvestrol (2) and aglaroxin C (3), have been identified.", [["flavaglines", "CHEMICAL", 47, 58], ["silvestrol", "CHEMICAL", 68, 78], ["flavaglines", "CHEMICAL", 47, 58], ["silvestrol", "CHEMICAL", 68, 78], ["aglaroxin C", "CHEMICAL", 87, 98], ["flavaglines", "SIMPLE_CHEMICAL", 47, 58], ["silvestrol (2)", "SIMPLE_CHEMICAL", 68, 82], ["aglaroxin C (3)", "SIMPLE_CHEMICAL", 87, 102], ["aglaroxin C", "TREATMENT", 87, 98]]], ["Strikingly, these compounds can selectively kill cancer cells, without being toxic to non-cancer cells.", [["cancer cells", "ANATOMY", 49, 61], ["non-cancer cells", "ANATOMY", 86, 102], ["cancer", "DISEASE", 49, 55], ["non-cancer", "DISEASE", 86, 96], ["cancer cells", "CELL", 49, 61], ["non-cancer cells", "CELL", 86, 102], ["cancer cells", "CELL_TYPE", 49, 61], ["non-cancer cells", "CELL_TYPE", 86, 102], ["selectively kill cancer cells", "PROBLEM", 32, 61], ["toxic to non-cancer cells", "PROBLEM", 77, 102]]], ["They can even protect neurons and cardiomyocytes against the adverse effect of clinically used cancer chemotherapeutics [2] [3] [4] .", [["neurons", "ANATOMY", 22, 29], ["cardiomyocytes", "ANATOMY", 34, 48], ["cancer", "ANATOMY", 95, 101], ["cancer", "DISEASE", 95, 101], ["neurons", "CELL", 22, 29], ["cardiomyocytes", "CELL", 34, 48], ["cancer", "CANCER", 95, 101], ["[2] [3] [4]", "SIMPLE_CHEMICAL", 120, 131], ["cardiomyocytes", "CELL_TYPE", 34, 48], ["cancer chemotherapeutics", "TREATMENT", 95, 119], ["cardiomyocytes", "ANATOMY", 34, 48]]], ["Flavaglines also possess potent anti-inflammatory effects, in particular in a mouse model of Crohn's disease [5] .", [["Flavaglines", "CHEMICAL", 0, 11], ["Crohn's disease", "DISEASE", 93, 108], ["Flavaglines", "CHEMICAL", 0, 11], ["Flavaglines", "SIMPLE_CHEMICAL", 0, 11], ["mouse", "ORGANISM", 78, 83], ["mouse", "SPECIES", 78, 83], ["mouse", "SPECIES", 78, 83], ["Flavaglines", "TREATMENT", 0, 11], ["potent anti-inflammatory effects", "TREATMENT", 25, 57], ["Crohn's disease", "PROBLEM", 93, 108], ["potent", "OBSERVATION_MODIFIER", 25, 31], ["anti-inflammatory effects", "OBSERVATION", 32, 57], ["Crohn", "OBSERVATION", 93, 98]]], ["These pharmacological effects are mediated by two classes of molecular targets: the translation initiation factor eIF4A and prohibitins-1 and 2 (PHB1/2) ( Table 1 ).", [["eIF4A", "GENE_OR_GENE_PRODUCT", 114, 119], ["prohibitins-1", "GENE_OR_GENE_PRODUCT", 124, 137], ["2", "GENE_OR_GENE_PRODUCT", 142, 143], ["PHB1/2", "GENE_OR_GENE_PRODUCT", 145, 151], ["Table 1", "GENE_OR_GENE_PRODUCT", 155, 162], ["translation initiation factor", "PROTEIN", 84, 113], ["eIF4A", "PROTEIN", 114, 119], ["prohibitins-1 and 2", "PROTEIN", 124, 143], ["PHB1", "PROTEIN", 145, 149], ["Table 1", "PROTEIN", 155, 162], ["prohibitins", "TEST", 124, 135]]], ["[6] MERS-CoV Silvestrol (2) eIF4A [7] HCoV-229E Silvestrol (2) eIF4A [7] Poliovirus type 1 Silvestrol (2) eIF4A [7] Chikungunya virus Silvestrol (2) eIF4A [8] Hepatitis E Silvestrol (2) * eIF4A [9, 10] Zika virus Silvestrol (2) eIF4A [11] Influenza A virus Silvestrol (2) eIF4A [12] HCoV-229E, MERS-CoV, Zika virus, Lassa virus and Crimean-Congo hemorrhagic fever virus Silvestrol (2) CR-31-B (5) eIF4A [13] Chikungunya virus FL3 (6), FL23 (7) PHBs [14] Hepatitis C virus Rocaglamide (1) aglaroxin C (3) PHBs [15] Hepatitis C virus CMLD012043 (8) CMLD012044 (9) PHBs [16] Enterovirus 71 Rocaglamide (1) PHBs [17] Zotatifin (4) SARS-CoV-2 eIF4A [18] * This compound was shown to be active in a mouse model of infection.Overview of the structure and pharmacological properties of flavaglinesAt the current time, no extensive exploration of flavaglines toxicity has been disclosed.", [["Silvestrol", "CHEMICAL", 213, 223], ["Silvestrol", "CHEMICAL", 257, 267], ["hemorrhagic fever", "DISEASE", 346, 363], ["Silvestrol", "CHEMICAL", 370, 380], ["Hepatitis C", "DISEASE", 454, 465], ["Rocaglamide", "CHEMICAL", 472, 483], ["Hepatitis C", "DISEASE", 514, 525], ["CMLD012044", "CHEMICAL", 547, 557], ["Rocaglamide", "CHEMICAL", 587, 598], ["infection", "DISEASE", 708, 717], ["flavaglines", "CHEMICAL", 778, 789], ["flavaglines", "CHEMICAL", 838, 849], ["toxicity", "DISEASE", 850, 858], ["eIF4A [7] HCoV-229E", "CHEMICAL", 28, 47], ["[17] Zotatifin", "CHEMICAL", 608, 622], ["flavaglines", "CHEMICAL", 778, 789], ["flavaglines", "CHEMICAL", 838, 849], ["[6] MERS-CoV Silvestrol (2) eIF4A [7] HCoV", "SIMPLE_CHEMICAL", 0, 42], ["eIF4A [7]", "SIMPLE_CHEMICAL", 106, 115], ["Chikungunya virus", "ORGANISM", 116, 133], ["Silvestrol (2) eIF4A [8] Hepatitis E Silvestrol (2) * eIF4A [9, 10]", "SIMPLE_CHEMICAL", 134, 201], ["Zika virus", "ORGANISM", 202, 212], ["Silvestrol (2) eIF4A [11]", "SIMPLE_CHEMICAL", 213, 238], ["Influenza A virus", "ORGANISM", 239, 256], ["Silvestrol (2) eIF4A [12]", "SIMPLE_CHEMICAL", 257, 282], ["HCoV-229E", "ORGANISM", 283, 292], ["MERS-CoV", "ORGANISM", 294, 302], ["Zika virus", "ORGANISM", 304, 314], ["Lassa virus", "ORGANISM", 316, 327], ["Crimean-Congo hemorrhagic fever virus", "ORGANISM", 332, 369], ["eIF4A [13]", "ORGANISM", 397, 407], ["Chikungunya virus FL3", "ORGANISM", 408, 429], ["Hepatitis C virus", "ORGANISM", 454, 471], ["aglaroxin C (3) PHBs [15]", "SIMPLE_CHEMICAL", 488, 513], ["Hepatitis C virus", "ORGANISM", 514, 531], ["PHBs [17] Zotatifin (4) SARS-CoV-2 eIF4A [18] *", "SIMPLE_CHEMICAL", 603, 650], ["mouse", "ORGANISM", 693, 698], ["flavaglines", "SIMPLE_CHEMICAL", 778, 789], ["flavaglines", "SIMPLE_CHEMICAL", 838, 849], ["Chikungunya virus", "SPECIES", 116, 133], ["Influenza A virus", "SPECIES", 239, 256], ["Zika virus", "SPECIES", 304, 314], ["Lassa virus", "SPECIES", 316, 327], ["Crimean-Congo hemorrhagic fever virus", "SPECIES", 332, 369], ["Chikungunya virus FL3", "SPECIES", 408, 429], ["Hepatitis C virus", "SPECIES", 454, 471], ["Hepatitis C virus", "SPECIES", 514, 531], ["mouse", "SPECIES", 693, 698], ["Chikungunya virus", "SPECIES", 116, 133], ["Influenza A virus", "SPECIES", 239, 256], ["MERS-CoV", "SPECIES", 294, 302], ["Zika virus", "SPECIES", 304, 314], ["Lassa virus", "SPECIES", 316, 327], ["Crimean-Congo hemorrhagic fever virus", "SPECIES", 332, 369], ["Chikungunya virus", "SPECIES", 408, 425], ["Hepatitis C virus", "SPECIES", 454, 471], ["Hepatitis C virus", "SPECIES", 514, 531], ["mouse", "SPECIES", 693, 698], ["MERS-CoV Silvestrol (2) eIF4A", "TREATMENT", 4, 33], ["HCoV", "TEST", 38, 42], ["Silvestrol (2) eIF4A [7] Poliovirus type 1 Silvestrol (2) eIF4A", "TREATMENT", 48, 111], ["Chikungunya virus Silvestrol (2) eIF4A", "TREATMENT", 116, 154], ["Hepatitis E Silvestrol (2) * eIF4A", "TREATMENT", 159, 193], ["Zika virus Silvestrol (2) eIF4A", "TREATMENT", 202, 233], ["Influenza A virus Silvestrol", "TREATMENT", 239, 267], ["eIF4A", "TEST", 272, 277], ["HCoV", "TEST", 283, 287], ["MERS", "TEST", 294, 298], ["Zika virus", "PROBLEM", 304, 314], ["Lassa virus", "PROBLEM", 316, 327], ["Crimean", "TEST", 332, 339], ["Congo hemorrhagic fever virus Silvestrol", "PROBLEM", 340, 380], ["CR", "TEST", 385, 387], ["Chikungunya virus FL3", "TEST", 408, 429], ["PHBs", "TEST", 444, 448], ["Hepatitis C virus Rocaglamide", "TREATMENT", 454, 483], ["aglaroxin C (3)", "TREATMENT", 488, 503], ["PHBs", "TEST", 504, 508], ["Hepatitis C virus CMLD012043", "TREATMENT", 514, 542], ["PHBs", "TEST", 562, 566], ["Enterovirus", "TREATMENT", 572, 583], ["Rocaglamide", "TREATMENT", 587, 598], ["Zotatifin", "TREATMENT", 613, 622], ["infection", "PROBLEM", 708, 717], ["flavaglines", "TREATMENT", 778, 789], ["flavaglines toxicity", "PROBLEM", 838, 858], ["active", "OBSERVATION", 681, 687], ["infection", "OBSERVATION", 708, 717], ["no", "UNCERTAINTY", 810, 812], ["extensive", "OBSERVATION_MODIFIER", 813, 822], ["exploration", "OBSERVATION", 823, 834]]], ["Yet, at doses where they exert potent cardioprotectant and anti-inflammatory effects, flavaglines did not exhibit any overt sign of toxicity [2, 5] .", [["toxicity", "DISEASE", 132, 140], ["flavaglines", "CHEMICAL", 86, 97], ["flavaglines", "SIMPLE_CHEMICAL", 86, 97], ["potent cardioprotectant", "TREATMENT", 31, 54], ["anti-inflammatory effects", "TREATMENT", 59, 84], ["flavaglines", "TREATMENT", 86, 97], ["toxicity", "PROBLEM", 132, 140]]], ["In addition a synthetic flavagline developed by the eFFECTOR Therapeutics company, Zotatifin (also called eFT226, 4, Figure 1 ) has passed the US regulatory toxicology requirements necessary to enter a phase 1/2 clinical trial against advanced solid tumors refractory or intolerant to standard treatments [19, 20] .", [["solid tumors", "ANATOMY", 244, 256], ["flavagline", "CHEMICAL", 24, 34], ["Zotatifin", "CHEMICAL", 83, 92], ["tumors", "DISEASE", 250, 256], ["flavagline", "CHEMICAL", 24, 34], ["Zotatifin", "CHEMICAL", 83, 92], ["flavagline", "SIMPLE_CHEMICAL", 24, 34], ["Zotatifin", "SIMPLE_CHEMICAL", 83, 92], ["solid tumors", "CANCER", 244, 256], ["a synthetic flavagline", "TREATMENT", 12, 34], ["Zotatifin", "TREATMENT", 83, 92], ["advanced solid tumors", "PROBLEM", 235, 256], ["standard treatments", "TREATMENT", 285, 304], ["tumors", "OBSERVATION", 250, 256]]], ["While it was shown to inhibit eIF4A, its putative effect on PHB signaling has not yet been disclosed.Viruses affected by flavaglinesThe importance of eIF4A during viral infections tends to be virus specific.", [["flavaglines", "CHEMICAL", 121, 132], ["viral infections", "DISEASE", 163, 179], ["eIF4A", "GENE_OR_GENE_PRODUCT", 30, 35], ["PHB", "GENE_OR_GENE_PRODUCT", 60, 63], ["eIF4A", "GENE_OR_GENE_PRODUCT", 150, 155], ["eIF4A", "PROTEIN", 30, 35], ["PHB", "PROTEIN", 60, 63], ["eIF4A", "PROTEIN", 150, 155], ["Viruses", "PROBLEM", 101, 108], ["eIF4A", "TREATMENT", 150, 155], ["viral infections", "PROBLEM", 163, 179], ["virus", "PROBLEM", 192, 197]]], ["In fact, viruses can either use it or not use it at all, or they may alternate between requiring and not requiring the eIF4A protein [21] .", [["eIF4A", "GENE_OR_GENE_PRODUCT", 119, 124], ["eIF4A protein", "PROTEIN", 119, 132], ["viruses", "PROBLEM", 9, 16], ["the eIF4A protein", "TREATMENT", 115, 132], ["viruses", "OBSERVATION", 9, 16]]], ["Several RNA viruses require eIF4A for the translation of their mRNAs, in particular those that are responsible for Ebola, chikungunya, hepatitis E, poliomyelitis, Zika fever, \"hand, foot and mouth\" disease, SARS, MERS and COVID-19 (recently reviewed in ref [21] ).", [["hand", "ANATOMY", 176, 180], ["foot", "ANATOMY", 182, 186], ["mouth", "ANATOMY", 191, 196], ["Ebola", "DISEASE", 115, 120], ["chikungunya", "DISEASE", 122, 133], ["hepatitis E", "DISEASE", 135, 146], ["poliomyelitis", "DISEASE", 148, 161], ["Zika fever", "DISEASE", 163, 173], ["hand, foot and mouth\" disease", "DISEASE", 176, 205], ["SARS", "DISEASE", 207, 211], ["eIF4A", "GENE_OR_GENE_PRODUCT", 28, 33], ["Ebola", "ORGANISM", 115, 120], ["hepatitis E", "ORGANISM", 135, 146], ["hand", "ORGANISM_SUBDIVISION", 176, 180], ["foot", "ORGANISM_SUBDIVISION", 182, 186], ["mouth", "ORGANISM_SUBDIVISION", 191, 196], ["eIF4A", "PROTEIN", 28, 33], ["mRNAs", "RNA", 63, 68], ["Several RNA viruses", "PROBLEM", 0, 19], ["eIF4A", "TREATMENT", 28, 33], ["Ebola", "PROBLEM", 115, 120], ["chikungunya", "PROBLEM", 122, 133], ["hepatitis E", "PROBLEM", 135, 146], ["poliomyelitis", "PROBLEM", 148, 161], ["Zika fever", "PROBLEM", 163, 173], ["\"hand, foot and mouth\" disease", "PROBLEM", 175, 205], ["SARS", "PROBLEM", 207, 211], ["COVID", "TEST", 222, 227], ["RNA viruses", "OBSERVATION", 8, 19], ["responsible for", "UNCERTAINTY", 99, 114], ["Ebola", "OBSERVATION", 115, 120], ["chikungunya", "OBSERVATION", 122, 133], ["poliomyelitis", "OBSERVATION", 148, 161], ["foot", "ANATOMY", 182, 186], ["mouth", "ANATOMY", 191, 196]]], ["As a consequence, eIF4A has emerged as a promising target to treat these viral infections and the use of compounds that inhibit the activity of eIF4A holds great interest as antiviral agents.Viruses affected by flavaglinesEbola is a deadly disease manifested by a hemorrhagic fever.", [["viral infections", "DISEASE", 73, 89], ["flavaglines", "CHEMICAL", 211, 222], ["Ebola", "DISEASE", 222, 227], ["hemorrhagic fever", "DISEASE", 264, 281], ["eIF4A", "GENE_OR_GENE_PRODUCT", 18, 23], ["eIF4A", "GENE_OR_GENE_PRODUCT", 144, 149], ["Ebola", "ORGANISM", 222, 227], ["eIF4A", "PROTEIN", 18, 23], ["eIF4A", "PROTEIN", 144, 149], ["eIF4A", "TREATMENT", 18, 23], ["these viral infections", "PROBLEM", 67, 89], ["eIF4A holds", "TREATMENT", 144, 155], ["antiviral agents", "TREATMENT", 174, 190], ["Viruses", "PROBLEM", 191, 198], ["a deadly disease", "PROBLEM", 231, 247], ["a hemorrhagic fever", "PROBLEM", 262, 281], ["viral", "OBSERVATION_MODIFIER", 73, 78], ["infections", "OBSERVATION", 79, 89], ["deadly", "OBSERVATION_MODIFIER", 233, 239], ["hemorrhagic", "OBSERVATION_MODIFIER", 264, 275], ["fever", "OBSERVATION", 276, 281]]], ["It is caused by a negative-stranded RNA virus, and Ebola is currently raging in the Democratic Republic of the Congo in spite of the recent approval of a vaccine [22] .", [["Ebola", "DISEASE", 51, 56], ["Ebola", "ORGANISM", 51, 56], ["a negative-stranded RNA virus", "PROBLEM", 16, 45], ["Ebola", "PROBLEM", 51, 56], ["a vaccine", "TREATMENT", 152, 161]]], ["At the current time, no antiviral treatment is available.Viruses affected by flavaglinesChikungunya virus (CHIKV) is a positive-sense single-stranded RNA Alphavirus that induces severe fever and joint pain [23] .", [["joint", "ANATOMY", 195, 200], ["flavaglines", "CHEMICAL", 77, 88], ["Chikungunya", "DISEASE", 88, 99], ["fever", "DISEASE", 185, 190], ["joint pain", "DISEASE", 195, 205], ["Chikungunya virus", "ORGANISM", 88, 105], ["CHIKV", "ORGANISM", 107, 112], ["joint", "ORGANISM_SUBDIVISION", 195, 200], ["Chikungunya virus", "SPECIES", 88, 105], ["Chikungunya virus", "SPECIES", 88, 105], ["CHIKV", "SPECIES", 107, 112], ["antiviral treatment", "TREATMENT", 24, 43], ["Viruses", "PROBLEM", 57, 64], ["Chikungunya virus", "PROBLEM", 88, 105], ["CHIKV", "PROBLEM", 107, 112], ["stranded RNA Alphavirus", "PROBLEM", 141, 164], ["severe fever", "PROBLEM", 178, 190], ["joint pain", "PROBLEM", 195, 205], ["no", "UNCERTAINTY", 21, 23], ["antiviral treatment", "OBSERVATION", 24, 43], ["severe", "OBSERVATION_MODIFIER", 178, 184], ["fever", "OBSERVATION", 185, 190], ["joint", "ANATOMY", 195, 200]]], ["Unfortunately, no vaccine or medicine is currently available to prevent and treat this disease.Viruses affected by flavaglinesFlaviviruses are single-stranded, positive-sense RNA viruses that include Zika virus (ZIKV), dengue virus (DENV), yellow fever virus (YFV) , and West Nile virus (WNV), which still represent a major public health problem in tropical and sub-tropical (ZIKV, DENV, YFV, WNV) and non-tropical (WNV) areas of the world [24] .", [["dengue", "DISEASE", 219, 225], ["yellow fever", "DISEASE", 240, 252], ["West Nile virus (WNV)", "DISEASE", 271, 292], ["tropical and sub-tropical (ZIKV, DENV, YFV, WNV) and non-tropical (WNV) areas", "DISEASE", 349, 426], ["flavaglinesFlaviviruses", "ORGANISM", 115, 138], ["Zika virus", "ORGANISM", 200, 210], ["ZIKV", "GENE_OR_GENE_PRODUCT", 212, 216], ["dengue virus", "ORGANISM", 219, 231], ["DENV", "ORGANISM", 233, 237], ["yellow fever virus", "ORGANISM", 240, 258], ["YFV", "ORGANISM", 260, 263], ["West Nile virus", "ORGANISM", 271, 286], ["WNV", "ORGANISM", 288, 291], ["YFV", "ORGANISM", 388, 391], ["Zika virus", "SPECIES", 200, 210], ["dengue virus", "SPECIES", 219, 231], ["yellow fever virus", "SPECIES", 240, 258], ["West Nile virus", "SPECIES", 271, 286], ["Zika virus", "SPECIES", 200, 210], ["ZIKV", "SPECIES", 212, 216], ["dengue virus", "SPECIES", 219, 231], ["DENV", "SPECIES", 233, 237], ["yellow fever virus", "SPECIES", 240, 258], ["YFV", "SPECIES", 260, 263], ["West Nile virus", "SPECIES", 271, 286], ["WNV", "SPECIES", 288, 291], ["ZIKV", "SPECIES", 376, 380], ["DENV", "SPECIES", 382, 386], ["YFV", "SPECIES", 388, 391], ["WNV", "SPECIES", 393, 396], ["WNV", "SPECIES", 416, 419], ["vaccine", "TREATMENT", 18, 25], ["medicine", "TREATMENT", 29, 37], ["this disease", "PROBLEM", 82, 94], ["Viruses", "PROBLEM", 95, 102], ["flavaglinesFlaviviruses", "PROBLEM", 115, 138], ["sense RNA viruses", "PROBLEM", 169, 186], ["Zika virus", "PROBLEM", 200, 210], ["ZIKV", "PROBLEM", 212, 216], ["dengue virus", "PROBLEM", 219, 231], ["DENV", "PROBLEM", 233, 237], ["yellow fever virus", "PROBLEM", 240, 258], ["West Nile virus (WNV", "PROBLEM", 271, 291], ["ZIKV", "PROBLEM", 376, 380], ["DENV", "PROBLEM", 382, 386], ["YFV", "PROBLEM", 388, 391], ["WNV", "PROBLEM", 393, 396], ["non-tropical (WNV", "PROBLEM", 402, 419], ["sense RNA viruses", "OBSERVATION", 169, 186], ["Zika virus", "OBSERVATION", 200, 210]]], ["Indeed, around 100 million people get symptomatic DENV infection each year, resulting in hundreds of thousands of severe cases and about 10 000 deaths in tropical and sub-tropical countries [25] .", [["DENV infection", "DISEASE", 50, 64], ["deaths", "DISEASE", 144, 150], ["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["DENV", "SPECIES", 50, 54], ["symptomatic DENV infection", "PROBLEM", 38, 64], ["severe cases", "PROBLEM", 114, 126], ["infection", "OBSERVATION", 55, 64], ["severe", "OBSERVATION_MODIFIER", 114, 120]]], ["Picornaviruses are small non-enveloped RNA viruses responsible for a very wide variety of diseases including the common cold which is caused by rhinoviruses.", [["rhinoviruses", "ORGANISM", 144, 156], ["Picornaviruses", "PROBLEM", 0, 14], ["small non-enveloped RNA viruses", "PROBLEM", 19, 50], ["a very wide variety of diseases", "PROBLEM", 67, 98], ["the common cold", "PROBLEM", 109, 124], ["rhinoviruses", "PROBLEM", 144, 156], ["small", "OBSERVATION_MODIFIER", 19, 24], ["non-enveloped RNA viruses", "OBSERVATION", 25, 50], ["very", "OBSERVATION_MODIFIER", 69, 73], ["wide", "OBSERVATION_MODIFIER", 74, 78], ["variety", "OBSERVATION_MODIFIER", 79, 86], ["diseases", "OBSERVATION", 90, 98], ["common cold", "OBSERVATION_MODIFIER", 113, 124], ["rhinoviruses", "OBSERVATION", 144, 156]]], ["However, picarnoviruses are also responsible for countless devastating epidemics, such as poliomyelitis caused by polioviruses, and hand, foot and mouth disease commonly caused by coxsackievirus A16 or enterovirus 71 (EV71) [26, 27] .Viruses affected by flavaglinesHepatitis E Virus (HEV) is a positive-sense single-stranded RNA virus member of the Hepeviridae family that represents a major cause of acute hepatitis in developing countries, but also in Europe and America [28] .Viruses affected by flavaglinesInfluenza A viruses (IAV) are negative-sense single-stranded RNA viruses that infect approximately 3 to 5 million people and kill up to 650 000 people each year [29] .Viruses affected by flavaglinesCoronaviruses represent a large family of RNA viruses that usually cause mild respiratory tract infections in animals and humans.", [["hand", "ANATOMY", 132, 136], ["foot", "ANATOMY", 138, 142], ["mouth", "ANATOMY", 147, 152], ["respiratory tract", "ANATOMY", 786, 803], ["poliomyelitis", "DISEASE", 90, 103], ["hand, foot and mouth disease", "DISEASE", 132, 160], ["coxsackievirus A16 or enterovirus 71", "DISEASE", 180, 216], ["EV71", "DISEASE", 218, 222], ["flavaglines", "CHEMICAL", 254, 265], ["Hepatitis E", "DISEASE", 265, 276], ["hepatitis", "DISEASE", 407, 416], ["flavaglines", "CHEMICAL", 499, 510], ["Influenza A viruses", "DISEASE", 510, 529], ["flavaglines", "CHEMICAL", 697, 708], ["respiratory tract infections", "DISEASE", 786, 814], ["picarnoviruses", "GENE_OR_GENE_PRODUCT", 9, 23], ["hand", "ORGANISM_SUBDIVISION", 132, 136], ["foot", "ORGANISM_SUBDIVISION", 138, 142], ["mouth", "ORGANISM_SUBDIVISION", 147, 152], ["coxsackievirus A16", "ORGANISM", 180, 198], ["enterovirus 71", "ORGANISM", 202, 216], ["EV71", "ORGANISM", 218, 222], ["Hepatitis E Virus", "ORGANISM", 265, 282], ["HEV", "ORGANISM", 284, 287], ["Hepeviridae", "GENE_OR_GENE_PRODUCT", 349, 360], ["Influenza A viruses", "ORGANISM", 510, 529], ["IAV", "ORGANISM", 531, 534], ["people", "ORGANISM", 624, 630], ["people", "ORGANISM", 654, 660], ["tract", "ORGANISM_SUBDIVISION", 798, 803], ["humans", "ORGANISM", 830, 836], ["Hepatitis E Virus", "SPECIES", 265, 282], ["Influenza A viruses", "SPECIES", 510, 529], ["people", "SPECIES", 624, 630], ["people", "SPECIES", 654, 660], ["humans", "SPECIES", 830, 836], ["coxsackievirus A16", "SPECIES", 180, 198], ["EV71", "SPECIES", 218, 222], ["Hepatitis E Virus", "SPECIES", 265, 282], ["HEV", "SPECIES", 284, 287], ["Influenza A viruses", "SPECIES", 510, 529], ["IAV", "SPECIES", 531, 534], ["humans", "SPECIES", 830, 836], ["picarnoviruses", "PROBLEM", 9, 23], ["countless devastating epidemics", "PROBLEM", 49, 80], ["poliomyelitis", "PROBLEM", 90, 103], ["polioviruses, and hand, foot and mouth disease", "PROBLEM", 114, 160], ["coxsackievirus A16", "PROBLEM", 180, 198], ["enterovirus", "PROBLEM", 202, 213], ["Viruses", "PROBLEM", 234, 241], ["Hepatitis E Virus", "PROBLEM", 265, 282], ["acute hepatitis", "PROBLEM", 401, 416], ["Viruses", "PROBLEM", 479, 486], ["Influenza", "PROBLEM", 510, 519], ["stranded RNA viruses", "PROBLEM", 562, 582], ["Viruses", "PROBLEM", 677, 684], ["Coronaviruses", "PROBLEM", 708, 721], ["RNA viruses", "PROBLEM", 750, 761], ["mild respiratory tract infections", "PROBLEM", 781, 814], ["responsible for", "UNCERTAINTY", 33, 48], ["poliomyelitis", "OBSERVATION", 90, 103], ["polioviruses", "OBSERVATION", 114, 126], ["hand", "ANATOMY", 132, 136], ["foot", "ANATOMY", 138, 142], ["mouth", "ANATOMY", 147, 152], ["disease", "OBSERVATION", 153, 160], ["acute", "OBSERVATION_MODIFIER", 401, 406], ["hepatitis", "OBSERVATION", 407, 416], ["large", "OBSERVATION_MODIFIER", 734, 739], ["RNA viruses", "OBSERVATION", 750, 761], ["mild", "OBSERVATION_MODIFIER", 781, 785], ["respiratory tract", "ANATOMY", 786, 803], ["infections", "OBSERVATION", 804, 814]]], ["However, three new coronaviruses that cause more serious, even lethal, infections have appeared in the last two decades: -severe acute respiratory syndrome (SARS) caused by SARS-CoV in 2002, Middle East respiratory syndrome (MERS) caused by MERS-CoV, and COVID-19 caused by SARS-CoV-2.", [["infections", "DISEASE", 71, 81], ["acute respiratory syndrome", "DISEASE", 129, 155], ["SARS", "DISEASE", 157, 161], ["SARS-CoV", "DISEASE", 173, 181], ["Middle East respiratory syndrome", "DISEASE", 191, 223], ["MERS", "DISEASE", 225, 229], ["coronaviruses", "ORGANISM", 19, 32], ["SARS-CoV", "ORGANISM", 173, 181], ["MERS-CoV", "ORGANISM", 241, 249], ["SARS-CoV-2", "ORGANISM", 274, 284], ["SARS-CoV", "SPECIES", 173, 181], ["Middle East respiratory syndrome (MERS)", "SPECIES", 191, 230], ["MERS-CoV", "SPECIES", 241, 249], ["SARS-CoV", "SPECIES", 274, 282], ["infections", "PROBLEM", 71, 81], ["severe acute respiratory syndrome", "PROBLEM", 122, 155], ["SARS", "PROBLEM", 157, 161], ["SARS", "PROBLEM", 173, 177], ["Middle East respiratory syndrome", "PROBLEM", 191, 223], ["COVID", "TEST", 255, 260], ["infections", "OBSERVATION", 71, 81], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["acute", "OBSERVATION_MODIFIER", 129, 134], ["respiratory syndrome", "OBSERVATION", 135, 155], ["Middle", "ANATOMY_MODIFIER", 191, 197], ["respiratory syndrome", "OBSERVATION", 203, 223]]], ["The current absence of an effective treatment for coronavirus infections poses a great public health problem and highlights the urgent need to develop efficient treatment for these diseases.The eukaryotic initiation factor 4A (eIF4A)Protein synthesis is a complex process tightly regulated by several proteins including eukaryotic initiation factor 4F (eIF4F), a heterotrimeric complex required for ribosome recruitment to capped mRNAs ( Figure 2 ).", [["ribosome", "ANATOMY", 399, 407], ["coronavirus infections", "DISEASE", 50, 72], ["coronavirus", "ORGANISM", 50, 61], ["eukaryotic initiation factor 4A", "GENE_OR_GENE_PRODUCT", 194, 225], ["eIF4A", "GENE_OR_GENE_PRODUCT", 227, 232], ["Protein", "GENE_OR_GENE_PRODUCT", 233, 240], ["eukaryotic initiation factor 4F", "GENE_OR_GENE_PRODUCT", 320, 351], ["eIF4F", "GENE_OR_GENE_PRODUCT", 353, 358], ["ribosome", "CELLULAR_COMPONENT", 399, 407], ["eukaryotic initiation factor 4A", "PROTEIN", 194, 225], ["eIF4A", "PROTEIN", 227, 232], ["eukaryotic initiation factor 4F", "PROTEIN", 320, 351], ["eIF4F", "PROTEIN", 353, 358], ["heterotrimeric complex", "PROTEIN", 363, 385], ["capped mRNAs", "RNA", 423, 435], ["an effective treatment", "TREATMENT", 23, 45], ["coronavirus infections", "PROBLEM", 50, 72], ["efficient treatment", "TREATMENT", 151, 170], ["these diseases", "PROBLEM", 175, 189], ["The eukaryotic initiation factor 4A (eIF4A)Protein synthesis", "TREATMENT", 190, 250], ["a complex process", "PROBLEM", 254, 271], ["eukaryotic initiation factor 4F", "TREATMENT", 320, 351], ["a heterotrimeric complex", "PROBLEM", 361, 385], ["ribosome recruitment to capped mRNAs", "TREATMENT", 399, 435]]], ["The eIF4F complex is composed of the helicase eIF4A, the cap-binding subunit eIF4E and the scaffold protein eIF4G that recruits the 40S ribosomal subunit to mRNA.", [["eIF4F", "GENE_OR_GENE_PRODUCT", 4, 9], ["eIF4A", "GENE_OR_GENE_PRODUCT", 46, 51], ["eIF4E", "GENE_OR_GENE_PRODUCT", 77, 82], ["eIF4G", "GENE_OR_GENE_PRODUCT", 108, 113], ["eIF4F complex", "PROTEIN", 4, 17], ["helicase eIF4A", "PROTEIN", 37, 51], ["cap-binding subunit", "PROTEIN", 57, 76], ["eIF4E", "PROTEIN", 77, 82], ["scaffold protein", "PROTEIN", 91, 107], ["eIF4G", "PROTEIN", 108, 113], ["40S ribosomal subunit", "PROTEIN", 132, 153], ["mRNA", "RNA", 157, 161], ["the helicase eIF4A", "TREATMENT", 33, 51], ["the cap-binding subunit eIF4E", "TREATMENT", 53, 82], ["the scaffold protein eIF4G", "TREATMENT", 87, 113], ["eIF4F", "OBSERVATION_MODIFIER", 4, 9], ["complex", "OBSERVATION_MODIFIER", 10, 17], ["protein eIF4G", "OBSERVATION", 100, 113]]], ["The helicase eIF4A unwinds a small number of cellular messenger RNAs (mRNAs), for instance those that harbor guanine-rich motifs forming G-quadruplexes in their 5'-untranslated region (5'-UTR) to facilitate binding of the 43S preinitiation complex [30, 31] .", [["cellular", "ANATOMY", 45, 53], ["guanine", "CHEMICAL", 109, 116], ["guanine", "CHEMICAL", 109, 116], ["eIF4A", "GENE_OR_GENE_PRODUCT", 13, 18], ["cellular", "CELL", 45, 53], ["G-quadruplexes", "GENE_OR_GENE_PRODUCT", 137, 151], ["43S", "GENE_OR_GENE_PRODUCT", 222, 225], ["helicase eIF4A", "PROTEIN", 4, 18], ["cellular messenger RNAs", "RNA", 45, 68], ["mRNAs", "RNA", 70, 75], ["guanine-rich motifs", "DNA", 109, 128], ["5'-untranslated region", "DNA", 161, 183], ["5'-UTR", "DNA", 185, 191], ["43S preinitiation complex", "PROTEIN", 222, 247], ["harbor guanine", "TREATMENT", 102, 116], ["small", "OBSERVATION_MODIFIER", 29, 34], ["messenger RNAs", "OBSERVATION", 54, 68]]], ["Importantly, most of these RNAs code for proteins involved in the etiology of cancers, explaining why eIF4A inhibitors exhibit potent anticancer effects without major toxicity to the organism.", [["cancers", "ANATOMY", 78, 85], ["anticancer", "ANATOMY", 134, 144], ["cancers", "DISEASE", 78, 85], ["toxicity", "DISEASE", 167, 175], ["cancers", "CANCER", 78, 85], ["eIF4A", "GENE_OR_GENE_PRODUCT", 102, 107], ["anticancer", "CANCER", 134, 144], ["eIF4A", "PROTEIN", 102, 107], ["cancers", "PROBLEM", 78, 85], ["eIF4A inhibitors", "TREATMENT", 102, 118], ["potent anticancer effects", "PROBLEM", 127, 152], ["major toxicity to the organism", "PROBLEM", 161, 191], ["cancers", "OBSERVATION", 78, 85]]], ["Flavaglines are the most characterized and potent inhibitors of eIF4A.", [["Flavaglines", "CHEMICAL", 0, 11], ["Flavaglines", "CHEMICAL", 0, 11], ["Flavaglines", "SIMPLE_CHEMICAL", 0, 11], ["eIF4A", "GENE_OR_GENE_PRODUCT", 64, 69], ["eIF4A", "PROTEIN", 64, 69], ["Flavaglines", "TREATMENT", 0, 11], ["potent inhibitors of eIF4A", "TREATMENT", 43, 69], ["most characterized", "OBSERVATION_MODIFIER", 20, 38]]], ["Their mode action was exemplified with rocaglamide by Iwasaki, Ito, Ingolia and coll.", [["rocaglamide", "CHEMICAL", 39, 50], ["rocaglamide", "CHEMICAL", 39, 50], ["rocaglamide", "SIMPLE_CHEMICAL", 39, 50], ["rocaglamide", "TREATMENT", 39, 50]]], ["Rocaglamide binds to a bimolecular cavity that is formed between eIF4A and a purine-rich RNA.", [["Rocaglamide", "CHEMICAL", 0, 11], ["purine", "CHEMICAL", 77, 83], ["Rocaglamide", "CHEMICAL", 0, 11], ["purine", "CHEMICAL", 77, 83], ["Rocaglamide", "SIMPLE_CHEMICAL", 0, 11], ["eIF4A", "GENE_OR_GENE_PRODUCT", 65, 70], ["purine", "SIMPLE_CHEMICAL", 77, 83], ["eIF4A", "PROTEIN", 65, 70], ["purine-rich RNA", "RNA", 77, 92], ["Rocaglamide binds", "TREATMENT", 0, 17], ["bimolecular cavity", "OBSERVATION", 23, 41], ["rich RNA", "OBSERVATION", 84, 92]]], ["Uniquely, the binding takes place only following an RNA-induced change in the structure of eIF4A.", [["eIF4A", "GENE_OR_GENE_PRODUCT", 91, 96], ["eIF4A", "PROTEIN", 91, 96], ["an RNA-induced change in the structure of eIF4A", "PROBLEM", 49, 96]]], ["The stable eIF4A-rocaglamide-RNA complexes block scanning ribosomes and consequently repress translation from the targeted mRNAs.", [["eIF4A", "GENE_OR_GENE_PRODUCT", 11, 16], ["ribosomes", "CELLULAR_COMPONENT", 58, 67], ["eIF4A", "PROTEIN", 11, 16], ["rocaglamide-RNA complexes", "PROTEIN", 17, 42], ["targeted mRNAs", "RNA", 114, 128], ["eIF4A-rocaglamide-RNA complexes block scanning ribosomes", "TREATMENT", 11, 67], ["stable", "OBSERVATION_MODIFIER", 4, 10], ["eIF4A", "OBSERVATION", 11, 16]]], ["In addition, since eIF4A is trapped to mRNAs, it is no longer available to be included in the eIF4F complex, thereby inhibiting eIF4F-dependent mRNA translation and preventing the recycling of eIF4A.", [["eIF4A", "GENE_OR_GENE_PRODUCT", 19, 24], ["eIF4F", "GENE_OR_GENE_PRODUCT", 94, 99], ["eIF4F", "GENE_OR_GENE_PRODUCT", 128, 133], ["eIF4A", "GENE_OR_GENE_PRODUCT", 193, 198], ["eIF4A", "PROTEIN", 19, 24], ["mRNAs", "RNA", 39, 44], ["eIF4F complex", "PROTEIN", 94, 107], ["eIF4F", "PROTEIN", 128, 133], ["eIF4A", "PROTEIN", 193, 198], ["eIF4A", "TREATMENT", 19, 24], ["eIF4F-dependent mRNA translation", "TREATMENT", 128, 160], ["the recycling of eIF4A", "TREATMENT", 176, 198], ["no longer", "UNCERTAINTY", 52, 61]]], ["As a consequence, eIF4A is no longer available for other mRNAs.Figure 2.Structure and role in viral translation of the eIF4F complex. eIF4F includes the helicase eIF4A that unwinds the highly structured 5' untranslated region (5'-UTR) sequence of some viral RNAs, the cap-binding protein eIF4E, and the scaffold protein eIF4G.", [["eIF4A", "GENE_OR_GENE_PRODUCT", 18, 23], ["eIF4F", "GENE_OR_GENE_PRODUCT", 119, 124], ["eIF4F", "GENE_OR_GENE_PRODUCT", 134, 139], ["eIF4A", "GENE_OR_GENE_PRODUCT", 162, 167], ["cap-binding protein", "GENE_OR_GENE_PRODUCT", 268, 287], ["eIF4E", "GENE_OR_GENE_PRODUCT", 288, 293], ["eIF4G", "GENE_OR_GENE_PRODUCT", 320, 325], ["eIF4A", "PROTEIN", 18, 23], ["mRNAs", "RNA", 57, 62], ["eIF4F complex", "PROTEIN", 119, 132], ["eIF4F", "PROTEIN", 134, 139], ["helicase eIF4A", "PROTEIN", 153, 167], ["5' untranslated region", "DNA", 203, 225], ["5'-UTR) sequence", "DNA", 227, 243], ["viral RNAs", "RNA", 252, 262], ["cap-binding protein", "PROTEIN", 268, 287], ["eIF4E", "PROTEIN", 288, 293], ["scaffold protein", "PROTEIN", 303, 319], ["eIF4G", "PROTEIN", 320, 325], ["the helicase eIF4A", "TREATMENT", 149, 167], ["some viral RNAs", "PROBLEM", 247, 262], ["the cap", "TEST", 264, 271], ["the scaffold protein eIF4G", "TREATMENT", 299, 325], ["no longer", "UNCERTAINTY", 27, 36], ["viral translation", "OBSERVATION", 94, 111], ["eIF4F complex", "OBSERVATION", 119, 132], ["highly", "OBSERVATION_MODIFIER", 185, 191], ["viral RNAs", "OBSERVATION", 252, 262], ["protein eIF4G", "OBSERVATION", 312, 325]]], ["Flavaglines stabilize the interaction between eIF4A and the 5'UTR by altering the conformation of both eIF4A and the mRNA.", [["Flavaglines", "CHEMICAL", 0, 11], ["Flavaglines", "CHEMICAL", 0, 11], ["Flavaglines", "SIMPLE_CHEMICAL", 0, 11], ["eIF4A", "GENE_OR_GENE_PRODUCT", 46, 51], ["eIF4A", "GENE_OR_GENE_PRODUCT", 103, 108], ["eIF4A", "PROTEIN", 46, 51], ["5'UTR", "DNA", 60, 65], ["eIF4A", "PROTEIN", 103, 108], ["mRNA", "RNA", 117, 121], ["Flavaglines", "TREATMENT", 0, 11], ["eIF4A", "TREATMENT", 46, 51], ["the 5'UTR", "TREATMENT", 56, 65]]], ["As a consequence, eIF4A recycling is blocked, which leads to an inhibition of cap-dependent translation.", [["eIF4A", "GENE_OR_GENE_PRODUCT", 18, 23], ["cap", "GENE_OR_GENE_PRODUCT", 78, 81], ["eIF4A", "PROTEIN", 18, 23], ["eIF4A recycling", "TREATMENT", 18, 33]]], ["AUG, translation initiation codon.", [["AUG", "DNA", 0, 3], ["translation initiation codon", "DNA", 5, 33], ["initiation codon", "OBSERVATION", 17, 33]]], ["40S, small ribosome subunit, m 7 G, 7methylguanosine located at the 5' end of the mRNA to which eIF4E binds.Figure 2.Recently, a synthetic flavagline developed by the eFFECTOR Therapeutics company, Zotatifin (also called eFT226, 4, Figure 1 ) has entered a phase 1/2 clinical trial against advanced solid tumors refractory or intolerant to standard treatments [19] .", [["solid tumors", "ANATOMY", 299, 311], ["flavagline", "CHEMICAL", 139, 149], ["Zotatifin", "CHEMICAL", 198, 207], ["tumors", "DISEASE", 305, 311], ["7methylguanosine", "CHEMICAL", 36, 52], ["flavagline", "CHEMICAL", 139, 149], ["Zotatifin", "CHEMICAL", 198, 207], ["40S", "GENE_OR_GENE_PRODUCT", 0, 3], ["m 7 G", "GENE_OR_GENE_PRODUCT", 29, 34], ["7methylguanosine", "AMINO_ACID", 36, 52], ["eIF4E", "GENE_OR_GENE_PRODUCT", 96, 101], ["flavagline", "SIMPLE_CHEMICAL", 139, 149], ["Zotatifin", "SIMPLE_CHEMICAL", 198, 207], ["solid tumors", "CANCER", 299, 311], ["40S", "PROTEIN", 0, 3], ["small ribosome subunit", "PROTEIN", 5, 27], ["5' end", "RNA", 68, 74], ["mRNA", "RNA", 82, 86], ["eIF4E", "PROTEIN", 96, 101], ["small ribosome subunit", "TREATMENT", 5, 27], ["7methylguanosine", "TREATMENT", 36, 52], ["a synthetic flavagline", "TREATMENT", 127, 149], ["Zotatifin", "TREATMENT", 198, 207], ["advanced solid tumors", "PROBLEM", 290, 311], ["standard treatments", "TREATMENT", 340, 359], ["small", "OBSERVATION_MODIFIER", 5, 10], ["ribosome subunit", "OBSERVATION", 11, 27], ["eIF4E binds", "OBSERVATION", 96, 107], ["tumors", "OBSERVATION", 305, 311]]], ["While it was shown to inhibit eIF4A, its putative effect on PHB signaling has not yet been disclosed.", [["eIF4A", "GENE_OR_GENE_PRODUCT", 30, 35], ["PHB", "GENE_OR_GENE_PRODUCT", 60, 63], ["eIF4A", "PROTEIN", 30, 35], ["PHB", "PROTEIN", 60, 63]]], ["A first description of the structure-activity relationships of flavaglines for the inhibition of eIF4A was disclosed in 2012 and 2014 [33, 34] .", [["flavaglines", "CHEMICAL", 63, 74], ["flavaglines", "CHEMICAL", 63, 74], ["flavaglines", "SIMPLE_CHEMICAL", 63, 74], ["eIF4A", "GENE_OR_GENE_PRODUCT", 97, 102], ["eIF4A", "PROTEIN", 97, 102], ["flavaglines", "TREATMENT", 63, 74], ["the inhibition of eIF4A", "PROBLEM", 79, 102]]], ["This model was more recently refined by Porco, Pelletier and collaborators [35] [36] [37] and also by eFFECTOR scientists [20] .Flavaglines as antiviral eIF4A inhibitorsMany viral mRNAs contain highly structured 5'-UTRs, suggesting that eIF4A inhibitors may block viral replication [21] .", [["Flavaglines", "CHEMICAL", 128, 139], ["Flavaglines", "CHEMICAL", 128, 139], ["Flavaglines", "SIMPLE_CHEMICAL", 128, 139], ["eIF4A", "GENE_OR_GENE_PRODUCT", 153, 158], ["eIF4A", "GENE_OR_GENE_PRODUCT", 237, 242], ["eIF4A", "PROTEIN", 153, 158], ["viral mRNAs", "RNA", 174, 185], ["5'-UTRs", "DNA", 212, 219], ["eIF4A", "PROTEIN", 237, 242], ["Flavaglines", "TREATMENT", 128, 139], ["antiviral eIF4A inhibitors", "TREATMENT", 143, 169], ["viral mRNAs", "TEST", 174, 185], ["eIF4A inhibitors", "TREATMENT", 237, 253], ["block viral replication", "TREATMENT", 258, 281]]], ["Indeed, Gr\u00fcnweller and collaborators found that silvestrol, at low nanomolar concentrations that are not toxic to cells, blocks viral mRNA translation and viral replication of Ebola virus and MERS-CoV in cells [6, 7] .", [["cells", "ANATOMY", 114, 119], ["cells", "ANATOMY", 204, 209], ["silvestrol", "CHEMICAL", 48, 58], ["silvestrol", "CHEMICAL", 48, 58], ["silvestrol", "SIMPLE_CHEMICAL", 48, 58], ["cells", "CELL", 114, 119], ["Ebola virus", "ORGANISM", 176, 187], ["MERS-CoV", "ORGANISM", 192, 200], ["cells", "CELL", 204, 209], ["viral mRNA", "RNA", 128, 138], ["Ebola virus", "SPECIES", 176, 187], ["Ebola virus", "SPECIES", 176, 187], ["MERS-CoV", "SPECIES", 192, 200], ["silvestrol", "PROBLEM", 48, 58], ["low nanomolar concentrations", "PROBLEM", 63, 91], ["toxic to cells", "PROBLEM", 105, 119], ["blocks viral mRNA translation", "PROBLEM", 121, 150], ["Ebola virus", "PROBLEM", 176, 187], ["CoV in cells", "PROBLEM", 197, 209], ["Ebola virus", "OBSERVATION", 176, 187]]], ["Silvestrol also blocked the replication of poliovirus type 1, but at higher concentrations with an EC 50 value of 20 nM [7] .Flavaglines as antiviral eIF4A inhibitorsSchnierle and collaborators showed that silvestrol inhibits the production of viral proteins and the replication of CHIKV in infected cells at low nanomolar concentrations [8] .", [["EC", "ANATOMY", 99, 101], ["cells", "ANATOMY", 300, 305], ["Silvestrol", "CHEMICAL", 0, 10], ["Flavaglines", "CHEMICAL", 125, 136], ["silvestrol", "CHEMICAL", 206, 216], ["Silvestrol", "CHEMICAL", 0, 10], ["Flavaglines", "CHEMICAL", 125, 136], ["silvestrol", "CHEMICAL", 206, 216], ["Silvestrol", "SIMPLE_CHEMICAL", 0, 10], ["poliovirus type 1", "ORGANISM", 43, 60], ["Flavaglines", "SIMPLE_CHEMICAL", 125, 136], ["eIF4A", "GENE_OR_GENE_PRODUCT", 150, 155], ["silvestrol", "SIMPLE_CHEMICAL", 206, 216], ["CHIKV", "ORGANISM", 282, 287], ["cells", "CELL", 300, 305], ["viral proteins", "PROTEIN", 244, 258], ["infected cells", "CELL_TYPE", 291, 305], ["poliovirus type 1", "SPECIES", 43, 60], ["CHIKV", "SPECIES", 282, 287], ["Silvestrol", "TREATMENT", 0, 10], ["poliovirus type 1", "PROBLEM", 43, 60], ["an EC", "TEST", 96, 101], ["Flavaglines", "TREATMENT", 125, 136], ["antiviral eIF4A inhibitors", "TREATMENT", 140, 166], ["silvestrol", "PROBLEM", 206, 216], ["viral proteins", "PROBLEM", 244, 258], ["CHIKV", "PROBLEM", 282, 287], ["infected cells at low nanomolar concentrations", "TREATMENT", 291, 337], ["poliovirus", "OBSERVATION", 43, 53]]], ["Importantly, silvestrol inhibited the production of the viral nsP2 protein that inhibits STAT1 to evade the innate immune system.Flavaglines as antiviral eIF4A inhibitorsHepatitis E virus (HEV) has a short 5'-UTR without a complex secondary RNA structure, but it still requires eIF4A for its replication [38] .", [["silvestrol", "CHEMICAL", 13, 23], ["Flavaglines", "CHEMICAL", 129, 140], ["Hepatitis E", "DISEASE", 170, 181], ["silvestrol", "CHEMICAL", 13, 23], ["Flavaglines", "CHEMICAL", 129, 140], ["silvestrol", "SIMPLE_CHEMICAL", 13, 23], ["nsP2", "GENE_OR_GENE_PRODUCT", 62, 66], ["STAT1", "GENE_OR_GENE_PRODUCT", 89, 94], ["Flavaglines", "SIMPLE_CHEMICAL", 129, 140], ["eIF4A", "GENE_OR_GENE_PRODUCT", 154, 159], ["Hepatitis E virus", "ORGANISM", 170, 187], ["HEV", "ORGANISM", 189, 192], ["eIF4A", "GENE_OR_GENE_PRODUCT", 278, 283], ["viral nsP2 protein", "PROTEIN", 56, 74], ["STAT1", "PROTEIN", 89, 94], ["eIF4A", "PROTEIN", 154, 159], ["short 5'-UTR", "DNA", 200, 212], ["eIF4A", "PROTEIN", 278, 283], ["Hepatitis E virus", "SPECIES", 170, 187], ["Hepatitis E virus", "SPECIES", 170, 187], ["HEV", "SPECIES", 189, 192], ["the viral nsP2 protein", "PROBLEM", 52, 74], ["Flavaglines", "TREATMENT", 129, 140], ["antiviral eIF4A inhibitors", "TREATMENT", 144, 170], ["Hepatitis E virus", "PROBLEM", 170, 187], ["a short 5'-UTR", "PROBLEM", 198, 212], ["a complex secondary RNA structure", "PROBLEM", 221, 254], ["viral nsP2", "OBSERVATION", 56, 66]]], ["Accordingly, Hildt and collaborators showed that silvestrol induced a significant reduction in viral particle release and viral protein biosynthesis in infected cells at low nanomolar concentrations [9] .", [["cells", "ANATOMY", 161, 166], ["silvestrol", "CHEMICAL", 49, 59], ["silvestrol", "CHEMICAL", 49, 59], ["silvestrol", "SIMPLE_CHEMICAL", 49, 59], ["cells", "CELL", 161, 166], ["viral protein", "PROTEIN", 122, 135], ["infected cells", "CELL_TYPE", 152, 166], ["a significant reduction", "PROBLEM", 68, 91], ["viral particle release", "TREATMENT", 95, 117], ["viral protein biosynthesis", "TREATMENT", 122, 148], ["infected cells", "PROBLEM", 152, 166], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["reduction", "OBSERVATION_MODIFIER", 82, 91], ["viral particle", "OBSERVATION", 95, 109], ["infected cells", "OBSERVATION", 152, 166]]], ["Independently, and at the same time, Steinmann and collaborators also found that silvestrol inhibits the replication of many subgenomic replicons in an additive manner with the clinically used antiviral drug ribavirin [10] .", [["silvestrol", "CHEMICAL", 81, 91], ["ribavirin", "CHEMICAL", 208, 217], ["silvestrol", "CHEMICAL", 81, 91], ["ribavirin", "CHEMICAL", 208, 217], ["silvestrol", "SIMPLE_CHEMICAL", 81, 91], ["ribavirin", "SIMPLE_CHEMICAL", 208, 217], ["subgenomic replicons", "DNA", 125, 145], ["silvestrol inhibits", "PROBLEM", 81, 100], ["many subgenomic replicons", "TREATMENT", 120, 145], ["antiviral drug ribavirin", "TREATMENT", 193, 217], ["subgenomic replicons", "OBSERVATION", 125, 145]]], ["Indeed, silvestrol (0.3 mg/kg ip.) rapidly and significantly lowered the amount of HEV RNA in the feces of humanized mice, while no effect was observed in control mice.", [["feces", "ANATOMY", 98, 103], ["silvestrol", "CHEMICAL", 8, 18], ["silvestrol", "CHEMICAL", 8, 18], ["silvestrol", "SIMPLE_CHEMICAL", 8, 18], ["HEV", "ORGANISM", 83, 86], ["feces", "ORGANISM_SUBDIVISION", 98, 103], ["mice", "ORGANISM", 117, 121], ["mice", "ORGANISM", 163, 167], ["HEV RNA", "RNA", 83, 90], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 163, 167], ["HEV", "SPECIES", 83, 86], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 163, 167], ["silvestrol", "TREATMENT", 8, 18], ["HEV RNA", "TREATMENT", 83, 90], ["HEV RNA", "OBSERVATION", 83, 90]]], ["At this stage, this is a unique study that reports an antiviral effect in vivo of a flavagline due to an inhibition of eIF4A.Flavaglines as antiviral eIF4A inhibitorsHildt and collaborators showed that silvestrol inhibits eiF4A dependent Zika virus translation of two strains originating from French Polynesia and Uganda [11] .", [["flavagline", "CHEMICAL", 84, 94], ["Flavaglines", "CHEMICAL", 125, 136], ["silvestrol", "CHEMICAL", 202, 212], ["eiF4A", "CHEMICAL", 222, 227], ["flavagline", "CHEMICAL", 84, 94], ["Flavaglines", "CHEMICAL", 125, 136], ["silvestrol", "CHEMICAL", 202, 212], ["flavagline", "SIMPLE_CHEMICAL", 84, 94], ["eIF4A", "GENE_OR_GENE_PRODUCT", 119, 124], ["Flavaglines", "SIMPLE_CHEMICAL", 125, 136], ["eIF4A", "GENE_OR_GENE_PRODUCT", 150, 155], ["silvestrol", "SIMPLE_CHEMICAL", 202, 212], ["eiF4A", "GENE_OR_GENE_PRODUCT", 222, 227], ["Zika virus", "ORGANISM", 238, 248], ["eIF4A", "PROTEIN", 119, 124], ["antiviral eIF4A inhibitors", "PROTEIN", 140, 166], ["eiF4A", "PROTEIN", 222, 227], ["Zika virus", "SPECIES", 238, 248], ["a unique study", "TEST", 23, 37], ["a flavagline", "TREATMENT", 82, 94], ["an inhibition of eIF4A", "TREATMENT", 102, 124], ["Flavaglines", "TREATMENT", 125, 136], ["antiviral eIF4A inhibitors", "TREATMENT", 140, 166], ["silvestrol inhibits eiF4A dependent", "PROBLEM", 202, 237], ["antiviral effect", "OBSERVATION", 54, 70], ["eiF4A dependent", "OBSERVATION", 222, 237]]], ["Silvestrol strongly reduced viral replication after 48 h and 72 h at non-toxic concentrations in primary human hepatocytes.Flavaglines as antiviral eIF4A inhibitorsInfluenza A virus (IAV) hijacks the host protein synthesis machinery to express its proteins and prevents this machinery from being blocked by cytoplasmic stress granule formation thanks to the viral nonstructural protein 1 (NS1) [39] .", [["hepatocytes", "ANATOMY", 111, 122], ["cytoplasmic", "ANATOMY", 307, 318], ["granule", "ANATOMY", 326, 333], ["Silvestrol", "CHEMICAL", 0, 10], ["Flavaglines", "CHEMICAL", 123, 134], ["Silvestrol", "CHEMICAL", 0, 10], ["Flavaglines", "CHEMICAL", 123, 134], ["Silvestrol", "SIMPLE_CHEMICAL", 0, 10], ["human", "ORGANISM", 105, 110], ["hepatocytes", "CELL", 111, 122], ["Flavaglines", "SIMPLE_CHEMICAL", 123, 134], ["eIF4A", "GENE_OR_GENE_PRODUCT", 148, 153], ["Influenza A virus", "ORGANISM", 164, 181], ["IAV", "ORGANISM", 183, 186], ["cytoplasmic", "ORGANISM_SUBSTANCE", 307, 318], ["stress granule", "CELLULAR_COMPONENT", 319, 333], ["viral nonstructural protein 1", "GENE_OR_GENE_PRODUCT", 358, 387], ["NS1", "GENE_OR_GENE_PRODUCT", 389, 392], ["primary human hepatocytes", "CELL_TYPE", 97, 122], ["eIF4A", "PROTEIN", 148, 153], ["viral nonstructural protein 1", "PROTEIN", 358, 387], ["NS1", "PROTEIN", 389, 392], ["human", "SPECIES", 105, 110], ["Influenza A virus", "SPECIES", 164, 181], ["human", "SPECIES", 105, 110], ["Influenza A virus", "SPECIES", 164, 181], ["IAV", "SPECIES", 183, 186], ["Silvestrol strongly reduced viral replication", "TREATMENT", 0, 45], ["Flavaglines", "TREATMENT", 123, 134], ["antiviral eIF4A inhibitors", "TREATMENT", 138, 164], ["Influenza A virus (IAV)", "TREATMENT", 164, 187], ["the host protein synthesis machinery", "TREATMENT", 196, 232], ["cytoplasmic stress granule formation", "PROBLEM", 307, 343], ["the viral nonstructural protein", "TEST", 354, 385], ["reduced", "OBSERVATION_MODIFIER", 20, 27], ["viral replication", "OBSERVATION", 28, 45], ["hepatocytes", "ANATOMY", 111, 122], ["stress granule formation", "OBSERVATION", 319, 343]]], ["Stress granules are composed of mRNAs, translation initiation complexes and other RNA-binding proteins that can redirect translation following a stress.", [["Stress granules", "ANATOMY", 0, 15], ["granules", "ORGANISM_SUBSTANCE", 7, 15], ["RNA-binding proteins", "GENE_OR_GENE_PRODUCT", 82, 102], ["mRNAs", "RNA", 32, 37], ["translation initiation complexes", "PROTEIN", 39, 71], ["RNA-binding proteins", "PROTEIN", 82, 102], ["Stress granules", "PROBLEM", 0, 15], ["other RNA-binding proteins", "PROBLEM", 76, 102]]], ["They can be induced by eIF4A inhibitors such as flavaglines [40] .", [["flavaglines", "CHEMICAL", 48, 59], ["eIF4A", "GENE_OR_GENE_PRODUCT", 23, 28], ["eIF4A", "PROTEIN", 23, 28], ["eIF4A inhibitors", "TREATMENT", 23, 39]]], ["McCormick and collaborators showed that silvestrol induces the formation of stress granules in several cell lines leading to an inhibition of viral protein accumulation and genome replication [12] .Flavaglines as antiviral eIF4A inhibitorsGr\u00fcnweller and collaborators showed that 10 nM silvestrol significantly inhibits the translation of mRNAs harboring 5\u2032-UTRs derived from the human coronavirus HCoV-229E associated with common cold symptoms and the highly pathogenic MERS-CoV [7] .", [["stress granules", "ANATOMY", 76, 91], ["cell lines", "ANATOMY", 103, 113], ["silvestrol", "CHEMICAL", 40, 50], ["Flavaglines", "CHEMICAL", 198, 209], ["silvestrol", "CHEMICAL", 286, 296], ["HCoV-229E", "CHEMICAL", 398, 407], ["silvestrol", "CHEMICAL", 40, 50], ["Flavaglines", "CHEMICAL", 198, 209], ["silvestrol", "CHEMICAL", 286, 296], ["silvestrol", "SIMPLE_CHEMICAL", 40, 50], ["stress granules", "CELLULAR_COMPONENT", 76, 91], ["cell lines", "CELL", 103, 113], ["Flavaglines", "SIMPLE_CHEMICAL", 198, 209], ["eIF4A", "GENE_OR_GENE_PRODUCT", 223, 228], ["silvestrol", "SIMPLE_CHEMICAL", 286, 296], ["human", "ORGANISM", 380, 385], ["coronavirus HCoV-229E", "ORGANISM", 386, 407], ["MERS-CoV", "ORGANISM", 471, 479], ["cell lines", "CELL_LINE", 103, 113], ["viral protein", "PROTEIN", 142, 155], ["mRNAs", "RNA", 339, 344], ["5\u2032-UTRs", "DNA", 355, 362], ["human", "SPECIES", 380, 385], ["coronavirus", "SPECIES", 386, 397], ["human coronavirus HCoV-229E", "SPECIES", 380, 407], ["MERS-CoV", "SPECIES", 471, 479], ["stress granules", "PROBLEM", 76, 91], ["several cell lines", "TREATMENT", 95, 113], ["viral protein accumulation", "PROBLEM", 142, 168], ["genome replication", "TREATMENT", 173, 191], ["Flavaglines", "TREATMENT", 198, 209], ["antiviral eIF4A inhibitors", "TREATMENT", 213, 239], ["nM silvestrol", "TEST", 283, 296], ["mRNAs harboring", "TEST", 339, 354], ["the human coronavirus HCoV", "TEST", 376, 402], ["common cold symptoms", "PROBLEM", 424, 444], ["stress granules", "OBSERVATION", 76, 91], ["several cell lines", "OBSERVATION", 95, 113], ["viral protein accumulation", "OBSERVATION", 142, 168]]], ["Silvestrol diminished the viral titer of these two viruses in human fetal lung fibroblast (MRC-5) cells, with EC 50 values of 1.3 nM and 3 nM respectively (EC 90 : 27 an 12 nM).", [["fetal lung fibroblast (MRC-5) cells", "ANATOMY", 68, 103], ["EC", "ANATOMY", 110, 112], ["Silvestrol", "CHEMICAL", 0, 10], ["Silvestrol", "CHEMICAL", 0, 10], ["Silvestrol", "SIMPLE_CHEMICAL", 0, 10], ["human", "ORGANISM", 62, 67], ["fetal lung fibroblast (MRC-5) cells", "CELL", 68, 103], ["EC", "CELL", 110, 112], ["human fetal lung fibroblast (MRC-5) cells", "CELL_LINE", 62, 103], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["Silvestrol diminished", "PROBLEM", 0, 21], ["the viral titer", "TEST", 22, 37], ["human fetal lung fibroblast", "TEST", 62, 89], ["MRC", "TEST", 91, 94], ["cells", "TEST", 98, 103], ["EC", "TEST", 110, 112], ["nM", "TEST", 130, 132], ["EC", "TEST", 156, 158], ["viral titer", "OBSERVATION", 26, 37], ["two", "OBSERVATION_MODIFIER", 47, 50], ["viruses", "OBSERVATION", 51, 58], ["fetal", "ANATOMY_MODIFIER", 68, 73], ["lung", "ANATOMY", 74, 78], ["fibroblast", "OBSERVATION", 79, 89]]], ["The antiviral effect of silvestrol was also found in peripheral blood mononuclear cells (PBMCs) with similar EC 50 values.", [["peripheral blood mononuclear cells", "ANATOMY", 53, 87], ["PBMCs", "ANATOMY", 89, 94], ["EC", "ANATOMY", 109, 111], ["silvestrol", "CHEMICAL", 24, 34], ["silvestrol", "CHEMICAL", 24, 34], ["silvestrol", "SIMPLE_CHEMICAL", 24, 34], ["peripheral blood mononuclear cells", "CELL", 53, 87], ["PBMCs", "CELL", 89, 94], ["EC", "CELL", 109, 111], ["peripheral blood mononuclear cells", "CELL_TYPE", 53, 87], ["PBMCs", "CELL_TYPE", 89, 94], ["peripheral blood mononuclear cells", "PROBLEM", 53, 87], ["PBMCs", "TEST", 89, 94], ["antiviral effect", "OBSERVATION", 4, 20], ["peripheral", "ANATOMY_MODIFIER", 53, 63], ["blood", "ANATOMY", 64, 69], ["mononuclear cells", "OBSERVATION", 70, 87]]], ["At 100 nM, silvestrol abolished the production of double-stranded RNA (dsRNA) and the HCoV-229E nsp8 protein in MRC-5 cells.Flavaglines as antiviral eIF4A inhibitorsRecently, this team compared for the first time the antiviral effects of silvestrol with another flavagline known to inhibit eIF4A, in this case CR-31-B (5) [13] .", [["MRC-5 cells", "ANATOMY", 112, 123], ["silvestrol", "CHEMICAL", 11, 21], ["Flavaglines", "CHEMICAL", 124, 135], ["silvestrol", "CHEMICAL", 238, 248], ["flavagline", "CHEMICAL", 262, 272], ["CR-31-B", "CHEMICAL", 310, 317], ["silvestrol", "CHEMICAL", 11, 21], ["Flavaglines", "CHEMICAL", 124, 135], ["silvestrol", "CHEMICAL", 238, 248], ["flavagline", "CHEMICAL", 262, 272], ["CR-31-B", "CHEMICAL", 310, 317], ["silvestrol", "SIMPLE_CHEMICAL", 11, 21], ["HCoV-229E nsp8", "GENE_OR_GENE_PRODUCT", 86, 100], ["MRC-5 cells", "CELL", 112, 123], ["Flavaglines", "SIMPLE_CHEMICAL", 124, 135], ["eIF4A", "GENE_OR_GENE_PRODUCT", 149, 154], ["silvestrol", "SIMPLE_CHEMICAL", 238, 248], ["flavagline", "SIMPLE_CHEMICAL", 262, 272], ["eIF4A", "GENE_OR_GENE_PRODUCT", 290, 295], ["double-stranded RNA", "RNA", 50, 69], ["HCoV-229E nsp8 protein", "PROTEIN", 86, 108], ["MRC-5 cells", "CELL_LINE", 112, 123], ["eIF4A", "PROTEIN", 149, 154], ["eIF4A", "PROTEIN", 290, 295], ["double-stranded RNA (dsRNA", "PROBLEM", 50, 76], ["the HCoV", "TEST", 82, 90], ["MRC", "TEST", 112, 115], ["Flavaglines", "TREATMENT", 124, 135], ["antiviral eIF4A inhibitors", "TREATMENT", 139, 165], ["silvestrol", "TREATMENT", 238, 248], ["another flavagline", "TREATMENT", 254, 272], ["this case CR", "TEST", 300, 312]]], ["Both compounds were found to display potent in vitro antiviral activities at similar non-cytotoxic concentration in the low nanomolar range against HCoV-229E, MERS-CoV, ZIKV, Lassa virus and Crimean-Congo hemorrhagic fever virus.Prohibitin signalingProhibitins-1 and -2 (PHB1/2) are evolutionary conserved scaffold proteins that control a myriad of signaling pathways [41] .", [["Crimean-Congo hemorrhagic fever", "DISEASE", 191, 222], ["HCoV-229E", "CELL", 148, 157], ["MERS-CoV", "ORGANISM", 159, 167], ["ZIKV", "ORGANISM", 169, 173], ["Lassa virus", "ORGANISM", 175, 186], ["Crimean-Congo hemorrhagic fever virus", "ORGANISM", 191, 228], ["Prohibitin", "GENE_OR_GENE_PRODUCT", 229, 239], ["Prohibitins-1", "GENE_OR_GENE_PRODUCT", 249, 262], ["-2", "GENE_OR_GENE_PRODUCT", 267, 269], ["PHB1", "GENE_OR_GENE_PRODUCT", 271, 275], ["2", "GENE_OR_GENE_PRODUCT", 276, 277], ["Prohibitin signalingProhibitins-1 and -2 (PHB1/2", "PROTEIN", 229, 277], ["scaffold proteins", "PROTEIN", 306, 323], ["Lassa virus", "SPECIES", 175, 186], ["Crimean-Congo hemorrhagic fever virus", "SPECIES", 191, 228], ["HCoV-229E", "SPECIES", 148, 157], ["MERS-CoV", "SPECIES", 159, 167], ["ZIKV", "SPECIES", 169, 173], ["Lassa virus", "SPECIES", 175, 186], ["Crimean-Congo hemorrhagic fever virus", "SPECIES", 191, 228], ["vitro antiviral activities", "TREATMENT", 47, 73], ["HCoV", "TEST", 148, 152], ["MERS", "PROBLEM", 159, 163], ["CoV", "PROBLEM", 164, 167], ["ZIKV", "PROBLEM", 169, 173], ["Lassa virus", "PROBLEM", 175, 186], ["Crimean", "TEST", 191, 198], ["Congo hemorrhagic fever virus", "PROBLEM", 199, 228], ["Prohibitin signalingProhibitins", "TEST", 229, 260], ["low nanomolar", "OBSERVATION_MODIFIER", 120, 133], ["hemorrhagic", "OBSERVATION_MODIFIER", 205, 216], ["scaffold proteins", "OBSERVATION", 306, 323]]], ["The multiple functions of PHBs are regulated not only by phosphorylation at different positions by Akt, Cam kinase IV, Aurora A, protein kinase C (PKC), Lyn and insulin receptor, but also by N-myristoylation, palmitoylation, tyrosine nitrosylation and sulfatation, transamidation, arginine deamination and O-GlcNAc modifications.", [["tyrosine", "CHEMICAL", 225, 233], ["arginine", "CHEMICAL", 281, 289], ["O-GlcNAc", "CHEMICAL", 306, 314], ["N", "CHEMICAL", 191, 192], ["tyrosine", "CHEMICAL", 225, 233], ["arginine", "CHEMICAL", 281, 289], ["O-GlcNAc", "CHEMICAL", 306, 314], ["PHBs", "GENE_OR_GENE_PRODUCT", 26, 30], ["Akt", "GENE_OR_GENE_PRODUCT", 99, 102], ["Cam kinase IV", "GENE_OR_GENE_PRODUCT", 104, 117], ["Aurora A", "GENE_OR_GENE_PRODUCT", 119, 127], ["protein kinase C", "GENE_OR_GENE_PRODUCT", 129, 145], ["PKC", "GENE_OR_GENE_PRODUCT", 147, 150], ["Lyn", "GENE_OR_GENE_PRODUCT", 153, 156], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 161, 177], ["tyrosine", "AMINO_ACID", 225, 233], ["arginine", "SIMPLE_CHEMICAL", 281, 289], ["O-GlcNAc", "SIMPLE_CHEMICAL", 306, 314], ["PHBs", "PROTEIN", 26, 30], ["Akt", "PROTEIN", 99, 102], ["Cam kinase IV", "PROTEIN", 104, 117], ["Aurora A", "PROTEIN", 119, 127], ["protein kinase C", "PROTEIN", 129, 145], ["PKC", "PROTEIN", 147, 150], ["Lyn", "PROTEIN", 153, 156], ["insulin receptor", "PROTEIN", 161, 177], ["Akt", "TEST", 99, 102], ["Cam kinase IV", "TEST", 104, 117], ["Aurora A, protein kinase C", "TEST", 119, 145], ["PKC", "TEST", 147, 150], ["Lyn and insulin receptor", "TREATMENT", 153, 177], ["palmitoylation", "TREATMENT", 209, 223], ["tyrosine nitrosylation", "TREATMENT", 225, 247], ["sulfatation", "TREATMENT", 252, 263], ["transamidation", "TREATMENT", 265, 279], ["arginine deamination", "TREATMENT", 281, 301], ["GlcNAc modifications", "TREATMENT", 308, 328], ["multiple", "OBSERVATION_MODIFIER", 4, 12]]], ["These post-translational modifications position PHBs in various cellular compartments and also regulate the interaction with their protein partners.", [["cellular compartments", "ANATOMY", 64, 85], ["PHBs", "GENE_OR_GENE_PRODUCT", 48, 52], ["cellular", "CELL", 64, 72], ["PHBs", "PROTEIN", 48, 52], ["These post-translational modifications position PHBs", "TREATMENT", 0, 52]]], ["PHBs are found in mitochondria, the endoplasmic reticulum, peroxisomes, the cytosol, the nucleus and the plasma membrane [42] .", [["mitochondria", "ANATOMY", 18, 30], ["endoplasmic reticulum", "ANATOMY", 36, 57], ["peroxisomes", "ANATOMY", 59, 70], ["cytosol", "ANATOMY", 76, 83], ["nucleus", "ANATOMY", 89, 96], ["plasma membrane", "ANATOMY", 105, 120], ["PHBs", "GENE_OR_GENE_PRODUCT", 0, 4], ["mitochondria", "CELLULAR_COMPONENT", 18, 30], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 36, 57], ["peroxisomes", "CELLULAR_COMPONENT", 59, 70], ["cytosol", "CELLULAR_COMPONENT", 76, 83], ["nucleus", "CELLULAR_COMPONENT", 89, 96], ["plasma membrane", "CELLULAR_COMPONENT", 105, 120], ["PHBs", "PROTEIN", 0, 4], ["the plasma membrane", "TEST", 101, 120], ["endoplasmic reticulum", "OBSERVATION", 36, 57], ["peroxisomes", "OBSERVATION_MODIFIER", 59, 70], ["nucleus", "ANATOMY", 89, 96], ["plasma membrane", "OBSERVATION", 105, 120]]], ["In the plasma membrane, PHBs are involved in cell-cell communication, the immune response, the activation of signaling kinases such as C-RAF or IKK, and also in the viral entry of DENV 2, hepatitis C virus (HCV), CHIKV and EV71.Flavaglines as antiviral PHB ligandsIn contrast to the role of eIF4A in viral replication [19] , the implication of PHBs in viral replication has not yet been reviewed.", [["plasma membrane", "ANATOMY", 7, 22], ["PHBs", "ANATOMY", 24, 28], ["cell", "ANATOMY", 45, 49], ["cell", "ANATOMY", 50, 54], ["hepatitis C", "DISEASE", 188, 199], ["EV71", "DISEASE", 223, 227], ["Flavaglines", "CHEMICAL", 228, 239], ["Flavaglines", "CHEMICAL", 228, 239], ["PHB", "CHEMICAL", 253, 256], ["plasma membrane", "CELLULAR_COMPONENT", 7, 22], ["PHBs", "GENE_OR_GENE_PRODUCT", 24, 28], ["cell", "CELL", 45, 49], ["cell", "CELL", 50, 54], ["C-RAF", "GENE_OR_GENE_PRODUCT", 135, 140], ["IKK", "GENE_OR_GENE_PRODUCT", 144, 147], ["DENV 2", "ORGANISM", 180, 186], ["hepatitis C virus", "ORGANISM", 188, 205], ["HCV", "ORGANISM", 207, 210], ["CHIKV", "ORGANISM", 213, 218], ["EV71", "ORGANISM", 223, 227], ["Flavaglines", "SIMPLE_CHEMICAL", 228, 239], ["eIF4A", "GENE_OR_GENE_PRODUCT", 291, 296], ["PHBs", "GENE_OR_GENE_PRODUCT", 344, 348], ["PHBs", "PROTEIN", 24, 28], ["signaling kinases", "PROTEIN", 109, 126], ["C-RAF", "PROTEIN", 135, 140], ["IKK", "PROTEIN", 144, 147], ["antiviral PHB ligands", "PROTEIN", 243, 264], ["eIF4A", "PROTEIN", 291, 296], ["PHBs", "PROTEIN", 344, 348], ["hepatitis C virus", "SPECIES", 188, 205], ["hepatitis C virus", "SPECIES", 188, 205], ["HCV", "SPECIES", 207, 210], ["CHIKV", "SPECIES", 213, 218], ["EV71", "SPECIES", 223, 227], ["signaling kinases", "PROBLEM", 109, 126], ["C-RAF", "PROBLEM", 135, 140], ["IKK", "PROBLEM", 144, 147], ["DENV", "PROBLEM", 180, 184], ["hepatitis C virus (HCV)", "PROBLEM", 188, 211], ["CHIKV", "PROBLEM", 213, 218], ["EV71", "PROBLEM", 223, 227], ["Flavaglines", "TREATMENT", 228, 239], ["antiviral PHB ligands", "TREATMENT", 243, 264], ["eIF4A in viral replication", "TREATMENT", 291, 317], ["PHBs in viral replication", "TREATMENT", 344, 369], ["plasma membrane", "ANATOMY", 7, 22], ["cell-cell communication", "OBSERVATION", 45, 68], ["DENV", "OBSERVATION", 180, 184], ["viral replication", "OBSERVATION", 352, 369]]], ["Several families of small molecules targeting PHBs, including flavaglines, have been shown to display promising activities in some animal models of cancers, osteoporosis, inflammation, cardiac and neurodegenerative diseases [41] , and also some viral infections, notably for inhibiting viral entry.Flavaglines as antiviral PHB ligandsDuncan Smith and collaborators were the first ones, in 2010, to show that a virus, in this case, DENV 2, interacts with PHBs to enter into cells (Figure 3 ) [43] .", [["cancers", "ANATOMY", 148, 155], ["cardiac", "ANATOMY", 185, 192], ["cells", "ANATOMY", 473, 478], ["PHBs", "CHEMICAL", 46, 50], ["flavaglines", "CHEMICAL", 62, 73], ["cancers", "DISEASE", 148, 155], ["osteoporosis", "DISEASE", 157, 169], ["inflammation", "DISEASE", 171, 183], ["cardiac and neurodegenerative diseases", "DISEASE", 185, 223], ["viral infections", "DISEASE", 245, 261], ["Flavaglines", "CHEMICAL", 298, 309], ["flavaglines", "CHEMICAL", 62, 73], ["Flavaglines", "CHEMICAL", 298, 309], ["PHB", "CHEMICAL", 323, 326], ["PHBs", "GENE_OR_GENE_PRODUCT", 46, 50], ["flavaglines", "SIMPLE_CHEMICAL", 62, 73], ["cancers", "CANCER", 148, 155], ["cardiac", "ORGAN", 185, 192], ["Flavaglines", "SIMPLE_CHEMICAL", 298, 309], ["DENV 2", "ORGANISM", 431, 437], ["PHBs", "GENE_OR_GENE_PRODUCT", 454, 458], ["cells", "CELL", 473, 478], ["PHBs", "PROTEIN", 46, 50], ["antiviral PHB ligands", "PROTEIN", 313, 334], ["PHBs", "PROTEIN", 454, 458], ["DENV", "SPECIES", 431, 435], ["small molecules targeting PHBs", "PROBLEM", 20, 50], ["cancers", "PROBLEM", 148, 155], ["osteoporosis", "PROBLEM", 157, 169], ["inflammation", "PROBLEM", 171, 183], ["cardiac and neurodegenerative diseases", "PROBLEM", 185, 223], ["some viral infections", "PROBLEM", 240, 261], ["inhibiting viral entry", "PROBLEM", 275, 297], ["Flavaglines", "TREATMENT", 298, 309], ["antiviral PHB ligands", "TREATMENT", 313, 334], ["a virus", "PROBLEM", 408, 415], ["DENV", "PROBLEM", 431, 435], ["small", "OBSERVATION_MODIFIER", 20, 25], ["cancers", "OBSERVATION", 148, 155], ["osteoporosis", "OBSERVATION", 157, 169], ["inflammation", "OBSERVATION", 171, 183], ["cardiac", "ANATOMY", 185, 192], ["neurodegenerative", "OBSERVATION_MODIFIER", 197, 214], ["diseases", "OBSERVATION", 215, 223], ["viral", "OBSERVATION_MODIFIER", 245, 250], ["infections", "OBSERVATION", 251, 261], ["virus", "OBSERVATION", 410, 415]]], ["DENV has four serotypes (DENV 1-4) that are transmitted to humans by Aedes aegypti and A. albopictus mosquitoes [44] .", [["DENV", "ORGANISM", 0, 4], ["DENV 1-4", "ORGANISM", 25, 33], ["humans", "ORGANISM", 59, 65], ["Aedes aegypti", "ORGANISM", 69, 82], ["A. albopictus mosquitoes", "ORGANISM", 87, 111], ["humans", "SPECIES", 59, 65], ["Aedes aegypti", "SPECIES", 69, 82], ["A. albopictus", "SPECIES", 87, 100], ["DENV", "SPECIES", 0, 4], ["humans", "SPECIES", 59, 65], ["Aedes aegypti", "SPECIES", 69, 82], ["A. albopictus", "SPECIES", 87, 100], ["DENV", "PROBLEM", 0, 4], ["four serotypes (DENV", "PROBLEM", 9, 29], ["four", "OBSERVATION_MODIFIER", 9, 13], ["serotypes", "OBSERVATION_MODIFIER", 14, 23]]], ["Each of these four serotypes can induce dengue fever, dengue hemorrhagic fever, and dengue shock syndrome.", [["dengue fever", "DISEASE", 40, 52], ["dengue hemorrhagic fever", "DISEASE", 54, 78], ["dengue shock syndrome", "DISEASE", 84, 105], ["dengue hemorrhagic fever", "SPECIES", 54, 78], ["dengue fever", "PROBLEM", 40, 52], ["dengue hemorrhagic fever", "PROBLEM", 54, 78], ["dengue shock syndrome", "PROBLEM", 84, 105], ["hemorrhagic", "OBSERVATION_MODIFIER", 61, 72], ["fever", "OBSERVATION", 73, 78], ["dengue", "OBSERVATION_MODIFIER", 84, 90], ["shock syndrome", "OBSERVATION", 91, 105]]], ["Using a combination of separation methodologies, virus overlay protein binding assays and mass spectrometry, they identified PHBs as the first DENV receptor in Aedes mosquitoes.", [["PHBs", "GENE_OR_GENE_PRODUCT", 125, 129], ["Aedes mosquitoes", "ORGANISM", 160, 176], ["PHBs", "PROTEIN", 125, 129], ["DENV receptor", "PROTEIN", 143, 156], ["Aedes mosquitoes", "SPECIES", 160, 176], ["separation methodologies", "TREATMENT", 23, 47], ["virus overlay protein binding assays", "TEST", 49, 85], ["mass spectrometry", "TEST", 90, 107]]], ["Next, the DENV 2 envelope (E) protein was shown to be coimmunoprecipitated and colocalized with PHB1.", [["DENV 2 envelope (E)", "GENE_OR_GENE_PRODUCT", 10, 29], ["PHB1", "GENE_OR_GENE_PRODUCT", 96, 100], ["DENV 2 envelope (E) protein", "PROTEIN", 10, 37], ["PHB1", "PROTEIN", 96, 100], ["the DENV 2 envelope (E) protein", "TEST", 6, 37], ["DENV", "OBSERVATION", 10, 14]]], ["Recently, using similar approaches, Desai and collaborators showed that DENV 3 also interacts with both PHB1 and PHB2 to enter into neuronal, astroglial and microglial cells [45] .", [["neuronal", "ANATOMY", 132, 140], ["astroglial", "ANATOMY", 142, 152], ["microglial cells", "ANATOMY", 157, 173], ["DENV 3", "ORGANISM", 72, 78], ["PHB1", "GENE_OR_GENE_PRODUCT", 104, 108], ["PHB2", "GENE_OR_GENE_PRODUCT", 113, 117], ["neuronal", "CELL", 132, 140], ["astroglial", "CELL", 142, 152], ["microglial cells", "CELL", 157, 173], ["DENV 3", "PROTEIN", 72, 78], ["PHB1", "PROTEIN", 104, 108], ["PHB2", "PROTEIN", 113, 117], ["neuronal, astroglial and microglial cells", "CELL_TYPE", 132, 173], ["DENV", "SPECIES", 72, 76], ["DENV", "PROBLEM", 72, 76], ["DENV", "OBSERVATION", 72, 76], ["microglial cells", "OBSERVATION", 157, 173]]], ["Smith and collaborators also identified PHB1 as the first CHIKV receptor in mammalian cells [46] .", [["cells", "ANATOMY", 86, 91], ["PHB1", "GENE_OR_GENE_PRODUCT", 40, 44], ["mammalian cells", "CELL", 76, 91], ["PHB1", "PROTEIN", 40, 44], ["CHIKV receptor", "PROTEIN", 58, 72], ["mammalian cells", "CELL_TYPE", 76, 91], ["CHIKV", "SPECIES", 58, 63]]], ["Using a combination of different techniques, they demonstrated that PHB1 (but not PHB2) interacts with the CHIKV E2 protein to mediate viral entry into microglial cells.", [["microglial cells", "ANATOMY", 152, 168], ["E2", "CHEMICAL", 113, 115], ["PHB1", "GENE_OR_GENE_PRODUCT", 68, 72], ["PHB2", "GENE_OR_GENE_PRODUCT", 82, 86], ["E2", "GENE_OR_GENE_PRODUCT", 113, 115], ["microglial cells", "CELL", 152, 168], ["PHB1", "PROTEIN", 68, 72], ["PHB2", "PROTEIN", 82, 86], ["CHIKV E2 protein", "PROTEIN", 107, 123], ["microglial cells", "CELL_TYPE", 152, 168], ["CHIKV", "SPECIES", 107, 112], ["different techniques", "TREATMENT", 23, 43], ["PHB1", "PROBLEM", 68, 72], ["the CHIKV E2 protein", "TREATMENT", 103, 123], ["microglial cells", "OBSERVATION", 152, 168]]], ["Considering that both DENV and CHIKV, which belong to very different families of RNA viruses use both PHBs as a receptor, it may be possible that PHBs also act as receptors for other human viruses.Flavaglines as antiviral PHB ligandsThereafter this team found that two synthetic flavaglines, FL3 (6, Figure 1 ) and FL23 (7), and another PHB ligand structurally unrelated to flavaglines, were all able to inhibit CHIKV infection in mammalian cells and reduce viral production when cells were treated before infection [14] .", [["mammalian cells", "ANATOMY", 431, 446], ["cells", "ANATOMY", 480, 485], ["Flavaglines", "CHEMICAL", 197, 208], ["flavaglines", "CHEMICAL", 279, 290], ["FL3", "CHEMICAL", 292, 295], ["FL23", "CHEMICAL", 315, 319], ["flavaglines", "CHEMICAL", 374, 385], ["infection", "DISEASE", 418, 427], ["infection", "DISEASE", 506, 515], ["Flavaglines", "CHEMICAL", 197, 208], ["PHB", "CHEMICAL", 222, 225], ["flavaglines", "CHEMICAL", 279, 290], ["FL3", "CHEMICAL", 292, 295], ["FL23", "CHEMICAL", 315, 319], ["PHB", "CHEMICAL", 337, 340], ["flavaglines", "CHEMICAL", 374, 385], ["DENV", "ORGANISM", 22, 26], ["CHIKV", "ORGANISM", 31, 36], ["PHBs", "GENE_OR_GENE_PRODUCT", 102, 106], ["PHBs", "GENE_OR_GENE_PRODUCT", 146, 150], ["human", "ORGANISM", 183, 188], ["Flavaglines", "SIMPLE_CHEMICAL", 197, 208], ["flavaglines", "SIMPLE_CHEMICAL", 279, 290], ["FL3", "SIMPLE_CHEMICAL", 292, 295], ["FL23 (7)", "SIMPLE_CHEMICAL", 315, 323], ["flavaglines", "SIMPLE_CHEMICAL", 374, 385], ["CHIKV", "ORGANISM", 412, 417], ["mammalian cells", "CELL", 431, 446], ["cells", "CELL", 480, 485], ["PHBs", "PROTEIN", 102, 106], ["PHBs", "PROTEIN", 146, 150], ["antiviral PHB ligands", "PROTEIN", 212, 233], ["mammalian cells", "CELL_TYPE", 431, 446], ["human", "SPECIES", 183, 188], ["DENV", "SPECIES", 22, 26], ["CHIKV", "SPECIES", 31, 36], ["human", "SPECIES", 183, 188], ["CHIKV", "SPECIES", 412, 417], ["both DENV", "PROBLEM", 17, 26], ["CHIKV", "PROBLEM", 31, 36], ["RNA viruses", "PROBLEM", 81, 92], ["PHBs", "PROBLEM", 146, 150], ["other human viruses", "PROBLEM", 177, 196], ["Flavaglines", "TREATMENT", 197, 208], ["antiviral PHB ligands", "TREATMENT", 212, 233], ["two synthetic flavaglines", "TEST", 265, 290], ["Figure", "TEST", 300, 306], ["FL23", "TEST", 315, 319], ["another PHB ligand", "PROBLEM", 329, 347], ["CHIKV infection in mammalian cells", "PROBLEM", 412, 446], ["viral production when cells", "PROBLEM", 458, 485], ["infection", "PROBLEM", 506, 515], ["DENV", "OBSERVATION", 22, 26], ["CHIKV", "OBSERVATION", 31, 36]]], ["Pretreatment of cells for only 15 minutes prior to infection followed by washing out of the compound resulted in significant inhibition of entry and as a consequence virus production, ruling out an involvement of eIF4 in these specific effects.", [["cells", "ANATOMY", 16, 21], ["infection", "DISEASE", 51, 60], ["cells", "CELL", 16, 21], ["eIF4", "GENE_OR_GENE_PRODUCT", 213, 217], ["eIF4", "PROTEIN", 213, 217], ["Pretreatment of cells", "PROBLEM", 0, 21], ["infection", "PROBLEM", 51, 60], ["the compound", "PROBLEM", 88, 100], ["significant inhibition of entry", "PROBLEM", 113, 144], ["a consequence virus production", "PROBLEM", 152, 182], ["an involvement of eIF4", "PROBLEM", 195, 217], ["infection", "OBSERVATION", 51, 60], ["significant", "OBSERVATION_MODIFIER", 113, 124], ["inhibition", "OBSERVATION_MODIFIER", 125, 135]]], ["As discussed, silverstol inhibits viral translation [8] , indicating that the effects of flavaglines could be dual.", [["silverstol", "CHEMICAL", 14, 24], ["flavaglines", "CHEMICAL", 89, 100], ["silverstol", "CHEMICAL", 14, 24], ["flavaglines", "CHEMICAL", 89, 100], ["silverstol", "SIMPLE_CHEMICAL", 14, 24], ["flavaglines", "SIMPLE_CHEMICAL", 89, 100], ["flavaglines", "TREATMENT", 89, 100]]], ["On one hand they could inhibit PHBdependent entry of CHIKV into microglial cells, and on the other hand they could block viral mRNA translation.Flavaglines as antiviral PHB ligandsWang and collaborators found that PHBs in lipid rafts interact with viral glycoprotein E2 to promote the entry of chronic hepatitis C virus (HCV) into hepatocytes at a post-binding step through the activation of the kinase C-RAF [15] .", [["microglial cells", "ANATOMY", 64, 80], ["lipid rafts", "ANATOMY", 222, 233], ["hepatocytes", "ANATOMY", 331, 342], ["Flavaglines", "CHEMICAL", 144, 155], ["PHBs", "CHEMICAL", 214, 218], ["E2", "CHEMICAL", 267, 269], ["chronic hepatitis C", "DISEASE", 294, 313], ["Flavaglines", "CHEMICAL", 144, 155], ["PHB", "CHEMICAL", 169, 172], ["PHBdependent", "SIMPLE_CHEMICAL", 31, 43], ["CHIKV", "ORGANISM", 53, 58], ["microglial cells", "CELL", 64, 80], ["Flavaglines", "SIMPLE_CHEMICAL", 144, 155], ["PHBs", "SIMPLE_CHEMICAL", 214, 218], ["lipid rafts", "CELLULAR_COMPONENT", 222, 233], ["E2", "GENE_OR_GENE_PRODUCT", 267, 269], ["chronic hepatitis C virus", "ORGANISM", 294, 319], ["HCV", "ORGANISM", 321, 324], ["hepatocytes", "CELL", 331, 342], ["C-RAF", "GENE_OR_GENE_PRODUCT", 403, 408], ["microglial cells", "CELL_TYPE", 64, 80], ["viral mRNA", "RNA", 121, 131], ["antiviral PHB ligands", "PROTEIN", 159, 180], ["PHBs", "PROTEIN", 214, 218], ["viral glycoprotein E2", "PROTEIN", 248, 269], ["hepatocytes", "CELL_TYPE", 331, 342], ["kinase C", "PROTEIN", 396, 404], ["RAF", "PROTEIN", 405, 408], ["hepatitis C virus", "SPECIES", 302, 319], ["CHIKV", "SPECIES", 53, 58], ["hepatitis C virus", "SPECIES", 302, 319], ["HCV", "SPECIES", 321, 324], ["CHIKV into microglial cells", "PROBLEM", 53, 80], ["Flavaglines", "TREATMENT", 144, 155], ["antiviral PHB ligands", "TREATMENT", 159, 180], ["PHBs in lipid rafts", "PROBLEM", 214, 233], ["viral glycoprotein E2", "TREATMENT", 248, 269], ["chronic hepatitis C virus (HCV) into hepatocytes", "PROBLEM", 294, 342], ["a post-binding step", "TREATMENT", 346, 365], ["viral mRNA", "OBSERVATION", 121, 131], ["chronic", "OBSERVATION_MODIFIER", 294, 301], ["hepatitis", "OBSERVATION", 302, 311], ["hepatocytes", "ANATOMY", 331, 342]]], ["Two flavaglines, rocaglamide and aglaroxin C (1 and 3, Figure 1 ) were found to prevent the localization of PHBs at the cell surface, and consequently to block C-RAF activation and to reduce HCV infection with an EC 50 of 4 and 0.04 nM (incubation of 48 h in Huh7.5.1 cells) respectively.", [["cell surface", "ANATOMY", 120, 132], ["EC", "ANATOMY", 213, 215], ["Huh7", "ANATOMY", 259, 263], ["5.1 cells", "ANATOMY", 264, 273], ["flavaglines", "CHEMICAL", 4, 15], ["rocaglamide", "CHEMICAL", 17, 28], ["aglaroxin", "CHEMICAL", 33, 42], ["HCV infection", "DISEASE", 191, 204], ["flavaglines", "CHEMICAL", 4, 15], ["rocaglamide", "CHEMICAL", 17, 28], ["aglaroxin C", "CHEMICAL", 33, 44], ["flavaglines", "SIMPLE_CHEMICAL", 4, 15], ["rocaglamide", "SIMPLE_CHEMICAL", 17, 28], ["aglaroxin C", "SIMPLE_CHEMICAL", 33, 44], ["PHBs", "GENE_OR_GENE_PRODUCT", 108, 112], ["cell surface", "CELLULAR_COMPONENT", 120, 132], ["C-RAF", "GENE_OR_GENE_PRODUCT", 160, 165], ["HCV", "ORGANISM", 191, 194], ["EC", "CELL", 213, 215], ["Huh7", "CELL", 259, 263], ["cells", "CELL", 268, 273], ["PHBs", "PROTEIN", 108, 112], ["RAF", "PROTEIN", 162, 165], ["Huh7", "CELL_LINE", 259, 263], ["HCV", "SPECIES", 191, 194], ["Two flavaglines", "TREATMENT", 0, 15], ["rocaglamide", "TREATMENT", 17, 28], ["aglaroxin C", "TREATMENT", 33, 44], ["C-RAF activation", "TREATMENT", 160, 176], ["HCV infection", "PROBLEM", 191, 204], ["an EC", "TEST", 210, 215], ["cell surface", "OBSERVATION", 120, 132]]], ["Thereafter Porco and collaborators synthesized aglaroxin C analogues and showed that two of them, CMLD012043 (8) and CMLD012044 (9), showed 3-fold greater inhibition of HCV infection in comparison to aglaroxin C and also with very low cytotoxicity [16] .Flavaglines as antiviral PHB ligandsThese compounds did not inhibit viral RNA replication or mRNA translation, confirming that the anti-HCV activity of these compounds is mediated through an effect on PHBs and not on eIF4A.", [["aglaroxin C", "CHEMICAL", 47, 58], ["CMLD012043", "CHEMICAL", 98, 108], ["CMLD012044", "CHEMICAL", 117, 127], ["HCV infection", "DISEASE", 169, 182], ["aglaroxin C", "CHEMICAL", 200, 211], ["Flavaglines", "CHEMICAL", 254, 265], ["aglaroxin C", "CHEMICAL", 47, 58], ["CMLD012043", "CHEMICAL", 98, 108], ["CMLD012044", "CHEMICAL", 117, 127], ["aglaroxin C", "CHEMICAL", 200, 211], ["Flavaglines", "CHEMICAL", 254, 265], ["PHB", "CHEMICAL", 279, 282], ["Porco", "SIMPLE_CHEMICAL", 11, 16], ["aglaroxin C analogues", "SIMPLE_CHEMICAL", 47, 68], ["CMLD012043", "SIMPLE_CHEMICAL", 98, 108], ["HCV", "ORGANISM", 169, 172], ["aglaroxin C", "SIMPLE_CHEMICAL", 200, 211], ["Flavaglines", "SIMPLE_CHEMICAL", 254, 265], ["PHBs", "SIMPLE_CHEMICAL", 455, 459], ["eIF4A", "GENE_OR_GENE_PRODUCT", 471, 476], ["antiviral PHB ligands", "PROTEIN", 269, 290], ["PHBs", "PROTEIN", 455, 459], ["eIF4A", "PROTEIN", 471, 476], ["HCV", "SPECIES", 169, 172], ["CMLD012043", "TEST", 98, 108], ["CMLD012044", "TEST", 117, 127], ["HCV infection", "PROBLEM", 169, 182], ["aglaroxin C", "TREATMENT", 200, 211], ["very low cytotoxicity", "PROBLEM", 226, 247], ["Flavaglines", "TREATMENT", 254, 265], ["antiviral PHB ligands", "TREATMENT", 269, 290], ["viral RNA replication", "TREATMENT", 322, 343], ["the anti-HCV activity of these compounds", "PROBLEM", 381, 421], ["PHBs", "TREATMENT", 455, 459], ["eIF4A", "TREATMENT", 471, 476], ["HCV", "OBSERVATION_MODIFIER", 169, 172], ["infection", "OBSERVATION", 173, 182]]], ["Importantly, these two compounds also significantly inhibited the infectivity of DENV and CHIKV, both of which also use PHBs as entry factors.Flavaglines as antiviral PHB ligandsEnterovirus 71 (EV71), which causes hand, foot and mouth disease, may result in neurological complications in young children.", [["hand", "ANATOMY", 214, 218], ["foot", "ANATOMY", 220, 224], ["mouth", "ANATOMY", 229, 234], ["neurological", "ANATOMY", 258, 270], ["PHBs", "CHEMICAL", 120, 124], ["Flavaglines", "CHEMICAL", 142, 153], ["EV71", "DISEASE", 194, 198], ["hand, foot and mouth disease", "DISEASE", 214, 242], ["neurological complications", "DISEASE", 258, 284], ["PHBs", "CHEMICAL", 120, 124], ["Flavaglines", "CHEMICAL", 142, 153], ["PHB", "CHEMICAL", 167, 170], ["DENV", "ORGANISM", 81, 85], ["CHIKV", "ORGANISM", 90, 95], ["PHBs", "SIMPLE_CHEMICAL", 120, 124], ["Flavaglines", "SIMPLE_CHEMICAL", 142, 153], ["Enterovirus 71", "ORGANISM", 178, 192], ["EV71", "ORGANISM", 194, 198], ["hand", "ORGANISM_SUBDIVISION", 214, 218], ["foot", "ORGANISM_SUBDIVISION", 220, 224], ["mouth", "ORGAN", 229, 234], ["children", "ORGANISM", 294, 302], ["entry factors", "PROTEIN", 128, 141], ["antiviral PHB ligands", "PROTEIN", 157, 178], ["children", "SPECIES", 294, 302], ["DENV", "SPECIES", 81, 85], ["CHIKV", "SPECIES", 90, 95], ["EV71", "SPECIES", 194, 198], ["DENV", "PROBLEM", 81, 85], ["CHIKV", "PROBLEM", 90, 95], ["Flavaglines", "TREATMENT", 142, 153], ["antiviral PHB ligands", "TREATMENT", 157, 178], ["Enterovirus", "TEST", 178, 189], ["hand, foot and mouth disease", "PROBLEM", 214, 242], ["neurological complications", "PROBLEM", 258, 284], ["infectivity", "OBSERVATION_MODIFIER", 66, 77], ["DENV", "OBSERVATION", 81, 85], ["CHIKV", "OBSERVATION", 90, 95], ["hand", "ANATOMY", 214, 218], ["foot", "ANATOMY", 220, 224], ["mouth", "ANATOMY", 229, 234], ["disease", "OBSERVATION", 235, 242]]], ["Alonso and collaborators found that EV71 uses cell surface-expressed PHB1 to facilitate its entry into neuronal cells specifically [17] .", [["cell surface", "ANATOMY", 46, 58], ["neuronal cells", "ANATOMY", 103, 117], ["EV71", "ORGANISM", 36, 40], ["cell", "CELL", 46, 50], ["PHB1", "GENE_OR_GENE_PRODUCT", 69, 73], ["neuronal cells", "CELL", 103, 117], ["PHB1", "PROTEIN", 69, 73], ["neuronal cells", "CELL_TYPE", 103, 117], ["EV71", "SPECIES", 36, 40], ["EV71", "PROBLEM", 36, 40], ["cell surface", "TEST", 46, 58]]], ["In addition, mitochondrial membrane-bound PHB1 was shown to facilitate viral replication through association with the replication complex.", [["mitochondrial membrane", "ANATOMY", 13, 35], ["mitochondrial", "CELLULAR_COMPONENT", 13, 26], ["membrane", "CELLULAR_COMPONENT", 27, 35], ["PHB1", "GENE_OR_GENE_PRODUCT", 42, 46], ["PHB1", "PROTEIN", 42, 46], ["replication complex", "PROTEIN", 118, 137], ["mitochondrial membrane-bound PHB1", "PROBLEM", 13, 46], ["viral replication", "TREATMENT", 71, 88], ["the replication complex", "TREATMENT", 114, 137], ["viral replication", "OBSERVATION", 71, 88]]], ["In line with these findings, rocaglamide was found to reduce the virus load in EV71-infected neuronal cells, due to diminution of the amount of mitochondria-associated PHB, and not through an inhibition of the C-RAF/MEK/ERK pathway.", [["neuronal cells", "ANATOMY", 93, 107], ["mitochondria", "ANATOMY", 144, 156], ["rocaglamide", "CHEMICAL", 29, 40], ["rocaglamide", "CHEMICAL", 29, 40], ["rocaglamide", "SIMPLE_CHEMICAL", 29, 40], ["EV71", "ORGANISM", 79, 83], ["neuronal cells", "CELL", 93, 107], ["mitochondria", "CELLULAR_COMPONENT", 144, 156], ["PHB", "GENE_OR_GENE_PRODUCT", 168, 171], ["C-RAF", "GENE_OR_GENE_PRODUCT", 210, 215], ["MEK", "GENE_OR_GENE_PRODUCT", 216, 219], ["ERK", "GENE_OR_GENE_PRODUCT", 220, 223], ["neuronal cells", "CELL_TYPE", 93, 107], ["PHB", "PROTEIN", 168, 171], ["RAF", "PROTEIN", 212, 215], ["MEK", "PROTEIN", 216, 219], ["ERK", "PROTEIN", 220, 223], ["EV71", "SPECIES", 79, 83], ["rocaglamide", "TREATMENT", 29, 40], ["the virus load", "PROBLEM", 61, 75], ["EV71", "PROBLEM", 79, 83], ["infected neuronal cells", "PROBLEM", 84, 107], ["associated PHB", "PROBLEM", 157, 171], ["the C", "TEST", 206, 211], ["MEK/ERK pathway", "TREATMENT", 216, 231], ["infected neuronal cells", "OBSERVATION", 84, 107], ["amount", "OBSERVATION_MODIFIER", 134, 140]]], ["In vivo, rocaglamide extended the life of EV71infected mice and lowered virus loads in the spinal cord and brain, but not in the limb muscles, indicating that flavaglines hold some potential to alleviate the neurological complications of hand, foot and mouth disease in children.Flavaglines as antiviral PHB ligandsConsidering that DENV, CHIKV, EV71 and HCV which belong to very different families of RNA viruses use PHBs as a receptor, it is likely that other viruses also interact with PHBs to infect cells.Interaction of the nonstructural protein nsp2 of SARS-CoV to prohibitins and putative implication of nsp2 in the enhanced contagiousness of SARS-CoV-2The genome of SARS-CoV-2 has about 14 open-reading frames (ORFs) that encode the four structural proteins spike (S), envelope (E), membrane (M), and nucleocapsid (N), in addition to sixteen nonstructural proteins (nsps) involved in the replication-transcription complex (RTC) [47] .", [["spinal cord", "ANATOMY", 91, 102], ["brain", "ANATOMY", 107, 112], ["limb muscles", "ANATOMY", 129, 141], ["neurological", "ANATOMY", 208, 220], ["hand", "ANATOMY", 238, 242], ["foot", "ANATOMY", 244, 248], ["mouth", "ANATOMY", 253, 258], ["cells", "ANATOMY", 503, 508], ["membrane", "ANATOMY", 790, 798], ["rocaglamide", "CHEMICAL", 9, 20], ["flavaglines", "CHEMICAL", 159, 170], ["hand, foot and mouth disease", "DISEASE", 238, 266], ["Flavaglines", "CHEMICAL", 279, 290], ["SARS", "DISEASE", 558, 562], ["SARS", "DISEASE", 649, 653], ["SARS", "DISEASE", 673, 677], ["rocaglamide", "CHEMICAL", 9, 20], ["Flavaglines", "CHEMICAL", 279, 290], ["PHB", "CHEMICAL", 304, 307], ["rocaglamide", "SIMPLE_CHEMICAL", 9, 20], ["mice", "ORGANISM", 55, 59], ["spinal cord", "ORGAN", 91, 102], ["brain", "ORGAN", 107, 112], ["limb muscles", "ORGANISM_SUBDIVISION", 129, 141], ["flavaglines", "SIMPLE_CHEMICAL", 159, 170], ["hand", "ORGANISM_SUBDIVISION", 238, 242], ["foot", "ORGANISM_SUBDIVISION", 244, 248], ["mouth", "ORGANISM_SUBDIVISION", 253, 258], ["children", "ORGANISM", 270, 278], ["Flavaglines", "SIMPLE_CHEMICAL", 279, 290], ["DENV", "ORGANISM", 332, 336], ["CHIKV", "ORGANISM", 338, 343], ["EV71", "ORGANISM", 345, 349], ["HCV", "ORGANISM", 354, 357], ["PHBs", "GENE_OR_GENE_PRODUCT", 417, 421], ["PHBs", "GENE_OR_GENE_PRODUCT", 488, 492], ["cells", "CELL", 503, 508], ["nsp2", "GENE_OR_GENE_PRODUCT", 550, 554], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 558, 566], ["prohibitins", "GENE_OR_GENE_PRODUCT", 570, 581], ["nsp2", "GENE_OR_GENE_PRODUCT", 610, 614], ["SARS-CoV-2", "ORGANISM", 649, 659], ["SARS-CoV-2", "ORGANISM", 673, 683], ["spike (S), envelope (E)", "GENE_OR_GENE_PRODUCT", 765, 788], ["membrane", "CELLULAR_COMPONENT", 790, 798], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 808, 824], ["nsps", "GENE_OR_GENE_PRODUCT", 873, 877], ["antiviral PHB ligands", "PROTEIN", 294, 315], ["PHBs", "PROTEIN", 417, 421], ["PHBs", "PROTEIN", 488, 492], ["nonstructural protein", "PROTEIN", 528, 549], ["nsp2", "PROTEIN", 550, 554], ["nsp2", "PROTEIN", 610, 614], ["SARS-CoV-2", "DNA", 673, 683], ["14 open-reading frames", "DNA", 694, 716], ["ORFs", "DNA", 718, 722], ["structural proteins spike (S), envelope (E), membrane (M)", "PROTEIN", 745, 802], ["nucleocapsid (N)", "PROTEIN", 808, 824], ["nonstructural proteins", "PROTEIN", 849, 871], ["nsps", "PROTEIN", 873, 877], ["replication-transcription complex", "PROTEIN", 895, 928], ["RTC", "PROTEIN", 930, 933], ["mice", "SPECIES", 55, 59], ["children", "SPECIES", 270, 278], ["mice", "SPECIES", 55, 59], ["DENV", "SPECIES", 332, 336], ["CHIKV", "SPECIES", 338, 343], ["EV71", "SPECIES", 345, 349], ["HCV", "SPECIES", 354, 357], ["SARS-CoV", "SPECIES", 558, 566], ["SARS-CoV", "SPECIES", 649, 657], ["SARS-CoV", "SPECIES", 673, 681], ["rocaglamide", "TREATMENT", 9, 20], ["EV71infected mice", "TREATMENT", 42, 59], ["lowered virus loads in the spinal cord and brain", "PROBLEM", 64, 112], ["flavaglines", "PROBLEM", 159, 170], ["the neurological complications of hand, foot and mouth disease in children", "PROBLEM", 204, 278], ["Flavaglines", "TREATMENT", 279, 290], ["antiviral PHB ligands", "TREATMENT", 294, 315], ["DENV", "PROBLEM", 332, 336], ["CHIKV", "PROBLEM", 338, 343], ["EV71", "PROBLEM", 345, 349], ["HCV", "PROBLEM", 354, 357], ["RNA viruses", "PROBLEM", 401, 412], ["PHBs", "TREATMENT", 417, 421], ["other viruses", "PROBLEM", 455, 468], ["PHBs to infect cells", "PROBLEM", 488, 508], ["SARS", "PROBLEM", 558, 562], ["CoV to prohibitins", "PROBLEM", 563, 581], ["nsp2", "PROBLEM", 610, 614], ["SARS", "PROBLEM", 649, 653], ["CoV", "TEST", 654, 657], ["SARS", "PROBLEM", 673, 677], ["CoV", "TEST", 678, 681], ["the four structural proteins spike", "PROBLEM", 736, 770], ["envelope (E), membrane (M), and nucleocapsid (N)", "PROBLEM", 776, 824], ["sixteen nonstructural proteins (nsps)", "PROBLEM", 841, 878], ["virus loads", "OBSERVATION", 72, 83], ["spinal cord", "ANATOMY", 91, 102], ["brain", "ANATOMY", 107, 112], ["limb muscles", "ANATOMY", 129, 141], ["neurological", "OBSERVATION_MODIFIER", 208, 220], ["complications", "OBSERVATION", 221, 234], ["hand", "ANATOMY", 238, 242], ["foot", "ANATOMY", 244, 248], ["mouth", "ANATOMY", 253, 258], ["disease", "OBSERVATION", 259, 266], ["DENV", "OBSERVATION", 332, 336], ["viruses", "OBSERVATION", 461, 468], ["nsp2", "OBSERVATION", 610, 614]]], ["Some ORFs also encode some very poorly characterized accessory proteins with no obvious effect in viral replication or pathogenicity.", [["ORFs", "DNA", 5, 9], ["accessory proteins", "PROTEIN", 53, 71], ["Some ORFs", "PROBLEM", 0, 9], ["accessory proteins", "PROBLEM", 53, 71], ["viral replication", "PROBLEM", 98, 115], ["pathogenicity", "PROBLEM", 119, 132], ["no obvious", "UNCERTAINTY", 77, 87], ["viral replication", "OBSERVATION", 98, 115], ["pathogenicity", "OBSERVATION", 119, 132]]], ["Indeed, Baric and collaborators showed that the systematic deletion of these accessory proteins does not dramatically alter the replication of SARS-CoV in vitro and in a murine model of SARS [48] .Interaction of the nonstructural protein nsp2 of SARS-CoV to prohibitins and putative implication of nsp2 in the enhanced contagiousness of SARS-CoV-2At an early stage of virus replication coronaviruses induce the formation of double-membrane vesicles (DMVs) in host cells, which serve as scaffolds for the RTCs and to protect newly synthesized viral RNA (Figure 4) [49, 50] .", [["double-membrane vesicles", "ANATOMY", 424, 448], ["DMVs", "ANATOMY", 450, 454], ["cells", "ANATOMY", 464, 469], ["RTCs", "ANATOMY", 504, 508], ["SARS", "DISEASE", 143, 147], ["SARS", "DISEASE", 186, 190], ["SARS", "DISEASE", 246, 250], ["SARS", "DISEASE", 337, 341], ["SARS-CoV", "ORGANISM", 143, 151], ["murine", "ORGANISM", 170, 176], ["nsp2", "GENE_OR_GENE_PRODUCT", 238, 242], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 246, 254], ["prohibitins", "GENE_OR_GENE_PRODUCT", 258, 269], ["nsp2", "GENE_OR_GENE_PRODUCT", 298, 302], ["SARS-CoV-2At", "ORGANISM", 337, 349], ["membrane vesicles", "CELLULAR_COMPONENT", 431, 448], ["host cells", "CELL", 459, 469], ["RTCs", "GENE_OR_GENE_PRODUCT", 504, 508], ["accessory proteins", "PROTEIN", 77, 95], ["nonstructural protein", "PROTEIN", 216, 237], ["nsp2", "PROTEIN", 238, 242], ["SARS-CoV", "PROTEIN", 246, 254], ["nsp2", "PROTEIN", 298, 302], ["host cells", "CELL_TYPE", 459, 469], ["RTCs", "CELL_TYPE", 504, 508], ["viral RNA", "RNA", 542, 551], ["murine", "SPECIES", 170, 176], ["SARS-CoV", "SPECIES", 143, 151], ["SARS-CoV", "SPECIES", 246, 254], ["SARS-CoV-2At", "SPECIES", 337, 349], ["the systematic deletion of these accessory proteins", "PROBLEM", 44, 95], ["SARS", "PROBLEM", 143, 147], ["SARS", "PROBLEM", 246, 250], ["CoV to prohibitins", "PROBLEM", 251, 269], ["nsp2", "PROBLEM", 298, 302], ["SARS", "PROBLEM", 337, 341], ["CoV", "TEST", 342, 345], ["virus replication coronaviruses", "PROBLEM", 368, 399], ["double-membrane vesicles", "TREATMENT", 424, 448], ["host cells", "PROBLEM", 459, 469], ["the RTCs", "TEST", 500, 508], ["newly synthesized viral RNA", "PROBLEM", 524, 551], ["nsp2", "OBSERVATION", 298, 302], ["virus", "OBSERVATION", 368, 373], ["membrane vesicles", "OBSERVATION", 431, 448], ["host cells", "OBSERVATION", 459, 469], ["viral RNA", "OBSERVATION", 542, 551]]], ["Buchmeier and collaborators discovered that PHB1 and PHB2 interact with nsp2 of SARS-CoV probably to divert PHB signaling and promote virus replication or to evade the innate immune system [51] .", [["SARS", "DISEASE", 80, 84], ["PHB1", "GENE_OR_GENE_PRODUCT", 44, 48], ["PHB2", "GENE_OR_GENE_PRODUCT", 53, 57], ["nsp2", "GENE_OR_GENE_PRODUCT", 72, 76], ["SARS-CoV", "ORGANISM", 80, 88], ["PHB", "GENE_OR_GENE_PRODUCT", 108, 111], ["PHB1", "PROTEIN", 44, 48], ["PHB2", "PROTEIN", 53, 57], ["nsp2", "PROTEIN", 72, 76], ["PHB", "PROTEIN", 108, 111], ["SARS-CoV", "SPECIES", 80, 88], ["SARS", "PROBLEM", 80, 84], ["CoV", "PROBLEM", 85, 88], ["PHB signaling", "PROBLEM", 108, 121], ["promote virus replication", "TREATMENT", 126, 151]]], ["This protein is located in the cytoplasmic side of the DMVs [52] .", [["cytoplasmic", "ANATOMY", 31, 42], ["cytoplasmic", "ORGANISM_SUBSTANCE", 31, 42], ["This protein", "TEST", 0, 12], ["cytoplasmic", "OBSERVATION_MODIFIER", 31, 42]]], ["Although the function of nsp2 remains unknown, nsp2 is not necessary for replication of SARS-CoV in cell culture and may therefore be involved in the inhibition of the host innate immune response.", [["cell culture", "ANATOMY", 100, 112], ["SARS", "DISEASE", 88, 92], ["nsp2", "GENE_OR_GENE_PRODUCT", 25, 29], ["nsp2", "GENE_OR_GENE_PRODUCT", 47, 51], ["SARS-CoV", "ORGANISM", 88, 96], ["cell culture", "CELL", 100, 112], ["nsp2", "PROTEIN", 25, 29], ["nsp2", "PROTEIN", 47, 51], ["SARS-CoV", "SPECIES", 88, 96], ["nsp2", "PROBLEM", 25, 29], ["nsp2", "PROBLEM", 47, 51], ["SARS", "PROBLEM", 88, 92], ["CoV in cell culture", "TEST", 93, 112]]], ["Indeed, Liu and collaborators found that nsp2 of another coronavirus (infectious bronchitis virus) inhibits protein kinase R (PKR) [53] .", [["coronavirus", "DISEASE", 57, 68], ["infectious bronchitis virus", "DISEASE", 70, 97], ["nsp2", "GENE_OR_GENE_PRODUCT", 41, 45], ["coronavirus", "ORGANISM", 57, 68], ["infectious bronchitis virus", "ORGANISM", 70, 97], ["protein kinase R", "GENE_OR_GENE_PRODUCT", 108, 124], ["PKR", "GENE_OR_GENE_PRODUCT", 126, 129], ["nsp2", "PROTEIN", 41, 45], ["protein kinase R", "PROTEIN", 108, 124], ["PKR", "PROTEIN", 126, 129], ["coronavirus", "SPECIES", 57, 68], ["infectious bronchitis virus", "SPECIES", 70, 97], ["infectious bronchitis virus", "SPECIES", 70, 97], ["nsp2", "PROBLEM", 41, 45], ["another coronavirus (infectious bronchitis virus", "PROBLEM", 49, 97], ["protein kinase R (PKR)", "TEST", 108, 130]]], ["PKR is a double-stranded-RNA-dependent kinase that phosphorylates eIF2\u03b1 to shut-down translation [54] .", [["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 66, 71], ["PKR", "PROTEIN", 0, 3], ["double-stranded-RNA-dependent kinase", "PROTEIN", 9, 45], ["eIF2\u03b1", "PROTEIN", 66, 71], ["PKR", "TEST", 0, 3]]], ["Whether SARS-CoV-2 also uses nsp2 to preserve protein synthesis and, meanwhile, enhance viral replication, has not been confirmed yet.Interaction of the nonstructural protein nsp2 of SARS-CoV to prohibitins and putative implication of nsp2 in the enhanced contagiousness of SARS-CoV-2A recent analysis of SARS-CoV-2 mutations caused by selective pressure combined with structural modeling indicates that mutations falling in the endosome-associated-protein-like domain of nsp2 stabilize this domain and enhance the contagious character of SARS-CoV-2 [55] .", [["endosome", "ANATOMY", 429, 437], ["SARS", "DISEASE", 183, 187], ["SARS", "DISEASE", 274, 278], ["SARS", "DISEASE", 305, 309], ["SARS", "DISEASE", 539, 543], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 8, 18], ["nsp2", "GENE_OR_GENE_PRODUCT", 29, 33], ["nsp2", "GENE_OR_GENE_PRODUCT", 175, 179], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 183, 191], ["prohibitins", "GENE_OR_GENE_PRODUCT", 195, 206], ["nsp2", "GENE_OR_GENE_PRODUCT", 235, 239], ["SARS-CoV-2A", "ORGANISM", 274, 285], ["SARS-CoV-2", "ORGANISM", 305, 315], ["endosome", "CELLULAR_COMPONENT", 429, 437], ["nsp2", "GENE_OR_GENE_PRODUCT", 472, 476], ["nsp2", "PROTEIN", 29, 33], ["nonstructural protein nsp2", "PROTEIN", 153, 179], ["SARS-CoV", "PROTEIN", 183, 191], ["nsp2", "PROTEIN", 235, 239], ["endosome-associated-protein-like domain", "PROTEIN", 429, 468], ["nsp2", "PROTEIN", 472, 476], ["SARS-CoV", "SPECIES", 183, 191], ["SARS-CoV", "SPECIES", 274, 282], ["SARS-CoV", "SPECIES", 305, 313], ["SARS-CoV", "SPECIES", 539, 547], ["SARS", "PROBLEM", 8, 12], ["CoV", "TEST", 13, 16], ["nsp2", "PROBLEM", 29, 33], ["preserve protein synthesis", "PROBLEM", 37, 63], ["enhance viral replication", "TREATMENT", 80, 105], ["SARS", "PROBLEM", 183, 187], ["CoV to prohibitins", "PROBLEM", 188, 206], ["nsp2", "PROBLEM", 235, 239], ["SARS", "PROBLEM", 274, 278], ["CoV", "TEST", 279, 282], ["SARS", "PROBLEM", 305, 309], ["CoV", "PROBLEM", 310, 313], ["2 mutations", "PROBLEM", 314, 325], ["selective pressure", "PROBLEM", 336, 354], ["structural modeling", "PROBLEM", 369, 388], ["mutations falling", "PROBLEM", 404, 421], ["the endosome", "TEST", 425, 437], ["nsp2 stabilize this domain", "PROBLEM", 472, 498], ["CoV", "TEST", 544, 547], ["nsp2", "OBSERVATION", 235, 239]]], ["Thus, this study suggests that manipulating the function of nsp2 may represent a therapeutic option to treat COVID-19.Involvement of LC3 in coronavirus replicationThe microtubule associated protein 1B light chain 3 (LC3) is an important autophagy marker regulated by PHBs, that interacts with PHB2 and is manipulated by coronaviruses to escape antiviral innate immunity.", [["microtubule", "ANATOMY", 167, 178], ["COVID", "DISEASE", 109, 114], ["COVID-19", "CHEMICAL", 109, 117], ["nsp2", "GENE_OR_GENE_PRODUCT", 60, 64], ["LC3", "GENE_OR_GENE_PRODUCT", 133, 136], ["coronavirus", "ORGANISM", 140, 151], ["microtubule associated protein 1B light chain 3", "GENE_OR_GENE_PRODUCT", 167, 214], ["LC3", "GENE_OR_GENE_PRODUCT", 216, 219], ["PHBs", "GENE_OR_GENE_PRODUCT", 267, 271], ["PHB2", "GENE_OR_GENE_PRODUCT", 293, 297], ["nsp2", "PROTEIN", 60, 64], ["LC3", "PROTEIN", 133, 136], ["microtubule associated protein 1B light chain 3", "PROTEIN", 167, 214], ["LC3", "PROTEIN", 216, 219], ["PHBs", "PROTEIN", 267, 271], ["PHB2", "PROTEIN", 293, 297], ["this study", "TEST", 6, 16], ["nsp2", "PROBLEM", 60, 64], ["COVID", "TEST", 109, 114], ["LC3", "PROBLEM", 133, 136], ["coronavirus replication", "TREATMENT", 140, 163], ["The microtubule associated protein", "TEST", 163, 197], ["may represent", "UNCERTAINTY", 65, 78], ["LC3", "OBSERVATION", 133, 136], ["coronavirus replication", "OBSERVATION", 140, 163], ["protein 1B", "OBSERVATION", 190, 200], ["important", "UNCERTAINTY", 227, 236], ["autophagy marker", "OBSERVATION", 237, 253]]], ["It is thus tempting to hypothesize that coronaviruses control LC3 via PHBs.", [["coronaviruses", "ORGANISM", 40, 53], ["LC3", "GENE_OR_GENE_PRODUCT", 62, 65], ["PHBs", "GENE_OR_GENE_PRODUCT", 70, 74], ["LC3", "PROTEIN", 62, 65], ["PHBs", "PROTEIN", 70, 74]]], ["Indeed, a wide variety of viruses hijack LC3 or other components of the autophagy machinery for their own replication and to escape autophagic degradation [56, 57] .", [["autophagic", "ANATOMY", 132, 142], ["LC3", "GENE_OR_GENE_PRODUCT", 41, 44], ["LC3", "PROTEIN", 41, 44], ["the autophagy machinery", "TREATMENT", 68, 91]]], ["LC3-I is a cytosolic protein that, upon autophagy induction, is cleaved and conjugated to phosphatidylethanolamine to form the active, lipidated form LC3-II.", [["cytosolic", "ANATOMY", 11, 20], ["phosphatidylethanolamine", "CHEMICAL", 90, 114], ["phosphatidylethanolamine", "CHEMICAL", 90, 114], ["LC3-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["phosphatidylethanolamine", "SIMPLE_CHEMICAL", 90, 114], ["LC3", "GENE_OR_GENE_PRODUCT", 150, 153], ["LC3-I", "PROTEIN", 0, 5], ["cytosolic protein", "PROTEIN", 11, 28], ["LC3", "PROTEIN", 150, 153], ["a cytosolic protein", "PROBLEM", 9, 28], ["autophagy induction", "TREATMENT", 40, 59], ["phosphatidylethanolamine", "TREATMENT", 90, 114], ["cytosolic protein", "OBSERVATION", 11, 28], ["active", "OBSERVATION_MODIFIER", 127, 133]]], ["LC3-II is then recruited to autophagosomal membranes to promote various forms of autophagy.", [["autophagosomal membranes", "ANATOMY", 28, 52], ["LC3-II", "GENE_OR_GENE_PRODUCT", 0, 6], ["autophagosomal membranes", "CELLULAR_COMPONENT", 28, 52], ["LC3-II", "PROTEIN", 0, 6], ["autophagy", "PROBLEM", 81, 90], ["autophagosomal membranes", "OBSERVATION", 28, 52], ["autophagy", "OBSERVATION", 81, 90]]], ["LC3-II interacts in particular with mitochondrial PHB2 to trigger mitophagy [58] .", [["mitochondrial", "ANATOMY", 36, 49], ["LC3-II", "CHEMICAL", 0, 6], ["LC3-II", "GENE_OR_GENE_PRODUCT", 0, 6], ["mitochondrial", "CELLULAR_COMPONENT", 36, 49], ["PHB2", "GENE_OR_GENE_PRODUCT", 50, 54], ["LC3-II", "PROTEIN", 0, 6], ["mitochondrial PHB2", "PROTEIN", 36, 54], ["mitochondrial PHB2", "TREATMENT", 36, 54]]], ["Recently, flavaglines have been shown to inhibit mitophagy, and a different class of PHB ligands was found to promote the conversion of LC3-I into LC3-II [59, 60] , suggesting that PHBs regulate the activity of LC3 in different contexts.Involvement of LC3 in coronavirus replicationLC3-I is also found at the surface of EDEMosomes that transport unfolded proteins from the ER to lysosomes [61] .", [["surface", "ANATOMY", 309, 316], ["ER", "ANATOMY", 373, 375], ["lysosomes", "ANATOMY", 379, 388], ["flavaglines", "CHEMICAL", 10, 21], ["flavaglines", "CHEMICAL", 10, 21], ["PHB", "CHEMICAL", 85, 88], ["flavaglines", "SIMPLE_CHEMICAL", 10, 21], ["PHB", "GENE_OR_GENE_PRODUCT", 85, 88], ["LC3-I", "GENE_OR_GENE_PRODUCT", 136, 141], ["LC3-II", "GENE_OR_GENE_PRODUCT", 147, 153], ["PHBs", "SIMPLE_CHEMICAL", 181, 185], ["LC3", "GENE_OR_GENE_PRODUCT", 211, 214], ["LC3", "GENE_OR_GENE_PRODUCT", 252, 255], ["coronavirus", "ORGANISM", 259, 270], ["replicationLC3-I", "GENE_OR_GENE_PRODUCT", 271, 287], ["surface", "CELLULAR_COMPONENT", 309, 316], ["EDEMosomes", "GENE_OR_GENE_PRODUCT", 320, 330], ["ER", "GENE_OR_GENE_PRODUCT", 373, 375], ["lysosomes", "CELLULAR_COMPONENT", 379, 388], ["flavaglines", "PROTEIN", 10, 21], ["PHB ligands", "PROTEIN", 85, 96], ["LC3-I", "PROTEIN", 136, 141], ["LC3", "PROTEIN", 147, 150], ["PHBs", "PROTEIN", 181, 185], ["LC3", "PROTEIN", 211, 214], ["LC3", "PROTEIN", 252, 255], ["coronavirus replicationLC3-I", "PROTEIN", 259, 287], ["EDEMosomes", "PROTEIN", 320, 330], ["unfolded proteins", "PROTEIN", 346, 363], ["ER", "PROTEIN", 373, 375], ["mitophagy", "PROBLEM", 49, 58], ["PHB ligands", "PROBLEM", 85, 96], ["LC3", "PROBLEM", 252, 255], ["activity", "OBSERVATION_MODIFIER", 199, 207], ["LC3", "OBSERVATION_MODIFIER", 252, 255], ["coronavirus", "OBSERVATION", 259, 270]]], ["Reggiori and colleagues showed that coronaviruses misdirect the machinery of EDEMosome formation for the generation of double-membrane vesicles (DMVs) [62] .", [["double-membrane vesicles", "ANATOMY", 119, 143], ["coronaviruses", "ORGANISM", 36, 49], ["EDEMosome", "GENE_OR_GENE_PRODUCT", 77, 86], ["membrane vesicles", "CELLULAR_COMPONENT", 126, 143], ["coronaviruses", "PROBLEM", 36, 49], ["double-membrane vesicles", "TREATMENT", 119, 143], ["coronaviruses", "OBSERVATION", 36, 49], ["membrane vesicles", "ANATOMY", 126, 143]]], ["DMVs are coated with non-lipidated LC3-I that allow them to hijack intracellular membranes for viral replication and escape autophagy, which often mediates the lysosomal degradation of viral elements [62] .", [["intracellular membranes", "ANATOMY", 67, 90], ["lysosomal", "ANATOMY", 160, 169], ["DMVs", "SIMPLE_CHEMICAL", 0, 4], ["LC3-I", "GENE_OR_GENE_PRODUCT", 35, 40], ["intracellular membranes", "CELLULAR_COMPONENT", 67, 90], ["lysosomal", "CELLULAR_COMPONENT", 160, 169], ["DMVs", "PROTEIN", 0, 4], ["non-lipidated LC3-I", "PROTEIN", 21, 40], ["viral elements", "DNA", 185, 199], ["DMVs", "PROBLEM", 0, 4], ["viral replication", "PROBLEM", 95, 112], ["escape autophagy", "PROBLEM", 117, 133], ["the lysosomal degradation of viral elements", "PROBLEM", 156, 199], ["viral elements", "OBSERVATION", 185, 199]]], ["Depletion of LC3 by specific RNA interference blocked the formation of doublemembrane vesicles, and protected cells from mouse hepatitis virus (Murine coronavirus) infection [62] .", [["doublemembrane vesicles", "ANATOMY", 71, 94], ["cells", "ANATOMY", 110, 115], ["hepatitis", "DISEASE", 127, 136], ["Murine coronavirus) infection", "DISEASE", 144, 173], ["LC3", "GENE_OR_GENE_PRODUCT", 13, 16], ["doublemembrane vesicles", "CELLULAR_COMPONENT", 71, 94], ["cells", "CELL", 110, 115], ["mouse hepatitis virus", "ORGANISM", 121, 142], ["Murine coronavirus", "ORGANISM", 144, 162], ["LC3", "PROTEIN", 13, 16], ["mouse", "SPECIES", 121, 126], ["hepatitis virus", "SPECIES", 127, 142], ["Murine coronavirus", "SPECIES", 144, 162], ["mouse hepatitis virus", "SPECIES", 121, 142], ["Murine coronavirus", "SPECIES", 144, 162], ["Depletion of LC3", "PROBLEM", 0, 16], ["specific RNA interference", "PROBLEM", 20, 45], ["doublemembrane vesicles", "PROBLEM", 71, 94], ["protected cells", "PROBLEM", 100, 115], ["mouse hepatitis virus", "PROBLEM", 121, 142], ["Murine coronavirus) infection", "PROBLEM", 144, 173], ["LC3", "OBSERVATION_MODIFIER", 13, 16], ["RNA interference", "OBSERVATION", 29, 45], ["doublemembrane vesicles", "OBSERVATION", 71, 94], ["mouse hepatitis virus", "OBSERVATION", 121, 142]]], ["Back transfection with a plasmid-expressing HA-tagged LC3 restored the infection, confirming that LC3-I is essential to coronavirus replication.Involvement of LC3 in coronavirus replicationInterestingly, LC3-I colocalizes with nsp2 at the cytosolic side of DMVs of coronaviruses [62] .", [["plasmid", "ANATOMY", 25, 32], ["cytosolic", "ANATOMY", 239, 248], ["infection", "DISEASE", 71, 80], ["HA", "GENE_OR_GENE_PRODUCT", 44, 46], ["LC3", "GENE_OR_GENE_PRODUCT", 54, 57], ["LC3-I", "GENE_OR_GENE_PRODUCT", 98, 103], ["coronavirus", "ORGANISM", 120, 131], ["LC3", "GENE_OR_GENE_PRODUCT", 159, 162], ["coronavirus", "ORGANISM", 166, 177], ["LC3-I", "GENE_OR_GENE_PRODUCT", 204, 209], ["nsp2", "GENE_OR_GENE_PRODUCT", 227, 231], ["plasmid", "DNA", 25, 32], ["HA", "PROTEIN", 44, 46], ["LC3", "PROTEIN", 54, 57], ["LC3-I", "PROTEIN", 98, 103], ["LC3", "PROTEIN", 159, 162], ["LC3-I", "PROTEIN", 204, 209], ["nsp2", "PROTEIN", 227, 231], ["DMVs", "PROTEIN", 257, 261], ["Back transfection", "PROBLEM", 0, 17], ["a plasmid", "TREATMENT", 23, 32], ["expressing HA", "PROBLEM", 33, 46], ["the infection", "PROBLEM", 67, 80], ["LC3", "TEST", 98, 101], ["coronavirus replication", "TREATMENT", 120, 143], ["LC3", "PROBLEM", 159, 162], ["coronavirus replication", "TREATMENT", 166, 189], ["nsp2", "PROBLEM", 227, 231], ["coronaviruses", "PROBLEM", 265, 278], ["infection", "OBSERVATION", 71, 80], ["coronavirus replication", "OBSERVATION", 120, 143], ["LC3", "OBSERVATION_MODIFIER", 159, 162], ["coronavirus replication", "OBSERVATION", 166, 189], ["nsp2", "OBSERVATION", 227, 231], ["coronaviruses", "OBSERVATION", 265, 278]]], ["Considering that both LC3and nsp2 interact with PHBs, one can speculate that PHBs, LC3-I and nsp2 are engaged in a joint complex.Interaction of SARS-CoV-2 proteins with prohibitins and eIF4A, and discovery of the strong in vitro antiviral activity of ZotatifinRecently, Krogan and collaborators identified host proteins that physically interact with each protein of SARS-CoV-2 [18] .", [["LC3and nsp2", "GENE_OR_GENE_PRODUCT", 22, 33], ["PHBs", "GENE_OR_GENE_PRODUCT", 48, 52], ["PHBs", "GENE_OR_GENE_PRODUCT", 77, 81], ["LC3-I", "GENE_OR_GENE_PRODUCT", 83, 88], ["nsp2", "GENE_OR_GENE_PRODUCT", 93, 97], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 144, 154], ["prohibitins", "GENE_OR_GENE_PRODUCT", 169, 180], ["eIF4A", "GENE_OR_GENE_PRODUCT", 185, 190], ["LC3and nsp2", "PROTEIN", 22, 33], ["PHBs", "PROTEIN", 48, 52], ["PHBs", "PROTEIN", 77, 81], ["LC3", "PROTEIN", 83, 86], ["I", "PROTEIN", 87, 88], ["nsp2", "PROTEIN", 93, 97], ["joint complex", "PROTEIN", 115, 128], ["SARS-CoV-2 proteins", "PROTEIN", 144, 163], ["prohibitins", "PROTEIN", 169, 180], ["eIF4A", "PROTEIN", 185, 190], ["SARS-CoV", "SPECIES", 366, 374], ["PHBs", "TEST", 77, 81], ["LC3", "TEST", 83, 86], ["nsp2", "PROBLEM", 93, 97], ["SARS", "PROBLEM", 144, 148], ["CoV", "TEST", 149, 152], ["prohibitins", "TREATMENT", 169, 180], ["eIF4A", "TREATMENT", 185, 190], ["SARS", "TEST", 366, 370], ["CoV", "TEST", 371, 374], ["joint", "ANATOMY", 115, 120]]], ["Surprisingly, they found that most of these viral proteins interact with both PHB1 and PHB2.", [["PHB1", "GENE_OR_GENE_PRODUCT", 78, 82], ["PHB2", "GENE_OR_GENE_PRODUCT", 87, 91], ["viral proteins", "PROTEIN", 44, 58], ["PHB1", "PROTEIN", 78, 82], ["PHB2", "PROTEIN", 87, 91], ["these viral proteins", "PROBLEM", 38, 58]]], ["The viral proteins that interact with PHBs are the following: three of the four structural proteins (spike (S), membrane (M), and envelope (E) proteins,) and 14 of the 16 non-structural proteins (nsp1 and nsp2 (papain-like protease), nsp4, nsp5 (3C-like protease), nsp6, nsp7, nsp8, nsp9, nsp10, nsp11and nsp12 (RNA-dependent RNA polymerase), nsp13 (helicase), nsp14 (3'-to-5' exoribonuclease), and nsp15 (mRNA cap-1 methyltransferase) and nine accessory proteins with unknown functions (ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF9c and ORF10 proteins).Interaction of SARS-CoV-2 proteins with prohibitins and eIF4A, and discovery of the strong in vitro antiviral activity of ZotatifinThese data strongly suggest that SARS-CoV-2 manipulates PHB signaling for its replication and/or host immune evasion.", [["PHBs", "GENE_OR_GENE_PRODUCT", 38, 42], ["spike (S)", "GENE_OR_GENE_PRODUCT", 101, 110], ["membrane", "CELLULAR_COMPONENT", 112, 120], ["envelope (E)", "GENE_OR_GENE_PRODUCT", 130, 142], ["nsp1", "GENE_OR_GENE_PRODUCT", 196, 200], ["nsp2", "GENE_OR_GENE_PRODUCT", 205, 209], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 211, 231], ["nsp4", "GENE_OR_GENE_PRODUCT", 234, 238], ["nsp5", "GENE_OR_GENE_PRODUCT", 240, 244], ["3C-like protease", "GENE_OR_GENE_PRODUCT", 246, 262], ["nsp6", "GENE_OR_GENE_PRODUCT", 265, 269], ["nsp7", "GENE_OR_GENE_PRODUCT", 271, 275], ["nsp8", "GENE_OR_GENE_PRODUCT", 277, 281], ["nsp9", "GENE_OR_GENE_PRODUCT", 283, 287], ["nsp10", "GENE_OR_GENE_PRODUCT", 289, 294], ["nsp11", "GENE_OR_GENE_PRODUCT", 296, 301], ["nsp12", "GENE_OR_GENE_PRODUCT", 305, 310], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 312, 340], ["nsp13", "GENE_OR_GENE_PRODUCT", 343, 348], ["nsp14", "GENE_OR_GENE_PRODUCT", 361, 366], ["3'-to-5' exoribonuclease", "GENE_OR_GENE_PRODUCT", 368, 392], ["nsp15", "GENE_OR_GENE_PRODUCT", 399, 404], ["mRNA cap-1 methyltransferase", "GENE_OR_GENE_PRODUCT", 406, 434], ["ORF3a", "GENE_OR_GENE_PRODUCT", 488, 493], ["ORF3b", "GENE_OR_GENE_PRODUCT", 495, 500], ["ORF6", "GENE_OR_GENE_PRODUCT", 502, 506], ["ORF7a", "GENE_OR_GENE_PRODUCT", 508, 513], ["ORF7b", "GENE_OR_GENE_PRODUCT", 515, 520], ["ORF8", "GENE_OR_GENE_PRODUCT", 522, 526], ["ORF9b", "GENE_OR_GENE_PRODUCT", 528, 533], ["ORF9c", "GENE_OR_GENE_PRODUCT", 535, 540], ["ORF10", "GENE_OR_GENE_PRODUCT", 545, 550], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 576, 586], ["prohibitins", "GENE_OR_GENE_PRODUCT", 601, 612], ["eIF4A", "GENE_OR_GENE_PRODUCT", 617, 622], ["SARS-CoV-2", "ORGANISM", 725, 735], ["PHB", "GENE_OR_GENE_PRODUCT", 748, 751], ["viral proteins", "PROTEIN", 4, 18], ["PHBs", "PROTEIN", 38, 42], ["structural proteins", "PROTEIN", 80, 99], ["spike (S)", "PROTEIN", 101, 110], ["membrane (M)", "PROTEIN", 112, 124], ["envelope (E) proteins", "PROTEIN", 130, 151], ["16 non-structural proteins", "PROTEIN", 168, 194], ["nsp1", "PROTEIN", 196, 200], ["nsp2", "PROTEIN", 205, 209], ["papain", "PROTEIN", 211, 217], ["protease", "PROTEIN", 223, 231], ["nsp4", "PROTEIN", 234, 238], ["nsp5", "PROTEIN", 240, 244], ["3C", "PROTEIN", 246, 248], ["protease", "PROTEIN", 254, 262], ["nsp6", "PROTEIN", 265, 269], ["nsp7", "PROTEIN", 271, 275], ["nsp8", "PROTEIN", 277, 281], ["nsp9", "PROTEIN", 283, 287], ["nsp10", "PROTEIN", 289, 294], ["nsp11", "PROTEIN", 296, 301], ["nsp12", "PROTEIN", 305, 310], ["RNA-dependent RNA polymerase", "PROTEIN", 312, 340], ["nsp13", "PROTEIN", 343, 348], ["helicase", "PROTEIN", 350, 358], ["nsp14", "PROTEIN", 361, 366], ["exoribonuclease", "PROTEIN", 377, 392], ["nsp15", "PROTEIN", 399, 404], ["mRNA cap-1 methyltransferase", "PROTEIN", 406, 434], ["accessory proteins", "PROTEIN", 445, 463], ["ORF3a", "PROTEIN", 488, 493], ["ORF3b", "PROTEIN", 495, 500], ["ORF6", "PROTEIN", 502, 506], ["ORF7a", "PROTEIN", 508, 513], ["ORF7b", "PROTEIN", 515, 520], ["ORF8", "PROTEIN", 522, 526], ["ORF9b", "PROTEIN", 528, 533], ["ORF9c", "PROTEIN", 535, 540], ["ORF10 proteins", "PROTEIN", 545, 559], ["SARS-CoV-2 proteins", "PROTEIN", 576, 595], ["prohibitins", "PROTEIN", 601, 612], ["eIF4A", "PROTEIN", 617, 622], ["PHB", "PROTEIN", 748, 751], ["The viral proteins", "PROBLEM", 0, 18], ["membrane (M)", "TEST", 112, 124], ["envelope (E) proteins", "TEST", 130, 151], ["nsp1", "TEST", 196, 200], ["nsp2", "TEST", 205, 209], ["papain", "TEST", 211, 217], ["protease", "TEST", 223, 231], ["nsp4", "TEST", 234, 238], ["nsp5", "TEST", 240, 244], ["3C", "TEST", 246, 248], ["protease", "TEST", 254, 262], ["nsp6", "TEST", 265, 269], ["nsp7", "TEST", 271, 275], ["nsp8", "TEST", 277, 281], ["nsp9", "TEST", 283, 287], ["nsp10", "TEST", 289, 294], ["nsp11", "TEST", 296, 301], ["nsp12", "TEST", 305, 310], ["RNA", "TEST", 312, 315], ["dependent RNA polymerase", "PROBLEM", 316, 340], ["nsp13", "TEST", 343, 348], ["helicase", "TEST", 350, 358], ["nsp14", "TEST", 361, 366], ["nsp15", "TEST", 399, 404], ["mRNA cap", "TEST", 406, 414], ["nine accessory proteins", "PROBLEM", 440, 463], ["ORF7b", "TEST", 515, 520], ["ORF8", "TEST", 522, 526], ["ORF9b", "TEST", 528, 533], ["SARS", "TEST", 576, 580], ["CoV", "TEST", 581, 584], ["prohibitins", "TREATMENT", 601, 612], ["eIF4A", "TREATMENT", 617, 622], ["ZotatifinThese data", "TEST", 683, 702], ["SARS", "PROBLEM", 725, 729], ["CoV", "TEST", 730, 733], ["PHB signaling", "TREATMENT", 748, 761], ["its replication", "TREATMENT", 766, 781], ["host immune evasion", "TREATMENT", 789, 808], ["viral proteins", "OBSERVATION", 4, 18]]], ["Coronavirus accessory proteins locate to many different cellular compartments, as do PHBs, and this may therefore be not entirely coincidental.", [["cellular compartments", "ANATOMY", 56, 77], ["Coronavirus accessory proteins", "GENE_OR_GENE_PRODUCT", 0, 30], ["cellular", "CELL", 56, 64], ["PHBs", "GENE_OR_GENE_PRODUCT", 85, 89], ["Coronavirus accessory proteins", "PROTEIN", 0, 30], ["Coronavirus accessory proteins", "PROBLEM", 0, 30], ["many", "OBSERVATION_MODIFIER", 41, 45], ["different", "OBSERVATION_MODIFIER", 46, 55], ["cellular compartments", "OBSERVATION", 56, 77]]], ["In addition PHBs have been shown to directly interact with DNA and long noncoding RNAs [42, [63] [64] [65] , raising the possibility that they may also interact with viral RNAs.Interaction of SARS-CoV-2 proteins with prohibitins and eIF4A, and discovery of the strong in vitro antiviral activity of ZotatifinImportantly, these authors identified 66 human proteins targeted by 29 FDA-approved drugs, 12 drugs in clinical trials and 28 preclinical compounds.", [["PHBs", "GENE_OR_GENE_PRODUCT", 12, 16], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 192, 202], ["prohibitins", "GENE_OR_GENE_PRODUCT", 217, 228], ["eIF4A", "GENE_OR_GENE_PRODUCT", 233, 238], ["ZotatifinImportantly", "SIMPLE_CHEMICAL", 299, 319], ["human", "ORGANISM", 349, 354], ["PHBs", "PROTEIN", 12, 16], ["long noncoding RNAs", "RNA", 67, 86], ["viral RNAs", "RNA", 166, 176], ["SARS-CoV-2 proteins", "PROTEIN", 192, 211], ["prohibitins", "PROTEIN", 217, 228], ["eIF4A", "PROTEIN", 233, 238], ["human proteins", "PROTEIN", 349, 363], ["human", "SPECIES", 349, 354], ["human", "SPECIES", 349, 354], ["long noncoding RNAs", "TEST", 67, 86], ["viral RNAs", "PROBLEM", 166, 176], ["SARS", "PROBLEM", 192, 196], ["CoV", "TEST", 197, 200], ["prohibitins", "TREATMENT", 217, 228], ["eIF4A", "TREATMENT", 233, 238], ["drugs", "TREATMENT", 392, 397], ["viral RNAs", "OBSERVATION", 166, 176]]], ["The screening of these compounds revealed 2 families of drugs with extremely promising antiviral activities: the modulators of Sigma1 and Sigma2 receptors and some inhibitors of translation.", [["Sigma1", "GENE_OR_GENE_PRODUCT", 127, 133], ["Sigma2 receptors", "GENE_OR_GENE_PRODUCT", 138, 154], ["Sigma1", "PROTEIN", 127, 133], ["Sigma2 receptors", "PROTEIN", 138, 154], ["The screening", "TEST", 0, 13], ["drugs", "TREATMENT", 56, 61], ["Sigma2 receptors", "TREATMENT", 138, 154], ["some inhibitors", "TREATMENT", 159, 174]]], ["This latter observation is not surprising, considering the established requirement of eIF4F for the translation of coronaviruses mRNAs.", [["eIF4F", "GENE_OR_GENE_PRODUCT", 86, 91], ["coronaviruses", "ORGANISM", 115, 128], ["eIF4F", "PROTEIN", 86, 91], ["coronaviruses mRNAs", "RNA", 115, 134], ["eIF4F", "TREATMENT", 86, 91], ["coronaviruses mRNAs", "PROBLEM", 115, 134]]], ["Zotatifin (4, figure 1 ) displayed an antiviral activity with a IC 90 of 37 nM (150 times lower than the IC 90 of hydroxychloroquine), which confirms the potential of flavaglines to treat Covid-19.ConclusionAlthough rare, flavaglines are not the only class of natural products to act on two very different families of proteins [66] .", [["Zotatifin", "CHEMICAL", 0, 9], ["hydroxychloroquine", "CHEMICAL", 114, 132], ["flavaglines", "CHEMICAL", 222, 233], ["Zotatifin", "CHEMICAL", 0, 9], ["hydroxychloroquine", "CHEMICAL", 114, 132], ["flavaglines", "CHEMICAL", 222, 233], ["Zotatifin", "SIMPLE_CHEMICAL", 0, 9], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 114, 132], ["flavaglines", "SIMPLE_CHEMICAL", 167, 178], ["flavaglines", "SIMPLE_CHEMICAL", 222, 233], ["Zotatifin", "TREATMENT", 0, 9], ["an antiviral activity", "TREATMENT", 35, 56], ["a IC", "TREATMENT", 62, 66], ["hydroxychloroquine", "TREATMENT", 114, 132], ["flavaglines", "TREATMENT", 167, 178], ["Covid", "TEST", 188, 193]]], ["By modulating the activity of PHBs and eIF4A, flavaglines display a wide therapeutic potential, in particular against devastating viral epidemics, including Ebola, dengue, chikungunya and COVID-19.", [["viral epidemics", "DISEASE", 130, 145], ["Ebola, dengue", "DISEASE", 157, 170], ["chikungunya", "DISEASE", 172, 183], ["PHBs", "GENE_OR_GENE_PRODUCT", 30, 34], ["eIF4A", "GENE_OR_GENE_PRODUCT", 39, 44], ["flavaglines", "SIMPLE_CHEMICAL", 46, 57], ["Ebola", "ORGANISM", 157, 162], ["PHBs", "PROTEIN", 30, 34], ["eIF4A", "PROTEIN", 39, 44], ["eIF4A", "TREATMENT", 39, 44], ["devastating viral epidemics", "PROBLEM", 118, 145], ["Ebola", "PROBLEM", 157, 162], ["dengue", "PROBLEM", 164, 170], ["chikungunya", "PROBLEM", 172, 183], ["COVID", "TEST", 188, 193], ["wide therapeutic", "OBSERVATION_MODIFIER", 68, 84]]], ["By targeting host proteins these compounds may overcome the problem of resistance that is likely to occur with RNA viruses, which have a high mutation rate.", [["resistance", "PROBLEM", 71, 81], ["RNA viruses", "PROBLEM", 111, 122], ["a high mutation rate", "PROBLEM", 135, 155]]], ["In addition to viruses, PHBs also interact with a wide variety of infectious agents diseases, such as Salmonella typhi, the causative agent of typhoid fever [67] .", [["infectious agents diseases", "DISEASE", 66, 92], ["Salmonella typhi", "DISEASE", 102, 118], ["typhoid fever", "DISEASE", 143, 156], ["PHBs", "GENE_OR_GENE_PRODUCT", 24, 28], ["Salmonella typhi", "ORGANISM", 102, 118], ["Salmonella typhi", "SPECIES", 102, 118], ["Salmonella typhi", "SPECIES", 102, 118], ["viruses", "PROBLEM", 15, 22], ["PHBs", "PROBLEM", 24, 28], ["infectious agents diseases", "PROBLEM", 66, 92], ["Salmonella typhi", "PROBLEM", 102, 118], ["typhoid fever", "PROBLEM", 143, 156], ["viruses", "OBSERVATION", 15, 22], ["infectious", "OBSERVATION_MODIFIER", 66, 76]]], ["Whether flavaglines could also be useful to eradicate these pathogens is also worthwhile to be explored.ConclusionIn addition, a large part of the world's population does not have access to modern medicine and relies on traditional medicine.", [["flavaglines", "CHEMICAL", 8, 19], ["flavaglines", "SIMPLE_CHEMICAL", 8, 19], ["flavaglines", "PROBLEM", 8, 19], ["these pathogens", "PROBLEM", 54, 69], ["modern medicine", "TREATMENT", 190, 205], ["traditional medicine", "TREATMENT", 220, 240], ["large", "OBSERVATION_MODIFIER", 129, 134]]], ["In Southeast Asia, India, South China, Indonesia, Cambodia, Vietnam and Thailand, plants of the genus Aglaia synthesizing flavaglines are commonly used for their therapeutic properties.", [["flavaglines", "CHEMICAL", 122, 133], ["flavaglines", "SIMPLE_CHEMICAL", 122, 133], ["the genus Aglaia synthesizing flavaglines", "TREATMENT", 92, 133], ["genus Aglaia", "ANATOMY", 96, 108]]], ["We can therefore wonder whether these plants could not also be effective as herbal therapies against emerging diseases such as COVID-19 by a population that cannot get access to expensive drugs.ConclusionAlmost 40 years after the first discovery of a natural flavagline in 1982, a synthetic one zotatifin, developed by eFFECTOR, has reached phase 1/2 clinical trial in cancer patients.", [["cancer", "ANATOMY", 369, 375], ["flavagline", "CHEMICAL", 259, 269], ["zotatifin", "CHEMICAL", 295, 304], ["cancer", "DISEASE", 369, 375], ["flavagline", "CHEMICAL", 259, 269], ["zotatifin", "CHEMICAL", 295, 304], ["zotatifin", "SIMPLE_CHEMICAL", 295, 304], ["cancer", "CANCER", 369, 375], ["patients", "ORGANISM", 376, 384], ["patients", "SPECIES", 376, 384], ["herbal therapies", "TREATMENT", 76, 92], ["emerging diseases", "PROBLEM", 101, 118], ["expensive drugs", "TREATMENT", 178, 193], ["a natural flavagline", "TREATMENT", 249, 269], ["a synthetic one zotatifin", "TREATMENT", 279, 304]]], ["This company is now exploring with members of the biopharmaceutical and scientific communities, NIAID and funding sources as to how to explore the potential of zotatifin against COVID-19.", [["zotatifin", "CHEMICAL", 160, 169], ["COVID-19", "CHEMICAL", 178, 186], ["zotatifin", "CHEMICAL", 160, 169], ["zotatifin", "SIMPLE_CHEMICAL", 160, 169], ["zotatifin", "TREATMENT", 160, 169], ["COVID", "TEST", 178, 183]]]], "f909064ec3b85464bf7a6c256780220e31abff64": [["Summary box\u25ba COVID-19 has further exposed the strong association between race, ethnicity, culture, socioeconomic status and health outcomes and illuminated monumental ethnoracialised differences reflecting the 'colour of disease'. \u25ba Racism, segregation and inequality have been invisibly and pervasively embedded in dominant cultures and social institutions for decades. \u25ba The socioeconomic factors that negatively influence health outcomes within the underserved minority communities must be identified and contextualised within historical, political, social and economic remits. \u25ba Acquisition of disaggregated data will be vital in identifying gaps in the social determinants of these health disparities and tailoring global policy responses.InTroduCTIonAs COVID-19 continues to sweep across the globe leaving thousands of victims in its wake, preliminary data from the USA suggest that minorities, especially black people, have been infected and killed at a disproportionate rate across the country.", [["people", "ORGANISM", 918, 924], ["people", "SPECIES", 918, 924], ["Summary box\u25ba COVID", "TEST", 0, 18], ["culture", "TEST", 90, 97], ["illuminated monumental ethnoracialised differences", "PROBLEM", 144, 194], ["disease'", "PROBLEM", 221, 229], ["The socioeconomic factors", "PROBLEM", 373, 398], ["disaggregated data", "TEST", 598, 616], ["InTroduCTIonAs COVID", "TREATMENT", 744, 764], ["preliminary data", "TEST", 846, 862], ["disease", "OBSERVATION", 221, 228], ["Racism", "OBSERVATION", 233, 239], ["segregation", "OBSERVATION_MODIFIER", 241, 252], ["dominant", "OBSERVATION_MODIFIER", 316, 324], ["globe", "ANATOMY", 798, 803], ["infected", "OBSERVATION", 936, 944]]], ["1 The most recent data released by the Center for Disease Control and Prevention suggests that black communities are disproportionately affected (when it comes to hospitalisation and deaths) by the coronavirus.", [["deaths", "DISEASE", 183, 189], ["coronavirus", "DISEASE", 198, 209], ["coronavirus", "ORGANISM", 198, 209], ["Disease Control", "TREATMENT", 50, 65], ["the coronavirus", "PROBLEM", 194, 209]]], ["In Illinois, 37% of the total confirmed cases and 45% of COVID-19 deaths are African Americans, although they account for only 16% of the state population.", [["deaths", "DISEASE", 66, 72], ["cases", "TEST", 40, 45], ["COVID", "TEST", 57, 62]]], ["2 There have been similar trends of infections and deaths in Michigan, Missouri, North Carolina and South Carolina.", [["infections", "DISEASE", 36, 46], ["deaths", "DISEASE", 51, 57], ["infections", "PROBLEM", 36, 46], ["similar", "OBSERVATION_MODIFIER", 18, 25], ["trends", "OBSERVATION_MODIFIER", 26, 32], ["infections", "OBSERVATION", 36, 46]]], ["Other evidence also revealed an over-representation of Latinos and Asians in COVID-19 infection rates when compared with their nationwide populations.", [["infection", "DISEASE", 86, 95], ["COVID-19", "ORGANISM", 77, 85], ["COVID", "TEST", 77, 82], ["infection rates", "PROBLEM", 86, 101], ["infection", "OBSERVATION", 86, 95]]], ["3 Similar patterns showing disproportionate infections and deaths in various parts of the globe including Asian countries, Nordic countries and the UK have emerged.", [["infections", "DISEASE", 44, 54], ["deaths", "DISEASE", 59, 65], ["disproportionate infections", "PROBLEM", 27, 54], ["deaths in various parts of the globe", "PROBLEM", 59, 95], ["disproportionate", "OBSERVATION_MODIFIER", 27, 43], ["infections", "OBSERVATION", 44, 54], ["globe", "ANATOMY", 90, 95]]], ["People belonging to black and Asian ethnic groups were found to be at a higher risk of in-hospital COVID-19 deaths partly due to deprivation compared with white people.", [["deaths", "DISEASE", 108, 114], ["People", "ORGANISM", 0, 6], ["people", "ORGANISM", 161, 167], ["People", "SPECIES", 0, 6], ["people", "SPECIES", 161, 167]]], ["6 Somalians in Norway have also recorded infection rates more than 10 times the national average, representing 1586 per 100 000 compared with 140 per 100 000.", [["infection", "DISEASE", 41, 50], ["infection rates", "PROBLEM", 41, 56], ["infection", "OBSERVATION", 41, 50]]], ["7 A survey in Sweden by the Public Health Agency similarly found that immigrants from Somalia, Syria and Iraq are disproportionately infected by COVID-19; although Somali Swedes are about 0.5% of the national population, they form 5% of confirmed cases.", [["disproportionately", "OBSERVATION_MODIFIER", 114, 132], ["infected", "OBSERVATION", 133, 141]]], ["8 The idea that health disparities are massively influenced by race, ethnicity and culture is not novel.", [["culture", "TEST", 83, 90]]], ["Despite significant advances in civil rights and the narrowing of differences in morbidity and death rates among disadvantaged communities, health disparities among ethnic groups remain a far-reaching issue globally.", [["death", "DISEASE", 95, 100], ["civil rights", "TREATMENT", 32, 44], ["the narrowing of differences in morbidity", "PROBLEM", 49, 90], ["significant", "OBSERVATION_MODIFIER", 8, 19], ["narrowing", "OBSERVATION", 53, 62], ["morbidity", "OBSERVATION", 81, 90]]], ["4 5 The world's poorest populations are disproportionately affected by malaria, tuberculosis and HIV/AIDS, which are the most fatal communicable diseases in the world.", [["malaria", "DISEASE", 71, 78], ["tuberculosis", "DISEASE", 80, 92], ["HIV/AIDS", "DISEASE", 97, 105], ["communicable diseases", "DISEASE", 132, 153], ["HIV", "SPECIES", 97, 100], ["HIV", "SPECIES", 97, 100], ["malaria", "PROBLEM", 71, 78], ["tuberculosis", "PROBLEM", 80, 92], ["HIV", "PROBLEM", 97, 100], ["AIDS", "PROBLEM", 101, 105], ["malaria", "OBSERVATION", 71, 78], ["tuberculosis", "OBSERVATION", 80, 92], ["most", "OBSERVATION_MODIFIER", 121, 125], ["fatal", "OBSERVATION_MODIFIER", 126, 131]]], ["6 The impoverished and underrepresented minority populations are also not spared the burden of chronic and debilitating infections aptly termed 'the neglected infections of poverty'.InTroduCTIonEthnic and racial discrimination and socioeconomic status (SES) are strongly associated with many health and healthcare outcomes.", [["infections", "DISEASE", 120, 130], ["infections", "DISEASE", 159, 169], ["poverty", "DISEASE", 173, 180], ["chronic and debilitating infections", "PROBLEM", 95, 130], ["impoverished", "OBSERVATION_MODIFIER", 6, 18], ["chronic", "OBSERVATION_MODIFIER", 95, 102], ["debilitating", "OBSERVATION_MODIFIER", 107, 119], ["infections", "OBSERVATION", 120, 130], ["neglected", "OBSERVATION_MODIFIER", 149, 158], ["infections", "OBSERVATION", 159, 169]]], ["Such disadvantages result in ethnic stigma and greater poverty which further lead to psychological distress, mental health-related disorders, drinking problems, chronic obstructive pulmonary disease and obesity.", [["pulmonary", "ANATOMY", 181, 190], ["psychological distress", "DISEASE", 85, 107], ["drinking problems", "DISEASE", 142, 159], ["chronic obstructive pulmonary disease", "DISEASE", 161, 198], ["obesity", "DISEASE", 203, 210], ["pulmonary", "ORGAN", 181, 190], ["ethnic stigma", "PROBLEM", 29, 42], ["psychological distress", "PROBLEM", 85, 107], ["related disorders", "PROBLEM", 123, 140], ["chronic obstructive pulmonary disease", "PROBLEM", 161, 198], ["obesity", "PROBLEM", 203, 210], ["chronic", "OBSERVATION_MODIFIER", 161, 168], ["obstructive", "OBSERVATION_MODIFIER", 169, 180], ["pulmonary", "ANATOMY", 181, 190], ["disease", "OBSERVATION", 191, 198], ["obesity", "OBSERVATION", 203, 210]]], ["12 13 A large body of evidence suggests that structural inequality is a key determinant of who gets affected by disease and its socioeconomic fallout, 14-16 the most affected being those who are most vulnerable with underlying conditions and limited access to quality care.", [["disease", "PROBLEM", 112, 119], ["underlying conditions", "PROBLEM", 216, 237], ["large", "OBSERVATION_MODIFIER", 8, 13], ["evidence suggests", "UNCERTAINTY", 22, 39], ["structural", "OBSERVATION_MODIFIER", 45, 55], ["inequality", "OBSERVATION", 56, 66]]], ["Such persons are also more prone to occupational exposure to infectious diseases, including COVID-19, as they tend to have employment in restaurants, food outlets, healthcare settings and essential services where contagion is more likely to occur.", [["infectious diseases", "DISEASE", 61, 80], ["persons", "ORGANISM", 5, 12], ["persons", "SPECIES", 5, 12], ["infectious diseases", "PROBLEM", 61, 80]]], ["17 These individuals are also prone to high exposure as they tend to commute to work by public transport where it may be difficult to practice physical distancing.InTroduCTIonThe COVID-19 pandemic has illuminated a disturbing and inconvenient truth: the 'colour of health' and how ethnoracialised differences in health outcomes have become the new normal across the world.", [["new", "OBSERVATION_MODIFIER", 344, 347], ["normal", "OBSERVATION", 348, 354]]], ["16 This commentary examines how racism, segregation and inequality, which have been for decades invisibly and pervasively embedded in dominant cultures and social institutions, now emerge as a monumental COVID-19 challenge.InTroduCTIon'THe Colour of dISeaSe': CoVId-19 and SoCIal deTermInanTS of HealTH Social determinants of health are key factors that shape the conditions surrounding how individuals are born, grow, live, work and age in specific environments.", [["a monumental COVID", "TREATMENT", 191, 209], ["CoVId", "TEST", 260, 265], ["Colour", "OBSERVATION_MODIFIER", 240, 246], ["dISeaSe", "OBSERVATION", 250, 257]]], ["18 These determinants are themselves influenced by the unequal distribution of resources, money and power at the local and global levels, leading to health inequities among groups of people.", [["people", "ORGANISM", 183, 189], ["people", "SPECIES", 183, 189], ["unequal", "OBSERVATION_MODIFIER", 55, 62], ["distribution", "OBSERVATION_MODIFIER", 63, 75]]], ["19 As the coronavirus continues to tighten its grip on many nations, states dominated by African Americans in the USA are recording high infection and mortality rates, as in the case of Illinois.", [["infection", "DISEASE", 137, 146], ["coronavirus", "ORGANISM", 10, 21], ["the coronavirus", "PROBLEM", 6, 21], ["high infection", "PROBLEM", 132, 146], ["coronavirus", "OBSERVATION", 10, 21], ["high", "OBSERVATION_MODIFIER", 132, 136], ["infection", "OBSERVATION", 137, 146]]], ["In Michigan, 33% of individuals who tested positive and 50% of those who died were African Americans although this group accounts for only 15% of the population.", [["individuals", "ORGANISM", 20, 31]]], ["10 In the UK, black and minority ethnic groups are 13% of the country's population but account for one-third of infected individuals who are admitted at critical care units in hospitals.", [["individuals", "ORGANISM", 121, 132], ["black", "OBSERVATION_MODIFIER", 14, 19]]], ["7 Persons who are socioeconomically disadvantaged, such as those who experience multidimensional poverty, have lower education levels and live in more dangerous neighbourhoods, also tend to have underlying health conditions that place them at higher risk for severe COVID-19.", [["COVID", "DISEASE", 266, 271], ["Persons", "ORGANISM", 2, 9], ["Persons", "SPECIES", 2, 9], ["underlying health conditions", "PROBLEM", 195, 223], ["severe COVID", "PROBLEM", 259, 271]]], ["12 20-24 The additional burden of racism which predisposes individuals to high-risk jobs and lower quality care has precipitated high rates of infections and death from COVID-19 among ethnic minorities.", [["infections", "DISEASE", 143, 153], ["death", "DISEASE", 158, 163], ["high rates of infections", "PROBLEM", 129, 153], ["death", "PROBLEM", 158, 163], ["COVID", "TEST", 169, 174], ["burden", "OBSERVATION_MODIFIER", 24, 30], ["racism", "OBSERVATION", 34, 40], ["infections", "OBSERVATION", 143, 153]]], ["25 26 In many Southeast Asian countries including Singapore, Malaysia and Thailand, millions of stranded foreign migrant workers from Myanmar, Philippines, Cambodia and Laos are at greater risks of COVID-19 infections, while Asian migrant workers in Gulf states face disproportionately high rates of COVID-19 infections, fore example, accounting for 70%-80% of all new cases in Saudi Arabia.", [["infections", "DISEASE", 207, 217], ["infections", "DISEASE", 309, 319], ["COVID-19", "ORGANISM", 198, 206], ["COVID-19 infections", "PROBLEM", 198, 217], ["COVID-19 infections", "PROBLEM", 300, 319]]], ["Similarly in the state of New York, poorer neighbourhoods in Queens are recording higher per capita rates of COVID-19 infections than richer neighbourhoods in Manhattan, while neighbourhoods with high proportions of black American (The term black Americans and African Americans are considered interchangeable) and Hispanic (Hispanic is a term referring to people of (generally) Latin American origin, primarily Mexican, living in the USA) populations are recording higher infection rates per capita.", [["infections", "DISEASE", 118, 128], ["infection", "DISEASE", 473, 482], ["people", "ORGANISM", 357, 363], ["people", "SPECIES", 357, 363], ["higher", "OBSERVATION_MODIFIER", 466, 472], ["infection", "OBSERVATION", 473, 482]]], ["27 However, these findings point to correlations and not causation; there may be other underlying causes of such high number of COVID-19 cases among these minority groups.InTroduCTIonRacism is a complex social system underpinned by unequal power relations and beliefs, resulting in ethnic minorities often being negatively stereotyped or marginalised.", [["InTroduCTIonRacism", "DISEASE", 171, 189], ["COVID", "TEST", 128, 133]]], ["10 28 29 Such ethnoracialised stereotypes lead to stress and impair decision-making processes resulting in further anxiety and aggressive behaviours.", [["anxiety", "DISEASE", 115, 122], ["aggressive behaviours", "DISEASE", 127, 148], ["stress", "PROBLEM", 50, 56], ["further anxiety", "PROBLEM", 107, 122], ["aggressive behaviours", "PROBLEM", 127, 148]]], ["29 Research has shown that black Americans tend to experience lower quality perinatal and neonatal care and such disparities are associated with behavioural, physical and neurodevelopmental impairment that affect these individuals in later life.", [["neurodevelopmental impairment", "DISEASE", 171, 200], ["lower quality perinatal and neonatal care", "PROBLEM", 62, 103], ["behavioural, physical and neurodevelopmental impairment", "PROBLEM", 145, 200]]], ["25 These factors contribute to the development of chronic health conditions that increase the risk of death from COVID-19.", [["death", "DISEASE", 102, 107], ["COVID-19", "CHEMICAL", 113, 121], ["chronic health conditions", "PROBLEM", 50, 75], ["death", "PROBLEM", 102, 107], ["COVID", "TEST", 113, 118], ["chronic", "OBSERVATION_MODIFIER", 50, 57]]], ["In this context, it is very concerning that ethnic and racial disparities also seem to be creeping into the care of persons with COVID-19.", [["persons", "ORGANISM", 116, 123], ["persons", "SPECIES", 116, 123], ["ethnic and racial disparities", "PROBLEM", 44, 73], ["COVID", "TEST", 129, 134]]], ["In states like Tennessee, African Americans with COVID-19 symptoms are reportedly less likely to be tested for the disease than white counterparts and the testing centres are preferentially located in areas occupied by predominantly white communities.", [["COVID-19 symptoms", "PROBLEM", 49, 66], ["the disease than white counterparts", "PROBLEM", 111, 146], ["the testing centres", "TEST", 151, 170], ["predominantly", "OBSERVATION_MODIFIER", 219, 232], ["white", "OBSERVATION_MODIFIER", 233, 238]]], ["16 WHy Colour-blInd daTa exaCerbaTeS raCIal InequITIeS In HealTH Healthcare data enable health systems to understand the pattern of diseases, develop holistic policies and enhance health outcomes.", [["diseases", "PROBLEM", 132, 140]]], ["Such data can also be used to determine how changes in healthcare systems and diseases impact ethnic and racial minorities differently in order to undertake timely interventions to improve quality of care.", [["timely interventions", "TREATMENT", 157, 177]]], ["30 This means that in places where BMJ Global Health minorities are increasing in number, ethnic and racial data will be essential to understanding and addressing the inequalities and challenges they face with respect to healthcare.", [["increasing", "OBSERVATION_MODIFIER", 68, 78]]], ["31 The need for such disaggregated data is becoming increasingly obvious as the COVID-19 pandemic continues to progress.", [["such disaggregated data", "TEST", 16, 39]]], ["Disaggregated data characteristically reveal patterns and underlying trends which become crucial to planning appropriate and efficient responses to pandemics.", [["Disaggregated data", "TEST", 0, 18], ["underlying trends", "PROBLEM", 58, 75], ["pandemics", "PROBLEM", 148, 157]]], ["In pandemics, highquality disaggregated data are vital to identifying the vulnerable populations and factors which impede or promote disease transmission within communities.", [["the vulnerable populations", "PROBLEM", 70, 96]]], ["However, it is well known that ethnic and racial minorities continue to experience disproportionate health outcomes which predate the current COVID-19 crisis.", [["the current COVID", "TEST", 130, 147]]], ["30 These groups record poorer health outcomes and have high prevalent rates in asthma, cancer, cardiovascular disease and HIV/AIDS.", [["cancer", "ANATOMY", 87, 93], ["cardiovascular", "ANATOMY", 95, 109], ["asthma", "DISEASE", 79, 85], ["cancer", "DISEASE", 87, 93], ["cardiovascular disease", "DISEASE", 95, 117], ["HIV/AIDS", "DISEASE", 122, 130], ["cancer", "CANCER", 87, 93], ["cardiovascular", "ANATOMICAL_SYSTEM", 95, 109], ["HIV", "SPECIES", 122, 125], ["HIV", "SPECIES", 122, 125], ["asthma", "PROBLEM", 79, 85], ["cancer", "PROBLEM", 87, 93], ["cardiovascular disease", "PROBLEM", 95, 117], ["HIV/AIDS", "PROBLEM", 122, 130], ["asthma", "OBSERVATION", 79, 85], ["cancer", "OBSERVATION", 87, 93], ["cardiovascular", "ANATOMY", 95, 109]]], ["20 Ethnic and racial minorities in the USA and UK record language barriers, poorer healthcare experiences and higher uninsured rates, which makes it less likely to access healthcare services.", [["higher uninsured rates", "PROBLEM", 110, 132]]], ["Ethnic minorities face economic and social disadvantages over the course of life and such inequalities result in low access and utilisation of healthcare.", [["social disadvantages", "TREATMENT", 36, 56]]], ["In places like Singapore, immigrants from neighbouring countries live in shared dormitories with poor working conditions.", [["poor working conditions", "PROBLEM", 97, 120]]], ["24 The current COVID-19 crisis appears to be aggravating an already very fragile situation which is characterised by these grave inequalities.InTroduCTIonWhile it is clear that the acquisition of disaggregated data will be crucial in tracking the spread of COVID-19 transmission and tailoring global policy responses, use of such data is not practised.", [["The current COVID", "TEST", 3, 20], ["crisis", "PROBLEM", 24, 30], ["an already very fragile situation", "PROBLEM", 57, 90], ["disaggregated data", "TEST", 196, 214], ["very", "OBSERVATION_MODIFIER", 68, 72], ["fragile", "OBSERVATION", 73, 80], ["grave", "OBSERVATION", 123, 128]]], ["32 With respect to COVID-19, and when challenged to provide more race-disaggregated data in Canada's pandemic briefings, federal and several provincial health officials pushed back arguing that 'Canada is a colour-blind society', or that 'race-based data are not necessary' during the pandemic.", [["COVID", "TEST", 19, 24]]], ["35 With lack of use of quality and available minority data, it is not only difficult for minority populations to understand the causes and patterns of diseases and their environment, but it also limits the government from recognising the impact of health and social policies.", [["diseases", "PROBLEM", 151, 159]]], ["35 TaCklIng eTHnIC HealTH Care dISparITIeS: uSIng THe aVaIlable eVIdenCe To aCT To reduce or prevent further ethnoracialised health disparities revealed by the COVID-19 pandemic, it will be important to conduct an intersectional analysis of the socioeconomic factors and social determinants of health.", [["further ethnoracialised health disparities", "PROBLEM", 101, 143]]], ["37 38 The socioeconomic factors that negatively influence health outcomes within the underserved minority communities must be identified and contextualised within historical, political, social and economic remits.", [["The socioeconomic factors", "PROBLEM", 6, 31]]], ["5 20 COVID-19 healthcare service delivery can have a direct impact on the overall health, quality of life and life expectancy of minority populations.", [["delivery", "TREATMENT", 33, 41], ["minority populations", "PROBLEM", 129, 149]]], ["But not all groups, and certainly not ethnic minorities in the USA, Singapore and Norway have equitable access to such care.", [["such care", "TREATMENT", 114, 123]]], ["The root cause of the differential treatment of minorities in healthcare settings, notably but not exclusively African Americans, Asians and Hispanics, will need to be identified and innovative policies aimed at closing access and treatment gaps introduced in ways that will guarantee a buy-in from all relevant parties.", [["root", "ANATOMY", 4, 8], ["root", "ORGAN", 4, 8], ["treatment gaps", "TREATMENT", 231, 245], ["root", "OBSERVATION_MODIFIER", 4, 8]]], ["20 Healthcare providers need to be equipped and well informed to address the health needs of the growing minority populations, especially during outbreaks such as COVID-19.ConCluSIonEthnic and racial health disparities continue to plague minority population across several countries resulting in worse health outcomes as reflected in the current COVID-19 crisis.", [["the current COVID", "TEST", 334, 351]]], ["Many ethnic minorities experience low socioeconomic deprivation, poorer healthcare experiences and low health insurance coverage which contribute to inadequate healthcare utilisation and therefore increase in long-term illnesses.", [["low socioeconomic deprivation", "PROBLEM", 34, 63], ["low health insurance coverage", "TREATMENT", 99, 128], ["long-term illnesses", "PROBLEM", 209, 228], ["increase", "OBSERVATION_MODIFIER", 197, 205], ["long-term", "OBSERVATION_MODIFIER", 209, 218]]], ["These persistent ethnic health disparities have been well known for many decades, but often systematically ignored.", [["persistent", "OBSERVATION_MODIFIER", 6, 16]]], ["The onset of COVID-19 exposes, once more, the racial fault lines that have been the norm in many countries' health systems, and social and economic policies.", [["fault lines", "CELL", 53, 64], ["COVID", "TEST", 13, 18], ["fault lines", "OBSERVATION", 53, 64]]], ["As governments' COVID-19 responses unfold, disaggregated data will be vital in identifying gaps in the social determinants of these health disparities and guiding appropriate prevention/response efforts.", [["COVID", "TEST", 16, 21]]]], "PMC7149470": [["For example, exobiology is concerned with the study of life beyond the Earth, but the search for extraterrestrial life needs to distinguish between inanimate and living entities (Oliver and Perry, 2006).", [["the study", "TEST", 42, 51]]], ["When studying the origin of life, researchers can use model chemical systems to simulate how life may have begun on the Earth.", [["model chemical systems", "TREATMENT", 54, 76]]], ["Finally, the field of artificial life (Alife) aims to fully simulate living organisms electronically.", [["artificial life (Alife)", "TREATMENT", 22, 45]]], ["Since we are still discovering new species and have competing hypotheses for how life originated, many feel that the issue of defining the concept of \u2018life\u2019 is a worthless pursuit as we do not understand enough about it (Raoult, 2009; Szostak, 2012).A history of defining lifeThe first-recorded person to define life was Aristotle, who defined it as \u2018grows, is self-sustaining and reproduces\u2019 (Popa, 2004).", [["person", "SPECIES", 295, 301], ["new species", "PROBLEM", 31, 42]]], ["This was an observational attempt that was unchallenged until the synthesis of cell theory by Schwann and Schleiden in 1855.", [["cell", "ANATOMY", 79, 83], ["Schwann", "ANATOMY", 94, 101], ["cell", "CELL", 79, 83], ["Schwann", "CELL", 94, 101]]], ["The basic tenets was that all life are formed of cells, which are created from pre-existing cells, and that cells are the smallest unit of life.", [["cells", "ANATOMY", 49, 54], ["cells", "ANATOMY", 92, 97], ["cells", "ANATOMY", 108, 113], ["cells", "CELL", 49, 54], ["cells", "CELL", 92, 97], ["cells", "CELL", 108, 113], ["pre-existing cells", "CELL_TYPE", 79, 97], ["pre-existing cells", "PROBLEM", 79, 97]]], ["This immediately excluded viruses and all non-cellular life forms (which at the time had not been discovered) from the definition.", [["viruses", "PROBLEM", 26, 33], ["viruses", "OBSERVATION", 26, 33]]], ["As cell theory became universally accepted, the definition of life being strictly cellular was also accepted (Wolfe, 1972).A history of defining lifeHowever with the advent of the electron microscope in 1939 (Kruger, 2000) and knowledge of viruses, researchers became aware of non-cellular entities.", [["cell", "ANATOMY", 3, 7], ["cellular", "ANATOMY", 82, 90], ["cell", "CELL", 3, 7], ["cellular", "CELL", 82, 90], ["the electron microscope", "TEST", 176, 199], ["viruses", "PROBLEM", 240, 247], ["non-cellular entities", "PROBLEM", 277, 298], ["viruses", "OBSERVATION", 240, 247]]], ["Although they interacted with cells causing major diseases, they were treated as transferable toxins rather than living organisms as cell theory dictates (Forterre, 2010).", [["cells", "ANATOMY", 30, 35], ["cell", "ANATOMY", 133, 137], ["cells", "CELL", 30, 35], ["cell", "CELL", 133, 137], ["major diseases", "PROBLEM", 44, 58], ["transferable toxins", "PROBLEM", 81, 100]]], ["In 1967, the virologist and Nobel laureate Andre Lwoff used the definition \u2018an integrated system of interdependent structures and functions\u2019 and \u2018an organism is constituted of cells\u2019 (Forterre, 2010), emphasizing the distinct and controlled nature of organelles inside cells.", [["cells", "ANATOMY", 176, 181], ["organelles", "ANATOMY", 251, 261], ["cells", "ANATOMY", 269, 274], ["cells", "CELL", 176, 181], ["organelles", "CELLULAR_COMPONENT", 251, 261], ["cells", "CELL", 269, 274], ["an organism", "PROBLEM", 146, 157], ["inside cells", "OBSERVATION", 262, 274]]], ["This is analogous to the organization of organs in multicellular organisms.", [["organs", "ANATOMY", 41, 47], ["multicellular organisms", "ANATOMY", 51, 74], ["organs", "ORGAN", 41, 47], ["organs", "ANATOMY", 41, 47], ["multicellular organisms", "OBSERVATION", 51, 74]]], ["This definition also conforms to the tenets of cell theory even though Lwoff was himself a virologist.", [["cell", "ANATOMY", 47, 51], ["cell", "CELL", 47, 51]]], ["However, this definition was criticized as it could include machines like cars or AI which have interdependent circuits (Oliver and Perry, 2006).A history of defining lifeThere have also been attempts at a definition outside biology, for example, by the physicist Erwin Schrodinger in 1945.", [["AI", "PROBLEM", 82, 84]]], ["He defined life as \u2018an entity that resists disorder and does not gain entropy\u2019 (Schr\u00f6dinger, 1945).", [["disorder", "DISEASE", 43, 51], ["resists disorder", "PROBLEM", 35, 51]]], ["To resist entropy, organisms must take in nutrients and metabolize them and so this definition was inclusive to all cells but again excluded viruses and acellular organisms.", [["cells", "ANATOMY", 116, 121], ["cells", "CELL", 116, 121], ["organisms", "TREATMENT", 19, 28], ["viruses", "PROBLEM", 141, 148], ["acellular organisms", "PROBLEM", 153, 172]]], ["However, this definition would also include crystals, which grow and can resist entropy by forming ordered lattices.A history of defining lifeAn alternative definition was proposed in 1992 by Gerald Joyce, an academic and member of the NASA exobiology advisory board.", [["crystals", "PROBLEM", 44, 52]]], ["The panel put forward a working definition of \u2018a self-sustaining system capable of Darwinian evolution\u2019 that the program used in its search for extraterrestrial life (Deemer, 1994).", [["The panel", "TEST", 0, 9]]], ["However, sterile hybrids like mules, which have a metabolism but cannot reproduce and therefore evolve, refute this rule (Cleland and Chyba, 2002).A history of defining lifeIn 2002, Daniel Koshland, an American Biochemist, proposed seven essential properties of life intending to create a universal definition to identify artificial and extraterrestrial life (Koshland, 2002).", [["sterile hybrids like mules", "PROBLEM", 9, 35]]], ["His \u2018Seven Pillars of life\u2019 were Program, Improvization, Compartmentalization, Energy, Regeneration, Adaptability, and Seclusion (PICERAS) (Koshland, 2002).", [["Pillars", "OBSERVATION_MODIFIER", 11, 18]]], ["Program refers to coding molecules, Improvization refers to evolution, Compartmentalization means organized in some sort of structure, Energy refers to metabolism, Regeneration means some sort of healing process, Adaptability means changing according to the environment and Seclusion is being able to protect against the environment.", [["healing process", "PROBLEM", 196, 211], ["Seclusion", "TREATMENT", 274, 283], ["healing", "OBSERVATION", 196, 203]]], ["Instead of defining life descriptively, he took all the varying definitions of life (123 in his study) and by looking at the common vocabulary he synthesized a consensus definition: \u2018Self-replication with variation\u2019 (Trifonov, 2011), which happened to be almost exactly the same as a definition by the Russian biochemist and origin-of-life researcher Oparin in 1924: \u2018Any system capable of replication and mutation is alive\u2019 (Oparin, 1924).", [["his study", "TEST", 92, 101]]], ["Regardless of older conventions such as cell theory, Trifonov also stated that this approach would be able to define all life, including artificial and extraterrestrial life, by looking at common characteristics (Trifonov, 2012).A history of defining lifeHowever, the response to this paper was mixed, with many researchers feeling that essential properties were missing and that the whole definition was too vague (Popa, 2012).", [["cell", "ANATOMY", 40, 44], ["cell", "CELL", 40, 44]]], ["For example, homoeostasis and metabolism were missing and the definition included viruses and computer viruses (Trifonov, 2012).", [["homoeostasis and metabolism", "PROBLEM", 13, 40], ["viruses", "PROBLEM", 82, 89]]], ["Moreover, there was no reference to the cell, which also invited criticisms from many fields (Trifonov, 2012).", [["cell", "ANATOMY", 40, 44], ["cell", "CELL", 40, 44]]], ["Trifonov was criticized for focussing his definition on the origins of life and not on what distinguishes life from non-life (Trifonov, 2012).", [["Trifonov", "CHEMICAL", 0, 8]]], ["He also pointed to a practical use for this definition for molecular experiments such as GCCn repeats replication errors in the origin-of-life field (Pino, Trifonov and Di Mauro, 2011).", [["GCCn", "CHEMICAL", 89, 93], ["molecular experiments", "PROBLEM", 59, 80], ["GCCn repeats replication errors", "PROBLEM", 89, 120]]], ["More noticeable is the fact that Trifonov\u2019s definition is almost exactly the same as that of Alexander Oparin, who proposed the Oparin\u2013Haldane hypothesis for how the early atmosphere could have produced molecules leading to life (Oparin, 1924).", [["Trifonov", "SIMPLE_CHEMICAL", 33, 41]]], ["As a consequence, critics were sceptical of his claim that this approach could be used universally (Popa, 2012).A history of defining lifeMoreover, this \u2018lexical\u2019 approach itself had some fundamental problems.", [["some fundamental problems", "PROBLEM", 183, 208]]], ["Many advances in science have come from challenging past conventional wisdom and this approach may not represent competing viewpoints in fast moving fields (Popa, 2012).", [["this approach", "TREATMENT", 81, 94]]], ["There were also many minor criticisms of his methodology as Trifonov grouped together words with similar meaning (Trifonov, 2012).", [["many", "OBSERVATION_MODIFIER", 16, 20], ["minor", "OBSERVATION_MODIFIER", 21, 26], ["criticisms", "OBSERVATION", 27, 37]]], ["Trifonov did acknowledge their concerns but stressed that there had to be some middle ground otherwise no consensus would be reached (Trifonov, 2012).", [["Trifonov", "CHEMICAL", 0, 8]]], ["Ultimately this leads to either a very strict definition with each criterion sieving out some undeniably living organisms or a broad definition that includes fire or crystals as living (Oliver and Perry, 2006).", [["some undeniably living organisms", "PROBLEM", 89, 121]]], ["There are difficulties with a theoretical definition as this requires a robust theory of living organisms that we do not yet have.", [["a theoretical definition", "PROBLEM", 28, 52]]], ["As an example, Joyce\u2019s definition described above as \u2018a self-sustained chemical system capable of Darwinian evolution\u2019 excludes sterile hybrids as they are not capable of Darwinian evolution since they cannot replicate.", [["sterile hybrids", "PROBLEM", 128, 143], ["Darwinian", "OBSERVATION", 98, 107], ["Darwinian", "OBSERVATION", 171, 180]]], ["Chemical systems can also be capable of error prone reproduction but need constant monitoring so cannot be self-sustaining (Benner, 2010).", [["error prone reproduction", "PROBLEM", 40, 64], ["constant monitoring", "TEST", 74, 93]]], ["Finally, it is problematic from a practical standpoint to determine whether a system is capable of Darwinian evolution as this requires studies over many generations and under different selection pressures (Oliver and Perry, 2006).Difficulties in defining lifeMoreover, defining life leads to a philosophical dilemma based on whether we treat the concept of life as a non-scientific folk concept (such as \u2018good\u2019 and \u2018justice\u2019) or as a scientific concept (such as \u2018molecule\u2019) (Machery, 2012).", [["justice\u2019", "DISEASE", 417, 425], ["a philosophical dilemma", "PROBLEM", 293, 316], ["Darwinian", "OBSERVATION", 99, 108]]], ["In the first instance, we assume that people\u2019s collective judgements on what is living or not can lead to a definition.", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44]]], ["However there is a strong evidence both in psychology and empirically that folk concepts are not strict definitions and that people\u2019s collective judgements are too contradictory to lead to one definition (Machery, 2012).", [["people", "ORGANISM", 125, 131], ["people", "SPECIES", 125, 131]]], ["Life as far as we know is found on the Earth and uses carbon-based molecules with specific coding molecules.", [["carbon", "CHEMICAL", 54, 60], ["specific coding molecules", "PROTEIN", 82, 107]]], ["It is entirely conceivable that life can exist with silicon-based molecules or with entirely different coding molecules.", [["silicon", "CHEMICAL", 52, 59], ["coding molecules", "PROTEIN", 103, 119], ["silicon-based molecules", "TREATMENT", 52, 75], ["entirely different coding molecules", "PROBLEM", 84, 119]]], ["However, arguably the main topic of contention are viruses.", [["main", "OBSERVATION_MODIFIER", 22, 26], ["viruses", "OBSERVATION", 51, 58]]], ["Viruses do not respire or have any metabolism; they complete their life cycle inside other cells, hijacking their ribosomes and enzymes to replicate.Fringe casesViruses are known to be able to evolve just like any other cellular organism.", [["cells", "ANATOMY", 91, 96], ["ribosomes", "ANATOMY", 114, 123], ["cellular", "ANATOMY", 220, 228], ["cells", "CELL", 91, 96], ["ribosomes", "CELLULAR_COMPONENT", 114, 123], ["cellular", "CELL", 220, 228], ["enzymes", "PROTEIN", 128, 135], ["Viruses", "PROBLEM", 0, 7], ["any metabolism", "PROBLEM", 31, 45], ["enzymes", "TEST", 128, 135], ["Viruses", "PROBLEM", 161, 168], ["any other cellular organism", "PROBLEM", 210, 237], ["cellular organism", "OBSERVATION", 220, 237]]], ["Genomic data shows that viruses have evolved unique genes with no cellular homologues (Forterre, 2010).", [["cellular", "ANATOMY", 66, 74], ["cellular", "CELL", 66, 74], ["Genomic data", "TEST", 0, 12], ["viruses", "PROBLEM", 24, 31], ["viruses", "OBSERVATION", 24, 31]]], ["This suggests that they have co-evolved with cellular life as far back as the LUCA according to the same rules of Darwinian evolution (Forterre, 2010).", [["cellular", "ANATOMY", 45, 53], ["cellular", "CELL", 45, 53], ["cellular life", "TREATMENT", 45, 58]]], ["This is corroborated by the fact that every cell can be infected by at least one virus and viruses are the most abundant life forms on the Earth with an estimated 1030 viruses in the ocean alone (Suttle, 2007).", [["cell", "ANATOMY", 44, 48], ["cell", "CELL", 44, 48], ["viruses", "PROBLEM", 91, 98]]], ["However, the fact remains that viruses need cells to replicate and as a selection pressure.Fringe casesSome researchers have argued that viruses can be considered living because of the special properties of the virion factory in the infected cell.", [["cells", "ANATOMY", 44, 49], ["cell", "ANATOMY", 242, 246], ["cells", "CELL", 44, 49], ["cell", "CELL", 242, 246], ["infected cell", "CELL_TYPE", 233, 246], ["a selection pressure", "TEST", 70, 90], ["viruses", "OBSERVATION", 31, 38], ["infected cell", "OBSERVATION", 233, 246]]], ["The virologist Andre Lwoff observed that viruses transform the whole infected cell into a virion factory (Lwoff, 1967).", [["cell", "ANATOMY", 78, 82], ["cell", "CELL", 78, 82], ["infected cell", "OBSERVATION", 69, 82]]], ["The virion factory (also called viroplasm or virus induced inclusion bodies) is the apparatus where new viral particles are assembled in the host and can be seen as a large organelle-like structure in the cytoplasm or nucleus (Neuman, Angelini and Buchmeier, 2014; Risco, Fernandez and Sanz-Sanchez, 2014).", [["organelle", "ANATOMY", 173, 182], ["cytoplasm", "ANATOMY", 205, 214], ["nucleus", "ANATOMY", 218, 225], ["viroplasm", "GENE_OR_GENE_PRODUCT", 32, 41], ["organelle", "CELLULAR_COMPONENT", 173, 182], ["cytoplasm", "ORGANISM_SUBSTANCE", 205, 214], ["nucleus", "CELLULAR_COMPONENT", 218, 225], ["viroplasm", "PROBLEM", 32, 41], ["virus induced inclusion bodies", "TREATMENT", 45, 75], ["new viral particles", "PROBLEM", 100, 119], ["virion factory", "OBSERVATION", 4, 18], ["new", "OBSERVATION_MODIFIER", 100, 103], ["viral particles", "OBSERVATION", 104, 119], ["large", "OBSERVATION_MODIFIER", 167, 172], ["cytoplasm", "ANATOMY_MODIFIER", 205, 214], ["nucleus", "ANATOMY", 218, 225]]], ["Virion factories usually have single or double membranes either taken from the host plasma membrane or made from lipids redirected from the endoplasmic reticulum (Neuman, Angelini and Buchmeier, 2014; Risco, Fernandez and Sanz-Sanchez, 2014).", [["membranes", "ANATOMY", 47, 56], ["plasma membrane", "ANATOMY", 84, 99], ["endoplasmic reticulum", "ANATOMY", 140, 161], ["membranes", "CELLULAR_COMPONENT", 47, 56], ["plasma membrane", "CELLULAR_COMPONENT", 84, 99], ["lipids", "SIMPLE_CHEMICAL", 113, 119], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 140, 161], ["Virion factories", "PROBLEM", 0, 16], ["single or double membranes", "PROBLEM", 30, 56], ["lipids", "TREATMENT", 113, 119], ["double membranes", "OBSERVATION_MODIFIER", 40, 56], ["endoplasmic reticulum", "ANATOMY", 140, 161]]], ["Virion factories show properties of cellular life such as \u2018metabolism, growth and reproduction\u2019.", [["cellular", "ANATOMY", 36, 44], ["cellular", "CELL", 36, 44], ["Virion factories", "PROBLEM", 0, 16], ["cellular life", "OBSERVATION", 36, 49]]], ["In this view, the extracellular virions are inert but the intracellular virus seen as a virion factory is living (Bandea, 1983).", [["extracellular virions", "ANATOMY", 18, 39], ["intracellular", "ANATOMY", 58, 71], ["extracellular virions", "CELLULAR_COMPONENT", 18, 39], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 71], ["virus", "ORGANISM", 72, 77], ["the extracellular virions", "TREATMENT", 14, 39], ["the intracellular virus", "PROBLEM", 54, 77], ["intracellular virus", "OBSERVATION", 58, 77]]], ["When this argument was first proposed in 1983, it was largely rejected by the scientific community as a biased attempt by virologists to classify their studied organism as living (Forterre, 2010).The mimivirusIn 2003, a new virus was rediscovered inside an amoeba from a water-cooling tower in Bradford, UK (La Scola and Audic, 2003).", [["a new virus", "PROBLEM", 218, 229]]], ["As it took up a gram stain, it was initially identified as a Gram-positive bacterium and named \u2018Bradfordcoccus\u2019 in 1997, but under closer inspection it was actually a virus (Birtles and Rowbotham, 1997).", [["a gram stain", "TEST", 14, 26], ["a Gram-positive bacterium", "PROBLEM", 59, 84]]], ["It was named the mimivirus as it mimicked Gram-positive bacteria and was added under a new taxon of giant viruses, Mimiviridae.The mimivirusThis virus had some novel characteristics that had previously only been found in cellular organisms.", [["cellular organisms", "ANATOMY", 221, 239], ["giant viruses", "DISEASE", 100, 113], ["cellular", "CELL", 221, 229], ["the mimivirus", "PROBLEM", 13, 26], ["Gram-positive bacteria", "PROBLEM", 42, 64], ["giant viruses", "PROBLEM", 100, 113], ["Mimiviridae", "TREATMENT", 115, 126], ["The mimivirusThis virus", "PROBLEM", 127, 150], ["giant viruses", "OBSERVATION", 100, 113], ["mimivirus", "OBSERVATION", 131, 140], ["cellular organisms", "OBSERVATION", 221, 239]]], ["First, it was bigger than many cellular organisms in diameter (750 nm) and was the first to be visible under a light microscope.", [["cellular organisms", "ANATOMY", 31, 49], ["cellular", "CELL", 31, 39], ["a light microscope", "TEST", 109, 127], ["bigger", "OBSERVATION_MODIFIER", 14, 20], ["cellular organisms", "OBSERVATION", 31, 49], ["diameter", "OBSERVATION_MODIFIER", 53, 61], ["750 nm", "OBSERVATION_MODIFIER", 63, 69]]], ["Its genome was large too at 1.2 Mb and with 911 functional protein coding genes, far beyond that needed for a viral life cycle (Claverie, 2006).", [["911 functional protein coding genes", "DNA", 44, 79], ["genome", "OBSERVATION", 4, 10], ["large", "OBSERVATION_MODIFIER", 15, 20]]], ["Since viruses need only code for their own capsid, receptors for host entry and hijacking the cell, they had not been expected to carry more than around 200 genes (Claverie, 2006).", [["cell", "ANATOMY", 94, 98], ["cell", "CELL", 94, 98], ["viruses", "PROBLEM", 6, 13]]], ["Moreover, viral genomes are limited by the structural instability of large amounts of naked DNA.", [["DNA", "CELLULAR_COMPONENT", 92, 95], ["viral genomes", "DNA", 10, 23], ["naked DNA", "DNA", 86, 95], ["viral genomes", "PROBLEM", 10, 23], ["naked DNA", "PROBLEM", 86, 95], ["viral genomes", "OBSERVATION", 10, 23], ["large", "OBSERVATION_MODIFIER", 69, 74], ["amounts", "OBSERVATION_MODIFIER", 75, 82], ["naked DNA", "OBSERVATION", 86, 95]]], ["This suggests that the virus was using other genes for purposes other than a typical viral life cycle, otherwise these extra genes would have been lost through evolution (Claverie, 2006).", [["the virus", "PROBLEM", 19, 28], ["a typical viral life cycle", "TREATMENT", 75, 101], ["virus", "OBSERVATION", 23, 28]]], ["The non-coding regions were also interesting as they had unique and strongly conserved promotor elements, hinting to the fact that this was a part of a long lineage existing at the same time as the first cells (Claverie and Abergel, 2009).", [["cells", "ANATOMY", 204, 209], ["cells", "CELL", 204, 209], ["non-coding regions", "DNA", 4, 22], ["promotor elements", "DNA", 87, 104], ["a long lineage", "PROBLEM", 150, 164]]], ["This notion is supported by more recent proteome analysis that concluded that viruses originated from ancient cells that had segmented RNA genomes (Nasir and Caetano-Anoll\u00e9s, 2015).", [["cells", "ANATOMY", 110, 115], ["cells", "CELL", 110, 115], ["segmented RNA genomes", "DNA", 125, 146], ["recent proteome analysis", "TEST", 33, 57], ["viruses", "PROBLEM", 78, 85], ["ancient cells", "PROBLEM", 102, 115], ["viruses", "OBSERVATION", 78, 85], ["ancient cells", "OBSERVATION", 102, 115]]], ["These RNA cells coexisted with the ancestors of the last universal modern ancestor (LUCA).", [["cells", "ANATOMY", 10, 15], ["RNA cells", "CELL", 6, 15], ["LUCA", "CANCER", 84, 88], ["These RNA cells", "PROBLEM", 0, 15], ["RNA cells", "OBSERVATION", 6, 15]]], ["Due to the selection pressure of genome and particle sizes these RNA cells eventually became viruses and became similar to parasitic bacteria that had similar pressures (Nasir and Caetano-Anoll\u00e9s, 2015).", [["cells", "ANATOMY", 69, 74], ["cells", "CELL", 69, 74], ["RNA cells", "CELL_TYPE", 65, 74], ["the selection pressure of genome and particle sizes these RNA cells", "PROBLEM", 7, 74], ["viruses", "PROBLEM", 93, 100], ["parasitic bacteria", "PROBLEM", 123, 141], ["Nasir", "TEST", 170, 175], ["particle", "OBSERVATION_MODIFIER", 44, 52], ["sizes", "OBSERVATION_MODIFIER", 53, 58], ["RNA cells", "OBSERVATION", 65, 74], ["viruses", "OBSERVATION", 93, 100], ["parasitic", "OBSERVATION_MODIFIER", 123, 132], ["bacteria", "OBSERVATION", 133, 141], ["pressures", "OBSERVATION_MODIFIER", 159, 168]]], ["The nucleocytoplasmic large DNA viruses which include the mimivirus form one paraphyletic group that diverged at varying times before the emergence of modern Archaea and Eukaryotes (Nasir and Caetano-Anoll\u00e9s, 2015).The mimivirusSecond, it possessed many genes that had only been previously found in cellular organisms, such as eukaryotic transcription factors and RNA synthesis that are essential for translation.", [["cellular organisms", "ANATOMY", 299, 317], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["cellular", "CELL", 299, 307], ["eukaryotic transcription factors", "PROTEIN", 327, 359], ["The nucleocytoplasmic large DNA viruses", "PROBLEM", 0, 39], ["cellular organisms", "PROBLEM", 299, 317], ["eukaryotic transcription factors", "PROBLEM", 327, 359], ["RNA synthesis", "PROBLEM", 364, 377], ["large", "OBSERVATION_MODIFIER", 22, 27], ["DNA viruses", "OBSERVATION", 28, 39], ["cellular organisms", "OBSERVATION", 299, 317]]], ["All these genes were fully functional when expressed and performed just as well as those found in cells (Claverie and Abergel, 2009).", [["cells", "ANATOMY", 98, 103], ["cells", "CELL", 98, 103]]], ["This went against the conventional belief that viruses are reliant on the infected host for translation machinery.", [["translation machinery", "TREATMENT", 92, 113], ["viruses", "OBSERVATION", 47, 54]]], ["However, as it does not code for its own ribosomes it still requires a host to synthesize proteins so is not free living.The mimivirusAdditionally, the viral factory where the new mimivirus virions are created was far larger and more sophisticated than other viral factories (Forterre, 2010; Risco, Fernandez and Sanz-Sanchez, 2014).", [["ribosomes", "CELLULAR_COMPONENT", 41, 50], ["mimivirus virions", "ORGANISM", 180, 197], ["the new mimivirus virions", "PROBLEM", 172, 197], ["new", "OBSERVATION_MODIFIER", 176, 179], ["mimivirus virions", "OBSERVATION", 180, 197], ["larger", "OBSERVATION_MODIFIER", 218, 224]]], ["In fact, the mimivirus viral factory is membrane bound and can take up huge volumes inside the cell, setting it apart from other viral factories (Forterre, 2010).", [["membrane", "ANATOMY", 40, 48], ["cell", "ANATOMY", 95, 99], ["membrane", "CELLULAR_COMPONENT", 40, 48], ["cell", "CELL", 95, 99], ["membrane bound", "PROBLEM", 40, 54], ["mimivirus", "OBSERVATION", 13, 22], ["viral factory", "OBSERVATION", 23, 36]]], ["This rekindled the argument made by Bandea (Bandea, 1983), emphasizing the fact that the viral factory is the virus organism itself, with the virions that are produced being vectors for this organism to be spread to other cells (Claverie, 2006).", [["virions", "ANATOMY", 142, 149], ["cells", "ANATOMY", 222, 227], ["cells", "CELL", 222, 227], ["the viral factory", "PROBLEM", 85, 102], ["the virus organism", "PROBLEM", 106, 124], ["the virions", "PROBLEM", 138, 149], ["this organism", "PROBLEM", 186, 199]]], ["This argument was extended to say that during the life cycle the whole infected cell becomes a virus and because of this we should consider viruses as both living and \u2018a particular form of cellular organism\u2019 (Forterre, 2010), with the proviso that they borrow from the cell they infect.", [["cell", "ANATOMY", 80, 84], ["cellular", "ANATOMY", 189, 197], ["cell", "ANATOMY", 269, 273], ["cell", "CELL", 80, 84], ["cellular", "CELL", 189, 197], ["cell", "CELL", 269, 273], ["the whole infected cell", "PROBLEM", 61, 84], ["a virus", "PROBLEM", 93, 100], ["viruses", "PROBLEM", 140, 147], ["infected cell", "OBSERVATION", 71, 84]]], ["The virion factory is also very similar to some intracellular parasitic bacteria such as Rickettsia buchnera, which also depend on the host metabolism to reproduce and are unanimously counted as living (Nasir and Caetano-Anoll\u00e9s, 2015).", [["intracellular", "ANATOMY", 48, 61], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 48, 61], ["Rickettsia buchnera", "ORGANISM", 89, 108], ["Rickettsia buchnera", "SPECIES", 89, 108], ["Rickettsia buchnera", "SPECIES", 89, 108], ["some intracellular parasitic bacteria", "PROBLEM", 43, 80], ["Rickettsia buchnera", "PROBLEM", 89, 108], ["virion factory", "OBSERVATION", 4, 18], ["intracellular", "OBSERVATION_MODIFIER", 48, 61], ["parasitic bacteria", "OBSERVATION", 62, 80]]], ["This metaphor can be extended to say that the virion and a host can be viewed as two gametes that fuse to create the virion factory, which then creates more virion progeny (Nasir and Caetano-Anoll\u00e9s, 2015).", [["virion", "CELLULAR_COMPONENT", 46, 52]]], ["This metaphor has been used to depict viruses as living (Hegde et al., 2009).The mimivirusHowever, the most striking feature of the mimivirus is that it can be infected by another virus dubbed a \u2018virophage\u2019, in the same way that bacteria infecting viruses are called bacteriophages (La Scola, Desnues and Pagnier, 2008).", [["mimivirus", "CANCER", 132, 141], ["The mimivirus", "PROBLEM", 77, 90], ["the mimivirus", "PROBLEM", 128, 141], ["another virus", "PROBLEM", 172, 185], ["a \u2018virophage\u2019", "TREATMENT", 193, 206], ["bacteria infecting viruses", "PROBLEM", 229, 255], ["mimivirus", "OBSERVATION", 81, 90], ["mimivirus", "OBSERVATION", 132, 141]]], ["The sputnik virophage requires coinfection with the mimivirus and both reduce the overall mimivirus particles created by 70% and increases the number of dysfunctional and misshapen mimiviruses (La Scola, Desnues and Pagnier, 2008).", [["sputnik", "CHEMICAL", 4, 11], ["sputnik", "GENE_OR_GENE_PRODUCT", 4, 11], ["The sputnik virophage", "TREATMENT", 0, 21], ["coinfection", "PROBLEM", 31, 42], ["the mimivirus", "TREATMENT", 48, 61], ["coinfection", "OBSERVATION", 31, 42], ["mimivirus particles", "OBSERVATION", 90, 109]]], ["It acts like any other virus, using the enzymes in the mimivirus factory for its own replication (Desnues and Raoult, 2010).", [["any other virus", "PROBLEM", 13, 28], ["the enzymes", "TEST", 36, 47], ["virus", "OBSERVATION", 23, 28]]], ["This implies that the mimivirus is functionally similar to a cellular organism as it can be infected by a virus (Claverie and Abergel, 2009).", [["cellular organism", "ANATOMY", 61, 78], ["mimivirus", "GENE_OR_GENE_PRODUCT", 22, 31], ["cellular", "CELL", 61, 69], ["the mimivirus", "PROBLEM", 18, 31], ["a cellular organism", "PROBLEM", 59, 78], ["mimivirus", "OBSERVATION", 22, 31]]], ["This property was highlighted as an argument that viruses are in fact living (La Scola, Desnues and Pagnier, 2008), as only living organisms can be parasitized (Forterre, 2010).The mimivirusSince the discovery of the mimivirus, other giant viruses with similar properties have been found such as the Klosneuvirus in Austria (Schulz, 2017).", [["mimivirus", "CANCER", 217, 226], ["viruses", "PROBLEM", 50, 57], ["The mimivirus", "PROBLEM", 177, 190], ["the mimivirus", "PROBLEM", 213, 226], ["other giant viruses", "PROBLEM", 228, 247], ["viruses", "OBSERVATION", 50, 57], ["mimivirus", "OBSERVATION", 181, 190], ["giant", "OBSERVATION_MODIFIER", 234, 239], ["viruses", "OBSERVATION", 240, 247]]], ["This virus had even more translational machinery coding for aminoacyl tRNA synthetase and a slightly bigger genome of 1.57 Mb (Schulz, 2017).", [["aminoacyl tRNA", "CHEMICAL", 60, 74], ["aminoacyl", "CHEMICAL", 60, 69], ["aminoacyl tRNA synthetase", "GENE_OR_GENE_PRODUCT", 60, 85], ["aminoacyl tRNA synthetase", "PROTEIN", 60, 85], ["This virus", "PROBLEM", 0, 10], ["aminoacyl tRNA synthetase", "TREATMENT", 60, 85], ["a slightly bigger genome", "PROBLEM", 90, 114]]], ["Schulz suggested that the giant virus family had originated from smaller viruses by gradually accumulating host genes and not from an ancient cellular ancestor (Schulz, 2017).", [["cellular", "ANATOMY", 142, 150], ["giant virus", "ORGANISM", 26, 37], ["cellular", "CELL", 142, 150], ["host genes", "DNA", 107, 117], ["the giant virus", "PROBLEM", 22, 37], ["smaller viruses", "PROBLEM", 65, 80], ["giant", "OBSERVATION_MODIFIER", 26, 31], ["virus", "OBSERVATION", 32, 37], ["smaller", "OBSERVATION_MODIFIER", 65, 72], ["viruses", "OBSERVATION", 73, 80], ["host genes", "OBSERVATION", 107, 117]]], ["Another notable giant virus discovery is the Turpanvirus, which was found in Brazil and had all the translational machinery required apart from the ribosome.", [["ribosome", "ANATOMY", 148, 156], ["ribosome", "CELLULAR_COMPONENT", 148, 156], ["Another notable giant virus discovery", "PROBLEM", 0, 37], ["notable", "OBSERVATION_MODIFIER", 8, 15], ["giant", "OBSERVATION_MODIFIER", 16, 21], ["virus", "OBSERVATION", 22, 27]]], ["Members of this family also have a large cylindrical tail meaning they can be up to 2.3 \u03bcm long overall (Abrah\u00e3o, Silva and Santos, 2018).The mimivirusSome researchers have proposed adding giant viruses into a fourth domain on the tree of life (Boyer et al., 2010; Nasir and Caetano-Anoll\u00e9s, 2015).", [["a large cylindrical tail meaning", "PROBLEM", 33, 65], ["giant viruses", "PROBLEM", 189, 202], ["large", "OBSERVATION_MODIFIER", 35, 40], ["cylindrical tail", "OBSERVATION_MODIFIER", 41, 57], ["giant", "OBSERVATION_MODIFIER", 189, 194], ["viruses", "OBSERVATION", 195, 202], ["tree", "ANATOMY_MODIFIER", 231, 235]]], ["The reasoning behind this is that nucleocytoplasmic large DNA viruses (NCLDVs) are an ancient lineage that have interacted with the earliest cells and may have predated them (Claverie and Abergel, 2009).", [["nucleocytoplasmic", "ANATOMY", 34, 51], ["cells", "ANATOMY", 141, 146], ["DNA", "CELLULAR_COMPONENT", 58, 61], ["NCLDVs", "GENE_OR_GENE_PRODUCT", 71, 77], ["cells", "CELL", 141, 146], ["nucleocytoplasmic large DNA viruses", "PROBLEM", 34, 69], ["large", "OBSERVATION_MODIFIER", 52, 57], ["DNA viruses", "OBSERVATION", 58, 69]]], ["There are some strongly supported phylogenetic trees that put the NCLDVs between Eukaryotes and archaea in a fourth domain (Br\u00fcssow, 2009; Boyer et al. 2010).", [["NCLDVs", "GENE_OR_GENE_PRODUCT", 66, 72], ["phylogenetic trees", "OBSERVATION", 34, 52]]], ["It has also been noted that traditional phylogenies were based on ribosomal proteins and were not representative of life as they precluded viruses (Boyer et al. 2010; Forterre, 2010).", [["ribosomal", "ANATOMY", 66, 75], ["ribosomal", "CELLULAR_COMPONENT", 66, 75], ["ribosomal proteins", "PROTEIN", 66, 84], ["traditional phylogenies", "PROBLEM", 28, 51], ["ribosomal proteins", "TEST", 66, 84]]], ["However, Boyer et al. (2010) analysed transcription factors and RNA polymerase proteins, which are found more universally across cellular life and viruses.The mimivirusUsing the same justifications, some researchers went further and argued that NCLDVs should be classed as living and on a new tree of life along with other acellular organisms that are at least as old as the earliest cells (Kejnovskya and Trifonov, 2016).", [["cellular", "ANATOMY", 129, 137], ["cells", "ANATOMY", 384, 389], ["cellular", "CELL", 129, 137], ["cells", "CELL", 384, 389], ["transcription factors", "PROTEIN", 38, 59], ["RNA polymerase proteins", "PROTEIN", 64, 87], ["transcription factors", "TEST", 38, 59], ["RNA polymerase proteins", "TEST", 64, 87], ["other acellular organisms", "PROBLEM", 317, 342], ["viruses", "OBSERVATION", 147, 154]]], ["Two virologists proposed a new classification with the highest division being between organisms containing ribosomes and those containing capsids (Forterre, 2010).", [["ribosomes", "ANATOMY", 107, 116], ["ribosomes", "CELLULAR_COMPONENT", 107, 116], ["organisms containing ribosomes", "TREATMENT", 86, 116], ["new", "OBSERVATION_MODIFIER", 27, 30]]], ["Subviral entities like plasmids, prions and viroids (Kejnovskya and Trifonov, 2016) were grouped together as \u2018orphan replicons\u2019 but separate from this tree (Forterre, 2010).", [["plasmids", "ANATOMY", 23, 31], ["plasmids", "DNA", 23, 31], ["Subviral entities like plasmids", "PROBLEM", 0, 31], ["plasmids", "OBSERVATION", 23, 31]]], ["There were other issues such that all ribosome-encoding organisms contained common rRNA proteins but there was no protein universally shared in the capsid-encoding organisms (Forterre, 2010).", [["common rRNA proteins", "PROTEIN", 76, 96], ["other issues", "PROBLEM", 11, 23], ["all ribosome-encoding organisms", "PROBLEM", 34, 65], ["common rRNA proteins", "PROBLEM", 76, 96], ["protein", "PROBLEM", 114, 121]]], ["The authors acknowledged that this would incite controversy but emphasized the need to promote more academic debate on this subject (Forterre, 2010).The mimivirusIt is worth noting that the idea of the \u2018Universal tree of life\u2019 is heavily challenged by horizontal gene transfer.", [["mimivirus", "OBSERVATION", 153, 162]]], ["Organisms can gain genes from a transducing virus or by plasmids and so organisms contain DNA from many different sources (Raoult, 2009).", [["plasmids", "ANATOMY", 56, 64], ["DNA", "CELLULAR_COMPONENT", 90, 93], ["plasmids", "DNA", 56, 64], ["Organisms", "PROBLEM", 0, 9], ["a transducing virus", "PROBLEM", 30, 49], ["organisms", "PROBLEM", 72, 81], ["DNA", "PROBLEM", 90, 93]]], ["As well as being a laborious task, a universal definition of life would also be irrelevant unless it is used in the emerging fields discussed above.ConclusionThe discovery of the mimivirus and other NCLDVs has resulted in new arguments for classifying some viruses as living or at least cellular.", [["cellular", "ANATOMY", 287, 295], ["mimivirus", "CANCER", 179, 188], ["NCLDVs", "CANCER", 199, 205], ["cellular", "CELL", 287, 295], ["a laborious task", "PROBLEM", 17, 33], ["the mimivirus and other NCLDVs", "PROBLEM", 175, 205], ["some viruses", "PROBLEM", 252, 264], ["mimivirus", "OBSERVATION", 179, 188], ["new", "OBSERVATION_MODIFIER", 222, 225], ["viruses", "OBSERVATION", 257, 264]]], ["It has properties that straddle cellular and non-cellular organisms, which strengthen some arguments to redefine life to include it (Kejnovskya and Trifonov, 2016), Even if it is not seen as living the fact that it has existed and co-evolved with cellular life since the LUCA makes it pivotal in the evolution of life on the Earth.", [["cellular", "ANATOMY", 32, 40], ["cellular", "ANATOMY", 247, 255], ["cellular", "CELL", 32, 40], ["cellular", "CELL", 247, 255], ["straddle cellular and non-cellular organisms", "PROBLEM", 23, 67], ["non-cellular organisms", "OBSERVATION", 45, 67]]]]}